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Abstract 
The aim of modern cancer chemotherapy is to develop targeted drugs designed to exploit 
pharmacological differences between tumour cells and healthy tissues. One focus of this 
effort has been the identification of protein kinases that are expressed at elevated levels or in 
mutated forms, indicating a reliance of the tumour on specific kinase function. Nek2 is a 
human serine/threonine protein kinase related to the fungal protein NIMA, a critical mediator 
of mitosis. Interestingly, Nek2 is found to be upregulated in a variety of tumour cell lines 
derived from breast, cervical and prostate carcinomas, as well as lymphomas. 
Human Nek2 is implicated in the regulation of the centrosome and formation of a bipolar 
spindle, a framework that is vital for correct separation of sister chromatids during mitosis. It 
is proposed that Nek2 may complex with, and phosphorylate, proteins accumulated at the 
centrosome, possibly playing a role in intercentriolar linker cleavage during the centrosome 
cycle. Abnormalities in centrosome number and function are common in many cancers, 
indicating that loss of centrosome cycle regulation may be a major contributing factor in 
tumour progression. Overexpression of Nek2 may result in premature centrosome 
disjunction, and deregulation of this tightly controlled mitotic machinery leads to chromatid 
segregation errors, aneuploidy and chromosomal instability, common genetic abnormalities 
observed in tumour cells. This indicates a role for abnormal Nek2 function in tumourigenesis, 
and Nek2 depletion in a number of tumour cell lines has been shown to cause growth 
suppression and apoptosis. 
Nek2 is thus a potentially attractive cancer therapeutic target for  small-molecule kinase 
inhibitors. Previous studies identified substituted purine derivatives as modest inhibitors of 
Nek2, leading to the discovery of two distinct inhibitor classes, exhibiting ATP-competitive 
and irreversible inhibition of the kinase, respectively. 
 
Purine-based compounds bearing substituents at the 8-position have emerged as modest 
competitive inhibitors of Nek2 that occupy the kinase ATP-domain through an unusual 
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binding orientation (45; IC50 = 51.8 M). Additional possible interactions within the ATP-
binding site available to inhibitors of this class were explored, with the objective of 
developing tight-binding type II reversible inhibitors of Nek2. Structure-activity relationship 
studies resulted in a 10-fold improvement in activity over the initial hit compounds and a 
substantial improvement in drug-like properties (e.g. 129; IC50 = 5.1 M)). However, all 
efforts to improve the potency of this series were unsuccessful. 
 
6-Ethynylpurines have been identified as irreversible inhibitors of Nek2 through covalent 
modification of an active-site cysteine residue. The initial hit compound (147; IC50 = 0.14 
M) was found to be a potent and selective inhibitor of the kinase in vitro, but with poor 
cellular activity attributed to limited permeability. Extensive structural modification of the 2-
arylamino side-chain of this series afforded cell permeable analogues with improved potency, 
both in vitro and in vivo (e.g. 177; IC50 = 0.062 ± 0.01 M).  
Biochemical studies using 177 suggested that inhibition of Nek2 resulted in an increase in 
mitotic abnormalities and a delay in mitotic progression, despite poor cellular growth 
inhibition being observed in initial tumour cell lines. Further cellular growth inhibition and 
cytotoxicity studies with selected compounds identified several sensitive tumour cell lines. 
However, kinase-inactive control compounds essentially devoid of Nek-inhibitory activity 
(e.g. 425; IC50 > 100 M) retained growth-inhibitory activity, indicating an alternative locus 
of activity for the 6-ethynylpurine chemotype.  
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Abbreviations 
A ADME  Absorption distribution metabolism excretion 
 ALL   Acute lymphoblastic leukaemia 
 AP   Alkaline phosphatase 
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 ATP   Adenosine triphosphate 
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 Rsk   Ribosomal s6 kinase 
 RT   Room temperature 
S s   Singlet 
 SAC   Spindle assembly checkpoint 
 SARs   Structure-activity relationships 
 SDS   Sodium dodecyl sulfate 
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Chapter 1: Chemotherapy and the Cell Cycle 
1.1. The Birth of Modern Chemotherapy 
1.1.1. The Discovery of Cellular Toxins as Chemotherapeutic Agents 
Despite the recognition of tumour formation in humans for centuries, a clear understanding of 
the biomolecular processes involved was not apparent until the later stages of the twentieth 
century. Prior to 1950, the mainstay of cancer treatment was the responsibility of surgeons, 
until the advent of the linear accelerator brought radiotherapy to the fore. However, the 
success of both techniques relies on early diagnosis and detection of the tumour, and both are 
relatively ineffective against metastatic cancers.
1
 In order to treat a patient with a liquid or 
metastatic tumour, a therapeutic effect is required throughout the entire body. It was therefore 
necessary to identify and develop chemical agents that could be administered systemically to 
treat a patient whose cancer could be present in any organ. 
It was not until the 1940s that such compounds were identified by Louis Goodman and 
Alfred Gilman, investigating the potential therapeutic value of chemical weapons stockpiled 
during World War II. It was noted that the autopsies of soldiers killed by exposure to mustard 
gas revealed high levels of myelosuppression, resulting in a low white blood cell count 
(leukopenia), underdeveloped (hypoplastic) lymphoid tissues, and ulceration of the 
gastrointestinal tract;
2
 all of these are indications that such compounds were having a 
cytotoxic effect on rapidly dividing cells. 
 
The active agent in mustard gas is sulfur mustard (1). However, the toxicity of sulfur mustard 
is too high for systemic use, and thus the structurally similar but less toxic nitrogen mustard 
(2) was investigated. Although limited in success, systemic treatment of a patient with non-
Hodgkin’s Lymphoma with nitrogen mustard provided the first example of tumour regression 
observed following administration of a chemical agent,
3, 4
 and the age of modern 
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chemotherapy was born. In the years following their discovery, the identification of more 
stable nitrogen mustards with electron-rich substituents, allowed the development of orally 
administered chemotherapeutics, such as chlorambucil (3).
1
 
The same scientists went on to devolve the now accepted mechanism of action of nitrogen 
mustards, which is initiated through the formation of a reactive aziridinium ion. This reactive 
alkylating species forms covalent adducts with DNA bases, in particular the N-7 position of 
guanine. The ability of nitrogen mustards to form two such species results in cross-linking of 
DNA strands.
5
 This induces DNA miscoding and strand breaks during replication, and 
triggers the cell to ‘self-destruct’, or undergo apoptosis. 
A further major development in modern cancer chemotherapy followed the observation of the 
renowned pathologist Sydney Farber, that treatment of patients suffering from leukaemia 
with the vitamin folic acid was detrimental to the patient’s disease, seeming to trigger 
proliferation of acute lymphoblastic leukaemia (ALL).
6
 The cellular substrate of folic acid is 
dihydrofolate reductase (DHFR), an enzyme that plays a key role in the biosynthesis of 
thymidylate and purines, essential components for cell viability due to their role in DNA and 
RNA synthesis.  
 
Amethopterin, or methotrexate (4), was synthesised as an analogue of folic acid, and acts as 
an inhibitor of DHFR, disrupting the ability of a cell to synthesise components essential for 
DNA and RNA biosynthesis and cellular growth. Compounds within this class are termed 
antifolates. Such compounds rely on active transport into the target cell through the reduced-
folate transporter 1 (RFT-1), followed by polyglutamation of the drug and subsequent 
binding to DHFR.
1
 Methotrexate (4) was successful in the treatment of a range of epithelial 
malignancies, including remission in patients suffering from cholangiocarcinoma, making it 
the first drug to successfully cure a solid tumour.
7
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Despite these initial successes, both nitrogen mustards and antifolates soon encountered the 
rapid onset of resistance in patient populations, a problem that has come to characterise many 
modern chemotherapeutic therapies. The evolutionary pressure exerted on a tumour cell 
population through administration of a cytotoxic drug, coupled with the elevated rate of cell 
proliferation and loss of regulation in cancer, increases the likelihood of the emergence of 
cells with genetic mutations sufficient to circumvent the desired therapeutic effect.
8
 
 
Methotrexate (4) is an antimetabolite, as it acts to inhibit the natural metabolism of folic acid 
for the biosynthesis of DNA and RNA. Additional advancements in the field of 
chemotherapy made during the 1950s included the discovery of further antimetabolites such 
as 6-mercaptopurine (6-MP, 5)
9
 and 5-fluorouracil (5-FU, 6).
10
 These antimetabolites 
highlighted the ability of such compounds to disrupt the life cycle of the cell, often through 
interference in DNA and RNA synthesis. Natural products such as the Vinca alkaloids (e.g. 
vincristine, 7)
11
 and taxanes (e.g. taxol, 8),
12
 which interfere with microtubule 
polymerisation, a vital event for the mitotic process (see chapter 2.2.), added to the growing 
repository of available chemotherapeutic agents. However, the development of resistance to 
single agent therapy remained, despite the diverse nature of the cellular targets and processes 
being targeted. 
  
In an attempt to address this problem, clinicians have administered chemotherapeutic agents 
from a variety of classes, with different modes of action, as a single regimen. For example, 
18 
 
the POMP regimen; a combination of prednisone, vincristine, methotrexate and 6-MP, has 
been commonly used, and shown to induce remissions in children suffering from ALL. 
Similarly, the MOPP regimen; a combination of a nitrogen mustard, vincristine, prednisone 
and procarbazine, has been used to successfully treat patients with Hodgkin’s and non-
Hodgkin’s lymphomas.13, 14 
During the 1970s and 1980s, additions to the arsenal of chemotherapeutic agents continued to 
be made, including widely used compound classes such as platinum complexes. These agents 
bind to DNA and cause DNA cross-linking, and include cisplatin (9) and its analogues.
15, 16
 A 
number of inhibitors of topoisomerase II, a key enzyme involved in DNA replication and 
repair, such as the anthracyclins (e.g. Daunorubicin, 10) were also discovered.
17
 However, at 
this time anticancer drug discovery was dominated by government-funded and academic 
laboratories, with very little representation from industry. This was driven by the high risk 
nature of the field, with a relatively low success rate of potential drugs passing from the clinic 
to the market. Progress towards novel treatments for patients was slow, particularly for the 
treatment of solid tumours, and very few truly novel classes of compounds emerged.
1
 
 
Throughout the development of early anticancer drugs, clinicians repeatedly encountered 
serious toxicities associated with the nature of the compounds used. Such agents inevitably 
carry with them a serious therapeutic disadvantage due to their lack of selectivity for tumour 
cells, as the compounds have an effect on all cells undergoing DNA replication and/or 
mitosis. This results in widespread destruction of tumour and healthy cells alike, and, as such, 
these compounds are associated with a high toxicity. In order to exert a therapeutic effect, 
such compounds rely on the fact that tumour cells have an increased rate of proliferation. 
This is often responsible for the side effects seen in regions of the body associated with rapid 
cell division, such as loss of hair, gastrointestinal toxicity and myelosuppression.
18
 This has 
long been accepted as the price for controlling a potentially fatal disease, but as treatments 
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have improved and patient survival increased, the need to eliminate serious long-term 
damage to off-target tissues and improve patient prognosis has become an important goal. 
1.1.2. Understanding the Molecular Pathology of Cancer 
It was not until the late 1980s that continuing research into the molecular and genetic 
composition of cells allowed researchers to gain a deeper understanding of the molecular 
processes involved in cell growth and division. A highly complex array of cellular processes 
was elucidated, regulating all aspects of the cell, including proliferation, survival, and 
apoptosis. The molecular pathology of such processes is now better understood, highlighting 
the key role of growth factors, signalling molecules, regulators of apoptosis and the cell 
cycle.
19
 Of particular interest to oncologists was the possibility of linking key cellular 
components to processes vital to the initiation and propagation of a tumour.  
All cancers arise by modification of the genome of a single healthy cell, leading to errors in 
transcription and subsequent modification of gene expression. Such genetic modification can 
be the result of random errors in DNA replication, or due to the mutagenic effect of 
exogenous or endogenous agents. The majority of modifications to a cell’s genetic material 
have little effect. However, such alterations can contribute to the development of neoplasia 
when they cause the mutation of a proto-oncogene, a gene coding for a protein involved in 
processes such as cell growth or differentiation. The resulting activation of the oncogene 
causes the transcription of mutated or elevated levels of proteins governing aspects of cell 
proliferation, driving aberrent cell growth and the development of a tumourigenic phenotype.   
Mutations may also cause damage to tumour suppressor genes, causing loss or 
downregulation of proteins involved in regulating cell division or promoting apoptosis.
20
 
Over the past two decades, our understanding of the key oncogenes and tumour suppressor 
genes involved in tumour progression has allowed the identification of a large number of 
novel targets for anti-cancer drug discovery. There are now understood to be several 
‘hallmarks of cancer’, which are acquired by normal cells as they progress towards a 
cancerous state (Figure 1).
19, 21
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Figure 1: The major characteristics a cell must acquire during the process of tumourigenesis.
19, 21
 
In normal cells, the formation and release of growth factors is tightly controlled, ensuring 
well maintained regulation of the cell’s ability to enter growth and division cycles. Cancer 
cells acquire the ability to circumvent this control and receive sustained proliferative 
signalling. This is possible either through the increased production of growth factors by the 
cancer cells, by signalling to the surrounding stroma to stimulate normal cells to release 
growth factors,
22
 or by the overexpression of receptor proteins, such as the epidermal growth 
factor receptor (EGFR) family, at the cell surface.
23
 
There are a number of tumour suppressor genes dedicated to the negative regulation of cell 
proliferation, by encoding for proteins such as retinoblastoma (Rb) and p53. These proteins 
interpret extra- and intra-cellular signals relating to the suitability of the cell to undergo 
growth and division, from both growth-inhibitory signals and indicators of cellular stress and 
abnormality.
24
 If overwhelming signals of the cells unsuitability to divide are received, 
tumour suppressor proteins can trigger the cell to enter senescence or undergo apoptosis. In 
order to undergo unrestricted proliferation, despite inherent defects within the tightly 
controlled cellular machinery, it is necessary for pre-malignant cells to overcome the action 
of these growth suppressors. Indeed, many tumour suppressor genes have been discovered 
owing to their inactivation in cancer.
19
  
Apoptosis serves as a major obstacle to the development of cancer from a pre-cancerous 
cell,
25
 and is initiated in response to a range of physiological stresses. Many of these are 
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experienced by the cell during the development of a tumourigenic phenotype, such as DNA 
damage and the inability to satisfy cell-cycle checkpoint requirements. For a cell to progress 
to an advanced cancerous state, the ability to resist cell death must be acquired, through 
mutation or deregulation of apoptotic machinery components.
19
 The most common mutation 
seen in cancer is the loss of p53 function,
26
 which compromises the cellular stress sensing 
component of the apoptotic framework. Another mechanism for resisting apoptosis acquired 
by cancerous cells is upregulation of antiapoptotic regulators such as Bcl-2 and Bcl-xL, or 
downregulation of proapoptotic factors including Bax and Bak.
27
 
To sustain the rapid proliferation exhibited by tumour tissue, extensive vasculature is 
required to provide the tumour with the necessary nutrients and oxygen, as well as to remove 
metabolic waste products and carbon dioxide. This vascular network is formed via the 
formation of new blood vessels from the existing system, in a process called angiogenesis. In 
healthy tissue this process is limited to wound healing and certain stages of the female 
reproductive cycle. However, in cancer, angiogenic signalling is often permanently activated, 
resulting in formation of the required neovasculature to support the growing tumour.
28
 Again, 
this process is controlled by growth factors and receptors, such as vascular endothelial growth 
factor (VEGF) and the vascular endothelial growth factor receptor (VEGFR), and 
upregulation of VEGF can be caused by oncogenic signalling.
29
 Indeed, one of the early 
examples of a targeted cancer therapy was the anti-angiogenic VEGFR inhibitor peptide 
endostatin.
1
 
A further obstacle for cells to overcome on the path to neoplasia is the inherent restriction on 
the proliferative potential of a cell. In normal cells the number of cycles of cell division 
through which any given cell can pass is limited by telomere length. These multiple 
hexanucleotide repeats at the terminus of a chromosome are sequentially removed upon each 
phase of DNA replication, until there is no protection at the end of chromosomal DNA to 
prevent end-to-end fusion. Such events terminate cell division and thus either force apoptosis 
through chromosomal instability (CIN) or cause the cell to enter senescence, or cellular 
dormancy (G0, see chapter 1.2.). However, oncogenic activation of telomerase, a DNA 
polymerase capable of adding telomere repeats to the ends of telomeric DNA, is acquired by 
many human cancers.
19, 30
 
The final major hallmark of cancer is the ability of a tumour to invade local tissue and 
ultimately metastasise. However, it is known that in healthy epithelial tissue, cells are 
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prevented from detaching from their parent sheet by adheren junctions, attachments between 
cells and from cells to the extracellular matrix (ECM). One key regulator of adheren 
formation is E-cadherin, and loss of this molecule is observed in cancer cells. Frequent down-
regulation and occasional mutation of E-cadherin affords human carcinomas the ability to 
invade local tissue and eventually produce metastatic tumours in other organs.
31
 
This complex set of characteristics adds to the difficult task facing the cancer research 
community, and the still relatively high mortality rate from cancer reinforces the need for 
continued research into the understanding of the processes behind cancer development and 
new targets for cancer chemotherapy. However, all of the hallmark traits highlight cellular 
processes in which the molecular pathology of a cancer cell differs from that of a normal cell. 
This raises the possibility that potential drug targets exist upon which cancer cells have 
become dependent for their tumourigenic phenotype. A further understanding of the 
molecular biology of the cell has helped to identify a wide range of cellular processes for 
which targeted therapies can be applied.  
To date, approximately 300 genes have been identified that are mutated in at least one 
cancer.
32
 Although this does not translate into over 300 druggable targets, protein and lipid 
kinases have emerged as some of the most suitable targets for the development of small 
molecule chemotherapeutic agents. This explosion of drug targets, many of which are present 
at elevated levels or in mutated forms in cancer, provides an opportunity to selectively disrupt 
processes vital to the survival of cancer, whilst limiting the cytotoxic effect on healthy tissue. 
The age of ‘targeted therapy’ has arrived, transforming the field into a multi-billion dollar 
industry, now led by pharmaceutical companies.
1
 
 
A prime example of the new found knowledge of cellular pharmacology generating novel 
targeted therapies is the discovery of imatinib (11), marketed as a mesylate salt under the 
name Glivec. The first specific genetic change associated with a human cancer was the 
translocation between chromosomes 9 and 22 in chronic myeloid leukaemia (CML). The 
result is the formation of a fusion gene due to translocation of the Abl1 gene on chromosome 
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9 to part of the breakpoint cluster region (BCR) on chromosome 22.
33
 The BCR-Abl fusion 
gene, also termed the Philadelphia chromosome, encodes the Bcr-Abl protein, a receptor 
tyrosine kinase with elevated activity, upregulation of which was shown to induce leukaemia 
in mice. The Bcr-Abl protein was therefore identified as a highly attractive target for the 
development of inhibitors,
34
 especially due to the absence of the Bcr-Abl kinase in normal 
tissue.  
Drug discovery efforts identified the kinase inhibitor imatinib, which gained Food and Drug 
Administration (FDA) approval in the United States in 2001, and has been shown to cause 
remission in approximately 90% of patients with the chronic-phase of CML.
35
 Further studies 
ascertained that imatinib was also an inhibitor of c-Kit, a tyrosine kinase strongly linked to 
gastrointestinal stromal tumours (GIST). Imatinib has gone on to be highly successful in the 
treatment of both chronic-stage CML and GIST, acting as ‘proof of concept’ for the 
development of targeted kinase inhibitors.
34
 
However, despite the success of imatinib, issues identified during the development of single 
agent cytotoxic therapies persist. In acute-stage CML, imatinib was shown to cause brief 
remission, although this was often followed by the emergence of drug-resistance. Under the 
evolutionary pressure of treatment with a chemotherapeutic agent, the genetic diversity 
within a tumour and the inherent mutability of the cancer cells, may give rise to an outgrowth 
of drug-resistant cells.
1
 This can result from mutation or upregulation of the target protein, 
modifications to the pathways involved in triggering cell death, or removal of the drug from 
the cell by means such as the multi-drug resistance (MDR) transporter.
36
 This may limit the 
effectiveness of some targeted therapies when administered as single agents. Fortunately, 
clinical trials have shown potential synergy between targeted molecules and traditional 
chemotherapy,
37, 38
 potentially reducing the risk of resistance. 
Furthermore, it has become apparent that specific groups within a larger patient population 
may exhibit particular sensitivity or resistance to a targeted therapy based on key genetic 
variations within a cancer type.
39, 40
 It is likely that as more targeted therapies are used, 
molecular or genomic markers of drug sensitivity will be developed to aid clinicians in the 
selection of patient populations most likely to benefit from the drug regimen.  
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1.2. The Eukaryotic Cell Cycle 
The phenotypic characteristics of unregulated cell growth and proliferation are present in all 
cancer types. It is therefore not surprising that a vast amount of research has investigated the 
misregulation of the cell cycle as a key factor in driving tumourigenesis. In basic terms, the 
role of the cell cycle is to accurately replicate the genetic information of a cell and precisely 
separate the resultant copies into two identical daughter cells. This cycle is divided into 4 
discrete biochemically defined phases. These are the presynthetic gap/growth phase G1, the 
DNA synthesis phase S, the premitotic gap/growth phase G2, and the mitotic phase M, with 
an additional quiescent G0 phase (Figure 2).
41, 42
 
 
Figure 2: The main cell cycle phases and associated protein kinases.
43
 
The cell cycle in rapidly dividing human cells lasts approximately 24 hours. The majority of 
this time is occupied by interphase (G1, S, and G2), with mitosis (M) taking less than 1 hour.
41
 
Cells in G1 must initiate the synthesis of proteins and organelles necessary to facilitate 
chromosomal duplication. During this time the external and internal environment of the cell 
is monitored to ensure that conditions are suitable for the cell to progress to the S phase. For 
this reason the length of G1 may vary, with cells remaining at early G1 or entering a 
prolonged period of inactivity, the quiescent or G0 phase, if the criteria to pass such 
checkpoints are not met. If checkpoint requirements are satisfied and growth signals are 
present, the cell passes a restriction point, after which it is committed to entering S phase.
41
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S-phase occurs at the midpoint of interphase and last for approximately 6 hours, a significant 
proportion of the cell cycle. The chromosomes of eukaryotic cells are large and dynamic 
structures consisting of DNA and protein packaging. During S phase the chromosomal 
structure must be dismantled and the DNA quickly and accurately replicated, minimising 
mutations passed to subsequent cellular generations. Upon completion, the DNA is rewound 
and the protein packaging must be reformed. The replicated chromosomes now exist as pairs 
of identical sister chromatids, joined together at multiple points along their length by cohesin, 
and remain so until the onset of mitosis.
41, 42
 
During G2 phase the cell again undergoes protein synthesis and checkpoint control in 
preparation for mitosis (see chapter 2). Entry into and progression through all stages of 
interphase is tightly controlled by a variety of cell cycle kinases (Figure 2).
43
 Significant 
research has been dedicated to an understanding of the roles of cell cycle kinases and their 
potential in cancer. 
1.3. Protein Kinases and Regulation of the Cell Cycle 
Protein kinases catalyse the transfer of the γ-phosphate of ATP to the hydroxyl group of a 
serine, threonine or tyrosine amino acid residue of their substrate (Figure 3). Phosphorylation 
can cause significant changes to the kinase substrate, such as enzyme activation, enzyme 
inhibition, alterations to protein conformation affecting recognition properties, or the creation 
of surfaces with novel binding characteristics. Such changes can trigger a host of downstream 
cellular events and responses, and in turn, this signal may be removed through 
dephosphorylation by protein phosphatases.
44
 The finely balanced nature of the equilibrium 
between protein phosphorylation/dephosphorylation, means that misregulation or mutation of 
a protein kinase or phosphatase may have detrimental consequences for a cell. 
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Figure 3: Protein kinase- and phosphatase-mediated phosphorylation/dephosphorylation of amino acid residues. 
Kinases are involved in a multitude of cellular processes, such as apoptosis, cell growth and 
proliferation, metabolism, differentiation, migration, and secretion of proteins including 
growth factors.
45
 However, despite almost 80% of targeted kinase therapeutics residing 
within the field of oncology, kinases are implicated in a variety of other disease types, such as 
inflammatory, immunological, metabolic, neurological and infectious diseases.
46
 Of the 
human kinases involved in the progression of a cell through interphase, there are two main 
families; the cyclin-dependent kinases (Cdks) and the checkpoint kinases (Chks). 
1.3.1. Cyclin-Dependent Kinases (Cdks) 
Accurate progression through the cell cycle is monitored through the use of checkpoints. 
These are activated in response to cellular defects such as DNA damage, as a means to allow 
the cell to repair such damage and prevent the transmission of irregularities to daughter cells. 
Alternatively, if the damage is too severe the cells may enter senescence or apoptosis. 
Checkpoint activation induces cell cycle arrest through effects on the activity of cyclin-
dependent kinases (Cdks).
47
 
The activity of Cdks relies on formation of an active heterodimer between the Cdk and a 
partner cyclin subunit. In normal cells the expression of specific cyclins is tightly controlled 
in order to maintain accurate regulation of the processes for which Cdks are responsible. 
However, in many human cancers mutations are present that contribute to misregulation of 
Cdk activity. These include overexpression of specific cyclins and inactivation of Cdk 
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inhibitors, such as members of the Inhibitor Kinase 4 (INK4) and Cip/Kip families.
48
 There 
are 12 members of the Cdk family identified thus far, although only five are directly 
implicated in cell cycle progression, namely Cdks 1, 2, 3, 4 and 6.
43
 
Cdk1, also known as cell division control protein 2 (Cdc2) in yeast, is the only Cdk regarded 
as a mitotic kinase, and is activated through binding cyclin A at the end of interphase to 
promote cellular entry into mitosis. Upon completion of nuclear envelope breakdown 
(NEBD), cyclin A is degraded and Cdk1-cyclin B complexes form, with the effect of driving 
the cell through mitosis.
47
 Cdk1 complexes with A- and B-type cyclins are implicated in a 
variety of roles, including centrosome duplication, chromosome condensation and assembly 
of the spindle.
43, 49
 These vital roles in mitosis are reflected in experimental outcomes of 
Cdk1 inhibition. Prior to mitosis, cells subjected to Cdk1 inhibition fail to progress through 
the G2/M transition, arresting in G2. If Cdk1 inhibition occurs during mitosis, cells exit 
mitosis without undergoing cytokinesis.
43
 Indeed, of the Cdk family it is only Cdk1 that is 
shown to cause cell cycle arrest upon systematic knockdown in healthy tissues, and there is 
no compensation for Cdk1 activity by other family members.
47
 For this reason it is likely that 
therapeutic modulation of Cdk1 activity may impose serious toxicity, limiting its usefulness 
as a drug target. 
The critical role of Cdk1 in cell cycle progression is similar to that in yeast, with a single Cdk 
responsible for cell cycle control. The reason for the presence of multiple Cdk members in 
eukaryotic cells is likely due to the need for mammalian systems to control a large number of 
distinct cell types. This is highlighted by the fact that systematic knockdown of Cdks 2, 4 and 
6 fails to cause cell cycle arrest in the majority of cells.
47
 However, detrimental effects are 
observed in distinct cell subtypes. Cdk2 activity is vital for meiotic division of germ cells,
50
 
Cdk4 is required for pancreatic β-cell proliferation,51 and Cdk6 knockdown causes erythroid 
cell lineage defects.
52
 
Despite the apparent lack of effect on cycle cycle arrest following depletion of Cdk2,
50, 53
 it is 
a key kinase in checkpoint control and homeostasis. Passage through the G1/S transition is 
reliant on the formation of a Cdk2-cyclin E complex. Subsequent formation of a Cdk2-cyclin 
A2 complex, which is present during the late stages of DNA replication, facilitates the S/G2 
transition.
54
 Further evidence links Cdk2, along with Cdk4, with a role in controlling the 
proliferative potential of stem and progenitor cells, as Cdk2 deficient progenitor cells are 
defective in their potential to self-renew and display increase differentiation.
55
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It has been shown that, unlike healthy tissue, a number of tumours have developed a reliance 
on Cdk2 activity for proliferation.
56
 Mutations in Cdk2 have not been found in such cells, but 
overexpression of E-type cyclins is a common trait of human tumours. Additionally, p21 and 
p27 inhibitors of Cdk2 are often downregulated, contributing further to misregulation of 
Cdk2 activity. This, coupled with the lack of effect of Cdk2 downregulation on normal cells, 
has highlighted Cdk2 as an attractive and highly investigated target for cancer drug 
discovery.
47
 
Cdk3 is inactive in laboratory mouse strains and has therefore been overlooked when 
compared to other members of the family. It is implicated with a role during interphase in 
complex with cyclin C.
47
 Cdks 4 and 6 are G1 kinases, playing a part in early cell cycle 
progression. The onset of mitogenic signals is triggered by expression of D-type cyclins, the 
regulatory partners of Cdks 4 and 6. Formation of the active complexes of these kinases 
results in inactivation of pocket proteins Rb, RbL1 and RbL2. This allows E-type cyclins to 
be expressed and enables eventual G1/S transition through activation of Cdk2-cyclin E.
57
 
Misregulation of Cdks 4 and 6 is common in many tumour types, particularly by effects on 
expression of D-type cyclins and INK4 family Cdk inhibitors.
47
 Cdk4 activity is further 
modulated through mutation to a form unable to bind INK4 inhibitors, as well as being 
overexpressed in a variety of epithelial malignancies. No Cdk6 mutation has been identified 
thus far but overexpression is often observed in leukaemias and sarcomas.
47
 This indicates 
that Cdk4 and Cdk6 appear to be upregulated in a variety of cancers, suggesting potential 
value for selective inhibitors. Of particular note is the observation that both Cdk4-deficient 
and cyclin D1-deficient mice are resistant to mammary tumour formation induced by the 
ERBB2 oncogene, responsible for the human EGFR2 (Her2) protein.
58
 This raises the 
possibility that Cdk4 inhibition may offer a therapeutic advantage in Her2-positive breast 
cancer patients. 
1.3.2. Checkpoint Kinases (Chks) 
Two structurally unrelated serine/threonine protein kinases have been identified that are 
major regulators of cell cycle checkpoints, checkpoint kinase 1 (Chk1) and checkpoint kinase 
2 (Chk2). Homozygous knockout of Chk1 results in non-viable mouse embryonic stem 
cells.
59
 However, in adult somatic cells a lack of Chk1 is non-lethal, although cells lack the 
G2 arrest of healthy cells upon exposure to ionizing radiation. This indicates a role of Chk1 in 
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the G2/M checkpoint. Chk2 shares several substrates with Chk1, including key cell cycle 
regulators Cdc25A, Cdc25B and Cdc25C. Chk2 has been shown to play a role in both S and 
G2 checkpoints in response to double strand breaks (DSBs) in several immortalized human 
cell lines.
60
 
It is thought that genotoxic stress activates ATM/ATR kinases, which phosphorylate and 
activate Chk1/Chk2. For genotoxic stress requiring S phase arrest, Chk1 and Chk2 target 
Cdc25A for ubiquitination and degradation, which suppresses Cdk2 activity, resulting in 
failure of the cell to exit S phase. In a similar manner, agents conferring G2/M arrest result in 
degradation of Cdc25A, but also sequestration of Cdc25B and Cdc25C. This results in a lack 
of Cdk1 activity and subsequent failure to satisfy the G2/M checkpoint.
60, 61
 
A major obstacle to many current DNA-damaging chemotherapeutic agents is the rapid 
emergence of resistant colonies. Contributing to this is the intricate machinery in the cell that 
detects DNA damage and arrests cells at different stages of the cell cycle. Due to abrogation 
of the p53-mediated checkpoint control apparatus in the majority of human tumours, it is 
likely that such cells are dependent on the checkpoint kinase pathways. Chk1 and Chk2, are 
therefore of potential interest for inhibition, as a means to confer selective chemosensitization 
to cancer cells over normal tissue on treatment with DNA-damaging therapies.
60
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Chapter 2: Mitosis and its Regulation by Kinases 
2.1. Stages of Eukaryotic Mitosis 
The M phase of the cell cycle is made up of two key events. The first event is mitosis, the 
process by which the sister chromatids generated during the S phase are separated and 
distributed into two identical daughter nuclei, each with a full copy of the parent genome. 
This is followed by cytokinesis, where the cell divides in two, giving a pair of cells with a full 
complement of genetic information with which to undergo a new round of the cell cycle. 
Alterations in the tightly controlled processes of mitosis can lead to cell death through mitotic 
catastrophe, or chromosome segregation errors, potentially resulting in unevenly distributed 
genetic material in daughter cells following cytokinesis. This phenotype is termed 
aneuploidy, and is a key characteristic of many cancers. 
 
Figure 4: The stages of eukaryotic mitosis.
62
  
The frequent occurrence of aneuploidy in cancer has generated considerable interest in the 
molecular biology of mitosis in both normal and cancer cells, to identify potential targets for 
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the development of cancer therapeutics. Mitosis is divided into five distinct stages; prophase, 
prometaphase, metaphase, anaphase and telophase (Figure 4).
62
 
During prophase, genetic information replicated during S phase condenses into well-defined 
sister chromatids. Outside of the nucleus the pair of centrosomes, or microtubule organising 
centres (MTOC), present at mitotic entry migrate to opposite poles of the cell and the mitotic 
spindle begins to form (see chapter 2.2.).
41
 
Prometaphase starts abruptly with the disappearance of the nucleus through nuclear envelope 
breakdown (NEBD). The nuclear envelope is composed of inner and outer nuclear 
membranes surrounding a protein layer called the lamina, punctuated by nuclear pores to 
allow transfer of components between the cytoplasm and nucleus. Phosphorylation of lamina 
components results in their disassembly and breakdown.
42
 The released sister chromatids are 
now free to attach to microtubule components of the spindle array, and undergo active 
movement facilitated by microtubule and kinesin motor proteins.
63
  
Cells reach metaphase when all chromosomes are oriented at the spindle equator and sister 
chromatids have formed kinetochore attachments to opposite poles of the mitotic spindle. 
Failure to form a proper attachment between a kinetochore and a microtubule results in the 
kinetochore sending a ‘wait-signal’ as part of the spindle assembly checkpoint (SAC – see 
chapter 2.2.1.). Correct attachment of all kinetochores culminates in checkpoint silencing and 
mitotic progression.
64
 
Transition into anaphase is triggered by activation of the anaphase promoting 
complex/cyclosome (APC/C), a multi-subunit E3 ubiquitin ligase, by the cell division cycle 
20 homologue (Cdc20).
65
 APC/C causes ubiquitination of key cell cycle regulators which 
targets them for destruction by the 26S proteasome.
66
 One such cell cycle regulator is the 
separase inhibitor securin, a protease that destroys the cohesin link between sister chromatids. 
Activation of APC/C results in a surge in separase activity and subsequent cleavage of the 
link between sister chromatids.
64
 This allows the chromatids to be drawn apart via spindle 
elongation, and as anaphase progresses a cleavage furrow forms as the plasma membrane 
begins to close in around the spindle midpoint.
41
 
During telophase the separated sister chromatids arrive at opposite spindle poles and 
decondense. The nuclear envelope reforms around each new genomic set, generating two new 
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nuclei and marking the end of mitosis. The M phase is completed when the contracting 
cleavage furrow divides the cytoplasm; yielding two identical interphase cells.
41
 
2.2. Centrosomes and the Mitotic Spindle 
Accurate chromatid attachment and separation is mediated by the mitotic spindle, a bipolar 
framework consisting of microtubules. Microtubules are made up of polymers of α- and β-
tubulin subunits, which form protofilaments. The tubule structure is a 25 nm diameter hollow 
tube, formed via the lateral association of 13 such protofilaments.
67
 Microtubules possess 
cytoplasmic ‘plus’ ends, which grow rapidly, in comparison to ‘minus’ ends, which grow 
relatively little. These minus ends are anchored at the centrosomes, which are the primary site 
of microtubule nucleation in most mammalian cells. In higher animal cells, the polarity of the 
spindle framework is usually directly related to the number of cellular centrosomes.
68
 
 
Figure 5: Structural elements of the centrosome.
68
 
Centrosomes were first observed in 1888 by Theodor Boveri, who identified small focal 
points of phase-dense material in the centre of cells.
69
 Centrosomes are made up of barrel-
shaped centrioles connected by an intercentriolar linker (see chapter 3.7.4.) and surrounded 
by pericentriolar material (PCM) (Figure 5). The centrioles are barrel-shaped configurations 
of nine microtubule triplets, giving nine-fold symmetry and lying perpendicularly to one 
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another. The two centrioles are distinguishable as maternal and daughter centrioles, with the 
maternal centriole possessing distal and subdistal appendages.
68
 
Microtubule nucleation occurs within the fibrillar mass of the PCM and is reliant on a further 
member of the tubulin family, γ-tubulin. The form of γ-tubulin that triggers microtubule 
nucleation is the γ-tubulin ring complex (γTuRC), in which γ-tubulin associates with γ-
complex proteins (GCPs) 1 and 2 with a ring shaped morphology.
70
 These γTuRCs are 
thought to cap the minus ends of microtubules and cause nucleation within the PCM.
71
 
However, it is thought that there is a distinction between microtubule nucleation and 
microtubule anchoring, with the latter being the process by which microtubules are attached 
to the centrosome during spindle formation. The subdistal appendages of the maternal 
centriole have been shown to act as further sites capable of capping the minus ends of 
microtubules, despite lacking the associated microtubule nucleating proteins. Instead, they 
associate with proteins ninein and centriolin.
68, 72, 73
 
Following nucleation and anchoring of microtubules, the mitotic spindle can be formed via 
continuous addition of α- and β-tubulin subunits from the plus end of the microtubule, 
accompanied by removal from the anchored minus end.
68
 The resultant highly dynamic 
spindle framework is maintained in position through the relatively static nature of the spindle 
poles. The centrosomes are typically in a ‘face-to-face’ configuration separated by 
overlapping pole-to-pole microtubules. Further sets of astral microtubules spread out from 
either centrosome to the cell cortex and kinetochore microtubules emanate and attach to the 
kinetochores, such that each sister chromatid in a pair is attached via its kinetochore to 
opposite poles of the mitotic spindle.
49
 Kinesin motor proteins are proteins capable of 
interacting with, and travelling along, the α- and β-tubulin protofilament tracks to aid in the 
trafficking of cellular components and signals.
63
 These proteins, along with inherent 
dynamics within the spindle framework, facilitate the mitotic spindle to carry out accurate 
mitotic segregation of the cell’s genome.  
2.2.1. The Spindle Assembly Checkpoint (SAC) 
As with other phases of the cell cycle, the division of sister chromatids is governed by a 
checkpoint; the spindle assembly checkpoint (SAC).
66
 The SAC detects the presence of 
unattached kinetochores or a lack of tension between sister centromeres in mitosis, and sends 
a ‘wait-anaphase’ signal, preventing cleavage of the cohesin link between centromeres. 
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Several proteins identified in budding yeast have vertebrate homologues that make up 
components of the SAC complex; Budding uninhibited by benomyl (Bub) proteins 1, 2 and 3, 
and mitotic arrest deficient (Mad) proteins 1, 2 and 3.
66
 In addition, higher eukaryotes also 
possess Bub-related-1 kinase (BubR1), centromere protein E (CENPE), the ZW10-ROD-
Zwilch complex, and mitogen-activated protein kinase (MAPK) as proteins associated with 
the SAC.
64
 
Unattached kinetochores transiently bind the mitotic checkpoint complex (MCC), comprising 
BubR1, Mad2, Bub3 and Cdc20. This holds Cdc20 within this stable complex, preventing 
activation of the APC/C and, ultimately, mitotic progression through ubiquitination of securin 
and chromatid separation.
74
 Furthermore, once activated, the APC/C triggers cyclin B1 
degradation and subsequent inactivation of Cdk1, driving mitotic exit.
64
  
In healthy cells the presence of a single unattached kinetochore is sufficient to trigger mitotic 
arrest. However, individual unattached kinetochores fail to produce a ‘wait signal’ strong 
enough to prevent mitotic progression in several tumour cell lines.
75, 76
 Modification to the 
expression levels of SAC components may lead to an inability to halt mitosis, although 
results for the misregulation of such protein levels in cancer cells through genetic analysis 
have been mixed. This highlights the probability that a weakened SAC response can act to 
facilitate cancer development, but not act as a causative effect of cancer. It has been found 
that complete inactivation of the SAC response can be lethal, rather than oncogenic, through 
mitotic crisis.
77
 However, incomplete inactivation of the checkpoint through sub-optimal 
inhibition will carry a serious risk of increasing CIN and driving tumourigenesis. 
2.3. The Centrosome Cycle 
Errors in the formation of a bipolar mitotic spindle can perpetuate aneuploidy and CIN 
through defects in chromosome segregation. The centrosome number in mitotic cells is 
therefore of vital importance. One exception to this requirement is observed with some plant 
cells, in which spindle formation and cell division can occur independently of the presence of 
centrosomes.
78
 However, in mammalian cells the lack of astral microtubules yields spindle 
frameworks that are mispositioned, resulting in aberrant cytokinesis.
68
 Upon completion of 
cytokinesis, each daughter cell possesses a single centrosome from opposite poles of the 
mitotic spindle. At the onset of mitosis a pair of centrosomes is required to form a bipolar 
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spindle framework. During the cell cycle, the cell replicates each progeny centrosome prior to 
the G2/M transition via the centrosome cycle (Figure 6). 
 
Figure 6: The centrosome cycle.
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The precise mechanism(s) triggering the onset of centrosome duplication is not fully 
understood.
79
 However, it is known that during healthy cell cycle transit the centrosome 
replicates only once. Importantly, this replication must be closely coordinated with DNA 
replication to ensure all necessary components are acquired by the cell prior to the key events 
of mitosis, preventing the risk of genomic instability (GIN). One potential source of such 
coordination is the Rb pathway; both cycles have been shown to require phosphorylation of 
Rb, and in particular the presence of the transcription factor E2F, the primary downstream 
effector of Rb. Due to this reliance on both cycles, it is likely that oncogenic mutation of the 
Rb pathway will lead to loss of cycle coordination and contribution to GIN. The same studies 
highlighted the key role of cyclin expression, in conjunction with Cdk2, in regulating both 
cycles. Cdk2-cyclin E appears to be the primary complex responsible for allowing G1/S 
 
The 
Centrosome 
Cycle 
M
< 
G1
< 
S
< 
G2
< 
Centriole 
disorientation 
Centriole 
duplication Centriole 
elongation 
Centriole 
maturation 
Centriole 
separation 
36 
 
transition and triggering DNA synthesis, whereas Cdk2-cyclin A was the favoured complex 
for inducing centrosome duplication.
80
 
The centrosome cycle commences during G1 as the maternal and daughter centrioles lose 
their orthogonal relationship. At the start of S phase the centrioles begin to duplicate, with the 
appearance of procentrioles growing perpendicularly from the proximal ends of both mother 
and daughter centrioles. By the completion of the S phase the procentrioles have reached 
maturation, matching the length of their parental centrioles, and the centrosome now has the 
configuration of two centriolar pairs connected by the flexible intercentriolar linkage. At a 
variable time prior to the G2/M transition, centrosomal disjunction occurs, and the PCM 
divides to form separate mother and daughter centrosomes. The centrosome cycle is 
completed with maturation of the daughter centrosomes upon acquisition of distal and 
subdistal appendages.
79, 81
 
2.4. Regulatory Kinases in Mitosis 
A number of non-targeted antitumour agents exert their cytotoxic activity in mitotic cells. 
Such compounds often act as spindle poisons, due to a locus of their toxic effect in mitotic 
spindle formation and dynamics (see Vincristine, Taxol, chapter 1.1.1.).
82
 Vinca alkaloids, 
such as vincristine and vinblastine, are cytotoxic through their effect on the ability of a cell 
undergoing mitosis to form a mitotic spindle. Vinca alkaloids bind to tubulin dimers and 
inhibit their ability to polymerise into the larger tubulin networks required for spindle 
formation.
83
 Taxol, on the other hand, binds to and stabilizes polymerised tubulin, and 
consequently interferes with the ability of the spindle framework to manipulate and traffic 
cellular components during mitosis.
84
 The effects of both classes of antitumour agents on the 
dynamics of the mitotic spindle result in apoptosis due to mitotic catastrophe. Such spindle 
poisons have provided some success as clinical treatments, despite a lack of selectivity for 
tumour cells over healthy tissue. As the chemotherapeutic effort has moved towards targeted 
therapy, driven by a deeper understanding of mitosis on a biomolecular level, several key 
kinases involved in mitosis have attracted attention.
43
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2.4.1. Aurora Kinases 
Aurora kinases were first identified during a screen to establish genetic mutations in yeast 
that correlate with an increase-in-ploidy phenotype. This identified the yeast protein termed 
Ilp1.
85
 Three vertebrate homologues were discovered that shared high sequence homology 
within the carboxy-terminal catalytic domain, but varied in their functions, all of which were 
mitotic. They were termed Aurora kinases A, B and C, owing to the observation that Ilp1 was 
associated to the cellular poles, analogous to the Aurora borealis and Aurora australis 
phenomena at the polar regions of our planet.
86
 Within the same screen a further pole-
associated kinase was identified and termed Polo-like kinase (Plk) – after the Spanish word 
for pole (see chapter 2.4.2.).
87
 
Aurora A activity is dependent upon phosphorylation of a key regulatory threonine residue 
(T288) on the kinase “activation loop”. Negative regulation of kinase activity is achieved 
through dephosphorylation by protein phosphatase 1 (PP1). Expression levels of Aurora A 
are tightly controlled, and the kinase is targeted for degradation by the APC/C during late 
M/early G1, through a C-terminal D-box (destruction box) and a D-box-activating-domain 
(DAD).
88, 89
 
Aurora A kinase localises in a dynamic equilibrium with separating centrosomes during late 
S/early G2 phases. Late in M phase, elevated Aurora A levels are reported at the spindle 
midzone and midbody.
87
 Depletion of Aurora A in a variety of systems has suggested a role 
for the kinase in centrosome separation.
90, 91
 With decreased levels of Aurora A, cells lack the 
ability to recruit necessary PCM components, including γ-tubulin.91, 92 In addition, the 
centrosome’s astral array of microtubules is disrupted, potentially due to alterations in the 
activity of transforming-acidic-coiled-coil containing protein 3 (TACC3), a regulator of 
microtubule dynamics, and the motor protein Eg5, both of which are substrates of Aurora 
A.
90, 93
 This implicates Aurora A with a role in centrosome maturation. 
A role for Aurora A has also been described in spindle assembly in association with the small 
GTPase Ran-GTP, and its associated protein TPX2.
94
 TPX2 activates Aurora A by binding to 
the kinase and countering the negative regulation of PP1. This complex subsequently 
associates to and orientates the spindle microtubules during mitosis.
95
 
Aurora B kinase is a chromosomal passenger protein, forming a complex with the proteins 
inner centromere protein (INCENP) and survivin. INCENP is both a substrate for and a 
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positive regulator of Aurora B, and is a microtubule associated protein (MAP) that targets 
chromosomes and centromeres.
87, 96
 Aurora B localises to centromeres in metaphase cells and 
associates tightly with central spindle microtubules during anaphase.
97
  
Aurora B is implicated with a role in ensuring bipolar kinetochore attachments supplementary 
to the SAC. Although the exact mechanism is poorly understood, it is proposed that Aurora B 
recognises the attachment of kinetochores to the same spindle (syntelic attachment) as a 
function of the reduced centromeric tension with regards to kinetochores attached to opposite 
centrosomes (amphitelic attachment).
87, 98
 
A further function has emerged for Aurora B as a regulator of chromosome bioorientation.
99
 
Prior to chromosomal segregation, microtubule dynamics orient the sister chromatids at the 
cellular equator. This bioorientation has been shown to be dependent on inner centromere 
KinI stimulator (ICIS) and mitotic centromere-associated kinesin (MCAK). ICIS is a 
substrate of Aurora B, and thus Aurora B has a direct impact on the microtubule-disassembly 
activity of MCAK.
85, 99
 
The role of the final family member, Aurora C, is poorly understood. However, it is thought 
that the kinase plays a role in mitosis, where it is associated to the centrosome. There is also 
evidence for Aurora C acting during spermatogenesis.
85, 100
  
Aurora A and B kinases are overexpressed in a range of tumours, and are associated with a 
poor prognosis. Overexpression of Aurora A may result in loss of coordination between the 
centrosome cycle and cell cycle, leading to centrosomal amplification and subsequent CIN. 
Interestingly, it has been shown that phenotypic abnormalities that are associated with loss of 
Aurora A regulation are found to be amplified in cells lacking p53.
101
 The common nature of 
this oncogenic modification, coupled with Aurora A overexpression, may result in a 
synergistic acceleration of CIN and aneuploidy. Aurora B has also been shown to be 
overexpressed in tumours, resulting in defects in mitosis and aneuploid progeny.
102
 These 
observations have led to Aurora A and B being thoroughly investigated kinases in the field of 
anticancer drug discovery. 
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2.4.2. Polo-like Kinases (Plks) 
Polo-like kinases (Plks) are a family of serine/threonine protein kinases of which there are 
four known members, Plk1, 2, 3 and 4. The Plk members have suggested roles in the 
mediation of a variety of mitotic events. They share high sequence homology across the 
family, with all kinases bearing a canonical N-terminal kinase domain and conserved C-
terminus polo-box domains (PBDs). Plks are activated through phosphorylation of residues 
within the activation loop (T-loop) of the catalytic domain.
103, 104
 
Regulation of activity is also mediated by the PBDs. These regions act as phosphopeptide-
binding domains, recognising and binding to proteins already phosphorylated by a ‘primer’ 
kinase.
105
 In the absence of a phosphorylated ligand, the PBD is thought to bind to the kinase 
catalytic domain, inhibiting substrate binding and preventing kinase activation through T-
loop phosphorylation. This reliance on substrate phosphorylation to allow kinase activation 
may aid in the temporal and spatial control of Plk activity.
103, 106
 
Of the Plk family, current understanding of the roles of Plk2, 3 and 4 is relatively poor. Plk1 
is thought to participate in several events during mitosis. Importantly, Plk1 is implicated in 
the recruitment of key centrosome components, including γ-TuRCs, through the Plk1 
substrate ninein-like-protein (Nlp).
107
 A further centrosomal protein with a potential Plk1-
mediated action in centrosome maturation is Asp-like microcephaly associated (ASPM), of 
which the Drosophila homologue Asp is phosphorylated by Polo and is needed for 
microtubule nucleation.
108
 However, a role for ASPM in mitosis has yet to be identified, with 
only activity in neurogenesis being described thus far.
103
 
In addition to the spindle poles, Plk1 also associates with kinetochores during mitosis, 
highlighting possible activity in chromosome segregation.
109
 It is thought that Plks may 
phosphorylate cohesin subunits, aiding the dissociation of sister chromatids.
110
 Further effects 
of Plk activity appear to be APC/C dependent, presenting Plk activity as a regulator of many 
mitotic processes, including mitotic entry and cytokinesis, as a consequence of APC/C 
substrate degradation.
111, 112
 
Of the other Plk family members, the function of Plk2, also called Snk, is not fully known. 
Although viable, Plk2-/- mice show retardation of growth and skeletal development.
113
 Plk3, 
also known as Fnk, has been implicated in G1/S transition via the induction of cyclin E 
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expression.
104
 Finally, Plk4 is a key component for the regulation of centriole replication in 
both Drosophila and humans.
114
 
  
41 
 
Chapter 3: NIMA-Related Kinases (Neks) 
A final key family of kinases involved in mitotic regulation are the never in mitosis gene A-
related kinases (Neks). In 1976 the genetic analysis of cell cycle mutants in the filamentous 
fungi Aspergillus nidulans was reported.
115
 During these studies, screening temperature-
sensitive mutant genes, the effect of genetic disruption was noted as either causing the fungal 
cells to be blocked in mitosis (bim) or never in mitosis (nim). Members of the bim subset 
were later found to be genes encoding for key proteins involved in mitotic progression, 
including components of the APC/C. Amongst several recognised cell cycle regulators, the 
nim subset also contained 4 alleles of an unknown gene, termed nimA. The protein encoded 
by the nimA gene is a 79 kDa serine/threonine protein kinase designated NIMA.
116
  
Interestingly, NIMA-null mutants were shown to possess an irregular nuclear envelope and 
lack a bipolar mitotic spindle, when expressed in conjunction with knockdown of bimE7, 
which was later found to encode an APC/C subunit.
117
 Induction of NIMA was shown to 
cause mitotic irregularities, including errors in spindle formation, and chromosome 
condensation was possible in cells blocked at S phase,
118
 related to the fact that 
overexpression of NIMA has the potential to induce mitosis in cells at any stage of the cell 
cycle.
118
 
3.1. NIMA in Aspergillus nidulans 
NIMA expression and activity are tightly controlled in a cell cycle-dependent manner through 
transcriptional means and post-translational modification (Figure 7). Prior to mitosis, NIMA 
expression and activity levels are low. At the G2/M transition, NIMA expression levels begin 
to rise in conjunction with its degree of phosphorylation. The expression and phosphorylation 
state of NIMA are mirrored by the activity of the cyclin B complex with Cdc2, the human 
counterpart (Cdk1) which is the so called ‘master regulator’ of mitotic entry.116 
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Figure 7: Dual regulation of NIMA and Cdc2 during mitosis in Aspergillus nidulans.
116
 
During G2, the Cdc2-cyclin B complex is maintained in an inactive state through inhibitory 
phosphorylation of a key tyrosine residue (Y15) on Cdc2 by the kinase Wee1. At the G2/M 
transition, Cdc25-mediated dephosphorylation of Y15 results in activation of Cdc2-cyclin B, 
with corresponding expression and phosphorylation of NIMA. Further Cdc2-mediated 
phosphorylation of NIMA occurs during mitosis, possibly by Cdc2 itself, until cells approach 
anaphase. At this point, the activity of Cdc2-cyclin B is lost though APC/C dependent 
ubiquitination of B type cyclins, and this coincides with degradation of NIMA via an 
unidentified ubiquitin ligase.
116
 Furthermore, destruction of NIMA has been shown to be 
required for mitotic exit.
119
 This tightly controlled expression and activity clearly indicates a 
role for NIMA during mitosis.  
3.2. Members of the Human Nek Family 
The critical role of NIMA in mitotic progression raised the possibility that NIMA 
counterparts may possess similar functions in higher vertebrates. Homologues of NIMA exist 
in other species, including the functionally related kinase in budding yeast, termed fin1, 
which is involved in spindle formation.
120
 Designation of human kinases that are related to 
NIMA has focussed on sequence homology within the catalytic domain. A family of 11 
NIMA-related kinases (Neks) has been identified to date (Figure 8), with varying degrees of 
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homology to NIMA. Several family members have a higher degree of similarity in their C-
terminal motifs than others, and can be classed as true NIMA homologues. Other members, 
however, have either lost such motifs or gained additional sequences, possibly relating to 
additional roles outside of mitosis.
116
 
 
Figure 8: Significant motifs and structural alignments of the 11 human members of the NIMA-related kinase 
family.
121
 
Outside of the catalytic domain, which is at the N-terminus in all members excluding Nek10, 
the homology of the family is variable.
121
 Neks 4, 6 and 7 contain no coiled-coil motif, a 
region conferring the structural characteristic of multiple coiled α-helices. Just over 50% of 
the Neks contain PEST sequences, motifs that participate in ubiquitin-dependent proteolysis. 
Furthermore, additional motifs are observed in selected members, such as regulator of 
chromosome condensation (RCC1) motifs in Nek8 and 9, which may be responsible for an 
interaction with the Ran GTPase.
121
 Nek5 bears a predicted DEAD-box (Asp-Glu-Ala-Asp), 
a motif that is conserved in a family of DEAD-box RNA helicases.
122
 Nek10 also contains a 
small region of armadillo repeats, motifs responsible for hairpin pairs of short α-helices, and 
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yielding α-solenoid protein folds.123 The majority of Nek family members contain a tyrosine-
down autoinhibitory motif within the catalytic domain, which projects a tyrosine residue into 
the active site maintaining the kinase in an inactive conformation. This motif was first 
observed in the X-ray crystal structure of Nek7, with autoinhibition being removed by 
phosphorylation of the kinase activation loop (T-loop).
121
 
The currently established roles of Nek members are not limited to the cell cycle and mitosis, 
with Nek1 and Nek8 in particular having been found to play important roles in ciliogenesis. 
Cilia are microtubule-based organelles that are organised by maternal centrioles during 
interphase prior to pre-mitotic disassembly. Motile cilia, such as those found in the trachea, 
act to move extracellular fluid and particulates. However, primary cilia are ubiquitous in the 
body and are responsible for detection and coordination of extracellular events with 
intracellular responses. Importantly, primary cilia mutations are responsible for a variety of 
genetic disorders, including retinal degradation and polycystic kidney disease (PKD).
121, 124
 
Nek1 and Nek 8 mutations are seen to result in PKD in mouse models,
125
 and mutations of 
Nek1 have been shown to be causal in a wide range of further ciliopathies,
126
 indicating a 
vital role for wild-type (WT) Nek1 in healthy ciliogenesis. Nek8 has been shown to associate 
with primary cilia, and mutations in Nek8 result in loss of cilia localization and increases in 
cilia length, affecting their function.
127
 The importance of Nek1 and Nek8 in cilia formation 
raises the point that inhibitors designed for other Nek members must exhibit high selectivity 
over Nek1 and Nek8, so as to avoid ciliopathy related toxicity. 
The functions of Nek3, 4 and 5 are poorly understood, with no characterisation of Nek5 being 
available at this time. However, a putative role for both Nek3 and Nek4 in microtubule 
dynamics has been suggested, with knockdown of either kinase resulting in spindle formation 
errors.
121
 Neks 6, 7 and 9 have more clearly understood roles in the control of spindle 
formation and suggested roles in cytokinesis. Nek6 and 7 are structurally very similar, 
sharing 87% homology within their catalytic domains,
121
 of which they are almost completely 
comprised. Depletion or inactivation of either kinase results in similar phenotypes of weak 
spindle formation and delays in SAC deactivation, suggesting very similar cellular 
functions.
128
 Nek6 and 7 operate downstream of Nek9, the knockdown of which results in 
related spindle defects and errors in chromosome alignment.
121
 More recently it has been 
suggested that Nek9 is phosphorylated during mitosis by both Cdk1 and Plk1, resulting in 
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Nek6/7-mediated phosphorylation of the Eg5 motor protein, activating Eg5 for centrosome 
disjunction.
129
 
The functions of Nek10 and Nek11 remain poorly understood. However, recent studies have 
suggested that the kinases are involved in cell cycle checkpoint control.
121
 The involvement 
of Nek10 in the process is less well understood, but depletion of Nek10 results in cells that 
are defective in their ability to arrest at G2/M in response to UV genotoxic stress.
130
 This is 
reported to be through a loss of Nek10 interaction with, and activation of, Raf1 and MEK1, 
members of the Erk signalling pathway with indications in checkpoint control.
131
 Nek11 has 
been shown to be a substrate of Chk1, and activation of Nek11 prompts phosphorylation of 
Cdc25A within the conserved DSG-motif, a region that promotes ubiquitin-mediated 
proteolysis. In relation to this, inactivation of Nek11 prevents Cdc25A degradation, and 
results in cells lacking the ability to arrest at G2/M in response to IR irradiation.
132
 
3.3. NIMA-Related Kinase 2 (Nek2) 
3.3.1. Nek2 Structure and Regulation 
Nek2 is the most closely related human Nek to NimA, sharing 44% homology in the amino 
acid sequence of the catalytic domain. Nek2A is a 445 amino acid (48 kDa) serine/threonine 
protein kinase bearing the conserved N-terminal kinase domain, and a C-terminal non-
catalytic regulatory domain with 2 coiled-coil regions akin to NIMA.
133
 Nek2 is expressed as 
two splice variants, Nek2A and Nek2B (Figure 9), with Nek2B diverging in sequence from 
the 8 exon encoded Nek2A at intron 7 shortly after the splice site. Nek2B is therefore a 
shorter 44 kDa protein, and lacks the second coiled-coil region present in Nek2A, with the 
initial leucine zipper coiled-coil conserved (see below). Furthermore, Nek2B lacks important 
motifs responsible for activity (PP1 binding site), ubiquitin proteolysis (KEN-box) and 
mitotic entry (D-box), indicating that Nek2B has a role distinct from Nek2A.
133
 Indeed, 
Nek2A is the abundant form in adult cells, whereas Nek2B is detected at higher levels during 
meiotic spermatogenesis and in meiotically active oocytes.
134
 This observation correlates 
with the lack of a KEN destruction box in Nek2B, as maintaining levels of a stable form of 
Nek2 may facilitate the rapid embryogenic cell cycles. Due to the primary role of Nek2A in 
mature cells and cancer, further discussions regarding function and regulation will refer to 
Nek2A unless stated otherwise. 
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Figure 9: Schematic representation of the Nek2 splice variants Nek2A and Nek2B.
133
 
The crystal structure of the mutant kinase domain (T175A) of Nek2A has been solved (Figure 
10), giving insights into regulatory motifs and residues within the kinase sequence.
135
 Several 
conserved motifs may be responsible for conformational changes of kinases upon activation. 
The DFG and HRD motifs both contain catalytically vital aspartic acid residues. The 
activation loop, which lies at the C-terminus of the DFG motif, acts to organise other motifs 
and aid in binding of the substrate. The conserved glutamic acid residue present in the C-
helix forms a crucial salt bridge with a conserved leucine residue in the ATP binding site.
135
  
Autophosphorylation can act as a key regulator of kinase activity on exogenous substrates. 
The non-catalytic domain of Nek2 has two predicted coiled-coil regions, one of which is at 
the end of the C-terminus, whilst the other is immediately downstream from the kinase 
domain. This initial coiled-coil contains six heptad-spaced leucine residues, which indicate 
the presence of a leucine zipper motif, and this promotes homodimerization between two 
Nek2 proteins allowing trans-autophosphorylation. This may be needed to generate the active 
conformer of Nek2 via disruption of the inhibitory αT helix, formed from the DFG motif and 
five following residues, in the activation or T-loop. This αT helix is well conserved in Nek 
family members, but is less common in other kinase families. However, more recently 
additional crystal structures of Nek2 bound to various inhibitors have been solved, showing 
that this region is able to adopt several different conformations, depending on the ligand 
occupying the ATP-binding site.
135
 In addition to the required phosphorylation of the Thr-175 
residue, autophosphorylation of activation/T-loop residues Thr-170 and/or Ser-171 has been 
shown to be necessary for kinase activity, and may act to fine-tune the overall activity of 
Nek2.
136
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Figure 10: A) X-ray crystal structure of the Nek2A-T175A catalytic domain in complex with SU11652 showing 
the N-terminal lobe (blue), C-terminal lobe (red), hinge region (yellow) and inhibitor (green); B) 
interactions of SU11652 with the kinase hinge region showing the inhibitory αT-helix.136 
Autophosphorylation has also been shown to play a possible role in inhibitory regulation of 
Nek2 activity. The T-loop residue Thr-179 acts as an anchor point for the C-terminus of the 
T-loop, stabilizing the conformation of key residues involved in phosphoryl transfer. 
Phosphomimetic mutation of this residue resulted in a marked decrease in kinase catalytic 
activity.
136
 This result is matched by mutation of the C-terminal domain residue Ser-241, 
located within the αH-helix. This residue is remote from the kinase active-site, but a 
mechanism for inhibitory autophosphorylation has been proposed to be due to effects on the 
homodimerization of Nek2. In EGFR kinase domains, the αH helix of one monomer stacks 
against the αC helix of its partner, disrupting the inhibitory αT helix and allowing the kinase 
to adopt an active conformation. Due to the importance of the phosphorylation state of the 
Ser-241 residue within the region, it is likely that a similar system exists in Nek2 
dimerization, and that pSer-241 inhibits this interaction, although further studies are required 
to validate this hypothesis.
136
 Further regulation of Nek2 activity is related to the binding of 
specific substrates and interactions with associated proteins. 
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3.3.2. Nek2 is a Cell Cycle Regulated Centrosome Associated Protein 
The cell cycle-dependent expression of Nek2 strongly indicates a role in mitotic entry. Cell-
synchronization studies have determined that Nek2 expression levels are extremely low at G1, 
with a steady rise in expression observed through S and G2.
133
 Nek2 protein levels reach a 
maximum at the G2/M transition, before rapid D-box targeted degradation mediated by the 
APC/C results in near undetectable levels during mitosis.
137
 This expression is slightly 
different from that of NIMA, which maintains expression and activity levels through to the 
onset of G1, suggesting that the key event that is mediated by Nek2 occurs prior to or very 
early in mitosis. Evidence suggests that Nek2 mRNA is repressed in G1 rather than stimulated 
in S and G2.
133
 
 
Figure 11: Immunofluorescence microscopy of U2OS cells showing Nek2 localisation to the centrosomes; A) 
Staining for anti-Nek2; B) Staining for anti-α-tubulin.138 
The use of anti-Nek2 antibodies has allowed the cellular localisation of Nek2 to be 
determined. Immunofluorescence microscopy (IFM), staining for Nek2 with fluorescent 
secondary antibodies, shows Nek2 to be localised in the cell at two neighbouring points, 
indicative of centrioles. Co-staining the same cells with α-tubulin allows visualisation of the 
spindle framework, and the Nek2 spots were observed at the centre of the interphase 
microtubule array (Figure 11; A).
138
 To confirm this result, purified human centrosomes were 
isolated from a variety of cells at different stages of the cell cycle. In all cases the 
centrosomes were shown to be strongly associated with Nek2 by staining with the anti-Nek2 
antibody.
138
 These observations confirm Nek2 to be a bona fide centrosomal protein. Initial 
attempts to establish the precise centrosomal location of Nek2 using immunoelectron 
microscopy (IEM) have shown that Nek2 appears to associate with the proximal ends of the 
centrioles.
139
 
A B 
49 
 
Despite this, the kinase is not exclusively located at the centrosome, with up to 90% of the 
cellular pool occupying the wider cellular space. It is possible for passive diffusion to be 
responsible for the association of centrosomal proteins to their site of action. However, 
endogenous levels of the kinase are of low abundance, and it is likely that active transport 
mechanisms are involved in its recruitment. The cellular pool of Nek2 is present in small 
cytoplasmic granules, which have been shown to traverse the cytoplasm in rapid linear 
trajectories, determined to be due to even distribution of the granules along the lengths of 
microtubules. A 36 amino acid region (335-370) in the C-terminal domain of the kinase has 
been shown to be essential for the binding of Nek2 to both microtubules and the 
centrosome.
140
 
The active transport of Nek2 along microtubules and subsequent recruitment to the 
centrosome has been shown to be dependent on the protein pericentriolar material 1 
(PCM1).
140
 Similar to Nek2, PCM1 is present in cytoplasmic granules, termed centriolar 
satellites. PCM1 is known to move towards the centrosome along microtubules via the motor 
protein dynein, mediated by dynactin, the protein that anchors the cellular cargo.
141
 However, 
the precise role of PCM1 in the transport of Nek2 to centrosomes is unclear, as the rate of 
Nek2 recruitment is distinct from the rate of recruitment of other proteins mediated by 
PCM1. Interestingly, it seems that localised degradation of Nek2 at the centrosome is 
required to maintain the cellular dynamics and ensure the recruitment of new Nek2.
140
  
3.3.3. Substrates and Regulators of Nek2 
In vitro studies were initially carried out to identify substrates of Nek2, with strong 
phosphorylation being observed in the case of β-casein, myelin basic protein (MBP), and 
microtubule associated protein 2 (Map2); moderate phosphorylation of histone H1 and 
phosphovitin was also encountered.
142
 However, as it has been determined that Nek2 
associates to the centrosomes, identification of centrosomal substrates of Nek2 has aided in 
the elucidation of a putative role for the kinase in mitosis. 
Apart from Nek2 itself, the first physiological substrate of Nek2 was identified as a high 
molecular weight protein with a predicated molecular mass of 281 kD, which interacted with 
Nek2 when used as ‘bait’ in a yeast two-hybrid screen. Nek2 was found to phosphorylate the 
C-terminal domain of the protein of interest both in vitro and in vivo. The protein was 
subsequently found not only to associate with Nek2, but also to localize at the centrosome, 
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and as such it was termed centrosomal Nek2-associated protein 1 (C-Nap1).
139
 C-Nap1 was 
shown to be a core component of the centrosome, which was specifically found at the 
proximal ends of both the maternal and daughter centrioles (Figure 12).
143
 Interestingly, this 
centriolar localisation of C-Nap1 is markedly reduced in mitotic cells, suggesting that C-
Nap1 is associated with centrosomes in a cell cycle-dependent manner.
139
 
 
Figure 12: IEM using two antibodies for C-Nap1 (N-Ab and M-Ab, dark spots) at the proximal ends of 
centrioles (single arrow) and procentrioles (double arrow) in U2OS cells.
143
  
The activity of many protein kinases, and hence their cellular effects, is often regulated by 
dephosphorylation by protein phosphatases. Protein phosphatase 1 (PP1) is a key member of 
this family that acts to dephosphorylate serine and threonine residues on a diverse range of 
substrates.
144
 The presence of a predicted PP1-binding motif in Nek2A raised the possibility 
that Nek2A is a substrate for PP1. This was confirmed with the identification of Nek2-PP1 
complexes both in cell-free and cell extracts.
145
 Nek2 has so far been shown to interact with 
two isoforms of PP1, namely PP1α and PP1γ. Interestingly, PP1α has been shown to 
associate to centrosomes during mitosis.
146
 
In this complex, PP1 is able to dephosphorylate Nek2 and reverse the effects of Nek2 
activity. At higher levels of activity, Nek2 is likely to partially inhibit PP1 through 
phosphorylation, allowing subsequent phosphorylation of Nek2 substrates. As Nek2 activity 
subsides and inhibition of PP1 is lost, rapid dephosphorylation of Nek2 would essentially 
abolish kinase activity on exogenous substrates.
145, 147
 This suggests the existence of a 
dynamic molecular switch for Nek2, allowing kinase activity to be triggered in a highly 
transient and cell cycle-dependent manner. Importantly, C-Nap1 is known to be a substrate 
for both Nek2 and the Nek2-PP1 complex, and the three proteins can form a ternary complex 
in vitro.
145
 This observation strongly suggests that PP1 acts to regulate the activity of Nek2 
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on C-Nap1, either by controlling the activity of Nek2 directly, or via dephosphorylation of C-
Nap1. 
 
Figure 13: A) IFM of U2OS cells showing staining for centrosomes (red), rootletin (green) and DNA (blue); B) 
IEM of U2OS cells showing localisation of rootletin (dark spots) to centriole proximal ends and 
formation of filaments.
148
 
Rootletin is a 228 kD protein that forms thin fibers protruding from the proximal ends of 
centrioles (Figure 13). Rootletin has been shown to associate with, and be phosphorylated by, 
Nek2. Association with C-Nap1 is also observed in vitro and in vivo, and the interaction 
between rootletin and C-Nap1 is dependent on the C-terminal domain of C-Nap1. In addition, 
association of rootletin with the proximal ends of the centrioles is through the N-terminal 
domain of the protein.
148
 Further insight into the relationship between C-Nap1 and rootletin 
was gained following the observation that localisation of C-Nap1 to the centrioles was not 
affected by rootletin siRNA, whereas the use of C-Nap1 siRNA clearly disrupted the ability 
of rootletin to associate with centriole ends.
148
 
β-Catenin is a well characterised protein with a variety of roles identified outside of the 
centrosome. However, more recently β-catenin has been identified as being centrosome 
associated by the use of IFM and immunoprecipitation techniques.
149
 Furthermore, β-catenin 
was found to be a binding partner and substrate for Nek2 in vitro and in vivo, and to associate 
with both C-Nap1 and rootletin at the centrosome. In particular, the protein was found to be 
in complex with rootletin in the region between the centrioles. In relation to this, a similar 
result was observed upon depletion of C-Nap1, resulting in initial disorganisation of β-
catenin at the centrioles, followed by a complete loss of centriolar association upon 
abrogation of C-Nap1. In the absence of rootletin, C-Nap1 association with the centrosomes 
is lost. This, together with studies on the organisation of the other centrosomal proteins, 
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supports a model in which C-Nap1 acts as an anchoring point for rootletin, which in turn 
recruits β-catenin to the proximal ends of centrioles.149 
The Hippo pathway is a signal transduction cascade with a variety of cellular roles, most 
notably the control of organ size.
150
 It was found that several Hippo pathway components 
localised to centrosomes, although little was known of their function at this site. 
Subsequently, Hippo components human Salvador 1 (hSav1) and mammalian sterile 20-like 
kinases 1 and 2 (Mst1 and Mst2) were found to interact with both Nek2 and C-Nap1.
151
 Nek2 
was shown to be phosphorylated by Mst2 within a hSav1-Mst1/Mst2 complex, with this 
phosphorylation facilitating recruitment of Nek2 to the centrosomes at the G2/M transition.
151
 
It is possible that this mechanism is working in conjunction with PCM-1-mediated transport 
of Nek2. 
A further centrosomal protein found to be involved in this system is the Plk1 binding partner 
Nlp, a substrate of Plk1 (see chapter 2.4.2.) that is associated to interphase centrosomes. 
However, Nlp is barely detectable at mitotic centrosomes,
107
 indicating that an event occurs 
at the G2/M transition resulting in protein displacement. As previously described, prior 
substrate phosphorylation is often required for recognition of Plk1 targets through the PBD. 
This led researchers to investigate kinases that are active at the G2/M transition, and the 
observation that Nlp is a substrate of Nek2 raised the possibility that Nek2 may act as a 
priming kinase for Plk1.
152
 Nlp associates to mother centrioles and is proposed to act as an 
anchoring site for γ-TuRCs and microtubules. Upon phosphorylation by Nek2 and Plk1 at 
mitotic entry, Nlp is lost from centrosomes. The precise role of Nlp in mitotic progression is 
poorly understood, but cells expressing Nlp that lacks N-terminal phosphorylation sites lead 
to severe defects in mitotic spindle formation.
107
 It is possible that phosphorylation of Nlp 
results in loss of astral microtubules, allowing centrosome dynamics within the cell, an event 
necessary for bipolar spindle formation.
152
 
Highly expressed in cancer 1 (Hec1) is a kinetochore outer layer component involved in the 
regulation of the spindle assembly checkpoint. Hec1 undergoes interactions with kinetochore 
components such as Nuf2, Spc25 and Zwint-1, as well as the mitotic kinases Aurora B and 
Nek2, identified though a yeast two-hybrid screen.
153, 154
 Hec1 mediates the correct formation 
of the spindle lattice between the kinetochores and centrosomes, and is thus responsible for 
the proper formation of kinetochore bipolar spindle attachments and subsequent symmetrical 
chromosome separation during mitosis. Although the regulation of Hec1 is not fully 
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understood, it appears that Nek2 binds and phosphorylates Hec1 in a cell cycle-dependent 
manner, and may be responsible for modulation of Hec1 activity
155
 and hence correct 
kinetochore attachment to the mitotic spindle. Small molecule antagonists of the Nek2-Hec1 
interaction have been developed, and are found to induce changes in cellular morphology 
indicative of cells undergoing apoptosis due to mitotic catastrophe (see chapter 4.3.).
156
 
3.3.4. Role of Nek2 in Centrosome Separation 
An understanding of Nek2 substrate specificity, combined with experimental misregulation 
of Nek2 and these binding partners, has allowed a putative role for Nek2 in mitotic entry to 
be detailed. During early studies into the action of Nek2, it was shown that upregulation of 
WT-Nek2 through transfection resulted in a significant increase in interphase cells exhibiting 
centrosomes seperated by several microns, accompanied by cells found to be lacking 
centrosomes altogether.
138
 This strongly indicated that Nek2 may be involved in centrosome 
separation, a process which has yet to be fully characterised and understood. In support of 
this, overexpression of Nek2 results in dissociation of centrosomal proteins including 
rootletin.
148
 
Use of a kinase dead (KD) inactive mutant of Nek2 (K37R) in transfection experiments 
prevented the centrosome split phenotype, although a loss of centrosomes was still apparent, 
indicating that these events originate from separate mechanistic events.
138
 Interestingly, 
centrosomes in cells after tetracycline-induced expression of Nek2-KD (see chapter 7) were 
classed as unsplit, despite being separated on average by 2.1 µm. The corresponding 
centrosomes in cells treated with inhibitors of the Eg5 motor protein had an intercentriolar 
distance of less than 2 µm, suggesting the possibility that, following Nek2-KD expression, 
motor proteins were attempting to separate centrosomes that were still physically 
connected.
157
 Knockdown of Nek2 using siRNA in early mouse embryos, resulted in the 
majority of embryos reaching the blastocyst stage with a high prevalence of abnormal spindle 
structures and M phase arrest.
121, 158
 
Supporting evidence for a role of Nek2 and associated proteins in centrosome separation is 
found upon misregulation of Nek2 substrates. Downregulation of C-Nap1 or Rootletin 
generated cells with a split centrosome phenotype. Disruption of C-Nap1 is also associated 
with disorganised Rootletin and β-catenin structures at centrosomes.148, 159 However, this is 
not the case for the other centrosome-associated proteins Cep170, centrin-2, BBS4, PCM-1 or 
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ninein, suggesting that the induced centrosome splitting is not as a result of general loss of 
centrosome proteins, and is specific to C-Nap1 and Rootletin. As would be anticipated, 
inhibition of PP1 in several cell lines also induced centrosome splitting, accompanied by loss 
of the centrosomal association of Rootletin.
148
 
In contrast to other centrosome-associated proteins, β-catenin acts as a negative regulator of 
centrosome cohesion. Depletion of β-catenin using siRNA techniques has been shown to 
generate cells with monopolar spindles consisting of replicated but unseparated 
centrosomes.
160
 In addition, cells expressing stabilised β-catenin, with a low turnover rate, 
showed increased intercentrosome distance, similar to the effect observed upon upregulating 
Nek2. Unlike C-Nap1 and Rootletin, β-catenin remains associated with centrosomes during 
mitosis.
149
 
  
Figure 14: Proposed model for Nek2-mediated centrosome separation at mitotic entry.
161
 
The aforementioned evidence allows a model to be proposed that provides potential structural 
insights into the intercentriolar linker, and the role that Nek2 plays in linker cleavage and 
ultimately centrosome separation (Figure 14). During interphase the activity of Nek2 is 
suppressed by PP1 through dephosphorylation of Nek2, and Nek2 substrates C-Nap1 and 
Rootletin. This highly sensitive molecular switch allows for precise temporal control of 
formation of the active Nek2 homodimer and phosphorylation of downstream targets. Spatial 
control of Nek2 activity is further controlled through association with Hippo pathway 
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components, triggering centrosome association at mitotic onset. At the G2/M transition 
phosphatase inhibitor 2 (Inh2) is activated, possibly due to activation of Cdk1, the ‘master 
regulator’ of mitosis. Activation of Inh2 has been shown to trigger immediate inhibition of 
PP1 and, ultimately, conformational inactivation.
162
 Release from PP1 suppression results in 
a surge of Nek2 activity and subsequent substrate phosphorylation.
161
 This system is 
analogous to the Cdc2-mediated activation of NIMA in Aspergillus nidulans. 
Since it was first proposed, owing to the correlated movements of sister centrioles, the exact 
composition of the intercentriolar linker is yet to be fully elucidated.
163
 Localisation and 
downregulation studies provide strong evidence to suggest that C-Nap1 attaches to the 
proximal ends of centrioles to act as an anchor for further linker components, consisting of 
Rootletin, β-catenin and possible additional proteins yet to be identified. The observed 
flexibility and variability in the distance between parental centrioles, makes the existence of a 
continuous protein linker unlikely. Instead, it has been proposed that the linker is in fact made 
up of an entanglement of fibers involving Rootletin and β-catenin anchored to C-Nap1, 
allowing for a highly dynamic linker.
148
 
Upon activation of Nek2, phosphorylation of linker components occurs, triggering a loss of 
centrosomal cohesion. Phosphorylation of rootletin and C-Nap1 may result in conformational 
changes or repulsion through surface charge effects. Alternatively, phosphorylation may 
target intercentriolar components for degradation. A model for the negative regulation of 
centrosome cohesion by β-catenin has been proposed, in which as yet unidentified rootletin-
independent β-catenin binding sites exist on centrosomes, which are required for 
separation.
149
 Prior to G2/M a pool of β-catenin is reserved at the centrosome but prevented 
from binding to such sites through interaction with Rootletin. However, upon cleavage of the 
intercentriolar linker, β-catenin is released and can bind to these sites, facilitating centrosome 
disjunction.
149
 
Following cleavage of the intercentriolar linker, centrosome duplication is complete and 
motor proteins are able to mediate migration of centrosomes to opposite poles of the cell to 
form a bipolar mitotic spindle and ensure accurate division of chromosomes during anaphase. 
3.3.5. Nek2 as a Cancer Therapeutic Target 
Owing to the prevalence of centrosomal abnormalities in the majority of tumour cells, loss of 
regulation of the tightly controlled machinery dictating centrosome duplication has been 
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implicated as a major contributor to tumourigenesis. Aberrant centrosome function is also 
strongly associated with CIN and aneuploidy, two major hallmarks of cancer. 
Nek2 was first implicated in cancer following the observation that the gene encoding Nek2 
was upregulated in Ewing’s osteosarcoma and diffuse large B-cell lymphoma (DLBCL), 
using a tumour-derived cell line screen for mRNA abundance.
164, 165
 Later work identified 
elevated Nek2 protein expression in cancer cell lines, with an approximate 2-5 fold increase 
in Nek2 levels detected in a variety of cell types originating from breast, cervical and prostate 
carcinomas, as well as various lymphomas.
166
 Loss of the transcriptional inhibitors p107 and 
p130 has been proposed as a potential mechanism of amplified gene expression for genes 
activated by the transcription factor E2F4, such as Nek2.
167
 
Nek2 overexpression has been shown to result in multinucleated cells and cells bearing extra-
chromosomal material; two potential indicators of aneuploidy. Such cells were found to 
contain extra centrosomes, likely due to aborted mitosis or failed cytokinesis.
166
 Such 
observations clearly show the potential of elevated Nek2 expression in the development of 
CIN.  
 
Figure 15: Increased cell death in HuCCT1 cholangiocarcinoma cells upon treatment with Nek2 siRNA, 
compared to control siRNA.
168
 
As a means to validate the disruption of Nek2 activity as a potential chemotherapeutic 
approach, depletion of Nek2 levels was attempted. Using siRNA in cholangiocarcinoma cell 
lines, it has been shown that Nek2 siRNA results in growth suppression and cell death in 
vitro (Figure 15), as well as increased survival in mouse models.
168
 
As described previously, Nek2 activation is controlled via a highly sensitive molecular 
switch. It is likely that misregulation of components within this system, including Nek2, may 
lead to gross errors in centrosome separation, bipolar spindle formation and chromosome 
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segregation, all factors that could drive mitotic errors and hence tumourigenesis. 
Upregulation of Nek2 in a variety of tumour types implies that such cancer cells may 
potentially have become dependent on the Nek2-mediated pathway for centrosome 
separation, possibly as a means to propagate CIN. From an understanding of the role of Nek2 
in mitosis, it can be predicted that upregulation of Nek2 may disrupt the finely balanced 
control system that regulates kinase activity. Deregulation of this control mechanism may 
result in a loss of cell cycle synchronicity with the centrosome cycle, and premature entry 
into mitosis. This would propagate abnormal spindle formation and hence chromosome 
segregation errors. These are all factors that can promote CIN and aneuploidy, driving further 
errors in progeny cells and facilitating tumourigenesis. 
Kinases are important mediators of many cellular processes and signalling events.
46
 The 
development of our understanding of kinase function and biology has introduced an emerging 
class of biological targets for the treatment of a variety of diseases.
169
 Through the clinical 
success of early inhibitors, targeting kinases has been confirmed as a viable approach for the 
treatment of disease where kinase activity is misregulated. As such, selective inhibition of 
Nek2 is an attractive prospect for the validation of this kinase as a chemotherapeutic target, 
with the potential to develop antitumour agents targeting a Nek2 dependent phenotype. 
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Chapter 4: Kinases as Targets in the Treatment of Cancer 
Upon selection of a suitable kinase target within a disease area of interest, it is important to 
identify hit compounds, usually simple inhibitors with modest activity against the kinase. To 
develop the initial hit compounds into more potent and more drug-like lead molecules, it is 
highly desirable to have insights into the structure of the target, usually through acquisition of 
a protein crystal structure. Not only can this inform medicinal chemists as to the potential 
effects of inhibitor modification within the binding site, it can also provide information as to 
the mechanism of kinase inhibition. 
4.1. Reversible Kinase Inhibitors 
4.1.1. Classes of Reversible Kinase Inhibitor 
The most common class of kinase inhibitors act in a reversible manner, forming a stable 
equilibrium between a non-bound pool of compound and compound bound to the target 
enzyme via non-covalent interactions. In particular, compounds that compete for binding 
with the natural ligand within the active-site are termed competitive reversible inhibitors. In 
kinases this is usually through competition with ATP within the ATP-binding domain. The 
majority of kinases possess a bi-lobal catalytic structure with a cleft located between the N- 
and C-terminal domains. This is termed the hinge region, and is the location of ATP binding 
through hydrogen bonding with the adenine ring and hinge amino acid residues.
45
 Despite the 
conserved nature of the ATP-binding domain, sufficient structural variation is present within 
the catalytic site and surrounding hydrophobic regions to allow selective inhibition, although 
selectivity between close family members can be more challenging to achieve.
170
 
As mentioned previously, access to the ATP-binding site can be hindered due to the 
activation loop residing within an inactive conformation. Most inhibitors are designed to 
mimic ATP, and are identified by the use of enzyme inhibition assays in which the kinase is 
pre-activated. Consequently, the majority of competitive reversible inhibitors bind to the 
active conformation of the target kinase.
45
 Such compounds are termed type I inhibitors, and 
generally comprise a heterocyclic core that makes hinge region H-bond interactions. This acts 
as a central template from which side-chains can be attached to make additional interactions 
within the kinase ATP-binding domain, to improve inhibitor potency and confer kinase 
selectivity.
45, 46
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Several early kinase inhibitors, including imatinib (see chapter 1.1.2.), were found to bind to 
and stabilise the inactive, or ‘DFG-out’, conformation of their target kinases. These 
compounds are termed type II inhibitors, and their binding exposes an allosteric hydrophobic 
pocket adjacent to the ATP-binding site through the positioning of the activation loop. 
Inhibitor interactions with this hydrophobic pocket often result in tight binding kinetics and 
potent target inhibition.
45
 
A third class of reversible kinase inhibitors bind outside of the ATP-binding site at an 
allosteric site. Allosteric inhibitors mediate their inhibitory activity through induction of 
conformational changes in the kinase, reducing the ability of the protein substrate or ATP to 
interact with the kinase.
5
 Allosteric inhibitors generally have an improved selectivity profile 
when compared to ATP-competitive inhibitors, because the likelihood of kinase allosteric 
binding sites sharing structural homology is very limited.
45
 In addition, the high ATP 
concentration in cells can restrict cellular activity to only the most potent ATP-competitive 
inhibitors. The absence of competition with a cellular substrate can improve the cellular 
profile of allosteric inhibitors. 
4.1.2. Examples of Known Reversible Kinase Inhibitors in Cancer Therapy 
 
As the focus of medicinal chemistry has been brought to bear on kinases, an increasing 
number of kinase inhibitors are progressing to clinical trials and reaching the market. 
Examples of type I kinase inhibitors licenced for clinical use include gefitinib (12) and 
sunitinib (13). Gefitinib, marketed as Iressa, was the first example of a selective inhibitor of 
the EFGR tyrosine kinase,
171
 and was approved in 2003 for use in non-small-cell lung 
carcinoma (NSCLC).
172
 Sunitinib (Sutent) is a type I inhibitor of multiple receptor tyrosine 
kinases,
173
 and gained approval for the treatment of renal cell carcinoma (RCC) and imatinib-
resistant GIST in 2006.
172
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In addition to imatinib, further type II inhibitors including sorafenib (14) and nilotinib (15) 
have been licensed. Sorafenib (Nexavar) is an inhibitor of multiple receptor tyrosine kinases 
including platelet-derived growth factor receptor (PDGFR) and VEGFR, as well as members 
of the Raf kinase family.
174
 Approved in 2005, sorafenib is used to treat both hepatocellular 
and renal cell carcinoma.
172
 Nilotinib (Tasigna) is also a multi-targeted kinase inhibitor, with 
targets including BCR-Abl and c-Kit.
175
 The drug was approved in 2007 for the treatment of 
chronic myeloid leukaemia.
172
 
 
The most well characterised allosteric kinase inhibitor is CI-1040 (16), an inhibitor of MEK1 
and MEK2 that is currently in clinical trials.
176
 This compound binds to a unique allosteric 
pocket adjacent to the ATP-binding site, locking the kinase into a closed catalytically-
inactive conformation.
177
 Another example of an allosteric inhibitor in early development is 
GNF-2 (17). This compound, and others in its class, interact with BCR-Abl through a 
myristate-binding site, indirectly inhibiting kinase activity.
178
 
4.2. Irreversible Kinase Inhibitors (Inactivators) 
An alternative type of kinase inhibitors act through covalent modification of the target. Such 
irreversible inhibitors can be categorised as affinity labelling, or mechanism-based (Figure 
16). Affinity labelling inhibitors compete initially with the substrate to form an enzyme-
inhibitor complex (E.I), followed by covalent reaction with an amino acid residue. The 
formation and dissociation of the E.I complex (Ki = koff/kon) is usually rapid when compared 
to covalent bond formation (kinact), and as such this is the rate determining step.
5
 The 
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incubation time between the drug and target enzyme is important, as the degree to which an 
enzyme is covalently inactivated is a function of time. When calculating IC50 values for 
irreversible inhibitors it is essential that the incubation time is kept constant. Furthermore, if 
the incubation time is too long, the enzyme will be saturated with inhibitor, and IC50 values 
will reflect total inhibition. Mechanism-based, or suicide, enzyme inactivators are unreactive 
species bearing a similarity to the natural substrate. Upon formation of the E.I complex, the 
normal catalytic activity of the enzyme converts the inhibitor into a reactive species (I’), 
which can either dissociate from the enzyme or react to form a covalent adduct.
5
 Affinity 
labelling compounds are most common in irreversible kinase inhibitor design, and further 
discussion will centre on this inhibitor class. 
 
Figure 16: Enzyme inhibition kinetics for affinity labels (A) and  mechanism-based enzyme inactivators (B).
5
 
It is interesting to note that providing that formation of the E.I complex is rapid, if the 
reactive warhead and nucleophilic residue are positioned close to their ideal Bürgi-Dunitz 
angle,
179
 the covalent bond formation essentially becomes unimolecular. The entropic 
advantage that this endows may result in a reaction rate many orders of magnitude faster than 
non-specific bimolecular reactions in solution.
5
 Once the covalent adduct is formed, these 
inhibitors are no longer in equilibrium between unbound drug and enzyme-inhibitor complex, 
and the duration of action is thus a direct function of the stability of the chemical bond or the 
turnover of the target protein. Turnover times may vary from several hours to days, and a 
circulating concentration of drug need not be maintained during this time. This has the 
potential to widen the therapeutic window of the drug and ultimately improves patient 
outlook.  
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4.2.1. Design Considerations for Irreversible Inhibitors 
In order to generate a covalent species it is necessary to design a compound with a reactive 
‘warhead’ functional group that is presented to a nucleophilic amino acid residue within the 
kinase. This approach brings with it problems of selectivity and toxicity, as reaction with 
collateral targets and/or general nucleophilic species (e.g. glutathione, DNA) within the body 
may be a primary source of adverse side-effects. Clearly, within the field of cancer therapy 
the tolerance for side effects is greater than for many clinical indications. However, as the 
focus moves towards targeted therapy with improved toxicity profiles, indiscriminant 
electrophilic compounds do not meet the desired requirements. One drug characteristic that 
may improve the therapeutic window is a rapid clearance rate, a factor that designers of 
reversible inhibitors normally endeavour to lower.
180
 The development of any irreversible 
inhibitor should be influenced both by the reversible binding affinity (structure-activity 
relationships, SARs) and the warhead reactivity (structure-reactivity relationships, SRRs).
180
 
If SRRs alone direct inhibitor design, the likelihood of poor selectivity and the inevitable 
toxicity issues are greatly enhanced. 
A wide range of reactive functional groups have been used to intercept nucleophilic amino 
acids (see below), including epoxides, sulfonyl halides, halomethylketones, and ring systems 
that are subject to nucleophilic ring opening. However, the most common class are Michael 
acceptors. To date, the majority of irreversible inhibitors react with lysine or cysteine 
residues within the ATP-binding domain of their kinase targets. No accounts of reactions 
with other potential residues such as serine or threonine have been reported.
180
 Due to its 
highly conserved nature, and key role in phosphate transfer the lysine residue is not an ideal 
target for selective irreversible inhibitors. Lysine residues positioned in unique locations 
within the active site may be suitable targets for covalent adduct formation, but this has been 
relatively poorly investigated.
180
 
By far the most interest has been directed towards covalent modifiers of cysteine residues. A 
bioinformatics analysis-based approach has been used to identify all kinases that possess 
cysteine residues amenable to covalent modification.
45, 181
 Approximately 200 kinases were 
found to contain a cysteine residue that could potentially be targeted by an ATP-binding site 
inhibitor. Analysis of the locations of the cysteine residues has allowed the kinases to be sub-
divided into distinct classes (Figure 17).
45, 180
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Figure 17: Schematic representation of cysteine locations in different classes of kinases.
45
 
Kinases in group 1 contain a cysteine residue within the glycine rich loop (dark blue), 
whereas group 2 kinases bear a cysteine in the 3 residues immediately following the glycine 
rich loop (pink). The cysteine in group 3 kinases is present within the amino acid residues 
constituting the hinge region (yellow). Kinases containing a cysteine residue at a single 
position adjacent to the DFG-motif, and the start of the activation loop (blue) are classed as 
group 4.
45
 More recently, a further 2 groups have been identified; group 5 kinases contain a 
cysteine on the flexible activation loop (dotted blue); a further class of miscellaneous 
cysteines are present in an allosteric pocket that are accessible by type II compounds binding 
to the DFG-out kinase conformation.
180
 Interestingly, Nek2 belongs to the 2B group of 
cysteine-containing kinases. 
4.2.2. Examples of Known Irreversible Kinase Inhibitors in Cancer Therapy 
Although relatively little focus has been attributed to inhibitors that covalently modify lysine 
residues, examples of such compounds do exist (reactive moieties shown in red).
180
 As 
described above, due to the highly conserved nature of the key binding site lysine residue 
throughout the kinome, such compounds are rarely selective. The ATP analogue 5’-
fluorosulfonylbenzoyl adenosine (FBSA, 18) is a multi-kinase affinity label used as a 
chemical probe rather than as a therapeutic agent. FBSA irreversibly inhibits kinases by 
v
 
v
 
v
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formation of a sulfonamide upon reaction with a binding site lysine.
180
 A class of 
pyrrolecarboxaldehydes (e.g. 19) have been identified as inhibitors of type 1 insulin-like 
growth factor receptor (IGF-1R) kinase. These inhibitors are examples where the chemical 
lifetime of the covalent bond formed dictates the nature of the inhibition, as they are found to 
be covalent reversible inhibitors through imine formation between the aldehyde and Lys1003 
of IGF-1R kinase. This interaction was identified through chemical reduction of the imine, 
allowing isolation of the inhibitor-kinase complex and analysis by X-ray crystallography.
182
 
The final example is one in which a slightly unorthodox electrophile has been utilised. 
Lys802 of phosphoinositide 3-kinase (PI3K) covalently reacts with wortmannin (20) via 
nucleophilic attack and subsequent ring opening of the activated furan ring.
183
 
 
By contrast, a large number of irreversible kinase inhibitors are known to react with kinase 
cysteine residues. Described herein are examples for each class of cysteine-containing 
kinases detailed previously, with variation in the electrophile used, although this does not 
reflect the overall abundance or chemical class of inhibitors for each group. Modification of 
established reversible inhibitors led to the indentification of FIIN-1 (21) as a potent 
irreversible inhibitor of members of the fibroblast growth factor receptor (FGFR) family of 
group 1 cysteine-containing kinases.
184
 Nucleophilic attack of the appropriate residue on the 
Michael acceptor acrylamide group gives rise to the covalent adduct. 
The presence of a conserved cysteine residue in the glycine rich loop of members of the p90 
ribosomal protein S6 kinase (Rsk) family identified these as members of the group 2 cysteine 
containing kinases.
181
 Structural biology studies with adenine analogues revealed the 
opportunity to trap the cysteine residue with electrophilic groups at the purine 8-position. The 
fluoromethyl ketone 22 was accordingly found to be a potent and selective irreversible 
inhibitor of Rsk1 and Rsk2.
181
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Detailed investigations have been carried out with the group 3 cysteine kinases, in particular 
kinases with a cysteine at 3F (Figure 17, cyan). Members of this group include the ErbB 
(EGFR) family, which has been validated as a target for cancer chemotherapy by the clinical 
utility of reversible inhibitors such as gefitinib (12). Inhibitor design for ErbB members is 
dominated by quinoline/quinazoline structures, and extensive modification of related 
compound side-chains has been undertaken in an attempt to capture the 3F cysteine residue. 
One such compound is the epoxide 23, a potent irreversible inhibitor of EGFR.
185
 
 
Despite the restriction of group 4 cysteine-containing kinases to a single amino acid position, 
almost 10% of the kinome possesses this highly conserved residue.
180
 Resorcyclic acid 
lactones such as hypothemicin (24) are known to irreversibly inactivate group 4 kinases 
through the cis-enone functionality. As would be expected with such a highly conserved 
amino acid, selectivity across the group 4 members is an issue.
186
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The kinase Akt1 contains two cysteine residues within the activation loop and is thus a 
member of the recently described group 5 cysteine-containing kinases.
187
 
Pyranonaphthoquinone analogues, such as frenolicin B (25) have been reported to act as 
irreversible inhibitors of Akt1 through the quinone moiety.
187
 Finally, modification of 
existing type II inhibitors, including imatinib, has allowed the generation of irreversible 
inhibitors of kinases containing cysteine residues within the allosteric binding pocket (e.g. 26, 
against cKit/PDGFR).
188
 
 
It is possible to combine some of the advantages of irreversible kinase inhibition, namely an 
extended duration of action and a good selectivity profile, whilst minimising the 
disadvantages of potential off-target reactivity. It has been reported recently that chemical 
modification of acrylate and acrylamide Michael acceptors can result in covalent, but rapidly 
reversible reactions with cysteine residues in target kinases.
189
 The use of doubly activated 
Michael acceptors appears to result in rapid exchange between thiol addition and elimination. 
Substituting acrylate and acrylamide analogues of the Rsk inhibitor 22 with a cyano group at 
the α-position (27 and 28) results in sustained, but reversible inhibition of Rsk2. Through this 
approach it may be possible to maintain tight-binding kinetics with the target kinase, whilst 
reducing the formation of covalent adducts of non-target cysteine containing proteins, such as 
glutathione. 
4.3. Inhibitors of Nek2 Kinase 
The first compounds to be described that interfered with a biological process involving Nek2 
were inhibitors of the Hec1/Nek2 interaction. The work of Qui et al.
156
 described the 
identification of hit compounds based upon an N-(4-phenylthiazol-2-yl)carboxamide core 
structure (29).  
67 
 
 
Following chemical modification of the initial hit compounds a series of inhibitors was 
prepared that exhibited effects upon cells similar to that of Hec1/Nek2 antagonism (siRNA or 
antibody). Thus, cells treated with these compounds exhibited mitotic abnormalities, an 
increased population of cells with multipolar spindle networks, and an increase in 
chromosomal misalignment. Furthermore, cells displayed changes in morphology 
characteristic of apoptosis due to mitotic catastrophe. Although mechanistic studies identified 
the molecular target of the inhibitors as Hec1 rather than Nek2, the growth-inhibitory activity 
of the compounds in cellular assays highlighted the potential benefit of disruption of Nek2 
function in suppressing tumour cell proliferation.
156, 190
 
More recently, several examples of small molecule inhibitors of Nek2 have been disclosed. A 
class of aminopyrazine-based inhibitors were the result of research at the Institute of Cancer 
Research (ICR).
191
 SAR studies culminated in the identification of the aminopyrazine 30 as a 
potent ATP-competitive inhibitor of Nek2 (IC50 = 0.23 µM). Interestingly, compounds of this 
class were found to bind to an unusual inactive conformation of Nek2 in which Tyr70 is 
directed down into the binding site, owing to the presence of a pocket formed by the Met86 
‘gatekeeper’ residue and an active site Leu89. Furthermore, structural biology studies 
identified a Phe148 residue within the ATP-binding site that exerted a strong influence on the 
active site and ligands that it can accommodate. A phenylalanine at this position is very rare 
among kinases, with only Wee1, Plk1 and Braf sharing this homology. These restraints 
within the ATP-binding site raise the possibility that Nek2 is a challenging target for ATP-
competitive inhibitor design. This notwithstanding, compounds within this class displayed 
good selectivity over Plk1, although selectivity over Nek1 was not achieved.
191
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A parallel class of compounds was identified during a selectivity screen of a series of Plk1 
inhibitors. SARs for this benzimidazole-based series eventually removed the original Plk1 
inhibitory activity, generating a potent compound with >200-fold selectivity for Nek2 over 
Plk1 (31). Crystallographic studies showed that these compounds were type II, binding to the 
inactive DFG-out conformation of Nek2 and inhibiting both autophosphorylation and 
substrate phosphorylation. However, such inhibitors suffered from a modest ligand efficiency 
(LE), attributed to inefficient binding of the core scaffold.
192
 
In order to resolve this problem, a hybrid class of compounds combining the core 
aminopyrazine moiety of the initial series with the side-chain characteristics of the 
benzimidazole series was generated. Optimisation of this new class of inhibitors improved 
potency, LE and kinase selectivity against a panel of cell cycle kinases, and culminated in the 
identification of 32 (Nek2; IC50 = 0.022 µM). The Z-configuration of the alkene, as well as 
the R-stereocentre, were found to be necessary for optimum positioning of the trifluoromethyl 
group into a pocket formed by the glycine rich loop of Nek2.
193
 
A series of ATP-competitive reversible Nek2 inhibitors was also identified via high-
throughput screening (HTS). These viridin/wortmannin-like compounds (e.g. 33) exhibited 
modest Nek2-inhibitory activity, with reasonable selectivity over other Nek family members. 
In addition, some activity was observed in cellular growth inhibition and centrosome splitting 
assays.
194
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Finally, a group of compounds based upon the common oxindole core have been 
identified.
195
 Analysis of the crystal structure of Nek2 in complex with these sunitinib-like 
analogues, including SU11652 (Figure 10)
136
, revealed that the 5-position of the indole was 
positioned within a suitable distance of Cys22 (a group 2B cysteine) such that electrophilic 
groups might intercept the residue. This was achieved with the addition of a propiolamide 
moiety at this position. Modification of the initial compounds afforded the irreversible 
inhibitor 34, which exhibited sub-micromolar activity and good selectivity over Cdk1 and 
other mitotic kinases.
195
 However, the selectivity results for 34 from a kinase screen 
(National Centre for Protein Kinase Profiling, Dundee University) revealed that the 
compound exhibited poor selectivity for Nek2 (see appendix, Table A2). 
4.4. Identification of Substituted Purines as Inhibitors of Nek2 
 
Figure 18: Elaboration of initial purine hit compounds to ATP-competitive inhibitors with improved Nek2 
potency and selectivity. 
In conjunction with the identification of aminopyrazine and benzimidazole inhibitors, 
collaborators at the ICR conducted a medium-throughput screen to identify other 
pharmacophores capable of inhibiting Nek2. The purine scaffold was highlighted as a modest 
inhibitor of the kinase worthy of further investigation. To validate this result, a range of 
purine derivatives from Newcastle University were submitted for screening against Nek2. 
Purines bearing 6-alkoxy substituents (e.g. 35) were found to inhibit Nek2 in the micromolar 
range. However, such compounds were developed as part of a Cdk2 inhibitor project, and 
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were also potent Cdk2 inhibitors. Modifications around the purine scaffold were carried out 
to improve the potency against Nek2, and to design out structural motifs that confer potency 
against Cdk2. This enabled the elucidation of initial SARs for ATP-competitive Nek2 
inhibition (Figure 18). 
The 2-arylamino group of the purine was found to be amenable to modification, and in 
particular meta- or para-substituted side-chains containing basic functionalities conferred 
potency against Nek2 (e.g. 39). X-ray crystallographic studies of Nek2 in complex with 
compounds of the 6-alkoxypurine series have revealed the binding mode of purines within 
the ATP-binding domain (Figure 19). The results of these studies have guided the design of 
further purine-based inhibitors of Nek2. 
 
Figure 19: X-ray crystal structure of Nek2 in complex with 6-alkoxypurine inhibitor 41. 
The X-ray crystal structure of 41 in complex with Nek2 revealed that the compound binds via 
a classical hydrogen bonding triplet between the purine N
9
-H, N
3
 and C
2
-NH, and the kinase 
hinge region residues Cys89 and Glu87. This dictates that alkylation or removal of the 
participating purine nitrogen atoms will be detrimental to activity. Furthermore, the 6-alkoxy 
substituent was adjudged to be non-critical for binding affinity, in contrast to Cdk2 inhibition 
where the 6-cyclohexylmethyl group occupies the ribose-binding pocket and is responsible 
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for binding affinity. Gratifyingly, removal of the 6-substituent (e.g. 40) was found to 
essentially abolish Cdk2 activity, although activity against Nek2 was also reduced. 
Unfortunately, compounds within the most active series against Nek2 (e.g. 39) were found to 
be poorly selective for Nek2 when tested in a small panel of mitotic kinases. It was therefore 
necessary to establish alternative points of modification on the purine pharmacophore to 
improve both potency and selectivity for the target kinase. 
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Chapter 5: 8-Alkyl-2-arylaminopurine Nek2 Inhibitors 
5.1. 8-Alkylpurines as Selective Nek2 Inhibitors 
I was responsible for all further chemical synthesis described,  unless stated otherwise. In an 
attempt to build on the promising improvement in selectivity observed for 6-unsubstituted 
purines, the crystal structure of Nek2 in complex with purine-based inhibitors was 
reconsidered. It was noted that the gatekeeper residue of the ATP-binding domain is located 
in close proximity to the purine C-8 position. For Nek2 this residue is Met86, a less common 
amino acid present at this location in kinases. Cdk2 contains the larger Phe80 gatekeeper, 
presenting the possibility that tighter steric constraints may be found within this region of 
Cdk2 compared with Nek2.  
 
   IC50 (µM) 
Compound R
1
 R
2
 Nek2
a
 Cdk2
b
 
42 
 
-Me 20.7 3.1 
43 
 
-Et 62.1 3.1 
44 
 
-
i
Pr 79.9 5.0 
45 
 
-Me 51.8 18% * 
46 
 
-Et 67.5 39% * 
IC50 = half maximal inhibitory concentration; 
a 
Nek2 IC50 values determined at 30 µM ATP concentration; 
b
 Cdk2 IC50 values determined at 12.5 µM ATP concentration; * = Percentage inhibition at 50 µM. 
Table 1: Inhibitory activity of initial 8-alkyl-2-arylaminopurines against Nek2, and Cdk2. 
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It was therefore proposed that simple substitution at the purine 8-position may be better 
tolerated in Nek2, and would serve to probe the binding site in a manner that would be 
detrimental to Cdk2 activity. As part of an earlier MSc project, a small series of compounds 
was prepared and evaluated against both Nek2 and Cdk2 (Table 1). Unfortunately, 
compounds bearing a sulfonamide group (42-44) were more potent against Cdk2, with only 
modest Nek2 inhibitory activity observed. This was postulated to be due to the sulfonamide 
group confering good potency against Cdk2 (e.g. 35), and so the alternative 4-
methoxyphenylamino side-chain was employed at the purine 2-position (45 and 46). This 
restored selectivity for Nek2, although the compounds were still considerably less potent than 
those lacking substitution at the 8-position. These limited results suggested that the largest 
alky substituent tolerated was a methyl group (e.g. 45).  
5.1.1. A Non-classical Binding Mode for 8-Alkyl-2-arylamino-purines 
In order to understand the loss in potency against Nek2, compounds 45 and 46 were co-
crystallised with the kinase and the resultant X-ray crystal structures analysed. Although 
crystal structures for both complexes were obtained, the resolution of the structure of 46 in 
complex with Nek2 (2.0 Ǻ) allowed for the most accurate assessment (Figure 20). 
 
Figure 20: X-ray crystal structure of 8-alkylpurine inhibitor 46 (yellow) in complex with Nek2 at 2.0 Ǻ, shown 
as stick and ribbon (A) and sphere (B) representations. Highlighted are Asp93 (purple), a water 
molecule (red), Phe148 (green), the Met86 gatekeeper residue (orange) and the DFG 
motif/hydrophobic pocket (blue). 
Interestingly, this revealed that compounds 45 and 46 were no longer interacting with the 
kinase through a triplet of hinge H-bonds. It was clear that even simple alkylation at the 
purine 8-position is not tolerated in Nek2, and the compounds adopt an unusual ‘flipped’ 
DFG 
motif 
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orientation, making hinge region H-bond interactions with the N
1
 and C
2
-NH of the purine 
(Figure 21). Fortunately, this presented opportunities to determine SARs for this alternative 
binding orientation through substitution on the purine previously not possible. 
 
Figure 21: Schematic representation of the conventional and ‘flipped’ purine binding modes, with the hinge 
region of the Nek2 ATP-binding domain. 
It was noted that the para-position of the 2-arylamino ring of 46 was directed towards a large 
hydrophobic pocket equivalent to the allosteric site occupied by type II kinase inhibitors. 
Expansion into this region may thus improve binding affinity as expected for type II kinase 
inhibitors. Furthermore, the DFG motif was now positioned to be probed for interactions 
from the purine 2-arylamino ring, allowing the potential for Nek2 to be stabilised in the DFG-
out inactive kinase conformation. The aromatic ring of the 2-arylamino side-chain also 
appears to be making an edge-face π-π, or T-stacking, interaction with Phe148 in the ATP-
binding site.  
A bound water molecule was found to be located adjacent to the purine N
9
-position of 46 in 
the ATP-binding site of Nek2, offering opportunities for expansion into this region, 
particularly given that this position no longer makes a hinge-binding interaction. Thus, it was 
likely that alkylation at the N
9
-position would be tolerated and may improve inhibitor 
potency through water molecule displacement. Finally, the 8-position of the purine was 
observed to occupy a region in the vicinity of an aspartate residue (Asp93). A potential 
improvement in binding affinity may thus be achieved by interaction with basic functional 
groups at the purine-C
8
 position. The identification of these possible points of interaction 
required the synthesis of several new 8-alkylpurines to test these hypotheses (Figure 22). 
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Figure 22: A) X-ray crystal structure of 8-alkylpurine inhibitor 46 (yellow) in complex with Nek2 at 2.0 Ǻ; B) 
Possible points of interaction to determine SARs for the 8-alkyl-2-arylaminopurine chemotype. 
5.2. Probing the Proposed Hydrophobic Pocket at R
1
 
5.2.1. Target Compound Selection and Synthesis 
Compounds within the 8-alkylpurine series were initially synthesised such that modification 
of the 8-position could be carried out at the final stage, in order to utilise common 
intermediates as extensively as possible. This involved the synthesis of a diaminopyrimidine 
with the desired substituted 2-arylamino side-chain, followed by a 2-step purine synthesis 
utilising the appropriate acyl chloride to acylate the 5-amino group, with subsequent base-
mediated cyclisation (Scheme 1). 
Scheme 1: Initial synthesis of 8-alkyl-2-arylaminopurines. 
 
Reagents and conditions: i) a) R
2
COCl, pyridine, DCM, RT, 3 h, b) NaOH, H2O, reflux, 2 h. 
Unfortunately, this cyclisation procedure was unsatisfactory for the generation of multiple 
analogues or for scale-up, as the yields obtained were highly variable and product isolation 
difficult. An alternative procedure was thus required to allow the synthesis of sufficient 
quantities of an intermediate suitable for the preparation of a series of 2-substituted purine 
derivatives. Due to the low tolerance for substitution at the C
8
-position previously observed, 
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it was decided that a methyl group would be employed from the outset, solely to induce 
binding via the alternative conformation and allow access to the putative hydrophobic pocket. 
 
An approach that had not previously been attempted within the group was halogenation at the 
purine 8-position. It was envisaged that a trihalogenated purine (47) would serve as a 
versatile intermediate for the stepwise functionalization of the purine. This would particularly 
be the case if different halogens were introduced at each position, allowing the inherent 
reactivity differences to be exploited for regioselective functionalisation. 
Initial studies established that when using classical bromination conditions of NBS in acidic 
media, the nature of the N
9
-substituent was important. With no protecting group at the N
9
-
position the reaction did not proceed. A common group utilised for purine N
9
-protection is 
THP, but the acid lability of this group meant that it was not suitable. A successful C
8
-
bromination was achieved employing an N
9
-benzylpurine, but all subsequent efforts to 
remove the benzyl moiety failed. 
To allow use of the more labile THP group, the method of bromination was revised. 
Following protection of the N
9
-position, C
8
-deprotonation was investigated to allow reaction 
of the resulting anion with an electrophilic bromine source. A synthetic strategy was designed 
(Scheme 2), which would allow the synthesis of the first compound to be prepared in this 
series, bearing a 4-phenoxyanilino substituent (48). This would enable validation of the 
strategy and initial assessment of the effect of probing the hydrophobic pocket with bulky 
substituents. 
Starting from the commercially available 2-amino-6-chloropurine (49), the 2-fluoropurine 50 
was prepared in moderate yield (61%) via a Balz-Schiemann reaction. Protection of the 
purine N
9
-position with THP gave the required substrate (51) for the base-mediated 
bromination reaction. 
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Scheme 2: Synthesis of 8-methylpurine 48. 
 
Reagents and conditions: i) NaNO2, HBF4, 0 °C to RT, 70 min; ii) DHP, CSA, EtOAc, reflux, 18 h; iii) a) 
nBuLi, DIPA, THF, -78 °C, 25 min, b) (CCl2Br)2, THF, -78 °C to RT, 3 h; iv) a) nBuLi, THF, -78 °C, 20 min, 
b) MeI, -78 °C to RT, 3 h; v) Pd(OH)2, NH4HCOO, MeOH, reflux, 2 h; vi) TFA, iPrOH, H2O, MW 130 °C, 15 
min; vii) 4-Phenoxyaniline, TFA, TFE, reflux, 24 h. 
Direct lithiation of the purine C-8 position has been reported previously as a route to 8-
functionalised nucleosides,
196
 and this approach was investigated with 51, using LDA as the 
base. Under these conditions it is possible to deprotonate both the 8-position and effect 
lithium-halogen exchange of the 6-chloro group. However, formation of the carbanion at the 
6-position has been reported to be the kinetically favoured product, with reaction at the 8-
position the thermodynamically favoured product. At reaction temperatures below -130 °C 
the principal product arises through reaction at the 6-position. However, at the higher 
temperature of -78 °C the desired 8-functionalised product prevails.
197
 Therefore, this higher 
temperature was used during the lithiation step. 
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Figure 23: Predicted and observed MS isotope profiles for 52. 
It was found that the lithiated species derived from 51 was very sensitive to the bromide 
source, with classical electrophilic bromine sources failing to afford the desired product (52). 
1,2-Dibromotetrachloroethane has been reported to brominate the purine 8-position under 
similar conditions,
198
 and clean conversion to the desired compound (52) was achieved in 
reasonable yield (69%) utilising this reagent. Spectroscopic analysis of 52 by 
1
H and 
13
C 
NMR did not give definitive confirmation of the structure of the product. However, EI mass 
spectrometry revealed the characteristic isotope profile expected for compound 52 (Figure 
23). 
Introduction of a methyl group at the 8-position was attempted using a palladium-mediated 
Suzuki coupling reaction between 52 and trimethylboroxine. However, it was found to be 
difficult to establish conditions in which selectivity was achieved for reaction at the 8-
position over the 6-position. It was therefore decided to generate the C
8
-lithiated species 
through lithium-bromine exchange and react with methyl iodide. Although this approach 
could be used on 51 at the previous step, the generation of the trihalogenated purine 52 was 
desirable as a reagent for polyfunctionalisation of the purine scaffold. 
After introduction of the 8-methyl group, the 6-chloro group of 53 was removed via a 
palladium-mediated reductive dehalogenation to give 54, from which the N
9
-THP protecting 
Observed Data: EI 
Theoretical Isotope Profile: M+ 
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group was cleaved (55). Due to electrostatic repulsion from the purine nitrogen lone pairs,
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SNAr reactions at the 2-position of a purine or pyrimidine are very slow under neutral 
conditions. Previous work within the group has identified a combination of TFA in TFE as an 
effective system for facilitation of SNAr reactions between an aniline and the 2-position of a 
purine.
200
 The stoichiometric ratio of aniline to TFA is important to minimise protonation of 
the aniline, whilst activating the purine to nucleophilic attack through N
1
/N
3 
protonation. The 
use of 2 equivalents of aniline and 2.5-5.0 equivalents of TFA was found to result in a 
significantly improved reaction rate for the coupling reaction. 4-Phenoxyaniline was coupled 
to the 2-fluoropurine intermediate 55 under these reaction conditions to give the target 
compound 48. 
Despite the successful synthesis of compound 48 using this synthetic strategy, the route was 
lengthy, and several steps, particularly the lithiation reactions, were poorly reproducible and 
not amenable to a larger scale. In order to generate a series of analogues it was necessary to 
redesign the synthesis to require fewer steps and more reproducible chemistry. In addition, to 
determine the effect of displacement of the water molecule adjacent to the purine N
9
-position 
in the kinase binding site, a strategy was needed by which the analogous N
9
-methyl purine 
(56) could be prepared. This was not desirable through direct alkylation of the purine, as the 
problem of N
7
/N
9
 regioselectivity, and separation of such regioisomers may arise. 
Scheme 3: Synthesis of 2-arylamino-8-methylpurines. 
 
Reagents and Conditions: i) RNH2, THF, 0 °C, 30 min; ii) SnCl2, EtOH, 80 °C, 1.5 h; iii) (EtO)3CCH3, TFA, 
TFE, MW 140 °C, 90 min; iv) ArNH2, TFA, TFE, MW 160 °C, 1 h. 
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A synthetic strategy was employed using simple, scalable reactions that would also allow the 
unequivocal assignment of the location of the N
9
-methyl group (Scheme 3). Due to 
electrostatic repulsion of the pyrimidine nitrogen lone pairs, it is possible to selectively 
displace the 4-chloro group of 2,4-dichloro-5-nitropyrimidine (57) with a variety of amines 
through SNAr reactions. Using ammonia and methylamine it was possible to prepare 
pyrimidines 58 and 59, respectively, under these conditions. 
The required purine was prepared by reduction of the 5-nitro group of 58 and 59 using 
stannous chloride in refluxing ethanol to give the diaminopyrimidines 60 and 61. This was 
followed by acid-catalysed cyclisation with triethyl orthoacetate to give purines 62 and 56. In 
order to further facilitate the cyclisation reaction, microwave heating was utilised; when 
using conventional heating, reactions of this type were found to proceed over several hours. 
However, under microwave irradiation conditions full conversion to the products was 
achieved in 90 minutes, giving the required purine intermediates 62 and 56 in good yields 
(86% and 94%, respectively). 
 
Unfortunately, incorporation of the 4-phenoxy substituent to give compound 48 did not 
translate to an improvement in potency over the 4-methoxy analogue 45. As a consequence 
the effect of simple alkyl and alkoxy substituents at the 4-position of the 2-arylamino ring 
was assessed to determine the steric constraints at this position. In addition, all compounds 
were synthesised as both the N
9
-unsubstituted and N
9
-methyl analogues, to validate the 
proposed improvement in binding affinity achieved by displacement of the bound water 
molecule in the Nek2 ATP-binding site. A small series of compounds was proposed (63-74). 
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It was intended to synthesise the corresponding 4-tert-butoxyarylamino analogues (72 and 
73) in addition to the isopropoxyanilines 70 and 71. However, the required aniline reagent 
proved unstable to the TFA/TFE mediated coupling conditions, and it was decided to 
determine the Nek2 inhibitory activity of the initial set of compounds prior to preparing 
further target compounds. For the synthesis of compounds 70 and 71 it was necessary to 
prepare 4-isopropoxyaniline (75). This was achieved through reaction of 4-
fluoronitrobenzene (76) with sodium isopropoxide to give 77, followed by reduction of the 
aromatic nitro group through a palladium-mediated transfer hydrogenation to afford the 
aniline 75 (Scheme 4). 
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Scheme 4: Synthesis of aniline 75. 
 
Reagents and conditions: i) NaH, 
i
PrOH, 0 °C to RT, 18 h; ii) Pd/C, NH4HCOO, MeOH, RT, 18 h. 
Reaction times for the TFA/TFE mediated SNAr coupling were improved by the use of 
microwave heating, with near complete consumption of starting material observed after 1 
hour at 160 °C (Scheme 5). The required anilines were coupled with intermediates 62 and 56 
to afford the desired target purines (63-71 and 74) in moderate to good yields (Table 2). 
Scheme 5: Coupling of required anilines to 2-chloropurines 62 and 56. 
 
Reagents and conditions: i) ArNH2, TFA, TFE, MW 160 °C, 1 h. 
Compound R
1
 R
2
 Yield (%) 
63 Me 
 
61 
74 Me 
 
78 
64 H 
 
83 
65 Me 
 
57 
66 H 
 
76 
    
83 
 
Compound R
1
 R
2
 Yield (%) 
67 Me 
 
57 
68 H 
 
53 
69 Me 
 
58 
70 H 
 
70 
71 Me 
 
86 
Table 2: Isolated yields for the coupling of anilines to the 2-chloropurine intermediates 62 and 56 under 
microwave assisted TFA/TFE mediated conditions. 
For the N
9
-unsubstituted inhibitors (64, 66, 68 and 70) a potential trend was observed in 
improved potency against Nek2, with the size of the alkyl substituent at the 4-position of the 
2-arylamino ring (e.g. 70; IC50 = 9.6 µM). Within the compound series with N
9
-methylation 
(63, 65, 67, 69, 71 and 74) there was limited SARs, with 4-methoxyarylamino compound 63 
being one of the most potent compounds. However, all compounds bearing methyl groups at 
the purine N
9
-position (63, 65, 67, 69, 71 and 74) exhibited increased potency when 
compared with their N
9
-unsubstituted counterparts (45, 48, 64, 66, 68 and 70). In the case of 
compounds 45 and 63 a 10-fold increase in potency was observed. 
 
To confirm whether the observed enhanced Nek2 inhibition was due to displacement of the 
binding site water molecule, compound 63 was co-crystallised with Nek2 and the crystal 
structure determined. When compared with that of 46 it was apparent that both 45 and 63 
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adopt a similar binding orientation, and that the water molecule is no longer present at the N
9
-
position when 63 is bound to Nek2 (Figure 24). 
 
Figure 24: Overlay of 46 (cyan) and 63 (magenta) within the ATP-binding domain of Nek2. Water molecules 
shown are either present with 46 bound (cyan) or with both inhibitors bound (cyan/magenta).  
As a result of this observation, it was decided that all subsequent inhibitors in this series 
would bear the N
9
-methyl group. It is possible that the lack of potency observed for the 4-
phenoxyarylamino compounds 48 and 74 was a result of the phenoxy substituent failing to 
occupy the hydrophobic pocket. It may be necessary to extend lipophilic groups further into 
this region to participate in potential interactions favourable to kinase binding affinity. To this 
end, the 4-benzyloxyarylamino analogue (78) was prepared. Attempts to couple 4-
benzyloxyaniline directly to the 2-chloropurine 56 resulted in formation of the ortho-benzyl 
phenol 79 in poor yield, owing to the inherent instability of this side-chain to acidic 
conditions, followed by electrophilic aromatic substitution between the phenol (80) and the 
resultant benzyltrifluoroacetate (Scheme 6).
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Scheme 6: Synthesis of the undesired ortho-benzyl phenol 79. 
 
Reagents and conditions: i) 4-Benzyloxyaniline, TFA, TFE, MW 160 °C, 1 h. 
To avoid this problem, and to facilitate the synthesis of further analogues, a route utilising a 
common phenol intermediate (80) followed by alkylation was employed (Scheme 7). A small 
series of 4-benzyloxyanilino purines (78 and 81-83) was readily prepared using this 
approach. 
Scheme 7: Alkylation of phenol 80 with substituted benzyl chlorides. 
 
Reagents and conditions: i) 4-Aminophenol, TFA, TFE, MW 160 °C, 1 h; ii) RCl, K2CO3, DMF, 60 °C, 18 h. 
In an attempt to probe further into the hydrophobic pocket, the benzyl group of 78 was 
homologated. The required aniline (85) was prepared in good yield (84%) through reaction of 
4-fluoronitrobenzene (76) with sodium 2-phenylethoxide, followed by reduction of the 
aromatic nitro group by catalytic transfer hydrogenation. Final coupling of the aniline 85 
under the established conditions afforded the target purine 86 (Scheme 8). 
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Scheme 8: Synthesis of purine 86. 
 
Reagents and conditions: i) NaH, 2-phenylethanol, 0 °C to RT, 18 h; ii) Pd/C, NH4HCOO, MeOH, RT, 18 h; 
iii) 56, TFA, TFE, MW 160 °C, 1 h. 
The loss of potency for the 4-phenoxyaryl compound 74 (Nek2; IC50 = 32.9 µM) compared 
with the 4-methoxyaryl analogue 63 (Nek2; IC50 = 5.2 µM), may indicate steric limitations 
within the hydrophobic pocket. To access the target pocket it may thus be necessary to direct 
substituents in such a way as to avoid binding site clashes. To investigate this, a small set of 
derivatives bearing alkyne groups at the 2-arylamino position was proposed. The target 
compounds (87-89) were prepared by coupling 4-bromoaniline with the 2-chloropurine 
intermediate 56 under microwave assisted TFA/TFE coupling conditions. The bromo group 
of the resultant compound (90) was substituted with the required functionalised alkynes using 
a palladium-mediated (Buchwald) coupling procedure (Scheme 9).  
 
Difficulties were encountered when attempting to isolate compounds 88 and 89 due to their 
co-elution with the starting material (90) under a variety of chromatography conditions. 
Compound 91 was prepared by coupling (triisopropylsilyl)acetylene with 90, followed by 
removal of the TIPS-protecting group using TBAF. Evaluation of the potency of 87 (Nek2; 
IC50 = 12.5 µM) suggested that it was not necessary to attempt to purify compounds 88 and 
89 further, as no significant improvement in binding affinity was observed. 
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Scheme 9: Synthesis of compound 87. 
 
Reagents and conditions: i) 4-Bromoaniline, TFA, TFE, MW 160 °C, 1 h; ii) TIPS-acetylene, PdCl2(MeCN)2, 
XPhos, Cs2CO3, MeCN, 80 °C, 2 h; iii) TBAF, THF, RT, 5 min. 
It has been reported that the binding energy for edge-face π-π interactions can be lowered by 
introducing fluorine atoms at the ortho- and para-positions to the ring hydrogen involved in 
the interaction.
202
 To this end, fluoro groups were introduced onto the 2-arylamino ring of 63 
by TFA/TFE mediated coupling of the required anilines to the 2-chloropurine intermediate 
56, to give compounds 92 and 93. 3-Fluoro-4-methoxyaniline 94, required for the synthesis 
of 93, was easily synthesised from 2-fluoro-4-nitroanisole (95) via catalytic transfer 
hydrogenation in good yield (89%) (Scheme 10). 
Scheme 10: Synthesis of fluorinated 2-arylamino-8-methylpurines 92 and 93. 
 
Reagents and conditions: i) Pd/C, NH4HCOO, MeOH, RT, 18 h; ii) 94 or 3,5-difluoro-4-methoxyaniline, TFA, 
TFE, MW 160 °C, 1 h. 
5.2.2. Biological Results 
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All compounds prepared were tested for inhibitory activity against both Nek2 and Cdk2. 
(Table 3).  
 
   IC50 (µM)   
Compound R
1
 R
2
 Nek2
a
 Cdk2
b
 LE
c
 LipE
d
 
45 
 
H 51.8 18%* 0.32 2.15 
63 
 
Me 5.2 21%* 0.37 2.90 
48 
 
H 70.5 17%* 0.24 0.35 
74 
 
Me 32.9 17%* 0.25 0.44 
64 
 
H 30.7 32%* 0.37 2.24 
65 
 
Me 11.2 30%* 0.39 2.45 
66 
 
H 17.4 26%* 0.35 1.59 
67 
 
Me 12.3 34%* 0.34 1.50 
68 
 
H 16.9 28%* 0.33 1.27 
69 
 
Me 11.9 15%* 0.33 1.18 
      
   IC50 (µM)   
Compound R
1
 R
2
 Nek2
a
 Cdk2
b
 LE
c
 LipE
d
 
89 
 
70 
 
H 9.6 22%* 0.33 2.22 
71 
 
Me 4.7 14%* 0.34 2.30 
78 
 
Me 40%* 13%* N/A N/A 
81 
 
Me 24%* 16%* N/A N/A 
82 
 
Me 27%* 13%* N/A N/A 
83 
 
Me 16%* 2%* N/A N/A 
86 
 
Me 34%* 14%* N/A N/A 
87 
 
Me 12.5 44%* 0.34 2.24 
92 
 
Me 8.40 - 0.34 2.55 
93 
 
Me 7.10 - 0.33 2.46 
79 
 
Me 7.30 45.8 0.28 0.93 
a 
Nek2 IC50 values determined at 30 µM ATP concentration; 
b
 Cdk2 IC50 values determined at 12.5 µM ATP 
concentration; 
c
 Ligand efficiency = ΔG/HA (where HA = number of heavy atoms); d Lipophilic efficiency 
= pIC50 – ClogP; * = Percentage inhibition at 100 µM. 
 
Table 3: Inhibitory activity of 8-alkyl-2-arylaminopurines against Nek2 and Cdk2. 
Compounds bearing a substituted benzyloxyarylamino group at the purine 2-position suffered 
a loss of Nek2 inhibitory activity with respect to 63, with inhibitors (78, 81-83 and 86) 
exhibiting an IC50 of greater than 100 µM. This indicates that there is limited tolerance for 
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substitution at the 4-position of the 2-arylamino ring, and that simple alkyl (66-69) and 
alkoxy (70 and 71) are the largest groups that can be accommodated. As such it was decided 
that targeting the hydrophobic pocket was not useful as a means to improve the potency of 
this compound class. It is possible that the compounds in this series are unable to stabilise the 
DFG motif in the DFG-out conformation necessary for the allosteric site to be accessed. 
Although modest Nek2 inhibitory activity was retained for compounds 87, 92 and 93, the 
lack of a marked improvement in potency lead to the conclusion that significant interactions 
were not being made within the kinase ATP-binding domain. Interestingly, the unexpected 
product resulting from the rearrangement of 78 (79; IC50 = 7.30 µM) was a modest inhibitor 
of Nek2. It is possible that the phenol group of 79 is able to form interactions with the DFG 
motif of Nek2, allowing the benzyl group to access the hydrophobic pocket. However, the 
modest activity of 79 was accompanied by a detrimental effect on both ligand efficiency (LE) 
and lipophilic efficiency (LipE). To investigate this result further a series of compounds was 
designed to incorporate functional groups capable of interacting with the DFG motif, whilst 
reducing CLogP with the intention of improving LipE (see chapter 5.4.). 
The compounds detailed in Table 3 retained selectivity for Nek2 over Cdk2 as observed for 
45. However, it was unnecessary to profile the selectivity of such compounds in a wider 
panel of kinases, or to evaluate their effect in cellular assays, owing to the general lack of 
Nek2 inhibitory potency. The synthesis of 8-alkypurines bearing lipophilic groups at the 4-
position of the 2-arylamino ring was thus seen as an inappropriate method for the 
improvement of such compounds as inhibitors of Nek2. 
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5.3. Investigating Interactions at the Purine N
9
-Position 
5.3.1. Target Compound Selection and Synthesis 
In addition to the bound water molecule observed adjacent to the N
9
-position of 46 within the 
Nek2 ATP-binding domain, it was proposed that it may be possible to make additional 
interactions with the kinase through further substitution at this position of the purine. This 
was highlighted by a comparison of the X-ray crystal structures of the 8-alkypurine 63 and 
the benzimidazole inhibitor 31
192
 in complex with Nek2 (Figure 25). 
  
Figure 25: Overlay of 63 (green) and 31 (cyan) within the ATP-binding domain of Nek2 with Cys22 shown. 
The trifluoromethyl group of 31 is known to be important for binding affinity, as a result of 
its location within a pocket formed by the glycine rich loop adjacent to Cys22. When the X-
ray crystal structure of 63 was compared with that of 31 (Figure 25) it was apparent that the 
purine N
9
-methyl group of 63 is positioned close to the pocket occupied by the 
trifluoromethyl moiety of 31. It was proposed that incorporation of hydrophobic groups at 
this position, including trifluoroalkyl moieties, may improve potency. A small series of 
compounds was to be prepared with groups introduced at the purine N
9
-position, to probe the 
hydrophobic pocket. To allow a direct comparison between inhibitor series the target 
compounds (96–101) were also designed bearing the 4-methoxyarylamino side-chain present 
in 63. 
  
Cys22 
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Scheme 11: Synthesis of 2-arylamino-8-methyl-N
9
-alkylpurines 96-101. 
 
Reagents and Conditions: i) RNH2, THF, 0 °C, 30 min; ii) SnCl2, EtOH, 80 °C, 1.5 h; iii) (EtO)3CCH3, TFA, 
TFE, MW 140 °C, 1.5-2.5 h; iv) ArNH2, TFA, TFE, MW 160 °C, 1 h. 
 Step in Scheme 11 
R i ii iii iv 
Et 57% 70% 78% 49% 
i
Pr 69% 85% 58% - 
t
Bu 63% 86% - - 
i
Bu 35% 67% 63% 47% 
Ph 34% 92% 81%* 36% 
Bn 36% 78% 73% 42% 
CH2CF3 62% 84% 76% 68% 
CH2CH2CF3 65% 88% 74% 62% 
* = Reaction time extended by 1 h 
Table 4: Isolated yields for reaction steps as shown in Scheme 11, for the synthesis of N
9
-functionalised 
purines. 
The synthetic strategy used previously was employed for the preparation of this series 
(Scheme 11). 2,4-Dichloro-5-nitropyrimidine (57) was treated with the appropriate amines to 
give pyrimidines 102-109. Reduction of the 5-nitro group of 102-109 was performed using 
tin(II) chloride in refluxing ethanol to give diaminopyrimidines 110-117, which were reacted 
with triethyl orthoacetate in the presence of TFA to give the required purine scaffold. 
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However, yields for this this cyclisation step varied with the substitution at the pyrimidine 
C
4
-position. As the steric bulk of the amine increased, conversion to the purine decreased 
(Table 4), to the point that there was no reaction for tert-butylamine analogue 112. In order to 
achieve a satisfactory conversion for the N-phenyl analogue 114 the reaction was carried out 
over 2.5 hours. Final coupling of 4-methoxyaniline to the purine intermediates (118-124) was 
accomplished in satisfactory yields. However, purification of the iso-propyl analogue 125 to 
sufficient purity for biological testing (>95%) proved difficult. 
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5.3.2. Biological Results 
All compounds were evaluated for inhibitory activity against Nek2 and Cdk2, and LE and 
LipE values were calculated (Table 5). 
 
  
IC50 (µM)   
Compound R Nek2
a
 Cdk2
b
 LE
c
 LipE
d
 
63 Me 5.23 21%* 0.37 2.90 
96 Et 21.3 49%* 0.31 1.96 
97 iBu 43%* 17.3 N/A N/A 
98 Ph 13%* 28%* N/A N/A 
99 Bn >100 23%* N/A N/A 
100 CH2CF3 51.4 91.8 0.25 0.94 
101 (CH2)2CF3 53.6 74.1 0.24 0.43 
a 
Nek2 IC50 values determined at 30 µM ATP concentration; 
b
 Cdk2 IC50 values determined at 12.5 
µM ATP concentration; 
c
 Ligand efficiency = ΔG/HA (where HA = number of heavy atoms);            
d
 Lipophilic efficiency = pIC50 – ClogP; * = Percentage inhibition at 100 µM; N/A = not applicable 
as no IC50. 
 
Table 5: Inhibitory activity of N
9
-substituted 8-alkyl-2-arylaminopurines against Nek2 and Cdk2.   
All attempts to increase the size of the substituent at the N
9
-position resulted in a significant 
loss in inhibitor potency against Nek2. Based on the X-ray crystal structure, it is surprising 
that such steric constraints exist, but it appears that a methyl group is the largest tolerated 
substituent at this position. The observed loss in potency against Nek2 was also reflected by 
changes in the degree of selectivity over Cdk2, with compound 97 reversing the desired 
selectivity trend. For these reasons, no further work was conducted at the purine N
9
-position, 
and subsequent compounds were synthesised with an N
9
-methyl group. 
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5.4. Attempts to Make Additional Interactions with the DFG Motif at the 2-
Arylamino Ring 
5.4.1. Target Compound Selection and Synthesis 
Previous attempts to probe the hydrophobic allosteric site of Nek2 in the vicinity of the 
purine 2-arylamino ring resulted in limited SARs and no appreciable improvement in activity. 
This may be a result of limited access to the hydrophobic pocket owing to the conformation 
of the DFG motif. It is known for classical type II ATP-competitive inhibitors that their 
ability to occupy the allosteric site is dependent on the compound’s ability to stabilise the 
kinase in the inactive DFG-out conformation. To achieve this, interactions must arise 
between the inhibitor and the aspartate of the DFG motif. A small series of 2-
arylaminopurines substituted with carboxamides and ureas (126-131) was proposed, to assess 
the hypothesis of interacting with the DFG motif, and hence to probe the allosteric site. 
 
The synthesis of the required carboxamides entailed treatment of a common carboxylic acid 
intermediate (132) with carbonyldiimidazole (CDI) to activate the acid, followed by 
treatment with the appropriate amines. Previous work had reported that the coupling of 
anilines bearing carboxylic acids using TFA/TFE conditions resulted in formation of a 
trifluoroethyl ester, which required saponification to the acid. The SNAr reactions also 
generally give rise to multiple products and contaminants, and isolation of a polar acid from 
this mixture can be challenging.  
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Scheme 12: Synthesis of carboxamide derivates 126-128. 
 
Reagents and conditions: i) Methyl-4-aminobenzoate, TFA, TFE, MW 160 °C, 1 h; ii) LiOH, THF, H2O, 65 
°C, 2 h; iii) RNH2, CDI, DIPEA, DMF, RT, 18 h; iv) TFA, reflux, 18 h. 
A synthetic strategy was developed whereby methyl-4-aminobenzoate was coupled to the 
purine (56), enabling isolation of the product (133) in high purity. Subsequent ester 
hydrolysis proceeded cleanly, allowing isolation of the intermediate (132). The CDI-mediated 
coupling of 132 with methylamine and aniline proceeded in good yields (72% and 77%, 
respectively). The primary carboxamide (126) was prepared by coupling with 4-
methoxybenzylamine in quantitative yield. Subsequent cleavage of the PMB group of 134 
afforded the primary carboxamide 126 in a modest overall yield (45%) (Scheme 12). 
Synthesis of the target ureas also proceeded through a common intermediate (135). In this 
case the required intermediate was prepared by coupling 4-nitroaniline with the purine 56 to 
give the nitro purine 136, followed by reduction of the nitro group to furnish 135. The poorly 
nucleophilic nature of 4-nitroaniline hampered the coupling reaction, with prolonged heating 
required and giving rise to side products. This was reflected in the poor yield for this reaction 
(30%). Intermediate 135 could subsequently be functionalised to the desired ureas through 
reaction with suitable reagents. Reaction of the aniline group of 135 with cyanic acid and 
phenyl isocyanate proceeded smoothly to afford the urea (129) and N-phenyl urea (131) 
derivatives in 44% and 73% yield, respectively (Scheme 13). Synthesis of the target N-
methylurea (130) was attempted by treating 135 with triphosgene, followed by reaction of the 
resultant isocyanate with methylamine. Although a product with the correct mass was 
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observed by LC-MS analysis, repeated attempts failed to improve the reaction sufficiently to 
afford the target compound 130 in suitable yield following purification.  
Scheme 13: Synthesis of ureas 129 and 131. 
 
Reagents and conditions: i) 4-Nitroaniline, TFA, TFE, MW 160 °C, 6 h; ii) Pd/C, NH4HCOO, MeOH, RT, 18 
h; iii) Sodium cyanate, AcOH, H2O, RT, 30 min; iv) Phenyl isocyanate, THF, RT, 18 h. 
To avoid resynthesis of intermediate 134, a synthetic approach to the N-methylurea 130 was 
employed in which formation of the urea moiety was carried out prior to coupling to the 
purine (56). Boc-protection of para-phenylenediamine (137) gave compound 138, which 
when treated with N-succinimidyl N-methyl carbamate furnished the required N-methylurea 
(139). Removal of the Boc-protecting group gave aniline 140 required for coupling to purine 
56. It is interesting to note that TFA/TFE coupling conditions failed to yield any product 
(130) with aniline 140. It is unlikely that this is due to the electron-withdrawing nature of the 
urea moiety of 140, as it has been shown that it is possible to couple electron-poor anilines 
such as 4-nitroaniline under these condition, albeit with extended reaction times and in poor 
yields. One possibility is that 140 is unstable to the reaction conditions, as it was no longer 
detectable by LC-MS analysis of the reaction mixture.  
  
98 
 
Scheme 14: Synthesis of N-methylurea 130. 
 
Reagents and conditions: i) Boc2O, K2CO3, THF, DMF, H2O, RT, 4 h; ii) N-succinimidyl N-methyl carbamate, 
DIPEA, DMF, 70 °C, 18 h; iii) TFA, DCM, RT, 18 h; iv) 56, Pd2(dba)3, XPhos, K2CO3, MeCN, 100 °C, 2 h. 
A Buchwald amination approach was employed as an alternative to TFA/TFE aniline 
coupling. A wide variety of conditions are available for such reactions.
203
 Work elsewhere 
within the group established optimised conditions comprising tris(dibenzylideneacetone) 
dipalladium(0) (Pd2(dba)3), 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (XPhos) 
and potassium carbonate in acetonitrile, as suitable for coupling of a variety of anilines to the 
purine (56). These reaction conditions were used successfully to couple aniline 140 to 56 in 
moderate yield (49%) (Scheme 14). 
Scheme 15: Buchwald amination approach to the synthesis of 141. 
 
Reagents and conditions: i) Pd2(dba)3, XPhos, K2CO3, MeCN, 100 °C, 2 h. 
A further functional group capable of forming interactions with the DFG motif is the N-acetyl 
amine 141. The required aniline, 4-aminoacetanilide (142), failed to yield the desired product 
(141) under TFA/TFE coupling conditions, and was again synthesised using the Buchwald 
approach, affording target compound 141 in moderate yield (62%) (Scheme 15). 
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5.4.2. Biological Results 
All target compounds (126-131 and 141) and the carboxylic acid intermediate 132 were 
evaluated for inhibitory activity against Nek2 and Cdk2, and LE and LipE values were 
calculated (Table 6).  
 
  
IC50 (µM)   
Compound R Nek2
a
 Cdk2
b
 LE
c
 LipE
d
 
63 OMe 5.23 21%* 0.37 2.90 
132 CO2H 8.3 43%* 0.34 3.02 
126 CONH2 4.3 40.0 0.36 3.96 
127 CONHMe 5.8 34%* 0.33 3.60 
128 CONHPh 11.3 39%* 0.26 1.64 
129 NHCONH2 5.1 31%* 0.34 4.21 
130 NHCONHMe 11.1 32%* 0.30 3.63 
131 NHCONHPh 3.4 26%* 0.27 2.49 
141 NHCOMe 8.2 23%* 0.32 3.68 
a 
Nek2 IC50 values determined at 30 µM ATP concentration; 
b
 Cdk2 IC50 values determined at 
12.5 µM ATP concentration; 
c
 Ligand efficiency = ΔG/HA (where HA = number of heavy 
atoms); 
d
 Lipophilic efficiency = pIC50 – ClogP; * = Percentage inhibition at 100 µM. 
Table 6: Kinase inhibitory activity of 2-arylamino-8-methylpurines 126-132 and 141 against Nek2 and Cdk2. 
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The inhibitory activities of compounds 126-132 and 141 against Nek2 indicate that all 
modifications made are tolerated at the 4-position of the purine 2-arylamino ring. When 
compared with the unsubstituted 2-phenyl analogue (65, Nek2; IC50 = 11.2 µM) it is clear 
that interactions are being made in the ATP-binding domain of Nek2, conferring improved 
potency. Furthermore, the polar nature of inhibitors in this series, in particular ureas 129-131, 
equates to substantially improved lipophilic efficiency. However, despite tolerance of the 
substitutions made with respect to Nek2 inhibition, significant improvements in potency were 
not observed over the 4-methoxyaryl compound 63 (Nek2; IC50 = 5.23 µM). This suggests 
that although interactions with the DFG motif may occur, this approach is not adequate for 
achieving significant improvements in the binding affinity of 8-alkyl-2-arylaminopurines to 
Nek2. 
5.5. Establishing Interactions with Asp93 at the C-8 of 2-Arylaminopurines  
5.5.1. Target Compound Selection and Synthesis 
Work within the group has attempted to establish an interaction between basic functional 
groups at the 8-position of 2-arylaminopurines and Asp93 of Nek2, observed to be close to 
this position when 46 is in complex with the ATP-binding site of Nek2 (see chapter 5.1.1.). 
To this end, a range of 2-arylamino-8-aminomethylpurines was synthesised, with variation of 
the basic group at the purine 8-position, culminating in the identification of 143. 
 
A comparison between the Nek2 inhibitory activities of 143 and 46 suggests that an 
interaction is being made within the kinase ATP-binding domain resulting in the observed 
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increase in potency. Previously it had been shown that when methylated at the purine N
9
-
position (e.g. 63, Nek2; IC50 = 5.23 µM), compounds within the 8-alkyl-2-arylaminopurine 
series have improved binding affinity for Nek2 compared with their N
9
-unsubstituted 
analogues (e.g. 45, Nek2; IC50 = 51.8 µM). Although the degree to which the potency of such 
compounds is improved is variable, synthesis of the N
9
-methylated analogue of 143 (144) is a 
potential approach to improve the activity of compounds within the 2-arylamino-8-
aminomethylpurine series. 
Intermediate 145, previously prepared within the group, was deprotonated at the purine 8-
position by treatment with LDA, and reaction with DMF afforded the 8-formylpurine 146, as 
observed by LC-MS analysis and TLC. In previous studies, reactions of this type were 
performed using an N
9
-THP protected purine, and were typically high yielding (81-91%). It 
is possible that the THP protecting group acts to coordinate the lithium base and facilitate 
deprotonation of the purine C
8
-carbon. In this case, the target compound 144 was prepared by 
reductive amination of the aldehyde group of crude 146 with aniline and sodium borohydride 
in relatively poor yield (36% over 2 steps) (Scheme 16). 
Scheme 16: Synthesis of 2-arylamino-8-aminomethylpurine 144.  
 
Reagents and conditions: i) a) LDA, THF, -90 °C, 15 min, b) DMF, -90 °C to RT, 2 h; ii) a) Aniline, Mg2SO4, 
DCM, RT, 2 h, b) NaBH4, DCM, RT, 6 h. 
  
102 
 
5.5.2. Biological Results 
Compound 144 was tested for inhibitory activity against Nek2 and Cdk2: 
 
The significant reduction in inhibitory potency for 144 with respect to 143 suggests that it is 
unlikely that these compounds occupy the ATP-binding site of Nek2 in the same orientation 
as 46. To investigate this, attempts were made to obtain an X-ray crystal structure of 144 in 
complex with Nek2. However, it was not possible to obtain such a structure as the electron 
density observed suggested that 144 binds to the ATP-binding site of Nek2 in more than one 
orientation. It is likely that compound 143 also resides within the kinase in a binding 
conformation distinct from that of 46, as previous SARs have indicated that methyl is the 
largest group tolerated at the purine C
8
-position (e.g. 45, Nek2; IC50 = 51.8 µM). 
5.6. Conclusions and Further Work 
 
To improve the selectivity of 2-arylaminopurines for Nek2 over Cdk2, a series of 8-
alkypurines was synthesised to take advantage of the disparity in gatekeeper residues between 
the two kinases. Such compounds (e.g. 45, Nek2; IC50 = 51.8 µM) were found to occupy the 
ATP-binding domain of Nek2 in an unusual conformation, presenting opportunities to 
substitute the purine scaffold at positions not previously viable. Efforts were made to improve 
the binding affinity of 8-alkyl-2-arylaminopurines by probing putative hydrophobic pockets 
at the 4-position of the 2-arylamino ring (e.g. 71; R = 
i
PrO, Nek2; IC50 = 4.7 µM) and at the 
purine N
9
-position (e.g. 63; R = Me, Nek2; IC50 = 5.2 µM), culminating in low micromolar 
inhibition of Nek2. 
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X-ray crystallographic analysis of 8-alkyl-2-arylaminopurines (e.g. 63) in complex with the 
ATP-binding domain of Nek2 indicated that interactions were possible with the DFG motif of 
Nek2 through substitution at the 2-arylamino ring. A series of 8-alkyl-2-arylaminopurines, 
bearing substituted carboxamides (e.g. 126, Nek2; IC50 = 4.3 µM) and ureas (e.g. 131, Nek2; 
IC50 = 3.4 µM) at the 4-position of the 2-arylamino ring, was prepared. Despite limited 
improvements in inhibitor potency, such compounds possessed enhanced ligand efficiency 
and lipophilic efficiency. The improved drug like properties and low molecular weight of 
such compounds indicated that they may serve as suitable starting points for the development 
of further inhibitors. However, at this stage in the project the focus of research was turned to 
a compound series with potency surpassing that achieved thus far. 
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Chapter 6: Synthesis of 6-Ethynylpurines 
6.1. Identification of 6-Ethynylpurines as Irreversible Inhibitors of Nek2 
As an additional area of research, with the intention of improving inhibitor potency and 
selectivity, SARs were conducted at the purine 6-position. These studies identified the 6-
ethynylpurine 147, which displayed significantly improved Nek2 inhibitory activity 
compared with 35 and moderate selectivity over Cdk2. 
 
The 6-ethynylpurine pharmacophore possesses a non-classical Michael acceptor motif, as the 
alkyne moiety is activated through the electron-withdrawing effect of the purine ring 
nitrogens. Interest in such compounds was heightened when it was noted that compound 147 
exhibited a kinetic profile characteristic of an irreversible inhibitor in a kinase inhibition 
reversibility assay (Figure 26). The assay evaluated the ability of an enzyme, pre-incubated 
with an inhibitor, to recover activity upon rapid dilution of the enzyme-inhibitor complex 
with a solution containing the natural cofactor of the enzyme (e.g. ATP) and a substrate 
peptide. Analysis of the kinetics of the recovery of enzyme activity can aid in determining the 
mechanism of action of an inhibitor when compared to inhibitors of known mechanism. 
Following a 30 minute pre-incubation with 147 at a concentration 10-fold in excess of its 
IC50, the enzymatic activity of Nek2 was slow to recover when the Nek2-147 complex was 
diluted with a solution containing ATP and a substrate ‘peptide-11’. 1 hour post-dilution the 
enzymatic activity of Nek2 had recovered to approximately 3%. When the assay was 
conducted with a known ATP-competitive inhibitor of Nek2, the enzyme activity had 
recovered to approximately 11% 1 hour post-dilution. This suggests that 147 is making 
significant interactions within the ATP-binding domain of Nek2 such that it is acting as a 
tight-binding reversible inhibitor, or as an irreversible inhibitor of Nek2. 
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Figure 26: Recovery of enzyme activity of Nek2 following dilution of the enzyme-inhibitor complex with ATP 
for 147 and a known ATP-competitive inhibitor of Nek2. 
Through our understanding of the binding mode of 8-unsubstituted purines, it was known that 
the terminal moiety of the alkyne of 147 would be presented towards the region of the Nek2 
ATP-domain containing the glycine rich loop. As previously mentioned, Nek2 is a group 2B 
cysteine containing kinase, with a cysteine (Cys22) occupying the second amino acid position 
following the glycine rich loop. To determine whether the tight-binding enzyme kinetics 
observed between 147 and Nek2 are due to nucleophilic attack of Cys22 at the Michael 
acceptor alkyne group, the X-ray crystal structure of the ATP-binding domain of Nek2 in 
complex with 147 was determined at 2.0 Ǻ (Figure 27). Compound 147 was found to interact 
with the hinge region of Nek2 through a triplet of hydrogen bonds as previously described for 
purine based inhibitors. The formation of a thioenol ether bond between the Cys22 residue of 
the protein and the purine 6-position was also observed, confirming that the purine acts as a 
Michael acceptor for the Cys22. 
The effect of 147 on the growth of U2OS (osteosarcoma) and HeLa (cervical) cancer cell 
lines was determined. Unfortunately, the activity of 147 was outside of the range of the assay 
(GI50; U2OS = >100 µM, HeLa = >100 µM), and this poor cellular activity was attributed to 
limited cell permeability. The sulfonamide moiety likely contributes to the highly polar 
nature of the compound (CLogP = 0.92), and this group is also known to confer potency 
towards Cdk2. It was therefore desirable to remove the sulfonamide to improve both cell 
permeability and selectivity. 
147 
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Figure 27: X-ray crystal structure of 147 in complex with Nek2 showing interactions with the hinge region and 
covalent modification of Cys22. 
6.2. Identification of Cell Permeable 6-Ethynylpurines 
6.2.1. Target Compound Selection and Synthesis 
In addition to removal of the sulfonamide moiety from 147, investigation of initial SARs for 
the 6-ethynylpurine series was undertaken. It was known that the H-bond motif (C
2
-
NH/N
3
/N
9
-H) is important for interactions with the kinase hinge region, which in turn 
positions the electrophilic 6-alkyne group towards Cys22. Observations from the 8-
alkylpurine series suggested that substitution at the 8-position would be unfavourable for 
compounds of this class. Other work within the group was focussed on alternative 
electrophiles at the purine 6-position, and as such the effect of modifying the 2-arylamino 
ring on inhibitor potency remained to be evaluated. 
To establish preliminary SARs at the 2-position, a defined series of compounds, bearing 
small alkyl and other simple substituents on the 2-arylamino ring, intended to probe this 
region of the kinase, was designed (148-158). Trends within previous series had suggested 
that ortho-substitution of the 2-arylamino ring is poorly tolerated. For this new inhibitor class 
it was necessary to corroborate these finding, and the ortho-methoxy (155) and ortho-chloro 
(158) analogues were included for this purpose. 
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Previous work within the group had established a viable synthetic route for the synthesis of 6-
ethynylpurines (Scheme 17).
204
 Synthesis of the THP-protected 2-fluoro-6-chloropurine (51) 
was achieved using a Balz-Schiemann reaction on 2-amino-6-chloropurine (49) followed by 
THP-protection of the purine N
9
-position of the resulting 2-fluoro-6-chloropurine (50). The 
ethynyl function was introduced selectively at the purine 6-position of 51 using Sonogashira 
methodology to give intermediate 159 in excellent yield (96%). Removal of the N
9
-THP 
protecting group from 159 under acidic conditions afforded the key 2-fluoropurine 
intermediate 160. Coupling of the appropriate anilines was carried out under the TFA/TFE 
conditions previously described, with variable yields attained. The reaction between 
intermediate 160 and 4-aminophenol was attempted for the synthesis of the 4-hydroxylphenyl 
analogue 152. However, this resulted in a complex mixture of products with only a trace 
amount of the desired compound evident by LC-MS, and it was thus deemed necessary to 
protect the phenol hydroxyl group. Treatment of 4-nitrophenol (161) with triisopropylsilyl 
chloride gave the TIPS-protected compound 162, and the aromatic nitro group was reduced 
with zinc powder in acetic acid to give the required aniline 163 (Scheme 18). 
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Scheme 17: Synthesis of 2-arylamino-6-ethynylpurines. 
 
Reagents and conditions: i) NaNO2, HBF4, 0 °C to RT, 70 min; ii) DHP, CSA, EtOAc, reflux, 18 h; iii) TIPS-
acetylene, Pd2Cl2(PPh3)2, CuI, Et3N, THF, RT, 18 h; iv) TFA, IPA, H2O, reflux, 2h; v) ArNH2, TFA, TFE, 
reflux, 24 h; vi) TBAF, THF, RT, 5 min. 
 Compound number 
R A B 
H 164 148 
p-Me 165 149 
p-Et 166 150 
p-iPr 167 151 
p-OTIPS 168 - 
p-OH - 152 
m-MeO 169 154 
o-MeO 170 155 
p-Cl 171 156 
m-Cl 172 157 
Table 7: 6-Ethynylpurines prepared according to Scheme 17. 
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Scheme 18: Synthesis of aniline 163. 
 
Reagents and conditions: i) TIPSCl, imidazole, DCM, RT, 2 h; ii) Zn, AcOH, RT, 2.5 h. 
Coupling of aniline 163 with the 2-fluoropurine intermediate 160 gave 168 in poor yield 
(27%), suggesting that the silyl ether was unstable under the reaction conditions used. 
Despite this, the quantity of product isolated was sufficient to furnish the target inhibitor 152 
on treatment of 168 with TBAF. No product was observed when attempting to couple ortho-
chloroaniline with 160 under the standard conditions. Efforts to identify alternative 
conditions in order to obtain this compound were postponed pending the results for the 
inhibitory activity of the ortho-methoxyphenyl compound 155, and the para-methoxyphenyl 
analogue 153 was prepared by a colleague within the group. The TIPS-protecting groups 
were removed from all compounds (164-172) with TBAF to afford the target inhibitors (148-
157) following purification. Unfortunately, it was not possible to isolate the ortho-
methoxyarylamino analogue 155 in sufficient purity for biological testing, and other results 
mitigated against further efforts to synthesise this compound.  
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6.2.2. Biological Results 
The substituted 2-arylaminopurines (148-154, 156 and 157) were tested for inhibitory activity 
against Nek2 and Cdk2. For quoted IC50 values (Table 8) the incubation time of inhibitor 
with kinase was 30 minutes. 
 
  IC50 (µM) 
Compound R Nek2
a
 Cdk2
b
 
148 
(NCL-00016727) 
H 0.14 ± 0.1 22.9 
149 p-Me 0.26 30.2 
150 p-Et 0.18 40.6 
151 p-
i
Pr 0.40 54.7 
152 p-OH 0.50 - 
153 p-OMe 0.16 - 
154 m-OMe 0.09 14.6 
156 p-Cl 0.16 - 
157 m-Cl 0.21 9.0 
a 
Nek2 IC50 values determined at 30 µM ATP concentration; 
b
 Cdk2 IC50 values 
determined at 12.5 µM ATP concentration. 
Table 8: Kinase inhibitory activity of substituted 2-arylamino-6-ethynylpurines against Nek2 and Cdk2. 
Compounds within this series (148-154, 156 and 157) combined good inhibitory potency 
against Nek2, with at least 40-fold selectivity over Cdk2. As was perhaps expected with time-
dependent inhibitors, SARs were difficult to evaluate. All compounds appear to exhibit the 
necessary initial competitive reversible binding to Nek2, allowing subsequent covalent 
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reaction between Cys22 and the alkyne moiety to take place. Therefore, if the initial binding 
affinity is relatively uniform across the compound series, it would perhaps be expected that 
the final IC50 values following 30 minutes incubation with the kinase may show little 
variation, giving the observed values within a relatively confined potency range (~0.10-0.50 
µM). This limits the conclusions that can be drawn from these data, apart from the fact that 
substitution on the 2-arylamino ring is generally well tolerated. It is possible that compounds 
151 and 152 undergo slower initial competitive binding, accounting for the modest loss of 
potency, although more detailed kinetic studies, for all compounds over short incubation 
times, would be required to confirm this. 
Enzyme Nek2 Nek1 Cdk1 Cdk2 Cdk4 Cdk7 Cdk9 Plk1 P70S6K 
IC50 (μM) 0.15 20.8 40.4 22.9 17%* 76.7 25% 15.0 16.0 
Enzyme Chk1 Chk2 Aur A PKCz Rsk1 PRAK Erk1 PKD2 CK1d 
IC50 (μM) 12.0 4.4 1.3 21.8%* 22.8 29%* 26.4 47%* 40.2 
Enzyme ABL FYN LYN MET LCK SRC GSK3b Erk2 PKA 
IC50 (μM) 13.1 20.9 24.8 86.8 14.4 11.2 7.4 22.2 46%* 
Enzyme AKT2 INSR P38a AKT1 Msk1     
IC50 (μM) 55.4 25%* 9%* 33%* 16%*     
* = Percentage inhibition at 100 µM. 
Table 9: Inhibitory activity of 148 (NCL-00016727) against selected kinases. 
The 2-phenylaminopurine 148, designated NCL-00016727, was selected for further studies to 
investigate initial cellular effects of inhibitors within this class. To improve the confidence 
that Nek2 inhibition was responsible for any observed cellular activity, 148 was tested against 
a small panel of in-house kinases to establish preliminary selectivity data (Table 9). Despite 
evidence of modest Aurora A and Chk2 inhibition, at least 10-fold selectivity for Nek2 was 
maintained. Interestingly, 148 was poorly active against Nek1 (IC50 = 20.8 µM), which shares 
a high sequence homology with Nek2 within the active site, but lacks the corresponding 
cysteine residue necessary for covalent modification to occur. Furthermore, selectivity was 
maintained over Rsk1, Plk1 and Msk1, kinases that contain active-site cysteine residues 
capable of reacting with 148. 
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Figure 28: Dose-response curves as a function of incubation time between 148 and Nek2-WT (A), and Nek2-
C22A (B). 
Further evidence for the irreversible mechanism by which compounds within this class inhibit 
Nek2 was obtained through the observation of a time-dependent inhibition profile when the 
duration of incubation of Nek2 with 148 was varied prior to measurement of an IC50 value 
(Figure 28; A). To confirm whether time-dependent inhibition was mediated through Cys22, 
site-directed mutagenesis of the Cys22 residue to an alanine (Nek2-C22A) was performed, 
resulting in only weak competitive inhibition by 148 (IC50, Nek2-C22A = 3.5 µM), with no 
increase in the degree of inhibition being observed with time of incubation (Figure 28; B). 
 GI50 (µM) 
a
 
Compound 
U2OS 
(Osteosarcoma) 
HeLa 
(Cervical) 
MDA-MB-231 
(Breast) 
HEK293 
(Kidney) 
147 
(NCL-00016066) 
>100 >100 N.D.
b
 N.D. 
148 
(NCL-00016727) 
1.8 1.2 1.1 0.1 
a
 Half maximal growth inhibitory concentration; 
b
 Not determined. 
Table 10: Growth-inhibitory activity of 147 and 148 in selected tumour cell lines. 
The effect of 148 on the growth of three tumour cell lines, as well as the ‘normal’ HEK293 
cells, was determined (Table 10). When compared to the 147, compound 148 showed 
markedly increased growth inhibitory activity in the cell lines studied. This indicated that 
removal of the polar sulfonamide group improved the cellular permeability of the 6-
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ethynylpurine. Activity in the HEK293 cell line raises the possibility of non-specific toxicity, 
although this cell line is of limited value as a surrogate for normal tissue. 
 
Figure 29: Comet assay results for cells treated with 148. 
There is literature evidence to implicate 6-vinylpurines as DNA damaging agents, thought to 
occur through covalent conjugate addition between the DNA bases and the vinyl 
substituent.
205
 Given the mechanism of the 6-ethynylpurine inhibitors, it was suggested that 
they could act as DNA alkylators via a similar mechanism. This could be an alternative locus 
of action for the cellular activity of 148. In order to determine the effect of treatment with the 
inhibitor on cellular DNA damage, a Comet assay
206
 was performed (Figure 29). MDA-MB-
231 breast cancer cells were treated with 148 for up to 96 hours before being embedded in 
agarose, lysed, and treated with alkali to denature and unwind the DNA. Gel electrophoresis 
causes any damaged DNA fragments to move with the electric field out of the nucleoid. 
Undamaged DNA migrates more slowly under the electric field, and so remains within the 
nucleoid. Damaged DNA fragments are observed to streak from the nucleoid in the shape of 
an olive when stained with a DNA-specific dye, and DNA damage is measured as an ‘Olive 
tail moment’ and compared to an IR positive control. Cells treated with 148 displayed minor 
olive tail moments when compared to the IR control, and were similar to untreated cells, 
confirming that DNA damage is not a major effect of inhibitor treatment.  
To confirm that cellular Nek2 is inhibited upon treatment with 148, a cellular biomarker was 
required. The phosphorylation state of C-Nap1 localised to the centrosomes was used. As C-
Nap1 is a substrate only for Nek2, this can be used as a direct measure of cellular Nek2 
activity. Staining of cells with an antibody specific for phosphorylated C-Nap1 (pC-Nap1, see 
chapter 7.3) allows for the percentage of cells containing pC-Nap1 at the centrosomes to be 
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determined by immunofluorescence microscopy (IFM). Treatment of U2OS cells with a dose 
range of inhibitor, followed by staining with the pC-Nap1 antibody, showed a dose-
dependent decrease in phosphorylated C-Nap1, analogous to inhibition of Nek2 activity, with 
increasing concentration of 148 (Figure 30). This indicated that not only does this compound 
enter cells and elicit growth inhibition, it also inhibits cellular Nek2 in a dose-dependent 
manner. 
 
Figure 30: Dose response of pC-Nap1 levels in U2OS cells following 148 treatment. 
The series of compounds synthesised exhibited good inhibitory activity against Nek2, with a 
small range of structural modifications at the 2-arylamino ring, confirming that this position 
is amenable to modification and worthy of further investigation. Limited SARs were 
apparent, owing to the irreversible action of compounds within this class. It is likely that 
significant differences in potency between compounds will be observed only when there is a 
large difference in the initial competitive binding affinity, or for compounds that do not react 
covalently with Nek2. 148 has been shown to be a cell permeable 6-ethynylpurine, exhibiting 
potent growth inhibition in all cell lines tested. Furthermore, the use of a pC-Nap1 biomarker 
confirmed inhibition of cellular Nek2 levels upon treatment with inhibitor. 6-Ethynylpurine 
148 was therefore a suitable starting point from which to conduct modification to further 
improve inhibitor potency. 
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6.3. Designing 6-Ethynylpurines with Improved Potency 
6.3.1. Target Compound Selection and Synthesis 
As a means to achieve improved activity for compounds within the 6-ethynylpurine class, it 
was proposed that 2-arylamino side-chains that had been shown to confer good potency 
against Nek2 when incorporated into Nek2 competitive inhibitors based on 6-alkoxypurines 
should be investigated. A common feature of potent compounds within previous purine 
classes was a 2-arylamino ring bearing a basic group. Several examples were selected to be 
incorporated onto the 6-ethynylpurine, based on the inhibitory activity of the corresponding 
2-arylamino-O
6
-cyclohexylmethoxypurines (Table 11). In doing so, it was proposed that 
improvement in the initial competitive binding component of inhibitors would translate into 
enhanced potency for the irreversible inhibitor. 
 
R Position Compound Nek2 IC50 (µM) 
 
para 173 0.93 
 
meta 174 1.00 
 
meta 175 0.89 
 
meta 176 1.70 
Table 11: Nek2 inhibitory activity of compounds bearing 2-arylamino side-chain groups known to confer 
favourable potency against Nek2 when incorporated into the 2-arylamino-O
6
-cyclohexylmethoxy purine 
scaffold. 
Owing to their ease of synthesis from common intermediates, it was also decided to prepare 
the primary carboxamide (177) and sulfonamide (178) to further establish potential SARs at 
this position. This generated a small series of target compounds (177-182). 
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Synthesis of the requisite aniline to prepare 179 involved a reaction between 4-nitrophenol 
(161) and 3-dimethylaminopropyl chloride to give 183. The nitro group of 183 was reduced 
by palladium-mediated hydrogenation to give aniline 184 in good yield (91%). Coupling of 
184 to the 2-fluoropurine intermediate 160 gave the TIPS-protected precursor (185) of the 
desired compound in moderate yield (41%) (Scheme 19). 
Scheme 19: Synthesis of the TIPS-protected purine 185. 
 
Reagents and conditions: i) (CH3)N(CH2)3Cl.HCl, K2CO3, DMF, 80 °C, 2 h; ii) H2, Pd/C, EtOH, RT, 18 h; iii) 
160, TFA, TFE, reflux, 24 h. 
In order to synthesise the desired carboxamides (177 and 180), a common intermediate 
coupled to the purine scaffold was required. This was generated through coupling of 3-
aminophenylacetic acid to 2-fluoropurine intermediate 160 under TFA/TFE mediated 
conditions. As previously mentioned, this resulted in the formation of a trifluoroethyl ester, 
which was hydrolysed to the required acid 186 without isolation. Carboxamide formation 
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reactions were performed using CDI coupling conditions with 4-methoxybenzylamine and 
N,N-dimethylethylenediamine to give 187 and 188 in excellent yields (99% and 100%, 
respectively). Acidic deprotection of the PMB-carboxamide 187 proceeded very slowly to 
give the desired primary carboxamide 189 in good yield (90%) (Scheme 20). 
Scheme 20: Synthesis of carboxamides 188 and 189. 
 
Reagents and conditions: i) a) 3-Aminophenylacetic acid, TFA, TFE, reflux, 24 h, b) 1M NaOH, THF, RT, 18 
h; ii) RNH2, CDI, DIPEA, DMF, RT, 18 h; iii) TFA, reflux, 72 h. 
It was demonstrated previously that fluorinated sulfonate esters are useful intermediates for 
the synthesis of substituted sulfonamides.
207
 To this end, the trifluoroethylsulfonate ester 190 
was prepared by treatment of 3-nitro-α-toluenesulfonyl chloride (191) with TFE in the 
presence of DMAP. Reduction of the nitro group of 190 and coupling with 2-fluoropurine 
160 gave 193 (Scheme 21). Conversion into the target sulfonamides was performed under 
microwave irradiation conditions in the presence of DBU. The reaction between sulfonate 
ester 193 and 4-methoxybenzylamine gave the PMB-protected sulfonamide 194, which was 
converted into the primary sulfonamide 195 on treatment with refluxing TFA. N,N-
Dimethylpropane-1,3-diamine was coupled with 193 to give sulfonamide 196. The 
piperazinyl analogue (197) was prepared from 193 and Boc-protected piperazine to give 198, 
which gave 197 on treatment with TFA in DCM.  
  
118 
 
Scheme 21: Synthesis of sulfonamides 195, 196 and 197. 
 
Reagents and conditions: i) TFE, DMAP, NEt3, RT, 3 h; ii) H2, Pd/C, TFE, EtOAc, RT, 18 h; iii) 160, TFA, 
TFE, reflux, 24 h; iv) R2NH, DBU, THF, MW 160 °C, 15 min; v) TFA, 70 C, 3 h; vi) TFA, DCM, RT, 18 h. 
Final treatment of the TIPS-protected purines with TBAF was required to give the 6-
ethynylpurines 177-182 (Scheme 22). However, only the carboxamide 177 and sulfonamide 
178 derivatives were isolated. Although evidence of product formation was observed by LC-
MS and TLC analysis, it was not possible to isolate any product for compounds 179-182 after 
purification, and degradation was observed in reaction mixtures when monitored by LC-MS 
over time. It became apparent that compounds with basic groups in the 2-arylamino side-
chain were subject to decomposition in solution following removal of the TIPS protecting 
group, implicating the 6-ethynyl substituent as the site of degradation. However, to date no 
explanation for the observed instability has been established. It was clear that subsequent 
compounds should lack strongly basic groups, and an alternative strategy for side-chain 
design was considered. 
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Scheme 22: Synthesis of 6-ethynylpurines 177-182. 
 
Reagents and conditions: i) TBAF, THF, RT, 5 min. 
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6.3.2. Identification of NCL-00017509 (177) 
Compounds 177 and 178 were tested for inhibitory activity against Nek2 and Cdk2. In 
addition, growth inhibition of 177 against U2OS and HeLa cell lines was evaluated (Table 
12). 
 
  IC50 (µM) GI50 (µM) 
Compound R Nek2
a
 Cdk2
b
 U2OS HeLa 
148 H 0.14 ± 0.1 22.9 2.1 ± 1.0 1.2 ± 0.5 
177 
 
0.062 ± 0.01 11.8 71.0 47.1 ± 2.1 
178 
 
0.13 14.0 N.D. N.D. 
a 
Nek2 IC50 values determined at 30 µM ATP concentration; 
b
 Cdk2 IC50 values determined at 12.5 
µM ATP concentration; N.D. not determined. 
Table 12: Biological evaluation of 177 and 178. 
The carboxamide derivative 177, designated NCL-00017509, proved the most potent 
inhibitor in this class to date. However, this improvement in kinase inhibitory activity did not 
correlate with the cellular activity observed. It was possible that this was again a consequence 
of the more polar nature of the 2-arylamino side-chain limiting cellular permeability. 
However, when 177 was evaluated in the pC-Nap1 assay, it was evident that the purine was 
entering cells and inhibiting cellular Nek2 activity (Figure 31). 
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Figure 31: Inhibition of C-Nap1 phosphorylation in U2OS cells by 177 compared with 148. 
Cells treated with 148 display inhibition of pC-Nap1 levels to approximately 20% of control 
at doses of 1 x GI50 (1.8 µM). Despite showing negligible inhibition of cell growth, cells 
treated with 177 have pC-Nap1 levels reduced to a comparable degree at 0.07-0.14 x GI50 
(5.0-10.0 µM). This strongly suggests that growth inhibition observed in U2OS cells 
following exposure to 148 arises via an alternative target. Cellular growth inhibition was not 
evident for 177, presumably owing to improved compound selectivity. X-ray crystallographic 
analysis confirmed that 177 is bound to the Nek2 ATP-binding site in the expected manner, 
with covalent modification of Cys22 evident (Figure 32). Potential interactions between the 
carboxamide side-chain and Ser96 were identified, although poor electron density within this 
region of the structure limited a more detailed analysis. 
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Figure 32: X-ray crystal structure of 177 in complex with Nek2. 
Although the initial kinase selectivity of 148 was good, further profiling studies were 
required for both 148 and 177. In addition, it is possible that the alternative locus of cellular 
activity may not be a kinase, and if this were the case, identification of the target would be 
more challenging. The inhibitory activity of 177 against a panel of 48 kinases selected from 
commercially available ProfilerPro
®
 plates was determined at 1 µM inhibitor concentration 
(see appendix, Table A1). Only two kinases other than Nek2 were inhibited by greater than 
50%, and IC50 values were determined for these; Aurora A (IC50 = 0.08 μM) and BMX (IC50 
= 0.83 μM). However, efforts to confirm the IC50 value for Aurora A using a cell-based assay 
at the Institute for Cancer Research, indicated no inhibitory activity against the kinase. It is 
notable that BMX kinase, a member of the EGFR tyrosine kinase family, possesses a cysteine 
residue within the ATP-binding domain that has been identified as a potential target in the 
design of irreversible inhibitors.
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In addition, both 148 and 177 were screened against 121 kinases (National Centre for Protein 
Kinase Profiling, Dundee University) at a single concentration of 1 μM (see appendix, Table 
A2). Greater than 50% inhibition of activity was observed for nine of the kinases tested by 
177, including Nek2, and IC50 values were determined (Table 13). Encouragingly, the IC50 of 
177 against Nek2 was 18 nM in this assay, giving the compound at least 5-10-fold selectivity 
for Nek2 over other kinases, and AurA was only weakly inhibited by 177 in this screen. For 
148, an additional 10 kinases were included owing to the screen being conducted at a later 
date. Interestingly, this inhibitor displayed a better overall selectivity profile for Nek2 
compared with 177. In addition to Nek2, only 2 other kinases (MLK3 and TAK1) were 
Asp93 
Ser96 
Cys22 
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inhibited by greater than 50%. It is possible that the alternative target responsible for the 
cellular activity of 148 is not included in the screen, as it is only a fraction of the human 
kinome. Alternatively, the locus of cellular activity for 148 may not be a kinase. 
Kinase MKK1 MLK1 MLK3 NUAK1 TBK1 TAK1 JAK2 Chk1 
IC50 (µM) 0.55 0.27 0.32 0.12 0.74 0.24 0.22 0.56 
Table 13: IC50 values for kinases inhibited by 177 by greater than 50% in the National Centre for Protein 
Kinase Profiling screen. 
It is possible that the lack of growth inhibition observed for 177 in U2OS and HeLa cells is a 
result of these cell lines possessing mechanisms by which to facilitate centrosome separation 
and bipolar spindle formation independently of Nek2 activity. In keeping with the objective 
of developing targeted therapy, it was necessary to screen a panel of cell lines to identify 
specific tumour types where depletion of Nek2 activity is growth inhibitory. Collaborators at 
the ICR had previously conducted a similar screen, and indicated a potential sensitivity of 
cell lines derived from breast tumours and leukaemias to treatment with 177. To validate 
these observations, the inhibitor was tested against a panel of available tumour cell lines, 
including those derived from breast and leukaemia. Cell lines were evaluated for growth 
inhibition upon incubation at a 10 µM concentration of NCL-00017509 over 72 hours (Figure 
33; A, B and C). 
 
Figure 33: A) Growth inhibition of solid tumour cell lines treated with 10 µM 177 (NCL-00017509) for 72 
hours. 
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Figure 33: B) Growth inhibition of solid tumour cell lines treated with 10 µM 177 (NCL-00017509) for 72 
hours. 
 
Figure 33: C) Growth inhibition of leukaemia cell lines treated with 10 µM 177 (NCL-00017509) for 72 hours. 
As was observed previously, the tumour cell lines most sensitive to inhibitor treatment were 
those derived from breast (MCF7, T47D, ZR75, SKBR3 and MDA-468) and leukaemia (Rec-
1 and RIVA), with all of these cell lines exhibiting greater than 50% growth inhibition at a 
dose of 10 µM 177. GI50 values were determined for these cell lines, along with HeLa and 
HCT116 (Figure 34), with the lymphoma Rec-1 (GI50 = 1.6 ± 0.1 µM) and breast cancer 
SKBR3 (GI50 = 2.2 ± 0.4 µM) cell lines being identified as particularly sensitive to 177 
treatment. 
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Cell Line MCF7 ZR75 T47D SKBR3 Rec-1 RIVA HCT116 HeLa 
GI50 (μM) 6.6 ± 0.9 3.7 ± 0.8 3.6 ± 0.5 2.2 ± 0.4 1.6 ± 0.1 5.8 ± 1.4 18.1 ± 1.6 32.2 ± 3.9 
Figure 34: Growth inhibition of cell lines identified as being sensitive to 177 (NCL-00017509) following 72 h 
exposure to inhibitor (n = 3). 
Furthermore, 177 was also found to be cytotoxic in SKBR3 cells; clonogenic assays with this 
cell line gave LC50 values in the low micromolar range following pre-incubation for as little 
as 3 hours prior to subculture (Figure 35).  
 
Figure 35: Cytotoxicity of 177 (NCL-00017509) in SKBR3 cells following incubation for a range of times. 
Crucially, during such short incubation times, a significant fraction of the cell population 
would be expected to be outside of the phase of the cell cycle in which active Nek2 is 
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present. This observation is consistent with, but not conclusive, that the observed cytotoxicity 
is not due to inhibition of Nek2 alone. 
6.4. Synthesis of Analogues of NCL-00017509 (177) 
6.4.1. Target Compound Selection and Synthesis 
 
In order to identify components of the carboxamide associated with the improved potency of 
177 compared with 148, a range of analogues was proposed. Systematic modification of 
potential carboxamide binding interactions may allow the activity of this compound to be 
further understood, in light of the poor resolution of the X-ray crystal structure in this region 
of the ATP-binding domain. In addition, further modifications in the positioning of the 
carboxamide within the binding domain may reveal additional SARs and facilitate improved 
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inhibitor binding. A series of compounds was thus designed to investigate the binding 
requirements and spatial optimization of the carboxamide moiety (199-213). 
Of the desired analogues, the synthesis of 201 was conducted initially, owing to the 
availability of the common acid intermediate 186 from the preparation of 177. A CDI-
mediated coupling between 186 and dimethylamine gave the TIPS-protected precursor of the 
desired compound (214) (Scheme 23). 
Scheme 23: Synthesis of carboxamide 214. 
 
Reagents and conditions: i) Me2NH.HCl, CDI, DIPEA, DMF, RT, 18 h. 
A similar approach was utilised for the synthesis of the 4-substituted analogue 202. 4-
Aminophenylacetic acid was coupled to the 2-fluoropurine intermediate 160, with subsequent 
base-catalysed hydrolysis of the resultant trifluoroethyl ester. The required acid (215) was 
obtained in moderate yield (53%), to which 4-methoxybenzylamine was coupled under CDI-
mediated conditions. The PMB-protected carboxamide (216) was converted into the TIPS-
protected precursor (217) in refluxing TFA (Scheme 24). Owing to the number of analogues 
required, and the lengthy process of hydrolysing the resultant trifluoroethyl ester, it was 
decided that subsequent compounds would not be prepared via this route. To preserve 
intermediate 160, the side-chain groups were synthesised prior to their addition to the purine 
scaffold. As such, a new synthetic approach was designed for the synthesis of the 
homologated and truncated analogues of 177 (212 and 205). 
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Scheme 24: Synthesis of the 4-substituted analogue 217. 
 
Reagents and conditions: i) a) 4-Aminophenylacetic acid, TFA, TFE, reflux, 24 h, b) 1M NaOH, THF, RT, 18 
h; ii) PMB-NH2, CDI, DIPEA, DMF, RT, 18 h; iii) TFA, reflux, 18 h. 
The appropriate anilines, 3-(aminophenyl)propionic acid (218) and 3-aminobenzoic acid 
(219), were Boc-protected and CDI-mediated coupling of acids 220 and 221 with 4-
methoxybenzylamine gave the protected carboxamides 222 and 223. Removal of the Boc-
protecting group gave anilines 224 and 225, which were coupled to the 2-fluoropurine (160) 
in moderate to poor yields (41% and 9%, respectively). Removal of the PMB-group from the 
protected carboxamides (226 and 227) under acid conditions gave the target TIPS-protected 
purines 228 and 229 (Scheme 25). 
Scheme 25: Synthesis of carboxamides 228 and 229. 
 
Reagents and conditions: i) Boc2O, 1,4-dioxane, NaOH, H2O, RT, 18 h; ii) PMB-NH2, CDI, DIPEA, DMF, 
RT, 18 h; iii) TFA, DCM, RT, 18 h; iv) 160, TFA, TFE, reflux, 24 h; v) TFA, reflux, 18 h. 
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The TIPS-protected purines 214, 217 and 228 were deprotected as described previously 
(Scheme 26). However, although compound 201 was isolated cleanly in 87% yield, a 
persistent impurity was present in both 202 and 212 following chromatography. Despite 
being shown to be greater than 95% pure by analytical HPLC, the 
1
H NMR spectra for each 
compound showed four multiplet signals in the aliphatic region (Figure 36). 
Scheme 26: Removal of TIPS-protecting groups with TBAF. 
 
Reagents and conditions: i) TBAF, THF, RT, 5 min. 
 
Figure 36: Contaminant signals observed in 
1
H NMR (DMSO-d6) spectra of compounds (202 and 212) treated 
with TBAF. 
The additional 
1
H NMR signals were attributed to the n-butyl groups of TBAF, although the 
precise nature of this contaminant remains unclear. Repeated attempts to purify the purines 
by chromatography failed to remove the contaminant. Compounds within this class had 
previously been seen to decompose upon heating, and hence recrystallization of the products 
was not an option. The absence of such contamination in previous compounds led to the 
proposal that the carboxamide may be involved. However, reports of similar contamination 
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problems by colleagues within the research group, following the use of TBAF, suggested that 
this problem is more widespread.  
Scheme 27: Removal of TBAF from solution using a sulfonic acid resin 231. 
 
It has been reported that a modified resin system can be used to sequester TBAF (230) from 
reaction mixtures generated in high-throughput syntheses.
209
 Treatment of the sulfonic acid-
based Amberlite 15 Ion exchange resin with calcium hydroxide gave the solid supported 
sulfonate calcium salt (231). This serves to scavenge TBAF from the reaction mixture in 
THF, with calcium fluoride precipitating from solution (Scheme 27). A solution of the crude 
products 202 and 212 in THF were agitated with the resin at room temperature overnight. 
Removal of the resin and calcium fluoride by simple filtration afforded 202 and 212 free 
from the TBAF derived contaminant. 
However, an alternative method was required for the deprotection of TIPS-protecting groups 
from subsequent compounds to avoid contamination with TBAF derived species. Potassium 
fluoride was a suitable fluoride source for the reaction, although it was necessary to conduct 
the deprotection of 6-ethynylpurines in relatively low boiling solvents due to the observed 
thermal sensitivity of this compound class. KF is poorly soluble in non-polar solvents, 
including THF; however, by adding catalytic amounts of 18-crown-6, it was possible to 
generate soluble fluoride and facilitate the deprotection of 229 to give the required 6-
ethynylpurine 205 in excellent yield (94%) (Scheme 28). 
Scheme 28: Removal of the TIPS-protecting group of 229 using KF and 18-crown-6. 
 
Reagents and conditions: i) KF, 18-crown-6, THF, RT, 24 h. 
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The synthesis of 228 and 229 detailed in Scheme 25 was further improved, as it was found 
that the protecting group strategy was unnecessary. Thus, the primary and N-
methylcarboxamides were prepared directly by reaction of the methyl ester with the 
appropriate amine, and this strategy was used to prepare compounds 200, 208 and 209. 
Addition of thionyl chloride to a solution of 3-aminophenylacetic acid (232) or 4-
aminobenzoic acid (233) in methanol afforded methyl esters 234 (85%) and 235 (94%), 
respectively, in good yields, and these were converted into the carboxamidoanilines 236, 237 
and 238 on treatment with the appropriate amine. Anilines 236, 237 and 238 were coupled to 
2-fluoropurine intermediate 160 in the presence of TFA to give TIPS-protected purines 239, 
240 and 241. The TIPS-protecting groups were removed from all compounds using KF in the 
presence of 18-crown-6 to yield the target inhibitors 200, 208 and 209 in good yields (74%, 
74% and 69%, respectively) (Scheme 29). 
Scheme 29: Synthesis of 6-ethynylpurines 200, 208 and 209. 
 
Reagents and conditions: i) SOCl2, MeOH, reflux, 1 h; ii) Aq. RNH2, RT to 60 °C, 18 h; iii) 160, TFA, TFE, 
reflux, 24 h; iv) KF, 18-crown-6, THF, RT, 24 h. 
Treatment of methyl ester 235 with dimethylamine resulted in ester hydrolysis, with only 
trace amounts of the desired product identified by LC-MS analysis. As an alternative 
approach for the synthesis of 210, 4-aminobenzoic acid (233) was converted into the acid 
chloride 242 on treatment with thionyl chloride, which was treated with dimethylamine to 
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give the carboxamidoaniline 243. This aniline was coupled to purine 160 as before to give the 
TIPS-protected purine 244. Removal of the TIPS-protecting group by treatment with KF/18-
crown-6 afforded 210 (Scheme 30). Despite the success of this reaction in avoiding the 
contamination associated with TBAF treatment, deprotection using KF generally proceeded 
less efficiently than that using TBAF. To obtain compounds in sufficient purity for biological 
testing (>95%) often required multiple chromatographic separations. The successful removal 
of tetra-n-butylammonium contamination from 202 and 212 with the scavenger beads, and 
the ease with which these compounds were isolated in high purity, highlighted the value of 
this approach for the synthesis of future compounds. 
Scheme 30: Synthesis of the 6-ethynylpurine 210. 
 
Reagents and conditions: i) SOCl2, DMF, reflux, 1 h; ii) Me2NH, NEt3, THF, RT, 18 h; iii) 160, TFA, TFE, 
reflux, 24 h; iv) KF, 18-crown-6, THF, RT, 24 h. 
The lack of reaction between methyl ester 235 and dimethylamine prompted the use of a 
different method for the synthesis of the N,N-dimethylcarboxamide 204. Preparation of the 
aniline derivatives required for the synthesis of N-methylcarboxamide 203 and N,N-
dimethylcarboxamide 204 was attempted using CDI coupling reactions between 4-
nitrophenylacetic acid (245) and the appropriate amine (Scheme 31). However, treatment of 
acid 245 with CDI and DIPEA resulted in a pale purple colour change of the reaction 
mixture, and following addition of methylamine the required product (246) was not observed 
by LC-MS analysis. In contrast, the synthesis of N,N-dimethylcarboxamide 247 proceeded 
cleanly to the desired product, albeit in poor yield (30%). 
Scheme 31: Attempted synthesis of carboxamides 246 and 247 using CDI/DIPEA. 
133 
 
 
Reagents and conditions: i) a) CDI, DIPEA, DMF, RT, 1.5 h, b) MeRNH, THF, RT, 18 h. 
Analysis of both the MS and 
1
H NMR spectrum of the product isolated from the attempted 
synthesis of 247 indicated that a malonamide derivative (248) had been formed. A 
mechanism for the formation of 248 is proposed in Scheme 32; an acidic proton in the 
activated acid intermediate (249) may be deprotonated to give the charged intermediate 250, 
perhaps responsible for the observed purple colouration. Reaction of 250 with a further 
equivalent of CDI (251) to give the activated malonamide 252, may explain the formation of 
the observed malonamide 248 upon addition of methylamine. 
Scheme 32: Proposed mechanism for the formation of malonamide 248. 
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It is unclear as to why the reaction outlined in Scheme 32 did not also occur during the 
synthesis of 247, as the proposed mechanism indicates that reaction at the benzylic carbon 
takes place prior to the addition of an amine, this being the only difference between reaction 
conditions for the synthesis of 247 and 248. The low yield of 247 may indicate that 
intermediate 252 was formed to some degree, but that the additional steric bulk of 
dimethylamine suppressed the reaction with 252. Despite formation of the undesired 
malonamide (248), it was decided to couple this compound with the purine scaffold to further 
investigate SARs at the 2-arylamino ring. Nitroaromatic compounds 247 and 248 were 
reduced to anilines 253 and 254, respectively. As an alternative to the conditions using 
palladium-catalysed transfer hydrogenation utilised previously, iron powder in warm acetic 
acid was employed for this conversion owing to the rapid reaction times and good yields 
achieved. Coupling of anilines 253 and 254 to the 2-fluoropurine intermediate 160 was 
carried out under microwave heating conditions, allowing the reaction time to be reduced 
from 24 hours to 2 hours, and affording the TIPS-protected purines 255 and 256, respectively 
(Scheme 33).  
Scheme 33: Synthesis of the 6-ethynylpurines 204 and 257. 
 
Reagents and conditions: i) Fe, AcOH, 50 °C, 15 min; ii) 160, TFA, TFE, MW 140 °C, 2 h; iii) a) TBAF, 
THF, RT, 5 min, b) 231, THF, RT, 48 h. 
Removal of the TIPS-protecting group from 255 and 256 was carried out using TBAF under 
the conditions previously used. However, the reaction mixture was diluted with THF to 
solubilise any material that had precipitated from solution and to provide sufficient volume to 
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utilise the TBAF scavenger beads 231. By varying the volume of beads added to the reaction 
mixture for 204, it was found that an approximate 10-fold w/w excess of 231 completely 
removed any trace of tetra-n-butylammonium contamination after 2 days, as confirmed by 
1
H 
NMR analysis. This method was then used for the deprotection of 255 and 256, to afford the 
target inhibitors 204 and 257 with no contamination. The success of this procedure prompted 
its use in all further TIPS-deprotection reactions. 
Synthesis of the target N-methylcarboxamide 203 was adapted to prevent formation of the 
undesired malonamide 248. The required aniline 258 was prepared from the methyl ester 
(259), which was converted into the N-methylcarboxamide 258 on treatment with aqueous 
methylamine analogously to that for 236. However, in this case the intermediate methyl ester 
259 was not isolated and amide formation was carried out as a single reaction. The aniline 
258 was coupled to the 2-fluoropurine 160 to give the TIPS-protected purine 260. Removal 
of the TIPS-protecting group from 260 using TBAF, followed by treatment of the reaction 
mixture with the TBAF scavenger 231, gave the target compound 203 in moderate yield 
(58%) (Scheme 34). 
Scheme 34: Synthesis of the 6-ethynylpurine 203. 
 
Reagents and conditions: i) SOCl2, MeOH, reflux, 1 h; ii) Aq. MeNH2, RT, 18 h; iii) 160, TFA, 
TFE, MW 140 °C, 2 h; iv) a) TBAF, THF, RT, 5 min, b) 231, THF, RT, 48 h. 
As an alternative method for the synthesis of carboxamides, the use of phosphorus trichloride 
under microwave heating conditions allowed short reaction times to be achieved.
210
 
Carboxamides 261 and 262 were prepared in this way from 3-nitrobenzoic acid (263). 
Anilines 264 and 265 were synthesised through aromatic nitro group reduction, as previously 
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described, and subsequently coupled with 160 to give the TIPS-protected purines 266 and 
267. Removal of the TIPS-protecting groups as before gave the target inhibitors 206 and 207 
(Scheme 35). 
Scheme 35: Synthesis of 6-ethynylpurines 206 and 207. 
 
Reagents and conditions: i) R2-NH, PCl3, MeCN, MW 150 °C, 5 min; ii) Fe, AcOH, 50 °C, 15 min; iii) 160, 
TFA, TFE, MW 140 °C, 3 h; iv) a) TBAF, THF, RT, 5 min, b) 231, THF, RT, 48 h. 
To prepare the ‘reverse carboxamide’ 211, 3-nitroaniline (268) was acetylated with acetic 
anhydride to give N-acetylaniline 269. Reduction of the aromatic nitro group of 269 gave 
aniline 270 in good yield (91%), which was coupled to the 2-fluoropurine 160 under 
microwave assisted conditions to afford the TIPS-protected purine 271. Deprotection of 271 
with TBAF, as described above, gave the target purine 211 in moderate yield (48%) (Scheme 
36). The ortho-substituted carboxamide required for the preparation of 213 was synthesised 
in an analogous manner to that of 258. However, due to availability, the synthesis 
commenced from 2-nitrophenylacetic acid (272), which was converted into methyl ester 273 
with thionyl chloride/methanol, and treated with aqueous ammonia to give the carboxamide 
274 in good yield (84%).  
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Scheme 36: Synthesis of the 6-ethynylpurine 211. 
 
Reagents and conditions: i) Ac2O, RT, 30 min; ii) Fe, AcOH, 50 °C, 15 min; iii) 160, TFA, TFE, MW 140 °C, 
2 h; iv) a) TBAF, RT, 5 min, b) 231, THF, RT, 48 h. 
Interestingly, reduction of the nitro group of 274 with iron-acetic acid gave only the 
indolinone 275, with none of the desired aniline product 276 being observed by LC-MS 
analysis. It was proposed that the acidic conditions used were responsible for the formation of 
275 (Scheme 37), and hence nitro group reduction was performed under neutral conditions 
using palladium-catalysed transfer hydrogenation to give the requisite aniline 276 (Scheme 
38). 
Scheme 38: Preparation of 2-aminophenylacetamide 276. 
 
Reagents and conditions: i) SOCl2, MeOH, reflux, 1 h; ii) Aq. NH3, RT, 18 h; iii) Fe, AcOH, 50 °C, 15 min; 
iv) Pd/C, NH4HCOO, MeOH, RT, 3 h. 
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Scheme 37: Proposed mechanism for the formation of indolinone 275. 
 
Reagents and conditions: i) Fe, AcOH, 50 °C, 15 min. 
Coupling of aniline 276 to purine 160 under standard conditions failed to yield any of the 
target product (277), likely as the indolinone 275 forms from the aniline under the TFA/TFE 
conditions. It was thus necessary to devise an alternative method for coupling 276 to the 
purine. It has previously been reported that palladium-catalysed (Buchwald) amination 
reactions are a suitable alternative to SNAr methods for the coupling of anilines to the purine 
scaffold (see chapter 5.4). However, the 2-fluoropurine intermediate 160 utilised thus far is 
unsuitable for such reactions, owing to the low rate of palladium insertion into the C-F bond. 
As such, the 2-iodopurine intermediate (278) was prepared using Sandmeyer reaction 
conditions (Scheme 39). 
Scheme 39: Synthesis of the 6-ethynylpurine 213 using a palladium-catalysed amination. 
 
Reagents and conditions: i) PMB-Cl, K2CO3, DMF, 60 °C, 18 h; ii) TIPS-acetylene, Pd2Cl2(PPh3)2, CuI, Et3N, 
DMF, RT, 18 h; iii) isoamyl nitrite, CuI, CH2I2, THF, reflux, 1 h; iv) 276, Pd2(dba)3, XPhos, K2CO3, MeCN, 
100 °C, 2 h; v) TFA, reflux, 18 h; vi) a) TBAF, THF, RT, 5 min, b) 231, THF, RT, 48 h. 
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Prior to conducting palladium-mediated amine coupling reactions on the purine scaffold it 
had previously been found within the research group that protection of the N
9
-position was 
required. This is possibly due to coordination of palladium to the purine N
9
-H and N
3
 
positions. At the outset of the synthesis, it was not known which reaction conditions would be 
employed to introduce an iodo group at the purine 2-position. As such, it was desirable to 
introduce a protecting group at the N
9
-position that was stable to a wide range of conditions 
compared with the THP group used previously. Furthermore, treatment of 2-amino-6-
chloropurine (49) with 4-methoxybenzyl chloride in the presence of base allowed selective 
N
9
/N
7
-protection to give compound 279, whereas the analogous reaction with DHP would 
result in additional reaction at the purine 2-amino position. However, unlike THP-protection 
of the purine (e.g. 51), PMB-protection (279) gives a mixture of N
9
/N
7
 regioisomers. 
Literature precedence reports the discrimination of purine N
9
/N
7
 regioisomers by observation 
of the H-8 
1
H NMR signal.
211
 Accordingly, the ratio of N
9 
to N
7
 PMB-protection was found 
to be approximately 7:3 (Figure 37). 
 
Figure 37: Comparison of the purine H-8 
1
H NMR signals for the N
9
- and N
7
-PMB regioisomers of 279. 
The ethynyl moiety was introduced at the 6-position of 279 employing a Sonogashira 
reaction with (triisopropylsilyl)acetylene to give the 6-ethynylpurine 280. Interestingly, this 
reaction only took place with the N
9
-PMB regioisomer of 279, possibly due to steric 
constraints encountered at the purine 6-position when the N
7
-position was protected by the 
PMB group. Despite a modest overall yield (69%) based on consumption of starting material, 
this equated to near quantitative yield with respect to the N
9
-PMB regioisomer of 279. 
Conversion of the purine 2-amino group of 280 into an iodo substituent was achieved by 
diazotisation of the amine with isoamyl nitrite under Sandmeyer conditions, with iodine in 
279 
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the presence of copper iodide and diiodomethane.
212
 This afforded the 2-iodopurine 
intermediate 278 in good yield (87%). 
 
Aniline 276 was successfully coupled to the 2-iodopurine 278 by a palladium-catalysed 
amination under the general conditions previously described (see 141) to give compound 281, 
and PMB-deprotection was achieved in refluxing TFA. The isolated yield of the deprotected 
purine 277 was relatively poor for this type of reaction (~35%), with some difficulties 
encountered during purification. In addition, evidence of isoindolinone 282 formation was 
observed by LC-MS analysis, indicating that the acid-catalysed isoindolinone formation 
observed during the preparation of 275 was taking place, albeit to a lesser degree. Due to the 
poor yield of 277 it was decided to remove the TIPS-protecting group from this compound 
directly without further characterisation to ensure sufficient material for biological studies. 
Treatment of 277 with TBAF, followed by incubation with the TBAF scavenger beads 231, 
afforded the desired inhibitor 280 (Scheme 39). Unfortunately, evidence of tetra-n-
butylammonium contamination was present in the 
1
H NMR spectrum of this material, 
indicating that the scavenger beads had failed to remove all of the contaminant, and the 
compound was purified by semi-preparative HPLC. Following purification, however, the 
sample of 280 was seen to darken in colour over the course of 2 weeks, after which 
1
H NMR 
and LC-MS analysis revealed that the purine had been subject to decomposition to a complex 
mixture of degradation products. Insufficient research time remained to investigate 
compound 280 further. 
To establish the role of the carboxamide amino group of 177, the ketone analogue 199 was 
synthesised. An efficient method for the conversion of an amino-acid into a ketoamide is the 
Dakin-West reaction,
213
 and a modification of this reaction can be used to convert a 
carboxylic acid with an enolisable carbon at the α-position into a methyl ketone.214 This 
method was employed to convert 3-nitrophenylacetic acid (283) into the ketone 284 on 
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treatment with acetic anhydride in the presence of pyridine. To prevent self-condensation, the 
ketone carbonyl group of 284 was protected by conversion into the dithiane 285 with 1,3-
propanedithiol (Scheme 40). 
Scheme 40: Synthesis of the ketone 199 using a modified Dakin-West reaction. 
 
Reagents and conditions: i) Ac2O, pyridine, reflux, 4 h; ii) 1,3-propanedithiol, BF3.Et2O, DCM, RT, 18 h; iii) 
SnCl2.H2O, EtOH, reflux, 1.5 h; iv) 160, TFA, TFE, MW 140 °C, 2 h; v) [bis(trifluoroacetoxy)iodo]benzene, 
MeOH, H2O, RT, 10 min; vi) a) TBAF, THF, RT 5 min, b) 231, THF, RT, 48 h. 
Attempts to reduce the aromatic nitro group of 285 using iron-acetic acid gave a complex 
mixture, suggesting that the dithiane moiety was unstable under these conditions. Palladium-
catalysed hydrogenation also failed, due perhaps to the metal-coordinating nature of the 
sulfur atoms. Reduction was finally achieved on treatment with stannous chloride in refluxing 
ethanol, to give the aniline 286 in good yield (85%), and coupling to the 2-fluoropurine 160, 
as detailed previously, gave purine 287. Removal of the dithiane protecting group was 
achieved on treatment of 287 with [bis(trifluoroacetoxy)iodo] benzene to give the TIPS-
protected purine 288. Final deprotection of the 6-ethynyl group of 288 with TBAF, in 
conjunction with scavenger beads (231) furnished the target inhibitor (199). 
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To undertake further SAR studies around the purine 2-arylamino ring, additional derivatives 
analogous to the sulfonamide 178 were desired. Removal of the H-bond donor properties of 
the sulfonamide was to be investigated through the synthesis of the N,N-dimethylsulfonamide 
289 and sulfone 290. For the synthesis of sulfonamide 289, methodology previously used was 
employed to prepare the protected N,N-dimethylsulfonamide 291 in quantitative yield by 
treatment of trifluoroethylsulfonate ester 193 with dimethylamine in the presence of DBU. 
Removal of the TIPS-protecting group of 291 under the optimised conditions described above 
gave the target 6-ethynylpurine 289 (Scheme 41). 
Scheme 41: Synthesis of the 6-ethynylpurine 289. 
 
Reagents and conditions: i) Dimethylamine, DBU, THF, MW 160 °C, 15 min; ii) a) TBAF, THF, RT, 5 min, 
b) 231, THF, RT, 48 h. 
The aniline derivative required for sulfone 290 was prepared by heating 3-nitrobenzyl 
bromide (292) in the presence of sodium methanesulfinate to give the benzylsulfone 293 in 
excellent yield (94%). Reduction with iron in acetic acid gave aniline 294, which was 
coupled with 160 to afford the TIPS-protected purine 295. Final removal of the TIPS-
protecting group gave the target inhibitor 290 (Scheme 42). 
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Scheme 42: Synthesis of compound 290. 
 
Reagents and conditions: i) NaSO2CH3, EtOH, reflux, 2 h; ii) Fe, AcOH, 50 °C, 15 min; iii) 160, TFA, TFE, 
MW 140 °C, 2 h; iv) a) TBAF, THF, RT, 5 min, b) 231, THF, RT, 48 h. 
To assess the degree to which irreversible inhibition by 6-ethynylpurines contributes to their 
observed potency in inhibiting Nek2, it was desirable to synthesise a structurally similar 
analogue of 177 that would act as only a competitive reversible inhibitor of Nek2. The design 
of such a compound focussed on an isosteric replacement of the 6-ethynyl moiety of 177, as 
this had been shown by X-ray crystallography to be responsible for the covalent modification 
of Cys22 in Nek2. A potential isosteric replacement for the ethynyl moiety is a cyano group, 
which cannot act as a Michael acceptor when present at the purine 6-position. Therefore, the 
6-cyanopurine analogue 296 was proposed as a suitable compound to serve as an equivalent 
reversible competitive inhibitor of Nek2. 
 
The required aniline 297 was synthesised in good yield by treatment of methyl ester 234 with 
concentrated ammonium hydroxide (77%) (Scheme 43). Previous work within the research 
group employed a reliable method to introduce a cyano group at the purine 6-position.
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Thus, addition of tetra-n-butylammonium cyanide and DABCO to the PMB-protected purine 
279 resulted in the initial activation of the purine 6-position through formation of the 
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‘DABCO-purine’ salt (298). This species has previously been isolated and characterised.204 
The DABCO group was subsequently displaced by cyanide to give the 6-cyanopurine 299, 
and removal of the PMB-protecting group with TFA gave compound 300 as a TFA salt, 
confirmed by 
19
F NMR spectroscopy. The purine 2-amino group was converted into a fluoro 
substituent under Balz-Schiemann conditions, to give the 2-fluoropurine 301. The poor yield 
for this reaction indicated the potential instability of the cyano group to aqueous acid, 
although no evidence of the amide or acid hydrolysis products of 301 were observed by LC-
MS analysis. 
Scheme 43: Synthesis of aniline 297. 
 
Reagents and conditions: i) Conc. NH4OH, RT, 18 h. 
Despite the stability of the cyano group to the strongly acidic PMB-deprotection conditions, it 
was thought that an SNAr reaction at the purine 2-position mediated by TFA/TFE may result 
in degradation of the nitrile moiety. For this reason, neutral conditions were required for the 
coupling of aniline 297 to 2-fluoropurine 301. It is necessary to use TFA when reacting 
anilines with the 2-fluoro-6-(TIPS-ethynyl)purine 160, as the purine 2-position is 
insufficiently electrophilic. However, owing to the electron-withdrawing effect of the 6-
cyano group, it was possible to couple the aniline 297 directly to the 2-fluoro-6-cyanopurine 
301 by heating in DMSO, although a protracted reaction time (72 h) was required for the 
reaction to proceed to completion. The target 6-cyanopurine 296 was obtained in moderate 
overall yield (50%) (Scheme 44). 
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Scheme 44: Synthesis of the 2-arylamino-6-cyanopurine 296. 
 
Reagents and conditions: i) (
n
Bu4N)CN, DABCO, MeCN, RT, 18 h; ii) TFA, 70 °C, 5 h; iii) NaNO2, HBF4, 
H2O, 0 °C to RT, 70 min; iv) 297, DMSO, 100 °C, 72 h. 
6.4.2. Restricting the Conformational Flexibility of the Carboxamide Group of 2-
Arylamino-6-ethynylpurines 
To investigate the relationship between the carboxamide conformation and biological activity 
of 6-ethynylpurine 177 (NCL-00017509), efforts to impart conformational restriction on the 
carboxamide group were undertaken. A common method for reducing the conformational 
flexibility of functional groups with a methylene group is the preparation of a geminal 
dimethyl analogue. Accordingly the dimethyl derivative 302 was synthesised (Scheme 45). 3-
Nitrophenylacetic acid (283) was converted into methyl ester 303 as detailed previously. It 
was now possible to dimethylate the benzylic position by deprotonation of the enolisable 
methylene in the presence of methyl iodide. The use of an excess of both sodium hydride and 
methyl iodide gave the gem-dimethyl compound 304 in moderate yield (55%). Attempted 
conversion of 304 into the carboxamide (305) by treatment with concentrated ammonium 
hydroxide was unsuccessful at room temperature, presumably as a consequence of additional 
steric hindrance at the ester carbonyl conferred by the gem-dimethyl groups. The reaction 
proceeded on heating at 60 °C, although a significant proportion of the methyl ester 304 was 
hydrolysed to the carboxylic acid 306. The crude mixture of 305 and 306 was treated directly 
with thionyl chloride, before being added to concentrated ammonium hydroxide, giving an 
increased yield of the required carboxamide 305. 
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Scheme 45: Synthesis of the gem-dimethyl carboxamide 302. 
 
Reagents and conditions: i) SOCl2, MeOH, reflux, 1 h; ii) NaH, MeI, THF, 0 °C to RT, 18 h; iii) Conc. 
NH4OH, 60 °C, 18 h; iv) a) SOCl2, DMF, DCM, RT, 15 min, b) Conc. NH4OH, THF, RT, 18 h; v) Pd/C, 
NH4HCOO, MeOH, RT, 18 h; vi) 160, TFA, TFE, reflux, 24 h; vii) KF, 18-crown-6, THF, RT, 24 h. 
Reduction of the nitro group of 305 was carried out via catalytic transfer hydrogenation, and 
the resultant aniline (307) was coupled to the 2-fluoropurine intermediate 160 in the presence 
of TFA, under conventional heating conditions, to give the TIPS-protected purine 308. 
Removal of the TIPS-protecting group of 308 was performed as previously using KF/18-
crown-6, to yield the target inhibitor 302. 
Further conformational restriction of the carboxamide substituent of 177 was possible by 
incorporation into a ring system. Thus, a small series of purines was designed bearing lactam 
groups at the 2-position, to give a number of possible carboxamide conformations (309-316). 
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The aniline (5-amino-1,3-dihydro-2H-indol-2-one, 318) required for the synthesis of the 5-
membered ring lactam 309 was commercially available, and was coupled to the 2-
fluoropurine 160 under standard conditions to give the TIPS-protected purine 319. 
Deprotection of the alkyne moiety under the previously optimised conditions gave the target 
inhibitor 309 (Scheme 46). 
Scheme 46: Synthesis of the 6-ethynylpurine 309 bearing a lactam at the purine 2-position. 
 
Reagents and conditions: i) 160, TFA, TFE, reflux, 24 h; ii) a) TBAF, THF, RT, 5 min, b) 231, THF, RT, 48 h. 
148 
 
The aminoindolinone required for the preparation of compound 310 was prepared following a 
modified literature procedure for lactam synthesis.
216
 2,6-Difluoronitrobenzene (320) was 
reacted with di-tert-butyl malonate to give compound 321. It was intended to perform a 
lactam ring forming reaction by reduction of the nitro group of 321 in the presence of acid, 
followed by nucleophilic attack of the resultant aniline on a malonate carbonyl group. To 
achieve this, the remaining fluoro group was substituted by 4-methoxybenzylamine to give 
322. It was important that di-tert-butyl malonate was used for this reaction sequence, as 
preliminary studies using dimethyl malonate failed owing to side-reactions between 4-
methoxybenzylamine and the diester, resulting in amide formation. 
Scheme 47: Synthesis of the 2-aminolactam-6-ethynylpurine 310. 
 
Reagents and conditions: i) Di-tert-butylmalonate, K2CO3, DMF, 60 °C, 18 h; ii) PMB-NH2, THF, 80 °C, 18 
h; iii) a) Pd/C, NH4HCOO, AcOH, MW 100 °C, 80 min, b) AcCl, MeOH, RT, 1 h; iv) 160, TFA, TFE, reflux, 
24 h; v) a) TBAF, THF, RT, 5 min, b) 231, THF, RT, 48 h. 
Malonate derivative 322 was subjected to palladium-catalysed transfer hydrogenation in 
acetic acid with microwave assisted heating, whereby lactam formation occured in 
conjunction with removal of the PMB group. However, the use of acetic acid as solvent 
resulted in acetylation of the aniline (323), and it was necessary to treat the crude product 
with methanolic HCl prior to purification to deacetylate the aniline. The required 
aminolactam 324 was obtained in poor yield (36%), although sufficient material was isolated 
to proceed with the synthesis of the target purine (310). Coupling of 324 with the 2-
fluoropurine 160 under microwave heating gave the TIPS-protected purine 325, with removal 
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of the TIPS-protecting group proceeding in moderate yield (67%) on treatment with TBAF as 
before (Scheme 47). 
Scheme 48: Synthesis of the 2-aminoisoquinolone-6-ethynylpurine 313. 
 
Reagents and conditions: i) MeCO2Cl, K2CO3, Et2O, H2O, RT, 1 h; ii) Eaton’s reagent, MW 120 °C, 15 min; 
iii) HNO3, H2SO4, 0 °C, 30 min; iv) Fe, AcOH, 50 °C, 15 min; v) 160, TFA, TFE, MW 140 °C, 2 h; vi) a) 
TBAF, THF, RT, 5 min, b) 231, THF, RT, 48 h. 
The synthesis of lactam 312 commenced with the preparation of carbamate 326 by treatment 
of N-methyl-phenethylamine (327) with methyl chloroformate. Cyclisations employing a 
Bischler-Napieralski reaction are often performed in polyphosphoric acid (PPA). However, 
owing to the viscosity of PPA, it was desirable to use an alternative reagent for the 
cyclisation of carbamate 326 to the tetrahydroisoquinolone 328. A literature procedure for the 
synthesis of lactam 333 utilised Eaton’s reagent (7.7% w/w phosphorus pentoxide in 
methanesulfonic acid) as an alternative to PPA with greatly improved ease of handling.
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Carbamate 326 was heated in Eaton’s reagent under microwave conditions to afford the 
lactam 328 in good yield (88%), and nitration using fuming nitric acid in sulfuric acid gave 
the nitroisoquinolone 330. Heteronuclear multiple bond correlation (HMBC) two-
dimensional NMR analysis of 330 confirmed the expected regioselectivity of this reaction. 
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Reduction of the nitro group of 330 using iron-acetic acid gave aniline 331, which was 
coupled to the 2-fluoropurine 160 under TFA catalysis. Final removal of the TIPS group 
under standard conditions afforded the target purine 312 (Scheme 48). The N-unsubstituted 
analogue 311 was successfully prepared employing a similar synthetic approach, and starting 
from phenethylamine. 
A literature procedure was available for the synthesis of the methyltetrahydroisoquinolone in 
314, utilising the Pictet-Spengler reaction between N-methylcarboxamide 332 and 
paraformaldehyde in the presence of Eaton’s reagent.217 It was proposed that this 
methodology would also be used for the synthesis of compounds 313- 316. The first 
compound investigated was the literature example (333) as a means to validate the procedure. 
4-Nitrophenylacetic acid (245) was converted into the N-methylcarboxamide 332 under 
conditions previously discussed. Although successful, this reaction required 72 hours reaction 
time, possibly as a consequence of deprotonation of the acidic benzylic proton by excess 
methylamine, hindering the reaction. Compound 332 and paraformaldehyde were reacted in 
Eaton’s reagent, under microwave conditions, to afford the tetrahydroisoquinolone 333, in 
good yield (75%). Reduction of the nitro group and coupling of the resultant aniline (334) to 
160 afford the TIPS-protected purine 335. Removal of the TIPS group under the optimised 
conditions gave the target purine 314 (Scheme 49). 
Scheme 49: Preparation of the 2-aminoisoquinolone-6-ethynylpurine 314. 
 
Reagents and conditions: i) a) SOCl2, MeOH, reflux, 1 h, b) Aq. MeNH2, RT, 72 h; ii) (CH2O)n, Eaton’s 
reagent, 80 °C, 6 h; iii) Fe, AcOH, 50 °C, 15 min; iv) 160, TFA, TFE, MW 140 °C, 2 h; v) a) TBAF, THF, RT, 
5 min, b) 231, THF, RT, 48 h. 
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However, when this approach was applied to the synthesis of compounds 313, 315 and 316, 
significant problems were encountered. For the synthesis of 313, an initial attempt was made 
to prepare lactam 336 by a Pictet-Spengler reaction between carboxamide 337 (synthesis not 
shown) and paraformaldehyde, resulting in a complex mixture of unidentified products by 
LC-MS analysis. It was thought that this may be due to side-reactions between the free NH of 
the carboxamide and reactive imine species in the reaction mixture following the initial 
cyclisation. It was therefore deemed necessary to identify a protecting group that could be 
used to prevent such non-specific reactions. However, selection of a protecting group that 
would be stable under the harsh reaction conditions, whilst being readily removable after the 
reaction, proved challenging. The cyclisation was attempted using both N-allylcarboxamide 
(338) and N-benzylcarboxamide (339) protection, despite concerns over the ease with which 
a benzyl group could be removed from the product 340. In any event, complete compound 
degradation was observed in both cases, with no product formation detectable by LC-MS 
analysis (Scheme 50). Owing to time constraints, this work was not pursued further. 
Scheme 50: Attempted Pictet-Spengler cyclisation reactions towards the synthesis of 313. 
 
Reagents and conditions: i) (CH2O)n, Eaton’s reagent, 80 °C, 3 h. 
The synthesis of compound 315 via the Pictet-Spengler approach was not attempted in light 
of the difficulties encountered as outlined in Scheme 50. For the preparation of 316 it was 
anticipated that formation of the N-methyllactam 341 under the conditions used for the 
synthesis of 333 would be challenging, as the aromatic carbon nucleophile of 342 is 
deactivated by the para-nitro group. However, it was proposed that microwave assisted 
heating conditions might enable the reaction to proceed. N-Methylcarboxamide 342 and 
paraformaldehyde were heated under microwave irradiation in Eaton’s reagent to 150 °C. 
After 4 hours, some starting material remained, evident by TLC analysis, although the 
reaction was deemed to have progressed sufficiently to warrant isolation of the target lactam 
341. Upon isolation of the major product of the reaction, 
1
H NMR analysis indicated the 
presence of two products, proposed to be the desired lactam 341 and the regioisomeric 
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compound 343 (Scheme 51). This was despite it being believed that formation of 343 would 
be sterically disfavoured due to the neighbouring nitro group. The regioisomers 341 and 343 
were separable by chromatography and characterised as approximately a 1:1 mixture of 
regioisomers. The yield of product recovered from the reaction (30%), however, suggested 
that this approach was unsuitable for the synthesis of the single regioisomer 341. No further 
efforts were made to synthesise compound 316 as alternative targets were pursued. 
Scheme 51: Synthesis of regioisomeric tetrahydroisoquinolones 341 and 343. 
 
Reagents and conditions: (CH2O)n, Eaton’s reagent, MW 150 °C, 4 h. 
6.4.3. Analogues of NCL00017509 (177) as Prospective Biochemical Probes 
The potent and irreversible inhibition observed for 6-ethynylpurine Nek2 inhibitors offered 
the possibility of such compounds being used as cellular probes of Nek2 localisation. 
Incorporation of a fluorescent group into the structure of such compounds may enable a better 
understanding of the cellular localisation of both drug and protein target through the use of 
IFM, in conjunction with protein specific fluorescent antibodies. It was desirable to develop 
an inhibitor based upon 177 (NCL-00017509) with a fluorophore attached to the structure 
such that Nek2 inhibitory activity was not compromised. From an understanding of the 
binding mode of 177 within the ATP domain of Nek2 (Figure 32), it was evident that the 
carboxamide moiety in the 2-arylamino side-chain is directed towards solvent. This indicated 
that substitution on the carboxamide group would be a viable approach by which to introduce 
a fluorescent tag. 
Nitrobenzoxadiazole (NBD) was considered to be a suitable fluorophore, as NBD is known to 
exhibit higher intensity fluorescence bound to a kinase compared to in free solution,
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 and 
this fluorophore may easily be incorporated into the inhibitor. The NBD group is non-
fluorescent in the absence of an amino group at the 4-position, and it was therefore designed 
to be attached to the carboxamide of 177 via an alkylamino spacer group (344). It was also 
necessary to design a control compound lacking the NBD group in order to assess the 
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contribution of this structural modification on Nek2 inhibitory activity. Prior experience 
indicated that compounds bearing basic groups in the 2-arylamino side-chain were subject to 
decomposition upon removal of the TIPS-protecting group from the 6-ethynyl substituent 
(see chapter 6.3.1.). Hence, it was inappropriate to simply remove the NBD group to leave a 
primary amine, and it was decided to prepare the N-acetylated compound 345 in parallel with 
344. 
 
A synthetic approach was identified for the preparation of both compounds 344 and 345 
(Scheme 52). The amino group of 3-aminophenylacetic acid (346) was Boc-protected (347), 
and the requisite alkylamino linker was introduced through a CDI-mediated coupling reaction 
between carboxylic acid 347 and 1,2-diaminoethane to give intermediate 348. Subsequent 
reaction with NBD-chloride or acetic anhydride gave compounds 349 and 350, respectively. 
The Boc-protecting group was removed from 349 and 350 with TFA to give anilines 351 and 
352, which were coupled to the 2-fluoropurine 160 to yield the TIPS-protected purines 353 
and 354, respectively. It was not clear why the coupling reactions for both anilines 351 and 
352 proceeded at a significantly slower rate (96 hours and 72 hours, respectively) compared 
with previous reactions of this type, and in low yield (14%) for 353. There was, however, 
sufficient material to proceed to the final step, and removal of the TIPS-protecting groups of 
compounds 353 and 354 as described previously afforded the target inhibitors 344 and 345. 
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Scheme 52: Synthesis of 6-ethynylpurines 344 and 345. 
 
Reagents and conditions: i) Boc2O, 1,4-dioxane, NaOH, H2O, RT, 18 h; ii) H2N(CH2)2NH2, CDI, DIPEA, 
THF, RT, 18 h; iii) NBD-Cl, NEt3, DMF, RT, 18 h; iv) Ac2O, pyridine, RT, 18 h; v) TFA, DCM, RT, 18 h; vi) 
160, TFA, TFE, reflux, 72-96 h; vii) KF, 18-crown-6, THF, RT, 18 h. 
Positron emission tomography (PET) is a useful imaging technique that can be used to 
monitor the distribution and localisation of drug molecules and their metabolites in vivo.
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Briefly, a PET scanner detects radiation in the form of gamma-rays, arising from the decay of 
positrons emitted from a positron-emitting radioisotope. Incorporation of such a radiolabel 
into a drug molecule may enable a 3-dimensional image to be generated showing drug 
distribution in vivo. A common radioisotope used for such studies is fluorine-18 (
18
F), owing 
to its reasonable half-life (109.7 minutes), and the ease with which it can often be 
incorporated into small molecules. The possibility of using this technique to determine the 
biological fate of 6-ethynylpurine Nek2 inhibitors was investigated. 
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Following discussions with Dr Michael Carroll (Radiopharmacology Group, Newcastle 
University) it was proposed that incorporation of 
18
F into the 2-arylamino side-chain of 177 
may be a suitable approach for this purpose. The manner by which 
18
F is generated indicated 
that 2-fluoroethylamine would be a suitable reagent, leading to the design of compound 355. 
Prior to the synthesis of a radiolabelled inhibitor, it was necessary to synthesise the 
corresponding 
19
F-analogue of 355 to establish that the Nek2 inhibitory activity of this 
compound is retained. As an additional compound to further investigate SARs on the 
carboxamide group of 177, the trifluoroethyl analogue (356) was also synthesised. 
Scheme 53: Synthesis of compound 356. 
 
Reagents and conditions: i) RCH2NH2, PCl3, MeCN, MW 150 °C, 5 min; ii) Pd/C, NH4HCOO, MeOH, RT, 18 
h; iii) 160, TFA, TFE, reflux, 48 h; iv) a) TBAF, THF, RT, 5 min, b) 231, THF, RT, 48 h. 
3-Nitrophenylacetic acid (283) was coupled with 2-fluoroethylamine or 2,2,2-
trifluoroethylamine using phosphorus trichloride as previously described, to generate 
fluoroethylcarboxamide 357 and trifluoroethylcarboxamide 358, respectively. Nitro group 
reduction of 357 and 358, gave anilines 359 and 360, respectively, which were reacted with 
the 2-fluoropurine 160 under standard conditions. However, whereas aniline 360 coupled to 
the purine, as expected, to afford 361, the reaction with 359 failed to yield any of the required 
product (362), although the aniline was consumed. It was proposed that the 
fluoroethylcarboxamide 359 may be subject to polymerisation under these reaction 
conditions, to give 363, by virtue of an SN2 reaction between the amino function and fluoro 
substituent (Scheme 54). 
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Scheme 54: Proposed mechanism for degradation of aniline 359. 
 
 
Reagents and conditions: i) TFA, TFE, reflux, 48 h. 
The TIPS-protecting group was removed from purine 361 with TBAF under established 
conditions to give the target compound 356 (Scheme 53). The instability of aniline 359 under 
the usual coupling conditions prompted an alternative approach to be employed for the 
synthesis of 355. Using carboxylic acid 186, it was possible to prepare the TIPS-protected 
purine 362 through a CDI-mediated amide coupling with 2-fluoroethylamine. Final removal 
of the TIPS-protecting group gave the required product 355 (Scheme 55). 
Scheme 55: Synthesis of the 6-ethynylpurine 355. 
 
Reagents and conditions: i) F(CH2)2NH2, CDI, DIPEA, THF, RT, 18 h; ii) a) TBAF, THF, RT, 5 min, b) 231, 
THF, RT, 48 h. 
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6.4.4. Biological Results 
All compounds synthesised were screened for inhibitory activity against both Nek2 and 
Cdk2. In addition, due to the observation that the SKBR3 cell line is sensitive to 6-
ethynylpurine Nek2 inhibitors, the purines were evaluated for growth inhibitory activity in 
vitro against this tumour cell line (Table 14). 
 
  IC50 (µM) GI50 (µM) 
Compound R Nek2
a
 Cdk2
b
 SKBR3 
177 
 
0.062 ± 0.01 11.8 2.2 ± 0.4 
200 
 
0.076 24.4 2.4 ± 0.1 
201 
 
0.088 17.0 0.4 ± 0.2 
202 
 
0.093 9.9 8.8 ± 1.8 
203 
 
0.072 20.0 4.9 ± 2.4 
204 
 
0.057 39.0 1.2 ± 0.6 
257 
 
0.071 18.0 87.8 
212 
 
0.079 32.8 3.9 ± 1.3 
205 
 
0.116 13.2 0.7 ± 0.1 
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  IC50 (µM) GI50 (µM) 
Compound R Nek2
a
 Cdk2
b
 SKBR3 
206 
 
0.026 26.5 0.9 ± 0.1 
207 
 
0.050 86.0 0.9 ± 0.1 
208 
 
0.110 8.8 7.4 ± 0.1 
209 
 
0.110 15.3 4.1 ± 0.5 
210 
 
0.064 24.8 1.4 ± 0.4 
211 
 
0.039 22.9 0.8 ± 0.5 
302 
 
0.210 46.0 1.4 ± 0.6 
344 
 
0.220 >100 >30 
345 
 
0.190 82.0 >30 
355 
 
0.056 26.4 2.6 ± 0.3 
356 
 
0.078 41.3 1.5 ± 0.1 
a 
Nek2 IC50 values determined at 30 µM ATP concentration; 
b
 Cdk2 IC50 values determined at 12.5 µM ATP 
concentration. 
Table 14: A) Biological evaluation of carboxamide based analogues of 177 (NCL-00017509). 
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  IC50 (µM) GI50 (µM) 
Compound R Nek2
a
 Cdk2
b
 SKBR3 
199 
 
0.076 21.6 0.4 ± 0.1 
178 
 
0.130 14.0 4.1 ± 2.2 
289 
 
0.010 20.0 0.8 ± 0.1 
290 
 
0.057 12.7 1.3 ± 0.0 
309 
 
0.100 10.9 10.3 
310 
 
0.820 62.3 1.3 ± 0.2 
311 
 
0.830 12.6 0.6 ± 0.1 
312 
 
0.010 19.2 0.3 ± 0.1 
314 
 
0.042 8.3 0.8 ± 0.1 
a 
Nek2 IC50 values determined at 30 µM ATP concentration; 
b
 Cdk2 IC50 values determined at 12.5 µM ATP 
concentration. 
Table 14: B) Biological evaluation of non-carboxamide analogues of 177 (NCL-00017509). 
All purine derivatives tested exhibited inhibitory activity against Nek2 with all but two 
compounds (310 and 311) possessing an IC50 of less than 0.25 µM. It is evident that the 
activity of 177 (IC50 = 0.062 ± 0.01 μM) is not affected by truncation (205; IC50 = 0.116 μM) 
or homologation (212; IC50 = 0.079 μM) of the methylene spacer group. The ability of the 
carboxamide group to act as an H-bond donor does not appear to be a significant contributory 
factor to the potency of 177, as sequential removal of the carboxamide amino hydrogen 
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atoms with the N-methylcarboxamide (200; IC50 = 0.076 μM) and N,N-dimethylcarboxamide 
(201; IC50 = 0.088 μM) analogues of 177 had little effect on Nek2 inhibitory activity. 
Interestingly, for the N,N-dimethylsulfonamide analogue (289; IC50 = 0.010 µM) the lack of 
an H-bond donor atom conferred a significantly improved potency when compared with the 
primary sulfonamide (178; IC50 = 0.130 µM). Furthermore, the position at which the 
acetamide substituent is attached to the 2-arylamino ring has limited influence on the potency 
of inhibitors, as was observed for the 4-substituted analogue (202; IC50 = 0.093 μM). 
Unfortunately, it was not possible to synthesise the 2-substituted analogue (213) to further 
validate this observation. However, for compound 310 (IC50 = 0.82 μM) it is likely that the 
conformational restriction imposed by the bicyclic 2-arylamino system forces steric clashes 
with the binding site of Nek2. This suggests that the optimal 2-arylamino side-chain 
characteristics are more linear with respect to the purine scaffold, as indicated by comparison 
of the activity of 310 with that of the regioisomeric analogue 309 (IC50 = 0.10 μM). This does 
not, however, explain the disparity in activity between lactams 311 (IC50 = 0.83 μM) and 312 
(IC50 = 0.01 μM). As previously seen for compounds of this class, only very limited SARs are 
evident, with no discernible trend observed between the activity of compounds against Nek2 
and the degree of modification of the carboxamide group. Presumably, all compounds 
excluding 310 and 311 exhibit sufficient initial competitive binding affinity for Nek2 to allow 
the purine to occupy the ATP-binding domain of the kinase and enable subsequent covalent 
modification of Cys22 to occur. The weaker activity observed for 310 and 311 does suggest 
that it is possible to elucidate SARs for this compound class and that potent activity is not 
common to all of the 6-ethynylpurines. Nevertheless, it is likely that both compounds 310 and 
311 exhibit a particularly weak initial competitive binding affinity for the kinase, as the 
diverse range of functionalities tolerated at the 2-arylamino position suggest that subtle 
changes in competitive binding for an irreversible binding series will be undetectable within 
this assay format. What these data do reveal, however, is that for irreversible inhibitors in the 
6-ethynylpurine class, there is a large degree of tolerance for substitution on the 2-arylamino 
ring. This is particularly relevant for the synthesis of compounds designed to act as 
biochemical tools for the study of cellular Nek2 activity (e.g. 344; IC50 = 0.22 μM, see 
chapter 6.4.3.). 
During the biochemical evaluation of 177 and related compounds in cellular systems (see 
chapter 7), U2OS cells overexpressing Nek2 were incubated with the fluorescently tagged 
irreversible inhibitor 344. Unfortunately, it was not possible to detect any significant 
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fluorescence signal, either at the centrosomes or within the cell as a whole by fluorescence 
microscopy. It is possible that the high CLogP of 344 (3.8) conferred poor cell permeability 
to this purine, thus limiting the suitability of this compound as a biochemical probe. This is 
also reflected by the lack of cellular growth inhibitory activity observed for the fluorescent 
inhibitor 344 and the control compound 345 (SKBR3; GI50 > 30 μM).  
All analogues of 177 maintained selectivity for Nek2 over Cdk2. Due to the expense and 
resource required, no further selectivity data were obtained for individual compounds. In 
addition, all compounds detailed in Tables 14 A and B exhibited growth inhibitory activity in 
the SKBR3 cell line. It was surprising to find that there appeared to be a poor correlation 
between the IC50 of compounds in the Nek2 kinase assay and their activity in the SKBR3 
cellular GI50 assay. In particular, compound 311 (Nek2; IC50 = 0.83 µM, SKBR3; GI50 = 0.6 
± 0.1 µM) was the least active inhibitor in the Nek2 assay, but proved one of the most potent 
growth inhibitors in SKBR3 cells.  
 
Figure 38: Dose-dependent reduction of pC-Nap1 levels for selected compounds within the 6-ethynylpurine 
series. 
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Selected purines were evaluated for inhibition of cellular pC-Nap1 levels (Figure 38). The 
majority of compounds reduced pC-Nap1 levels in a dose-dependent manner, although to 
varying degrees. However, the levels of pC-Nap1 inhibition did not correlate with the Nek2 
IC50 or the growth inhibitory activity of compounds in the SKBR3 cell line. A more 
comprehensive selection of the inhibitors synthesised would need to be evaluated in this 
assay to further investigate this observation. A possible reason for the disparity between 
cellular growth activity and Nek2 inhibitory activity may be the cellular permeability of 
compounds. Although values from the pC-Nap1 assay are not quantitative, it may be possible 
to correlate cellular activity with cellular permeability by relating the GI50 of compounds in 
the SKBR3 cell line to their CLogP values (Figure 39; corrected to remove compounds with a 
GI50 greater than 10 µM). Unfortunately, there was no clear correlation, and without 
evaluation of all synthesised inhibitors in the pC-Nap1 assay it is not possible to draw further 
conclusions from these results. 
 
Figure 39: Relationship between the cellular growth inhibitory activity of 6-ethynylpurines in the SKBR3 cell 
line and their CLogP values for compounds with a GI50 <10 µM. 
In addition to the 6-ethynylpurine analogues within the series, the 6-cyano derivative (296) 
was synthesised as a purely competitive control compound of 177. As expected, 296 was 
much less active against Nek2 when compared with compounds in the 6-ethynylpurine series, 
highlighting the requirement for the Michael acceptor motif for potent kinase inhibition. The 
6-cyanopurine retains low micromolar potency against Nek2, perhaps reflecting the 
competitive binding component of 177, and suggests that without covalent modification, the 
purine template remains a moderately potent competitive Nek2 inhibitor. Furthermore, 296 
was significantly less growth inhibitory in the SKBR3 cell line than 177, likely due to the 
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modest potency of the compound towards Nek2. However, it must also be noted that 296 
(CLogP = 0.64) is more polar than 177 (CLogP = 1.24) and the weak growth inhibition in 
cells may be a result of poor cellular permeability. 
 
6.4.5. Further Studies with NCL-00017509 (177) 
The 6-ethynylpurine 177 (NCL-00017509) was an attractive early stage lead inhibitor of 
Nek2, with good potency and kinase selectivity. Cell lines have been identified in which the 
compound is not only growth inhibitory, but also cytotoxic (SKBR3 and Rec-1). As such, 
further studies to characterise 177 as a lead compound were undertaken, including 
preliminary in vitro ADME testing (Cyprotex Discovery, Macclesfield) (Table 15). These 
studies suggested that 177 possessed the attributes of a drug-like compound. The purine was 
found to combine an excellent plasma protein binding profile (<80%) with good aqueous 
solubility within the constraints of the assay. No inhibition of hERG (human Ether-a-go-go-
Related Gene product) was observed at 25 μM, and 177 exhibited a good stability profile in 
both human and mouse liver microsomes, despite the electrophilic 6-ethynyl group.  
Studies employing the Caco-2 cell line allowed an estimation of compound permeability and 
efflux to be determined. The direction [A → B] equates to compound passing from the 
gastrointestinal tract into the blood, with [B → A] relating to drug efflux in the reverse 
direction. The inhibitor showed low permeability and high efflux, suggesting that the oral 
bioavailablility of 177 may be poor. It is possible, however, that the inherent permeability of 
the compound is good, but that it is also a substrate for drug efflux transporters. 
  
± 
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Plasma Protein Binding: 
Fraction Unbound Mean 
Fraction 
Unbound 
Standard 
deviation (n = 2) 
Mean recovery 
% Replicate 1 Replicate 2 
0.219 0.228 0.223 0.00668 86.3 
 
Microsomal Stability: 
Microsomal Stability (Human) Microsomal Stability (Mouse) 
CLint 
(µl/min/mg) 
S.E. 
CLint 
T1/2 
(min) 
n 
CLint 
(µl/min/mg) 
S.E. 
CLint 
T1/2 
(min) 
n 
6.21 0.681 223 5 10.2 1.82 136 5 
Solubility: 
Estimated Precipitation Range (µM) 
Lower Bound Upper Bound Calculated mid-range 
100 >100 >100 
Caco-2 Permeability: 
 Papp (x 10
-6
 cm
-1
) 
Mean Papp 
(x 10
-6
 cm
-1
) 
  
Mean 
recovery (%) 
Direction 1 2 SD n 
A → B 0.0534 0.0421 0.0477 0.00799 2 57.6 
B → A 4.88 5.29 5.08 0.293 2 64.0 
Table 15: in vitro ADME properties for 177 (NCL-00017509) at Cyprotex Discovery, Macclesfield. 
The promising in vitro results prompted the evaluation of 177 in in vivo models for both 
pharmacokinetics (PK) and antitumour efficacy, by collaborators within the NICR. For 
preliminary PK evaluation 177 was administered at a single dose (10 mg/kg) to female CD1 
mice (n = 24). Three routes of administration were used; intravenous (i.v.) via the tail vein, 
intraperitoneal (i.p.), or orally (p.o.) by gavage. The purine was administered in a vehicle 
comprising 10% (w/w) PEG400 and sterile 0.9% w/v saline. Blood samples were taken (n = 3 
mice) at selected time points post treatment, HPLC analysis was used to determine inhibitor 
concentrations at each time point, and PK parameters were calculated (Figure 40). 
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The compound was rapidly cleared from the blood following i.v. administration, with a low 
area under the curve (AUC), high clearance and a short half-life (t1/2). No inhibitor was 
detected in blood samples for animals treated p.o., indicating that 177 has poor oral 
bioavailability, either due to poor absorption, or, as implied by the Caco-2 permeability 
assay, active efflux. It has been proposed that dosing 177 i.p. may increase exposure and 
hence the AUC due to prolonged absorption of the compound from the peritoneal cavity. 
 
 
AUC 
(µg/ml.min) 
Clearance 
(ml/min/kg) 
t1/2  
(min) 
Cmax 
(µg/ml) 
Tmax 
 (min) 
Time > 1 
µM (min) 
Vdss 
(L/kg) 
Bioavail. 
i.v. 2.52 3965 2.52 0.37 ± 0.34 5 < 10 24.2 - 
i.p. 5.93 1687 16.46 0.30 ± 0.11 5 < 10 29.3 235% 
p.o. N/A N/A N/A < 0.05 N/A N/A N/A 0 
Figure 40: Preliminary PK parameters for 177 (NCL-00017509) administered i.v., i.p. or orally to mice (n = 24) 
over 6 h (undetectable after 2 h).  
To understand the rapid clearance of 177, stability studies were performed for the compound 
in buffered solutions at pH 2, 7.4 and 10, and in a solution containing 5 mM glutathione 
(GSH), which approximates to intracellular concentrations. Samples of 177 in the three 
solutions were incubated at 37 °C and the concentration of 177 determined by HPLC at time 
points over 18 hours (Figure 41). It is likely that 177 is poorly soluble in solutions at higher 
pH, and therefore the concentration only becomes consistent once the sample is incubated at 
37 °C for 10 minutes. It was evident that under the assay conditions, 177 is degraded in a 
166 
 
time dependent manner in the presence of glutathione. This suggests that reaction with 
glutathione may contribute to the rapid clearance observed for 177 in Figure 40.  
 
Figure 41: Stability of 177 at pH 2, 7.4 and 10 (37 °C), and in a phosphate buffered saline solution (ph 7.4) 
containing 5 mM GSH (n = 1); concentration determined by HPLC. 
For efficacy studies, i.p. administration of 177 was selected, and it was first necessary to 
determine the maximum tolerated dose (MTD) of the purine in i.p. treated mice. Female CD1 
mice (n = 12) were treated with 50, 100 or 200 mg/kg 177 i.p. and clinical signs and body 
temperature were monitored over 6 hours, with body weight also being recorded daily for 18 
days, as a measure of toxicity (Figure 42). 
 
Figure 42: Determination of MTD for mice (n = 12; 3 per group) treated i.p. with 177 (NCL-00017509); A) 
Body temperature measurements recorded over 6 hours post-treatment; B) Calculated variations in 
starting body weight over 18 days post-treatment. 
A B 
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The mice were able to tolerate 100 mg/kg 177 acutely, whereas animals treated with 200 
mg/kg inhibitor exhibited a marked hypothermia that normalised slowly over time. Over 24 
hours, mice treated with 100 mg/kg inhibitor showed moderate signs of toxicity, including 
some weight loss, and appeared ungroomed; however, all signs of toxicity disappeared by 48 
hours post-treatment. Apart from some evidence of bloating on close inspection no further 
clinical toxicity was observed over the 18 day period, after which the mice were monitored 
for a further 10 days. However, under post-mortem examination 28 days post-treatment, signs 
of severe reaction in the peritoneum manifesting as adhesion of the gut and abdominal organs 
was observed, attributed to the local toxicity of the compound.  
 
 Time to RTV 4 (d) 
Control 13 16 10 13 7 
+ 177 N/A >100 23 >100 11 
Figure 43: Efficacy study for mice with RIVA B-cell lymphoma xenograft treated with 177 (n = 5) at 50 mg/kg 
hourly i.v. injections ( < 6 per mouse); A) relative tumour volume measurements over the course of 
the study; B) Percentage body weight variations for both study populations. 
To circumvent this local toxicity is was necessary to attempt i.v. dosing for the efficacy 
studies. For this study, 20 mice were transplanted with subcutaneous RIVA tumours, and 10 
were randomised and selected for trial. Owing to the rapid clearance of 177 following i.v. 
administration, six hourly dosing at 50 mg/kg was required to achieve potentially active 
exposures (AUC), with a total dose of 300 mg/kg. This regimen had previously been shown 
to cause no appreciable toxicity (data not shown). For both control and 177 treated groups, 
the tumour volume was monitored over a time period required to allow a 4-fold increase in 
A B 
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relative tumour volume (RTV 4) in the control group. In addition, body weights were 
recorded to reflect potential compound toxicity (Figure 43). 
One mouse within the treated group was killed prior to reaching RTV 4 owing to tumour 
burden. The initial efficacy results obtained for the remaining mice were promising, with two 
mice failing to reach RTV 4 within the study period. However, this study would need to be 
expanded to establish the statistical significance of the results, and subsequent concerns over 
the selectivity of the inhibitor precluded further studies with 177. 
6.5. 6-Ethynylpurines with Heterocycles at the 2-Position 
6.5.1. Target Compound Selection and Synthesis 
Although it was apparent that structural variation of the substituent on the 2-arylamino side-
chain was tolerated with respect to Nek2-inhibitory activity for the 6-ethynylpurine 
pharmacophore, little was known about the effect of modifying the 2-aryl ring. To investigate 
this, a small series of compounds containing six-membered ring nitrogen heterocycles (364-
369) was selected for synthesis. 
 
Ar =  
      
 364 365 366 367 368 369 
Initial efforts to couple 2-, 3-, and 4-aminopyridine to the 2-fluoropurine intermediate 160 
suggested that the usual acid-catalysed SNAr approach was unsuitable. Under microwave 
conditions using TFA, only very low conversion into the desired products was observed by 
LC-MS analysis for the three aminopyridines. It is likely that, when using a weakly basic 
heterocycle, the quantity of TFA required for optimum reaction conditions is different to that 
necessary when using anilines. To study this, the reaction between 4-aminopyridine and 2-
fluoropurine 160 was carried out in TFE, whilst varying the number of equivalents of TFA 
added. In each case the reaction was performed at 140 °C with microwave irradiation for 2 
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hours, after which the percentage conversion to the product (380) was estimated by LC-MS 
analysis (Scheme 56). The reaction mixture using 3 equivalents of TFA was worked-up and 
the product isolated. Analysis by 
1
H NMR spectroscopy revealed that, in fact, the product 
was the zwitterionic pyridinium species 371. 
Scheme 56: Attempted coupling of 4-aminopyridine with 160 using acid-catalysis. 
 
Reagents and conditions: i) 4-Aminopyridine, TFA, TFE, MW 140 °C, 2 h. 
Equiv. TFA Yield of 380 (%)* Comments 
0 0 Degradation 
1 0 Degradation 
2 4 Degradation 
3 24 Clean conversion 
4 21 Clean conversion 
5 22 Clean conversion 
* = Estimated by LC-MS      
Table 16: Estimated yields for the coupling of 4-aminopyridine with 160 with varying equivalents of TFA. 
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In light of this, it was apparent that this approach was not suitable for the coupling of 
aminoheterocycles to the purine scaffold. For this reason, a palladium-mediated amination 
was preferred for the key step by which the two heterocycles were to be coupled. The 2-
iodopurine intermediate 278 coupled successfully with 2-, 3-, and 4-aminopyridine, as well as 
2-, 4- and 5-aminopyrimidine, to give PMB-protected purines 372-377, which were converted 
into the TIPS-protected purines (378-383) on heating in TFA. Final deprotection with TBAF 
gave the target 2-arylaminopurines 364-369 (Scheme 57). Unfortunately, it was not possible 
to isolate 367 in sufficient purity for biological testing, but the Nek2 inhibitory activity of the 
other compounds was determined (Table 17). 5-Aminopyrimidine (384) required for the 
preparation of compound 369 was prepared by the reductive dehalogenation of 2,4-dichloro-
5-aminopyrimidine. 
Scheme 57: Synthesis of 2-arylamino-6-ethynylpurines 364-369. 
 
R =  
      
A 372 373 374 375 376 377 
B 378 379 380 381 382 383 
C 364 365 366 367 368 369 
Reagents and conditions: i) Ar-NH2, Pd2(dba)3, XPhos, K2CO3, MeCN, 100 °C, 1 h; ii) TFA, reflux, 18 h; iii) 
a) TBAF, THF, RT, 5 min, b) 231, THF, RT, 48 h. 
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6.5.2. Biological Results 
Compounds (364-366, 368 and 369) were evaluated for inhibitory activity (IC50) against both 
Nek2 and Cdk2. In addition, growth inhibition in SKBR3 cells was determined (Table 17). 
 
  IC50 (µM) GI50 (µM) 
Compound R Nek2
a
 Cdk2
b
 SKBR3 
148 
(NCL-00016727) 
 
0.14 ± 0.1 22.9 0.3 ± 0.04 
364 
 
2.0 20%** 0.2 ± 0.01 
365 
 
0.6 18.4 0.6 ± 0.06 
366 
 
0.1 7.5 0.6 ± 0.4 
368 
 
19%* 10%** 2.4 ± 0.8 
369 
 
0.2 49.1 0.4 ± 0.1 
a 
Nek2 IC50 values determined at 30 µM ATP concentration; 
b
 Cdk2 IC50 values determined at 12.5 µM ATP 
concentration;  * = Percentage inhibition at 10 µM; ** = Percentage inhibition at 100 µM 
Table 17: Biological evaluation of 6-ethynylpurines bearing heterocyclic groups at the purine 2-position. 
The IC50 values obtained for compounds 364 and 368 suggest that there is a poor tolerance of 
both Nek2 and Cdk2 to inhibitors containing a heterocyclic nitrogen at the ortho-position on 
the 2-arylamino ring. It is possible that this is as a consequence of electrostatic clash between 
the ring nitrogen electron lone pair and amino acids of the kinase hinge region. Of the 
compounds retaining potency against Nek2 (365, 366 and 369) there appears to be little 
advantage in terms of potency from incorporating heterocyclic rings at the purine 2-position 
when compared with the parent phenyl derivative (148, NCL-00016727) In addition, the 
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synthesised heterocyclic compounds strengthen the observation that there appears to be poor 
correlation between the Nek2 kinase inhibitory activity of 6-ethynylpurines and their 
corresponding growth inhibitory activity in the SKBR3 cell line (e.g. 364, Nek2; IC50 = 2.0 
µM, SKBR3; GI50 = 0.2 µM). 
6.6. Purines Bearing Disubstituted 2-Arylamino Groups 
6.6.1. Target Compound Selection and Synthesis 
From modification of the 2-arylamino ring of 6-ethynylpurines, it was apparent that there is a 
high degree of tolerance with respect to activity against Nek2. This has limited the extent to 
which such modifications have generated meaningful SARs. However, it may be possible to 
exploit the tolerance to functional group modification at the 2-arylamino ring to fine-tune the 
reactivity of the 6-ethynyl Michael acceptor group of the purine. Thus, it was proposed that 
introducing electron-withdrawing or electron-donating groups at the para-position of the 2-
arylamino group may influence the reactivity of the ethynyl group and, hence modulate 
potency against Nek2. In addition, varying the electron-withdrawing nature of the group on 
the 2-arylamino ring may also influence the H-bond donor properties of the 2-NH, and thus 
affect initial competitive binding affinity. 
 
A small series of compounds (385-389) was proposed based upon the N-methylbenzamide 
derivative 206. This purine combined potent Nek2 inhibitory activity (Nek2; IC50 = 26 nM) 
with synthetic tractability of the required disubstituted aromatic groups. The majority of 
target purines contain an electron-withdrawing group on the 2-arylamino ring as a means to 
increase the reactivity of the 6-ethynyl group. The compound bearing an electron-donating 
methoxy group (387) was included to aid in the understanding of any observed effects on 
activity. 
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Scheme 58: Synthesis of the disubstituted 2-arylaminopurine 385. 
 
Reagents and conditions: i) SOCl2, MeOH, reflux, 1 h; ii) Aq. MeNH2, RT, 18 h; iii) 160, TFA, TFE, MW 140 
°C, 2 h; iv) a) TBAF, TF, RT, 5 min, b) 231, THF, RT, 48 h. 
Synthesis of the para-fluoro analogue (385) utilised the commercially available 5-amino-2-
fluorobenzoic acid (390), which was converted into the methyl ester 391 on treatment with 
thionyl chloride in methanol and reacted directly with aqueous methylamine to afford the N-
methylcarboxamide 392. Compound 392 was coupled to the 2-fluoropurine 160 under 
microwave conditions as before, to give the TIPS-protected purine 393. TIPS-deprotection 
using the established conditions gave the target inhibitor 385 (Scheme 58). 
For the preparation of the para-chloro analogue (386), the commercially available methyl 2-
chloro-5-nitrobenzoate (394) was reduced to the aniline 395 using iron-acetic acid. Treatment 
of 395 with aqueous methylamine gave the N-methylcarboxamide (396), which was coupled 
to the 2-fluoropurine 160. The TIPS-protected purine 397 was treated with TBAF to give the 
target inhibitor 386 (Scheme 59). 
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Scheme 59: Synthesis of the disubstituted 2-arylaminopurine 386. 
 
Reagents and conditions: i) Fe, AcOH, 50 °C, 15 min; ii) Aq. MeNH2, RT, 18 h; iii) 160, TFA, TFE, MW 140 
°C, 2 h; iv) a) TBAF, THF, RT, 5 min, b) 231, THF, RT, 48 h. 
The initial attempted synthesis of the trifluoromethyl compound 398 by treatment of 
commercially available 5-chloro-2-(trifluoromethyl)benzoic acid (399) with thionyl chloride 
was unsuccessful. Attempts to prepare 398 by reaction of the acid chloride of 399 with 
methanol also failed. However, the use of O-methyl-N,N’-diisopropylisourea,220 under 
microwave heating gave the desired methyl ester 398 from 399. Subsequent attempts to 
substitute the chloro group of 398 by an amine through SNAr reactions proved unsuccesful. In 
an alternative approach, the chloro group of 398 was substituted by 4-methoxybenzylamine, 
in a palladium-mediated amination, to give compound 400. Removal of the PMB-group from 
400, with refluxing TFA, gave aniline 401, which was treated with aqueous methylamine to 
yield the N-methylcarboxamide 402. The lengthy reaction time (48 hours) required perhaps 
reflects the steric hindrance imposed on the ester of 401 by the neighbouring trifluoromethyl 
group. Coupling of aniline 402 with the 2-fluoropurine 160 was attempted under standard 
reaction conditions. Unfortunately, no reaction was observed, presumably as a consequence 
of the electron-withdrawing effect of the para-trifluoromethyl group reducing the 
nucleophilicity of the aniline. However, aniline 402 was coupled successfully to the 2-
iodopurine 278 using a palladium-mediated amination to give the purine 403. Removal of the 
PMB-protecting group at N-9 of 403 with TFA gave compound 404, from which the TIPS-
protecting group was removed under the established conditions (Scheme 60). 
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Scheme 60: Synthesis of the disubstituted 2-arylaminopurine 388. 
 
Reagents and conditions: i) 
i
PrNC(OCH3)NH
i
Pr, MeCN, MW 120 °C, 5 min; ii) PMB-NH2, Pd(OAc)2, 
BrettPhos, Cs2CO3, THF, 90 °C, 1 h; iii) TFA, reflux, 18 h; iv) Aq. MeNH2, RT, 18 h; v) 278, Pd2(dba)3, XPhos, 
K2CO3, MeCN, 100 °C, 1 h; vi) TFA, reflux, 18 h; vii) a) TBAF, THF, RT, 5 min, b) 231, THF, RT, 48 h. 
Methyl 2-chloro-5-nitrobenzoate (394) was treated with sodium methoxide to give the 
nitroanisole 405. Nitro group reduction and conversion into N-methylcarboxamide 407 was 
achieved as previously, after which the aniline group of 407 was coupled with the 2-
fluoropurine 160. The TIPS-protecting group was removed from the resultant compound 
(408) to yield the target purine 387 (Scheme 61). 
For the synthesis of the para-cyano analogue 389, a palladium-mediated Negishi cyanation 
reaction was used.
221
 Reaction of methyl 2-chloro-5-nitrobenzoate (394) with zinc cyanide in 
the presence of bis(tri-tert-butylphosphino)palladium(0) resulted in clean conversion to the 
aromatic nitrile 409 in excellent yield (96%), and nitro group reduction gave the aniline 410. 
Conversion of the methyl ester of 410 into the N-methylcarboxamide (411) was attempted 
using methylamine (40% aqueous solution) as for the previous reactions. 
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Scheme 61: Synthesis of the disubstituted 2-arylaminopurine 387. 
 
Reagents and conditions: i) NaOMe, MeOH, 50 °C, 4 h; ii) Fe, AcOH, 50 °C, 15 min; iii) Aq. MeNH2, RT, 18 
h; iv) 160, TFA, TFE, MW 140 °C, 2 h; v) a) TBAF, THF, RT, 5 min, b) 231, THF, RT, 48 h. 
However, LC-MS analysis of the reaction mixture indicated that a single product was formed 
with a mass corresponding to the N,N-dimethylcarboxamide derivative 412 ([ES+] m/z = 
190). Indeed, upon product isolation, the 
1
H NMR spectrum was consistent with the N,N-
dimethylcarboxamide 412. It was initially assumed that dimethylamine had been used 
erroneously instead of methylamine, despite previous observations indicating that this 
reaction was unsuccessful using aqueous dimethylamine. Moreover, the reaction between 410 
and aqueous methylamine was repeated, and the same result was observed. A literature 
review revealed that there is a literature precedent for aromatic ortho-cyano methyl esters to 
undergo spontaneous cyclisations to imidines (e.g. 413).
222-224
 In an excess of aqueous 
methylamine, as was used in the reaction of compound 410, a mechanism was proposed for 
the formation of imidine 413 (Scheme 62). 
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Scheme 62: Proposed mechanism for the formation of imidine 413. 
 
Treatment of 410 with methylamine generates the desired N-methylcarboxamide 411, which 
undergoes a cyclisation with the nitrile moiety to give the imine 414. A second equivalent of 
methylamine attacks the imine, to form the aminal 415, which eliminates ammonia to give 
the imidine 413. Confirmation of the structure of 413, and assignment of the (E)-geometry 
about the imine, was provided by an X-ray crystal structure determination of 413 (Figure 44). 
This is counter to literature reports that the (Z)-isomer predominates due to steric effects.
223
 
         
Figure 44: X-ray crystal structure of 413 indicating the (E)-geometry of the imine. 
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Coupling of aniline 413 to the 2-fluoropurine 160 was attempted but proved unsuccessful 
under TFA-mediated conditions. As such 413 was coupled to the 2-iodopurine 278 
employing the Buchwald amination approach to give purine 416. Removal of the PMB group 
at N-9 and subsequent deprotection of the 6-ethynyl group as previously described, yielded 
the target purine 418 (Scheme 63). 
Scheme 63: Synthesis of the target purine 418. 
 
Reagents and conditions: i) Zn(CN)2, Zn, Pd
0
(P
t
Bu3)2, DMA, 95 °C, 1 h; ii) Fe, AcOH, 50 C, 15 min; iii) Aq. 
MeNH2, RT, 18 h; iv) 278, Pd2(dba)3, XPhos, K2CO3, MeCN, 100 °C, 1 h; v) TFA, reflux, 18 h; vi) a) TBAF, 
THF, RT, 5 min, b) 231, THF, RT, 48 h. 
It was evident that ortho-cyanocarboxamides were subject to cyclisation under very mild 
conditions. As such it was anticipated that formation of 413 would be likely to occur during 
the synthesis of 389 by alternative routes. For this reason, it was decided to prepare the N,N-
dimethylcarboxamide 416, where imidine formation cannot occur. The methyl ester of 
compound 409 was saponified by treatment with aqueous sodium hydroxide, to give 
carboxylic acid 420 without detriment to the nitrile group. As an alternative to CDI, 1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC.HCl) was used in conjunction 
with hydroxybenzotriazole (HOBt) to couple dimethylamine to the acid 420 in excellent yield 
(92%). Nitro group reduction gave aniline 422, which was coupled to the 2-iodopurine 278 
under the established conditions. However, attempted removal of the PMB-protecting group 
from the purine 423 using TFA resulted in compound degradation after only 2 hours at 60 °C, 
and none of the expected product (424) was observed in the reaction mixture by LC-MS 
analysis (Scheme 64). 
179 
 
Scheme 64: Attempted synthesis of the target purine 419. 
 
Reagents and conditions: i) NaOH, H2O, MeOH, RT, 30 min; ii) Me2NH.HCl, EDC.HCl, HOBt, DIPEA, 
DMF, RT, 18 h; iii) Fe, AcOH, 50 °C, 15 min; iv) 278, Pd2(dba)3, XPhos, K2CO3, MeCN, 100 °C, 1 h; v) TFA, 
60 °C, 2 h.Despite the general applicability of the TFA-mediated PMB-deprotection reaction, it 
was clear that the cyano substituent was unstable under these conditions and hence 
responsible for the observed decomposition. An alternative synthetic strategy was required, 
utilizing a protecting group that could be removed under different conditions. However, 
owing to time constraints no further efforts were made towards the synthesis of 429. 
As a preliminary measure of the electronic effect of groups at the para-position of the 2-
arylamino ring of the purine on both the purine C
2
-NH and 6-ethynyl terminal CH, the 
relative 
1
H NMR chemical shifts of these substituents were compared for compounds 385-
388 (Figure 45). The trend in 
1
H NMR chemical shift, as a measure of proton deshielding, for 
both proton environments, generally mirrored the relative electron-withdrawing and electron-
donating potential of the substituents, with the possible exception of the chloro (386) and 
fluoro (385) analogues. However, an aromatic fluorine group may be less electron 
withdrawing than an aromatic chloro group, despite being more electronegative. This is due 
to fluorine possessing greater resonance-stabilisation characteristics than other halogens as a 
result of improved orbital overlap between the fluorine 2p orbital and the π-system.225 
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Figure 45: 
1
H NMR chemical shifts for the C
2
-NH (A) and terminal alkyne (B) protons for compounds 385-
388. 
The observed effect is much more pronounced in the case of the C
2
-NH proton, due possibly 
to the greater distance over which the electron-withdrawing/donating groups must act in order 
to modulate the electron density of the alkyne group. Despite the initial results being as 
expected, testing of additional analogues with a wider range of substituents at the 2-
arylamino ring is warranted to improve the statistical significance of the results. 
6.6.2. Biological Results 
Disubstituted 2-arylaminopurines of sufficient purity for biological evaluation were tested for 
inhibitory activity against both Nek2 and Cdk2. In addition, the effect of cellular growth 
inhibition in SKBR3 cells was determined (Table 18). 
A 
B 
C2-NH 
C≡CH 
R = CF3 
R = CF3 
R = Cl 
R = Cl 
R = F 
R = OMe 
R = F 
R = OMe 
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  IC50 (µM) GI50 (µM) 
Compound R Nek2
a
 Cdk2
b
 SKBR3 
385 
 
0.16 13.2 0.3 ± 0.2 
386 
 
0.08 22.9 0.4 ± 0.2 
388 
 
0.14 29.3 0.8 ± 0.3 
387 
 
0.44 49.1 0.5 ± 0.1 
418 
 
0.33 25%* 2.3 ± 0.6 
a 
Nek2 IC50 values determined at 30 µM ATP concentration; 
b
 Cdk2 IC50 values determined at 12.5 µM ATP 
concentration;  * = percentage inhibition at 100 µM. 
Table 18: Biological evaluation of disubstituted 2-arylamino-6-ethynylpurines. 
All of the purines within this series were active as Nek2 inhibitors. Although only limited 
SARs can be ascribed to inhibitors 385-386 and 388, which all have electron-withdrawing 
groups, it is interesting that the para-methoxy analogue 387 is the least active of the 
derivatives. This may support the approach of positioning electron-withdrawing groups on 
the 2-arylamino ring as a means of activating the 6-ethynyl group. It would be necessary to 
synthesise additional compounds within this series to verify this observation, and strengthen 
the conclusions that can be drawn from these results. It is clear, however, that there is a high 
degree of tolerance within the Nek2 ATP-binding domain for inhibitors with diverse 
functionality at the 2-arylamino ring. As has been seen previously, there appears to be no 
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clear correlation between the activity of 6-ethnylpurine inhibitors in the Nek2 kinase assay 
and growth inhibition of SKBR3 cells. 
6.7. Conclusions and Further Work 
Through modification of the 6-position of purine-based inhibitors of Nek2 kinase it has been 
possible to identify 6-ethynylpurines as potent, irreversible inhibitors of Nek2. Such 
compounds act as covalent modifiers of Cys22, a residue immediately following the glycine 
rich loop in Nek2, by virtue of their ability to act as Michael acceptors. For this inhibitor 
class it is evident that there is a large degree of tolerance within the Nek2 ATP-binding 
pocket for substituents on the purine 2-arylamino ring. In addition, it has been found that 
inhibitors with adequate initial competitive binding affinity for the kinase, result in potent 
inhibition of Nek2 upon irreversible inactivation. This has limited the extent to which SARs 
have been determined. 
 
 IC50 (µM) GI50 (µM) 
Compound Nek2
a
 Cdk2
b
 SKBR3 
177 0.062 ± 0.01 11.8 2.2 ± 0.4 
425 50%* 25%* 2.9 
426 4.0 22%* 1.1 
a 
Nek2 IC50 values determined at 30 µM ATP concentration; 
b
 Cdk2 IC50 values 
determined at 12.5 µM ATP concentration; * = Percentage inhibition at 100 µM. 
Table 19: Comparison of the biological activity of 177 with control compounds 425 and 426. 
From studies with the benchmark inhibitor, 177 (NCL-00017509), it was possible to identify 
tumour cell lines sensitive to treatment in vitro with inhibitors of this class. However, it was 
subsequently found that there was a poor correlation between Nek2 kinase inhibitory activity 
and growth inhibition of SKBR3 cells, with several purines that are weak kinase inhibitors 
183 
 
proving highly growth inhibitory (e.g. 364). This raised that possibility that the observed 
growth inhibition in SKBR3 cells was unrelated to Nek2 inhibition.  
The essential H-bonding interactions between the purine and kinase hinge region were 
exploited in the synthesis of the N
7
-methyl and N
9
-methyl analogues of 177 (425 and 426) as 
control compounds. Both compounds are only very weak Nek2 kinase inhibitors but exhibit 
potent growth-inhibitory activity in the SKBR3 cell line. This strongly suggests that 
compounds within the 6-ethynylpurine class possess an alternative locus of activity to Nek2 
kinase. It may thus be necessary to revisit the known SARs for this chemotype for the 
identification of truly selective Nek2 inhibitors. Moreover, once a truly selective Nek2 
inhibitor is found, it will be necessary for additional screening of tumour cell lines to be 
performed, to identify cell lines that are sensitive to Nek2 inhibition. However, the findings 
of this series may suggest that Nek2 function is not essential for cancer cell survival, and it is 
possible that Nek2 is not a valid cancer therapeutic target.  
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Chapter 7: Investigating the Cellular Effects of Nek2 Inhibition 
using NCL-00017509 (177) 
7.1. Development of a Nek2 Inducible Cell Line 
Tetracycline-inducible gene expression is a common tool used to artificially induce or repress 
the translation of desired genes in cells stably expressing the relevant DNA construct. Such 
systems exploit the natural Escherichia coli bacterial promoter protein Ptet, which expresses 
the TetR repressor protein. Fusion of TetR with an activation domain, VP16, creates a 
tetracycline-controlled transactivator (tTA) protein, that upon binding of tetracycline 
response elements (TREs) triggers the transcription of genes directly downstream of 
tetracycline operator (tetO) sequences.
226
 Generation of constructs bearing the tetO sequence 
directly upstream of the gene coding for a protein of interest allows the induction of gene 
expression upon treatment with tetracycline in a system known as TET-ON.  
Through the use of tetracycline-inducible gene expression, a U2OS cell line was developed to 
express myc-tagged Nek2 upon treatment with tetracycline, or the more stable analogue 
doxycycline. Myc-tagging allows a determination of the level of induced Nek2 as opposed to 
endogenous Nek2, through the use of myc antibodies in both Western blotting and 
immunofluorescence microscopy. Due to the low levels of active endogenous Nek2 
throughout most of the cell cycle, it is necessary to up-regulate Nek2 gene expression, and 
therefore activity, in order to observe effects of inhibitor treatment in a population of non-
synchronised cells. 
The effect of doxycycline on the myc-Nek2 inducible cell line was investigated by the 
administration of doxycycline at 1 µg/ml to the cell media for varying times. After inhibitor 
treatment, the cells were fixed and lysed, and the protein expression levels visualised by 
Western blotting (Figure 46; A). It was apparent from the results that expression of induced 
myc-Nek2 reaches a maximum level after 8 hours. 
Induction of myc-Nek2 was further observed by the probing of cells, treated with and without 
doxycycline at 1 µg/ml for 16 hours, with myc and C-Nap1 antibodies. Cellular staining with 
fluorescently tagged secondary antibodies allows the presence and localisation of induced 
myc-Nek2 to be observed (Figure 46; B). Both assays confirmed that treatment of the Tet-ON 
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myc-Nek2 cell line with doxycycline results in upregulated expression of Nek2, enabling the 
cell line to be used in further studies. 
 
Figure 46: Induction of myc-Nek2 in a U2OS cell line; A) Total protein from U2OS myc-Nek2 TET-ON cells 
treated with doxycycline at 1 µg/ml for varying times separated by SDS-PAGE, immunoblotting with 
myc and α-tubulin antibodies; B) Representative U2OS myc-Nek2 TET-ON cells treated with or 
without doxycycline at 1 µg/ml for 16 hours, and visualised using anti-mouse myc and anti-rabbit C-
Nap1. DNA was visualised with Hoescht dye. 
7.2. Effect of Nek2 Inhibition on Centrosome Splitting 
It was proposed that as a consequence of the key role of Nek2 in centrosome splitting, 
upregulation of active Nek2 with doxycycline induction would cause an increased percentage 
of cells displaying split centrosomes in interphase. Subsequent treatment with varying 
concentrations of the Nek2 inhibitor 177 (NCL-00017509), will enable an evaluation of the 
effect of Nek2 inhibition on cellular centrosome splitting. 
 
Figure 47: Classification of centrosomes as split or non-split. 
Populations of U2OS myc-Nek2 inducible cells grown on microscope coverslips were treated 
both with and without doxycycline at 1 µg/ml for 16 hours, followed by 4 hours of treatment 
with 177 at doses of 5 µM, 500 nM and 50 nM. The cells were fixed and probed with a myc 
antibody to observe induction of myc-Nek2, and a γ-tubulin antibody to allow visualisation of 
the centrosomes, upon secondary incubation with fluorescently tagged antibodies.  
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Figure 48: Treatment with NCL-00017509 (177) decreases the percentage of cells possessing split centrosomes; 
A) Representative U2OS myc-Nek2 TET-ON cells treated with or with doxycycline at 1 µg/ml for 16 
hours, followed by inhibitor treatment for 4 hours. Cells were visualised using immunofluorescence 
microscopy, staining with anti-rabbit γ-tubulin, anti-mouse myc and Hoescht dye; B) Percentage of 
cells possessing split centrosomes for – Dox/+ Dox populations against inhibitor concentration. 
Immunofluorescence microscopy was used to give a qualitative determination of whether 
centrosomes are split or non-split in 100 cells per population, repeated in triplicate. Visual 
judgement was used to classify centrosomes to be split if they were separated by equal to or 
% Centrosome 
Splitting 
γ-tubulin myc merge γ-tubulin myc merge Conc. 177 
- 
50 nM 
500 nM 
5 µM 
A 
B 
Conc. 177 
- Dox + Dox 
  -      50 nM   500 nM  5 µM   -      50 nM   500 nM  5 µM 
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greater than the diameter of 1 centrosome (Figure 47). Quantitative measurement of the 
distance of centrosome separation was not carried out to increase the rapid throughput of the 
assay with an understanding that upon cleavage of the intercentriolar linkage, the distance of 
separation would be a dynamic process. As anticipated, induction of myc-Nek2 expression 
with doxycycline treatment resulted in a large increase in the percentage of interphase cells 
possessing split centrosomes. For both induced and non-induced populations, a dose-
dependent decrease in the number of split centrosomes was observed with increasing 
concentration of Nek2 inhibitor (177), with 5 µM compound decreasing centrosome splitting 
to the level of that in the non-induced population (Figure 48). This observation highlights a 
potentially interesting aspect of the nature of centrosome splitting, as this appears to be a 
reversible process. It has previously been assumed that protein components of the 
intercentriolar linkage connecting the centrosomes were phosphorylated by Nek2, resulting in 
dissociation and centrosomal separation.
161
 Under these conditions, it would be anticipated 
that, once cleaved, the intercentriolar linkage would remain so. However, as Nek2 
expression, and therefore centrosomal disjunction, is activated prior to inhibitor treatment, it 
is clear that the dose response observed is due to the reversibility of this process. 
7.3. Cellular Inhibition of C-Nap1 Phosphorylation 
The processes by which centrosomal separation is mediated remains to be fully elucidated, 
and additional cellular biomarkers of Nek2 activity are required to validate the results 
obtained in the centrosome splitting assay. One such biomarker in use is the level of 
phosphorylated C-Nap1 present in cell populations. At present, C-Nap1 is thought to be 
exclusively phosphorylated by Nek2, allowing the levels of phosphorylated C-Nap1 to be 
used as a direct measure of Nek2 activity. Work within the laboratory of Professor Andrew 
Fry (University of Leicester) has enabled the development of antibodies raised against four 
phosphorylation sites on C-Nap1. The antibodies were generated using peptides prepared 
with phosphate groups attached to the serine or threonine of interest. These peptides were 
injected into rabbits and purified from serum. Antibodies were separated into phospho- and 
non-phospho antibodies by elution on a phosphate column. Such antibodies make it possible 
to measure Nek2 activity using immunofluorescence microscopy. One antibody is raised 
against the phosphorylation site Ser2164, named pAQDL. Antibody nomenclature uses the 
start of the amino acid sequence upstream of the site in question. 
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Figure 49: Treatment with NCL-00017509 (177) decreases the intensity of pC-Nap1 staining in cells; A) 
Representative U2OS myc-Nek2 TET-ON cells treated with or with doxycycline at 1 µg/ml for 16 
hours, followed by inhibitor treatment for 4 hours. Cells were visualised using IFM, staining with 
anti-rabbit pAQDL, anti-mouse myc and Hoescht dye; B) Percentage pC-Nap1 intensity with respect 
to 177 treatment for - Dox/+ Dox populations. 
The cell treatment protocol utilised in the centrosome splitting assay was repeated, and the 
resulting coverslips were probed with a myc antibody and the pAQDL antibody. The use of 
Velocity (PerkinElmer) software allowed a quantitative determination of fluorescence 
intensity for pC-Nap1, enabling a determination of pC-Nap1 levels and therefore Nek2 
activity. For each cell population, fluorescence intensity was measured for 20 centrosomes, 
and average intensity with respect to background determined. Measurements were carried out 
myc myc merge merge pC-Nap1 pC-Nap1 
+ Dox - Dox A 
B 
Conc. 177 
- 
50 nM 
500 nM 
5 µM 
% pC-Nap1 
Intensity 
  -     50 nM   500 nM  5 µM   -    50 nM   500 nM  5 µM Conc. 177 
- Dox + Dox 
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in triplicate for induced cells, and average intensities with respect to induced cells with no 
inhibitor treatment calculated (Figure 49). However, measurements were only made in 
duplicate for uninduced cells, as it was not possible to reliably identify centrosomes without a 
myc co-stain when their intensities were very low. This was observed in the first assay, and 
hence all subsequent uninduced cells were co-stained with a γ-tubulin rather than a myc 
antibody, so that centrosomes could be easily identified.  
Under these assay conditions, pC-Nap1 intensity did not give the same dose-response 
relationship as observed in the centrosome splitting assay. However, as can be seen from the 
high degree of error, the reliability of this assay is questionable. There are many variables 
during the experimental procedure that may result in variable antibody binding from one 
experiment to another. There was observed to be a sharp decrease in pC-Nap1 intensity to 
that of the level of uninduced cells between 500 nM and 5 µM 177. Due to limitations in 
time, it was not possible to investigate this result further, but it would be important to repeat 
this assay at dose ranges between 500 nM and 5 µM in an attempt to observe a dose-response 
between pC-Nap1 intensity and Nek2 inhibitor concentration. 
Although C-Nap1 is known to localise to the terminal ends of centrioles and is proposed to be 
a key component of the intercentriolar linkage, these results may indicate that 
phosphorylation of C-Nap1 is not the key process in cleavage of this linker. At present, C-
Nap1 is thought to be a substrate only of Nek2, but it is possible that another kinase is 
performing this phosphorylation in the absence of active Nek2. It may be that the 
phosphorylation site of C-Nap1 targeted by Nek2 is not that which is responsible for 
centrosomal disjunction. In order to investigate this further, it was necessary to determine the 
selectivity of Nek2 for the phosphorylation sites of C-Nap1.  
There are 22 in vitro phosphorylation sites on C-Nap1 identified to date,
227
 but at present 
antibodies have been developed within the group for only four of these sites; Ser2064 
(pLLEK), Thr2102 (pRELQ), Ser2164 (pAQDL) and Ser2417 (pRRLD). U2OS myc-Nek2 
inducible cells were grown on coverslips, and all cells were induced with doxycycline for 16 
hours. Pairs of coverslips were selected for staining by each phospho-specific antibody, as 
well as total C-Nap1, and one coverslip was treated with 177 at 5 µM for 4 hours. Following 
incubation with primary and secondary antibodies, immunofluorescence microscopy was 
used to determine fluorescence intensity for both untreated and 177 treated cells ascribed to 
each phosphorylation site (Figure 50 and Figure 51). 
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In order to relate all intensities to one another, the exposure of the camera used to capture the 
cellular images was fixed such that the most intense fluorescence staining did not overexpose 
the camera. As such, differences in the overall fluorescence intensity, possibly due to variable 
antibody affinity, did not allow the results for each phospho-specific antibody to be directly 
compared. It was necessary to adjust measurements for 177 treated cells to give a percentage 
of the intensity of untreated cells. It was apparent that once this had been performed, all 
phosphorylation sites excluding pRELQ were sensitive to Nek2 inhibition.  
 
Figure 50: NCL-00017509 (177) inhibits phosphorylation of three known sites of C-Nap1 in U2OS myc-Nek2 
TET-ON cells; A) Phospho-specific antibody fluorescence intensity for untreated and 177 treated 
cells, at 5 µM inhibitor concentration; B) Phospho-specific antibody fluorescence intensity as a 
percentage of untreated level for each antibody. 
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Figure 51: NCL-00017509 (177) inhibits phosphorylation of three known sites of C-Nap1; C) Representative 
U2OS myc-Nek2 TET-ON cells treated with doxycycline at 1 µg/ml for 16 hours, followed by 177 
treatment for 4 hours. Cells were visualised using immunofluorescence microscopy, staining with 
anti-rabbit pC-Nap1, anti-mouse myc and Hoescht dye. 
Owing to the relatively low intensities of pAQDL and pLLEK fluorescence, it was not 
possible to use these results to evaluate degrees of sensitivity between each site. In order to 
do this, the assay would need to be repeated over a dose range with camera exposure 
calibrated for each antibody individually. It may be noted that due to Nek2 inhibition, and 
therefore inhibition of C-Nap1 phosphorylation, there was a greater quantity of C-Nap1 at the 
centrosomes, as seen by the increase in intensity for total C-Nap1. Monitoring of pC-Nap1 
was therefore from a larger protein sample, and hence the true inhibition of pC-Nap1 may be 
more pronounced than is shown in Figure 50. 
7.4. Evaluating Mitotic Progression Using Live Cell Imaging 
By the use of confocal microscopy, it is possible to clearly image structures, such as cells, 
that are thicker than the focal plane. This allows for 3-dimensional images to be reconstructed 
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by layering of multiple planes through a structure, allowing the detailed visualisation of 
cellular components and, hence, processes. Collating images taken at regular intervals 
throughout the growth cycle of a cellular population, allows in-depth analysis of the success 
and duration of such processes, and hence can be used in conjunction with NCL-00017509 
(177) to evaluate the effect of Nek2 inhibition on mitotic progression and spindle assembly. 
A HeLa cell line has been developed within the research group at the University of Leicester, 
to stably express fluorescent tags on key cellular structures, with green fluorescent protein 
(GFP, λex = 482 nm, λem = 502 nm) tagged α-tubulin, and mCherry (λex = 587 nm, λem = 610 
nm) tagged histone, a protein involved in DNA ordering and nucleosome formation. This cell 
line allows an observation of a cell’s mitotic spindle and DNA to be carried out under live 
cell conditions using confocal microscopy. 
GFP-α-tubulin/mCherry-histone HeLa cells were grown to ~80% confluency and divided into 
two populations, one of which was treated with 177 at 5 µM for 4 hours. At this point, live 
cell imaging was initiated, with cells imaged at 5 minute intervals for 15 hours, both with and 
without inhibitor treatment. The images were used to analyse the progression of cells through 
mitosis, starting with mitotic duration. At the onset of mitosis, cells lose their flattened 
morphology and adopt a spherical structure.  
 
Figure 52: Representative images of cells, highlighting the events used to time mitotic progression. 
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Figure 53: Treatment with NCL-00017509 (177) causes a delay in mitotic progression; A) Representative HeLa 
GFP-α-tubulin/mCherry-Histone cells treated without and with inhibitor for 4 hours and observed 
over 15 hours using confocal laser scanning microscopy; B) Box-whisker plot showing minimum 
value, lowest quartile (Q1), median, mean, upper quartile (Q3) and maximum values for untreated 
cells and cells treated with inhibitor; C) Total time for mitosis for untreated cells and cells treated 
with inhibitor divided into observable stages of mitosis. 
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The point at which the cells reached their maximum spherical shape during prophase was 
classed as t = 0 min, and all timings of mitosis were calculated from this point forward. 
Timings were made from prophase to anaphase, the first point at which the DNA was seen to 
be divided from its alignment along the spindle meridian, and from anaphase to cytokinesis, 
the point at which the cell is fully divided and all spindle networks between cells are 
disconnected (Figure 52). By measuring these times for 268 cells from 6 distinct populations, 
it was possible to determine the average times for cells to complete mitosis, to enter 
anaphase, and to pass between anaphase and cytokinesis, for cells treated both with and 
without Nek2 inhibitor (Figure 53). From these results, it was apparent that cells treated with 
NCL-00017509 (177) experience a mean delay in mitotic completion of 24 minutes. When 
this delay was divided into the two defined cell cycle stages, prophase to anaphase and 
anaphase to cytokinesis, it is clear that the delay is a consequence of the cells requiring 
greater time to exit mitosis after anaphase. The hypothesised role of Nek2 is in centrosome 
separation, which would suggest that Nek2 inhibition would result in a delay in bipolar 
spindle formation, and therefore an increase in the time taken from mitotic entry to anaphase. 
However, the specific dynamics of this process and the exact role of Nek2 is yet to be fully 
elucidated, and disruption of Nek2 activity may thus have unexpected effects on spindle 
assembly and function. 
Upon detailed examination of the image sequences, it became apparent that there was an 
increased occurrence of cells with an irregular mitotic phenotype. These included cells 
undergoing apoptosis following mitotic entry, those forming a monopolar mitotic spindle 
with a delay in bipolar spindle formation, and cells with irregular spindle movement and 
shape. To establish the relevance of these observations, all cells entering mitosis were 
assessed for successful or failed mitosis, and for the presence of a bipolar or abnormal 
spindle. Once tabulated, there was seen to be an increase from 7% to 15% in cells failing to 
complete mitosis upon treatment with the Nek2 inhibitor. Furthermore, the number of cells 
developing a regular mitotic spindle fell from 86% to 58%, and the number of cells 
proceeding through an abnormal mitotic division increased from 14% to 42% (Figure 54). 
This supports the proposed effect of Nek2 inhibition, whereby centrosomal separation is 
delayed or adversely affected, which may result in the observed abnormalities and delay in 
bipolar spindle formation. 
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Figure 54: Treatment with NCL-00017509 (177) causes an increase in mitotic abnormalities and failure; A) 
Representative HeLa GFP-α-tubulin/mCherry-Histone cells showing mitotic abnormalities and 
mitosis with respect to control cells. 
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Figure 54: Treatment with NCL-00017509 (177) causes an increase in mitotic abnormalities and failure; B) 
Total percentage of cells failing during mitosis for untreated and 177 treated cell populations; C) 
Total percentage of cells possessing bipolar and abnormal spindles for untreated and 177 treated cell 
populations. 
7.5. Confirmation of Mitotic Delay by Flow Cytometry 
Flow cytometry is a technique used to analyse a characteristic of individual cells, or similar 
biological structures, in solution, using an electronic detector. Of particular interest when 
investigating the cell cycle is fluorescence-activated cell sorting (FACS), a technique that 
utilises a fluorescent DNA dye to allow the quantification of cellular DNA content, and 
therefore determine the stage of the cell cycle in which the cell resides. FACS analysis relies 
on the principle of hydrodynamic focussing to generate a single stream of particles, such as 
cells, which can subsequently be analysed, allowing highly accurate cell counting to be 
carried out. After staining with the fluorescent DNA intercalator propidium iodide (PI) a 
sample profile is acquired, which separates cells depending on fluorescence intensity, and 
therefore DNA content. Analysis of this profile can provide information of the relative 
distribution of cells in the cell cycle (Figure 55).
228
 
% Cells 
B C 
Untreated + 177 
% Cells 
failing 
mitosis 
Bipolar Abnormal 
Untreated 
+ 177 
197 
 
 
Figure 55: Example profile from PI FACS analysis indicating regions relating to cell cycle stages. 
To determine the effect of Nek2 inhibition on cellular outcome over longer treatment 
durations than those used in live-cell imaging, it was decided to treat uninduced U2OS myc-
Nek2 inducible cells with NCL-00017509 (177) for times of up to 72 hours, with the cell 
cycle distribution of the population being analysed by FACS. To do this, cells were treated 
with 177 at 72, 48, 24, and 4 hours prior to fixing, and an asynchronous sample was grown 
alongside those selected for treatment. In order to ensure that cells were subject to the same 
conditions excluding treatment duration, all populations had their growth media changed at 
24 hour intervals, with fresh aliquots of 177 administered at each point. This was to prevent 
pressures on growth through a lack of fresh media, and to replace any Nek2 inhibitor 
removed on changing media, or that which is lost in kinase degradation. 
After staining the cells and applying FACS analysis, the DNA content was quantified and 
hence the cell cycle stage determined for each condition (Figure 56). The results support the 
findings of live cell imaging, with a delay in mitotic exit resulting in an increase in the cell 
population in G2/M and a decrease in cells in G1 with increasing duration of inhibitor 
treatment. However, due to time constraints, this experiment was only conducted once, and 
validation of these results would require the experiment in triplicate.  
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Figure 56: Treatment with NCL-00017509 (177) causes cells to delay in mitosis; A) FACS profiles for HeLa 
GFP-α-tubulin/mCherry-Histone cells treated with inhibitor at 5 µM for times up to 72 hours, DNA 
staining using propidium iodide; B) Total percentage of cells in G1 and G2/M stages of the cell cycle 
for each treatment duration. 
7.6. Assessing the Selectivity of NCL-00017509 Against Nek and Mitotic 
Kinases 
Selectivity testing of NCL-00017509 (177) provided some evidence of inhibitory activity 
against Aurora A kinase, although studies by collaborators at the Institute for Cancer 
Research suggested that this may have been a false positive result. However, it is known that 
the cellular phenotype of Aurora A inhibition is an increase in monopolar spindles and a 
delay in mitotic progression.
229
 Due to the similarity in phenotypes observed, it was 
necessary to further investigate the selectivity of 177 against Aurora A. In conjunction with 
this work, the inhibitory activity of 177 in a panel of Nek kinases and the mitotic kinases Plk1 
and Cdk1 was determined. 
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Figure 57: NCL-00017509 (177) is selective for Nek2 over other members of the Nek family and mitotic 
kinases in a recombinant kinase assay; A & C) Substrate Coumassie staining from SDS-PAGE and X-ray 
development of 
32
P labelled substrate; B & D) Scintillation counts for substrate bands removed from SDS-
PAGE gel for untreated and 177 treated kinase. 
Using recombinant kinases, inhibition values were measured at a single inhibitor 
concentration of 1 µM, with the assay conducted in triplicate. Kinases were incubated with 
the appropriate substrate, Nek2 inhibitor and 
32
P-ATP in kinase buffer at 30 °C for 30 
minutes, followed by boiling in sample buffer, resulting in differing quantities of 
32
P-
radiolabelled substrate depending on kinase activity. Sample mixtures were subjected to 
SDS-PAGE electrophoresis and the gels stained with Coumassie blue to visualise substrate 
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bands. Gels were dried and developed on X-ray film to give a visual representation of kinase 
activity, and the substrate bands were removed and relative radioactivity determined using a 
scintillation counter (Figure 57). As seen previously, 177 displays good selectivity for Nek2 
over other members of the Nek family, with only weak inhibition of Nek6 and Nek11 activity 
being observed. However, although the compound exhibited only modest potency against 
Plk1 and Cdk1, under these conditions significant inhibition of Aurora A was observed. To 
further quantify the extent of this inhibition, it would be necessary to repeat the assay over a 
range of inhibitor concentrations, allowing the calculation of an IC50 value. 
 
Figure 58: Cells treated with the Aurora A inhibitor MLN-8054 present a different phenotype to NCL-
00017509 (177) treated cells; A) Representative HeLa GFP-α-tubulin/mCherry-Histone cells treated 
with MLN-8054 for 4 hours observed over 15 hours, showing mitotic failure; B) Total percentage of 
cells failing during mitosis for untreated cells and cells treated with 177 and MLN-8054; C) Total 
percentage of cells with bipolar and monopolar spindles for untreated cells and cells treated with 177 
and MLN-8054. 
In an attempt to determine whether the effect observed in cells from live cell imaging and 
FACS analysis was due to the inhibition of Nek2 or Aurora A, the known Aurora A inhibitor 
MLN-8054 was evaluated.
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previously used, with MLN-8054 administered at 5 µM. Upon imaging of cells undergoing 
mitosis after treatment with MLN-8054, it became apparent that Aurora A inhibition 
presented as a previously unseen phenotype (Figure 58; A). Cells entered mitosis and 
remained in prophase with monopolar spindles before returning to a flattened interphase state 
without dividing. This was quantified by counting the percentage of cells failing to complete 
mitosis (Figure 58; B). Although cells treated with 177 showed a small increase in failed 
mitosis with respect to untreated cells (15%) all failed mitotic events were due to apoptosis. 
In contrast, there was a large increase in cells failing to complete mitosis with MLN-8054 
treatment (71%), although the majority of these cells were not apoptotic and instead re-
entered interphase.  
 
Furthermore, there was a significant difference in the number of cells possessing bipolar and 
monopolar spindles between each treatment condition (Figure 58; C), with just 3% of cells 
treated with MLN-8054 bearing a bipolar spindle, and 96% exhibiting monopolar spindles. 
These findings strongly indicated that the phenotypes observed for treatment with each 
inhibitor were due to inhibition of different cellular processes; although 177 was shown to 
inhibit Aurora A in vitro, it appears that in vivo this does not predominate. 
To further support this proposal, FACS analysis of cells treated with MLN-8054, as described 
previously, was carried out (Figure 59). Due to the observation during live cell imaging that 
cells return to an interphase state without dividing, it would be anticipated that cellular DNA 
content would continue to double beyond that seen for G2/M cells, a so called 8N number. 
Indeed, it was found that over increasing treatment times for cells incubated with MLN-8054 
there was a build-up of cells displaying a DNA content profile indicative of 8N cells. The 
lack of cells showing 8N DNA from those treated with 177 provides further evidence that any 
cellular effect observed for Nek2 inhibitor treatment is not solely due to off-target inhibition 
of Aurora A. In order to further strengthen these data, the assays would need to be repeated at 
higher concentrations of 177, to establish the level at which an Aurora A inhibition 
phenotype becomes apparent. 
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Figure 59: Cells treated with MLN-8054 show an increase in 8N DNA number, indicating failed mitosis; A) 
FACS profiles for HeLa GFP-α-tubulin/mCherry-Histone cells treated with MLN-8054 at 5 µM for 
times up to 72 hours, DNA staining using propidium iodide; B) Total percentage of cells with 2N, 4N 
and 8N DNA number for cells treated with MLN-8054 and NCL-00017509 (177). 
7.7. Conclusions and Further Work 
The irreversible Nek2 inhibitor NCL-00017509 (177) was evaluated in several assays for its 
effects on cellular Nek2 activity and mitotic outcome. Through an observation of the 
percentage of cells displaying split centrosomes, a biomarker proposed to be indicative of 
Nek2 activity, a clear dose-response with increasing inhibitor concentration has been shown. 
A more accurate cellular biomarker of Nek2 activity is the level of phosphorylated C-Nap1. 
However, when cells dosed with inhibitor were assayed for antibodies for pC-Nap1, this dose 
response was lost, with a decrease in pC-Nap1 levels only being seen between 500 nM and 5 
µM. This may be as a consequence of phosphorylation of C-Nap1 not being a critical factor 
in centrosome separation as hypothesised. The results from this assay must be considered 
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with some caution, as the variability of intensity measurements obtained for each condition 
introduced a large degree of error in values, and highlights the limitations of this technique. 
Further work should be carried out on reaction standardisation, together with experiments 
over dose ranges between 500 nM and 5 µM to validate the results obtained thus far. 
To understand the effect of 177 treatment on cellular Nek2 activity in greater detail, further 
experimental techniques were undertaken. During the course of these studies, it was 
attempted to extract cellular Nek2 from treated cells and perform 
32
P-kinase assays. This was 
investigated using immunoprecipitation with myc antibodies on cell lysates. Unfortunately, 
during the time of the study this technique was not successful in effectively isolating active 
Nek2 kinase from cells, as extracts from induced cells lacking inhibitor treatment were 
inactive in kinase assays. In spite of this, western blot analysis of the extracts with a myc 
antibody did indeed show that myc-Nek2 had been retrieved from the cells. However, the 
protein appeared either to be in an inactive form, or a component of the kinase assay was 
ineffective. Further investigation of this result, and the development of a reliable 
immunoprecipitation-kinase assay procedure, is needed to obtain conclusive results from this 
assay and to further evaluate the effect of inhibitor treatment of cellular Nek2 activity. 
Live cell imaging using confocal microscopy was used to show that cells treated with 
inhibitor are delayed in mitosis with respect to untreated cells, particularly between anaphase 
and cytokinesis. An increase in the prevalence of abnormal mitotic phenotypes was also 
observed, indicating that treatment with 177 has a detrimental effect on the tightly controlled 
mitotic machinery. In conjunction with this, FACS analysis supported these findings by 
indicating that cells treated with inhibitor stall in mitosis with increasing incubation time, 
albeit that this assay was performed only once, and would need to be repeated to improve the 
reliability of the data. Interestingly, both the live cell imaging and FACS analysis were 
performed on cells that have previously been shown to have low sensitivity to 177 in classical 
growth inhibition assays. It would be informative to develop cell lines that are sensitive to 
inhibitor, such as SKBR3 or Rec-1, that stably express both the myc-Nek2 TET-ON system 
and GFP-α-tubulin/mCherry-Histone tags. This would allow the assays to be repeated on 
sensitive cell lines, where one may anticipate an enhanced effect with respect to U2OS/HeLa 
cells. 
With only limited success being achieved in assays designed to directly examine Nek2 
activity in cells, it is not possible to determine whether the effects of 177 on mitotic delay or 
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the phenotypes observed in cells are due to Nek2 inhibition alone. Thorough kinase 
selectivity testing has been carried out previously on 177 (see appendix, Table A2), 
indicating good selectivity, with greater than 10-fold selectivity seen for all kinases tested, 
and greater than 100-fold selectivity observed for all but 9 kinases. To further support these 
data, determinations of 177 inhibition at single concentrations of 1 µM were carried out on 
Neks 2, 3, 6, 7 and 11, and mitotic kinases Plk1, Cdk1 and Aurora A. As observed 
previously, good selectivity was seen for Nek2 over these kinases, with the exception of 
Aurora A. To fully investigate the activity seen against Aurora A it would be necessary to 
repeat the kinase assay over a wider range of inhibitor concentrations for the determination of 
an IC50 value.  
Evidence that 177 does not elicit significant inhibition of cellular Aurora A was adduced 
from a comparison of the inhibition phenotypes observed in live cell imaging and FACS 
analysis with 177 and the known Aurora A inhibitor MLN-8054. However, questions as to 
whether the cellular effects seen for 177 are due to Nek2 inhibition alone remain. Preventing 
the covalent inactivation of Nek2 by such inhibitors may allow this question to be addressed. 
This may be possible through modification of the 6-ethynyl position into a non-electrophilic 
isostere, such as the 6-cyanopurine 296.  
 
However, initial cellular studies with 296 indicated that the increased polarity of the 6-
cyanopurine compared with 177, compromised cellular permeability and reduced effective 
intercellular compound concentrations to levels that prevented direct comparison. The 
alternative modification that can be made is to the Cys22 residue. If cells containing a 
tetracycline-inducible Nek2 Cys22 mutant display the same growth inhibitory response to 
177 as Nek2-WT, this would suggest that off-target effects are responsible for any observed 
growth inhibition. Site directed mutagenesis of WT Nek2 followed by polymerase chain 
reaction gave Cys22Val/Ala mutant constructs. Unfortunately, during the time of the study, 
all attempted transient transfections of the constructs into HeLa cells gave insufficient 
transfection efficiency to be suitable for the available assays. However, evaluation of 
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analogues of 177 has suggested that additional efforts to address this question are 
unneccessary. The poor correlation between the Nek2 kinase IC50 and SKBR3 cellular GI50 
for these inhibitors, in conjunction with the identification of analogues of 177 that combine 
potent cellular growth inhibition with only modest Nek2 kinase potency, strongly indicates 
that the cellular potency of 177 is independent of Nek2 activity.  
7.8. Materials and Methods 
 7.8.1. Tissue Culture 
 7.8.1.1. Cell Maintenance 
U2OS myc-Nek2 cells were grown as adherent colonies on tissue culture dishes in 
Dulbecco’s Modified Eagle Medium (DMEM) tissue culture medium (Gibco®, Invitrogen), 
with G418 (Gibco
®
, 500 µg/ml), puromycin (3 µg/ml), foetal calf serum (FCS, 10%) and 
penicillin (100 µg/ml)/streptomycin (100 µg/ml) as additives. G418 and puromycin, which 
are toxic to both prokaryotic and eukaryotic cells, act as selectivity reagents, ensuring the cell 
population is predominantly made up of cells possessing the desired mutation, in this case the 
myc-Nek2 TET-ON system. This is due to the construct encoding for the tetracycline-
inducible gene expression system bearing G418 and puromycin resistance factors. Penicillin 
and streptomycin are added to act as antibacterial agents, reducing the likelihood of bacterial 
infection of cell culture colonies. FCS acts as a serum supplement, as it contains many 
growth factors that are advantageous to eukaryotic cell growth. 
GFP-α-tubulin/mCherry-Histone HeLa cells were grown as adherent colonies on tissue 
culture dishes in Minimum Essential Media (MEM) tissue culture medium (Gibco
®
, 
Invitrogen) containing FCS (10%) and penicillin (100 µg/ml)/streptomycin (100 µg/ml). 
  
206 
 
 7.8.1.2. Lifting of Adherent Cell Colonies 
In order to maintain optimal colony sizes on plates, cells must be regularly passaged, or split. 
In order to do this, and to harvest cells for use in assays, adherent cells must be lifted from 
tissue culture dishes. Cell media was removed via aspiration, and the cells monolayer was 
washed with phosphate buffered saline (PBS) solution, which was subsequently aspirated. 
The cells were lifted from the plate through incubation with a solution of 
ethylenediaminetetraacetic acid (EDTA, 5 mM) in PBS for 15 minutes. 
Phosphate Buffered Saline (10x): NaCl (4% w/v), KCl (0.1% w/v), Na2HPO4.7H2O (0.6% 
w/v), KH2PO4 (0.1% w/v), NaN3 (0.01% w/v). 
7.8.1.3.  Harvesting and Lysis of Cell Suspension 
The suspended cells in PBS/EDTA were centrifuged at 1,100 rpm for 5 minutes, before the 
supernatant was removed through aspiration, leaving a cell pellet. The pellet was washed 
with PBS solution and centrifuged for a further 5 minutes at 1,100 rpm. The supernatant 
liquid was again removed, leaving a cleaned pellet of cells which was kept on ice. 
Lysis of the cell wall will result in cell lysate containing proteins of interest. However, this 
will also result in loss of the cells metabolic regulation, and enzymes such as proteases may 
result in sample degradation prior to analysis. In addition to cooling of the cell sample, 
inhibitors are added to the lysis buffer to inhibit these processes. 
NebA buffer: (for 5 ml) 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, 0.5M, 
0.5 ml), MnCl2 (0.5M, 50 µl), MgCl2 (0.5M, 100 µl), ethylene glycol tetraacetic acid 
(EGTA, 0.5M, 100 µl), EDTA (0.5M, 20 µl), NaCl (5M, 100 µl), KCl (1M, 25 µl) and 
Nonident (10%, 50 µl) in ddH2O (3.915 ml). 
Inhibitors: (to 1 ml NebA) RNAse A (10 mg/ml, 3 µl), DNAse I (10 mg/ml, 3 µl), Protease 
inhibitor cocktail (PIC, Sigma) containing 4-(2-aminoethyl)benzenesulfonyl fluoride, 
pepstatin A, trans-epoxysuccinyl -L-leucylamido(4-guanido)butane, bestatin, leupeptin and 
aprotinin in DMSO (10 mg/ml, 1 µl), phenylmethylsulfonyl fluoride (PMSF, 1M, 1 µl), NaF 
(0.5M, 10 µl) and β-glycerophosphate (0.5M, 10 µl). 
Cell pellets were suspended in NebA lysis buffer (50-250 µL, based on pellet size) and kept 
on ice for 30 minutes. The samples were subsequently passed through a 27 gauge needle 10 
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times to mechanically break up the cell membrane, before being centrifuged for 10 minutes at 
4 °C and 13,000 rpm. The supernatant liquid was removed, affording a pellet of lysed cellular 
material, which can be carried forward for further experimentation. 
7.8.2. Gel Electrophoresis 
7.8.2.1. Principle 
In order to study proteins from cell lysate or immunoprecipitation, it is necessary to separate 
the proteins using gel electrophoresis, using an electric field and separating the proteins based 
on molecular weight. In order for molecular weight to be the only factor in their separation, 
the proteins must be denatured from their original tertiary structure and given an overall net 
negative charge to negate the intrinsic variable charge of proteins. This is achieved by heating 
the protein samples to 100 °C in sample buffer, containing the anionic detergent sodium 
dodecyl sulfate (SDS), 2-mercaptoethanol for the cleavage of disulfide bonds, and 
bromophenol blue to act as a marker dye running in front of the protein samples.  
Polyacrylamide gel is utilised as the support medium due to its active participation in the 
separation process, as it has pores in the same order of magnitude as the peptide units, 
allowing it to act as a molecular ‘sieve’. Furthermore, it is chemically inert, stable to 
temperature and pH, and is transparent which allows the progress of marker proteins to be 
monitored during electrophoresis. Gel density can be adjusted depending on the molecular 
weight of the proteins of interest; increasing density by using a higher percentage of 
acrylamide will decrease pore size, allowing separation of smaller molecular weight peptide 
units. This process is known as sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE). 
7.8.2.2. General Reagents 
SDS Sample Buffer: Tris(hydroxymethyl)aminomethane hydrochloride pH 6.8 (Tris.HCl, 63 
mM), SDS (2% w/v), 2-mercaptoethanol (5% w/v), glycerol (20% v/v) and bromophenol 
blue (0.005% w/v) in ddH2O. 
Tris-Glycine-SDS Running Buffer: Tris (0.025 M), glycine (0.20 M) and SDS (3.5 mM) in 
ddH2O. 
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Stacking Polyacrylamide Gel: (1 gel) 30% ProtoGel® (37.5:1 Acrylamide:Bisacrylamide, 
0.65 ml), ddH2O (3.0 ml), stacking buffer (0.5M Tris pH 6.8, 0.4% SDS, 1.25 ml), 10% 
ammonium persulfate (APS, 75 µl), tetramethylethylenediamine (TEMED, 5 µl). 
Resolving Polyacrylamide Gel (10%): (1 gel) 30% ProtoGel® (2.0 ml), ddH2O (2.5 ml), 
resolving buffer (1.5M Tris pH 6.8, 0.4% SDS, 1.5 ml), 10% APS (75 µl), TEMED (5 µl). 
7.8.2.3. General Procedure 
Cell lysate pellets are suspended in SDS sample buffer (10-100 µl, based on pellet size) and 
boiled at 100 °C for 5 minutes. Samples (10-30 µl) are added along with a protein size ladder 
to the stacking layer of a polyacrylamide gel, and sample wells filled with Tris-Glycine-SDS 
running buffer. The gel is run in Tris-Glycine-SDS running buffer at 180 volts until the 
bromophenol blue reaches the bottom of the resolving gel (approx. 1 hour). The gel is 
removed from the buffer, the stacking layer is cut away and the resolving layer is washed 
with water. 
7.8.3. Western Blotting and Immunodetection 
7.8.3.1. Principle 
It is necessary to identify and analyse proteins separated by SDS-PAGE, which is not 
possible when the proteins remain on the gel. In order to transfer the proteins to a suitable 
medium and detect proteins of interest, the techniques of Western blotting and 
immunodetection may be used. In order to probe for proteins of interest using antibodies, the 
proteins residing on the acrylamide gel are first transferred to a thin membrane, such as 
nitrocellulose.  
Nitrocellulose membrane is a thin film of nitrocellulose, generated through the exposure of 
cellulose to nitric acid, which has a high affinity for proteins and nucleic acids. This allows 
proteins transferred to the membrane to be immobilised on its surface for detection using 
immuno-antibodies. The net negative charge given to the proteins during SDS-PAGE can be 
used to transfer proteins from the gel to nitrocellulose through the application of an electric 
current perpendicular to the plane of the gel. 
Due to the high affinity of nitrocellulose membrane to proteins, prior to treating the 
membrane with antibodies, it is necessary to block all unoccupied sites on the membrane. 
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This can be achieved using both bovine serum albumin (BSA) or milk, in buffer containing 
the polysorbate surfactant Tween-20, which further aids in non-specific antibody binding. 
After blocking the membrane, the membrane can be probed with primary antibodies, which 
have been specifically raised against the protein of interest, resulting in specific binding of 
the antibody to regions of the membrane at which the protein is present. Following primary 
antibody incubation, the membrane can be probed with secondary antibodies, which are 
targeted for the species specific immunoglobulin heavy chain of the primary antibody. This 
allows membranes to be probed with antibodies for alternative proteins raised in different 
species, and these proteins to be identified using species specific secondary antibodies. The 
secondary antibodies can be used to visually detect proteins due to the fact that they can bear 
enzymes that can be used to catalyse reactions that illicit a visual response. The two most 
common types of reporter assay utilise alkaline phosphatase (AP) and horseradish peroxidase 
(HRP) secondary conjugates. 
 
Figure 60: Mechanism of colour generation using AP conjugate secondary antibodies. 
Alkaline phosphatase is used to generate a colourimetric assay, through the use of the 
developing agents 5-bromo-4-chloroindolyl phosphate (BCIP) and nitro blue tetrazolium 
chloride (NBT). AP catalyses the dephosphorylation of BCIP to 5-bromo-4-chloroindolin-3-
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ol, which undergoes a redox reaction with NBT to generate the strongly blue coloured 
precipitates 5,5’-dibromo-4,4’-dichloro-indigo and formazan (Figure 60). 
 
Figure 61: Mechanism of light generation using ECL conjugate secondary antibodies. 
Horseradish peroxidase is used in enhanced chemiluminescence (ECL) systems, in which 
HRP in the presence of hydrogen peroxide and an enhancer,usually in the form of a 
substituted phenol, catalyses the conversion of luminol to an aminophthalate, with the 
production of light (Figure 61). This light can be detected through the development of 
photographic films exposed to membranes after treatment with ECL systems. Bleaching of 
the photographic film not only provides information as to the presence of protein, but also the 
relative abundance. 
7.8.3.2. General Reagents 
Transfer Buffer: Tris (0.025M), glycine (0.20M), and methanol (10% v/v) in ddH2O. 
Ponceau Stain: Ponceau S (0.2% w/v), trichloroacetic acid (3% w/v) and sulfosalicylic acid 
(3% w/v) in ddH2O. 
Blocking Solution: Milk powder (5% w/v), Tween20 (0.1% v/v) in PBS. 
AP Buffer pH 9.5: Tris.HCl (100mM), NaCl (100mM), MgCl2 (5mM) and Tween20 (0.1% 
v/v) in ddH2O). 
AP Developing Solution: BCIP (0.02% w/v) and NBT (0.03% w/v) in AP buffer pH 9.5. 
7.8.3.3. General Procedure 
A film of nitrocellulose membrane is soaked in transfer buffer and placed on 3 sheets of 
blotting paper, also soaked in buffer, in a blotting unit. A polyacrylamide gel from SDS-
PAGE is carefully soaked in transfer buffer and placed on top of the membrane, followed by 
a further 3 soaked sheets of blotting paper. The resulting layers are gently rolled to remove 
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any air bubbles and further transfer buffer is poured over them. The lid of the blotting unit is 
closed and a current of 70 mA/gel is passed through the system for 1-2 hours depending on 
protein size. Upon completion, the membrane is removed and stained with ponceau stain for 
5 minutes, after which water is used to destain the membrane so only protein locations can be 
seen. At this point, the location of the channels and marker ladder can be marked with pencil, 
and the membrane can be imaged to record relative protein levels in each channel. 
The unoccupied sites of the membrane are subsequently blocked by covering the membrane 
in blocking solution and placing the membrane on an agitator for 10 minutes. The blocking 
solution is changed and the process repeated a further 2 times. The primary antibody is 
prepared as a dilution, according to suppliers instructions, in blocking solution (3-5 ml, 
depending on membrane size), and the membrane is incubated in this solution for 1 hour at 
room temperature, or for 18 hours at 4 °C. The primary antibody solution is removed and the 
membrane is washed with PBS-Tween (10 ml) for 10 minutes, 3 times. 
The requisite secondary antibody conjugate solution is prepared as for the primary solution in 
blocking solution (3-5 ml, depending on membrane size), and the membrane is incubated in 
this solution for a further 1 hour at room temperature. This is followed by a further course of 
washes with PBS-Tween (10 ml) for 10 minutes, 3 times. 
For the development of blots incubated with AP conjugate secondary antibodies, the 
developing solution (3-5 ml) is prepared and added to the membrane. The membrane is 
incubated with the developing solution until protein bands have developed to the desired 
level (5-30 minutes), at which point the developing solution is removed and the membrane is 
washed with PBS-Tween (10 ml). The membrane can now be imaged to record the resultant 
band pattern. 
For the development of blots incubated with ECL conjugate secondary antibodies, the 
developing solution (ThermoScientific, Pierce ECL WB substrate, 32106) is prepared as per 
suppliers instructions and added to the dry membrane for 60 seconds. The developing 
solution is removed by blotting with paper towel and the membrane is loaded into a film 
cassette and exposed to photographic film (<1 min – 1 hour, depending on protein 
abundance). Development of the photographic film reveals the band pattern, which can be 
imaged. 
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7.8.4. Immunofluorescence Microscopy 
7.8.4.1. Principle 
When working with cellular populations, it is desirable to determine the location and 
abundance of target proteins within the cell. One such technique that allows this is 
immunofluorescence microscopy. Similar to immunodetection of proteins on membranes, 
this technique relies on the specificity of antibodies for target proteins to allow this 
information to be acquired from whole cell populations. When working with adherent cell 
lines, it is possible to grow cell colonies on microscope cover slips that have been etched 
using acetic acid, followed by sterilization in an autoclave. 
Upon completion of a desired cell treatment protocol, it is possible to fix cells in their present 
state using cold methanol, preventing any further cell growth or death. This allows the cells 
to be probed with antibodies, and detailed information about the location and abundance of 
proteins at the time of fixation to be ascertained. The coverslips that are removed from cell 
culture dishes possess large areas of glass that are free of cells, and glass has a latent affinity 
for proteins. It is therefore necessary to block the vacant sites of the coverslips in a similar 
manner to nitrocellulose membrane, to limit non-specific antibody binding. This is done 
using BSA. The coverslips can subsequently be probed with antibodies raised against the 
proteins of interest. It is common when conducting immunofluorescence microscopy to probe 
cells with more than one antibody at a time, relying on the differing species specific 
immunoglobulin heavy chain of the primary antibodies to ensure these proteins can be 
differentiated once imaged.  
 
A secondary antibody mix can now be applied to the cover slips, containing antibodies 
targeting the species specific immunoglobulin heavy chain, bearing fluorescent reporter 
proteins. It is also common for the secondary antibody mix to contain a fluorescent DNA 
minor groove binder of the Hoechst family, to allow the visualisation of DNA within the cell. 
During the course of this work Hoechst33258 was used, displaying blue fluorescence. 
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The coverslips now bear cells within which proteins of interest are tagged with fluorescent 
reporter proteins, and microscopy utilising laser excitation of the relevant wavelength can be 
used for detection. 
7.8.4.2. General Reagents 
Blocking Solution: BSA (3% w/v) in PBS. 
Incubation Solution: BSA (1% w/v) in PBS. 
7.8.4.3. General Procedure 
Upon completion of the desired cell treatment regimen, the cell media is removed by 
aspiration, and the coverslips are transferred to clean wells. The remaining cells in the cell 
culture dish may be used for further assay techniques. The coverslips are fixed using 
methanol (-20 °C, 2-5 ml, depending on size of cover slip) at -20 °C for 15 minutes. The 
methanol is removed from the cover slips and they are washed with PBS (2-5 ml) for 5 
minutes, 3 times. Each cover slip is blocked with blocking solution (1-3 ml) for 10 minutes, 
before the solution is removed. The primary antibody mix is prepared in incubation solution 
at concentrations as per supplier’s instructions, and the solution (100-200 µl) is pipetted 
directly onto each cover slip, ensuring that the entire surface is covered. The cover slips are 
incubated with primary antibody in the dark for 1 hour, before being washed with PBS (2-5 
ml) for 5 minutes, 3 times. The secondary antibody mix is prepared in incubation solution 
and pipetted directly onto the cover slips. Incubation is repeated for a further 1 hour in the 
dark. The cover slips are washed with PBS (2-5 ml) for 5 minutes, 3 times, before being 
mounted onto microscope slides. At this point, the slides can be stored at 4 °C in the dark 
prior to microscopy. 
7.8.5. Fluorescence-Activated Cell Sorting (FACS) 
7.8.5.1. Principle 
When subjecting cells to a treatment regimen that is proposed to affect progression through 
the cell cycle, it is desirable to determine the relative distribution of a cell population through 
the cell cycle. Due to the complexity of this process, it can be very challenging to do this. 
However, one factor that can be used as a measure of cell cycle progression is DNA content 
in cells. In a given asynchronous cell population, the majority of cells will be in a quiescent, 
214 
 
or resting, state, or in G1. Thus, DNA content will be equal to that which is resultant from the 
previous cycle of mitosis, and hence will be 1 copy of the cells genetic information. Once the 
cell cycle has entered the S-phase, the cells genetic information is replicated, resulting in a 
doubling of DNA content. From this point, the cell cycle progresses relatively quickly 
through to mitosis, yielding new daughter cells with a DNA content equal to that of G1. 
It is possible to utilise this disparity in DNA content of cells in G1 with respect to those at 
G2/M to gauge the cells progression through mitosis, and in particular identify cell 
populations experiencing mitotic delay, through an increase in cells with a DNA indicative of 
a G2/M profile. Once such method used to determine this distribution is fluorescence-
activated cell sorting (FACS).  
FACS uses the techniques of flow cytometry, and in particular hydrodynamic focussing, to 
allow samples of particles, such as cells, to be analysed individually. Under hydrodynamic 
focussing conditions, a sample flow may be passed down a capillary into the flow of a 
separate fluid, known as the sheath. If the velocities of the two media differ sufficiently, 
essentially no mixing occurs, and through narrowing of the chamber through which the 
sample and sheath fluids flow, a very narrow sample flow can be achieved (Figure 62).
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Figure 62: Hydrodynamic focussing used in flow cytometry.
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In FACS, fluorescence spectroscopy of the resultant flow allows the determination of the 
relative DNA content in individual cells of an entire cell population. In order to do this, the 
DNA must be labelled in a quantitative manner with a fluorescent marker molecule. For this 
purpose, the fluorescent DNA intercalating agent propidium iodide is used. Incubation of cell 
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samples with propidium iodide, followed by FACS analysis results in a fluorescence readout 
which reflects the abundance of DNA in cells with respect to their cumulative abundance.  
7.8.5.2. General Reagents 
Staining Solution: RNAse A (100 µg/ml), propidium iodide (50 µg/ml) in PBS. 
7.8.5.3. General Procedure 
For asynchronous and G1/S cells, cell culture media is removed via aspiration, and the cell 
monolayer is washed with PBS (5 ml). The PBS is removed and the cells are incubated with 
PBS/EDTA (1-3 ml). Cells are collected and transferred to centrifuge tubes. Due to the fact 
that G2/M cells have rounded up and partially detached from the cell culture dish, for these 
cells the cell culture media is removed and added to a centrifuge tube. Any remaining cell 
monolayer is harvested as per G1/S cells. All cell harvests are subsequently centrifuged at 
room temperature for 5 minutes at 1,000 rpm. 
Once centrifuged, the supernatant is removed from all cells via aspiration, and the cell pellet 
is resuspended in PBS (5 ml), followed by a further centrifugation at room temperature for 5 
minutes at 1,000 rpm. Again, the supernatant is removed, and the cell pellets are resuspended 
in PBS (200 µl). In order to fix the cells, 70% ice-cold ethanol (2.0 ml) is added drop-wise, 
whilst the cells are gently vortexed to prevent aggregation. At this point, the fixed cells can 
be stored at 4  C. 
The fixed cells are now centrifuged at 4 °C for 5 minutes at 3,000 rpm, and the supernatant 
removed via aspiration. The cell pellets are washed with PBS (5 ml) twice, with 
centrifugation and aspiration, to remove all ethanol. The resulting pellets are resuspended in 
staining solution (1 ml) and incubated at 4 °C in the dark for 18 hours. The resulting samples 
are subjected to FACS analysis, with the use of asynchronous, mitotic and S-phase control 
samples used to control the calibration of cell counting population restrictions. 
7.8.6. In Vitro 
32
P Kinase Assay 
7.8.6.1. Principle 
It is often necessary to determine the catalytic activity of kinases, either purchased as 
recombinant kinases, or as purified kinases from immunoprecipitation. One method to 
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achieve this is the use of 
32
P in a kinase assay. 
32
P is one of 23 known isotopes of phosphorus, 
and long with 
33P is a β-emitting radioisotope. It is possible to take advantage of this β-
emission to monitor kinase activity through incorporation of 
32
P into kinase substrates. 
Incubation of a kinase of interest with its substrate in the presence of 
32
P-ATP will result in 
radiolabelling of the substrate through phosphorylation. When compared to a control kinase 
assay, the relative level of radioactivity will give a direct measure of kinase activity.  
Boiling of assay samples in SDS sample buffer will halt any further reaction through 
denaturing of the proteins, and the samples can be subjected to SDS-PAGE. This results in a 
gel with bands of radiolabelled substrate. There are two ways in which kinase activity can be 
determined from this gel. Exposure of the radioactive gel to X-ray film will result in 
bleaching of the film, which when developed can be analysed by densitometry, to give the 
integrated optical density (IOD) of each band. However, this technique has a relatively large 
error associated, and as such can only be used to give semi-quantitative analysis. A much 
more accurate measure of activity can be acquired by drying the gel and manually removing 
each substrate band. The substrate can now be subjected to scintillation counting, allowing an 
accurate numerical figure for the relative kinase activity to be determined. 
7.8.6.2. General Reagents 
Kinase Buffer: (for 10 reactions) HEPES (0.5M, 50 µl), NaF (0.5M, 5 µl), β-
glycerophosphate (0.5M, 5 µl), MnCl2 (0.5M, 5 µl), ATP (100µM, 20 µl), dithiothrietol 
(DTT, 1M, 0.5 µl) and 
32
P-γ-ATP (~100 µCi, 10 µl) in ddH2O (404.5 µl). 
Coumassie Blue: Coumassie brilliant blue (2.25% w/v), methanol (45% v/v), acetic acid 
(10% v/v) and ddH2O (45% v/v). 
Coumassie Destain: Methanol (20% v/v), acetic acid (10% v/v) and ddH2O (70% v/v). 
7.8.6.3. General Procedure 
The kinase of interest (0.1 µg/µl, 5 µl) is added to the side of two eppendorf tubes, followed 
by substrate (5 mg/ml, 5 µl), and inhibitor at a desired concentration to 1 tube, ensuring all 
reagents do not mix. All tubes are stored on ice, and kinase buffer (50 µl) is added to each, 
with gently vortexing to mix. Samples are incubated at 30 °C for 30 minutes, after which 
point SDS sample buffer (50 µl) is added and samples are boiled at 100 °C for 5 minutes.  
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Samples are subjected to SDS-PAGE and the resultant gel is washed with water, covered 
with Coumassie blue stain (10-20 ml), and left on a shaker for 1-2 hours at room temperature. 
The Coumassie blue stain is removed and any excess washed with water, after which the gel 
is washed with Coumassie destain (10-20 ml) until the substrate bands are visible. It may be 
necessary during this time to change the destain solution.  
The gel is removed from the destain solution, with any excess removed with water, and dried 
under vacuum at 40 °C for 1-2 hours. At this point the gel can be imaged to record substrate 
bands to confirm substrate loading is equal in comparative lanes. The gel is then exposed to 
X-ray film (<5 min – 24 h, depending on kinase activity), after which the developed film can 
be recorded via densitometry. However, in the work described herein, all kinase activity 
measurements were determined using scintillation counting. The substrate bands are cut from 
the gel and added to scintillation fluid (2 ml) in scintillation vials. Kinase activity in each 
sample is determined using a scintillation counter, and the relative activity between the 
control and inhibitor treated samples can be used to determine kinase inhibition. 
7.9. Experimental and Results 
7.9.1. Monitoring Induction of myc-Nek2 in U2OS Cell Line 
7.9.1.1. Antibodies 
Primary: Myc-mouse (Cell Signalling, 2276), α-tubulin-mouse (Sigma, T5168), pAQDL-
rabbit (500 µg/ml). 
Secondary: Anti-mouse AP conjugate (Promega, S3721), Goat-anti-mouse 488 (Invitrogen, 
A11001), Goat-anti-rabbit 594 (Invitrogen, A11012). 
7.9.1.2. Procedure 
U2OS myc-Nek2 inducible cells were grown in 7 x 10 cm cell culture dishes in 10 ml 
DMEM until ~80% confluent. Doxycycline (1 µg/ml) was added at time points of 48, 36, 24, 
26, 8 and 4 hours, in addition to a population lacking doxycycline treatment. All cell 
populations were lifted from the dish, lysed, and subjected to SDS-PAGE. Western blotting 
of the resultant gels with myc-mouse (1/1000) and α-tubulin-mouse (1/2000) antibodies, 
followed by development of the membrane with anti-mouse AP conjugate (1/7500) allowed 
the observation of protein bands by colourimetric analysis.  
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Immunofluorescence observation of myc-Nek2 induction was carried out using 2 populations 
of U2OS myc-Nek2 cells grown on cover slips, one treated with doxycycline (1 µg/ml) for 18 
hours, and one with no treatment. Upon completion of the treatment regimen, the cover slips 
were removed from media, fixed with cold methanol, and stained primary antibodies myc-
mouse (1/1000) and pAQDL-rabbit (1/500). Fluorescent tagging of the primary antibodies 
with goart-anti-mouse 488 (1/200) and goat-anti-rabbit 594 (1/200), in conjunction with 
Hoechst (1/1000) allowed visualisation of proteins via immunofluorescence microscopy and 
hence confirmation of myc-Nek2 induction. 
7.9.2. Evaluating the Effect of NCL-00017509 (177) on Centrosome Splitting 
7.9.2.1. Antibodies 
Primary: Myc-mouse (Cell Signalling, 2276), γ-tubulin-rabbit (Sigma, T3559). 
Secondary: Goat-anti-mouse 594 (Invitrogen, A11005), goat-anti-rabbit 488 (Invitrogen, 
A11008). 
7.9.2.2. Procedure 
U2OS myc-Nek2 cells were grown on 8 x 6 cm cell culture dishes in 5 ml DMEM containing 
cover slips until ~80% confluent. The cell populations on 4 of the pleates were treated with 
doxycycline (1 µg/ml) for 16 hours, after which both +Dox and -Dox sets of cells were 
treatment with NCL-00017509 at doses of 50nM, 500nM and 5µM. All cover slips were 
lifted from the media and fixed with cold methanol, followed by immunofluorescence 
staining.  
Myc-mouse (1/1000) primary antibody was used to confirm induction, and γ-tubulin-rabbit 
(1/2000) primary antibody was used to stain the centrosomes to score for splitting. A 
seconday antibody mixture of goat-anti-mouse 594 (1/200), goat-anti-rabbit 488 (1/200) and 
Hoechst (1/1000) was applied to the cover slips, and the cells were imaged using 
fluorescence microscopy. Cells were scored for splitting (see Figure 48), and >100 cells were 
counted on each cover slip. The assay was carried out in triplicate, with fresh cell colonies 
used in each case. 
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7.9.2.3. Results 
Condition (Dox/Inhibitor) Centrosomes split Centrosomes non-split % Split centrosomes 
˗ / ˗ 73 241 23 
˗ / 50nM 55 253 18 
˗ / 500nM 49 275 15 
˗ / 5µM 38 275 12 
+ / ˗ 187 120 61 
+ / 50nM 128 191 40 
+ / 500nM 85 217 28 
+ / 5µM 47 268 15 
Table 20: Percentage of centrosomes split for tetracycline induced and non-induced cells treated with NCL-
00017509 (177) (n = 3). 
7.9.3. Evaluating the Effect of NCL-00017509 (177) on pC-Nap1 Intensity 
7.9.3.1. Antibodies 
Primary: pAQDL-rabbit (500 µg/ml), myc-mouse (Cell Signalling, 2276), γ-tubulin-mouse 
(Sigma, T6557), C-Nap1-rabbit (500 µg/ml), pLLEK-rabbit (500 µg/ml), pRELQ-rabbit (500 
µg/ml), pRRLD-rabbit (500 µg/ml).  
Secondary: Goat-anti-mouse 594 (Invitrogen, A11005), goat-anti-rabbit 488 (Invitrogen, 
A11008). 
7.9.3.2. Procedure 
Cells were grown as detailed above (3.2.2.), and the cover slips incubated with the primary 
antibodies pAQDL-rabbit (1/500) and myc-mouse (1/1000). However, after the first 
completion of this assay, it became apparent that a clear indicator of centrosome location was 
necessary for uninduced cells, as pC-Nap1 intensity was sufficiently low to make 
identification difficult. In subsequent repeats of this assay, uninduced cells were incubated 
with γ-tubulin-mouse (1/2000) in place of myc-mouse. The seconday antibody mixture of 
goat-anti-mouse 594 (1/200), goat-anti-rabbit 488 (1/200) and Hoechst (1/1000) was applied 
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to the cover slips, and the cells were imaged using fluorescence microscopy. The average 
intensity of 20 centrosomes under each condition were calculated and given as a percentage 
of the intensity for induced cells lacking inhibitor treatment, as this is expected to give the 
most intense reading. This assay was repeated in triplicate. 
In order to determine the selectivity of Nek2 inhibition over the 4 phosphorylation sites of C-
Nap1 to which antibodies are available, the assay was repeated on 10 x 6 cm cell culture 
plates with DMEM (5 ml). All cells were induced with doxycycline (1 µg/ml) for 16 hours, 
after which 5 cell populations were treated with NCL-00017509 at 5µM. Cover slips were 
removed and fixed, and the cover slips were divided into 5 pairs of untreated and inhibitor 
treated cells. The primary antibody mixture were prepared consisting γ-tubulin-mouse 
(1/2000) and a C-Nap1 antibody; total C-Nap1-rabbit (1/500), pAQDL-rabbit (1/500), 
pLLEK-rabbit (1/500), pRELQ-rabbit (1/500) and pRRLD-rabbit (1/500). Following 
incubation, treatment with the secondary antibody mixture of goat-anti-mouse 594 (1/200), 
goat-anti-rabbit 488 (1/200) and Hoechst (1/1000) was applied. Cells were imaged and 20 
centrosome intensity measurements made under each condition. During the course of this 
study, it was not possible to repeat this assay. 
7.9.3.3. Results 
 pAQDL Percentage Intensity 
Condition + / ˗ + / 50nM + / 500nM + / 5µM ˗ / ˗ ˗ / 50nM ˗ / 500nM ˗ / 5µM 
1 100 106.9 76.4 21.2 20.8 34.8 34.1 20.9 
2 100 114.8 177.5 27.5 71.8 45.5 50.3 16.8 
3 100 96.6 120.5 27.3     
Average 100 106.1 124.8 25.3 46.3 40.2 42.2 18.9 
Std. dev. - 9.13 50.7 3.58 36.1 7.57 11.5 2.90 
Std. error - 5.27 29.3 2.07 25.5 5.35 8.10 2.05 
Table 21: Percentage pAQDL intensity with respect to untreated cells for tetracycline induced and non-induced 
cells treated with NCL-00017509 (177) (n = 3). 
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Antibody C-Nap1 pAQDL pLLEK pRELQ pRRLD 
177 - + - + - + - + - + 
Average 152.3 399.1 60.4 43.0 67.4 49.5 271.0 267.0 153.4 81.5 
Percent 100 262.1 100 71.2 100 73.5 100 98.5 100 53.1 
Std. dev. 68.1 130 29.8 18.8 32.3 42.6 164 183 63.5 31.7 
Std. err. 15.2 29.3 6.66 4.21 7.23 9.52 36.7 41.0 14.2 7.09 
Table 22: C-Nap1 phospo-specific antibody intensity values for tetracycline induced cells both treated and 
untreated with NCL-00017509 (177) (n = 1). 
7.9.4. Monitoring Mitotic Progression Using Live Cell Imaging 
7.9.4.1. Reagents 
Opti-MEM® I (Gibco
®
, Invitrogen): Reduced serum Eagle’s Minimum Essential Medium – 
reduced serum media gives improved performance in microscopic analysis. 
7.9.4.2. Procedure 
HeLa GFP-α-tubulin/mCherry-Histone cells grown in a 10 cm plate in 10 ml MEM were 
passaged into a 4 chamber microscope dish in MEM (1 ml) and incubated for 16 hours to 
adhere to the dish. The media was aspirated and Opti-MEM® I (1 ml) was added to each 
chamber, and 2 chambers were treated with either 177 (5µM), or MLN-8054 (5µM) for 4 
hours. The cells were loaded into a Leica TCS SP5 confocal laser scanning microscope, with 
the chamber maintained at 38 °C and 5.0% CO2, and the cells were visualised. 2 fields of 
view for each treatment condition were acquired, where mitotic cells were present with 
surrounding free space for further division, and the maximum and minimum focal planes of a 
mitotic cell were defined. This focal field was divided into 5 µm planes (~20-25), and an 
image was taken at each focal plane for all positions every 5 minutes for 15 hours. 
Compression of focal planes allows a representative image of the cell to be acquired, and all 
positions were viewed and cells scored for time from prometaphase to anaphase, and time 
from anaphase to mitosis. Further analysis made note of the presence cells with spindle 
abnormalities, and cells entering but failing to complete mitosis. This process was repeated 6 
times, using distinct cell populations on each occasion. 
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7.9.4.3. Results 
 Average Time (min) 
177 Total mitosis 
Prometaphase to 
anaphase 
Anaphase to cytokinesis 
˗ 116.2 77.2 48.8 
+ 140.8 79.8 66.1 
Table 23: Duration of mitosis for cells treated with NCL-00017509 (177) compared with untreated cells. 
 Total cells 
 Untreated 177 MLN-8054 
Division 70 101 2 
Apoptosis/failure 6 22 67 
Bipolar spindle 82 94 3 
Monopolar spindle 7 34 91 
Bipolar spindle delay 1 15 1 
Other defects 5 18 9 
Table 24: Number of cells exhibiting specific mitotic characteristics for untreated cells and cells treated with 
NCL-00017509 (177) and MLN-8054. 
7.9.5. Confirming Mitotic Delay Using FACS Analysis 
7.9.5.1. Procedure 
U2OS myc-Nek2 cells were plated into 10 x 6 cm cell culture dishes in DMEM (5 ml) at low 
confluency (~30%). Both NCL-00017509 and MLN-8054 were administered to separate 
dishes at 5µM, and further dishes were treated with inhibitor at 24, 48, 68 and 72 hours point. 
This resulted in cell populations treated with either inhibitor for 4, 24, 28 and 72 hours. Of 
the remaining dishes, 1 was maintained as an untreated sample, and the other was treated 
with Nocodazole (0.5 µg/.ml) to generate a mitotic block control sample. This was used to 
calibrate the analysis software to ensure the correct counting of mitotic cells.  
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In order to maintain fresh media, every 24 hours the media was aspirated from all cells and 
replaced with fresh DMEM (5 ml). Furthermore, in order to maintain compound 
concentration in media, which may be lost due to chemical degradation and kinase turnover, 
inhibitor was readministered to all previously treated cells during the change of media. 
Upon completion of the treatment regimen, all cell populations were lifted and prepared for 
FACS analysis as detailed above (2.5.3.). FACS counting of populations afforded 
quantitative data on relative population distribution between G1 (2N DNA), G2/M (4N DNA) 
and failed mitosis (8N DNA). 
7.9.5.2. Results 
 + 177 + MLN-8054 
 Async. 4 h 24 h 48 h 72 h 4 h 24 h 48 h 72 h 
2N 56.6 50.3 41.5 42.4 37.1 46.4 7.1 2.6 2.6 
4N 19.4 18.6 27.2 18.6 23.9 19.3 54.8 57.7 27.1 
8N 3.0 4.6 3.7 2.6 4.4 4.2 9.3 14.4 31.5 
Table 25: DNA number assigned by FACS analysis for cells treated with NCL-00017509 (177) and MLN-8054 
for times up to 72 h. 
7.9.6. Testing Selectivity of NCL-00017509 (177) using In Vitro 
32
P Kinase Assay 
7.9.6.1. Reagents 
Kinases: Nek2A (Upstate, 14-545), Nek3 (Upstate, 14-694), Nek6 (Upstate, 14-578), Nek7 
(Upstate, 14-567), Nek11 (Upstate, 14-700), Cdk1/Cyclin A2 (Sigma, C0244), Aurora A 
(Upstate, 14-511), Plk1 (Cell Sciences, CSI10299). 
Substrates: β-casein (5 mg/ml), Histone H1 (5 mg/ml). 
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7.9.6.2. Procedure 
All kinases (0.1 mg/ml, 1 µl) were subjected to 
32
P kinase assay conditions as described 
above (2.6.) with β-casein (5 mg/ml, 5 µl) as substrate, excluding Plk1, with which Histone 
H1 (5 mg/ml, 5 µl) was used as substrate. Inhibitor concentration was 1µM in all cases. Prior 
to assay execution, it was necessary to pre-activate Nek11. This was achieved through 
incubation of Nek11 kinase in kinase buffer (50 µl) lacking 
32
P-γ-ATP at 30 °C for 30 
minutes, followed by addition of substrate, inhibitor and 
32
P-γ-ATP. All assays were repeated 
in triplicate. 
Kinase activity was determined via scintillation counting, with average activity with respect 
to untreated kinase calculated to give a single point indicator of kinase inhibition at 1µM 177. 
7.9.6.3. Results 
 Nek2 Nek3 
 Scintillation count Percentage Scintillation count Percentage 
177 - + - + - + - + 
 242604.5 47794.2 100 19.7 44531.0 44748.0 100 100.5 
 266813.0 52359.0 100 19.6 32110.1 54141.5 100 168.6 
 321872.9 47351.6 100 14.7 73606.4 61951.3 100 84.2 
Avg.   100 18.0   100 117.8 
Std. dev.   - 2.86   - 44.8 
Std. err.   - 1.68   - 26.3 
 
 Nek6 Nek7 
 Scintillation count Percentage Scintillation count Percentage 
177 - + - + - + - + 
 86220.4 55.360.5 100 64.2 233102.5 219120.4 100 94.0 
 67342.0 61657.3 100 91.6 391537.6 236611.8 100 60.4 
 98924.9 60411.6 100 61.1 432639.5 445174.5 100 102.9 
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Avg.   100 72.3   100 85.8 
Std. dev.   - 16.8   - 22.4 
Std. err.   - 9.87   - 13.2 
 
 Nek11 Cdk1/Cyclin A2 
 Scintillation count Percentage Scintillation count Percentage 
177 - + - + - + - + 
 17021.4 9724.4 100 57.1 39534.9 37965.9 100 96.0 
 20255.0 13585.0 100 67.1 43801.2 27502.2 100 62.8 
 11399.0 10546.0 100 92.5 64297.8 51110.3 100 79.5 
Avg.   100 72.2   100 79.4 
Std. dev.   - 18.3   - 16.6 
Std. err.   - 10.7   - 9.78 
   
 Aurora A Plk1 
 Scintillation count Percentage Scintillation count Percentage 
177 - + - + - + - + 
 70337.2 14818.2 100 21.1 443152.0 351452.6 100 79.3 
 52628.6 30293.6 100 57.6 441453.2 338621.7 100 76.7 
 44562.2 11011.4 100 24.7 - - 100 - 
Avg.   100 34.4   100 78.0 
Std. dev.   - 20.1   - 1.84 
Std. err.   - 11.6   - 1.08 
Table 26: Scintillation count data for NCL-00017509 (177) in 
32
P in vitro kinase assays. 
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Chapter 8: Experimental 
8.1. Chemicals and Solvents 
All chemical reagents were purchased from the Aldrich Chemical Company, Apollo 
Scientific or Alfa Aesar Chemicals and were of the highest available purity. Chemicals were 
used as supplied with no further treatment. If chemicals used were stated as dry/anhydrous, 
they were stored in SureSeal™ septum-sealed bottles and removed under an inert nitrogen 
environment, with the reaction being carried out under the relevant inert atmosphere. 
Palladium catalysts were stored and measured out under an inert atmosphere. 
8.2. Chromatography 
Reaction monitoring and compounds identification was aided using Thin Layer 
Chromatography (TLC) and Retardation factor (Rf) values. TLC was conducted with Merck 
aluminium backed Si F254, NH2 F254s and RP-18 F254s plates. Fluorescent compounds were 
visualised under short wave (254 nm) UV irradiation. Compound purification was achieved 
using medium pressure ‘Flash’ column chromatography, with the use of Davisil silica 40-
60μm as the stationary phase, or Biotage automated chromatography using pre-packed silica 
cartridges. A Biotage SP4 automated flash purification system was used with UV monitoring 
at 298 nm and compound collection at 254 nm. Biotage KP-NH cartridges were employed for 
the separation of secondary, tertiary, and heterocyclic amines; using a primary amine (propyl 
amine) bonded silica. When stated, compounds were purified via semi-preparative HPLC, 
using an ACE 5 Phenyl 150 x 21.2 mm column using an Agilent 1200 Modular Preparative 
HPLC system. 
8.3. Analytical Techniques 
All melting points were determined using a Stuart Scientific SMP3 or a Stuart Scientific 
SMP40 melting point apparatus and are uncorrected. 
1
H and 
13
C nuclear magnetic resonance 
(NMR) spectra were obtained as solutions in deuterated solvents DMSO-d6, MeOD or CDCl3 
using a Bruker Avance III 500 spectrometer recording at 500 MHz. Chemical shifts (δ) are 
reported in parts per million (ppm) and the spin-multiplicity abbreviated as: s (singlet), d 
(doublet), t (triplet), q (quartet), quin (quintet), sept (septet), m (multiplet), or br (broad), with 
coupling constants (J) given in Hertz (Hz). Liquid Chromatography – Mass Spectrometry 
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(LC-MS) was carried out on a Micromass Platform LC running in both positive and negative 
electrospray mode with a PDA 240-400 nm detector using a Waters Symmetry Shield RP18 3 
μm, 4.6 x 20 mm column with a flow rate of 3.0 mL/min. Alternatively, a Waters Acquity 
UPLC system was used, with a Waters SQD ESCi source using an Acquity UPLC BEH C18 
1.7 µm, 2.1 x 50 mm column with a flow rate of 0.6 ml/min. The mobile phase used was 
0.1% v/v Formic acid (aq.)/MeCN. Fourier Transform Infrared (FTIR) spectra were obtained 
using a Bio-Rad FTS 3000MX diamond ATR as a neat sample. Ultraviolet (UV) absorption 
data were collected using a Hitachi U-2800A spectrophotometer in ethanol. High-resolution 
mass spectra were performed by the ESPRC National Mass Spectrometry Service, University 
of Wales Swansea, Singleton Park, Swansea, SA2 8PP. 
8.4. Microwave Assisted Synthesis 
When stated, reactions were carried out under microwave irradiation, in sealed vessels, using 
the Biotage Initiator Sixty with robotic sample bed. Samples were irradiated at 2.45 GHz, 
able to reach temperatures of 60 - 250 ºC with a rate of heating at 2-5 °C/sec, and pressures of 
up to 20 bar. 
8.5. Biological Evaluation 
Inhibitors were tested for their Nek2 inhibitory activity by Kathy Boxall, Sam Burns, Yvette 
Newblatt and Maura Westlake under the supervision of Dr. Wynne Aherne in the Analytical 
Screening and Technology Laboratory of the CR UK Centre for Cancer Therapeutics, The 
Institute for Cancer Research, Sutton, Surrey, UK, SM2 5NG. Inhibitory potencies are 
reported as half maximal inhibitory concentrations (IC50) or percentage inhibition where 
necessary. Assays were performed in the presence of 30 µM ATP, 1 µM ‘peptide 11’ 
substrate (5-FAM-KKLNRTLSVA-COOH) and 4 nM Nek2, using a microfluidic Caliper 
methodology as previously reported.
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Inhibitors were tested for their CDK2/cyclin A3 inhibitory activity by Lan-Zhen Wang at The 
Northern Institute for Cancer Research, Paul O’Gorman Building, Newcastle University, 
Newcastle upon Tyne, NE2 4HH. Assays were performed in the presence of 12.5 µM ATP, 
14 µM histone H1 substrate and 1.9 µM recombinant CDK2/cyclin A3, using a scintillation 
count 
32
P kinase assay according to literature procedure.
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8.6. General Procedures 
General procedure A: Balz-Schiemann Reaction of 2-aminopurines 
A solution of sodium nitrite (2.0 equiv.) in water (1 ml/mmol) was added to a solution of the 
purine substrate (1.0 equiv.) in HBF4 (48 wt. % in H2O, 3.5 ml/mmol), cooled to 0 °C, over 
50 min. Upon completion of addition the reaction mixture was stirred at RT for 20 min, after 
which the solution was cooled to 0 °C and neutralised with a saturated aqueous solution of 
NaOH. The product was extracted with EtOAc (3 x 10 ml/mmol) and the combined extracts 
were dried (MgSO4) and concentrated in vacuo. Further purification was carried out if 
necessary. 
General Procedure B: TFA/TFE coupling of anilines with 2-fluoropurines using 
conventional heating 
TFA (2.5-5.0 equiv.) was added to a solution of the purine substrate (1.0 equiv.) and the 
required aniline (2.0 equiv.) in TFE (10 ml/mmol). The reaction mixture was heated at reflux 
for 24 h unless otherwise stated, after which the solution was cooled and evaporated to 
dryness. The resulting residue was dissolved in EtOAc (10 ml/mmol) and washed with a 
saturated aqueous solution of NaHCO3 (5 ml/mmol) and brine (5 ml/mmol). The combined 
aqueous layers were extracted with EtOAc (10 ml/mmol), and the combined organic extracts 
were dried (MgSO4) and concentrated in vacuo to give the crude product for chromatographic 
purification. 
General Procedure C: Nucleophilic substitution of 2,4-dichloro-5-nitropyrimidine with 
amines 
The required amine (2.2-3.3 equiv.) was added to a solution of 2,4-dichloro-5-
nitropyrimidine (1.0 equiv.) in THF (10 ml/mmol) at 0 °C. The reaction mixture was stirred 
at 0 °C for 30 min before being evaporated to dryness, and the crude product purified via 
chromatography. 
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General Procedure D: Aromatic nitro group reduction using tin(II) chloride in ethanol 
Tin(II) chloride (4.0 equiv.) was added to a mixture of the aromatic nitro substrate (1.0 
equiv.) in ethanol (10 ml/mmol). The reaction mixture was heated at reflux for 1.5 h, unless 
otherwise stated, after which the solvent was removed in vacuo. The resulting residue was 
dissolved in EtOAc (20 ml/mmol) and a saturated aqueous solution of NaHCO3 was added 
until the aqueous phase was at pH 9-10. The resulting precipitate was removed by filtration 
through Celite
®
 and the organic phase was collected, washed with brine (5 ml/mmol) and 
evaporated to dryness. The crude residue was subsequently purified by chromatography to 
give the desired compound. 
General Procedure E: Synthesis of 8-methylpurine derivatives using 4,5-
diaminopyrimidines and triethyl orthoacetate 
The pyrimidine substrate (1.0 equiv.), triethyl orthoacetate (2.5 equiv.) and TFA (0.1 equiv.) 
were combined in TFE (5 ml/mmol) and heated under microwave irradiation at 140 °C for 
1.5 h, unless otherwise stated, before being concentrated to dryness. The resulting residue 
was dissolved in EtOAc (10 ml/mmol) and washed with a saturated aqueous solution of 
NaHCO3 (5 ml/mmol) and brine (5 ml/mmol). The combined aqueous layers were extracted 
with EtOAc (10 ml/mmol), and the combined organic extracts were dried (MgSO4) and 
concentrated in vacuo to give the crude product for chromatographic purification. 
General Procedure F: TFA/TFE coupling of anilines with 2-chloro-8-methylpurines 
using microwave heating 
The purine substrate (1.0 equiv.), the required aniline (2.0 equiv.) and TFA (2.5-5.0 equiv.) 
were dissolved in TFE (10 ml/mmol) and heated under microwave irradiation at 160 °C for 1 
h, unless otherwise stated. Following removal of the solvent in vacuo, the resulting residue 
was dissolved in EtOAc (10 ml/mmol) and washed with a saturated aqueous solution of 
NaHCO3 (5 ml/mmol) and brine (5 ml/mmol). The combined aqueous layers were extracted 
with EtOAc (10 ml/mmol), and the combined organic extracts were dried (MgSO4) and 
concentrated in vacuo to give the crude product for chromatographic purification. 
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General Procedure G: Reduction of aromatic nitro groups using palladium-catalysed 
transfer hydrogenation 
Palladium on carbon (10% w/w) and ammonium formate (10.0 equiv.) were added to a 
solution of the nitro aromatic substrate (1.0 equiv.) in methanol (10 ml/mmol). The reaction 
mixture was stirred at RT for 18 h, before being filtered through Celite
®
. The solvent was 
removed in vacuo and the resulting residue was purified via chromatography to give the 
target compound. 
General Procedure H: Alkylation of phenols with benzyl halides 
The required benzyl halide (1.2-4.0 equiv.) was added to a mixture of the phenol substrate 
(1.0 equiv.) and K2CO3 (1.1 equiv.) in dry DMF (10 ml/mmol) in a sealed vial. The reaction 
mixture was heated at 60 °C for 18 h before being evaporated to dryness. The resulting 
residue was dissolved in EtOAc (10 ml/mmol) and washed with brine (10 ml/mmol) before 
being dried (MgSO4) and concentrated in vacuo. The crude residue was subsequently purified 
via chromatography to give the desired product. 
General Procedure I: Removal of TIPS-protecting groups using TBAF 
TBAF (1.2 equiv.) was added to a solution of the TIPS-protected substrate (1.0 equiv.) in 
THF (10-20 ml/mmol). The reaction mixture was stirred at RT for 5 min before being 
concentrated in vacuo and the crude residue purified by chromatography to afford the target 
compound. 
General Procedure J: CDI mediated amide coupling reactions 
CDI (2.0 equiv.) and DIPEA (2.0 equiv.) were added to a solution of the carboxylic acid 
substrate (1.0 equiv.) in dry DMF (10 ml/mmol). The mixture was stirred at RT for 1.5 h, at 
which point the required amine (4.0 equiv.) was added. Following a further 18 h stirring at 
RT, the solvent was removed in vacuo and the resulting residue was purified by 
chromatography to give the desired product. 
General Procedure K: Removal of PMB protecting groups using TFA 
The PMB-protected substrate (1.0 equiv.) was dissolved in TFA (10-20 ml/mmol) and the 
resulting solution was heated at reflux for 24 h, unless stated otherwise. The reaction mixture 
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was evaporated to dryness and the resulting residue was dissolved in EtOAc (20 ml/mmol) 
and washed with a saturated aqueous solution of NaHCO3 (2 x 10 ml/mmol) and brine (10 
ml/mmol). The combined aqueous layers were extracted with EtOAc (20 ml/mmol) and the 
combined organic extracts were dried (MgSO4), concentrated in vacuo, and the residue 
purified by chromatography to give the desired compound. 
General Procedure L: Cleavage of N-Boc protecting groups using TFA 
TFA (10.0 equiv.) was added to a solution of the Boc-protected substrate (1.0 equiv.) in 
DCM (10 ml/mmol). The resulting mixture was stirred at RT for 18 h, before being diluted 
with DCM (10 ml/mmol) and washed with a saturated aqueous solution of NaHCO3 (10 
ml/mmol). The biphasic mixture was passed through an Isolute
®
 phase separator, and the 
organic phase concentrated to dryness. The resulting crude residue was purified by 
chromatography to give the target compound. 
General Procedure M: Palladium-mediated Buchwald amination reactions 
The aryl halide substrate (1.0 equiv.) and the required aniline (1.2 equiv.) were combined 
with tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3, 10 mol. %), 2-dicyclohexyl 
phosphino-2′,4′,6′-triisopropylbiphenyl (XPhos, 10 mol. %) and K2CO3 (2.2 equiv.) in dry 
MeCN (10 ml/mmol) in a sealed vial. The solution was degassed with a stream of N2, after 
which the reaction mixture was heated at 100 °C for 1 h, unless otherwise stated, before 
being cooled and filtered through Celite
®
. The filtrate was concentrated in vacuo and purified 
by chromatography to afford the desired product. 
General Procedure N: Palladium-mediated Sonogashira couplings 
The aryl halide substrate (1.0 equiv.), copper iodide (2 mol. %) and bis(triphenylphosphine) 
palladium(II) dichloride (Pd(PPh3)2Cl2, 2 mol. %) were combined in dry THF or dry DMF 
(10 mmol/ml) in a sealed vial. Triethylamine (2.5 equiv.) and (triisopropylsilyl)acetylene (1.1 
equiv.) were added and the mixture was degassed with a stream of N2 for 15 min. The 
reaction mixture was stirred at RT for 18 h before being filtered through Celite
®
. The filtrate 
was concentrated in vacuo and purified by chromatography to give the desired product. 
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General Procedure O: Sulfonamide synthesis by treatment of trifluoroethyl sulfonate 
esters with amines 
The trifluoroethyl sulfonate ester substrate (1.0 equiv.), the required amine (1.3 equiv.) and 
DBU (2.0 equiv.) were combined in dry THF (10 ml/mmol) in a sealed vial. The reaction 
mixture was heated under microwave irradiation at 160 °C for 15 min, before being 
evaporated to dryness. The resulting residue was dissolved in DCM (10 ml/mmol) and 
washed with a saturated aqueous solution of NaHCO3 (10 ml/mmol), after which the biphasic 
mixture was passed through an Isolute
®
 phase separator and the organic phase was 
concentrated in vacuo. The crude residue was purified via chromatography to give the target 
compound. 
General Procedure P: Boc-protection of anilines bearing carboxylic acid moieties 
Di-tert-butyl dicarbonate (1.1 equiv.) was added to a solution of the aniline substrate (1.0 
equiv.) in a mixture of 1,4-dioxane (2.0 ml/mmol), 1 M NaOH solution (1.0 ml/mmol) and 
water (1.0 ml/mmol). The reaction mixture was stirred at RT for 18 h, after which the volume 
was reduced by half in vacuo and the solution taken to pH 3 with 2M KHSO4 solution. The 
aqueous mixture was extracted with EtOAc (2 x 10 ml/mmol) and the combined organic 
extracts were dried (MgSO4) and concentrated in vacuo. The crude residue was purified by 
chromatography to give the desired product. 
General Procedure Q: Removal of TIPS-protecting groups using KF and 18-crown-6 
KF (1.2 equiv.) and 18-crown-6 (0.1 equiv.) were added to a solution of the TIPS-protected 
substrate (1.0 equiv.) in THF (10 ml/mmol) and the reaction mixture was stirred at RT for 24 
h. The solvent was removed in vacuo and the crude product was purified by chromatography. 
General Procedure R: Esterification of carboxylic acids 
Thionyl chloride (2.0 equiv.) was added to a solution of the carboxylic acid substrate (1.0 
equiv.) in methanol (10 ml/mmol). The resulting solution was heated at reflux for 1 h, after 
which the solvent was removed in vacuo. The crude residue was purified by chromatography 
to give the target compound. 
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General Procedure S: Synthesis of carboxamides by treatment of methyl esters with 
amines 
The methyl ester substrate (1.0 equiv.) was suspended in a concentrated aqueous solution of 
the required amine (10 ml/mmol) and the reaction mixture was stirred at RT for 24 h, unless 
otherwise stated. The solvent was removed in vacuo and the crude residue was purified by 
chromatography to give the target product. 
General Procedure T: Reduction of aromatic nitro groups using iron powder in acetic 
acid 
Iron powder (10.0 equiv.) was added to a solution of the aromatic nitro substrate (1.0 equiv.) 
in acetic acid (10 ml/mmol). The reaction mixture was heated at 50 °C for 15 min, before 
being filtered through Celite
®
 and the filtrate concentrated in vacuo. The residue was 
dissolved in EtOAc (20 ml/mmol) and washed with a saturated aqueous solution of NaHCO3 
(2 x 20 ml/mmol) and brine (10 ml/mmol). The combined aqueous layers were extracted with 
EtOAc (20 ml/mmol) and the combined organic extracts were dried (MgSO4) and evaporated 
to dryness. The resulting residue was purified by chromatography to afford the target 
compound. 
General Procedure U: Removal of TIPS-protecting groups using TBAF followed by 
removal of TBAF contaminant 
TBAF (1.2 equiv.) was added to a solution of the TIPS-protected substrate (1.0 equiv.) in 
THF (10-20 ml/mmol). The reaction mixture was stirred at RT for 5 min before being diluted 
with THF (100-200 ml/mmol) and the TBAF scavenger bead system (231, 10x w/w) added. 
The resulting suspension was agitated at RT for 48 h, before being filtered and the filtrate 
concentrated in vacuo. The resulting residue was purified by chromatography to afford the 
target compound. 
General Procedure V: TFA/TFE coupling of anilines with 2-fluoropurines using 
microwave heating 
The purine substrate (1.0 equiv.), the required aniline (2.0 equiv.) and TFA (2.5-5.0 equiv.) 
were dissolved in TFE (10 ml/mmol) and heated under microwave irradiation at 140 °C for 2 
h, unless otherwise stated. Following removal of the solvent in vacuo, the resulting residue 
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was dissolved in EtOAc (10 ml/mmol) and washed with a saturated aqueous solution of 
NaHCO3 (5 ml/mmol) and brine (5 ml/mmol). The combined aqueous layers were extracted 
with EtOAc (10 ml/mmol), and the combined organic extracts were dried (MgSO4) and 
concentrated in vacuo to give the crude product for chromatographic purification. 
General Procedure W: Direct synthesis of carboxamides from carboxylic acids via a 
methyl ester intermediate 
Thionyl chloride (2.0 equiv.) was added to a solution of the carboxylic acid substrate (1.0 
equiv.) in methanol (10 ml/mmol). The resulting solution was heated at reflux for 1 h, after 
which the solvent was removed in vacuo. A concentrated aqueous solution of the required 
amine (10 ml/mmol) was added to the residue and the reaction mixture was stirred at RT for 
24 h, unless otherwise stated. The solvent was removed in vacuo and the crude residue was 
purified by chromatography to give the target product. 
General Procedure X: Phosphorus trichloride mediated amide coupling reactions 
Phosphorus trichloride (1.1 equiv.) was added to a solution of the carboxylic acid substrate 
(1.0 equiv.) and the required amine (2.5 equiv.) in dry MeCN (5 ml/mmol) in a sealed vial. 
The reaction mixture was heated under microwave irradiation at 150 C for 5 min, before 
being concentrated to dryness. The resulting residue was dissolved in DCM (10 ml/mmol) 
and washed with a saturated aqueous solution of NaHCO3 (10 ml/mmol). The biphasic 
mixture was passed through an Isolute
®
 phase separator and the organic phase was 
concentrated in vacuo. The crude residue was purified by chromatography to afford the target 
compound. 
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8.7. Index of Synthesised Compounds 
6-Chloro-2-fluoro-9H-purine (50)  Pg. 243 
6-Chloro-2-fluoro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (51)  Pg. 243 
8-Bromo-6-chloro-2-fluoro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (52) Pg. 244 
6-Chloro-2-fluoro-9-(tetrahydro-2H-pyran-2-yl)-8-methyl-9H-purine (53) Pg. 245 
2-Fluoro-9-(tetrahydro-2H-pyran-2-yl)-8-methyl-9H-purine (54) Pg. 245 
2-Fluoro-8-methyl-9H-purine (55) Pg. 246 
8-Methyl-N-(4-phenoxyphenyl)-9H-purin-2-amine (48) Pg. 247 
2-Chloro-5-nitropyrimidin-4-amine (58)  Pg. 247 
2-Chloropyrimidine-4,5-diamine (60)  Pg. 248 
2-Chloro-8-methyl-9H-purine (62) Pg. 248 
2-Chloro-N-methyl-5-nitropyrimidin-4-amine (59)  Pg. 249 
2-Chloro-N
4
-methylpyrimidine-4,5-diamine (61)  Pg. 249 
2-Chloro-8,9-dimethyl-9H-purine (56) Pg. 249 
N-(4-Methoxyphenyl)-8,9-dimethyl-9H-purin-2-amine (63) Pg. 250 
8,9-Dimethyl-N-(4-phenoxyphenyl)-9H-purin-2-amine (74) Pg. 250 
8-Methyl-N-phenyl-9H-purin-2-amine (64) Pg. 251 
N-(4-Ethylphenyl)-8-methyl-9H-purin-2-amine (66) Pg. 251 
N-(4-Isopropylphenyl)-8-methyl-9H-purin-2-amine (68) Pg. 252 
8,9-Dimethyl-N-phenyl-9H-purin-2-amine (65) Pg. 252 
N-(4-Ethylphenyl)-8,9-dimethyl-9H-purin-2-amine (67) Pg. 253 
N-(4-Isopropylphenyl)-8,9-dimethyl-9H-purin-2-amine (69) Pg. 253 
1-Isopropoxy-4-nitrobenzene (77)  Pg. 254 
4-Isopropoxyaniline (75)  Pg. 254 
N-(4-Isopropoxyphenyl)-8-methyl-9H-purin-2-amine (70) Pg. 255 
N-(4-Isopropoxyphenyl)-8,9-dimethyl-9H-purin-2-amine (71) Pg. 255 
2-Benzyl-4-((8,9-dimethyl-9H-purin-2-yl)amino)phenol (79) Pg. 256 
4-(8,9-Dimethyl-9H-purin-2-ylamino)phenol (80) Pg. 256 
N-(4-(Benzyloxy)phenyl)-8,9-dimethyl-9H-purin-2-amine (78) Pg. 257 
N-(4-(4-Methoxybenzyloxy)phenyl)-8,9-dimethyl-9H-purin-2-amine (81) Pg. 258 
N-(4-(4-Chlorobenzyloxy)phenyl)-8,9-dimethyl-9H-purin-2-amine (82) Pg. 258 
N-(4-(4-tert-Butylbenzyloxy)phenyl)-8,9-dimethyl-9H-purin-2-amine (83) Pg. 259 
1-(2-(4-Nitrophenoxy)ethyl)benzene (84)  Pg. 259 
4-(Phenethyloxy)aniline (85)  Pg. 260 
8,9-Dimethyl-N-(4-(phenethyloxy)phenyl)-9H-purin-2-amine (86) Pg. 260 
N-(4-Bromophenyl)-8,9-dimethyl-9H-purin-2-amine (90) Pg. 261 
8,9-Dimethyl-N-(4-((triisopropylsilyl)ethynyl)phenyl)-9H-purin-2-amine (91) Pg. 262 
N-(4-Ethynylphenyl)-8,9-dimethyl-9H-purin-2-amine (87) Pg. 262 
3-Fluoro-4-methoxyaniline (94)  Pg. 263 
N-(3-fluoro-4-methoxyphenyl)-8,9-dimethyl-9H-purin-2-amine (92) Pg. 263 
N-(3,5-Difluoro-4-methoxyphenyl)-8,9-dimethyl-9H-purin-2-amine (93) Pg. 264 
2-Chloro-N-ethyl-5-nitropyrimidin-4-amine (102) Pg. 264 
236 
 
2-Chloro-N-isopropyl-5-nitropyrimidin-4-amine (103) Pg. 265 
N-tert-Butyl-2-chloro-5-nitropyrimidin-4-amine (104) Pg. 265 
2-Chloro-N-isobutyl-5-nitropyrimidin-4-amine (105) Pg. 266 
2-Chloro-5-nitro-N-phenylpyrimidin-4-amine (106) Pg. 266 
N-Benzyl-2-chloro-5-nitropyrimidin-4-amine (107) Pg. 267 
2-Chloro-5-nitro-N-(2,2,2-trifluoroethyl)pyrimidin-4-amine (108) Pg. 267 
2-Chloro-5-nitro-N-(3,3,3-trifluoropropyl)pyrimidin-4-amine (109) Pg. 268 
2-Chloro-N
4
-ethylpyrimidine-4,5-diamine (110)  Pg. 268 
2-Chloro-N
4
-isopropylpyrimidine-4,5-diamine (111) Pg. 269 
N
4
-tert-Butyl-2-chloropyrimidine-4,5-diamine (112) Pg. 269 
2-Chloro-N
4
-isobutylpyrimidine-4,5-diamine (113) Pg. 270 
2-Chloro-N
4
-phenylpyrimidine-4,5-diamine (114) Pg. 270 
N
4
-Benzyl-2-chloropyrimidine-4,5-diamine (115) Pg. 271 
2-Chloro-N
4
-(2,2,2-trifluoroethyl)pyrimidine-4,5-diamine (116) Pg. 271 
2-Chloro-N
4
-(3,3,3-trifluoropropyl)pyrimidine-4,5-diamine (117) Pg. 272 
2-Chloro-9-ethyl-8-methyl-9H-purine (118) Pg. 272 
2-Chloro-9-isopropyl-8-methyl-9H-purine (119) Pg. 273 
2-Chloro-9-isobutyl-8-methyl-9H-purine (120) Pg. 273 
2-Chloro-8-methyl-9-phenyl-9H-purine (121) Pg. 274 
9-Benzyl-2-chloro-8-methyl-9H-purine (122) Pg. 274 
2-Chloro-8-methyl-9-(2,2,2-trifluoroethyl)-9H-purine (123) Pg. 275 
2-Chloro-8-methyl-9-(3,3,3-trifluoropropyl)-9H-purine (124) Pg. 275 
9-Ethyl-N-(4-methoxyphenyl)-8-methyl-9H-purin-2-amine (96) Pg. 276 
9-Isobutyl-N-(4-methoxyphenyl)-8-methyl-9H-purin-2-amine (97) Pg. 276 
N-(4-Methoxyphenyl)-8-methyl-9-phenyl-9H-purin-2-amine (98) Pg. 277 
9-Benzyl-N-(4-methoxyphenyl)-8-methyl-9H-purin-2-amine (99) Pg. 277 
N-(4-methoxyphenyl)-8-methyl-9-(2,2,2-trifluoroethyl)-9H-purin-2-amine (100) Pg. 278 
N-(4-methoxyphenyl)-8-methyl-9-(3,3,3-trifluoropropyl)-9H-purin-2-amine (101) Pg. 279 
Methyl 4-((8,9-dimethyl-9H-purin-2-yl)amino)benzoate (133) Pg. 279 
4-((8,9-Dimethyl-9H-purin-2-yl)amino)benzoic acid (132) Pg. 280 
4-((8,9-Dimethyl-9H-purin-2-yl)amino)-N-(4-methoxybenzyl)benzamide (134) Pg. 280 
4-((8,9-Dimethyl-9H-purin-2-yl)amino)benzamide (126) Pg. 281 
4-((8,9-Dimethyl-9H-purin-2-yl)amino)-N-methylbenzamide (127) Pg. 281 
4-((8,9-Dimethyl-9H-purin-2-yl)amino)-N-phenylbenzamide (128) Pg. 282 
8,9-Dimethyl-N-(4-nitrophenyl)-9H-purin-2-amine (136) Pg. 283 
N
1
-(8,9-Dimethyl-9H-purin-2-yl)benzene-1,4-diamine (135) Pg. 283 
1-(4-((8,9-Dimethyl-9H-purin-2-yl)amino)phenyl)urea (129) Pg. 284 
tert-Butyl (4-aminophenyl) carbamate (138)  Pg. 284 
tert-Butyl (4-(3-methylureido)phenyl) carbamate (139) Pg. 285 
1-(4-Aminophenyl)-3-methylurea (140)  Pg. 285 
1-(4-((8,9-Dimethyl-9H-purin-2-yl)amino)phenyl)-3-methylurea (130) Pg. 286 
1-(4-((8,9-Dimethyl-9H-purin-2-yl)amino)phenyl)-3-phenylurea (131) Pg. 286 
N-(4-((8,9-Dimethy l-9H-purin-2-yl)amino)phenyl)acetamide (141) Pg. 287 
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N-(4-Methoxyphenyl)-9-methyl-8-((phenylamino)methyl)-9H-purin-2-amine 
(144) 
 
Pg. 288 
2-Fluoro-9-(tetrahydro-2H-pyran-2-yl)-6-(2-(triisopropylsilyl)ethynyl)-9H-purine 
(159) 
 
Pg. 289 
2-Fluoro-6-(2-(triisopropylsilyl)ethynyl)-9H-purine (160) Pg. 289 
6-(2-(Triisopropylsilyl)ethynyl)-N-phenyl-9H-purin-2-amine (164) Pg. 290 
6-(2-(Triisopropylsilyl)ethynyl)-N-p-tolyl-9H-purin-2-amine (165) Pg. 291 
N-(4-Ethylphenyl)-6-(2-(triisopropylsilyl)ethynyl)-9H-purin-2-amine (166) Pg. 291 
N-(4-Isopropylphenyl)-6-(2-(triisopropylsilyl)ethynyl)-9H-purin-2-amine (167) Pg. 292 
(4-Nitrophenoxy)triisopropylsilane (162)  Pg. 293 
4-Triisopropylsilyloxyaniline (163)  Pg. 293 
6-((Triisopropylsilyl)ethynyl)-N-(4-((triisopropylsilyl)oxy)phenyl)-9H-purin-2-
amine (168) 
 
Pg. 294 
6-(2-(Triisopropylsilyl)ethynyl)-N-(3-methoxyphenyl)-9H-purin-2-amine (169) Pg. 294 
N-(2-Methoxyphenyl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (170) Pg. 295 
6-(2-(Triisopropylsilyl)ethynyl)-N-(4-chlorophenyl)- 9H-purin-2-amine (171) Pg. 296 
N-(3-Chlorophenyl)-6-(2-(triisopropylsilyl)ethynyl)-9H-purin-2-amine (172) Pg. 296 
6-Ethynyl-N-phenyl-9H-purin-2-amine (148) Pg. 297 
6-Ethynyl-N-p-tolyl-9H-purin-2-amine (149) Pg. 297 
N-(4-Ethylphenyl)-6-ethynyl-9H-purin-2-amine (150) Pg. 298 
N-(4-Isopropylphenyl)-6-ethynyl-9H-purin-2-amine (151) Pg. 298 
4-(6-Ethynyl-9H-purin-2-ylamino)phenol (152) Pg. 299 
6-Ethynyl-N-(3-methoxyphenyl)-9H-purin-2-amine (154) Pg. 299 
N-(4-Chlorophenyl)-6-ethynyl-9H-purin-2-amine (156) Pg. 300 
N-(3-Chlorophenyl)-6-ethynyl-9H-purin-2-amine (157) Pg. 300 
3-(4-Nitrophenoxy)-N,N-dimethylpropan-1-amine (183)  Pg. 301 
4-(3-(Dimethylamino)propoxy)benzenamine (184)  Pg. 301 
N-(4-(3-(Dimethylamino)propoxy)phenyl)-6-((triisopropylsilyl)ethynyl)-9H-purin-
2-amine (185) 
 
Pg. 302 
2-(3-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)phenyl)acetic acid 
(186) 
 
Pg. 302 
N-(4-Methoxybenzyl)-2-(3-(6-(2-(triisopropylsilyl)ethynyl)-9H-purin-2-ylamino) 
phenyl)acetamide (187) 
 
Pg. 303 
2-(3-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)phenyl) acetamide 
(189) 
 
Pg. 304 
2-(3-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)phenyl)-N-(2-
(dimethylamino)ethyl)acetamide (188) 
 
Pg. 305 
2,2,2-Trifluoroethyl (3-nitrophenyl)methanesulfonate (190)  Pg. 305 
2,2,2-Trifluoroethyl (3-aminophenyl)methanesulfonate (192)  Pg. 306 
2,2,2-Trifluoroethyl (3-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino)  
phenyl) methanesulfonate (193) 
 
Pg. 307 
N-(4-Methoxybenzyl)-1-(3-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino) 
phenyl) methanesulfonamide (194) 
 
Pg. 308 
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(3-((6-((Triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino)phenyl) 
methanesulfonamide (195) 
 
Pg. 309 
N-(3-(Dimethylamino)propyl)-1-(3-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-
yl)amino)phenyl)methanesulfonamide (196) 
 
Pg. 309 
tert-Butyl-4-((3-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino)benzyl) 
sulfonyl) piperazine-1-carboxylate (198) 
 
Pg. 310 
N-(3-((Piperazin-1-ylsulfonyl)methyl)phenyl)-6-((triisopropylsilyl)ethynyl)-9H-
purin-2-amine (197) 
 
Pg. 311 
2-(3-(6-Ethynyl-9H-purin-2-ylamino)phenyl)acetamide (177) Pg. 312 
(3-((6-Ethynyl-9H-purin-2-yl)amino)phenyl)methanesulfonamide (178) Pg. 312 
2-(3-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)phenyl)-N,N-
dimethylacetamide (214) 
 
Pg. 313 
2-(4-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)phenyl)acetic acid 
(215) 
 
Pg. 314 
N-(4-Methoxybenzyl)-2-(4-(6-(2-(triisopropylsilyl)ethynyl)-9H-purin-2-ylamino) 
phenyl) acetamide (216) 
 
Pg. 315 
2-(4-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)phenyl) acetamide 
(217) 
 
Pg. 315 
3-(3-(tert-Butoxycarbonylamino)phenyl)propanoic acid (220) Pg. 316 
tert-Butyl-3-(2-(4-methoxybenzylcarbamoyl)ethyl)phenyl carbamate (222) Pg. 317 
N-(4-Methoxybenzyl)-3-(3-aminophenyl)propanamide (224) Pg. 317 
N-(4-Methoxybenzyl)-3-(3-(6-(2-(triisopropylsilyl)ethynyl)-9H-purin-2-ylamino) 
phenyl)propanamide (226) 
 
Pg. 318 
3-(3-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)phenyl) propanamide 
(228) 
 
Pg. 319 
3-((tert-Butoxycarbonyl)amino)benzoic acid (221)  Pg. 319 
tert-Butyl 3-(4-methoxybenzylcarbamoyl)phenyl carbamate (223) Pg. 320 
N-(4-Methoxybenzyl)-3-aminobenzamide (225) Pg. 320 
N-(4-Methoxybenzyl)-3-(6-(2-(triisopropylsilyl)ethynyl)-9H-purin-2-ylamino) 
benzamide (227) 
 
Pg. 321 
3-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)benzamide (229) Pg. 322 
2-(3-(6-Ethynyl-9H-purin-2-ylamino)phenyl)-N,N-dimethylacetamide (201) Pg. 322 
Solid supported TBAF scavenger (231)  Pg. 323 
2-(4-(6-Ethynyl-9H-purin-2-ylamino)phenyl)acetamide (202) Pg. 323 
3-(3-(6-Ethynyl-9H-purin-2-ylamino)phenyl)propanamide (212) Pg. 324 
3-(6-Ethynyl-9H-purin-2-ylamino)benzamide (205) Pg. 325 
Methyl 2-(3-aminophenyl)acetate (234)  Pg. 325 
2-(3-Aminophenyl)-N-methylacetamide (236)  Pg. 326 
2-(3-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)phenyl)-N- 
methylacetamide (239) 
 
Pg. 326 
2-(3-(6-Ethynyl-9H-purin-2-ylamino)phenyl)-N-methylacetamide (200) Pg. 327 
Methyl 4-aminobenzoate (235)  Pg. 327 
4-Aminobenzamide (237)  Pg. 328 
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4-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)benzamide (240) Pg. 328 
4-(6-Ethynyl-9H-purin-2-ylamino)benzamide (208) Pg. 329 
4-Amino-N-methylbenzamide (238)  Pg. 329 
4-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)-N-methyl benzamide 
(241) 
 
Pg. 330 
4-(6-Ethynyl-9H-purin-2-ylamino)-N-methylbenzamide (209) Pg. 331 
4-Amino-N,N-dimethylbenzamide (243)  Pg. 331 
4-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)-N,N-dimethyl benzamide 
(244) 
 
Pg. 332 
4-(6-Ethynyl-9H-purin-2-ylamino)-N,N-dimethylbenzamide (210) Pg. 333 
N
1
,N
3
-Dimethyl-2-(4-nitrophenyl)malonamide (248) Pg. 333 
2-(4-Aminophenyl)-N
1
,N
3
-dimethylmalonamide (254) Pg. 334 
N
1
,N
3
-Dimethyl-2-(4-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino) 
phenyl) malonamide (256) 
 
Pg. 334 
2-(4-((6-Ethynyl-9H-purin-2-yl)amino)phenyl)-N
1
,N
3
-dimethylmalonamide (257) Pg. 335 
N,N-Dimethyl-2-(4-nitrophenyl)acetamide (247)  Pg. 336 
2-(4-Aminophenyl)-N,N-dimethylacetamide (253)  Pg. 336 
N,N-Dimethyl-2-(4-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino)phenyl) 
acetamide (255) 
 
Pg. 337 
2-(4-((6-Ethynyl-9H-purin-2-yl)amino)phenyl)-N,N-dimethylacetamide (204) Pg. 337 
2-(4-Aminophenyl)-N-methylacetamide (258)  Pg. 338 
N-Methyl-2-(4-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino)phenyl) 
acetamide (260) 
 
Pg. 339 
2-(4-((6-Ethynyl-9H-purin-2-yl)amino)phenyl)-N-methylacetamide (203) Pg. 339 
N-Methyl-3-nitrobenzamide (261)  Pg. 340 
3-Amino-N-methylbenzamide (264)  Pg. 340 
N-Methyl-3-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino) benzamide 
(266) 
 
Pg. 341 
3-((6-Ethynyl-9H-purin-2-yl)amino)-N-methylbenzamide (206) Pg. 342 
N,N-Dimethyl-3-nitrobenzamide (262)  Pg. 342 
3-Amino-N,N-dimethylbenzamide (265)  Pg. 343 
N,N-Dimethyl-3-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino) benzamide 
(267) 
 
Pg. 343 
3-((6-Ethynyl-9H-purin-2-yl)amino)-N,N-dimethylbenzamide (207) Pg. 344 
N-(3-Nitrophenyl)acetamide (269)  Pg. 344 
N-(3-Aminophenyl)acetamide (270)  Pg. 345 
N-(3-((6-((Triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino)phenyl) acetamide 
(271) 
 
Pg. 346 
N-(3-((6-Ethynyl-9H-purin-2-yl)amino)phenyl)acetamide (211) Pg. 346 
2-(2-Nitrophenyl)acetamide (274)  Pg. 347 
2-(2-Aminophenyl)acetamide (276)  Pg. 347 
6-Chloro-9-(4-methoxybenzyl)-9H-purin-2-amine (279) Pg. 348 
9-(4-Methoxybenzyl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (280) Pg. 349 
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2-Iodo-9-(4-methoxybenzyl)-6-((triisopropylsilyl)ethynyl)-9H-purine (278) Pg. 349 
2-(2-((9-(4-Methoxybenzyl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino) 
phenyl) acetamide (281) 
 
Pg. 350 
1-(3-Nitrophenyl)propan-2-one (284)  Pg. 351 
2-Methyl-2-(3-nitrobenzyl)-1,3-dithiane (285) Pg. 351 
3-((2-Methyl-1,3-dithian-2-yl)methyl)aniline (286) Pg. 352 
N-(3-((2-methyl-1,3-dithian-2-yl)methyl)phenyl)-6-((triisopropylsilyl)ethynyl)-
9H-purin-2-amine (287) 
 
Pg. 353 
1-(3-((6-((Triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino)phenyl)propan-2-one 
(288) 
 
Pg. 353 
1-(3-((6-Ethynyl-9H-purin-2-yl)amino)phenyl)propan-2-one (199) Pg. 354 
N,N-Dimethyl-1-(3-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino)phenyl)  
methanesulfonamide (291) 
 
Pg. 355 
1-(3-((6-Ethynyl-9H-purin-2-yl)amino)phenyl)-N,N-dimethylmethane sulfonamide 
(289) 
 
Pg. 355 
1-((Methylsulfonyl)methyl)-3-nitrobenzene (293)  Pg. 356 
3-((Methylsulfonyl)methyl)aniline (294)  Pg. 356 
N-(3-((Methylsulfonyl)methyl)phenyl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-
amine (295) 
 
Pg. 357 
6-Ethynyl-N-(3-((methylsulfonyl)methyl)phenyl)-9H-purin-2-amine (290) Pg. 358 
9-(4-Methoxybenzyl)-2-amino-9H-purine-6-carbonitrile (299) Pg. 358 
2-Amino-9H-purine-6-carbonitrile trifluoroacetate (300) Pg. 359 
2-Fluoro-9H-purine-6-carbonitrile (301) Pg. 359 
2-(3-Aminophenyl)acetamide (297) Pg. 360 
2-(3-(6-Cyano-9H-purin-2-ylamino)phenyl)acetamide (296) Pg. 360 
Methyl 2-(3-nitrophenyl)acetate (303)  Pg. 361 
Methyl 2-methyl-2-(3-nitrophenyl)propanoate (304) Pg. 361 
2-Methyl-2-(3-nitrophenyl)propanamide (305) Pg. 362 
2-(3-Aminophenyl)-2-methylpropanamide (307) Pg. 362 
2-(3-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)phenyl)-2-
methylpropanamide (308) 
 
Pg. 363 
2-(3-(6-Ethynyl-9H-purin-2-ylamino)phenyl)-2-methylpropanamide (302) Pg. 364 
5-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)indolin-2-one (319) Pg. 364 
5-((6-Ethynyl-9H-purin-2-yl)amino)indolin-2-one (309) Pg. 365 
Di-tert-butyl 2-(3-fluoro-2-nitrophenyl)malonate (321)  Pg. 366 
Di-tert-butyl 2-(3-(4-methoxybenzylamino)-2-nitrophenyl)malonate (322) Pg. 366 
7-Aminoindolin-2-one (324)  Pg. 367 
7-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)indolin-2-one (325) Pg. 368 
7-((6-Ethynyl-9H-purin-2-yl)amino)indolin-2-one (310) Pg. 368 
Methyl methyl(phenethyl) carbamate (326)  Pg. 369 
2-Methyl-3,4-dihydroisoquinolin-1(2H)-one (328)  Pg. 369 
2-Methyl-7-nitro-3,4-dihydroisoquinolin-1(2H)-one (330) Pg. 370 
7-amino-2-methyl-3,4-dihydroisoquinolin-1(2H)-one (331) Pg. 370 
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2-Methyl-7-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino)-3,4-
dihydroisoquinolin-1(2H)-one (317) 
 
Pg. 371 
7-((6-Ethynyl-9H-purin-2-yl)amino)-2-methyl-3,4-dihydroisoquinolin-1(2H)-one 
(312) 
 
Pg. 372 
N-Methyl-2-(4-nitrophenyl)acetamide (332)  Pg. 372 
2-Methyl-7-nitro-1,2-dihydroisoquinolin-3(4H)-one (333)  Pg. 373 
7-Amino-2-methyl-1,2-dihydroisoquinolin-3(4H)-one (334) Pg. 373 
2-Methyl-7-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino)-1,2-
dihydroisoquinolin-3(4H)-one (335) 
 
Pg. 374 
7-((6-Ethynyl-9H-purin-2-yl)amino)-2-methyl-1,2-dihydroisoquinolin-3(4H)-one 
(314) 
 
Pg. 374 
2-(3-Amino-(N-tert-Butyloxycarbonyl)phenyl)acetic acid (347)  Pg. 375 
tert-Butyl 3-((2-aminoethylcarbamoyl)methyl)phenyl carbamate (348) Pg. 376 
tert-Butyl 3-((2-(4-nitrobenzo[c][1,2,5]oxadiazol-7-ylamino)ethyl-carbamoyl) 
methyl) phenyl carbamate (349) 
 
Pg. 376 
N-(2-(4-Nitrobenzo[c][1,2,5]oxadiazol-7-ylamino)ethyl)-2-(3-aminophenyl) 
acetamide (351) 
 
Pg. 377 
N-(2-(4-Nitrobenzo[c][1,2,5]oxadiazol-7-ylamino)ethyl)-2-(3-(6-(2-
(triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)phenyl)acetamide (353) 
 
Pg. 378 
N-(2-(4-Nitrobenzo[c][1,2,5]oxadiazol-7-ylamino)ethyl)-2-(3-(6-ethynyl-9H-
purin-2-ylamino)phenyl)acetamide (344) 
 
Pg. 378 
tert-Butyl (3-(2-((2-acetamidoethyl)amino)-2-oxoethyl)phenyl) carbamate (350) Pg. 379 
N-(2-Acetamidoethyl)-2-(3-aminophenyl)acetamide (352) Pg. 380 
N-(2-Acetamidoethyl)-2-(3-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino) 
phenyl)acetamide (354) 
 
Pg. 380 
N-(2-Acetamidoethyl)-2-(3-((6-ethynyl-9H-purin-2-yl)amino)phenyl)acetamide 
(345) 
 
Pg. 381 
N-(2-Fluoroethyl)-2-(3-nitrophenyl)acetamide (357) Pg. 382 
2-(3-Aminophenyl)-N-(2-fluoroethyl)acetamide (359) Pg. 382 
2-(3-Nitrophenyl)-N-(2,2,2-trifluoroethyl)acetamide (358) Pg. 383 
2-(3-Aminophenyl)-N-(2,2,2-trifluoroethyl)acetamide (360) Pg. 383 
N-(2,2,2-Trifluoroethyl)-2-(3-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl) 
amino)phenyl)acetamide (361) 
 
Pg. 384 
2-(3-((6-Ethynyl-9H-purin-2-yl)amino)phenyl)-N-(2,2,2-trifluoroethyl) acetamide 
(356) 
 
Pg. 385 
N-(2-Fluoroethyl)-2-(3-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino) 
phenyl) acetamide (362) 
Pg. 385 
2-(3-((6-Ethynyl-9H-purin-2-yl)amino)phenyl)-N-(2-fluoroethyl)acetamide (355) Pg. 386 
9-(4-Methoxybenzyl)-N-(pyridin-2-yl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-
amine (372) 
 
Pg. 387 
9-(4-Methoxybenzyl)-N-(pyridin-3-yl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-
amine (373) 
 
Pg. 388 
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9-(4-Methoxybenzyl)-N-(pyridin-4-yl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-
amine (374) 
 
Pg. 389 
9-(4-Methoxybenzyl)-N-(pyrimidin-4-yl)-6-((triisopropylsilyl)ethynyl)-9H-purin-
2-amine (375) 
 
Pg. 390 
9-(4-Methoxybenzyl)-N-(pyrimidin-2-yl)-6-((triisopropylsilyl)ethynyl)-9H-purin-
2-amine (376) 
 
Pg. 391 
5-Aminopyrimidine (384)  Pg. 391 
9-(4-Methoxybenzyl)-N-(pyrimidin-5-yl)-6-((triisopropylsilyl)ethynyl)-9H-purin-
2-amine (377) 
 
Pg. 392 
 N-(Pyridin-2-yl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (378) Pg. 393 
N-(Pyridin-3-yl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (379) Pg. 393 
N-(Pyridin-4-yl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (380) Pg. 394 
N-(Pyrimidin-4-yl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (381) Pg. 394 
N-(Pyrimidin-2-yl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (382) Pg. 395 
N-(Pyrimidin-5-yl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (383) Pg. 396 
6-Ethynyl-N-(pyridin-2-yl)-9H-purin-2-amine (364) Pg. 396 
6-Ethynyl-N-(pyridin-3-yl)-9H-purin-2-amine (365) Pg. 397 
6-Ethynyl-N-(pyridin-4-yl)-9H-purin-2-amine (366) Pg. 397 
6-Ethynyl-N-(pyrimidin-2-yl)-9H-purin-2-amine (368) Pg. 398 
6-Ethynyl-N-(pyrimidin-5-yl)-9H-purin-2-amine (369) Pg. 398 
5-Amino-2-fluoro-N-methylbenzamide (392) Pg. 399 
2-Fluoro-N-methyl-5-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino) 
benzamide (393) 
 
Pg. 400 
2-Fluoro-5-((6-ethynyl-9H-purin-2-yl)amino)-N-methylbenzamide (385) Pg. 400 
Methyl 5-amino-2-chlorobenzoate (395)  Pg. 401 
5-Amino-2-chloro-N-methylbenzamide (396) Pg. 401 
2-Chloro-N-methyl-5-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino) 
benzamide (397) 
 
Pg. 402 
2-Chloro-5-((6-ethynyl-9H-purin-2-yl)amino)-N-methylbenzamide (386) Pg. 403 
Methyl 5-chloro-2-(trifluoromethyl)benzoate (398) Pg. 403 
Methyl 5-((4-methoxybenzyl)amino)-2-(trifluoromethyl)benzoate (400) Pg. 404 
Methyl 5-amino-2-(trifluoromethyl)benzoate (401) Pg. 404 
5-Amino-N-methyl-2-(trifluoromethyl)benzamide (402) Pg. 405 
5-((9-(4-Methoxybenzyl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino)-N-
methyl-2-(trifluoromethyl)benzamide (403) 
 
Pg. 406 
N-Methyl-2-(trifluoromethyl)-5-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl) 
amino) benzamide (404) 
 
Pg. 407 
5-((6-Ethynyl-9H-purin-2-yl)amino)-N-methyl-2-(trifluoromethyl) benzamide 
(388) 
 
Pg. 407 
Methyl 2-methoxy-5-nitrobenzoate (405)  Pg. 408 
Methyl 5-amino-2-methoxybenzoate (406)  Pg. 409 
5-Amino-2-methoxy-N-methylbenzamide (407) Pg. 409 
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2-Methoxy-N-methyl-5-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino) 
benzamide (408) 
 
Pg. 410 
2-Methoxy-5-((6-ethynyl-9H-purin-2-yl)amino)-N-methylbenzamide (387) Pg. 410 
Methyl 2-cyano-5-nitrobenzoate (409) Pg. 411 
Methyl 5-amino-2-cyanobenzoate (410) Pg. 412 
(E)-6-Amino-2-methyl-3-(methylimino)isoindolin-1-one (413) Pg. 412 
(E)-6-((9-(4-Methoxybenzyl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino) 
-2-methyl-3-(methylimino)isoindolin-1-one (416) 
 
Pg. 413 
(E)-2-Methyl-3-(methylimino)-6-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl) 
amino) isoindolin-1-one (417) 
 
Pg. 414 
(E)-6-((6-Ethynyl-9H-purin-2-yl)amino)-2-methyl-3-(methylimino) isoindolin-1-
one (418) 
 
Pg. 414 
2-Cyano-5-nitrobenzoic acid (420) Pg. 415 
2-Cyano-N,N-dimethyl-5-nitrobenzamide (421) Pg. 416 
5-Amino-2-cyano-N,N-dimethylbenzamide (422) Pg. 416 
2-Cyano-5-((9-(4-methoxybenzyl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl) 
amino)-N,N-dimethylbenzamide (423) 
 
Pg. 417 
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8.8. Intermediates and Final Compounds 
6-Chloro-2-fluoro-9H-purine (50)
233
 
 
2-Amino-6-chloropurine (9.0 g, 53 mmol), sodium nitrite (7.3 g, 106 mmol) and HBF4 (48 
wt. % in H2O, 180 mL) were reacted according to general procedure A, yielding the desired 
product as a pale yellow solid (5.57 g, 32.3 mmol, 61%). Rf 0.41 (9:1 DCM/MeOH); M.p. 
169-173 °C (Lit.
233
 161-162 °C); λmax (EtOH/nm) 271; IR (cm
-1
) 3488, 2961, 2802, 2569, 
2155, 1584; 
1
H NMR (500 MHz, DMSO-d6) 8.62 (1H, s, H-8), 14.01 (1H, s, br, H-9);
 13
C 
NMR (125 MHz, DMSO-d6) 147.5 (C-Ar), 156.2 (d, JCF = 210.1 Hz, C
2
-Ar), 162.3 (C-Ar); 
19
F NMR (470 MHz, DMSO-d6) -52.8 (C
2
-F); LRMS (ES+) m/z 173.2 [M
35
Cl+H]
+
, 175.2 
[M
37
Cl+H]
+
. 
Note: Unable to visualise all quaternary carbon signals by 
13
C NMR. 
6-Chloro-2-fluoro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (51)
234
 
 
3,4-Dihydro-2H-pyran (2.12 mL, 23.2 mmol) was added dropwise over 10 min to a rapidly 
stirred mixture of purine 50 (4.00 g, 23.2 mmol) and (Rac)-camphor sulfonic acid (0.186 g, 
0.80 mmol) in dry EtOAc (350 mL). The mixture was heated at reflux for 18 h before being 
cooled, neutralised (conc. NH3), and washed with water (2 × 100 mL) and brine (80 mL). The 
organic phase was dried (MgSO4) and concentrated, and the resulting residue purified by 
chromatography on silica (7:3 Petrol/EtOAc) to give the desired product as an off-white 
crystalline solid (4.38 g, 17.2 mmol, 74%). Rf 0.22 (7:3 Petrol/EtOAc); M.p. 92-94 °C; λmax 
(EtOH/nm) 269; IR (cm
-1
) 3132, 2955, 2876, 1574; 
1
H NMR: (500 MHz, DMSO-d6) 1.57-
1.64 (2H, m, OCH2CH2), 1.70-1.80 (1H, m, CHCHH’), 1.94-2.02 (2H, m, CHCH2CH2), 2.23-
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2.32 (1H, m, CHCHH’), 3.70-3.77 (1H, m, CHOCHH’), 4.00-4.06 (1H, m, CHOCHH’), 5.71 
(1H, dd, J = 2.3 and 10.9 Hz, CH), 8.92 (1H, s, H-8);
 13
C NMR (125 MHz, DMSO-d6) 22.0 
(CHCH2), 24.3 (OCH2CH2), 29.6 (CHCH2CH2), 67.7 (NOCH2), 81.7 (CH), 130.1 (d, JCF = 
4.8 Hz, C-Ar), 146.4 (d, JCF = 2.8 Hz, C-Ar), 150.6 (d, JCF = 18.5 Hz, C-Ar), 153.2 (d, JCF = 
17.6 Hz, C-Ar), 156.2 (d, JCF = 213.7 Hz, C
2
-Ar); LRMS (ES+) m/z 257.2 [M
35
Cl+H]
+
, 259.2 
[M
37
Cl+H]
+
. 
8-Bromo-6-chloro-2-fluoro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (52) 
 
n-Butyllithium (2.5 M in THF, 234 μl, 0.58 mmol) was added dropwise to a solution of 
diisopropylamine (82 μl, 0.58 mmol) in dry THF (1.5 ml) at -78 °C under N2. After addition, 
the mixture was allowed to warm to RT for 20 min before being cooled to -78 °C. The 
resulting LDA solution was added dropwise to a solution of the THP-protected purine 51 
(0.100 g, 0.39 mmol) in dry THF (2.5 ml) at -78 °C under N2. The mixture was stirred at -78 
°C for 25 min, after which a solution of 1,2-dibromotetrachloroethane (0.254 g, 0.78 mmol) 
in dry THF (1 ml) cooled to -78 °C was added dropwise to the reaction mixture. The solution 
was allowed to warm to RT whilst stirred under N2 over 3 h. The reaction solvent was 
removed in vacuo and the residue was purified via chromatography on silica (7:3 
Petrol/EtOAc) to give the desired compound as an off-white solid (91 mg, 0.27 mmol, 69%). 
Rf 0.50 (7:3 Petrol/EtOAc); M.p. 110-112 °C; λmax (EtOH/nm) 275; IR (cm
-1
) 2963, 2931, 
2837, 2161, 1576; 
1
H NMR (500 MHz, DMSO-d6) 1.57-1.64 (2H, m, OCH2CH2), 1.70-1.78 
(1H, m, CHCH2CHH’), 1.92-1.98 (1H, m, CHCH2CHH’), 1.98-2.05 (1H, m, CHCHH’), 
2.73-2.80 (1H, m, CHCHH’), 3.72 (1H, ddd, J = 3.7, 11.2 and 11.4 Hz, OCHH’), 4.02-4.10 
(1H, br, OCHH’), 5.69 (1H, dd, J = 2.4 and 11.1 Hz, CH); 13C NMR (125 MHz, DMSO-d6) 
22.3 (CHCH2), 24.3 (OCH2CH2), 27.8 (CHCH2CH2), 68.2 (OCH2), 85.0 (CH), 120.1 (C-Ar), 
156.0 (d, JCF = 212.8 Hz, C
2
-Ar); LRMS (EI) m/z 333.9 [M
35
Cl
79
Br+H]
+
, 335.9 
[M
37
Cl
79
Br+H]
+ 
/[M
35
Cl
81
Br+H]
+
, 337.9 [M
37
Cl
81
Br+H]
+
. 
Note: Unable to visualise all quaternary carbon signals by 
13
C NMR.  
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6-Chloro-2-fluoro-9-(tetrahydro-2H-pyran-2-yl)-8-methyl-9H-purine (53) 
 
2.5 M n-butyllithium (133 μl, 0.33 mmol) was added to a solution of the 8-bromopurine 52 
(0.102 g, 0.30 mmol) in dry THF (2 ml) at -78 °C under N2. The solution was stirred at -78 
°C for 20 min, after which iodomethane (37 μl, 0.61 mmol) was added dropwise. The mixture 
was allowed to warm to RT whilst stirred under N2 over 3 h. The reaction solvent was 
removed in vacuo and the residue was purified via chromatography on silica (7:3 
Petrol/EtOAc) to give the desired compound as an off-white waxy solid (76 mg, 0.28 mmol, 
93%). Rf 0.24 (7:3 Petrol/EtOAc); M.p. 98-100 °C; λmax (EtOH/nm) 273; IR (cm
-1
) 2945, 
2855, 2157, 2021, 1607; 
1
H NMR (500 MHz, CDCl3) 1.59-1.70 (3H, m, OCH2CH2 & 
CHCH2CHH’), 1.80-1.87 (1H, m, CHCH2CHH’), 2.01-2.08 (1H, m, CHCHH’), 2.32-2.39 
(1H, m, CHCHH’), 2.72 (3H, s, C8-CH3), 3.66 (1H, ddd, J = 2.5, 11.8 and 11.9 Hz, OCHH’), 
4.10-4.17 (1H, m, OCHH’-), 5.63 (1H, dd, J = 2.5 and 11.3 Hz, CH); 13C NMR (125 MHz, 
CDCl3) 16.4 (C
8
-CH3), 23.0 (CHCH2), 24.8 (OCH2CH2), 30.1 (CHCH2CH2), 69.3 (OCH2), 
83.4 (CH), 129.2 (C-Ar), 150.4 (d, JCF = 17.4 Hz, C-Ar), 154.4 (d, JCF = 16.3 Hz, C-Ar), 
156.0 (d, JCF = 3.2 Hz, C-Ar), 156.6 (d, JCF = 218.1 Hz, C
2
-Ar); LRMS (ES+) m/z 187.0 
[M
35
Cl-THP+H]
+
, 189.0 [M
37
Cl-THP+H]
+
. 
2-Fluoro-9-(tetrahydro-2H-pyran-2-yl)-8-methyl-9H-purine (54) 
 
Palladium hydroxide (0.102 g, 100% w/w) and ammonium formate (70 mg, 1.11 mmol) were 
added to a solution of the 6-chloropurine 53 (0.101 g, 0.37 mmol) in methanol (10 ml). The 
mixture was heated at reflux for 2 h, after which the catalyst was removed by filtration 
through Celite
®
. The solvent was removed in vacuo and the residue was purified via 
chromatography on silica (7:3 Petrol/EtOAc) to give the desired compound as an off-white 
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waxy solid (74 mg, 0.32 mmol, 86%). Rf 0.37 (7:3 Petrol/EtOAc); M.p. 92-94 °C; λmax 
(EtOH/nm) 270; IR (cm
-1
) 2922, 2155, 2030, 1664; 
1
H NMR (500 MHz, DMSO-d6) 1.60-
1.70 (3H, m, OCH2CH2 & CHCH2CHH’), 1.82-1.91 (1H, m, CHCH2CHH’), 2.00-2.07 (1H, 
m, CHCHH’), 2.38 (1H, m, CHCHH’), 2.71 (3H, s, C8-CH3), 3.67 (1H, ddd, J = 2.4, 11.7 and 
11.8 Hz, OCHH’), 4.09-4.15 (1H, m, OCHH’), 5.67 (1H, dd, J = 2.5 and 11.3 Hz, CH), 8.69 
(1H, s, H-6); 
13
C NMR (125 MHz, DMSO-d6) 16.4 (C
8
-CH3), 23.1 (CHCH2), 24.9 
(OCH2CH2), 30.1 (CHCH2CH2), 69.2 (OCH2), 82.9 (CH), 131.8 (d, JCF = 3.5 Hz, C-Ar), 
148.5 (d, JCF = 13.2 Hz, C-Ar), 155.8 (m, C-Ar); LRMS (ES+) m/z 153.1 [M+H]
+
. 
Note: Unable to visualise all quaternary carbon signals by 
13
C NMR. 
2-Fluoro-8-methyl-9H-purine (55) 
 
The THP-protected purine 54 (0.136 g, 0.58 mmol) was combined with TFA (1 ml) and H2O 
(1  ml) in 2-propanol (6 ml) and heated under microwave irradiation at 130 °C for 15 min, 
after which the reaction mixture was taken to pH 7 (conc. NH3) and concentrated to dryness. 
The residue was dissolved in EtOAc (15 ml) and washed with sat. NaHCO3 solution (10 ml), 
and the organic phase was dried (Na2SO4) and the solvent removed in vacuo. The crude 
residue was purified on silica gel (9:1 DCM/MeOH) to give the desired compound as a white 
solid (79 mg, 0.52 mmol, 90%). Rf 0.36 (9:1 DCM/MeOH); M.p. 225-228 °C; λmax 
(EtOH/nm) 394; IR (cm
-1
) 2898, 2584, 1610, 1562; 
1
H NMR (500 MHz, DMSO-d6) 2.58 
(3H, s, C
8
-CH3), 8.31 (1H, d, J = 0.9 Hz, H-6), 13.32 (1H, s, H-9); 
13
C NMR (125 MHz, 
DMSO-d6) 15.24 (C
8
-CH3), 144.2 (d, JCF = 17.8 Hz, C-Ar), 157.8 (d, JCF = 206.5 Hz, C-Ar); 
LRMS (ES+) m/z 153.1 [M+H]
+
. 
Note: Unable to visualise all quaternary carbon signals by 
13
C NMR. 
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8-Methyl-N-(4-phenoxyphenyl)-9H-purin-2-amine (48) 
 
2-Fluoropurine intermediate 55 (0.070 g, 0.46 mmol) and 4-phenoxyaniline (0.170 g, 0.92 
mmol) were reacted with TFA (177μl, 2.30 mmol) in TFE (6 ml) according to general 
procedure B. Chromatgraphy on silica (19:1 DCM/MeOH) afforded the target compound as 
a pale pink solid (0.101 g, 0.32 mmol, 75%). Rf 0.39 (19:1 DCM/MeOH); M.p.  228-231 °C; 
λmax (EtOH/nm) 277; IR (cm
-1
) 3454, 3253, 3194, 3044, 2924, 2161, 1617; 
1
H NMR (500 
MHz, DMSO-d6) 2.46 (3H, s, C
8
-CH3), 6.95 (2H, dd, J = 1.1 and 7.7 Hz, H-2’’/H-6’’), 7.00 
(2H, d, J = 9.0 Hz, H-3’/H-5’), 7.07 (1H, dddd, J = 1.1, 1.1, 7.4 and 7.4 Hz, H-4’’), 7.36 (2H, 
ddd, J = 1.1,7.4 and 7.7 Hz, H-3’’/H-5’’), 7.83 (2H, d, J = 9.0 Hz, H-2’/H-6’), 8.63 (1H, s, H-
6), 9.45 (1H, s, C
2
-NH), 12.68 (1H, s, H-9); 
13
C NMR (125 MHz, DMSO-d6) 14.93 (C
8
-
CH3), 117.1 (C-Ar), 119.7 (C-Ar), 119.8 (C-Ar), 122.4 (C-Ar), 128.3 (C-Ar), 129.8 (C-Ar), 
137.5 (C-Ar), 146.4 (C-Ar), 149.3 (C-Ar), 151.4 (C-Ar), 154.3 (C-Ar), 155.9 (C-Ar), 158.1 
(C-Ar); HRMS calcd. for C18H16N5O (ES+) m/z 318.1349 [M+H]
+
, found 318.1352. 
2-Chloro-5-nitropyrimidin-4-amine (58)
235
 
 
2,4-Dichloro-5-nitropyrimidine (1.00 g, 5.16 mmol) and ammonia (2M in EtOH, 6.00 ml, 
12.0 mmol) were reacted in THF (50 ml) according to general procedure C. Purification on 
silica gel (9:1 Petrol/EtOAc) gave the desired product as a yellow solid (0.557 g, 3.19 mmol, 
57%). Rf 0.20 (9:1 Petrol/EtOAc); M.p. 207-209 °C (Lit.
235
 215-217 °C); λmax (EtOH/nm) 
217, 258; IR (cm
-1
) 3435, 3344, 3063, 1717, 1649, 1567, 1509; 
1
H NMR (500 MHz, DMSO-
d6) 8.61 (1H, s, H-6), 9.02 (1H, s, NHH’), 9.20 (1H, s, NHH’); 
13
C NMR (125 Hz, DMSO-d6) 
126.6 (C-Ar), 157.1 (C-Ar), 157.6 (C-Ar), 162.1 (C-Ar); LRMS (ES+) m/z 175.1 
[M
35
Cl+H]
+
, 177.1 [M
37
Cl+H]
+
.  
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2-Chloropyrimidine-4,5-diamine (60)
236
 
 
5-Nitropyrimidine 58 (0.203 g, 1.15 mmol) and tin(II) chloride (0.870 g, 4.58 mmol) were 
reacted in ethanol (12 ml) according to general procedure D. Purification via 
chromatography on silica (9:1 DCM/MeOH) afforded the desired compound as a white solid 
(0.138 g, 0.95 mmol, 83%). Rf 0.33 (9:1 DCM/MeOH); M.p. 218-221 °C (Lit.
236
 230-232 
°C); λmax (EtOH/nm) 268, 315; IR (cm
-1
) 3162, 3031, 2024, 1603; 
1
H NMR (500 MHz, 
DMSO-d6) 4.85 (2H, s, C
5
-NH2), 6.85 (2H, br, C
4
-NH2), 7.41 (1H, s, H-6); 
13
C NMR (125 
Hz, DMSO-d6) 126.7 (C-Ar), 136.7 (C-Ar), 146.7 (C-Ar), 155.2 (C-Ar); LRMS (ES+) m/z 
145.1 [M
35
Cl+H]
+
, 147.1 [M
37
Cl+H]
+
.  
2-Chloro-8-methyl-9H-purine (62) 
 
The diaminopyrimidine 60 (0.460 g, 3.18 mmol), triethyl orthoacetate (1.50 ml, 7.95 mmol) 
and TFA (25 μl, 0.32 mmol) were reacted in TFE (20 ml) according to general procedure E. 
Silica gel purification (19:1 DCM/MeOH) gave the target compound as a beige solid (0.461 
g, 2.73 mmol, 86%). Rf 0.50 (19:1 DCM/MeOH); M.p. 239-241 °C; λmax (EtOH/nm) 275; IR 
(cm
-1
) 3414, 2889, 2804, 1537; 
1
H NMR (500 MHz, DMSO-d6) 2.59 (3H, s, C
8
-CH3), 8.87 
(1H, s, H-6), 13.36 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 15.2 (C
8
-CH3), 137.6 (C-
Ar), 144.3 (C-Ar), 151.9 (C-Ar), 158.4 (C-Ar); HRMS calcd. for C6H6ClN4 (ES+) m/z 
169.0276 [M+H]
+
, found 169.0274. 
Note: Unable to visualise all quaternary carbon signals by 
13
C NMR. 
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2-Chloro-N-methyl-5-nitropyrimidin-4-amine (59)
237
 
 
2,4-Dichloro-5-nitropyrimidine (0.502 g, 2.58 mmol) and methylamine (2M in THF, 3.9 ml, 
7.75 mmol) were reacted in THF (25 ml) according to general procedure C. Purification on 
silica gel (9:1 Petrol/EtOAc) gave the desired product as a yellow solid (0.423 g, 2.24 mmol, 
87%). Rf 0.22 (9:1 Petrol/EtOAc); M.p. 86-89 °C (Lit.
237
 85-86 °C); λmax (EtOH/nm) 356, 
256, 233; IR (cm
-1
) 3377, 3280, 3054, 2166, 1608; 
1
H NMR (500 MHz, DMSO-d6) 2.89 (3H, 
d, J = 5.0 Hz, NHCH3), 8.89 (1H, s, H-6), 9.02 (1H, br, NH); 
13
C NMR (125 MHz, DMSO-
d6) 28.66 (NHCH3), 119.0 (C-Ar), 151.1 (C-Ar), 155.2 (C-Ar); LRMS (ES+) m/z 189.1 
[M
35
Cl+H]
+
, 191.1 [M
37
Cl+H]
+
. 
2-Chloro-N
4
-methylpyrimidine-4,5-diamine (61)
238
 
 
5-Nitropyrimidine 59 (0.502 g, 2.66 mmol) and tin(II) chloride (2.01 g, 10.6 mmol) were 
reacted in ethanol (20 ml) according to general procedure D. Purification via 
chromatography on silica (9:1 DCM/MeOH) afforded the desired compound as a white solid 
(0.330 g, 2.10 mmol, 78%). Rf 0.45 (9:1 DCM/MeOH); M.p. 118-121 °C (Lit.
238
 145.5-146.5 
°C); λmax (EtOH/nm) 264, 301; IR (cm
-1
) 3162, 3031, 2024, 1603; 
1
H NMR (500 MHz, 
DMSO-d6) 2.86 (3H, d, J = 4.5 Hz, NHCH3), 4.83 (2H, s, Ar-NH2), 6.94 (1H, br, NHCH3), 
7.37 (1H, s, H-6); 
13
C NMR (125 MHz, DMSO-d6) 27.4 (NHCH3), 127.2 (C-Ar), 135.3 (C-
Ar), 147.2 (C-Ar), 154.4 (C-Ar); LRMS (ES+) m/z 159.1 [M
35
Cl+H]
+
, 161.1 [M
37
Cl+H]
+
. 
2-Chloro-8,9-dimethyl-9H-purine (56) 
 
The diaminopyrimidine 61 (0.250 g, 1.57 mmol), triethyl orthoacetate (740 μl, 3.93 mmol) 
and TFA (12 μl, 0.16 mmol) were reacted in TFE (10 ml) according to general procedure E. 
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Chromatography on silica (19:1 DCM/MeOH) gave the desired compound as a white solid 
(0.265 g, 1.45 mmol, 94%). Rf 0.55 (19:1 DCM/MeOH); M.p. 189-192 °C; λmax (EtOH/nm) 
274; IR (cm
-1
) 2924, 2159, 1989, 1600; 
1
H NMR (500 MHz, DMSO-d6) 2.62 (3H, s, C
8
-
CH3), 3.72 (3H, s, N
9
-CH3), 8.90 (1H, s, H-6); 
13
C NMR (125 MHz, DMSO-d6) 14.0 (C
8
-
CH3), 28.6 (N
9
-CH3), 132.5 (C-Ar), 147.3 (C-Ar), 151.7 (C-Ar), 154.6 (C-Ar), 157.4 (C-Ar); 
HRMS calcd. for C7H8ClN4 (ES+) m/z 183.0432 [M+H]
+
, found 183.0431. 
N-(4-Methoxyphenyl)-8,9-dimethyl-9H-purin-2-amine (63) 
 
The 2-chloropurine intermediate 56 (30 mg, 0.16 mmol), 4-methoxyaniline (39 mg, 0.32 
mmol) and TFA (63 μl, 0.82 mmol) were reacted in TFE (6 ml) according to general 
procedure F. Silica gel chromatography (9:1 DCM/MeOH) afforded the target compound as 
a beige solid (27 mg, 0.10 mmol, 61%). Rf 0.47 (9:1 DCM/MeOH); M.p. 183-185 °C; λmax 
(EtOH/nm) 275; IR (cm
-1
) 3261, 3051, 2925, 2839, 2040, 1602; 
1
H NMR (500 MHz, DMSO-
d6) 2.35 (3H, s, C
8
-CH3), 3.49 (3H, s, N
9
-CH3), 3.57 (3H, s, OCH3), 6.67 (2H, d, J = 9.1 Hz, 
H-3’/H-5’), 7.40 (2H, d, J = 9.1 Hz, H-2’/H-6’), 8.28 (1H, s, H-6); 13C NMR (125 MHz, 
DMSO-d6) 13.8 (C
8
-CH3), 28.0 (N
9
-CH3), 55.1 (OCH3), 113.7 (C-Ar), 119.7 (C-Ar), 127.1 
(C-Ar), 134.4 (C-Ar), 146.6 (C-Ar), 152.1 (C-Ar), 153.7 (C-Ar), 153.8 (C-Ar), 156.1 (C-Ar); 
HRMS calcd. for C14H16N5O (ES+) m/z 270.1349 [M+H]
+
, found 270.1348. 
8,9-Dimethyl-N-(4-phenoxyphenyl)-9H-purin-2-amine (74) 
 
The 2-chloropurine intermediate 56 (70 mg, 0.38 mmol), 4-phenoxyaniline (0.142 g, 0.77 
mmol) and TFA (146 μl, 1.90 mmol) were reacted in TFE (6 ml) according to general 
procedure F. Purification by chromatography on silica (19:1 DCM/MeOH) gave the desired 
compound as a pale pink solid (0.098 g, 0.30 mmol, 78%). Rf 0.48 (19:1 DCM/MeOH); M.p. 
185-188 °C; λmax (EtOH/nm) 277, 331; IR (cm
-1
) 3262, 3193, 3117, 3038, 2026, 1617; 
1
H 
NMR (500 MHz, DMSO-d6) 2.29 (3H, s, C
8
-CH3), 3.43 (3H, s, N
9
-CH3), 6.73 (2H, ddd, J = 
1.0 and 8.7 Hz, H-2’’/H-6’’), 6.77 (2H, d, J = 8.9 Hz, H-3’/H-5’), 6.82-6.85 (1H, m, H-4’’), 
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7.13 (2H, ddd, J = 1.1, 8.6 and 8.7 Hz, H-3’’/H-5’’), 7.66 (2H, d, J = 8.9 Hz, H-2’/H-6’), 8.41 
(1H, s, H-6), 9.34 (1H, s, C
2
-NH); 
13
C NMR (125 MHz, DMSO-d6) 13.8 (C
8
-CH3), 28.0 (N
9
-
CH3), 117.3 (C-Ar), 119.6 (C-Ar), 119.7 (C-Ar), 122.5 (C-Ar), 127.4 (C-Ar), 129.8 (C-Ar), 
137.4 (C-Ar), 146.5 (C-Ar), 149.5 (C-Ar), 152.5 (C-Ar), 153.8 (C-Ar), 155.8 (C-Ar), 158.0 
(C-Ar); HRMS calcd. for C19H18N5O (ES+) m/z 332.1506 [M+H]
+
, found 332.1509. 
8-Methyl-N-phenyl-9H-purin-2-amine (64) 
 
2-Chloropurine intermediate 62 (20 mg, 0.12 mmol), aniline (22 μl, 0.24 mmol) and TFA (45 
μl, 0.59 mmol) were reacted in TFE (1 ml) according to general procedure F. Purification 
via chromatography on KP-NH silica (19:1 DCM/MeOH) afforded the desired compound as 
a pale pink solid (23 mg, 0.10 mmol, 83%). Rf 0.41 (19:1 DCM/MeOH, KP-NH); M.p. 238-
240 °C; λmax (EtOH/nm) 260, 330; IR (cm
-1
) 3260, 3187, 3044, 2362, 1601; 
1
H NMR (500 
MHz, DMSO-d6) 2.46 (3H, s, C
8
-CH3), 6.87-6.92 (1H, m, H-4’), 7.25 (2H, dd, J = 7.4 and 
7.4 Hz, H-3’/H-5’), 7.79-7.83 (2H, m, H-2’/H-6’), 8.62 (1H, s, H-6), 9.38 (1H, s, C2-NH), 
12.67 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 15.0 (C
8
-CH3), 118.0 (C-Ar), 120.4 (C-
Ar), 128.3 (C-Ar), 141.3 (C-Ar), 155.9 (C-Ar); HRMS calcd. for C12H12N5 (ES+) m/z 
226.1088 [M+H]
+
, found 226.1087. 
Note: Unable to visualise all carbon signals by NMR. 
N-(4-Ethylphenyl)-8-methyl-9H-purin-2-amine (66) 
 
2-Chloropurine intermediate 62 (20 mg, 0.12 mmol), 4-ethylaniline (30 μl, 0.24 mmol) and 
TFA (45 μl, 0.59 mmol) were reacted in TFE (1 ml) according to general procedure F. 
Purification via chromatography on KP-NH silica (19:1 DCM/MeOH) afforded the desired 
compound as a pale pink solid (23 mg, 0.09 mmol, 76%). Rf 0.39 (19:1 DCM/MeOH, KP-
NH); M.p. 286-289 °C; λmax (EtOH/nm) 283, 331; IR (cm
-1
) 3262, 3192, 2963, 2156, 2030, 
1603; 
1
H NMR (500 MHz, DMSO-d6) 1.17 (3H, t, J = 7.6 Hz, -CH2CH3), 2.46 (3H, s, C
8
-
CH3), 2.55 (2H, q, J = 7.6 Hz, -CH2CH3), 7.10 (2H, d, J = 8.6 Hz, H-3’/H-5’), 7.70 (2H, d, J 
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= 8.6 Hz, H-2’/H-6’), 8.60 (1H, s, H-6), 9.28 (1H, s, C2-NH), 12.64 (1H, br, H-9); 13C NMR 
(125 MHz, DMSO-d6) 15.0 (C
8
-CH3), 15.9 (CH2CH3), 27.5 (CH2CH3), 118.3 (C-Ar), 127.6 
(C-Ar), 135.8 (C-Ar), 139.0 (C-Ar), 156.1 (C-Ar); HRMS calcd. for C14H16N5 (ES+) m/z 
254.1402 [M+H]
+
, found 254.1400. 
Note: Unable to visualise all carbon signals by NMR. 
N-(4-Isopropylphenyl)-8-methyl-9H-purin-2-amine (68) 
 
2-Chloropurine intermediate 62 (20 mg, 0.12 mmol), 4-isopropylaniline (34 μl, 0.24 mmol) 
and TFA (45 μl, 0.59 mmol) were reacted in TFE (1 ml) according to general procedure F. 
Purification via chromatography on KP-NH silica (19:1 DCM/MeOH) afforded the desired 
compound as a pale pink solid (17 mg, 0.06 mmol, 53%). Rf 0.33 (19:1 DCM/MeOH, KP-
NH); M.p. 276-278 °C; λmax (EtOH/nm) 273, 332; IR (cm
-1
) 3455, 3225, 3190, 3107, 3049, 
2957, 2160, 1976, 1610; 
1
H NMR (500 MHz, DMSO-d6) 1.20 (6H, d, J = 6.8 Hz, -
CH(CH3)2), 2.46 (3H, s, C
8
-CH3), 2.83 (1H, sept, J = 6.8 Hz, -CH(CH3)2), 7.13 (2H, d, J = 
8.2 Hz, H-3’/H-5’), 7.69 (2H, d, J = 8.2 Hz, H-2’/H-6’), 8.60 (1H, s, H-6), 9.27 (1H, s, C2-
NH), 12.63 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 15.0 (C
8
-CH3), 24.1 (-CH(CH3)2), 
32.8 (-CH(CH3)2), 118.4 (C-Ar), 126.0 (C-Ar), 139.0 (C-Ar), 140.6 (C-Ar), 156.2 (C-Ar); 
HRMS calcd. for C15H18N5 (ES+) m/z 268.1559 [M+H]
+
, found 268.1557. 
Note: Unable to visualise all carbon signals by NMR. 
8,9-Dimethyl-N-phenyl-9H-purin-2-amine (65) 
 
2-Chloropurine intermediate 56 (20 mg, 0.11 mmol), aniline (20 μl, 0.22 mmol) and TFA (42 
μl, 0.55 mmol) were reacted in TFE (1 ml) according to general procedure F. Purification 
via chromatography on KP-NH silica (1:1 Petrol/EtOAc) afforded the desired compound as a 
pale pink solid (15 mg, 0.06 mmol, 57%). Rf 0.35 (1:1 Petrol/EtOAc, KP-NH); M.p. 238-240 
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°C; λmax (EtOH/nm) 273, 328; IR (cm
-1
) 3360, 3258, 3196, 3020, 1603; 
1
H NMR (500 MHz, 
MeOD) 2.58 (3H, s, C
8
-CH3), 3.74 (3H, s, N
9
-CH3), 6.97 (1H, dddd, J = 1.0, 1.0, 7.4 and 7.4 
Hz, H-4’), 7.29 (2H, ddd, J = 7.0, 7.4 and 7.4 Hz, H-3’/H-5’), 7.74-7.77 (2H, m, H-2’/H-6’), 
8.45 (1H, s, H-6), 9.48 (1H, s, C
2
-NH); 
13
C NMR (125 MHz, DMSO-d6) 13.8 (C
8
-CH3), 28.0 
(N
9
-CH3), 118.1 (C-Ar), 120.6 (C-Ar), 127.4 (C-Ar), 128.4 (C-Ar), 141.2 (C-Ar), 146.5 (C-
Ar), 152.6 (C-Ar), 153.8 (C-Ar), 155.8 (C-Ar); HRMS calcd. for C13H14N5 (ES+) m/z 
240.1246 [M+H]
+
, found 240.1244. 
N-(4-Ethylphenyl)-8,9-dimethyl-9H-purin-2-amine (67) 
 
2-Chloropurine intermediate 56 (20 mg, 0.11 mmol), 4-ethylaniline (28 μl, 0.22 mmol) and 
TFA (42 μl, 0.55 mmol) were reacted in TFE (1 ml) according to general procedure F. 
Purification via chromatography on KP-NH silica (1:1 Petrol/EtOAc) afforded the desired 
compound as a pale pink solid (17 mg, 0.06 mmol, 57%). Rf 0.32 (1:1 Petrol/EtOAc, KP-
NH); M.p. 197-199 °C; λmax (EtOH/nm) 275, 333; IR (cm
-1
) 3372, 2962, 2926, 2866, 2158, 
1615; 
1
H NMR (500 MHz, DMSO-d6) 1.18 (3H, t, J = 7.6 Hz, -CH2CH3), 2.56 (2H, q, J = 7.6 
Hz, -CH2CH3), 2.50 (3H, s, C
8
-CH3), 3.66 (3H, s, N
9
-CH3), 7.12 (2H, d, J = 8.7 Hz, H-3’/H-
5’), 7.75 (2H, d, J = 8.7 Hz, H-2’/H-6’), 8.62 (1H, s, H-6), 9.41 (1H, s, C2-NH); 13C NMR 
(125 MHz, DMSO-d6) 13.8 (C
8
-CH3), 15.9 (CH2CH3), 27.5 (CH2CH3), 28.0 (N
9
-CH3), 118.3 
(C-Ar), 127.3 (C-Ar), 127.6 (C-Ar), 135.9 (C-Ar), 138.8 (C-Ar), 146.5 (C-Ar), 152.3 (C-Ar), 
153.8 (C-Ar), 155.9 (C-Ar); HRMS calcd. for C15H18N5 (ES+) m/z 268.1559 [M+H]
+
, found 
268.1557. 
N-(4-Isopropylphenyl)-8,9-dimethyl-9H-purin-2-amine (69) 
 
2-Chloropurine intermediate 56 (20 mg, 0.11 mmol), 4-isopropylaniline (31 μl, 0.22 mmol) 
and TFA (42 μl, 0.55 mmol) were reacted in TFE (1 ml) according to general procedure F. 
Purification via chromatography on KP-NH silica (1:1 Petrol/EtOAc) afforded the desired 
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compound as a pale pink solid (18 mg, 0.06 mmol, 58%). Rf 0.31 (1:1 Petrol/EtOAc, KP-
NH); M.p. 188-190 °C; λmax (EtOH/nm) 275, 333; IR (cm
-1
) 3359, 2957, 2868, 2158, 2031, 
1615; 
1
H NMR (500 MHz, MeOD) 1.07 (6H, d, J = 7.0 Hz, -CH(CH3)2), 2.39 (3H, s, C
8
-
CH3), 2.69 (1H, sept, J = 7.0 Hz, -CH(CH3)2), 3.55 (3H, s, N
9
-CH3), 7.00 (2H, d, J = 8.8 Hz, 
H-3’/H-5’), 7.47 (2H, d, J = 8.8 Hz, H-2’/H-6’), 8.34 (1H, s, H-6), 9.41 (1H, s, C2-NH); 13C 
NMR (125 MHz, DMSO-d6) 13.8 (C
8
-CH3), 24.1 (-CH(CH3)2), 28.0 (N
9
-CH3), 32.8 (-
CH(CH3)2), 118.3 (C-Ar), 126.1 (C-Ar), 127.2 (C-Ar), 138.9 (C-Ar), 140.7 (C-Ar), 146.5 (C-
Ar), 152.3 (C-Ar), 153.8 (C-Ar), 155.9 (C-Ar); HRMS calcd. for C16H20N5 (ES+) m/z 
282.1715 [M+H]
+
, found 282.1713. 
1-Isopropoxy-4-nitrobenzene (77)
239
 
 
Sodium hydride (92 mg, 3.90 mmol) was added portionwise to dry isopropanol (3 ml). Once 
the resultant reaction had subsided, the solution was cooled to 0 °C and a solution of 4-
fluoronitrobenzene (0.501 g, 3.54 mmol) in dry isopropanol (2 ml) was added drop-wise. The 
reaction mixture was stirred at RT for 18 h, after which point the solvent was removed in 
vacuo. The crude residue was purified via chromatography on silica (9:1 Petrol/EtOAc) to 
give the desired compound as a golden oil (0.550 g, 3.04 mmol, 86%). Rf 0.38 (1:1 
Petrol/EtOAc); λmax (EtOH/nm) 229, 318; IR (cm
-1
) 2981, 2936, 1912, 1591; 
1
H NMR (500 
MHz, CDCl3) 1.41 (6H, d, J = 6.1 Hz, OCH(CH3)2), 4.69 (1H, sept, J = 6.1 Hz, OCH(CH3)2), 
6.94 (2H, d, J = 9.3 Hz, H-2/H-6), 8.21 (2H, d, J = 9.3 Hz, H-3/H-5); 
13
C NMR (125 MHz, 
CDCl3) 21.8 (OCH(CH3)2), 70.9 (OCH(CH3)2), 115.2 (C-Ar), 126.0 (C-Ar), 141.1 (C-Ar), 
163.2 (C-Ar); LRMS (ES+) m/z 182.2 [M+H]
+
. 
4-Isopropoxyaniline (75)
240
 
 
Nitro aromatic 77 (0.448 g, 2.47 mmol), palladium on carbon (50 mg, 10% w/w) and 
ammonium formate (1.56 g, 24.7 mmol) were reacted in methanol (25 ml) according to 
general procedure G. Chromatography on silica (7:3 Petrol/EtOAc) afforded the target 
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compound as an orange oil (0.307 g, 2.03 mmol, 82%). Rf 0.44 (7:3 Petrol/EtOAc); λmax 
(EtOH/nm) 231, 273; IR (cm
-1
) 3433, 3352, 3228, 2975, 2360, 1624, 1505; 
1
H NMR (500 
MHz, DMSO-d6) 1.18 (6H, d, J = 6.0 Hz, OCH(CH3)2), 4.31 (1H, sept, J = 6.0 Hz, 
OCH(CH3)2), 4.60 (2H, s, Ar-NH2), 6.49 (2H, d, J = 8.8 Hz, H-2/H-6), 6.62 (2H, d, J = 8.8 
Hz, H-3/H-5); 
13
C NMR (125 MHz, DMSO-d6) 22.0 (OCH(CH3)2), 70.0 (OCH(CH3)2), 114.9 
(C-Ar), 117.4 (C-Ar), 142.5 (C-Ar), 148.4 (C-Ar); LRMS (ES+) m/z 152.1 [M+H]
+
. 
N-(4-Isopropoxyphenyl)-8-methyl-9H-purin-2-amine (70) 
 
2-Chloropurine intermediate 62 (20 mg, 0.12 mmol), aniline 75 (36 mg, 0.24 mmol) and TFA 
(45 μl, 0.59 mmol) were reacted in TFE (1 ml) according to general procedure F. 
Purification via chromatography on KP-NH silica (19:1 DCM/MeOH) afforded the desired 
compound as a pale pink solid (23 mg, 0.08 mmol, 70%). Rf 0.36 (19:1 DCM/MeOH, KP-
NH); M.p. 196-198 °C; λmax (EtOH/nm) 274; IR (cm
-1
) 3254, 3048, 2977, 1612; 
1
H NMR 
(500 MHz, DMSO-d6) 1.25 (6H, d, J = 6.0 Hz, OCH(CH3)2), 2.45 (3H, s, C
8
-CH3), 4.52 (1H, 
sept, J = 6.0 Hz, OCH(CH3)2), 6.85 (2H, d, J = 8.9 Hz, H-3’/H-5’), 7.66 (2H, d, J = 8.9 Hz, 
H-2’/H-6’), 8.58 (1H, s, H-6), 9.17 (1H, s, C2-NH), 12.60 (1H, s, H-9); 13C NMR (125 MHz, 
DMSO-d6) 14.9 (C
8
-CH3), 21.9 (OCH(CH3)2), 69.4 (OCH(CH3)2), 115.9 (C-Ar), 119.9 (C-
Ar); HRMS calcd. for C15H18N5O (ES+) m/z 284.1509 [M+H]
+
, found 284.1506. 
Note: Unable to visualise all carbon signals by NMR. 
N-(4-Isopropoxyphenyl)-8,9-dimethyl-9H-purin-2-amine (71) 
 
2-Chloropurine intermediate 56 (20 mg, 0.11 mmol), aniline 75 (33 mg, 0.22 mmol) and TFA 
(42 μl, 0.55 mmol) were reacted in TFE (1 ml) according to general procedure F. 
Purification via chromatography on KP-NH silica (1:1 Petrol/EtOAc) afforded the desired 
compound as a pale pink solid (28 mg, 0.09 mmol, 86%). Rf 0.27 (1:1 Petrol/EtOAc, KP-
NH); M.p. 204-205 °C; λmax (EtOH/nm) 276; IR (cm
-1
) 3251, 3195, 3115, 3045, 2975, 2932, 
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2164, 1613; 
1
H NMR (500 MHz, DMSO-d6) 1.26 (6H, d, J = 6.0 Hz, OCH(CH3)2), 2.52 (3H, 
s, C
8
-CH3), 3.65 (3H, s, N
9
-CH3), 4.52 (1H, sept, J = 6.0 Hz, OCH(CH3)2), 6.86 (2H, d, J = 
9.0 Hz, H-3’/H-5’), 7.72 (2H, d, J = 9.0 Hz, H-2’/H-6’), 8.59 (1H, s, H-6), 9.31 (1H, s, C2-
NH); 
13
C NMR (125 MHz, DMSO-d6) 13.8 (C
8
-CH3), 21.9 (OCH(CH3)2), 28.0 (N
9
-CH3), 
69.4 (OCH(CH3)2), 115.9 (C-Ar), 119.7 (C-Ar), 127.3 (C-Ar),134.4 (C-Ar), 146.5 (C-Ar), 
151.7 (C-Ar), 152.1 (C-Ar), 153.8 (C-Ar), 156.1 (C-Ar); HRMS calcd. for C16H20N5O (ES+) 
m/z 298.1665 [M+H]
+
, found 298.1662. 
2-Benzyl-4-((8,9-dimethyl-9H-purin-2-yl)amino)phenol (79) 
 
2-Chloropurine intermediate 56 (70 mg, 0.38 mmol), 4-benzyloxyaniline hydrochloride 
(0.180 g, 0.77 mmol) and TFA (150 μl, 1.92 mmol) were reacted in TFE (2 ml) according to 
general procedure F. Purification via chromatography on KP-NH silica (1:1 Petrol/EtOAc) 
afforded the described compound as a beige solid (16 mg, 0.05 mmol, 12%). Rf 0.21 (1:1 
Petrol/EtOAc, KP-NH); M.p. 170-190 °C (decomposed); λmax (EtOH/nm) 277, 336; IR (cm
-1
) 
3026, 2158, 2015, 1613, 1589; 
1
H NMR (500 MHz, DMSO-d6) 2.49 (3H, s, C
8
-CH3), 3.55 
(3H, s, N
9
-CH3), 3.87 (2H, s, OCH2Ar), 6.74 (1H, d, J = 8.7 Hz, H-6’), 7.14-7.19 (1H, m, H-
4’’), 7.25-7.29 (4H, m, H-2’’/H-3’’/H-5’’/H-6’’), 7.36 (1H, dd, J = 2.7 and 8.7 Hz, H-5’), 
7.56 (1H, d, J = 2.7 Hz, H-3’), 8.53 (1H, s, H-6), 9.01 (1H, br, Ar-OH), 9.10 (1H, s, C2-NH); 
HRMS calcd. for C20H20N5O (ES+) m/z 346.1668 [M+H]
+
, found 346.1662. 
Note: Insufficient material for 
13
C NMR. 
4-(8,9-Dimethyl-9H-purin-2-ylamino)phenol (80) 
 
2-Chloropurine intermediate 56 (0.200 g, 1.10 mmol), 4-aminophenol (0.240 g, 2.20 mmol) 
and TFA (0.420 μl, 5.50 mmol) were reacted in TFE (6 ml) according to general procedure 
F. Purification via chromatography on KP-NH silica (19:1 DCM/MeOH) afforded the desired 
compound as a pale pink solid (0.174 g, 0.68 mmol, 62%). Rf 0.24 (19:1 DCM/MeOH, KP-
258 
 
NH); M.p. 260-270 °C (decomposed); λmax (EtOH/nm) 249, 338; IR (cm
-1
) 1696, 2597, 2676, 
3037, 3262; 
1
H NMR (500 MHz, DMSO-d6) 2.50 (3H, s, C
8
-CH3), 3.63 (3H, s, N
9
-CH3), 
6.70 (2H, d, J = 8.8 Hz, H-2’/H-6’), 7.59 (2H, d, J = 8.8 Hz, H-3’/H-5’), 8.56 (1H, s, H-6), 
8.96 (1H, br, Ar-OH), 9.17 (1H, s, C
2
-NH); 
13
C NMR (125 MHz, DMSO-d6) 13.7 (C
8
-CH3), 
27.9 (N
9
-CH3), 114.9 (C-Ar), 120.2 (C-Ar), 126.9 (C-Ar), 132.9 (C-Ar), 146.5 (C-Ar), 151.7 
(C-Ar), 151.9 (C-Ar), 153.9 (C-Ar), 156.3 (C-Ar); HRMS calcd. for C13H14N5O (ES+) m/z 
256.1193 [M+H]
+
, found 256.1197. 
N-(4-(Benzyloxy)phenyl)-8,9-dimethyl-9H-purin-2-amine (78) 
 
Phenol 80 (40 mg, 0.16 mmol), benzyl chloride (74µl, 0.64 mmol) and potassium carbonate 
(26 mg, 0.18 mmol) were reacted in dry DMF (1.5 ml) according to general procedure H. 
Purification via chromatography on KP-NH silica (1:1 Petrol/EtOAc) afforded the desired 
compound as a beige solid (24 mg, 0.07 mmol, 18%). Rf 0.21 (1:1 Petrol/EtOAc, KP-NH); 
M.p. 202-204 °C; λmax (EtOH/nm) 277, 336; IR (cm
-1
) 3255, 3155, 3116, 3051, 1624, 1548, 
1510; 
1
H NMR (500 MHz, DMSO-d6) 2.50 (3H, s, C
8
-CH3), 3.64 (3H, s, N
9
-CH3), 5.07 (2H, 
s, ArCH2), 6.96 (2H, d, J = 9.1 Hz, H-3’/H-5’), 7.31-7.36 (1H, m, H-4’’), 7.40 (2H, dd, J = 
7.3 and 7.6 Hz, H-3’’/H-5’’), 7.44-7.48 (2H, m, H-2’’/H-6’’), 7.74 (2H, d, J = 9.1 Hz, H-
2’/H-6’), 8.60 (1H, s, H-6), 9.35 (1H, s, C2-NH); 13C NMR (125 MHz, DMSO-d6) 13.8 (C
8
-
CH3), 28.0 (N
9
-CH3), 69.4 (ArCH2), 114.7 (C-Ar), 119.7 (C-Ar), 127.1 (C-Ar), 127.6 (C-Ar), 
127.7 (C-Ar), 128.4 (C-Ar), 134.7 (C-Ar), 137.4 (C-Ar), 146.5 (C-Ar), 152.2 (C-Ar), 152.7 
(C-Ar), 153.8 (C-Ar), 156.0 (C-Ar); HRMS calcd. for C20H20N5O (ES+) m/z 346.1668 
[M+H]
+
, found 346.1665. 
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N-(4-(4-Methoxybenzyloxy)phenyl)-8,9-dimethyl-9H-purin-2-amine (81) 
 
Phenol 80 (40 mg, 0.16 mmol), 4-methoxybenzyl chloride (26 μl, 0.18 mmol) and potassium 
carbonate (26 mg, 0.18 mmol) were reacted in dry DMF (1.5 ml) according to general 
procedure H. Purification via chromatography on silica (19:1 DCM/MeOH) afforded the 
desired compound as a pale pink solid (48 mg, 0.13 mmol, 80%) Rf 0.31 (19:1 DCM/MeOH); 
M.p. 178-180 °C; λmax (EtOH/nm) 276; IR (cm
-1
) 3257, 3199, 3117, 3059, 2836, 1609; 
1
H 
NMR (500 MHz, DMSO-d6) 2.52 (3H, s, C
8
-CH3), 3.64 (3H, s, N
9
-CH3), 3.76 (3H, s, OCH3), 
4.98 (2H, s, OCH2Ar), 6.94 (2H, d, J = 9.2 Hz, H-3’/H-5’), 6.95 (2H, d, J = 8.5 Hz, H-3’’/H-
5’’), 7.38 (2H, d, J = 8.5 Hz, H-2’’/H-6’’), 7.74 (2H, d, J = 9.2 Hz, H-2’/H-6’), 8.60 (1H, s, 
H-6), 9.34 (1H, s, C
2
-NH); 
13
C NMR (125 MHz, DMSO-d6) 13.8 (C
8
-CH3), 28.0 (N
9
-CH3), 
55.1 (OCH3), 69.2 (OCH2Ar), 113.7 (C-Ar), 114.8 (C-Ar), 119.6 (C-Ar), 127.1 (C-Ar), 129.3 
(C-Ar), 129.4 (C-Ar), 134.6 (C-Ar), 146.6 (C-Ar), 152.1 (C-Ar), 152.8 (C-Ar), 152.8 (C-Ar), 
156.0 (C-Ar), 158.9 (C-Ar); HRMS calcd. for C21H22N5O2 (ES+) m/z 376.1768 [M+H]
+
, 
found 376.1768. 
N-(4-(4-Chlorobenzyloxy)phenyl)-8,9-dimethyl-9H-purin-2-amine (82) 
 
Phenol 80 (30 mg, 0.12 mmol), 4-chlorobenzyl chloride (57 mg, 0.35 mmol) and potassium 
carbonate (18 mg, 0.14 mmol) were reacted in dry DMF (1 ml) according to general 
procedure H. Purification via chromatography on silica (19:1 DCM/MeOH) afforded the 
desired compound as a pale pink solid (31 mg, 0.08 mmol, 68%). Rf 0.32 (19:1 
DCM/MeOH); M.p. 206-207 °C; λmax (EtOH/nm) 276; IR (cm
-1
) 3263, 3201, 3125, 3065, 
1618; 
1
H NMR (500 MHz, DMSO-d6) 2.52 (3H, s, C
8
-CH3), 3.64 (3H, s, N
9
-CH3), 5.08 (2H, 
s, OCH2Ar), 6.96 (2H, d, J = 9.0 Hz, H-3’/H-5’), 7.46 (2H, d, J = 8.7 Hz, H-2’’/H-6’’), 4.49 
(2H, d, J = 8.7 Hz, H-3’’/H-5’’), 7.75 (2H, d, J = 9.0 Hz, H-2’/H-6’), 8.60 (1H, s, H-6), 9.35 
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(1H, s, C
2
-NH); 
13
C NMR (125 MHz, DMSO-d6) 13.8 (C
8
-CH3), 28.0 (N
9
-CH3), 68.6 
(OCH2Ar), 114.8 (C-Ar), 119.6 (C-Ar), 128.4 (C-Ar), 129.4 (C-Ar), 134.8 (C-Ar), 136.5 (C-
Ar), 146.6 (C-Ar), 152.5 (C-Ar), 153.8 (C-Ar), 156.0 (C-Ar); HRMS calcd. for C20H19ClN5O 
(ES+) m/z 380.1272 [M+H]
+
, found 380.1273.  
Note: Unable to visualise all carbon signals by NMR. 
N-(4-(4-tert-Butylbenzyloxy)phenyl)-8,9-dimethyl-9H-purin-2-amine (83) 
 
Phenol 80 (40 mg, 0.16 mmol), 4-tert-butylbenzyl chloride (35 μl, 0.18 mmol) and potassium 
carbonate (26 mg, 0.18 mmol) were reacted in dry DMF (1.5 ml) according to general 
procedure H. Purification via chromatography on silica (19:1 DCM/MeOH) afforded the 
desired compound as a pale pink solid (44 mg, 0.11 mmol, 69%) Rf 0.28 (19:1 DCM/MeOH); 
M.p. 228-229 °C; λmax (EtOH/nm) 277; IR (cm
-1
) 3272, 3202, 2958, 2853, 1608, 1558; 
1
H 
NMR (500 MHz, DMSO-d6) 1.29 (9H, s, -C(CH3)3), 2.52 (3H, s, C
8
-CH3), 3.64 (3H, s, N
9
-
CH3), 5.03 (2H, s, OCH2Ar), 6.95 (2H, d, J = 9.1 Hz, H-3’/H-5’), 7.38 (2H, d, J = 8.4 Hz, H-
3’’/H-5’’), 7.42 (2H, d, J = 8.4 Hz, H-2’’/H-6’’), 7.45 (2H, d, J = 9.1 Hz, H-2’/H-6’), 8.59 
(1H, s, H-6), 9.33 (1H, s, C
2
-NH); 
13
C NMR (125 MHz, DMSO-d6) 13.8 (C
8
-CH3), 28.0 (N
9
-
CH3), 31.1 (-C(CH3)3), 34.3 (-C(CH3)3), 69.1 (OCH2Ar), 114.7 (C-Ar), 119.7 (C-Ar), 125.1 
(C-Ar), 127.1 (C-Ar), 127.5 (C-Ar), 134.4 (C-Ar), 134.6 (C-Ar), 146.6 (C-Ar), 150.1 (C-Ar), 
152.2 (C-Ar), 152.8 (C-Ar), 153.8 (C-Ar), 156.0 (C-Ar); HRMS calcd. for C24H28N5O (ES+) 
m/z 402.2285 [M+H]
+
, found 402.2288. 
1-(2-(4-Nitrophenoxy)ethyl)benzene (84)
241
 
 
Sodium hydride (60% dispersion in mineral oil, 0.17 g, 4.3 mmol) was added portion-wise to 
a solution of 2-phenylethanol (0.51 ml, 4.3 mmol) in dry THF (4 ml) at 0 °C. The suspension 
was allowed to warm to room-temperature, after which point a solution of 1-fluoro-4-
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nitrobenzene (0.500 g, 3.54 mmol) in dry THF (3 ml) was added drop-wise. The mixture was 
stirred at room-temperature for 18 h, after which point the solvent was removed in vacuo. 
The crude residue was purified via chromatography on silica (4:1 Petrol/EtOAc) to give the 
desired compound as a yellow oil (0.868 g, 3.57 mmol, 84%). Rf 0.64 (4:1 Petrol/EtOAc); 
λmax (EtOH/nm) 232, 323; IR (cm
-1
) 3116, 3025, 2935, 1591, 1507; 
1
H NMR (500 MHz, 
DMSO-d6) 3.09 (2H, t, J = 6.8 Hz, OCH2CH2), 4.36 (2H, t, J = 6.8 Hz, OCH2CH2), 7.16 (2H, 
d, J = 9.2 Hz, H-2/H-6), 7.22-7.26 (1H, m, H-4’), 7.30-7.37 (4H, m, H-2’/3’/5’/6’), 8.20 (2H, 
d, J = 9.2 Hz, H-3/H-5); 
13
C NMR (125 MHz, DMSO-d6) 34.6 (CH2CH2O), 69.1 
(CH2CH2O), 115.0 (C-Ar), 125.9 (C-Ar), 126.4 (C-Ar), 128.3 (C-Ar), 129.0 (C-Ar), 137.8 
(C-Ar), 140.8 (C-Ar), 163.7 (C-Ar); LRMS (ES+) m/z 244.3 [M+H]
+
. 
4-(Phenethyloxy)aniline (85)
242
 
 
Nitro aromatic 84 (0.651 g, 2.67 mmol), palladium on carbon (65 mg, 10% w/w) and 
ammonium formate (1.70 g, 26.7 mmol) were reacted in methanol (25 ml) according to 
general procedure G.  Silica gel chromatography (4:1 Petrol/EtOAc) afforded the target 
compound as an orange/red oil (0.307 g, 2.03 mmol, 82%). Rf 0.35 (4:1 Petrol/EtOAc); λmax 
(EtOH/nm) 229, 273; IR (cm
-1
) 3318, 3034, 2937, 2872, 1626, 1508; 
1
H NMR (500 MHz, 
DMSO-d6) 2.97 (2H, t, J = 6.9 Hz, OCH2CH2), 4.03 (2H, t, J = 6.9 Hz, OCH2CH2), 4.61 (2H, 
s, Ar-NH2), 6.50 (2H, d, J = 8.9 Hz, H-2/H-6), 6.65 (2H, d, J = 8.9 Hz, H-3/H-5), 7.20-7.25 
(1H, m, H-4’), 7.29-7.33 (4H, m, H-2’/3’/5’/6’); 13C NMR (125 MHz, DMSO-d6) 35.2 
(CH2CH2O), 68.7 (CH2CH2O), 114.9 (C-Ar), 115.4 (C-Ar), 126.1 (C-Ar), 128.2 (C-Ar), 
128.9 (C-Ar), 138.6 (C-Ar), 142.4 (C-Ar), 149.6 (C-Ar); LRMS (ES+) m/z 214.2 [M+H]
+
. 
8,9-Dimethyl-N-(4-(phenethyloxy)phenyl)-9H-purin-2-amine (86) 
 
2-Chloropurine intermediate 56 (50 mg, 0.27 mmol), aniline 84 (0.117 g, 0.55 mmol) and 
TFA (53 μl, 0.69 mmol) were reacted in TFE (1.5 ml) according to general procedure F. 
Purification via chromatography on silica (19:1 DCM/MeOH) afforded the desired compound 
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as a pale pink solid (66 mg, 0.18 mmol, 68%). Rf 0.19 (19:1 DCM/MeOH); M.p. 180-182 °C; 
λmax (EtOH/nm) 276; IR (cm
-1
) 3266, 3203, 3023, 2891, 1970, 1607, 1550; 
1
H NMR (500 
MHz, DMSO-d6) 2.52 (3H, s, C
8
-CH3), 3.03 (2H, t, J = 7.0 Hz, CH2), 3.64 (3H, s, N
9
-CH3), 
4.16 (2H, t, J = 7.0 Hz, CH2), 6.89 (2H, d, J = 8.9 Hz, H-3’/H-5’), 7.2-7.4 (5H, m, H-
2’’/3’’/4’’/5’’/6’’), 7.73 (2H, d, J = 8.9 Hz, H-2’/H-6’), 8.59 (1H, s, H-6), 9.32 (1H, s, C2-
NH); 
13
C NMR (125 MHz, DMSO-d6) 13.8 (C
8
-CH3), 27.9 (N
9
-CH3), 35.1 (CH2CH2O), 68.3 
(CH2CH2O), 114.4 (C-Ar), 119.7 (C-Ar), 126.2 (C-Ar), 128.3 (C-Ar), 128.9 (C-Ar), 134.5 
(C-Ar), 138.5 (C-Ar), 146.5 (C-Ar), 147.3 (C-Ar), 152.2 (C-Ar), 152.8 (C-Ar), 153.8 (C-Ar), 
156.0 (C-Ar); HRMS calcd. for C21H22N5O (ES+) m/z 360.1819 [M+H]
+
, found 360.1821. 
N-(4-Bromophenyl)-8,9-dimethyl-9H-purin-2-amine (90) 
 
2-Chloropurine intermediate 56 (0.200 g, 1.10 mmol), 4-bromoaniline (0.380 g, 2.20  mmol) 
and TFA (420 μl, 5.50 mmol) were reacted in TFE (6 ml) according to general procedure F. 
Purification via chromatography on KP-NH silica (1:1 Petrol/EtOAc) afforded the desired 
compound as a pale pink solid (0.247 g, 0.78 mmol, 71%). Rf 0.39 (1:1 Petrol/EtOAc, KP-
NH); M.p. 248-250 °C; λmax (EtOH/nm) 274, 323; IR (cm
-1
) 3362, 3110, 1619; 
1
H NMR (500 
MHz, DMSO-d6) 2.53 (3H, s, C
8
-CH3), 3.68 (3H, s, N
9
-CH3), 7.45 (2H, d, J = 9.0 Hz, H-
2’/H-6’), 7.86 (2H, d, J = 9.0 Hz, H-3’/H-5’), 8.67 (1H, s, H-6), 9.72 (1H, s, C2-NH); 13C 
NMR (125 MHz, DMSO-d6) 13.8 (C
8
-CH3), 28.1 (N
9
-CH3), 118.8 (C-Ar), 119.9 (C-Ar), 
131.1 (C-Ar), 146.5 (C-Ar), 155.4 (C-Ar); HRMS calcd. for C13H13N5Br (ES+) m/z 318.0349 
[M+H]
+
, found 318.0358. 
Note: Unable to visualise all carbon signals by NMR. 
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8,9-Dimethyl-N-(4-((triisopropylsilyl)ethynyl)phenyl)-9H-purin-2-amine (91) 
 
Acetonitrile (1 ml) and triisopropylsilylacetylene (65µl, 0.20 mmol) were added to a vial 
charged with arylbromide 90 (50 mg, 0.16 mmol), XPhos (4 mg, 0.008 mmol), 
PdCl2(CH3CN)2 (2 mg, 0.008 mmol) and Cs2CO3 (0.135 g, 0.41 mmol). The resultant mixture 
was degassed for 15 min, before being heated at 80 °C for 2 h. The reaction mixture was 
passed through Celite
®
 and evaporated to dryness, and the resultant residue was purified by 
reverse phase chromatography (9:1 MeOH/H2O, 0.1% HCOOH) to give the target compound 
as a pale orange oil/gum (62 mg, 0.15 mmol, 93%). Rf 0.17 (9:1 MeOH/H2O, 0.1% 
HCOOH); λmax (EtOH/nm) 302; IR (cm
-1
) 3257, 2940, 2864, 2145, 1601, 1513; 
1
H NMR 
(500 MHz, DMSO-d6) 1.02-1.18 (21H, m, Si(CH(CH3)2)3), 2.54 (3H, s, C
8
-CH3), 3.69 (3H, s, 
N
9
-CH3), 7.39 (2H, d, J = 8.8 Hz, H-3’/H-5’), 7.90 (2H, d, J = 8.8 Hz, H-2’/H-6’), 8.69 (1H, 
s, H-6), 9.86 (1H, s, C
2
-NH); 
13
C NMR (125 MHz, DMSO-d6) 10.8 (Si(CH(CH3)2)3), 13.8 
(C
8
-CH3), 18.5 (Si(CH(CH3)2)3), 28.1 (N
9
-CH3), 117.7 (C-Ar), 132.3 (C-Ar), 146.5 (C-Ar); 
HRMS calcd. for C24H34N5Si (ES+) m/z 420.2578 [M+H]
+
, found 420.2578. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
N-(4-Ethynylphenyl)-8,9-dimethyl-9H-purin-2-amine (87) 
 
The TIPS-protected purine 91 (50 mg, 0.15 mmol) and TBAF (1M in THF, 0.13 ml, 0.13 
mmol) were reacted in THF (5 ml) according to general procedure I. Silica gel 
chromatography (19:1 DCM/MeOH) afforded the desired compound as a white solid (12 mg, 
0.05 mmol, 42%). Rf 0.27 (19:1 DCM/MeOH); M.p. 210-214 °C; λmax (EtOH/nm) 294, 329; 
IR (cm
-1
) 3314, 3273, 2104, 1607, 1517; 
1
H NMR (500 MHz, DMSO-d6) 2.54 (3H,s, C
8
-
CH3), 3.68 (3H, s, N
9
-CH3), 4.01 (1H, s, C≡CH), 7.39 (2H, d, J = 8.7 Hz, H-3’/H-5’), 7.90 
(2H, d, J = 8.7 Hz, H-2’/H-6’), 8.69 (1H, s, H-6), 9.81 (1H, s, C2-NH); 13C NMR (125 MHz, 
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DMSO-d6) 13.8 (C
8
-CH3), 28.1 (N
9
-CH3), 79.0 (C≡CH), 84.2 (C≡CH), 113.1 (C-Ar), 117.6 
(C-Ar), 127.8 (C-Ar), 132.2 (C-Ar), 141.8 (C-Ar), 146.5 (C-Ar), 153.0 (C-Ar), 153.7 (C-Ar), 
155.2 (C-Ar); HRMS calcd. for C15H14N5 (ES+) m/z 264.1244 [M+H]
+
, found 264.1243. 
3-Fluoro-4-methoxyaniline (94)
243
 
 
2-Fluoro-4-nitroanisole (0.250 g, 1.46 mmol), palladium on carbon (25 mg, 10% w/w) and 
ammonium formate (0.920 g, 14.6 mmol) were reacted in methanol (15 ml) according to 
general procedure G. Purification by silica gel chromatography (7:3 Petrol/EtOAc) gave the 
product as an off-white solid (0.183 g, 1.30 mmol, 89%). Rf 0.38 (7:3 Petrol/EtOAc); M.p. 
80-83 °C (Lit.
243
 83-83.5 °C); λmax (EtOH/nm) 235, 296; IR (cm
-1
) 3412, 3307, 3212, 2971, 
2844, 2040, 1633, 1588, 1511; 
1
H NMR (500 MHz, DMSO-d6) 3.68 (3H, s, OCH3), 4.90 
(2H, s, Ar-NH2), 6.31 (1H, ddd, J = 1.3, 2.6 and 8.7 Hz, H-6), 6.41 (1H, dd, J = 2.6 and 13.9 
Hz, H-2), 6.84 (1H, dd, J = 8.7 and 9.8 Hz, H-5); 
13
C NMR (125 MHz, DMSO-d6) 57.0 
(OCH3), 102.1 (d, JCF = 20.5 Hz, C-Ar), 109.2 (d, JCF = 2.8 Hz, C-Ar), 116.1 (d, JCF = 2.7 
Hz, C-Ar), 137.5 (d, JCF = 11.0 Hz, C-Ar), 143.7 (d, JCF = 10.0 Hz, C-Ar), 152.4 (d, JCF = 
240.4 Hz, C-Ar); LRMS (ES+) m/z 142.1 [M+H]
+
. 
N-(3-fluoro-4-methoxyphenyl)-8,9-dimethyl-9H-purin-2-amine (92) 
 
3-Fluoro-4-methoxyaniline 94 (62 mg, 0.44 mmol), 2-chloropurine intermediate 56 (40 mg, 
0.22 mmol) and TFA (42 µl, 0.55 mmol) were reacted in TFE (2 ml) according to general 
procedure F. Chromatography on KP-NH silica (1:1 Petrol/EtOAc) gave the desired product 
was an off-white solid (39 mg, 0.14 mmol, 62%). Rf 0.27 (1:1 Petrol/EtOAc, KP-NH Si); 
M.p. 193-195 °C; λmax (EtOH/nm) 274.5, 329.5; IR (cm
-1
) 3356, 2934, 1978, 1621; 
1
H NMR 
(500 MHz, DMSO-d6) 2.52 (3H, s, C
8
-CH3), 3.66 (3H, s, N
9
-CH3), 3.81 (3H, s, OCH3), 7.10 
(1H, dd, J = 9.5 Hz, H-5’), 7.50-7.53 (1H, m, H-6’), 7.88 (1H, dd, J = 2.5 and 14.5 Hz, H-2’), 
, 8.64 (1H, s, H-6), 9.53 (1H, s, C
2
-NH); 
13
C NMR (125 MHz, DMSO-d6) 13.8 (C
8
-CH3), 
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28.0 (N
9
-CH3), 56.4 (OCH3), 113.8 (d, JCF = 2.1 Hz, C-Ar), 114.4 (d, JCF = 4.1 Hz, C-Ar), 
135.1 (d, JCF = 13.0 Hz, C-Ar), 146.5 (C-Ar); HRMS calcd. for C14H15FN5O (ES+) m/z 
288.1257 [M+H]
+
, found 288.1255. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
N-(3,5-Difluoro-4-methoxyphenyl)-8,9-dimethyl-9H-purin-2-amine (93) 
 
The 2-chloropurine intermediate 56 (80 mg, 0.44 mmol), 3,5-difluoro-4-methoxyaniline 
(0.140 g, 0.88 mmol) and TFA (85 µl, 1.10 mmol) were reacted in TFE (4 ml) according to 
general procedure F. Purification through chromatography on silica (19:1 DCM/MeOH) 
afforded the desired compound as a pale brown solid (26 mg, 0.09 mmol, 20%). Rf 0.23 (19:1 
DCM/MeOH); M.p. 239-241 °C; λmax (EtOH/nm) 273.5, 324.5; IR (cm
-1
) 3256, 3197, 3069, 
3003, 2834, 1611; 
1
H NMR (500 MHz, DMSO-d6) 2.54 (3H, s, C
8
-CH3), 3.68 (3H, s, N
9
-
CH3), 3.85 (3H, s, OCH3), 7.67 (2H, d, J = 11.7 Hz, H-2’/H-6’), 8.70 (1H, s, H-6), 9.84 (1H, 
s, C
2
-NH); 
13
C NMR (125 MHz, DMSO-d6) 13.8 (C
8
-CH3), 28.1 (N
9
-CH3), 62.0 (OCH3), 
101.5 (d, JCF = 27.8 Hz, C-Ar), 127.9 (C-Ar), 128.9 (C-Ar), 137.2 (dd, JCF = 13.4 and 13.7 
Hz, C-Ar), 146.5 (C-Ar), 153.2 (C-Ar), 153.6 (C-Ar), 155.0 (C-Ar), 155.1 (dd, JCF = 8.2 and 
241.9 Hz, Ar-CF); HRMS calcd. for C14H14F2N5O (ES+) m/z 306.1161 [M+H]
+
, found 
306.1163. 
2-Chloro-N-ethyl-5-nitropyrimidin-4-amine (102) 
 
2,4-Dichloro-5-nitropyrimidine (0.550 g, 2.84 mmol) and ethylamine (2M in THF, 4.70 ml, 
9.37 mmol) were reacted in THF (12 ml) according to general procedure C. 
Chromatography on silica (9:1 Petrol/EtOAc) afforded the target compound as a yellow solid 
(0.331 g, 1.63 mmol, 57%). Rf 0.41 (9:1 Petrol/EtOAc); M.p. 62-64 °C; λmax (EtOH/nm) 261, 
322; IR (cm
-1
) 3362, 2977, 2933, 2871, 1613, 1565; 
1
H NMR (500 MHz, DMSO-d6) 1.18 
(3H, t, J = 7.1 Hz, NHCH2CH3), 3.56 (2H, dt, J = 6.0 and 7.1  Hz, NHCH2CH3), 9.01 (1H, s, 
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H-6), 9.14-9.17 (1H, m, C
4
-NH); 
13
C NMR (125 MHz, DMSO-d6) 13.9 (CH3), 36.1 (CH2), 
127.2 (C-Ar), 154.7 (C-Ar), 157.3 (C-Ar), 162.4 (C-Ar); LRMS (ES+) m/z 203.2 
[M
35
Cl+H]
+
, 205.2 [M
37
Cl+H]
+
. 
2-Chloro-N-isopropyl-5-nitropyrimidin-4-amine (103) 
 
2,4-Dichloro-5-nitropyrimidine (0.520 g, 2.68 mmol) and isopropylamine (500 μl, 5.90 
mmol) were reacted in THF (12 ml) according to general procedure C. Purification via 
chromatography on silica (9:1 Petrol/EtOAc) afforded the desired compound as a yellow 
solid (0.403 g, 1.85 mmol, 69%). Rf 0.48 (9:1 Petrol/EtOAc); M.p. 84-87 °C; λmax (EtOH/nm) 
261, 348; IR (cm
-1
) 3354, 2985, 2931, 2881, 1565; 
1
H NMR (500 MHz, DMSO-d6) 1.27 (6H, 
d, J = 6.6 Hz, NHCH(CH3)2), 4.44 (1H, d sept, J = 6.6 and 7.8 Hz, NHCH(CH3)2), 8.60 (1H, 
d, J = 7.8 Hz, C
4
-NH), 9.02 (1H, s, H-6); 
13
C NMR (125 MHz, DMSO-d6) 21.6 (-CH(CH3)2), 
43.4 (-CH(CH3)2), 127.0 (C-Ar), 154.0 (C-Ar), 157.3 (C-Ar), 162.0 (C-Ar); LRMS (ES+) m/z 
217.2 [M
35
Cl+H]
+
, 219.2 [M
37
Cl+H]
+
. 
N-tert-Butyl-2-chloro-5-nitropyrimidin-4-amine (104) 
 
2,4-Dichloro-5-nitropyrimidine (0.519 g, 2.68 mmol) and tert-butylamine (620 μl, 5.90 
mmol) were reacted in THF (12 ml) according to general procedure C. Purification via 
chromatography on silica (9:1 Petrol/EtOAc) afforded the desired compound as a yellow 
solid (0.392 g, 1.70 mmol, 63%). Rf 0.55 (9:1 Petrol/EtOAc); M.p. 71-74 °C; λmax (EtOH/nm) 
234, 259, 363; IR (cm
-1
) 3336, 2981, 1573; 
1
H NMR (500 MHz, DMSO-d6) 1.51 (9H, s, 
NHC(CH3)3), 8.33 (1H, s, C
4
-NH), 9.04 (1H, s, H-6); 
13
C NMR (125 MHz, DMSO-d6) 28.1 
(-C(CH3)3), 53.7 (-C(CH3)3), 127.5 (C-Ar), 154.6 (C-Ar), 157.4 (C-Ar), 161.3 (C-Ar); LRMS 
(ES+) m/z 231.2 [M
35
Cl+H]
+
, 233.2 [M
37
Cl+H]
+
. 
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2-Chloro-N-isobutyl-5-nitropyrimidin-4-amine (105) 
 
2,4-Dichloro-5-nitropyrimidine (0.543 g, 2.80 mmol) and isobutylamine (610 μl, 6.16 mmol) 
were reacted in THF (12 ml) according to general procedure C. Purification via 
chromatography on silica (9:1 Petrol/EtOAc) afforded the desired compound as a yellow 
solid (0.225 g, 0.98 mmol, 35%). Rf 0.50 (9:1 Petrol/EtOAc); M.p. 66-69 °C; λmax (EtOH/nm) 
260, 367; IR (cm
-1
) 3386, 2970, 2936, 2873, 1572; 
1
H NMR (500 MHz, DMSO-d6) 0.91 (6H, 
d, J = 7.0 Hz, CH2CH(CH3)2), 2.00 (1H, sept, J = 7.0 Hz, CH2CH(CH3)2), 3.38 (2H, dd, J = 
6.2 and 7.0 Hz, CH2CH(CH3)2), 9.02 (1H, s, H-6), 9.08 (1H, t, J = 6.2 Hz, C
4
-NH); 
13
C NMR 
(125 MHz, DMSO-d6) 19.9 (CH2CH(CH3)2), 27.5 (CH2CH(CH3)2), 48.0 (CH2CH(CH3)2), 
127.3 (C-Ar), 155.1 (C-Ar), 157.3 (C-Ar), 162.3 (C-Ar); LRMS (ES+) m/z 231.2 
[M
35
Cl+H]
+
, 233.2 [M
37
Cl+H]
+
. 
2-Chloro-5-nitro-N-phenylpyrimidin-4-amine (106) 
 
2,4-Dichloro-5-nitropyrimidine (0.508 g, 2.63 mmol) and aniline (530 μl, 5.79 mmol) were 
reacted in THF (12 ml) according to general procedure C. Purification via chromatography 
on silica (9:1 Petrol/EtOAc) afforded the desired compound as an orange solid (0.226 g, 0.90 
mmol, 34%). Rf 0.42 (9:1 Petrol/EtOAc); M.p. 169-171 °C; λmax (EtOH/nm) 234, 274, 364; 
IR (cm
-1
) 3305, 3052, 1574; 
1
H NMR (500 MHz, DMSO-d6) 7.30 (1H, dddd, J = 1.2, 1.2, 7.4 
and 7.4 Hz, H-4’), 7.46 (2H, ddd, J = 1.2, 7.4 and 7.4 Hz, H-3’/H-5’), 7.55 (2H, ddd, J = 1.2, 
1.2 and 7.4 Hz, H-2’/H-6’), 9.17 (1H, s, H-6), 10.46 (1H, s, C4-NH); 13C NMR (125 MHz, 
DMSO-d6) 123.6 (C-Ar), 124.8 (C-Ar), 126.3 (C-Ar), 128.6 (C-Ar), 128.7 (C-Ar), 136.2 (C-
Ar), 153.8 (C-Ar), 157.6 (C-Ar); LRMS (ES+) m/z 251.2 [M
35
Cl+H]
+
, 253.2 [M
37
Cl+H]
+
. 
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N-Benzyl-2-chloro-5-nitropyrimidin-4-amine (107) 
 
2,4-Dichloro-5-nitropyrimidine (0.501 g, 2.58 mmol) and benzylamine (620 μl, 5.67 mmol) 
were reacted in THF (12 ml) according to general procedure C. Purification via 
chromatography on silica (9:1 Petrol/EtOAc) afforded the desired compound as a yellow 
solid (0.249 g, 0.94 mmol, 36%). Rf 0.38 (9:1 Petrol/EtOAc); M.p. 101-104 °C; λmax 
(EtOH/nm) 259, 357; IR (cm
-1
) 3066, 3033, 1739, 1574, 1376; 
1
H NMR (500 MHz, DMSO-
d6) 4.75 (2H, d, J = 6.2 Hz, NHCH2), 7.27 (1H, dddd, J = 1.4, 1.4, 7.1 and 7.1 Hz, H-4’), 
7.32-7.40 (4H, m, H-2’/H-3’/H-5’/H-6’), 9.05 (1H, s, H-6), 9.63 (1H, t, J = 6.2 Hz, NHCH2); 
13
C NMR (125 MHz, DMSO-d6) 44.2 (NHCH2), 127.1 (C-Ar), 127.4 (C-Ar), 127.5 (C-Ar), 
128.3 (C-Ar), 137.7 (C-Ar), 155.0 (C-Ar), 157.3 (C-Ar), 162.2 (C-Ar); LRMS (ES+) m/z 
265.2 [M
35
Cl+H]
+
, 267.2 [M
37
Cl+H]
+
. 
2-Chloro-5-nitro-N-(2,2,2-trifluoroethyl)pyrimidin-4-amine (108) 
 
2,4-Dichloro-5-nitropyrimidine (0.602 g, 3.09 mmol) and 2,2,2-trifluoroethylamine (730 µl, 
9.28 mmol) were reacted in THF (15 ml) according to general procedure C. Purification by 
silica gel chromatography (9:1 Petrol/EtOAc) gave the desired compound as a pale yellow 
solid (0.497 g, 1.93 mmol, 62%). Rf 0.54 (9:1 Petrol/EtOAc); M.p. 280-282 °C; λmax 
(EtOH/nm) 225, 314; IR (cm
-1
) 3333, 3178, 3035, 1687, 1622, 1568, 1515; 
1
H NMR (500 
MHz, CDCl3) 4.40 (2H, dq, J = 6.4 and 8.6 Hz, CH2), 8.57 (1H, br, NH), 9.13 (1H, s, H-6); 
13
C NMR (125 MHz, CDCl3) 42.0 (q, JCF = 35.4 Hz, CH2), 123.5 (q, JCF = 279.6 Hz, CF3), 
127.2 (C-Ar), 156.1 (C-Ar), 157.5 (C-Ar), 164.5 (C-Ar); LRMS (ES+) m/z 257.1 
[M
35
Cl+H]
+
, 259.1[M
37
Cl+H]
+
. 
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2-Chloro-5-nitro-N-(3,3,3-trifluoropropyl)pyrimidin-4-amine (109) 
 
3,3,3-Trifluoropropylamine hydrochloride (0.118 g, 0.78 mmol) was added to a mixture of 
2,4-dichloro-5-nitropyrimidine (0.100 g, 0.52 mmol) and cesium carbonate (0.423 g, 1.30 
mmol) in THF (5 ml) at 0 °C. After stirring at 0 °C for 20 mins, the reaction mixture was 
filtered, and the filtrate was concentrated in vacuo. The resultant residue was purified by 
chromatography on silica (9:1 Petrol/EtOAc) to give the target compound as a yellow solid 
(91 mg, 0.34 mmol, 65%). Rf 0.44 (9:1 Petrol/EtOAc); M.p. 176-179 °C; λmax (EtOH/nm) 
228, 324; IR (cm
-1
) 3056, 2651, 1751, 1649, 1538; 
1
H NMR (500 MHz, CDCl3) 2.58 (2H, tq, 
J = 6.5 and 10.5 Hz, CH2CF3), 3.98 (2H, t, J = 6.5 Hz, NHCH2), 8.58 (1H, br, NH), 9.11 (1H, 
s, H-6); 
13
C NMR (125 MHz, DMSO-d6) 33.2 (q, JCF = 28.5 Hz, CH2CF3), 35.0 (q, JCF = 3.5 
Hz, NHCH2), 155.7 (C-Ar), 157.2 (C-Ar), 158.2 (C-Ar); LRMS (ES+) m/z 271.1 
[M
35
Cl+H]
+
, 273.1 [M
37
Cl+H]
+
. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
2-Chloro-N
4
-ethylpyrimidine-4,5-diamine (110)
244
 
 
5-Nitropyrimidine 102 (0.298 g, 1.47 mmol) and tin(II) chloride (1.12 g, 5.88 mmol) were 
reacted in ethanol (6 ml) according to general procedure D. Purification via chromatography 
on silica (9:1 DCM/MeOH) afforded the desired compound as a beige solid (0.178 g, 1.03 
mmol, 70%). Rf 0.38 (9:1 DCM/MeOH); M.p. 102-104 °C; λmax (EtOH/nm) 260, 306; IR 
(cm
-1
) 3385, 3359, 3326, 3249, 3036, 2972, 1584; 
1
H NMR (500 MHz, DMSO-d6) 1.17 (3H, 
t, J = 7.2 Hz, NHCH2CH3), 3.35 (2H, dt, J = 5.0 and 7.2 Hz,  NHCH2CH3), 4.88 (2H, s, C
5
-
NH2), 6.84 (1H, t, J = 5.0 Hz, C
4
-NH), 7.37 (1H, s, H-6); 
13
C NMR (125 MHz, DMSO-d6) 
14.2 (CH3), 35.2 (CH2), 127.0 (C-Ar), 135.5 (C-Ar), 147.1 (C-Ar), 153.5 (C-Ar); LRMS 
(ES+) m/z 173.1 [M
35
Cl+H]
+
, 175.1 [M
37
Cl+H]
+
. 
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2-Chloro-N
4
-isopropylpyrimidine-4,5-diamine (111) 
 
5-Nitropyrimidine 103 (0.324 g, 1.50 mmol) and tin(II) chloride (1.13 g, 5.98 mmol) were 
reacted in ethanol (6 ml) according to general procedure D. Purification via chromatography 
on silica (9:1 DCM/MeOH) afforded the desired compound as a beige solid (0.238 g, 1.28 
mmol, 85%). Rf 0.45 (9:1 DCM/MeOH); M.p. 111-113 °C; λmax (EtOH/nm) 263, 309; IR 
(cm
-1
) 3345, 3248, 2970, 1584; 
1
H NMR (500 MHz, DMSO-d6) 1.19 (6H, d, J = 6.5 Hz, 
NHCH(CH3)2), 4.14 (1H, d sept, J = 6.5 and 7.2 Hz, NHCH(CH3)2), 4.92 (2H, s, C
5
-NH2), 
6.59 (1H, d, J = 7.2 Hz, C
4
-NH), 7.36 (1H, s, H-6); 
13
C NMR (125 MHz, DMSO-d6) 22.2 (-
CH(CH3)2), 41.9 (-CH(CH3)2), 126.9 (C-Ar), 135.5 (C-Ar), 147.0 (C-Ar), 152.7 (C-Ar); 
HRMS calcd. for C7H12N4Cl (ES+) m/z 187.0745 [M+H]
+
, found 187.0745. 
N
4
-tert-Butyl-2-chloropyrimidine-4,5-diamine (112) 
 
5-Nitropyrimidine 104 (0.337 g, 1.46 mmol) and tin(II) chloride (1.11 g, 5.85 mmol) were 
reacted in ethanol (6 ml) according to general procedure D. Purification via chromatography 
on silica (9:1 DCM/MeOH) afforded the desired compound as an off-white solid (0.250 g, 
1.25 mmol, 86%). Rf 0.48 (9:1 DCM/MeOH); M.p. 123-125 °C; λmax (EtOH/nm) 221, 298; 
IR (cm
-1
) 3340, 3242, 3197, 2965, 2934, 1579; 
1
H NMR (500 MHz, DMSO-d6) 1.43 (9H, s, 
NHC(CH3)3), 5.00 (2H, s, C
5
-NH2), 6.08 (1H, s, C
4
-NH), 7.37 (1H, s, H-6); 
13
C NMR (125 
MHz, DMSO-d6) 28.4 (-C(CH3)3), 51.7 (-C(CH3)3), 127.4 (C-Ar), 135.9 (C-Ar), 146.2 (C-
Ar), 153.0 (C-Ar); HRMS calcd. for C8H14N4Cl (ES+) m/z 201.0902 [M+H]
+
, found 
201.0902. 
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2-Chloro-N
4
-isobutylpyrimidine-4,5-diamine (113) 
 
5-Nitropyrimidine 105 (0.190 g, 0.82 mmol) and tin(II) chloride (0.625 g, 3.29 mmol) were 
reacted in ethanol (4 ml) according to general procedure D. Purification via chromatography 
on silica (9:1 DCM/MeOH) afforded the desired compound as a orange/brown oil (0.111 g, 
0.55 mmol, 67%). Rf 0.50 (9:1 DCM/MeOH); λmax (EtOH/nm) 260, 311; IR (cm
-1
) 3351, 
3254, 2959, 2871, 2360, 1585; 
1
H NMR (500 MHz, DMSO-d6) 0.92 (6H, d, J = 6.7 Hz, 
NHCH2CH(CH3)2), 1.89 (1H, sept, J = 6.7 Hz, NHCH2CH(CH3)2), 3.16 (2H, dd, J = 5.5 and 
6.7 Hz, NHCH2CH(CH3)2), 4.93 (2H, s, C
5
-NH2), 6.80 (1H, t, J = 5.5 Hz, C
4
-NH), 7.37 (1H, 
s, H-6); 
13
C NMR (125 MHz, DMSO-d6) 20.2 (CH2CH(CH3)2), 27.4 (CH2CH(CH3)2), 47.9 
(CH2CH(CH3)2), 126.9 (C-Ar), 135.5 (C-Ar), 146.9 (C-Ar), 153.7 (C-Ar); LRMS (ES+) m/z 
201.2 [M
35
Cl+H]
+
, 203.2 [M
37
Cl+H]
+
. 
2-Chloro-N
4
-phenylpyrimidine-4,5-diamine (114) 
 
5-Nitropyrimidine 106 (0.220 g, 0.88 mmol) and tin(II) chloride (0.665 g, 3.51 mmol) were 
reacted in ethanol (4 ml) according to general procedure D. Purification via chromatography 
on silica (9:1 DCM/MeOH) afforded the desired compound as a brown oil (0.179 g, 0.81 
mmol, 92%). Rf 0.28 (9:1 DCM/MeOH); λmax (EtOH/nm) 270, 318; IR (cm
-1
) 3347, 3284, 
2360, 1570; 
1
H NMR (500 MHz, DMSO-d6) 5.32 (2H, s, C
5
-NH2), 7.07 (1H, dddd, J = 1.1, 
1.1, 7.3 and 7.3 Hz, H-4’), 7.36 (2H, ddd, J = 1.1, 7.3 and 7.3 Hz, H-3’/H-5’), 7.66 (1H, s, H-
6), 7.68 (2H, ddd, J = 1.1, 1.1 and 7.3 Hz, H-2’/H-6’), 8.64 (1H, s, C4-NH); 13C NMR (125 
MHz, DMSO-d6) 120.4 (C-Ar), 122.9 (C-Ar), 128.0 (C-Ar), 128.7 (C-Ar), 138.5 (C-Ar), 
139.2 (C-Ar), 145.7 (C-Ar), 150.2 (C-Ar); HRMS calcd. for C10H10N4Cl (ES+) m/z 221.0589 
[M+H]
+
, found 221.0591. 
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N
4
-Benzyl-2-chloropyrimidine-4,5-diamine (115) 
 
5-Nitropyrimidine 107 (0.219 g, 0.83 mmol) and tin(II) chloride (0.631 g, 3.31 mmol) were 
reacted in ethanol (4 ml) according to general procedure D. Purification via chromatography 
on silica (9:1 DCM/MeOH) afforded the desired compound as a brown/red solid (0.152 g, 
0.65 mmol, 78%). Rf 0.37 (9:1 DCM/MeOH); M.p. 186-188 °C; λmax (EtOH/nm) 260, 311; 
IR (cm
-1
) 3423, 3356, 3300, 3250, 3026, 2869, 1580; 
1
H NMR (500 MHz, DMSO-d6) 4.58 
(2H, d, J = 5.7 Hz, NHCH2), 4.97 (2H, s, C
5
-NH2), 7.25-7.29 (1H, m, H-4’), 7.32-7.39 (5H, 
m, C
4
-NH/H-2’/H-3’/H-5’/H-6’), 7.43 (1H, s, H-6); 13C NMR (125 MHz, DMSO-d6) 43.7 
(NHCH2), 126.9 (C-Ar), 127.1 (C-Ar), 127.5 (C-Ar), 128.3 (C-Ar), 136.0 (C-Ar), 139.0 (C-
Ar), 146.8 (C-Ar), 153.4 (C-Ar); HRMS calcd. for C11H12N4Cl (ES+) m/z 235.0745 [M+H]
+
, 
found 235.0750. 
2-Chloro-N
4
-(2,2,2-trifluoroethyl)pyrimidine-4,5-diamine (116) 
 
The nitropyrimidine 108 (0.461 g, 1.80 mmol) and tin(II) chloride (1.36 g, 7.20 mmol) were 
reacted in ethanol (18 ml) according to general procedure D. Purification on silica (9:1 
DCM/MeOH) afforded the desired compound as a red waxy solid (0.342 g, 1.51 mmol, 
84%). Rf 0.33 (9:1 DCM/MeOH); M.p. 137-139 °C; λmax (EtOH/nm) 259, 303; IR (cm
-1
) 
3429, 3344, 3258, 3057, 1588; 
1
H NMR (500 MHz, CDCl3) 3.08 (2H, br, C
5
-NH2), 4.23 (2H, 
dq, J = 6.6 and 8.9 Hz, CH2), 5.38 (1H, br, C
4
-NH), 7.75 (1H, s, H-6); 
13
C NMR (125 MHz, 
CDCl3) 41.8 (q, JCF = 35.3, CH2), 123.9 (C-Ar) 124.3 (q, JCF = 278.9 Hz, CF3), 144.3 (C-Ar), 
152.7 (C-Ar), 156.6 (C-Ar); HRMS calcd. for C6H7ClF3N4 (ES+) m/z 227.0306 [M+H]
+
, 
found 227.0310. 
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2-Chloro-N
4
-(3,3,3-trifluoropropyl)pyrimidine-4,5-diamine (117) 
 
The nitropyrimidine 109 (0.506 g, 1.87 mmol) and tin(II) chloride (1.42 g, 7.48 mmol) were 
reacted in ethanol (19 ml) according to general procedure D. Silica chromatography (9:1 
DCM/MeOH) gave the target compound as a red oil (0.394 g, 1.64 mmol, 88%). Rf 0.36 (9:1 
DCM/MeOH); λmax (EtOH/nm) 262, 302; IR (cm
-1
) 3340, 3247, 3045, 1586; 
1
H NMR (500 
MHz, CDCl3) 2.49 (2H, tq, J = 6.4 and 10.8 Hz, CH2CF3), 2.99 (2H, br, C
5
-NH2), 3.78 (2H, 
q, J = 6.4 Hz, NHCH2), 5.33 (1H, br, C
4
-NH), 7.66 (1H, s, H-6); 
13
C NMR (125 MHz, 
CDCl3) 33.3 (q, JCF = 27.6 Hz, CH2CF3), 34.5 (q, JCF = 3.4 Hz, NHCH2), 123.8 (C-Ar), 126.6 
(q, JCF = 276.5 Hz, CF3), 142.9 (C-Ar), 152.9 (C-Ar), 156.9 (C-Ar); HRMS calcd. for 
C7H9ClF3N4 (ES+) m/z 241.0462 [M+H]
+
, found 241.0466. 
2-Chloro-9-ethyl-8-methyl-9H-purine (118) 
 
Diaminopyrimidine 110 (0.157 g, 0.91 mmol), triethyl orthoacetate (430 μl, 2.27 mmol) and 
TFA (7 μl, 0.09 mmol) were reacted in TFE (5 ml) according to general procedure E. 
Purification via chromatography on silica (19:1 DCM/MeOH) afforded the desired compound 
as a pale yellow solid (0.140 g, 0.71 mmol, 78%). Rf 0.36 (19:1 DCM/MeOH); M.p. 103-105 
°C; λmax (EtOH/nm) 224, 264; IR (cm
-1
) 2975, 1600; 
1
H NMR (500 MHz, DMSO-d6) 1.31 
(3H, t, J = 7.2 Hz, N
9
-CH2CH3), 2.61 (3H, s, C
8
-CH3), 4.19 (2H, q, J = 7.2 Hz, N
9
-CH2CH3), 
8.82 (1H, s, H-6); 
13
C NMR (125 MHz, DMSO-d6) 13.8 (C
8
-CH3), 14.2 (CH2CH3), 37.5 
(CH2CH3), 132.2 (C-Ar), 147.2 (C-Ar), 151.8 (C-Ar), 153.9 (C-Ar), 157.0 (C-Ar); HRMS 
calcd. for C8H10N4Cl (ES+) m/z 197.0589 [M+H]
+
, found 197.0589. 
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2-Chloro-9-isopropyl-8-methyl-9H-purine (119) 
 
Diaminopyrimidine 111 (0.181 g, 0.97 mmol), triethyl orthoacetate (455 μl, 2.42 mmol) and 
TFA (7 μl, 0.10 mmol) were reacted in TFE (5 ml) according to general procedure E. 
Purification via chromatography on silica (19:1 DCM/MeOH) afforded the desired compound 
as a pale yellow solid (0.118 g, 0.56 mmol, 58%). Rf 0.46 (19:1 DCM/MeOH); M.p. 133-136 
°C; λmax (EtOH/nm) 260; IR (cm
-1
) 2987, 1597; 
1
H NMR (500 MHz, DMSO-d6) 1.57 (6H, d, 
J = 6.8 Hz, N
9
-CH(CH3)2), 2.62 (3H, s, C
8
-CH3), 4.74 (1H, sept, J = 6.8 Hz, N
9
-CH(CH3)2), 
8.82 (1H, s, H-6); 
13
C NMR (125 MHz, DMSO-d6) 14.7 (C
8
-CH3), 20.4 (N
9
-CH(CH3)2), 48.4 
(N
9
-CH(CH3)2), 132.3 (C-Ar), 147.4 (C-Ar), 150.7 (C-Ar), 153.8 (C-Ar), 157.0 (C-Ar); 
HRMS calcd. for C9H12N4Cl (ES+) m/z 211.0745 [M+H]
+
, found 211.0747. 
2-Chloro-9-isobutyl-8-methyl-9H-purine (120) 
 
Diaminopyrimidine 113 (0.105 g, 0.52 mmol), triethyl orthoacetate (245 μl, 1.31 mmol) and 
TFA (4 μl, 0.05 mmol) were reacted in TFE (3 ml) according to general procedure E. 
Purification via chromatography on silica (19:1 DCM/MeOH) afforded the desired compound 
as a pale yellow solid (74 mg, 0.33 mmol, 63%). Rf 0.36 (19:1 DCM/MeOH); M.p. 101-104 
°C; λmax (EtOH/nm) 219, 275; IR (cm
-1
) 2965, 1595; 
1
H NMR (500 MHz, DMSO-d6) 0.88 
(6H, d, J = 6.8 Hz, -CH(CH3)2), 2.20 (1H, d sept, J = 6.8 and 7.8 Hz, -CH(CH3)2), 2.63 (3H, 
s, C
8
-CH3), 4.01 (2H, d, J = 7.8 Hz, N
9
-CH2), 8.90 (1H, s, H-6); 
13
C NMR (125 MHz, 
DMSO-d6) 14.3 (C
8
-CH3), 19.6 (CH3), 28.0 (CH), 49.4 (CH2), 132.3 (C-Ar), 147.6 (C-Ar), 
151.8 (C-Ar), 154.6 (C-Ar), 157.0 (C-Ar); HRMS calcd. for C10H14N4Cl (ES+) m/z 225.0902 
[M+H]
+
, found 225.0905. 
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2-Chloro-8-methyl-9-phenyl-9H-purine (121) 
 
Diaminopyrimidine 114 (0.175 g, 0.79 mmol), triethyl orthoacetate (370 μl, 1.98 mmol) and 
TFA (6 μl, 0.08 mmol) were reacted in TFE (4 ml) according to general procedure E over 
2.5 h. Purification via chromatography on silica (19:1 DCM/MeOH) afforded the desired 
compound as a orange solid (0.156 g, 0.64 mmol, 81%). Rf 0.44 (19:1 DCM/MeOH); M.p. 
157-160 °C; λmax (EtOH/nm) 227, 274; IR (cm
-1
) 3060, 1588; 
1
H NMR (500 MHz, DMSO-
d6) 2.49 (C
8
-CH3), 7.58-7.68 (5H, m, H-2’/3’/4’/5’/6’), 9.01 (1H, s, H-6); 
13
C NMR (125 
MHz, DMSO-d6) 14.7 (C
8
-CH3), 127.5 (C-Ar), 129.6 (C-Ar), 129.8 (C-Ar), 132.5 (C-Ar), 
132.9 (C-Ar), 148.0 (C-Ar), 152.4 (C-Ar), 154.9 (C-Ar), 156.4 (C-Ar); HRMS calcd. for 
C12H10N4Cl (ES+) m/z 245.0589 [M+H]
+
, found 245.0594. 
9-Benzyl-2-chloro-8-methyl-9H-purine (122) 
 
Diaminopyrimidine 115 (0.122 g, 0.52 mmol), triethyl orthoacetate (245 μl, 1.30 mmol) and 
TFA (4 μl, 0.05 mmol) were reacted in TFE (3 ml) according to general procedure E. 
Purification via chromatography on silica (19:1 DCM/MeOH) afforded the desired compound 
as a pale pink solid (97 mg, 0.38 mmol, 73%). Rf 0.42 (19:1 DCM/MeOH); M.p. 128-130 °C; 
λmax (EtOH/nm) 223, 273; IR (cm
-1
) 3031, 1598; 
1
H NMR (500 MHz, DMSO-d6) 2.54 (3H, s, 
C
8
-CH3), 5.46 (2H, s, N
9
-CH2), 7.17-7.21 (2H, m, H-2’/H-6’), 7.29-7.38 (3H, m, H-3’/H-
4’/H-5’), 8.94 (1H, s, H-6); 13C NMR (125 MHz, DMSO-d6) 14.2 (C
8
-CH3), 45.2 (N
9
-CH2), 
126.9 (C-Ar), 127.9 (C-Ar), 128.9 (C-Ar), 132.3 (C-Ar), 135.5 (C-Ar), 147.8 (C-Ar), 152.1 
(C-Ar), 154.4 (C-Ar), 156.9 (C-Ar); HRMS calcd. for C13H12N4Cl (ES+) m/z 259.0745 
[M+H]
+
, found 259.0752. 
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2-Chloro-8-methyl-9-(2,2,2-trifluoroethyl)-9H-purine (123) 
 
The diaminopyrimidine 116 (0.297 g, 1.31 mmol), triethyl orthoacetate (615 µl, 3.28 mmol) 
and TFA (10 µl, 0.13 mmol) were reacted in TFE (13 ml) according to general procedure E. 
Purification on silica (9:1 DCM/MeOH) gave the desired compound as a beige solid (0.250 g, 
1.00 mmol, 76%). Rf 0.41 (9:1 DCM/MeOH); M.p. 140-143 °C; λmax (EtOH/nm) 273; IR 
(cm
-1
) 3000, 2955, 1599, 1577; 
1
H NMR (500 MHz, DMSO-d6) 2.68 (3H, s, C
8
-CH3), 5.29 
(2H, q, J = 9.2 Hz, CH2CF3), 9.02 (1H, s, H-6); 
13
C NMR (125 MHz, DMSO-d6) 13.9 (CH3), 
42.9 (q, JCF = 35.1 Hz, CH2CF3), 123.7 (q, JCF = 279.5 Hz, CF3), 132.3 (C-Ar), 140.5 (C-Ar), 
152.4 (C-Ar), 154.6 (C-Ar), 156.9 (C-Ar); HRMS calcd. for C8H7ClF3N4 (ES+) m/z 251.0306 
[M+H]
+
, found 251.0310. 
2-Chloro-8-methyl-9-(3,3,3-trifluoropropyl)-9H-purine (124) 
 
The diaminopyrimidine 117 (0.262 g, 1.09 mmol), triethyl orthoacetate (510 µl, 2.72 mmol) 
and TFA (8 µl, 0.11 mmol) were reacted in TFE (11 ml) according to general procedure E. 
Chromatography on silica (9:1 DCM/MeOH) gave the target compound as a beige solid 
(0.214 g, 0.81 mmol, 74%). Rf 0.43 (9:1 DCM/MeOH); M.p. 81-84 °C; λmax (EtOH/nm) 274; 
IR (cm
-1
) 3045, 1599, 1523; 
1
H NMR (500 MHz, DMSO-d6) 2.68 (3H, s, C
8
-CH3), 2.94 (2H, 
tq, J = 7.0 and 11.3 Hz, CH2CF3), 4.48 (2H, t, J = 7.0 Hz, N
9
-CH2), 8.94 (1H, s, H-6); 
13
C 
NMR (125 MHz, DMSO-d6) 14.0 (CH3), 31.7 (q, JCF = 27.9 Hz, CH2CF3), 35.8 (q, JCF = 3.6 
Hz, N-CH2), 126.3 (q, JCF = 277.8 Hz, CF3), 132.5 (C-Ar), 147.7 (C-Ar), 151.9 (C-Ar), 154.3 
(C-Ar), 156.7 (C-Ar); HRMS calcd. for C9H9ClF3N4 (ES+) m/z 265.0462 [M+H]
+
, found 
265.0469. 
  
277 
 
9-Ethyl-N-(4-methoxyphenyl)-8-methyl-9H-purin-2-amine (96) 
 
N
9
-Ethylpurine 118 (30 mg, 0.15 mmol), 4-methoxyaniline (38 mg, 0.31 mmol) and TFA (60 
μl, 0.77 mmol) were reacted in TFE (1 ml) according to general procedure F. Purification 
via chromatography on KP-NH silica (1:1 Petrol/EtOAc) afforded the desired compound as a 
pink solid (21 mg, 0.07 mmol, 49%). Rf 0.20 (1:1 Petrol/EtOAc, KP-NH); M.p. 160-163 °C; 
λmax (EtOH/nm) 250, 335; IR (cm
-1
) 3252, 3197, 3054, 3004, 1617; 
1
H NMR (500 MHz, 
DMSO-d6) 1.35 (3H, t, J = 7.3 Hz, -CH2CH3), 2.54 (3H, s, C
8
-CH3), 3.73 (3H, s, OCH3), 4.15 
(2H, q, J = 7.3 Hz, -CH2CH3), 6.88 (2H, d, J = 9.1 Hz, H-3’/H-5’), 7.73 (2H, d, J = 9.1 Hz, 
H-2’/H-6’), 8.60 (1H, s, H-6), 9.31 (1H, s, C2-NH); 13C NMR (125 MHz, DMSO-d6) 13.7 
(CH2CH3), 14.5 (C
8
-CH3), 36.7 (CH2CH3), 55.1 (OCH3), 113.7 (C-Ar), 119.7 (C-Ar), 128.7 
(C-Ar), 134.4 (C-Ar), 142.1 (C-Ar), 154.2 (C-Ar); HRMS calcd. for C15H18N5O (ES+) m/z 
284.1506 [M+H]
+
, found 284.1508. 
Note: Unable to visualise all carbon signals by NMR. 
9-Isobutyl-N-(4-methoxyphenyl)-8-methyl-9H-purin-2-amine (97) 
 
N
9
-isobutylpurine 120 (30 mg, 0.13 mmol), 4-methoxyaniline (33 mg, 0.27 mmol) and TFA 
(50 μl, 0.67 mmol) were reacted in TFE (1 ml) according to general procedure F. 
Purification via chromatography on KP-NH silica (1:1 Petrol/EtOAc) afforded the desired 
compound as a pink solid (19 mg, 0.06 mmol, 47%). Rf 0.24 (1:1 Petrol/EtOAc, KP-NH); 
M.p. 152-154 °C; λmax (EtOH/nm) 252, 332; IR (cm
-1
) 3246, 3193, 3116, 2956, 2021, 1619; 
1
H NMR (500 MHz, DMSO-d6) 0.93 (6H, d, J = 6.8 Hz, -CH(CH3)2), 2.20-2.26 (1H, m, -
CH(CH3)2), 2.52 (3H, s, C
8
-CH3), 3.73 (3H, s, OCH3), 3.92 (2H, d, J = 7.5 Hz, N
9
-CH2), 6.88 
(2H, d, J = 9.1 Hz, H-3’/H-5’), 7.73 (2H, d, J = 9.1 Hz, H-2’/H-6’), 8.61 (1H, s, H-6), 9.30 
(1H, s, C
2
-NH); 
13
C NMR (125 MHz, DMSO-d6) 14.2 (C
8
-CH3), 19.9 (CH(CH3)2), 28.4 
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(CH(CH3)2), 49.2 (N
9
-CH2), 55.2 (OCH3), 113.6 (C-Ar), 119.7 (C-Ar), 135.6 (C-Ar), 154.3 
(C-Ar); HRMS calcd. for C17H22N5O (ES+) m/z 312.1822 [M+H]
+
, found 312.1819. 
Note: Unable to visualise all carbon signals by NMR. 
N-(4-Methoxyphenyl)-8-methyl-9-phenyl-9H-purin-2-amine (98) 
 
N
9
-Phenylpurine 121 (30 mg, 0.14 mmol), 4-methoxyaniline (36 mg, 0.29 mmol) and TFA 
(55 μl, 0.71 mmol) were reacted in TFE (1 ml) according to general procedure F. KP-NH 
silica gel chromatography (1:1 Petrol/EtOAc) gave the target compound as a pale pink solid 
(14 mg, 0.05 mmol, 36%). Rf 0.26 (1:1 Petrol/EtOAc, KP-NH); M.p. 192-195 °C; λmax 
(EtOH/nm) 276; IR (cm
-1
) 3267, 3119, 2162, 1603; 
1
H NMR (500 MHz, DMSO-d6) 2.42 
(3H, s, C
8
-CH3), 3.70 (3H, s, OCH3), 6.79 (2H, d, J = 9.0 Hz, H-3’/H-5’), 7.57-7.67 (7H, m, 
H-2’/H-6’ & H-2’’/3’’/4’’/5’’/6’’), 8.72 (1H, s, H-6), 9.32 (1H, s, C2-NH); 13C NMR (125 
MHz, DMSO-d6) 14.6 (C
8
-CH3), 55.1 (OCH3), 113.6 (C-Ar), 119.9 (C-Ar), 127.4 (C-Ar), 
128.9 (C-Ar), 129.5 (C-Ar), 134.2 (C-Ar), 139.5 (C-Ar), 139.8 (C-Ar), 147.1 (C-Ar), 153.7 
(C-Ar); HRMS calcd. for C19H18N5O (ES+) m/z 332.1506 [M+H]
+
, found 332.1508. 
Note: Unable to visualise all carbon signals by NMR. 
9-Benzyl-N-(4-methoxyphenyl)-8-methyl-9H-purin-2-amine (99) 
 
N
9
-Benzylpurine 122 (30 mg, 0.12 mmol), 4-methoxyaniline (28 mg, 0.23 mmol) and TFA 
(45 μl, 0.58 mmol) were reacted in TFE (1 ml) according to general procedure F. 
Purification via chromatography on KP-NH silica (1:1 Petrol/EtOAc) afforded the desired 
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compound as a pink solid (16 mg, 0.05 mmol, 42%). Rf 0.24 (1:1 Petrol/EtOAc); M.p. 185-
187 °C; λmax (EtOH/nm) 275; IR (cm
-1
) 3248, 3194, 2956, 2922, 2362, 1617; 
1
H NMR (500 
MHz, DMSO-d6) 2.46 (3H, s, C
8
-CH3), 3.72 (3H, s, OCH3), 5.37 (2H, s, N
9
-CH2), 6.86 (2H, 
d, J = 9.1 Hz, H-3’/H-5’), 7.25-7.28 (2H, m, H-2’’/H-6’’), 7.28-7.32 (1H, m, H-4’’), 7.35-
7.39 (2H, m, H-3’’/H-5’’), 7.69 (2H, d, J = 9.1 Hz, H-2’/H-6’), 8.65 (1H, s, H-6), 9.35 (1H, s, 
C
2
-NH); 
13
C NMR (125 MHz, DMSO-d6) 55.2 (OCH3), 113.7 (C-Ar), 119.8 (C-Ar), 127.0 
(C-Ar), 128.8 (C-Ar), 135.2 (C-Ar), 140.5 (C-Ar), 141.5 (C-Ar), 148.0 (C-Ar), 156.6 (C-Ar); 
HRMS calcd. for C20H19N5O (ES+) m/z 346.1665 [M+H]
+
, found 346.1662. 
Note: Unable to visualise all carbon signals by NMR. 
N-(4-methoxyphenyl)-8-methyl-9-(2,2,2-trifluoroethyl)-9H-purin-2-amine (100) 
 
The 2-chloropurine intermediate 123 (98 mg, 0.39 mmol), 4-methoxyaniline (0.100 g, 0.80 
mmol) and TFA (77 µl, 1.00 mmol) were reacted in TFE (4 ml) according to general 
procedure F. Purification on KP-NH silica (1:1 Petrol/EtOAc) afforded the desired 
compound as an off-white solid (89 mg, 0.27 mmol, 68%). Rf 0.21 (1:1 Petrol/EtOAc, KP-
NH); M.p. 187-189 °C; λmax (EtOH/nm) 275, 329; IR (cm
-1
) 3253, 3199, 3125, 3070, 2965, 
2836, 2361, 1621; 
1
H NMR (500 MHz, DMSO-d6) 2.56 (3H, s, C
8
-CH3), 3.74 (3H, s, OCH3), 
5.11 (2H, q, J = 9.0 Hz, CH2CF3), 6.88 (2H, d, J = 9.2 Hz, H-3’/H-5’), 7.73 (2H, d, J = 9.2 
Hz, H-2’/H-6’), 8.68 (1H, s, H-6), 9.45 (1H, s, C2-NH); 13C NMR (125 MHz, DMSO-d6) 13.6 
(C
8
-CH3), 55.2 (OCH3), 113.7 (C-Ar), 120.0 (C-Ar), 126.6 (C-Ar), 134.0 (C-Ar), 147.6 (C-
Ar), 151.3 (C-Ar), 153.9 (C-Ar), 156.4 (C-Ar); HRMS calcd. for C15H15F3N5O (ES+) m/z 
338.1222 [M+H]
+
, found 338.1223. 
Note: Unable to visualise all carbon environments by 
13
C NMR – masked by solvent peak. 
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N-(4-methoxyphenyl)-8-methyl-9-(3,3,3-trifluoropropyl)-9H-purin-2-amine (101) 
 
The 2-chloropurine intermediate 124 (0.100 mg, 0.38 mmol), 4-methoxyaniline (94 mg, 0.76 
mmol) and TFA (73 µl, 0.94 mmol) were reacted in TFE (4 ml) according to general 
procedure F. Chromatography on silica (9:1 DCM/MeOH) gave the desired compound as an 
off-white solid (83 mg, 0.24 mmol, 62%). Rf 0.20 (1:1 Petrol/EtOAc, KP-NH); M.p. 148-150 
°C; λmax (EtOH/nm) 277, 330; IR (cm
-1
) 3261, 3197, 1608; 
1
H NMR (500 MHz, DMSO-d6) 
2.55 (3H, s, C
8
-CH3), 2.94 (2H, tq, J = 6.8 and 10.5 Hz, CH2CF3), 3.73 (3H, s, OCH3), 4.38 
(2H, t, J = 6.8 Hz, N
9
-CH2), 6.87 (2H, d, J = 9.0 Hz, H-3’/H-5’), 7.73 (2H, d, J = 9.0 Hz, H-
2’/H-6’), 8.62 (1H, s, H-6), 9.36 (1H, s, C2-NH); 13C NMR (125 MHz, DMSO-d6) 13.7 (C
8
-
CH3), 31.7 (q, JCF = 27.8 Hz, CH2CF3), 35.2 (q, JCF = 4.0 Hz, N
9
-CH2), 55.1 (OCH3), 113.6 
(C-Ar), 119.9 (C-Ar), 126.9 (C-Ar), 134.3 (C-Ar), 147.0 (C-Ar), 151.3 (C-Ar), 153.8 (C-Ar), 
156.1 (C-Ar); HRMS calcd. for C16H17F3N5O (ES+) m/z 352.1380 [M+H]
+
, found 352.1380. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
Methyl 4-((8,9-dimethyl-9H-purin-2-yl)amino)benzoate (133) 
 
Methyl-4-aminobenzoate (0.497 g, 3.29 mmol), 2-chloropurine intermediate 56 (0.308 g, 
1.64 mmol) and TFA (315 µl, 4.11 mmol) were reacted in TFE (16 ml) according to general 
procedure B over 72 h. Purification on KP-NH silica (1:1 Petrol/EtOAc) gave the desired 
product as a pale yellow solid (0.213 g, 0.71 mmol, 43%). Rf 0.16 (1:1 Petrol/EtOAc); M.p. 
259-261 °C; λmax (EtOH/nm) 225, 302, 330; IR (cm
-1
) 3250, 3183, 2953, 1706, 1596, 1533; 
1
H NMR (500 MHz, DMSO-d6) 2.54 (3H, s, C
8
-CH3), 3.70 (3H, s, N
9
-CH3), 3.82 (3H, s, 
OCH3), 7.90 (2H, d, J = 8.9 Hz, H-3’/H-5’), 8.01 (2H, d, J = 8.9 Hz, H-2’/H-6’), 8.72 (1H, 
H-6), 10.06 (1H, s, C
2
-NH); 
13
C NMR (125 MHz, DMSO-d6) 13.8 (C
8
-CH3), 28.2 (N
9
-CH3), 
51.6 (OCH3), 117.0 (C-Ar), 120.9 (C-Ar), 128.1 (C-Ar), 130.2 (C-Ar), 145.8 (C-Ar), 146.4 
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(C-Ar), 153.4 (C-Ar), 153.6 (C-Ar), 154.9 (C-Ar), 166.1 (C=O); HRMS calcd. for 
C15H16N5O2 (ES+) m/z 298.1299 [M+H]
+
, found 298.1307. 
4-((8,9-Dimethyl-9H-purin-2-yl)amino)benzoic acid (132) 
 
Lithium hydroxide (0.305 g, 12.8 mmol) was added to a suspension of the methyl ester 133 
(0.190 g, 0.64 mmol) in THF/H2O (1:1, 12 ml) at 65 °C. After stirring at this temperature for 
2 h, the mixture was allowed to cool to RT and the pH adjusted to pH 7 with 2M HCl. The 
resultant white precipitate was collected by filtration, washed with cold water (5 ml) and 
dried in a vacuum oven. The desired product was obtained as an off-white solid (0.154 g, 
0.54 mmol, 85%). Rf 0.24 (9:1 DCM/MeOH, 0.1% AcOH); M.p. 346-349 °C; λmax 
(EtOH/nm) 293.5, 329.0; IR (cm
-1
) 3297, 3037, 2157, 1976, 1684; 
1
H NMR (500 MHz, 
DMSO-d6) 2.58 (3H, s, C
8
-CH3), 3.72 (3H, s, N
9
-CH3), 7.88 (2H, d, J = 8.9 Hz, H-3’, H-5’), 
7.99 (2H, d, J = 8.9 Hz, H-2’, H-6’), 8.76 (1H, s, H-6), 10.06 (1H, s, C2-NH), 12.47 (1H, br, 
COOH); 
13
C NMR (125 MHz, TFA) 10.9 (C
8
-CH3), 28.4 (N
9
-CH3), 115.3 (C-Ar), 120.4 (C-
Ar), 124.9 (C-Ar), 130.6 (C-Ar), 138.0 (C-Ar), 139.6 (C-Ar), 150.8 (C-Ar), 153.7 (C-Ar), 
161.6 (C-Ar), 170.8 (C=O); HRMS calcd. for C14H14N5O2 (ES+) m/z 284.1142 [M+H]
+
, 
found 284.1144. 
4-((8,9-Dimethyl-9H-purin-2-yl)amino)-N-(4-methoxybenzyl)benzamide (134) 
 
The carboxylic acid 132 (50 mg, 0.18 mmol), CDI (57 mg, 0.35 mmol), DIPEA (62 µl, 0.35 
mmol) and 4-methoxybenzylamine (92 µl, 0.71 mmol) were reacted in dry DMF (2 ml) 
according to general procedure J. Purification on silica gel (9:1 DCM/MeOH) gave the 
desired compound as an off-white waxy solid (71 mg, 0.18 mmol, 100%). Rf 0.44 (9:1 
DCM/MeOH); M.p. 246-248 °C; λmax (EtOH/nm) 300, 329; IR (cm
-1
) 3340, 2922, 2834, 
1609, 1509; 
1
H NMR (500 MHz, DMSO-d6) 2.54 (3H, s, C
8
-CH3), 3.69 (3H, s, N
9
-CH3), 
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3.73 (3H, s, OCH3), 4.41 (2H, d, J = 6.0 Hz, NHCH2), 6.89 (2H, d, J = 8.7 Hz, H-3’’/H-5’’), 
7.25 (2H, d, J = 8.7 Hz, H-2’’/H-6’’), 7.84 (2H, d, J = 8.9 Hz, H-2’/H-6’), 7.94 (2H, d, J = 
8.9 Hz, H-3’/H-5’), 8.70 (1H, s, H-6), 8.77 (1H, t, J = 6.0 Hz, NHCH2), 9.86 (1H, s, C
2
-NH); 
13
C NMR (125 MHz, DMSO-d6) 13.8 (C
8
-CH3), 28.1 (N
9
-CH3), 41.9 (NHCH2), 55.0 (OCH3), 
113.6 (C-Ar), 116.9 (C-Ar), 126.1 (C-Ar), 127.8 (C-Ar), 128.0 (C-Ar), 128.5 (C-Ar), 132.0 
(C-Ar), 143.9 (C-Ar), 146.5 (C-Ar), 153.1 (C-Ar), 153.7 (C-Ar), 155.2 (C-Ar), 158.1 (C-Ar), 
165.8 (C=O); HRMS calcd. for C22H23N6O2 (ES+) m/z 403.1877 [M+H]
+
, found 403.1879. 
4-((8,9-Dimethyl-9H-purin-2-yl)amino)benzamide (126) 
 
4-Methoxybenzamide 134 (55 mg, 0.14 mmol) and TFA (1.5 ml) were reacted according to 
general procedure K. Chromatography on silica (9:1 DCM/MeOH) gave the desired 
compound as an off-white solid (18 mg, 0.06 mmol, 45%). Rf 0.31 (9:1 DCM/MeOH); M.p. 
314-317 °C; λmax (EtOH/nm) 299.0, 329.0; IR (cm
-1
) 3366, 3269, 3172, 2938, 2161, 1666, 
1605; 
1
H NMR (500 MHz, DMSO-d6) 2.54 (3H, s, C
8
-CH3), 3.69 (3H, s, N
9
-CH3), 7.13 (1H, 
br, CONHH’), 7.77 (1H, br, CONHH’), 7.83 (2H, d, J = 8.9 Hz, H-2’/H-6’), 7.93 (2H, d, J = 
8.9 Hz, H-3’/H-5’), 8.70 (1H, s, H-6), 9.85 (1H, s, C2-NH); 13C NMR (125 MHz, DMSO-d6) 
13.8 (C
8
-CH3), 28.1 (N
9
-CH3), 116.8 (C-Ar), 128.3 (C-Ar), 146.7 (C-Ar); HRMS calcd. for 
C14H15N6O (ES+) m/z 283.1302 [M+H]
+
, found 283.1299. 
Note: Unable to visualise all carbon environments by 
13
C NMR – insufficient material. 
4-((8,9-Dimethyl-9H-purin-2-yl)amino)-N-methylbenzamide (127) 
 
The carboxylic acid 132 (50 mg, 0.18 mmol), CDI (58 mg, 0.35 mmol), DIPEA (62 µl, 0.35 
mmol) and methylamine (2M solution in THF, 0.35 ml) were reacted in dry DMF (2 ml) 
according to general procedure J. Purification by column chromatography on silica (9:1 
DCM/MeOH) gave the target compound with imidazole contamination observed by 
1
H 
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NMR. The crude product was suspended in water and stirred at RT for 30 mins, before being 
filtered, washed with cold water (1 ml) and dried in a vacuum oven. The pure target 
compound was acquired as an off-white solid (39 mg, 0.13 mmol, 72%). Rf 0.33 (9:1 
DCM/MeOH); M.p. 313-315 °C; λmax (EtOH/nm) 297.0; IR (cm
-1
) 3585, 3277, 3108, 3012, 
2914, 2796, 2609, 1605, 1507; 
1
H NMR (500 MHz, DMSO-d6) 2.54 (3H, s, C
8
-CH3), 2.78 
(3H, d, J = 4.5 Hz, NHCH3), 3.69 (3H, s, N
9
-CH3), 7.79 (2H, d, J = 8.8 Hz, H-2’/H-6’), 7.93 
(2H, d, J = 8.8 Hz, H-3’/H-5’), 8.22 (1H, q, J = 4.5 Hz, NHCH3), 8.70 (1H, s, H-6), 9.84 (1H, 
s, C
2
-NH); 
13
C NMR (125 MHz, DMSO-d6) 13.8 (C
8
-CH3), 26.1 (NHCH3), 28.1 (N
9
-CH3), 
116.9 (C-Ar), 127.7 (C-Ar), 143.7 (C-Ar), 146.5 (C-Ar), 166.3 (C=O); HRMS calcd. for 
C15H17N6O (ES+) m/z 297.1458 [M+H]
+
, found 297.1461. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
4-((8,9-Dimethyl-9H-purin-2-yl)amino)-N-phenylbenzamide (128) 
 
The carboxylic acid 132 (50 mg, 0.18 mmol), CDI (55 mg, 0.34 mmol), DIPEA (62 µl, 0.35 
mmol) and aniline (65 µl, 0.71 mmol) were reacted in dry DMF (2 ml) according to general 
procedure J. Purification via silica gel chromatography (9:1 DCM/MeOH) gave the desired 
compound as an off-white solid (50 mg, 0.14 mmol, 77%). Rf 0.38 (9:1 DCM/MeOH); M.p. 
282-285 °C; λmax (EtOH/nm) 306, 333; IR (cm
-1
) 3470, 3331, 3033, 1595, 1525; 
1
H NMR 
(500 MHz, DMSO-d6) 2.55 (3H, s, C
8
-CH3), 3.71 (3H, s, N
9
-CH3), 7.06-7.11 (1H, m, H-4’’), 
7.33-7.37 (2H, m, H-3’’/H-5’’), 7.77-7.81 (2H, m, H-2’’/H-6’’), 7.94 (2H, d, J = 8.8 Hz, H-
2’/H-6’), 8.02 (2H, d, J = 8.8 Hz, H-3’/H-5’), 8.73 (1H, s, H-6), 9.96 (1H, s, NH), 10.04 (1H, 
s, NH); 
13
C NMR (125 MHz, DMSO-d6) 13.8 (C
8
-CH3), 28.1 (N
9
-CH3), 116.9 (C-Ar), 120.2 
(C-Ar), 123.2 (C-Ar), 126.3 (C-Ar), 127.9 (C-Ar), 128.5 (C-Ar), 139.5 (C-Ar), 144.3 (C-Ar), 
146.6 (C-Ar), 153.7 (C-Ar), 155.2 (C-Ar), 165.1 (C=O); HRMS calcd. for C20H19N6O (ES+) 
m/z 359.1615 [M+H]
+
, found 359.1610. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
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8,9-Dimethyl-N-(4-nitrophenyl)-9H-purin-2-amine (136) 
 
The 2-chloropurine intermediate 56 (0.500 mg, 2.74 mmol), 4-nitroaniline (0.755 g, 5.48 
mmol) and TFA (1.05 ml, 13.7 mmol) were reacted in TFE (20 ml) according to general 
procedure F over 6 h. Purification through chromatography on silica (19:1 DCM/MeOH) 
afforded the desired compound as a pale brown solid (0.232 g, 0.82 mmol, 30%). Rf 0.40 
(19:1 DCM/MeOH); M.p. 267-268 °C; λmax (EtOH/nm) 237, 370; IR (cm
-1
) 3245, 3197, 
3120, 3063, 2413, 1586, 1551; 
1
H NMR (500 MHz, DMSO-d6) 2.57 (3H, s, C
8
-CH3), 3.73 
(3H, s, N
9
-CH3), 8.12 (2H, d, J = 9.4 Hz, H-2’/H-6’), 8.21 (2H, d, J = 9.4 Hz, H-3’/H-5’), 
8.78 (1H, s, H-6), 10.45 (1H, s, C
2
-NH); 
13
C NMR (125 MHz, DMSO-d6) 13.8 (C
8
-CH3), 
28.3 (N
9
-CH3), 116.9 (C-Ar), 125.1 (C-Ar), 128.6 (C-Ar), 139.7 (C-Ar), 146.4 (C-Ar), 147.7 
(C-Ar), 153.6 (C-Ar), 154.0 (C-Ar), 154.4 (C-Ar); HRMS calcd. for C13H13N6O2 (ES+) m/z 
285.1095 [M+H]
+
, found 285.1092. 
N
1
-(8,9-Dimethyl-9H-purin-2-yl)benzene-1,4-diamine (135) 
 
The nitro compound 136 (0.197 g, 0.69 mmol), palladium on carbon (20 mg, 10% w/w) and 
ammonium formate (0.435 g, 6.93 mmol) were reacted in methanol (7 ml) according to 
general procedure G. Silica gel chromatography (9:1 DCM/MeOH) gave the target 
compound as a pale brown solid (0.156 g, 0.61 mmol, 89%). Rf 0.36 (9:1 DCM/MeOH); M.p. 
198-201 °C; λmax (EtOH/nm) 281, 334; IR (cm
-1
) 3590, 3439, 3333, 3247, 3192, 3052, 1639, 
1512; 
1
H NMR (500 MHz, DMSO-d6) 2.49 (3H, s, C
8
-CH3), 3.61 (3H, s, N
9
-CH3), 5.11 (2H, 
br, Ar-NH2), 6.53 (2H, d, J = 8.7 Hz, H-3’/H-5’), 7.43 (2H, d, J = 8.7 Hz, H-2’/H-6’), 8.53 
(1H, s, H-6), 8.97 (1H, s, C
2
-NH); 
13
C NMR (125 MHz, DMSO-d6) 13.7 (C
8
-CH3), 28.0 (N
9
-
CH3), 114.0 (C-Ar), 120.5 (C-Ar), 126.7 (C-Ar), 130.5 (C-Ar), 143.1 (C-Ar), 146.5 (C-Ar), 
151.6 (C-Ar), 153.9 (C-Ar), 156.5 (C-Ar); HRMS calcd. for C13H15N6 (ES+) m/z 255.1353 
[M+H]
+
, found 255.1359. 
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1-(4-((8,9-Dimethyl-9H-purin-2-yl)amino)phenyl)urea (129) 
 
Sodium cyanate (12 mg, 0.19 mmol) in water (1 ml) was added to a solution of the aniline 
135 (40 mg, 0.16 mmol) in acetic acid (1 ml) and water (2 ml). The mixture was stirred at RT 
for 30 min, before being taken to pH 7-8 through addition of sat. NaHCO3 solution and 
extracted with EtOAc (4 x 15 ml). The combined organic extracts were dried (MgSO4) and 
concentrated, and the crude residue purified on silica (9:1 DCM/MeOH) to afford the desired 
compound as a white solid (20 mg, 0.07 mmol, 44%). Rf 0.34 (9:1 DCM/MeOH); M.p. 316-
319 °C; λmax (EtOH/nm) 282.0; IR (cm
-1
) 3362, 3285, 3178, 2361, 2164, 1662, 1604; 
1
H 
NMR (500 MHz, DMSO-d6) 3.65 (3H, s, N
9
-CH3), 5.73 (2H, s, NHCONH2), 7.29 (2H, d, J = 
9.0 Hz, H-3’/H-5’), 7.69 (2H, d, J = 9.0 Hz, H-2’/H-6’), 8.33 (1H, s, NHCONH2), 8.59 (1H, 
s, H-6), 9.32 (1H, s, C
2
-NH); 
13
C NMR (125 MHz, DMSO-d6) 13.8 (C
8
-CH3), 28.0 (N
9
-CH3), 
118.4 (C-Ar), 118.8 (C-Ar), 126.2 (C-Ar), 127.1 (C-Ar), 135.1 (C-Ar), 146.6 (C-Ar), 156.0 
(quat-C); HRMS calcd. for C14H16N7O (ES+) m/z 298.1411 [M+H]
+
, found 298.1414. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
tert-Butyl (4-aminophenyl) carbamate (138)
245
 
 
K2CO3 (0.470 g, 3.39 mmol) in water (2 ml) was added to a solution of 4-phenylenediamine 
(1.00 g, 9.25 mmol) in THF (10 ml) and DMF (3 ml). Boc2O (0.672 g, 3.08 mmol) in THF (2 
ml) was added dropwise and the resultant solution was stirred at RT for 4 h. The reaction 
mixture was poured onto ice (15 g) and extracted with chloroform (3 x 20 ml). The combined 
organic extracts were dried through a phase separator, evaporated to dryness, and the 
resultant residue was purified though chromatography on silica (1:1 Petrol/EtOAc). The 
target compound was obtained as a pale orange oil which crystallised on cooling (0.612 g, 
2.94 mmol, 95%). Rf 0.39 (1:1 Petrol/EtOAc); M.p. 114-117 °C (Lit.
245
 105-106 °C); λmax 
(EtOH/nm) 251, 300; IR (cm
-1
) 3372, 3298, 3213, 2989, 1687, 1523; 
1
H NMR (500 MHz, 
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DMSO-d6) 1.45 (9H, s, OC(CH3)3), 4.73 (2H, s, Ar-NH2), 6.47 (2H, d, J = 8.8 Hz, H-3/H-5), 
7.07 (2H, d, J = 8.8 Hz, H-2/H-6), 8.78 (1H, s, NHCO); 
13
C NMR (125 MHz, DMSO-d6) 
28.2 (-OC(CH3)3), 78.1 (-OC(CH3)3), 113.9 (C-Ar), 120.1 (C-Ar), 128.5 (C-Ar), 143.9 (C-
Ar), 153.1 (C=O); LRMS (ES+) m/z 209.2 [M+H]
+
. 
tert-Butyl (4-(3-methylureido)phenyl) carbamate (139) 
 
N-Succinimidyl N-methyl carbamate (0.605 g, 3.51 mmol) was added to a solution of the 
aniline 138 (0.488 g, 2.34 mmol) and DIPEA (0.61 ml, 3.51 mmol) in dry DMF (12 ml). The 
reaction mixture was heated at 70 °C for 18 h, before being cooled to RT and concentrated in 
vacuo. The crude residue was purified using silica gel chromatography (19:1 DCM/MeOH) 
to afford the target compound as pale yellow oil which solidified on cooling (0.410 g, 1.54 
mmol, 66%). Rf 0.41 (19:1 DCM/MeOH); M.p. 155-158 °C; λmax (EtOH/nm) 257; IR (cm
-1
) 
3380, 3263, 2976, 2929, 1696, 1662, 1537; 
1
H NMR (500 MHz, DMSO-d6) 1.45 (9H, s, 
OC(CH3)3), 2.62 (3H, d, J = 4.6 Hz, NHCH3), 5.91 (1H, q, J = 4.6 Hz, NHCH3), 7.22-7.31 
(4H, m, H-2/H-3/H-5/H-6), 8.32 (1H, s, NH), 9.10 (1H, s, NH); 
13
C NMR (125 MHz, 
DMSO-d6) 25.2 (NHCH3), 28.1 (-OC(CH3)3), 78.6 (-OC(CH3)3), 118.2 (C-Ar), 118.7 (C-Ar), 
133.1 (C-Ar), 135.2 (C-Ar), 152.9 (C=O), 155.9 (C=O); LRMS (ES+) m/z 266.1 [M+H]
+
, 
166.1 [M+H-Boc]
+
. 
1-(4-Aminophenyl)-3-methylurea (140)
246
 
 
The Boc-protected aniline 139 (0.578 g, 2.18 mmol) and TFA (1.68 ml, 21.8 mmol) were 
reacted in DCM (20 ml) according to general procedure L. Silica gel chromatography (9:1 
DCM/MeOH) gave the target compound as an off-white solid (0.328 g, 1.98 mmol, 91%). Rf 
0.26 (9:1 DCM/MeOH); M.p. 150-153 °C (Lit.
246
 147-148 °C); λmax (EtOH/nm) 252, 302; IR 
(cm
-1
) 3331, 3302, 3038, 2944, 2902, 2808, 1876, 1596, 1577, 1506; 
1
H NMR (500 MHz, 
DMSO-d6) 2.60 (3H, d, J = 4.7 Hz, NHCH3), 4.67 (2H, s, Ar-NH2), 5.74 (1H, q, J = 4.7 Hz, 
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NHCH3), 6.46 (2H, d, J = 8.7 Hz, H-3/H-5), 6.99 (2H, d, J = 8.7 Hz, H-2/H-6), 7.89 (1H, s, 
CONH); 
13
C NMR (125 MHz, DMSO-d6) 26.3 (NHCH3), 114.1 (C-Ar), 120.5 (C-Ar), 129.6 
(C-Ar), 143.4 (C-Ar), 156.4 (C=O); LRMS (ES-) m/z 166.1 [M+H]
+
. 
1-(4-((8,9-Dimethyl-9H-purin-2-yl)amino)phenyl)-3-methylurea (130) 
 
The 2-chloropurine 56 (50mg, 0.27 mmol), aniline 140 (55 mg, 0.33 mmol), Pd2(dba)3 (26 
mg, 0.03 mmol), XPhos (15 mg, 0.03 mmol) and K2CO3 (84 mg, 0.60 mmol) were reacted in 
MeCN (3 ml) according to general procedure M. Purification on silica (9:1 DCM/MeOH) 
afforded the target compound as an off-white solid (41 mg, 0.13 mmol, 49%). Rf 0.20 (9:1 
DCM/MeOH); M.p. 253-256 °C; λmax (EtOH/nm) 283; IR (cm
-1
) 3363, 3281, 1613, 1551, 
1510; 
1
H NMR (500 MHz, DMSO-d6) 2.52 (3H, s, C8-CH3), 2.64 (3H, d, J = 4.6 Hz, 
NHCH3), 3.65 (3H, s, N9-CH3), 5.92 (1H, q, J = 4.6 Hz, NHCH3), 7.29 (2H, d, J = 8.9 Hz, 
H-3’/H-5’), 7.68 (2H, d, J = 8.9 Hz, H-2’/H-6’), 8.30 (1H, s, CONH), 8.59 (1H, s, H-6), 9.32 
(1H, s, C2-NH); 
13
C NMR (125 MHz, DMSO-d6) 13.8 (C
8
-CH3), 26.2 (NHCH3), 28.0 (N
9
-
CH3), 118.4 (C-Ar), 118.8 (C-Ar), 127.1 (C-Ar), 134.1 (C-Ar), 135.0 (C-Ar), 146.5 (C-Ar), 
152.1 (C-Ar), 153.8 (C-Ar), 156.0, 156.1; HRMS calcd. for C15H18N7O (ES+) m/z 312.1567 
[M+H]
+
, found 312.1566. 
Note: Unable to distinguish carbon signals at 156.0 and 156.1 by 
13
C NMR. 
1-(4-((8,9-Dimethyl-9H-purin-2-yl)amino)phenyl)-3-phenylurea (131) 
 
Phenyl isocyanate (21 µl, 0.19 mmol) in dry THF (0.5 ml) was added dropwise to a solution 
of the 2-anilinopurine 135 (40 mg, 0.16 mmol) in dry THF (2 ml). The mixture was stirred at 
RT for 18 h, before being concentrated in vacuo and the residue dissolved in EtOAc (5 ml). 
The organic was washed with sat. NaHCO3 solution (5 ml) and brine (5 ml) before being 
dried (MgSO4) and evaporated to dryness. The crude residue was purified by silica gel 
288 
 
chromatography (9:1 DCM/MeOH) to give the desired compound as an off-white solid (44 
mg, 0.12 mmol, 73%). Rf 0.36 (9:1 DCM/MeOH); M.p. 310-313 °C; λmax (EtOH/nm) 253.5, 
286.5; IR (cm
-1
) 3271, 3048, 2159, 1617; 
1
H NMR (500 MHz, DMSO-d6) 2.52 (3H, s, C
8
-
CH3), 3.66 (3H, s, N
9
-CH3), 6.96 (1H, dddd, J = 1.2, 1.2, 7.4 and 7.4 Hz, H-4’’), 7.28 (2H, 
dd, J = 7.4 and 7.5 Hz, H-3’’/H-5’’), 7.36 (2H, d, J = 8.9 Hz, H-3’/H-5’), 7.45 (2H, dd, J = 
1.2 and 7.5 Hz, H-2’’/H-6’’), 7.76 (2H, d, J = 8.9 Hz, H-2’/H-6’), 8.50 (1H, br, NHCONH), 
8.60-8.64 (2H, m, H-6 & NHCONH), 9.40 (1H, s, C
2
-NH); 
13
C NMR (125 MHz, DMSO-d6) 
13.8 (C
8
-CH3), 28.0 (N
9
-CH3), 118.0 (C-Ar), 118.8 (C-Ar), 118.9 (C-Ar), 128.7 (C-Ar), 
131.8 (C-Ar), 133.0 (C-Ar), 152.6 (quat-C), 153.8 (quat-C), 155.9 (quat-C); HRMS calcd. for 
C20H20N7O (ES+) m/z 374.1724 [M+H]
+
, found 374.1727. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
N-(4-((8,9-Dimethyl-9H-purin-2-yl)amino)phenyl)acetamide (141) 
 
The 2-chloropurine 56 (50mg, 0.27 mmol), 4-aminoacetanilide (49 mg, 0.33 mmol), 
Pd2(dba)3 (27 mg, 0.03 mmol), XPhos (14 mg, 0.03 mmol) and K2CO3 (83 mg, 0.60 mmol) 
were reacted in MeCN (3 ml) according to general procedure M. Silica gel chromatography 
(9:1 DCM/MeOH) gave the desired compound as a beige solid (49 mg, 0.17 mmol, 62%). Rf 
0.22 (9:1 DCM/MeOH); M.p. 291-293 °C; λmax (EtOH/nm) 286.5, 333.0; IR (cm
-1
) 3635, 
3292, 3061, 1616, 1563, 1511; 
1
H NMR (500 MHz, DMSO-d6) 2.02 (3H, s, COCH3), 2.49 
(3H, s, C
8
-CH3), 3.66 (3H, s, N
9
-CH3), 7.48 (2H, d, J = 9.0 Hz, H-3’/H-5’), 7.76 (2H, d, J = 
9.0 Hz, H-2’/H-6’), 8.61 (1H, s, H-6), 9.43 (1H, s, C2-NH); 13C NMR (125 MHz, DMSO-d6) 
13.8 (C
8
-CH3), 23.8 (COCH3), 28.0 (N
9
-CH3), 118.4 (C-Ar), 119.5 (C-Ar), 127.2 (C-Ar), 
132.7 (C-Ar), 136.6 (C-Ar), 146.5 (C-Ar), 152.3 (C-Ar), 153.8 (C-Ar), 155.8 (C-Ar), 167.6 
(C=O); HRMS calcd. for C15H17N6O (ES+) m/z 297.1458 [M+H]
+
, found 297.1464. 
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N-(4-Methoxyphenyl)-9-methyl-8-((phenylamino)methyl)-9H-purin-2-amine (144) 
 
n-Butyllithium (0.37 ml, 0.94 mmol) was added dropwise to a solution of distilled DIPA 
(0.13 ml, 0.94 mmol) in dry THF (1.5 ml) at -90 °C under N2. After 10 min, the LDA 
solution added dropwise to a solution of the purine 144 (100 mg, 0.39 mmol) in dry THF (3.5 
ml) at -90 °C under N2. The mixture was maintained at -90 °C for 15 min, before dry DMF 
(0.18 ml, 2.34 mmol) was added dropwise. The resultant suspension was allowed to warm to 
RT over 2 h and quenched with sat. NH4Cl solution (2 ml). The mixture was extracted with 
EtOAc (2 x 8 ml) and the combined organic extracts were evaporated to dryness. The crude 
aldehyde residue was dissolved in DCM (4 ml) to which MgSO4 was added, followed by 
aniline (35 µl, 0.39 mmol). The reaction mixture was stirred at RT for 2 h, before NaBH4 (44 
mg, 1.17 mmol) was added, and the mixture stirred at RT for a further 6 h. The drying 
reagent was removed through filtration and the filtrate concentrated in vacuo. 
Chromatography on silica (19:1 DCM/MeOH) of the crude residue gave the target compound 
as a yellow solid (52 mg, 0.14 mmol, 36%). Rf 0.38 (19:1 DCM/MeOH); M.p. 174-176 °C; 
λmax (EtOH/nm) 245.0, 276.5, 340.5; IR (cm
-1
) 3387, 3001, 2901, 2831, 1626, 1599, 1506; 
1
H 
NMR (500 MHz, DMSO-d6) 3.72-3.75 (6H, m, N
9
-CH3 & -OCH3), 4.52 (2H, d, J = 5.7 Hz, 
NHCH2), 6.25 (1H, t, J = 5.7 Hz, NHCH2), 6.58 (1H, dddd, J = 0.9, 0.9, 7.3 and 7.3 Hz, H-
4’’), 6.76 (2H, dd, J = 0.9 and 8.5 Hz, H-2’’/H-6’’), 6.88 (2H, d, J = 9.1 Hz, H-3’/H-5’), 7.09 
(2H, dd, J = 7.3 and 8.5 Hz, H-3’’/H-5’’), 7.74 (2H, d, J = 9.1 Hz, H-2’/H-6’), 8.70 (1H, s, H-
6), 9.38 (1H, s, C
2
-NH); 
13
C NMR (125 MHz, DMSO-d6) 28.2 (N
9
-CH3), 40.8 (NHCH2), 
55.1 (OCH3), 112.4 (C-Ar), 113.7 (C-Ar), 116.4 (C-Ar), 119.9 (C-Ar), 126.7 (C-Ar), 128.9 
(C-Ar), 134.3 (C-Ar), 147.7 (C-Ar), 148.2 (C-Ar), 152.4 (C-Ar), 153.8 (C-Ar), 153.9 (C-Ar), 
156.4 (C-Ar); HRMS calcd. for C20H21N6O (ES+) m/z 361.1771 [M+H]
+
, found 361.1776. 
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2-Fluoro-9-(tetrahydro-2H-pyran-2-yl)-6-(2-(triisopropylsilyl)ethynyl)-9H-purine (159) 
 
6-Chloropurine intermediate 51 (0.500 g, 1.95 mmol), (triisopropylsilyl)acetylene (0.49 ml, 
2.20 mmol), copper iodide (7 mg, 0.02 mmol), Pd(PPh3)2Cl2 (27 mg, 0.02 mmol) and 
triethylamine (0.68 ml, 4.88 mmol) were reacted in THF (20 ml) according to general 
procedure N. Purification by chromatography on silica (9:1 Petrol/EtOAc) gave the target 
compound as a golden oil (0.754 g, 1.87 mmol, 96%). Rf 0.30 (9:1 Petrol/EtOAc); λmax 
(EtOH/nm) 303; IR (cm
-1
) 3433, 2946, 2866, 2706, 2361, 1703; 
1
H NMR (500 MHz, DMSO-
d6) 1.12-1.25 (21H, m, Si(CH(CH3)2)3), 1.56-1.63 (2H, m, OCH2CH2), 1.71-1.80 (1H, m, 
CHCHH’), 1.94-2.03 (2H, m, CHCH2CH2), 2.20-2.30 (1H, m, CHCHH’), 3.70-3.78 (1H, m, 
OCHH’), 4.01-4.07 (1H, m, OCHH’), 5.70 (1H, dd, J = 2.2 and 10.8 Hz, CH), 8.89 (1H, s, H-
8);
 13
C NMR (125 MHz, DMSO-d6) 10.5 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 22.0 
(CHCH2), 24.4 (OCH2CH2), 29.7 (CHCH2CH2), 67.7 (OCH2), 81.4 (CH), 100.2 (C≡C), 102.8 
(C≡C), 133.9 (d, JCF = 4.6 Hz, C-Ar), 140.8 (d, JCF = 17.9 Hz, C-Ar), 146.6 (d, JCF = 2.8 Hz, 
C-Ar), 153.8 (d, JCF = 17.8 Hz, C-Ar), 157.4 (d, JCF = 210.6 Hz, C
2
-Ar); HRMS calcd. for 
C21H32FN4OSi (ES+) m/z 403.2324 [M+H]
+
, found 403.2324. 
2-Fluoro-6-(2-(triisopropylsilyl)ethynyl)-9H-purine (160) 
 
TFA (3 mL) was added to a solution of THP-protected purine 159 (0.644 g, 1.60 mmol) in 
IPA (15 mL). Water (3 mL) was added and the solution was heated to reflux for 2 h. The 
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mixture was cooled and neutralised (conc. NH3) before being extracted with EtOAc (3 × 50 
mL) and the combined organic extracts dried (MgSO4) and concentrated. The resulting 
residue was purified by chromatography on silica (7:3 Petrol/EtOAc) to give the desired 
product as a pale yellow oil (0.461 g, 1.45 mmol, 91%). Rf 0.25 (7:3 Petrol/EtOAc); λmax 
(EtOH/nm) 302; IR (cm
-1
) 2945, 2866, 2361, 2000, 1584; 
1
H NMR (500 MHz, DMSO-d6) 
1.12-1.21 (21H, m, Si(CH(CH3)2)3), 8.68 (1H, s, H-8), 13.89 (1H, br, H-9);
 13
C NMR (125 
MHz, CDCl3) 11.1 (Si(CH(CH3)2)3), 18.5 (Si(CH(CH3)2)3), 99.5 (C≡C), 106.1 (C≡C), 131.2 
(m, C-Ar), 141.6 (m, C-Ar), 145.3 (m, C-Ar), 156.6 (m, C-Ar), 158.6 (d, JCF = 217.4 Hz, C
2
-
Ar); HRMS calcd. for C16H24FN4Si (ES+) m/z 319.1749 [M+H]
+
, found 319.1752. 
6-(2-(Triisopropylsilyl)ethynyl)-N-phenyl-9H-purin-2-amine (164) 
 
2-Fluoropurine intermediate 160 (0.455 g, 1.43 mmol), aniline (260 µL, 2.86 mmol), TFA 
(551 µL, 7.15 mmol) and TFE (7 mL) were reacted according to general procedure B. The 
dried (MgSO4) and concentrated crude material was purified using chromatography on silica 
(19:1 DCM/MeOH) to give the desired product as a yellow oil/gum (0.390 g, 1.00 mmol, 
70%). Rf 0.39 (19:1 DCM/MeOH); λmax (EtOH/nm) 276; IR (cm
-1
) 3389, 2361, 2021; 
1
H 
NMR (500 MHz, CDCl3) 1.09-1.22 (21H, m, Si(CH(CH3)2)3), 7.00-7.04 (1H, m, H-4’), 7.22 
(1H, s, C
2
-NH), 7.29 (2H, dd, J = 7.7 and 8.1 Hz, H-3’/H-5’), 7.46 (1H, s, H-8), 7.52 (2H, dd, 
J = 1.7 and 7.7 Hz, H-2’/H-6’), 10.42 (1H, s, H-9); 13C NMR (125 MHz, CDCl3) 11.3 
(Si(CH(CH3)2)3), 18.7 (Si(CH(CH3)2)3), 100.8 (C≡C), 101.8 (C≡C), 120.7 (C-Ar), 123.7 (C-
Ar), 129.4 (C-Ar), 139.2 (C-Ar), 141.0 (C-Ar), 142.6 (C-Ar), 153.4 (C-Ar), 156.5 (C-Ar); 
HRMS calcd. for C22H30N5Si (ES+) m/z 392.2271 [M+H]
+
, found 392.2263. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
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6-(2-(Triisopropylsilyl)ethynyl)-N-p-tolyl-9H-purin-2-amine (165) 
 
2-Fluoropurine intermediate 160 (0.357 g, 1.12 mmol) and 4-methylaniline (0.241 g, 2.25 
mmol) were reacted with TFA (432 μl, 5.61 mmol) in TFE (6 ml) according to general 
procedure B. The resulting crude residue was purified by chromatography on reverse phase 
silica (19:1 MeOH/H2O 0.1% HCOOH) to give the desired compound as a yellow oil (0.215 
g, 0.53 mmol, 47%). Rf 0.27 (19:1 MeOH/H2O, 0.1% HCOOH, C18); λmax (EtOH/nm) 276; 
IR (cm
-1
) 2942, 2865, 2361, 2336, 1605; 
1
H NMR (500 MHz, DMSO-d6) 1.13-1.22 (21H, m, 
Si(CH(CH3)2)3), 2.31 (3H, s, -CH3), 7.14 (2H, d, J = 8.4 Hz, H-3’/H-5’), 7.74 (2H, d, J = 8.4 
Hz, H-2’/H-6’), 8.28 (1H, s, H-8), 9.65 (1H, s, C2-NH), 13.11 (1H, br, H-9); 13C NMR (125 
MHz, CDCl3) 11.3 (Si(CH(CH3)2)3), 18.7 (Si(CH(CH3)2)3), 20.9 (CH3), 120.8 (C-Ar), 129.8 
(C-Ar), 136.4 (C-Ar); HRMS calcd. for C23H32N5Si (ES+) m/z 406.2421 [M+H]
+
, found 
406.2423. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
N-(4-Ethylphenyl)-6-(2-(triisopropylsilyl)ethynyl)-9H-purin-2-amine (166) 
 
2-Fluoropurine intermediate 160 (0.394 g, 1.24 mmol) and 4-ethylaniline (310 μl, 2.48 
mmol) were reacted with TFA (477 μl, 6.19 mmol) in TFE (6 ml) according to general 
procedure B. The resulting residue was purified by chromatography on reverse phase silica 
(19:1 MeOH/H2O 0.1% HCOOH) to give the desired compound as a yellow oil/gum (0.281 
g, 0.67 mmol, 54%). Rf 0.27 (19:1 MeOH/H2O, 0.1% HCOOH, C18); λmax (EtOH/nm) 277; 
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IR (cm
-1
) 2941, 2865, 2361, 2338, 2160, 1605; 
1
H NMR (500 MHz, DMSO-d6) 1.13-1.21 
(21H, m, Si(CH(CH3)2)3), 1.23 (3H, t, J = 7.6 Hz, -CH2CH3), 2.61 (2H, q, J = 7.6 Hz, -
CH2CH3) 7.17 (2H, d, J = 8.4 Hz, H-3’/H-5’), 7.75 (2H, d, J = 8.4 Hz, H-2’/H-6’), 8.27 (1H, 
s, H-8), 9.66 (1H, s, C
2
-NH), 13.11 (1H, br, H-9);
 13
C NMR (125 MHz, CDCl3) 11.3 
(Si(CH(CH3)2)3), 15.7 (CH3), 18.7 (Si(CH(CH3)2)3), 28.3 (CH2), 100.6 (C≡C), 121.0 (C-Ar), 
128.7 (C-Ar), 136.7 (C-Ar), 139.9 (C-Ar), 140.8 (C-Ar), 156.7 (C-Ar); HRMS calcd. for 
C24H34N5Si (ES+) m/z 420.2578 [M+H]
+
, found 420.2579. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
N-(4-Isopropylphenyl)-6-(2-(triisopropylsilyl)ethynyl)-9H-purin-2-amine (167) 
 
2-Fluoropurine intermediate 160 (0.395 g, 1.24 mmol) and 4-isopropylaniline (353 μl, 2.48 
mmol) were reacted with TFA (478 μl, 6.21 mmol) in TFE (6 ml) according to general 
procedure B. The resulting residue was purified by chromatography on reverse phase silica 
(19:1 MeOH/H2O, 0.1% HCOOH) to give the desired compound as a yellow oil/gum (0.314 
g, 0.72 mmol, 58%). Rf 0.23 (19:1 MeOH/H2O, 0.1% HCOOH, C18); λmax (EtOH/nm) 277; 
IR (cm
-1
) 2956, 2866, 2360, 2157, 1607; 
1
H NMR (500 MHz, DMSO-d6) 1.12-1.21 (21H, m, 
Si(CH(CH3)2)3), 1.25 (6H, d, J = 7.0 Hz, -CH(CH3)2), 2.89 (1H, sept, J = 7.0 Hz, -
CH(CH3)2), 7.19 (2H, d, J = 8.6 Hz, H-3’/H-5’), 7.74 (2H, d, J = 8.6 Hz, H-2’/H-6’), 8.26 
(1H, s, H-8), 9.65 (1H, s, C
2
-NH), 13.10 (1H, br, H-9);
 13
C NMR (125 MHz, CDCl3) 11.3 
(Si(CH(CH3)2)3), 18.7 (Si(CH(CH3)2)3), 24.1 (CH3), 33.6 (CH), 100.7 (C≡C), 120.5 (C-Ar), 
127.1 (C-Ar), 136.7 (C-Ar), 155.7 (C-Ar); HRMS calcd. for C25H36N5Si (ES+) m/z 434.2734 
[M+H]
+
, found 434.2735. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
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(4-Nitrophenoxy)triisopropylsilane (162)
247
 
 
Imidazole (0.735 g, 10.8 mmol) was added to a solution of 4-nitrophenol (0.502 g, 3.60 
mmol) in dry DCM (10 ml). Triisopropylsilyl chloride (1.5 ml, 7.20 mmol) was added, and 
the reaction mixture was stirred at RT for 2 h. The mixture was washed with sat. brine 
solution (2 x 10 ml) and the combined aqueous washings were extracted with DCM (3 x 10 
ml). The combined organic extracts were dried (Na2SO4) and concentrated, and the resulting 
residue was purified using chromatography on silica (Petrol). The desired compound was 
obtained as a colourless oil (0.998 g, 3.38 mmol, 94%). Rf 0.40 (Petrol); λmax (EtOH/nm) 245, 
295; IR (cm
-1
) 2980, 2930, 2156; 
1
H NMR (500 MHz, DMSO-d6) 1.13 (18H, d, J = 7.6 Hz, 
Si(CH(CH3)2)3), 1.38 (3H, sept, J = 7.6 Hz, Si(CH(CH3)2)3), 7.14 (2H, d, J = 9.2 Hz, H-2/H-
6), 8.24 (2H, d, J = 9.2 Hz, H-3/H-5);
 
LRMS (ES+) m/z 296.2 [M+H]
+
. 
4-Triisopropylsilyloxyaniline (163)
248
 
 
Zinc (0.454 g, 6.94 mmol) was added to a solution of the nitro compound 162 (0.205 g, 0.69 
mmol) in acetic acid (10 ml) and the mixture was stirred at RT for 2.5 h. The solvent was 
removed in vacuo and the residue was dissolved in water. The solution was adjusted to pH 8 
(conc. NH3) and extracted with EtOAc (2 x 20 ml). The combined organic extracts were dried 
(Na2SO4) and concentrated, and the residue was purified by chromatography on silica (9:1 
Petrol/EtOAc). The desired compound was obtained as an orange oil (0.132 g, 0.50 mmol, 
72%). Rf 0.76 (7:3 Petrol/EtOAc); λmax (EtOH/nm) 236, 301; IR (cm
-1
) 2944, 2866, 1613; 
1
H 
NMR (500 MHz, DMSO-d6) 0.94 (18H, d, J = 7.3 Hz, Si(CH(CH3)2)3), 1.07 (3H, sept, J = 
7.3 Hz, Si(CH(CH3)2)3), 4.64 (2H, s, Ar-NH2), 6.36 (2H, d, J = 8.9 Hz, H-2/H-6), 6.47 (2H, 
d, J = 8.9 Hz, H-3/H-5);
 13
C NMR (125 MHz, CDCl3) 12.6 (Si(CH(CH3)2)3), 17.9 
(Si(CH(CH3)2)3), 116.5 (C-Ar), 120.4 (C-Ar), 139.6 (C-Ar), 148.9 (C-Ar); LRMS (ES+) m/z 
266.2 [M+H]
+
. 
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6-((Triisopropylsilyl)ethynyl)-N-(4-((triisopropylsilyl)oxy)phenyl)-9H-purin-2-amine 
(168) 
 
2-Fluoropurine intermediate 160 (0.379 g, 1.19 mmol) and aniline 163 (0.610 g, 2.38 mmol) 
were reacted with TFA (460 μl, 5.96 mmol) in TFE (8 ml) according to general procedure 
B. Purification on silica (7:3 Petrol/EtOAc)) gave the target compound as an orange oil 
(0.181 g, 0.32 mmol, 27%). Rf 0.44 (7:3 Petrol/EtOAc); λmax (EtOH/nm) 277; IR (cm
-1
) 2944, 
2866, 2367, 2343, 2187, 1607; 
1
H NMR (500 MHz, DMSO-d6) 1.08 (18H, d, J = 7.3 Hz, 
OSi(CH(CH3)2)3), 1.12-1.24 (24H, m, OSi(CH(CH3)2)3 & Si(CH(CH3)2)3), 6.80 (2H, d, J = 
9.3 Hz, H-3’/H-5’), 7.64 (2H, d, J = 9.3 Hz, H-2’/H-6’), 8.20 (1H, s, H-8), 9.54 (1H, s, C2-
NH), 13.01 (1H, br, H-9);
 13
C NMR (125 MHz, CDCl3) 11.2 (Si(CH(CH3)2)3), 12.7 
(Si(CH(CH3)2)3), 17.9 (Si(CH(CH3)2)3), 18.7 (Si(CH(CH3)2)3), 101.3 (C≡C), 115.1 (C-Ar), 
117.5 (C-Ar), 120.2 (C-Ar), 122.1 (C-Ar), 156.7 (C-Ar); HRMS calcd. for C31H50N5OSi2 
(ES+) m/z 564.3548 [M+H]
+
, found 564.3543. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
6-(2-(Triisopropylsilyl)ethynyl)-N-(3-methoxyphenyl)-9H-purin-2-amine (169) 
 
2-Fluoropurine intermediate 160 (0.421 g, 1.32 mmol) and 3-methoxyaniline (298 μl, 2.65 
mmol) were reacted with TFA (510 μl, 6.62 mmol) in TFE (6 ml) according to general 
procedure B. Chromatography on reverse phase silica (19:1 MeOH/H2O 0.1% HCOOH) 
afforded the target compound as a yellow oil/gum (0.297 g, 0.70 mmol, 53%). Rf 0.33 (19:1 
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MeOH/H2O, 0.1% HCOOH, C18); λmax (EtOH/nm) 274; IR (cm
-1
) 3147, 2943, 2865, 2360, 
1600; 
1
H NMR (500 MHz, DMSO-d6) 1.14-1.23 (21H, m, Si(CH(CH3)2)3), 3.76 (3H, s, 
OCH3), 6.52 (1H, ddd, J = 2.3, 2.5 and 8.5 Hz, H-4’), 7.17 (1H, dd, J = 8.1 and 8.2 Hz, H-5’), 
7.29-7.33 (1H, m, H-6’), 7.64-7.67 (1H, m, H-2’), 8.26 (1H, s, H-8), 9.71 (1H, s, C2-NH), 
13.12 (1H, br, H-9);
 13
C NMR (125 MHz, CDCl3) 11.3 (Si(CH(CH3)2)3), 18.7 
(Si(CH(CH3)2)3), 55.3 (OCH3), 101.6 (C≡C), 108.0 (C-Ar), 117.9 (C-Ar), 129.8 (C-Ar), 
138.7 (C-Ar), 160.3 (C-Ar); HRMS calcd. for C23H32N5OSi (ES+) m/z 422.2371 [M+H]
+
, 
found 422.2372. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
N-(2-Methoxyphenyl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (170) 
 
2-Fluoropurine 160 (0.169 g, 0.53 mmol), 2-methoxyaniline (120 µl, 1.06 mmol) and TFA 
(102 µl, 1.33 mmol) were reacted in TFE (5 ml) according to general procedure V. 
Purification by KP-NH silica chromatography (19:1 DCM/MeOH) afforded the target 
compound as a yellow oil/gum (98 mg, 0.23 mmol, 43%). Rf 0.39 (19:1 DCM/MeOH, KP-
NH); λmax (EtOH/nm) 271; IR (cm
-1
) 3421, 3071, 2942, 2864, 1600, 1572, 1531; 
1
H NMR 
(500 MHz, DMSO-d6) 1.13-1.22 (21H, m, Si(CH(CH3)2)3), 3.86 (3H, s, OCH3), 6.95 (1H, 
ddd, J = 1.5, 7.5 and 7.7 Hz, H-5’), 7.01 (1H, dd, J = 1.5 and 8.0 Hz, H-3’), 7.04 (1H, ddd, J 
= 1.6, 7.5 and 8.0 Hz, H-4’), 8.11 (1H, s, C2-NH), 8.20-8.23 (1H, m, H-6’), 8.26 (1H, s, H-8), 
13.10 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 
(Si(CH(CH3)2)3), 55.7 (OCH3), 98.1 (C≡C), 101.8 (C≡C), 110.9 (C-Ar), 119.8 (C-Ar), 120.3 
(C-Ar), 122.4 (C-Ar), 129.0 (C-Ar), 143.0 (C-Ar), 149.1 (C-Ar), 156.2 (C-Ar); HRMS calcd. 
for C23H32N5OSi (ES+) m/z 422.2371 [M+H]
+
, found 422.2375. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
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6-(2-(Triisopropylsilyl)ethynyl)-N-(4-chlorophenyl)- 9H-purin-2-amine (171) 
 
2-Fluoropurine intermediate 160 (0.200 g, 0.62 mmol), 4-chloroaniline (0.161 g, 1.26 mmol), 
TFA (242 µL, 3.14 mmol) and TFE (6 mL) were reacted according to general procedure B. 
The dried (MgSO4) and concentrated crude material was purified using chromatography on 
silica (7:3 Petrol/EtOAc) to give the desired product as a yellow oil (0.165 g, 0.38 mmol, 
61%). Rf 0.25 (7:3 Petrol/EtOAc); λmax (EtOH/nm) 289; IR (cm
-1
) 3118, 2945, 2866, 2361, 
1541; 
1
H NMR (500 MHz, DMSO-d6) 1.13-1.22 (21H, m, Si(CH(CH3)2)3), 7.33 (2H, d, J = 
8.9 Hz, H-2’/H-6’), 7.85 (2H, d, J = 8.9 Hz, H-3’/H-5’), 8.27 (1H, s, H-8), 9.91 (1H, s, C2-
NH), 13.17 (1H, br, H-9); LRMS (ES+) m/z 426.2 [M
35
Cl+H]
+
, 428.2 [M
37
Cl+H]
+
. 
N-(3-Chlorophenyl)-6-(2-(triisopropylsilyl)ethynyl)-9H-purin-2-amine (172) 
 
2-Fluoropurine intermediate 160 (0.354 g, 1.11 mmol) and 3-chloroaniline (234 μl, 2.23 
mmol) were reacted with TFA (429 μl, 5.57 mmol) in TFE (6 ml) according to general 
procedure B. Purification of the crude residue by chromatography on reverse phase silica 
(19:1 MeOH/H2O 0.1% HCOOH) gave the desired compound as a yellow oil/gum (0.281 g, 
0.66 mmol, 59%). Rf 0.27 (19:1 MeOH/H2O, 0.1% HCOOH, C18); λmax (EtOH/nm) 276; IR 
(cm
-1
) 3278, 2944, 2866, 2363, 1596; 
1
H NMR (500 MHz, DMSO-d6) 1.13-1.22 (21H, m, 
Si(CH(CH3)2)3), 6.96 (1H, ddd, J = 2.0, 2.2 and 8.0 Hz, H-4’), 7.29 (1H, dd, J = 8.0 and 8.1 
Hz, H-5’), 7.64 (1H, ddd, J = 2.0, 2.1 and 8.1 Hz, H-6’), 8.11-8.14 (1H, m, H-2’), 8.30 (1H, 
s, H-8), 9.96 (1H, s, C
2
-NH), 13.21 (1H, br, H-9);
 13
C NMR (125 MHz, CDCl3) 11.2 
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(Si(CH(CH3)2)3), 18.7 (Si(CH(CH3)2)3), 117.1 (C-Ar), 118.9 (C-Ar), 122.6 (C-Ar), 129.9 (C-
Ar), 134.7 (C-Ar), 135.7 (C-Ar), 140.2 (C-Ar); HRMS calcd. for C22H29ClN5Si (ES+) m/z 
426.1875 [M+H]
+
, found 426.1877. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
6-Ethynyl-N-phenyl-9H-purin-2-amine (148) 
 
The TIPS-protected purine 164 (0.330 g, 0.84 mmol) and TBAF (1M in THF, 930 µL, 0.93 
mmol) were reacted in THF (10 ml) according to general procedure I, with purification by 
chromatography on silica (EtOAc) to give the desired product as a yellow solid (0.201 g, 0.85 
mmol, 100%). Rf 0.27 (EtOAc); M.p. 140-160 °C (decomposed); λmax (EtOH/nm) 243; IR 
(cm
-1
) 3414, 3111, 3072, 2920, 2110, 1704; 
1
H NMR (500 MHz, DMSO-d6) 4.86 (1H, s, 
C≡CH), 6.91-6.96 (1H, m, H-4’), 7.29 (2H, dd, J = 7.6 and 8.0 Hz, H-3’/H-5’), 7.80 (2H, dd, 
J = 2.0 and 8.0 Hz, H
3
), 8.30 (1H, s, H-8), 9.70 (1H, s, C
2
-NH), 13.17 (1H, br, H-9);
 13
C 
NMR (125 MHz, DMSO-d6) 87.0 (C≡CH), 118.3 (C-Ar), 120.0 (C-Ar), 128.4 (C-Ar), 140.8 
(C-Ar), 156.2 (C-Ar); HRMS calcd. for C13H10N5 (ES+) m/z 236.0934 [M+H]
+
, found 
236.0931. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
6-Ethynyl-N-p-tolyl-9H-purin-2-amine (149) 
 
The TIPS-protected purine 165 (0.208 g, 0.51 mmol) was reacted with TBAF (1M in THF, 
770 μl, 0.77 mmol) in THF (5 ml) according to general procedure I. Chromatography on 
silica (1:4 Petrol/EtOAc) afforded the desired compound as a yellow solid (0.102 g, 0.41 
mmol, 80%). Rf 0.33 (EtOAc); M.p. 110-120 °C (decomposed); λmax (EtOH/nm) 271; IR (cm
-
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1
) 3409, 3268, 2852, 2721, 2110; 
1
H NMR (500 MHz, DMSO-d6) 2.26 (3H, s, -CH3), 4.82 
(1H, s, C≡CH), 7.10 (2H, d, J = 8.4 Hz, H-2’/H-6’), 7.67 (2H, d, J = 8.4 Hz, H-3’/H-5’), 8.24 
(1H, s, H-8), 9.57 (1H, s, C
2
-NH), 13.09 (1H, br, H-9);
 
HRMS calcd. for C14H12N5 (ES+) m/z 
250.1087 [M+H]
+
, found 250.1084. 
N-(4-Ethylphenyl)-6-ethynyl-9H-purin-2-amine (150) 
 
The TIPS-protected purine 166 (0.258 g, 0.61 mmol) was reacted with TBAF (1M in THF, 
920 μl, 0.92 mmol) in THF (6 ml) according to general procedure I. Purification via 
chromatography on silica (1:4 Petrol/EtOAc) gave the desired compound as a yellow solid 
(0.119 g, 0.45 mmol, 74%). Rf 0.36 (EtOAc); M.p. 120-140 °C (decomposed); λmax 
(EtOH/nm) 274; IR (cm
-1
) 3408, 3109, 2961, 2923, 2110, 1748; 
1
H NMR (500 MHz, DMSO-
d6) 1.17 (3H, t, J = 7.7 Hz, -CH2CH3), 2.56 (2H, q, J = 7.7 Hz, -CH2CH3), 4.83 (1H, s, 
C≡CH), 7.13 (2H, d, J = 8.5 Hz, H-3’/H-5’), 7.68 (2H, d, J = 8.5 Hz, H-2’/H-6’), 8.26 (1H, s, 
H-8), 9.57 (1H, s, C
2
-NH), 13.11 (1H, br, H-9);
 
HRMS calcd. for C15H14N5 (ES+) m/z 
264.1246 [M+H]
+
, found 264.1244. 
N-(4-Isopropylphenyl)-6-ethynyl-9H-purin-2-amine (151) 
 
The TIPS-protected purine 167 (0.259 g, 0.60 mmol) was reacted with TBAF (1M in THF, 
900 μl, 0.90 mmol) in THF (6 ml) according to general procedure I. Purification by silica 
gel chromatography (1:4 Petrol/EtOAc) afforded the target compound as a yellow solid 
(0.104 g, 0.37 mmol, 62%). Rf 0.40 (EtOAc); M.p. 120-140 °C (decomposed); λmax 
(EtOH/nm) 277; IR (cm
-1
) 3408, 3275, 2957, 2814, 2366, 2111; 
1
H NMR (500 MHz, DMSO-
d6) 0.97 (6H, d, J = 7.1 Hz, -CH(CH3)2), 2.61 (1H, sept, J = 7.1 Hz, -CH(CH3)2), 4.59 (1H, s, 
C≡CH), 6.92 (2H, d, J = 8.5 Hz, H-3’/H-5’), 7.44 (2H, d, J = 8.5 Hz, H-2’/H-6’), 8.02 (1H, s, 
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H-8), 9.32 (1H, s, C
2
-NH), 12.88 (1H, br, H-9); HRMS calcd. for C16H16N5 (ES+) m/z 
278.1404 [M+H]
+
, found 278.1400. 
4-(6-Ethynyl-9H-purin-2-ylamino)phenol (152) 
 
The TIPS-protected purine 168 (0.167 g, 0.30 mmol) was reacted with TBAF (1M in THF, 
0.66 ml, 0.66 mmol) in THF (3 ml) according to general procedure I. Silica gel 
chromatography (9:1 DCM/MeOH) afforded the desired compound as a beige solid (36 mg, 
0.14 mmol, 48%). Rf 0.36 (9:1 DCM/MeOH); M.p. 275-290 °C (decomposed); λmax 
(EtOH/nm) 274; IR (cm
-1
) 3391, 3257, 3059, 2921, 2849, 2567, 2114, 1623; 
1
H NMR (500 
MHz, DMSO-d6) 4.60 (1H, s, C≡CH), 6.51 (2H, d, J = 8.9 Hz, H-2’/H-6’), 7.32 (2H, d, J = 
8.9 Hz, H-3’/H-5’), 8.00 (1H, s, H-8), 8.83 (1H, s, C2-NH), 9.12 (1H, s, OH), 12.80 (1H, s, 
H-9); HRMS calcd. for C13H10N5O (ES+) m/z 252.0886 [M+H]
+
, found 252.0880. 
Note: Insufficient material for 13C NMR. 
6-Ethynyl-N-(3-methoxyphenyl)-9H-purin-2-amine (154) 
 
The TIPS-protected purine 169 (0.271 g, 0.64 mmol) was reacted with TBAF (1M in THF, 
960 μl, 0.96 mmol) in THF (6 ml) according to general procedure I. Silica gel 
chromatography (1:4 Petrol/EtOAc) gave the target compound as a yellow solid (0.119 g, 
0.45 mmol, 70%). Rf 0.30 (EtOAc); M.p. 130-150 °C (decomposed); λmax (EtOH/nm) 272; IR 
(cm
-1
) 3410, 3264, 3108, 2958, 2868, 2112, 1703; 
1
H NMR (500 MHz, DMSO-d6) 3.76 (3H, 
s, OCH3), 4.86 (1H, s, C≡CH), 6.53 (1H, ddd, J = 2.1 and 8.1 Hz, H-4’), 7.18 (1H, dd, J = 8.2 
Hz, H-5’), 7.30-7.34 (1H, m, H-6’), 7.59-7.62 (1H, m, H-2’), 8.30 (1H, s, H-8), 9.68 (1H, s, 
C
2
-NH), 13.20 (1H, s, H-9); HRMS calcd. for C14H12N5O (ES+) m/z 266.1036 [M+H]
+
, 
found 266.1038.  
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N-(4-Chlorophenyl)-6-ethynyl-9H-purin-2-amine (156) 
 
The TIPS-protected purine 171 (0.125 g, 0.29 mmol) and TBAF (1M in THF, 440 µL, 0.44 
mmol) were reacted in THF (5 ml) according to general procedure I, with purification by 
chromatography on silica (EtOAc) to give the desired product as a yellow solid (77 mg, 0.28 
mmol, 81%). Rf 0.34 (EtOAc); M.p. 180-200 °C (decomposed); λmax (EtOH/nm) 241; IR (cm
-
1
) 3414, 3278, 2921, 2848, 2108, 1576, 1522; 
1
H NMR (500 MHz, DMSO-d6) 4.87 (1H, s, 
C≡CH), 7.34 (2H, d, J = 8.9 Hz, H-2’/H-6’), 7.84 (2H, d, J = 8.9 Hz, H-3’/H-5’), 8.32 (1H, s, 
H-8), 9.85 (1H, s, C
2
-NH), 13.21 (1H, br, H-9); HRMS calcd. for C13H9N5Cl (ES+) m/z 
270.0541 [M+H]
+
, found 270.0540. 
N-(3-Chlorophenyl)-6-ethynyl-9H-purin-2-amine (157) 
 
The TIPS-protected purine 172 (0.255 g, 0.60 mmol) was reacted with TBAF (1M in THF, 
900 μl, 0.90 mmol) in THF (6 ml) according to general procedure I. Purification by 
chromatography on silica (1:4 Petrol/EtOAc) afforded the desired compound as a yellow 
solid (0.126 g, 0.47 mmol, 78%). Rf 0.35 (EtOAc); M.p. 130-150 °C (decomposed); λmax 
(EtOH/nm) 273; IR (cm
-1
) 3407, 3282, 3078, 2926, 2812, 2110, 1706; 
1
H NMR (500 MHz, 
DMSO-d6) 4.93 (1H, s, C≡CH), 7.00 (1H, ddd, J = 2.0, 2.1 and 8.0 Hz, H-6’), 7.34 (1H, dd, J 
= 8.0 Hz, H-5’), 7.71 (1H, ddd, J = 2.0, 2.1 and 8.1 Hz, H-4’), 8.09 (1H, br, H-2’), 8.37 (1H, 
s, H-8), 9.97 (1H, s, C
2
-NH), 13.31 (1H, s, H-9); HRMS calcd. for C13H9ClN5 (ES+) m/z 
270.0541 [M+H]
+
, found 270.0546.  
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3-(4-Nitrophenoxy)-N,N-dimethylpropan-1-amine (183)
249
 
 
K2CO3 (2.78 g, 20.1 mmol) was added to a solution of 4-nitrophenol (1.00 g, 7.20 mmol) in 
DMF (20 mL) and the mixture was stirred at RT for 15 min. 3-Dimethylaminopropylchloride 
hydrochloride (2.02 g, 12.9 mmol) was added portionwise and the mixture was heated at 80 
°C for 2 h. The solvent was removed in vacuo and the residue was dissolved in water (70 mL) 
and extracted with DCM (4 × 40 mL). The combined organic extracts were washed with 1M 
NaOH (100 mL), dried (MgSO4) and concentrated to give the desired product as a yellow oil 
(1.18 g, 5.25 mmol, 73%). Rf 0.34 (19:1 DCM/MeOH); λmax (EtOH/nm) 331; IR (cm
-1
) 3412, 
2948, 2819, 2770, 1592; 
1
H NMR (500 MHz, DMSO-d6) 1.89 (2H, tt, J = 6.8 and 6.9 Hz, 
OCH2CH2), 2.15 (6H, s, N(CH3)2), 2.36 (2H, t, J = 6.9 Hz, CH2N(CH3)2), 4.15 (2H, t, J = 6.8 
Hz, OCH2CH2), 7.15 (2H, d, J = 9.2 Hz, H-2/H-6), 8.21 (2H, d, J = 9.2 Hz, H-3/H-5); LRMS 
(ES+) m/z 225.2 [M+H]
+
. 
4-(3-(Dimethylamino)propoxy)benzenamine (184)
249
 
 
Palladium on carbon (0.10 g, 10% w/w) was added to a solution of the nitro compound 183 
(1.00 g, 4.50 mmol) in EtOH (20 mL) and the mixture was hydrogenated at RT for 18 h. The 
catalyst was removed by filtration through Celite
®
 and the solvent removed in vacuo to give 
the desired product as a pale red oil (0.789 g, 4.06 mmol, 91%). Rf 0.40 (9:1 DCM/MeOH); 
λmax (EtOH/nm) 235; IR (cm
-1
) 3323, 2359, 2180, 2004, 1630, 1511; 
1
H NMR (500 MHz, 
DMSO-d6) 1.77 (2H, tt, J = 6.7 and 6.9 Hz, OCH2CH2), 2.13 (6H, s, N(CH3)2), 2.32 (2H, t, J 
= 6.9 Hz, CH2N(CH3)2), 3.84 (2H, t, J = 6.7 Hz, OCH2CH2), 4.58 (2H, s, Ar-NH2), 6.50 (2H, 
d, J = 8.6 Hz, H-3/H-5), 6.63 (2H, d, J = 8.6 Hz, H-2/H-6); LRMS (ES+) m/z 195.1 [M+H]
+
. 
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N-(4-(3-(Dimethylamino)propoxy)phenyl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-
amine (185) 
 
2-Fluoropurine intermediate 160 (0.179 g, 0.56 mmol), aniline 184 (0.225 g, 1.15 mmol), 
TFA (216 µL, 2.81 mmol) and TFE (6 mL) were reacted according to general procedure B. 
The crude material was purified using chromatography on C18 silica (1:19 H2O/MeOH, 0.1% 
HCOOH) to give the desired compound as a yellow oil/gum (0.116 g, 0.24 mmol, 41%). Rf 
0.40 (19:1 MeOH/H2O, 0.1% HCOOH, C18); λmax (EtOH/nm) 279; IR (cm
-1
) 3401, 2945, 
2866, 1704, 1573; 
1
H NMR (500 MHz, DMSO-d6) 1.13-1.26 (23H, m, Si(CH(CH3)2)3 & -
OCH2CH2), 2.95 (6H, s, N(CH3)2), 3.37 (2H, t, J = 6.5 Hz, CH2N(CH3)2), 4.11 (2H, t, J = 5.7 
Hz, OCH2CH2), 6.92, (2H, d, J = 9.0 Hz, H-3’/H-5’), 7.67 (2H, d, J = 9.0 Hz, H-2’/H-6’), 
8.27 (1H, s, H-8), 9.52 (1H, s, C
2
-NH);
 13
C NMR (125 MHz, DMSO-d6) 10.6 
(Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 25.8 (CH2), 43.9 (N(CH3)2), 55.1 (CH2), 65.6 (CH2), 
97.5 (C≡C), 101.8 (C≡C), 114.4 (C-Ar), 120.0 (C-Ar), 134.2 (C-Ar), 139.5 (C-Ar), 142.7 (C-
Ar), 153.1 (C-Ar), 156.5 (C-Ar), 164.2 (C-Ar); HRMS calcd. for C27H41N6OSi (ES+) m/z 
493.3106 [M+H]
+
, found 493.3100. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
2-(3-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino) phenyl)acetic acid (186) 
 
2-Fluoropurine intermediate 160 (1.06 g, 3.32 mmol) and 3-aminophenyl acetic acid (1.00 g, 
6.64 mmol) were reacted with TFA (1.28 ml, 16.6 mmol) in TFE (25 ml) according to 
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general procedure B. Upon completion of the reaction, the reaction solvent was removed in 
vacuo and the resultant residue was dissolved in THF (20 ml) and 1M NaOH solution (15 
ml). The mixture was stirred at RT for 18 h before the THF was removed in vacuo. The 
aqueous solution was then taken to pH 3 with 4M HCl solution and extracted with EtOAc (3 
x 75 ml). The combined organic extracts were dried (Na2SO4) and concentrated, and the 
resulting orange residue was purified via chromatography on silica (9:1 DCM/MeOH) 
followed by chromatography on reverse phase silica (9:1 MeOH/H2O 0.1% HCOOH). The 
desired product was obtained as an orange oil/gum (0.952 g, 2.12 mmol, 64%). Rf 0.32 (9:1 
DCM/MeOH); λmax (EtOH/nm) 275; IR (cm
-1
) 2972, 2360, 2340, 1977, 1702; 
1
H NMR (500 
MHz, DMSO-d6) 1.13-1.22 (21H, m, Si(CH(CH3)2)3), 3.51 (2H, s, -CH2CO2H), 6.82-6.85 
(1H, m, H-6’), 7.22 (1H, dd, J = 7.7 and 7.8 Hz, H-5’), 7.65-7.68 (1H, m, H-2’), 7.72-7.76 
(1H, m, H-4’), 8.25 (1H, s, H-8), 9.71 (1H, s, C2-NH), 12.33 (1H, br, -CO2H), 13.10 (1H, br, 
H-9);
 13
C NMR (125 MHz, DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 41.2 
(COCH2), 116.7 (C-Ar), 119.2 (C-Ar), 122.0 (C-Ar), 128.2 (C-Ar), 135.2 (C-Ar), 140.9 (C-
Ar), 156.2 (C-Ar), 172.6 (C=O); HRMS calcd. for C24H32N5O2Si (ES+) m/z 450.2320 
[M+H]
+
, found 450.2320. 
Note: Unable to visualise quaternary carbon signals by 
13
C NMR. 
N-(4-Methoxybenzyl)-2-(3-(6-(2-(triisopropylsilyl)ethynyl)-9H-purin-2-
ylamino)phenyl)acetamide (187) 
 
Carboxylic acid 186 (0.193 g, 0.43 mmol), CDI (0.140 g, 0.86 mmol), DIPEA (150 μl, 0.86 
mmol) and 4-methoxybenzylamine (223 μl, 1.72 mmol) were reacted in dry DMF (5 ml) 
according to general procedure J. Chromatography on KP-NH silica (19:1 DCM/MeOH) 
gave the desired compound as a yellow oil/gum (0.238 g, 0.42 mmol, 99%). Rf 0.48 (19:1 
DCM/MeOH, KP-NH); λmax (EtOH/nm) 277; IR (cm
-1
) 2360, 2153, 2120, 1980; 
1
H NMR 
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(500 MHz, DMSO-d6) 1.12-1.25 (21H, m, Si(CH(CH3)2)3), 3.42 (2H, s, COCH2), 3.71 (3H, s, 
OCH3), 4.20 (2H, d, J = 5.8 Hz, NHCH2), 6.85 (2H, d, J = 8.8 Hz, H-3’’/H-5’’), 6.86-6.91 
(1H, m, H-6’), 7.17 (2H, d, J = 8.8 Hz, H-2’’/H-6’’), 7.20 (1H, dd, J = 7.9 and 8.0 Hz, H-5’), 
7.59-7.62 (1H, m, H-2’), 7.74-7.78 (1H, m, H-4’), 8.24 (1H, s, H-8), 8.44 (1H, t, J = 5.8 Hz, 
NHCH2), 9.65 (1H, s, C
2
-NH), 12.06 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 10.6 
(Si(CH(CH3)2)3), 18.5 (Si(CH(CH3)2)3), 41.7 (CH2), 42.6 (CH2), 55.0 (OCH3), 97.9 (C≡C), 
113.6 (C-Ar), 121.8 (C-Ar), 128.6 (C-Ar), 131.7 (C-Ar), 136.7 (C-Ar), 141.0 (C-Ar), 156.4 
(C-Ar), 158.1 (C-Ar), 169.9 (C=O); HRMS calcd. for C32H41N6O2Si (ES+) m/z 569.3055 
[M+H]
+
, found 569.3057. 
Note: Unable to visualise all quaternary carbon signals by 
13
C NMR. 
2-(3-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)phenyl) acetamide (189) 
 
The PMB-amide 187 (0.232 g, 0.41 mmol) was reacted in TFA (6 ml) according to general 
procedure K over 72 h. Purification via chromatography on KP-NH silica (19:1 
DCM/MeOH) gave the desired compound as a yellow oil/gum (0.170 g, 0.37 mmol, 90%). Rf 
0.24 (19:1 DCM/MeOH, KP-NH); λmax (EtOH/nm) 276; IR (cm
-1
) 3282, 2965, 2943, 2362, 
1669; 
1
H NMR (500 MHz, DMSO-d6) 1.13-1.21 (21H, m, Si(CH(CH3)2)3), 3.34 (2H, s, 
COCH2), 6.83-6.86 (1H, m, H-6’), 6.88 (1H, s, -CONHH’), 7.19 (1H, dd, J = 8.5 and 8.7 Hz, 
H-5’), 7.42 (1H, s, -CONHH’), 7.57-7.60 (1H, m, H-2’), 7.72-7.76 (1H, m, H-4’), 8.23 (1H, 
s, H-8), 9.65 (1H, s, C
2
-NH), 13.08 (1H, s, H-9);
 13
C NMR (125 MHz, CDCl3) 11.2 
(Si(CH(CH3)2)3), 18.7 (Si(CH(CH3)2)3), 46.9 (COCH2), 98.3 (C≡C), 119.0 (C-Ar), 120.6 (C-
Ar), 123.6 (C-Ar), 124.8 (C-Ar), 135.5 (C-Ar), 153.4 (C-Ar); HRMS calcd. for C24H33N6OSi 
(ES+) m/z 449.2480 [M+H]
+
, found 449.2480. 
Note: Unable to visualise all quaternary carbon signals by 
13
C NMR. 
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2-(3-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)phenyl)-N-(2-
(dimethylamino)ethyl)acetamide (188) 
 
Carboxylic acid 186 (0.188 g, 0.42 mmol), CDI (0.136 g, 0.84 mmol), DIPEA (145 μl, 0.84 
mmol) and N,N-dimethylethylenediamine (183 μl, 1.67 mmol)  were reacted in dry DMF (5 
ml) according to general procedure J. Chromatography on KP-NH silica (19:1 
DCM/MeOH) afforded the desired compound as a yellow oil/gum (0.222 g, 0.42 mmol, 
100%). Rf 0.42 (19:1 DCM/MeOH, KP-NH); λmax (EtOH/nm) 276; IR (cm
-1
) 2966, 2942, 
2344, 2158, 1653; 
1
H NMR (500 MHz, DMSO-d6) 1.13-1.22 (21H, m, Si(CH(CH3)2)3), 2.13 
(6H, s, N(CH3)2), 2.28 (2H, t, J = 6.7 Hz, CH2CH2N(CH3)2), 3.15 (2H, dt, J = 5.8 and 6.7 Hz, 
CH2CH2N(CH3)2), 3.37 (2H, s, COCH2) 6.82-6.86 (1H, m, H-6’), 7.19 (1H, dd, J = 7.7 and 
7.8 Hz, H-5’), 7.55-7.58 (1H, m, H-2’), 7.73-7.77 (1H, m, H-4’), 7.93 (1H, t, J = 5.8 Hz, 
CONH), 8.24 (1H, s, H-8), 9.66 (1H, s, C
2
-NH), 13.06 (1H, s, H-9); 
13
C NMR (125 MHz, 
DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 36.8 (CH2), 40.1 (CH2), 45.2 
(N(CH3)2), 58.2 (CH2), 113.6 (C-Ar), 122.6 (C-Ar), 128.1 (C-Ar), 135.2 (C-Ar), 136.6 (C-
Ar), 143.7 (C-Ar), 156.3 (C-Ar), 169.9 (C=O); HRMS calcd. for C28H42N7OSi (ES+) m/z 
520.3215 [M+H]
+
, found 520.3211. 
Note: Unable to visualise quaternary carbon signals by 
13
C NMR. 
2,2,2-Trifluoroethyl (3-nitrophenyl)methanesulfonate (190)
250
 
 
3-Nitro-α-toluenesulfonyl chloride (1.00 g, 4.24 mmol) was added to a solution of DMAP 
(0.052 g, 0.42 mmol) and triethylamine (1.77 ml, 12.7 mmol) in TFE (10 ml). The mixture 
was stirred at RT for 3 hour, after which the solvent was removed in vacuo. The residue was 
dissolved in DCM (60 ml) and washed with 0.05 M HCl (60 ml) and water (60 ml), and the 
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organic phase was passed through a phase separator and concentrated. The resulting oil was 
sonicated with water (5 ml), resulting in the formation of the product as a white precipitate 
which was collected via filtration and dried (1.25 g, 4.19 mmol, 99%). Rf 0.73 (7:3 
Petrol/EtOAc); M.p. 89-91 °C (Lit.
250
 84-85 °C); λmax (EtOH/nm) 257; IR (cm
-1
) 2998, 2950, 
2160, 1977, 1531; 
1
H NMR (500 MHz, DMSO-d6) 5.00 (2H, q, J = 8.4 Hz, F3CCH2), 5.19 
(2H, s, Ar-CH2), 7.76 (1H, dd, J = 8.0 and 8.2 Hz, H-5), 7.90-7.95 (1H, m, H-6), 8.30 (1H, 
ddd, J = 2.3, 2.4 and 8.2 Hz, H-4), 8.37-8.39 (1H, m, H-2); 
13
C NMR (125 MHz, DMSO-d6) 
53.9 (Ar-CH2), 65.0 (q, JCF = 36.6 Hz, CH2CF3), 122.5 (q, JCF = 276.9 Hz, CF3), 123.8 (C-
Ar), 125.5 (C-Ar), 130.2 (C-Ar), 130.3 (C-Ar), 137.4 (C-Ar), 147.8 (C-Ar);
 19
F NMR (470 
MHz, DMSO-d6) -72.9 (CF3); LRMS (ES-) m/z 298.1 [M-H]
-
. 
2,2,2-Trifluoroethyl (3-aminophenyl)methanesulfonate (192)
250
 
 
Palladium on carbon (0.30 g, 10% w/w) was added to a solution of the nitro compound 190 
(1.00 g, 3.34 mmol) in TFE (10 ml) and EtOAc (3 ml). The mixture was hydrogenated at RT 
for 18 h before being passed through Celite
®
 and concentrated. The crude oil was purified via 
chromatography on silica (7:3 Petrol/EtOAc) to give an oil, which was triturated with petrol 
(10 ml) to give the desired compound as a white solid (0.789 g, 2.93 mmol, 88%). Rf 0.36 
(7:3 Petrol/EtOAc); M.p. 74-76 °C (Lit.
250
 77-78 °C); λmax (EtOH/nm) 243; IR (cm
-1
) 3502, 
3397, 2945, 2359, 1619; 
1
H NMR (500 MHz, DMSO-d6) 4.76 (2H, s, Ar-NH2), 4.95 (2H, q, J 
= 8.7 Hz, F3CCH2O), 5.28 (2H, s, Ar-CH2), 6.59-6.64 (2H, m, H-4/H-6), 6.65-6.68 (1H, m, 
H-2), 7.09 (1H, dd, J = 7.7 and 7.9 Hz, H-5); 
13
C NMR (125 MHz, DMSO-d6) 55.6 (Ar-
CH2), 64.8 (q, JCF = 35.0 Hz, CH2CF3), 114.3 (C-Ar), 115.9 (C-Ar), 118.1 (C-Ar), 122.6 (q, 
JCF = 276.9 Hz, CF3), 128.0 (C-Ar), 129.1 (C-Ar), 148.9 (C-Ar); 
19
F NMR (470 MHz, 
DMSO-d6) -72.87 (CF3); LRMS (ES+) m/z 270.0 [M+H]
+
. 
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2,2,2-Trifluoroethyl (3-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino)phenyl) 
methanesulfonate (193) 
 
2-Fluoropurine intermediate 160 (0.416 g, 1.31 mmol) and aniline 192 (0.704 g, 2.62 mmol) 
were reacted with TFA (504 μl, 6.54 mmol) in TFE (10 ml) according to general procedure 
B. The resulting orange oil was purified via chromatography on reverse phase silica (19:1 
MeOH/H2O 0.1% HCOOH) followed by chromatography on silica (7:3 Petrol/EtOAc) to 
give the desired compound as a yellow/orange oil/gum (0.506 g, 0.89 mmol, 68%). Rf 0.34 
(9:1 MeOH/H2O, 0.1% HCOOH, C18); λmax (EtOH/nm) 368, 277; IR (cm
-1
) 2950, 2365, 
2161, 2011, 1967, 1601; 
1
H NMR (500 MHz, DMSO-d6) 1.13-2.23 (21H, m, Si(CH(CH3)2)3), 
4.85 (2H, s, Ar-CH2), 4.95 (2H, q, J = 8.7 Hz, F3CCH2O), 7.00-7.04 (1H, m, H-6’), 7.34 (1H, 
dd, J = 7.9 and 8.1 Hz, H-5’), 7.74-7.77 (1H, m, H-2’), 7.96-8.00 (1H, m, H-4’), 8.28 (1H, s, 
H-8), 9.84 (1H, s, C
2
-NH), 13.12 (1H, br, H-9); 
13
C NMR (125 MHz, CDCl3) 11.2 
(Si(CH(CH3)2)3), 18.7 (Si(CH(CH3)2)3), 57.8 (Ar-CH2), 65.2 (q, JCF = 38.0 Hz, CH2CF3), 
102.0 (C≡C), 120.0 (C-Ar), 121.0 (C-Ar), 121.9 (q, JCF = 277.8 Hz, CF3), 124.5 (C-Ar), 
127.4 (C-Ar), 129.7 (C-Ar), 140.5 (C-Ar), 156.1 (C-Ar); HRMS calcd. for C25H33F3N5O3SSi 
(ES+) m/z 568.2020 [M+H]
+
, found 568.2015. 
Note: Unable to visualise all quaternary carbon signals by 
13
C NMR. 
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N-(4-Methoxybenzyl)-1-(3-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-
yl)amino)phenyl)methanesulfonamide (194) 
 
Trifluoroethylsulfonate ester 193 (0.215 g, 0.38 mmol), 4-methoxybenzylamine (64 μl, 0.49 
mmol) and DBU (115 μl, 0.76 mmol) were reacted in dry THF (3 ml) according to general 
procedure O. Chromatography on silica (19:1 DCM/MeOH) gave the desired compound as a 
yellow oil (0.224 g, 0.37 mmol, 97%).  Rf 0.44 (19:1 DCM/MeOH); λmax (EtOH/nm) 276; IR 
(cm
-1
) 2361, 2341, 2162, 1992, 1969, 1609; 
1
H NMR (500 MHz, DMSO-d6) 1.13-1.22 (21H, 
m, Si(CH(CH3)2)3), 3.72 (3H, s, OCH3), 4.05 (2H, d, J = 6.0 Hz, NHCH2), 4.23 (2H, s, Ar-
CH2), 6.87 (2H, d, J = 8.7 Hz, H-3’’/H-5’’), 6.91-6.95 (1H, m, H-6’), 7.23 (2H, d, J = 8.7 Hz, 
H-2’’/H-6’’), 7.28 (1H, dd, J = 8.0 and 8.2 Hz, H-5’), 7.55 (1H, t, J = 6.0 Hz, NHCH2), 7.72-
7.75 (1H, m, H-2’), 7.87-7.91 (1H, m, H-4’), 8.26 (1H, s, H-8), 9.76 (1H, s, C2-NH), 13.06 
(1H, s, H-9); 
13
C NMR (125 MHz, DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 
45.7 (NHCH2), 55.0 (OCH3), 58.1 (Ar-CH2), 97.9 (C≡C), 113.6 (C-Ar), 118.0 (C-Ar), 120.7 
(C-Ar), 123.4 (C-Ar), 128.3 (C-Ar), 129.0 (C-Ar), 130.0 (C-Ar), 130.4 (C-Ar), 140.9 (C-Ar), 
156.2 (C-Ar), 158.4 (C-Ar); HRMS calcd. for C31H41N6O3SSi (ES+) m/z 605.2725 [M+H]
+
, 
found 605.2723. 
Note: Unable to visualise all carbon signals by 
13
C NMR.  
310 
 
(3-((6-((Triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino)phenyl) methanesulfonamide 
(195) 
 
PMB-sulfonamide 194 (0.221 g, 0.37 mmol) was reacted in TFA (6 ml) according to general 
procedure K over 3 h. The crude product was purified via chromatography on KP-NH silica 
(19:1 DCM/MeOH) to give the desired compound as a yellow oil/gum (0.108 g, 0.22 mmol, 
60%). Rf 0.21 (19:1 DCM/MeOH, KP-NH); λmax (EtOH/nm) 276; IR (cm
-1
) 3367, 2943, 
2865, 2160, 2021, 1606; 
1
H NMR (500 MHz, DMSO-d6) 1.13-1.23 (21H, m, Si(CH(CH3)2)3), 
4.21 (2H, s, Ar-CH2), 6.84 (2H, s, SO2NH2), 6.95-6.98 (1H, br, H-6’), 7.13 (1H, dd, J = 7.9 
and 8.0 Hz, H-5’), 7.68-7.71 (1H, m, H-2’), 7.90 (1H, ddd, J = 1.0, 1.9 and 8.0 Hz, H-4’), 
8.25 (1H, s, H-8), 9.75 (1H, s, C
2
-NH), 13.07 (1H, s, H-9);
 13
C NMR (125 MHz, DMSO-d6) 
10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 60.6 (Ar-CH2), 97.9 (C≡C), 117.9 (C-Ar), 120.8 
(C-Ar), 123.4 (C-Ar), 128.3 (C-Ar), 130.8 (C-Ar), 139.8 (C-Ar), 140.8 (C-Ar), 156.2 (C-Ar); 
HRMS calcd. for C23H33N6O2SSi (ES+) m/z 485.2149 [M+H]
+
, found 485.2147. 
Note: Unable to visualise all carbon signals by 
13
C NMR. 
N-(3-(Dimethylamino)propyl)-1-(3-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-
yl)amino)phenyl)methanesulfonamide (196) 
 
Trifluoroethylsulfonate ester 193 (0.227 g, 0.40 mmol), N,N-dimethylpropane-1,3-diamine 
(65 μl, 0.52 mmol) and DBU (120 μl, 0.80 mmol) were reacted in dry THF (3 ml) according 
to general procedure O. Purification by chromatography on KP-NH silica (9:1 
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DCM/MeOH) afforded the target compound as a yellow oil/gum (0.130 g, 0.23 mmol, 58%). 
Rf 0.38 (9:1 DCM/MeOH, KP-NH); λmax (EtOH/nm) 372, 276; IR (cm
-1
) 2941, 2864, 2364, 
2166, 2015, 1602; 
1
H NMR (500 MHz, DMSO-d6) 1.13-1.21 (21H, m, S(CH(CH3)2)3), 1.58 
(2H, tt, J = 6.9, 7.0 Hz, NHCH2CH2), 2.11 (6H, s, N(CH3)2), 2.25 (2H, t, J = 6.9 Hz, -
CH2N(CH3)2), 2.97 (2H, dt, J = 4.7 and 7.0 Hz, NHCH2CH2), 4.25 (2H, s, Ar-CH2), 6.92-
6.96 (1H, m, H-6’), 7.11 (1H, q, J = 4.7 Hz, NHCH2), 7.28 (1H, dd, J = 7.9 and 8.1 Hz, H-
5’), 7.77-7.80 (1H, m, H-2’), 7.82-7.86 (1H, m, H-4’), 8.28 (1H, s, H-8), 9.80 (1H, s, C2-NH);  
13
C NMR (125 MHz, DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3),  27.4 (CH2), 
41.1 (CH2), 44.8 (N(CH3)2), 56.3 (CH2), 57.4 (CH2), 97.9 (C≡C), 117.9 (C-Ar), 120.4 (C-Ar), 
123.4 (C-Ar), 128.3 (C-Ar), 130.5 (C-Ar), 140.9 (C-Ar), 156.1 (C-Ar); HRMS calcd. for 
C28H44N7O2SSi (ES+) m/z 570.3041 [M+H]
+
, found 570.3043. 
Note: Unable to visualise all quaternary carbon signals by 
13
C NMR. 
tert-Butyl-4-((3-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino)benzyl)sulfonyl) 
piperazine-1-carboxylate (198) 
 
Trifluoroethylsulfonate ester 193 (0.233 g, 0.41 mmol), tert-butyl piperazine-1-carboxylate 
(0.100 g, 0.53 mmol) and DBU (123 μl, 0.82 mmol) were reacted in dry THF (3 ml) 
according to general procedure O. Chromatography on KP-NH silica (9:1 DCM/MeOH) 
gave the desired compound as a yellow oil (0.186 g, 0.28 mmol, 68%). Rf 0.44 (9:1 
DCM/MeOH, KP-NH); λmax (EtOH/nm) 370, 277; IR (cm
-1
) 2941, 2866, 2362, 2159, 2031, 
1691, 1604; 
1
H NMR (500 MHz, DMSO-d6) 1.13-1.22 (21H, m, Si(CH(CH3)2)3), 1.33 (9H, s, 
C(CH3)3), 3.06-3.12 (4H, m, SO2N(CH2CH2)2), 3.30-3.35 (4H, br, SO2N(CH2CH2)2), 4.36 
(2H, s, Ar-CH2), 6.81-6.85 (1H, m, H-6’), 7.30 (1H, dd, J = 7.9 and 8.0 Hz, H-5’), 7.80-7.82 
(1H, m, H-2’), 7.88-7.92 (1H, m, H-4’), 8.27 (1H, s, H-8), 9.84 (1H, s, C2-NH), 13.10 (1H, s, 
H-9);
 13
C NMR (125 MHz, DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 27.87 
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(CH2), 30.68 (CH2), 45.26 Ar-CH2), 79.18 (C≡C), 122.6 (C-Ar), 127.1 (C-Ar), 153.52 (quat-
C); HRMS calcd. for C32H48N7O4SSi (ES+) m/z 654.3252 [M+H]
+
, found 654.3262. 
Note: Unable to visualise all quaternary carbon signals by 
13
C NMR. 
N-(3-((Piperazin-1-ylsulfonyl)methyl)phenyl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-
amine (197) 
 
The Boc-protected amine 198 (0.179 g, 0.27 mmol) and TFA (210 μl, 2.70 mmol) were 
reacted in DCM (5 ml) according to general procedure L. Purification via chromatography 
on silica (19:1 DCM/MeOH) afforded the desired compound as a yellow oil/gum (0.140 g, 
0.25 mmol, 93%). Rf 0.36 (19:1 DCM/MeOH); λmax (EtOH/nm) 276; IR (cm
-1
) 3325, 3252, 
2940, 2864, 2456, 1733; 
1
H NMR (500 MHz, DMSO-d6) 1.12-1.25 (21H, m, Si(CH(CH3)2)3), 
2.72-2.78 (4H, m, SO2N(CH2CH2)2), 3.20-3.25 (4H, br, SO2N(CH2CH2)2), 4.36 (2H, s, Ar-
CH2), 6.98 (1H, dd, J = 1.4, 1.5 and 7.6 Hz, H-6’), 7.27 (1H, dd, J = 7.6 and 7.8 Hz, H-5’), 
7.52-7.56 (1H, m, H-4’), 7.86-7.89 (1H, m, H-2’), 8.20 (1H, s, H-8), 9.72 (1H, s, C2-NH); 13C 
NMR (125 MHz, DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.5 (Si(CH(CH3)2)3), 27.2 (CH2), 33.8 
(CH2), 43.6 (Ar-CH2), 94.3 (C≡C), 118.3 (C-Ar), 130.4 (C-Ar), 156.1 (C-Ar); HRMS calcd. 
for C27H40N7O2SSi (ES+) m/z 554.2728 [M+H]
+
, found 554.2724. 
Note: Unable to visualise all carbon signals by 
13
C NMR. 
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2-(3-(6-Ethynyl-9H-purin-2-ylamino)phenyl)acetamide (177) 
 
The TIPS-protected purine 189 (0.165 g, 0.37 mmol) was reacted with TBAF (1M in THF, 
0.55 ml, 0.55 mmol) in THF (4 ml) according to general procedure I. The residue was 
purified via semi-preparative HPLC (17:3 H2O/MeCN), to give the desired compound as a 
yellow solid (0.084 g, 0.28 mmol, 76 %). Rf 0.32 (17:3 DCM/MeOH, KP-NH); M.p. 250-270 
°C (decomposed); λmax (EtOH/nm) 274; IR (cm
-1
) 3359, 3170, 2921, 2107, 1658; 
1
H NMR 
(500 MHz, DMSO-d6) 4.76 (1H, s, C≡CH), 6.77-6.81 (1H, m, H-6’), 6.83 (1H, s, CONHH’), 
7.15 (1H, dd, J = 8.0 and 8.1 Hz, H-5’), 7.38 (1H, s, CONHH’), 7.47-7.50 (1H, m, H-2’), 
7.68-7.73 (1H, m, H-4’), 8.19 (1H, s, H-8), 9.52 (1H, s, C2-NH), 13.06 (1H, s, H-9); 13C 
NMR (125 MHz, DMSO-d6) 48.6 (COCH2), 79.1 (C≡CH), 86.7 (C≡CH), 116.4 (C-Ar), 
119.2 (C-Ar), 121.8 (C-Ar), 128.2 (C-Ar), 136.6 (C-Ar), 140.8 (C-Ar), 144.5 (C-Ar), 156.1 
(C-Ar), 172.2 (C=O); HRMS calcd. for C15H13N6O (ES+) m/z 293.1149 [M+H]
+
, found 
293.1145. 
(3-((6-Ethynyl-9H-purin-2-yl)amino)phenyl)methanesulfonamide (178) 
 
The TIPS-protected purine 195 (60 mg, 0.12 mmol), TBAF (1M in THF, 0.15 ml, 0.15 
mmol) and the TBAF scavenger bead system 231 (0.60 g, 10 x w/w) were reacted in THF (5 
ml) according to general procedure U. Silica gel chromatography (9:1 DCM/MeOH) gave 
the target compound as a pale yellow solid (23 mg, 0.07 mmol, 58%). Rf 0.29 (9:1 
DCM/MeOH); M.p. 190-210 °C (decomposed); λmax (EtOH/nm) 273.5, 359.0; IR (cm
-1
) 
3361, 3248, 2976, 2809, 2707, 2114, 1701, 1610, 1583, 1491; 
1
H NMR (500 MHz, DMSO-
d6) 4.22 (2H, s, SO2CH2), 4.85 (1H, s, C≡CH), 6.86 (2H, s, SO2NH2), 6.94-6.98 (1H, m, H-
6’), 7.30 (1H, dd, J = 7.7 and 8.0 Hz, H-5’), 7.64-7.68 (1H, m, H-2’), 7.88-7.92 (1H, m, H-
4’), 8.29 (1H, s, H-8), 9.72 (1H, s, C2-NH), 13.13 (1H, br, H-9); 13C NMR (125 MHz, 
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DMSO-d6) 60.6 (SO2CH2), 78.9 (C≡CH), 87.1 (C≡CH), 118.0 (C-Ar), 120.8 (C-Ar), 123.5 
(C-Ar), 128.3 (C-Ar), 130.8 (C-Ar), 140.8 (C-Ar), 156.2 (C-Ar); HRMS calcd. for 
C14H13N6O2S (ES+) m/z 329.0815 [M+H]
+
, found 329.0821. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
2-(3-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)phenyl)-N,N-
dimethylacetamide (214) 
 
Carboxylic acid 186 (54 mg, 0.12 mmol), CDI (40 mg, 0.24 mmol), DIPEA (125 μl, 0.72 
mmol) and dimethylamine hydrochloride (40 mg, 0.48 mmol) were reacted in dry DMF (1 
ml) according to general procedure J. Chromatography on KP-NH silica (19:1 
DCM/MeOH) gave the desired compound as a yellow oil (51 mg, 0.11 mmol, 92%). Rf 0.38 
(19:1 DCM/MeOH, KP-NH); λmax (EtOH/nm) 275, 368; IR (cm
-1
) 3117, 2965, 2943, 2363, 
2160, 1711, 1598; 
1
H NMR (500 MHz, CDCl3) 1.14-1.18 (21H, m, Si(CH(CH3)2)3), 2.96 
(3H, s, N-CH3), 3.01 (3H, s, N-CH3), 3.68 (2H, s, CH2), 6.82-6.85 (1H, m, H-6’), 7.16 (1H, 
dd, J = 7.9 and 8.0 Hz, H-5’), 7.34-7.38 (1H, m, H-4’), 7.61 (1H, s, H-8), 7.65 (1H, br, H-2’), 
7.86 (1H, s, C
2
-NH); 
13
C NMR (125 MHz, CDCl3) 11.3 (Si(CH(CH3)2)3), 18.7 
(Si(CH(CH3)2)3), 35.8 (N-CH3), 37.8 (N-CH3), 40.9 (COCH2), 100.9 (C≡C), 101.1 (C≡C), 
117.9 (C-Ar), 119.7 (C-Ar), 122.8 (C-Ar), 129.2 (C-Ar), 135.6 (C-Ar), 137.0 (C-Ar), 140.3 
(C-Ar), 142.4 (C-Ar), 156.2 (C-Ar), 171.6 (C=O); HRMS calcd. for C26H37N6OSi (ES+) m/z 
477.2793 [M+H]
+
, found 477.2797. 
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2-(4-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)phenyl)acetic acid (215) 
 
2-Fluoropurine intermediate 160 (0.485 g, 1.53 mmol), (4-aminophenyl)acetic acid (0.460 g, 
3.05 mmol) and TFA (588 μl, 7.63 mmol) were reacted in TFE (15 ml) according to general 
procedure B. Upon completion of the reaction, the residue was dissolved in THF (15 ml) and 
1M NaOH solution (10 ml). The mixture was stirred at RT for 18 h before the THF was 
removed in vacuo. The aqueous solution was then taken to pH 3 with 4M HCl solution and 
extracted with EtOAc (3 x 30 ml). The combined organic extracts were dried (Na2SO4) and 
concentrated, and the resulting orange residue was purified via chromatography on reverse 
phase silica (9:1 MeOH/H2O 0.1% HCOOH). The desired product was obtained as an orange 
oil (0.365 g, 0.81 mmol, 53%). Rf 0.44 (9:1 MeOH/H2O, 0.1% HCOOH, C18); λmax 
(EtOH/nm) 263, 368; IR (cm
-1
) 2942, 2866, 2540, 2161, 2037, 1636; 
1
H NMR (500 MHz, 
DMSO-d6) 1.16 (21H, m, Si(CH(CH3)2)3), 3.34 (2H, s, CH2), 7.16 (2H, d, J = 8.6 Hz, H-
2’/H-6’), 7.73 (2H, d, J = 8.6 Hz, H-3’/H-5’), 8.24 (1H, s, H-8), 9.66 (1H, s, C2-NH), 13.10 
(1H, br, H-9);
 13
C NMR (125 MHz, MeOD) 12.5 (Si(CH(CH3)2)3), 19.1 (Si(CH(CH3)2)3), 
41.4 (COCH2), 100.4 (C≡C), 102.5 (C≡C), 120.0 (C-Ar), 109.2 (C-Ar), 130.5 (C-Ar), 140.8 
(C-Ar), 143.9 (C-Ar), 158.4 (C-Ar), 176.1 (C=O); HRMS calcd. for C24H30N5O2Si (ES-) m/z 
448.2174 [M-H]
-
 found 448.2163. 
Note: Unable to visualise all carbon signals by NMR.  
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N-(4-Methoxybenzyl)-2-(4-(6-(2-(triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)phenyl) 
acetamide (216) 
 
The carboxylic acid 215 (0.160 g, 0.36 mmol), CDI (0.115 g, 0.71 mmol), DIPEA (125 μl, 
0.71 mmol) and 4-methoxybenzylamine (185 μl, 1.43 mmol) were reacted in dry DMF (2 ml) 
according to general procedure J. Purification on KP-NH silica (19:1 DCM/MeOH) gave 
the desired compound as a yellow oil (0.159 g, 0.28 mmol, 78%). Rf 0.48 (19:1 DCM/MeOH, 
KP-NH); λmax (EtOH/nm) 278, 370; IR (cm
-1
) 3102, 2965, 2943, 2364, 2154, 1646; 
1
H NMR 
(500 MHz, CDCl3) 1.14-1.23 (21H, m, Si(CH(CH3)2)3), 3.62 (2H, s, CH2CO), 3.80 (3H, s, 
OCH3), 4.41 (2H, d, J = 5.8 Hz, CH2NH), 6.13 (1H, br, CH2NH), 6.86 (2H, d, J = 8.8 Hz, H-
2’/H-6’), 7.18 (2H, d, J = 8.8 Hz, H-3’/H-5’), 7.21 (2H, d, J = 8.5 Hz, H-3’’/H-5’’), 7.56 (2H, 
d, J = 8.5 Hz, H-2’’/H-6’’), 8.08 (1H, s, C2-NH), 8.23 (1H, s, H-8); 13C NMR (125 MHz, 
CDCl3) 11.3 (Si(CH(CH3)2)3), 18.7 (Si(CH(CH3)2)3), 43.0 (CH2), 43.3 (CH2), 55.3 (OCH3), 
114.1 (C-Ar), 120.8 (C-Ar), 121.6 (C-Ar), 129.0 (C-Ar), 129.9 (C-Ar), 134.8 (C-Ar), 141.9 
(C-Ar), 174.6 (C=O); HRMS calcd. for C32H41N6O2Si (ES+) m/z 569.3055 [M+H]
+
, found 
569.3051. 
Note: Unable to visualise all carbon signals by NMR. 
2-(4-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)phenyl) acetamide (217) 
 
PMB-carboxamide 216 (87 mg, 0.15 mmol) and TFA (2 ml) were reacted according to 
general procedure K. Chromatography on KP-NH silica (9:1 DCM/MeOH) gave the target 
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compound as a yellow oil (60 mg, 0.13 mmol, 87%). Rf 0.37 (9:1 DCM/MeOH, KP-NH); 
λmax (EtOH/nm) 278, 370; IR (cm
-1
) 3472, 2943, 2865, 2040, 1659; 
1
H NMR (500 MHz, 
DMSO-d6) 1.13-1.23 (21H, m, Si(CH(CH3)2)3), 3.31 (2H, s, COCH2), 6.83 (1H, s, -
CONHH’), 7.16 (2H, d, J = 8.6 Hz, H-2’/H-6’), 7.38 (1H, s, CONHH’), 7.71 (2H, d, J = 8.6 
Hz, H-3’/H-5’), 8.22 (1H, s, H-8), 9.64 (1H, s, C2-NH), 13.06 (1H, br, H-9); 13C NMR (125 
MHz, DMSO-d6) 10.4 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 118.4 (C-Ar), 129.0 (C-Ar), 
142.6 (C-Ar), 172.6 (C=O); HRMS calcd. for C24H33N6OSi (ES+) m/z 449.2480 [M+H]
+
, 
found 449.2480. 
Note: Unable to visualise all carbon signals by NMR. 
3-(3-(tert-Butoxycarbonylamino)phenyl)propanoic acid (220) 
 
(3-Aminophenyl)propionic acid (1.00 g, 6.06 mmol) and di-tert-butyl dicarbonate (1.45 g, 
6.66 mmol) were reacted in 1,4-dioxane (12 ml), 1 M NaOH (6 ml) and water (6 ml) 
according to general procedure P. The desired compound was obtained as an off-white 
waxy solid (1.42 g, 5.35mmol, 88%). Rf 0.18 (1:1 Petrol/EtOAc); M.p. 120-123 °C; λmax 
(EtOH/nm) 249, 276; IR (cm
-1
) 3307, 2927, 1690; 
1
H NMR (500 MHz, DMSO-d6) 1.48 (9H, 
s, C(CH3)3), 2.50 (2H, t, J = 7.7 Hz, ArCH2), 2.76 (2H, t, J = 7.7 Hz, COCH2), 6.81-6.85 (1H, 
m, H-6), 7.11-7.16 (1H, m, H-5), 7.22-7.26 (1H, m, H-4), 7.34-7.37 (1H, m, H-2), 9.27 (1H, 
s, Ar-NH), 12.13 (1H, s, COOH); 
13
C NMR (125 MHz, DMSO-d6) 28.1 (-C(CH3)3), 30.5 
(CH2), 35.2 (CH2), 78.9 (-C(CH3)3), 116.0 (C-Ar), 117.9 (C-Ar), 121.9 (C-Ar), 128.5 (C-Ar), 
139.5 (C-Ar), 141.3 (C-Ar), 152.7 (carbamate C=O), 173.6 (acid C=O); HRMS calcd. for 
C14H18NO4 (ES-) m/z 264.1241 [M-H]
-
 found 264.1233. 
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tert-Butyl-3-(2-(4-methoxybenzylcarbamoyl)ethyl)phenyl carbamate (222) 
 
Carboxylic acid 220 (0.762 g, 2.87 mmol), CDI (0.932 g, 5.74 mmol), DIPEA (1.00 ml, 5.74 
mmol) and 4-methoxybenzylamine (1.50 ml, 11.5 mmol) were reacted in dry DMF (15 ml) 
according to general procedure J. Chromatography on silica (1:1 Petrol/EtOAc) gave the 
desired compound as a colourless oil (1.08 g, 2.80 mmol, 98%). Rf 0.48 (1:1 Petrol/EtOAc); 
λmax (EtOH/nm) 232, 274; IR (cm
-1
) 3363, 3271, 2971, 2933, 1698, 1643; 
1
H NMR (500 
MHz, DMSO-d6) 1.47 (9H, s, -C(CH3)3), 2.40 (2H, t, J = 7.6 Hz, CH2CH2), 2.78 (2H, t, J = 
7.6 Hz, CH2CH2), 3.72 (3H, s, OCH3), 4.18 (2H, d, J = 5.9 Hz, CH2NH), 6.79-6.83 (1H, m, 
H-4’), 6.84 (2H, d, J = 8.4 Hz, H-3’/H-5’), 7.07 (2H, d, J = 8.4 Hz, H-2’/H-6’), 7.14 (1H, dd, 
J = 8.1 and 8.2 Hz, H-5’), 7.21-7.24 (1H, m, H-6’), 7.35-7.38 (1H, m, H-2’), 8.25 (1H, t, J = 
5.9 Hz, CH2NH), 9.27 (1H, s, Ar-NH); 
13
C NMR (125 MHz, DMSO-d6) 28.1 (-C(CH3)3), 
31.4 (CH2), 37.1 (CH2), 41.4 (CH2), 55.0 (OCH3), 79.2 (-C(CH3)3), 113.6 (C-Ar), 115.9 (C-
Ar), 118.1 (C-Ar), 122.0 (C-Ar), 128.4 (C-Ar), 131.4 (C-Ar), 139.5 (C-Ar), 141.7 (C-Ar), 
152.7 (carbamate C=O), 158.1 (C-Ar), 160.8 (C-Ar), 171.0 (amide C=O); HRMS calcd. for 
C22H29N2O4 (ES+) m/z 385.2122 [M+H]
+
, found 385.2126. 
N-(4-Methoxybenzyl)-3-(3-aminophenyl)propanamide (224) 
 
Boc-protected aniline 222 (1.00 g, 2.60 mmol) was reacted with TFA (2.00 ml, 26.0 mmol) in 
DCM (25 ml) according to general procedure L. Silica gel chromatography (1:1 
Petrol/EtOAc) afforded the desired compound as a white solid (0.643 g, 2.26 mmol, 87%). Rf 
0.46 (1:1 Petrol/EtOAc); M.p. 88-91 °C; λmax (EtOH/nm) 231, 274; IR (cm
-1
) 3424, 3337, 
3241, 3063, 2945, 2904, 1629; 
1
H NMR (500 MHz, DMSO-d6) 2.36 (2H, t, J = 7.8 Hz, 
CH2CH2), 2.67 (2H, t, J = 7.8 Hz, CH2CH2), 3.73 (3H, s, OCH3), 4.18 (2H, d, J = 5.9 Hz, 
CH2NH), 4.95 (2H, s, Ar-NH2), 6.33-6.40 (3H, m, H-2/H-4/H-6), 6.86 (2H, d, J = 7.9 Hz, H-
3’/H-5’), 6.90 (1H, dd, J = 7.4 and 7.5 Hz, H-5), 7.11 (2H, d, J = 7.9 Hz, H-2’/H-6’), 8.25 
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(1H, t, J = 5.9 Hz, CH2NH); 
13
C NMR (125 MHz, DMSO-d6) 31.4 (CH2), 37.1 (CH2), 41.4 
(CH2), 55.0 (OCH3), 111.6 (C-Ar), 113.6 (C-Ar), 113.9 (C-Ar), 115.7 (C-Ar), 128.4 (C-Ar), 
128.7 (C-Ar), 131.5 (C-Ar), 141.8 (C-Ar), 148.5 (C-Ar), 158.1 (C-Ar), 171.3 (C=O); HRMS 
calcd. for C17H21N2O2 (ES+) m/z 285.1598 [M+H]
+
, found 285.1603. 
N-(4-Methoxybenzyl)-3-(3-(6-(2-(triisopropylsilyl)ethynyl)-9H-purin-2-
ylamino)phenyl)propanamide (226) 
 
2-Fluoropurine intermediate 160  (0.273 g, 0.86 mmol), aniline 224 (0.490 g, 1.72 mmol) and 
TFA (330 μl, 4.29 mmol) were reacted in TFE (5 ml) according to general procedure B. 
Chromatography on KP-NH silica (19:1 DCM/MeOH) gave the target compound as a yellow 
oil (0.205 g, 0.35 mmol, 41%). Rf 0.35 (19:1 DCM/MeOH, KP-NH); λmax (EtOH/nm) 277, 
363; IR (cm
-1
) 3278, 3082, 2944, 2865, 2359, 1644; 
1
H NMR (500 MHz, CDCl3) 1.17-1.31 
(21H, m, Si(CH(CH3)2)3), 2.57 (2H, t, J = 7.3 Hz, CH2CH2), 2.99 (2H, t, J = 7.3 Hz, 
CH2CH2), 3.73 (3H, s, OCH3), 4.31 (2H, d, J = 5.5 Hz, CH2NH), 6.12 (1H, br, CH2NH), 6.72 
(2H, d, J = 8.8 Hz, H-3’’/H-5’’), 6.82-6.86 (1H, m, H-6’), 7.01 (2H, d, J = 8.8 Hz, H-2’’/H-
6’’), 7.17-7.23 (2H, m, H-4’/H-5’), 7.37 (1H, s, C2-NH), 7.79 (1H, s, H-8), 7.83 (1H, br, H-
2’), 11.94 (1H, br, H-9); 13C NMR (125 MHz, CDCl3) 11.3 (Si(CH(CH3)2)3), 18.7 
(Si(CH(CH3)2)3), 31.8 (CH2), 38.1 (CH2), 43.2 (CH2), 55.2 (OCH3), 101.2 (C≡C), 113.9 (C-
Ar), 117.3 (C-Ar), 119.0 (C-Ar), 122.5 (C-Ar), 129.0 (C-Ar), 129.1 (C-Ar), 129.9 (C-Ar), 
139.9 (C-Ar), 141.4 (C-Ar), 156.3 (C-Ar), 158.9 (C-Ar), 172.5 (C=O); HRMS calcd. for 
C33H43N6O2Si (ES+) m/z 583.3211 [M+H]
+
, found 583.3212. 
Note: Unable to visualise all carbon signals by NMR. 
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3-(3-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)phenyl) propanamide (228) 
 
PMB-carboxamide 226 (0.178 g, 0.31 mmol) and TFA (3 ml) were reacted according to 
general procedure K. Chromatography on KP-NH silica (19:1 DCM/MeOH) gave the 
desired compound as a yellow oil (81 mg, 0.18 mmol, 58%). Rf 0.38 (19:1 DCM/MeOH, KP-
NH); λmax (EtOH/nm) 260, 368; IR (cm
-1
) 3185, 2942, 2864, 2159, 2030, 1660; 
1
H NMR 
(500 MHz, DMSO-d6) 1.10-1.23 (21H, m, Si(CH(CH3)2)3), 2.37 (2H, t, J = 7.6 Hz, CH2CH2), 
2.78 (2H, t, J = 7.6 Hz, CH2CH2), 6.77-6.80 (2H, m, CONHH’/H-6’), 7.17 (1H, dd, J = 7.8 
and 7.9 Hz, H-5’), 7.31 (1H, s, CONHH’), 7.61-7.64 (1H, m, H-4’), 7.66-7.69 (1H, m, H-2’), 
8.25 (1H, s, H-8), 9.63 (1H, s, C
2
-NH), 13.08 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 
10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 31.3 (CH2), 36.8 (CH2), 116.1 (C-Ar), 118.1 (C-
Ar), 120.8 (C-Ar), 128.3 (C-Ar), 140.9 (C-Ar), 141.6 (C-Ar), 156.2 (C-Ar), 173.4 (C=O); 
HRMS calcd. for C25H35N6OSi (ES+) m/z 463.2636 [M+H]
+
, found 463.2634. 
Note: Unable to visualise all carbon signals by NMR. 
3-((tert-Butoxycarbonyl)amino)benzoic acid (221)
251
 
 
3-Aminobenzoic acid (1.00 g, 7.29 mmol) and di-tert-butyl dicarbonate (1.75 g, 8.02 mmol) 
were reacted in 1,4-dioxane (15 ml), 0.5M NaOH (15 ml) according to general procedure P. 
The desired compound was obtained as a white waxy solid (1.61 g, 6.77 mmol, 93%). Rf 0.15 
(1:1 Petrol/EtOAc); M.p. 183-185 °C (Lit.
251
 189-190 °C); λmax (EtOH/nm) 247, 301; IR (cm
-
1
) 3352, 3002, 2971, 1690; 
1
H NMR (500 MHz, DMSO-d6) 1.49 (9H, s, -C(CH3)3), 7.37 (1H, 
dd, J = 7.9 and 8.0 Hz, H-5), 7.54 (1H, ddd, J = 1.2, 1.3 and 7.9 Hz, H-6), 7.61-7.65 (1H, m, 
H-4), 8.13-8.16 (1H, m, H-2), 9.55 (1H, br, Ar-NH), 12.88 (1H, br, COOH); 
13
C NMR (125 
321 
 
MHz, DMSO-d6) 28.1 (C(CH3)3), 79.3 (C(CH3)3), 122.2 (C-Ar), 122.9 (C-Ar), 128.8 (C-Ar), 
131.3 (C-Ar), 139.8 (C-Ar), 152.7 (carbamate C=O), 167.3 (acid C=O); LRMS (ES-) m/z 
236.2 [M-H]
-
. 
tert-Butyl 3-(4-methoxybenzylcarbamoyl)phenyl carbamate (223) 
 
Carboxylic acid 221 (0.601 g, 2.53 mmol), CDI (0.823 g, 5.07 mmol), DIPEA (885 μl, 5.07 
mmol) and 4-methoxybenzylamine (1.31 ml, 10.1 mmol) were reacted in dry DMF (13 ml) 
according to general procedure J. Purification via chromatography on silica (7:3 
Petrol/EtOAc) gave the desired compound as a white solid (0.841 g, 2.36 mmol, 93%). Rf 
0.27 (7:3 Petrol/EtOAc); M.p. 166-170 °C; λmax (EtOH/nm) 234; IR (cm
-1
) 3349, 3274, 3062, 
2931, 2836, 1697, 1644; 
1
H NMR (500 MHz, DMSO-d6) 1.49 (9H, s, -C(CH3)3), 3.74 (3H, s, 
OCH3), 4.38 (2H, d, J = 6.0 Hz, CH2NH), 6.89 (2H, d, J = 8.4 Hz, H-3’/H-5’), 7.24 (2H, d, J 
= 8.4 Hz, H-2’/H-6’), 7.33 (1H, dd, J = 7.9 and 8.1 Hz, H-5), 7.43-7.47 (1H, m, H-4), 7.52-
7.56 (1H, m, H-6), 7.98-8.00 (1H, m, H-2), 8.89 (1H, t, J = 6.0 Hz, CH2NH), 9.48 (1H, s, Ar-
NH); 
13
C NMR (125 MHz, DMSO-d6) 28.1 (C(CH3)3), 42.4 (NHCH2), 55.0 (OCH3), 79.2 
(C(CH3)3), 113.8 (C-Ar), 117.4 (C-Ar), 120.8 (C-Ar), 128.3 (C-Ar), 128.5 (C-Ar), 128.6 (C-
Ar), 132.8 (C-Ar), 135.3 (C-Ar), 139.6 (C-Ar), 152.8 (carbamate C=O), 160.9 (C-Ar), 166.3 
(amide C=O); HRMS calcd. for C20H25N2O4 (ES+) m/z 357.1809 [M+H]
+
, found 357.1812. 
N-(4-Methoxybenzyl)-3-aminobenzamide (225) 
 
Boc-protected aniline 223 (0.831 g, 2.33 mmol) was reacted with TFA (1.80 ml, 23.3 mmol) 
in DCM (25 ml) according to general procedure L. Purification via chromatography on 
silica (1:1 Petrol/EtOAc) gave the target compound as a white waxy solid (0.472 g,1.84 
mmol, 79%). Rf 0.30 (1:1 Petrol/EtOAc); M.p. 90-93 °C; λmax (EtOH/nm) 242, 306; IR (cm
-1
) 
3349, 3274, 2972, 2930, 1697, 1643; 
1
H NMR (500 MHz, DMSO-d6) 3.73 (3H, s, OCH3), 
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4.36 (2H, d, J = 6.1 Hz, CH2NH), 5.22 (2H, s, Ar-NH2), 6.89 (1H, ddd, J = 2.3, 2.4 and 7.9 
Hz, H-4), 6.88 (2H, d, J = 8.8 Hz, H-3’/H-5'), 6.97-7.00 (1H, m, H-6), 7.04-7.09 (2H, m, H-
2/H-5), 7.23 (2H, d, J = 8.8 Hz, H-2’/H-6’), 8.73 (1H, t, J = 6.1 Hz, CH2NH); 
13
C NMR (125 
MHz, DMSO-d6) 41.9 (CH2), 55.0 (OCH3), 112.8 (C-Ar), 113.6 (C-Ar), 113.7 (C-Ar), 114.2 
(C-Ar), 116.3 (C-Ar), 128.5 (C-Ar), 128.6 (C-Ar), 131.9 (C-Ar), 135.4 (C-Ar), 148.6 (C-Ar), 
166.8 (C=O); HRMS calcd. for C15H17N2O2 (ES+) m/z 257.1285 [M+H]
+
, found 257.1289. 
N-(4-Methoxybenzyl)-3-(6-(2-(triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)benzamide 
(227) 
 
2-Fluoropurine intermediate 160 (0.265 g, 0.83 mmol), aniline 225 (0.428 g, 1.67 mmol) and 
TFA (320 μl, 4.17 mmol) were reacted in TFE (5 ml) according to general procedure B. 
Purification via chromatography on KP-NH silica (19:1 DCM/MeOH) followed by normal 
phase silica (1:1 Petrol/EtOAc) gave the desired compound as a yellow oil (88 mg, 0.16 
mmol, 9%). Rf 0.42 (1:1 Petrol/EtOAc); λmax (EtOH/nm) 279, 364; IR (cm
-1
) 2864, 2159, 
1739, 1641; 
1
H NMR (500 MHz, DMSO-d6) 1.13-1.18 (21H, m, Si(CH(CH3)2)3), 3.74 (3H, s, 
OCH3), 4.40 (2H, d, J = 5.9 Hz, CH2NH), 6.90 (2H, d, J = 8.9 Hz, H-3’’/H-5’’), 7.27 (2H, d, 
J = 8.9 Hz, H-2’’/H-6’’), 7.35 (1H, m, H-5’), 7.41 (1H, m, H-6’), 7.95 (1H, m, H-4’), 8.22-
8.25 (2H, m, H-8/H-2’), 8.89 (1H, t, J = 5.9 Hz, CH2NH), 9.83 (1H, s, C
2
-NH), 13.16 (1H, br, 
H-9); 
13
C NMR (125 MHz, DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 42.1 
(CH2), 55.0 (OCH3), 113.6 (C-Ar), 117.9 (C-Ar), 121.0 (C-Ar), 128.2 (C-Ar), 128.6 (C-Ar), 
131.8 (C-Ar), 135.3 (C-Ar), 156.1 (C-Ar), 158.1 (C-Ar), 166.5 (C=O); HRMS calcd. for 
C31H39N6O2Si (ES+) m/z 555.2898 [M+H]
+
, found 555.2893. 
Note: Unable to visualise all carbon signals by NMR. 
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3-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)benzamide (229) 
 
PMB-carboxamide 227 (82 mg, 0.15 mmol) and TFA (2 ml) were reacted according to 
general procedure K over 24 h. Chromatography on KP-NH silica (9:1 DCM/MeOH) 
afforded the target compound as a yellow oil (55 mg, 0.13 mmol, 87%). Rf 0.41 (9:1 
DCM/MeOH, KP-NH); λmax (EtOH/nm) 263, 365; IR (cm
-1
) 3295, 2964, 2943, 1660; 
1
H 
NMR (500 MHz, DMSO-d6) 1.14-1.19 (21H, m, Si(CH(CH3)2)3), 7.30-7.36 (2H, m, 
CONHH’/H-5’), 7.40-7.42 (1H, m, H-6’), 7.85 (1H, s, CONHH’), 7.90-7.93 (1H, m, H-4’), 
8.23 (1H, br, H-2’), 8.31 (1H, s, H-8), 9.83 (1H, s, C2-NH); 13C NMR (125 MHz, DMSO-d6) 
10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 98.1 (C≡C), 101.6 (C≡C), 118.0 (C-Ar), 119.9 
(C-Ar), 121.1 (C-Ar), 128.1 (C-Ar), 135.1 (C-Ar), 139.1 (C-Ar), 140.8 (C-Ar), 143.2 (C-Ar), 
156.2 (C-Ar), 168.4 (C=O); HRMS calcd. for C23H31N6OSi (ES+) m/z 435.2323 [M+H]
+
, 
found 435.2325. 
Note: Unable to visualise all carbon signals by NMR. 
2-(3-(6-Ethynyl-9H-purin-2-ylamino)phenyl)-N,N-dimethylacetamide (201) 
 
TIPS-protected purine 214 (48 mg, 0.10 mmol) and TBAF (1M in THF, 110 μl, 0.11 mmol) 
were reacted in THF (2 ml) according to general procedure I. Purification on silica gel (9:1 
DCM/MeOH) afforded the desired compound as a yellow solid (28 mg, 0.087 mmol, 87%). 
Rf 0.45 (9:1 DCM/MeOH); M.p. 120-130 °C (decomposed); λmax (EtOH/nm) 274; IR (cm
-1
) 
3084, 2818, 2161, 2110, 2029, 1596; 
1
H NMR (500 MHz, DMSO-d6) 2.65 (3H, s, N-CH3), 
2.83 (3H, s, -N-CH3), 3.45 (2H, s, CH2CO), 4.65 (1H, s, C≡CH), 6.57-6.60 (1H, m, H-6’), 
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7.02 (1H, dd, J = 7.8 and 8.0 Hz, H-5’), 7.31-7.34 (1H, m, H-2’), 7.54 (1H, ddd, J = 1.0, 1.2 
and 7.8 Hz, H-4’), 8.08 (1H, s, H-8), 9.44 (1H, s, C2-NH), 12.93 (1H, br, H-9); 13C NMR 
(125 MHz, DMSO-d6) 34.98 (N-CH3), 37.29 (N-CH3), 40.2 (COCH2) 87.0 (C≡CH), 116.5 
(C-Ar), 119.1 (C-Ar), 121.8 (C-Ar), 128.3 (C-Ar), 136.1 (C-Ar), 140.8 (C-Ar), 156.2 (C-Ar), 
170.2 (C=O); HRMS calcd. for C17H17N6O (ES+) m/z 321.1462 [M+H]
+
, found 321.1458. 
Note: Unable to visualise all carbon signals by NMR. 
Solid supported TBAF scavenger (231)
209
 
 
Amberlite 15 Ion exchange resin (SO3H, 100 ml) was loaded into a column and washed with 
water (400 ml). The column was eluted with sat. calcium hydroxide solution whilst the pH of 
the eluent was monitored. Once the initially pH neutral eluent became strongly basic, the 
column was eluted with water until the pH of the eluent returned to neutral. The resin was 
washed with DCM (300 ml), THF (300 ml) and Et2O (300 ml), before being removed from 
the column and dried in a vacuum oven at 40 °C. 
2-(4-(6-Ethynyl-9H-purin-2-ylamino)phenyl)acetamide (202) 
 
TIPS-protected purine 217 (53 mg, 0.12 mmol) and TBAF (1M in THF, 130 μl, 0.13 mmol) 
were reacted in THF (2 ml) according to general procedure I. Upon completion of the 
reaction, the solution was diluted with THF (10 ml) and treated with the solid supported 
TBAF scavenger 231 (0.20 g, 4 x w/w) at RT for 18 h. The resin was removed via filtration 
and the solvent removed in vacuo. The crude residue was purified via chromatography on 
silica (9:1 DCM/MeOH) to give the desired compound as a yellow solid (16 mg, 0.055 mmol, 
46%). Rf 0.24 (9:1 DCM/MeOH); M.p. 140-150 °C (decomposed); λmax (EtOH/nm) 275; IR 
(cm
-1
) 3375, 3287, 3193, 3127, 2157, 2119, 2030, 1653, 1604; 
1
H NMR (500 MHz, DMSO-
d6) 3.31 (2H, s, COCH2), 4.84 (1H, s, -C≡CH), 6.85 (1H, s, -CONHH’), 7.17 (2H, d, J = 8.6 
Hz, H-2’/H-6’), 7.40 (1H, s, -CONHH’), 7.69 (2H, d, J = 8.6 Hz, H-3’/H-5’), 8.27 (1H, s, H-
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8), 9.62 (1H, s, C
2
-NH), 13.12 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 41.7 
(COCH2), 86.9 (C≡CH), 118.5 (C-Ar), 129.0 (C-Ar), 139.1 (C-Ar), 156.3 (C-Ar), 172.5 
(C=O); HRMS calcd. for C15H13N6O (ES+) m/z 293.1148 [M+H]
+
, found 293.1145. 
Note: Unable to visualise all carbon signals by NMR. 
3-(3-(6-Ethynyl-9H-purin-2-ylamino)phenyl)propanamide (212) 
 
TIPS-protected purine 228 (45 mg, 0.097 mmol) and TBAF (1M in THF, 106 μl, 0.106 
mmol) were reacted in THF (2 ml) according to general procedure I. Upon completion of 
the reaction, the solution was diluted with THF (10 ml) and treated with solid supported 
TBAF scavenger 231 (0.20 g, 4 x w/w) at RT for 18 h. The resin was removed via filtration 
and the solvent removed in vacuo. The crude residue was purified via chromatography on 
silica (17:3 DCM/MeOH) to give the desired compound as a yellow solid (16 mg, 0.055 
mmol, 46%). Rf 0.45 (17:3 Petrol/EtOAc); M.p. 135-145 °C (decomposed); λmax (EtOH/nm) 
273; IR (cm
-1
) 3380, 3249, 3093, 2828, 2779, 2160, 2116, 2030, 1653; 
1
H NMR (500 MHz, 
DMSO-d6) 2.37 (2H, t, J = 7.6 Hz, -COCH2CH2), 2.78 (2H, t, J = 7.6 Hz, -COCH2CH2), 4.84 
(1H, s, -C≡CH), 6.77-6.81 (2H, m, -CONHH’ & H-6’), 7.19 (1H, dd, J = 7.9 and 8.0 Hz, H-
5’), 7.32 (1H, s, -CONHH’), 7.57-7.60 (1H, br, H-2’), 7.66-7.69 (1H, m, H-4’), 8.27 (1H, s, 
H-8), 9.60 (1H, s, C
2
-NH), 13.13 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 31.3 (CH2), 
36.7 (CH2), 86.9 (C≡CH), 116.1 (C-Ar), 118.2 (C-Ar), 120.9 (C-Ar), 128.3 (C-Ar), 140.8 (C-
Ar), 141.6 (C-Ar), 156.2 (C-Ar), 173.4 (C=O); HRMS calcd. for C16H15N6O (ES+) m/z 
307.1305 [M+H]
+
, found 307.1302. 
Note: Unable to visualise all carbon signals by NMR. 
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3-(6-Ethynyl-9H-purin-2-ylamino)benzamide (205) 
 
TIPS-protected purine 229 (33 mg, 0.076 mmol), KF (22 mg, 0.38 mmol) and 18-crown-6 (3 
mg, 0.008 mmol) were reacted in THF (1 ml) according to general procedure Q. 
Purification via chromatography on silica (17:3 DCM/MeOH) afforded the desired compound 
as a yellow solid (20 mg, 0.071 mmol, 94%). Rf 0.38 (17:3 Petrol/EtOAc); M.p. 170-180 °C 
(decomposed); λmax (EtOH/nm) 274; IR (cm
-1
) 3254, 3085, 2830, 2775, 2551, 2162, 2117, 
1659; 
1
H NMR (500 MHz, DMSO-d6) 4.89 (1H, s, -C≡CH), 7.35 (1H, s, -CONHH’), 7.39 
(1H, dd, J = 7.8 and 7.9 Hz, H-5’), 7.43-7.46 (1H, m, H-6’), 7.90 (1H, s, -CONHH’), 7.97-
7.80 (1H, m, H-4’), 8.20-8.23 (1H, m, H-2’), 8.32 (1H, s, H-8), 9.80 (1H, s, C2-NH), 13.21 
(1H, br, H-9); HRMS calcd. for C14H11N6O (ES+) m/z 279.0993 [M+H]
+
, found 279.0989. 
Note: Insufficient material for 
13
C NMR. 
Methyl 2-(3-aminophenyl)acetate (234)
252
 
 
(3-Aminophenyl)acetic acid (1.00 g, 6.62 mmol) and thionyl chloride (970 μl, 13.2 mmol) 
were reacted in dry MeOH (35 ml) according to general procedure R. Chromatography on 
silica (7:3 Petrol/EtOAc) gave the target compound as a pale yellow oil (0.927 g, 5.61 mmol, 
85%). Rf 0.32 (7:3 Petrol/EtOAc); λmax (EtOH/nm) 221, 285; IR (cm
-1
) 3369, 2952, 1724; 
1
H 
NMR (500 MHz, DMSO-d6) 3.50 (2H, s, CH2), 3.61 (3H, s, OCH3), 5.70 (2H, br, Ar-NH2), 
6.45-6.48 (1H, m, H-4), 6.51-6.54 (2H, m, H-2/H-6), 6.97-7.01 (1H, m, H-5); 
13
C NMR (125 
MHz, DMSO-d6) 40.5 (CH2), 51.6 (OCH3), 113.3 (C-Ar), 115.3 (C-Ar), 117.7 (C-Ar), 128.9 
(C-Ar), 134.8 (C-Ar), 147.2 (C-Ar), 171.7 (C=O); LRMS (ES+) m/z 166.2 [M+H]
+
. 
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2-(3-Aminophenyl)-N-methylacetamide (236)
253
 
 
Methyl ester 234 (0.250 g, 1.51 mmol) and methylamine (40% aqueous solution, 8 ml) were 
reacted according to general procedure S. Chromatography on silica (9:1 DCM/MeOH) 
afforded the desired compound was obtained as a pale yellow oil (0.233 g, 1.42 mmol, 94%). 
Rf 0.38 (9:1 DCM/MeOH); λmax (EtOH/nm) 220; IR (cm
-1
) 3331, 3091, 2943, 1629; 
1
H NMR 
(500 MHz, DMSO-d6) 2.56 (3H, d, J = 4.8 Hz, NHCH3), 3.20 (2H, s, CH2), 4.98 (2H, s, Ar-
NH2), 6.37-6.41 (2H, m, H-4/H-6), 6.42-6.45 (1H, br, H-2), 6.91 (1H, dd, J = 7.7 and 7.9 Hz, 
H-5), 7.82 (1H, br, NHCH3); 
13
C NMR (125 MHz, DMSO-d6) 25.6 (NHCH3), 42.7 (CH2), 
112.0 (C-Ar), 114.4 (C-Ar), 116.5 (C-Ar), 128.6 (C-Ar), 136.8 (C-Ar), 148.5 (C-Ar), 170.7 
(C=O); LRMS (ES+) m/z 165.2 [M+H]
+
. 
2-(3-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)phenyl)-N-methylacetamide 
(239) 
 
2-Fluoropurine intermediate 160 (0.127 g, 0.40 mmol), aniline 236 (0.130 g, 0.80 mmol) and 
TFA (155 μl, 2.00 mmol) were reacted in TFE (2 ml) according to general procedure B. 
Purification via chromatography on KP-NH silica (19:1 DCM/MeOH) afforded the desired 
compound as a yellow oil (70 mg, 0.15 mmol, 38%). Rf 0.41 (19:1 DCM/MeOH, KP-NH); 
λmax (EtOH/nm) 264, 368; IR (cm
-1
) 2942, 2864, 2159, 1641; 
1
H NMR (500 MHz, DMSO-d6) 
1.13-1.17 (21H, m, Si(CH(CH3)2)3), 2.59 (3H, d, J = 4.6 Hz, NHCH3), 3.36 (2H, s, CH2), 
6.83-6.85 (1H, m, H-6’), 7.20 (1H, dd, J = 7.9 and 7.9 Hz, H-5’), 7.57 (1H, br, H-2’), 7.74-
7.77 (1H, m, H-4’), 7.90 (1H, br, NHCH3), 8.25 (1H, s, H-8), 9.66 (1H, s, C
2
-NH), 13.08 
(1H, s, H-9); 
13
C NMR (125 MHz, DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 
25.6 (NHCH3), 42.6 (CH2), 116.6 (C-Ar), 119.3 (C-Ar), 121.7 (C-Ar), 128.2 (C-Ar), 136.5 
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(C-Ar), 140.8 (C-Ar), 156.3 (C-Ar), 170.4 (C=O); HRMS calcd. for C25H35N6OSi (ES+) m/z 
463.2636 [M+H]
+
, found 463.2640. 
Note: Unable to visualise all carbon signals by NMR. 
2-(3-(6-Ethynyl-9H-purin-2-ylamino)phenyl)-N-methylacetamide (200) 
 
TIPS-protected purine 239 (50 mg, 0.11 mmol), KF (31 mg, 0.54 mmol) and 18-crown-6 (3 
mg, 0.011 mmol) were reacted in THF (1 ml) according to general procedure Q. 
Purification via chromatography on silica (9:1 DCM/MeOH) afforded the desired compound 
as a yellow solid (24 mg, 0.078 mmol, 73%). Rf 0.41 (9:1 DCM/MeOH); M.p. 170-180 °C 
(decomposed); λmax (EtOH/nm) 274; IR (cm
-1
) 3270, 3088, 2158, 2025, 1596; 
1
H NMR (500 
MHz, DMSO-d6) 2.59 (3H, d, J = 4.7 Hz, NHCH3), 3.36 (2H, s, CH2CO), 4.84 (1H, s, -
C≡CH), 6.81-6.84 (1H, m, H-6’), 7.21 (1H, dd, J = 7.8 and 7.9 Hz, H-5’), 7.52-7.55 (1H, m, 
H-2’), 7.74-7.77 (1H, m, H-4’), 7.92 (1H, br, CONH), 8.27 (1H, s, H-8), 9.62 (1H, s, C2-NH), 
13.12 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 23.6 (NHCH3), 42.6 (COCH2), 87.0 
(C≡CH), 116.6 (C-Ar), 119.2 (C-Ar), 121.8 (C-Ar), 128.2 (C-Ar), 136.6 (C-Ar), 140.7 (C-
Ar), 156.3 (C-Ar), 170.4 (C=O); HRMS calcd. for C16H15N6O (ES+) m/z 307.1305 [M+H]
+
, 
found 307.1302. 
Note: Unable to visualise all carbon signals by NMR. 
Methyl 4-aminobenzoate (235)
254
 
 
4-Aminobenzoic acid (0.500 g, 3.65 mmol) and thionyl chloride (0.53 ml, 7.29 mmol) were 
reacted in dry methanol (20 ml) according to general procedure R. Chromatography on 
silica (7:3 Petrol/EtOAc) afforded the desired compound as a white solid (0.520 g, 3.44 
mmol, 94%). Rf 0.42 (7:3 Petrol/EtOAc); M.p. 111-114 °C (Lit.
254
 109-110 °C); λmax 
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(EtOH/nm) 255, 309; IR (cm
-1
) 3407, 3336, 3298, 2944, 1681; 
1
H NMR (500 MHz, DMSO-
d6) 3.74 (3H, s, OCH3), 5.97 (2H, s, Ar-NH2), 6.57 (2H, d, J = 8.8 Hz, H-3/H-5), 7.64 (2H, d, 
J = 8.8 Hz, H-2/H-6); 
13
C NMR (125 MHz, DMSO-d6) 51.1 (OCH3), 112.8 (C-Ar), 115.7 (C-
Ar), 131.0 (C-Ar), 153.5 (C-Ar), 166.3 (C=O); LRMS (ES+) m/z 152.2 [M+H]
+
. 
4-Aminobenzamide (237)
255
 
 
Methyl ester 235 (0.408 g, 2.70 mmol) was dissolved in concentrated ammonium hydroxide 
(10 ml) and the resulting solution was heated at 60 °C for 18 h. The solvent was removed in 
vacuo and the crude product was purified via chromatography on KP-NH silica (19:1 
DCM/MeOH) to give the desired compound as a white solid (0.214 g, 1.57 mmol, 58%). Rf 
0.31 (19:1 DCM/MeOH); M.p. 178-181 °C (Lit.
255
 175-179 °C); λmax (EtOH/nm) 230, 262; 
IR (cm
-1
) 3463, 3317, 3205, 1591; 
1
H NMR (500 MHz, DMSO-d6) 5.59 (2H, s, Ar-NH2), 
6.52 (2H, d, J = 8.6 Hz, H-3/H-5), 6.82 (1H, br, CONHH’), 7.50 (1H, br, CONHH’), 7.58 
(2H, d, J = 8.6 Hz, H-2/H-6); 
13
C NMR (125 MHz, DMSO-d6) 112.4 (C-Ar), 120.9 (C-Ar), 
129.1 (C-Ar), 151.6 (C-Ar), 168.0 (C=O); LRMS (ES+) m/z 137.1 [M+H]
+
. 
4-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)benzamide (240) 
 
2-Fluoropurine intermediate 160 (0.216 g, 0.68 mmol), aniline 237 (0.185 g, 1.36 mmol) and 
TFA (262 μl, 3.40 mmol) were reacted in TFE (4 ml) according to general procedure B. 
Purification via chromatography on KP-NH silica (9:1 DCM/MeOH) afforded the desired 
compound as a yellow oil (0.114 g, 0.26 mmol, 38%). Rf 0.29 (9:1 DCM/MeOH); λmax 
(EtOH/nm) 224, 301, 363; IR (cm
-1
) 3113, 2942, 2864, 2160, 1653; 
1
H NMR (500 MHz, 
DMSO-d6) 1.14-1.18 (21H, m, Si(CH(CH3)2)3), 7.16 (1H, br, CONHH’), 7.79-7.82 (3H, m, 
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CONHH’/H-3’/H-5’), 7.89 (2H, d, J = 8.9 Hz, H-2’/H-6’), 8.31 (1H, s, H-8), 10.01 (1H, s, 
C
2
-NH), 13.17 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 
(Si(CH(CH3)2)3), 98.2 (C≡C), 116.8 (C-Ar), 126.2 (C-Ar), 128.2 (C-Ar), 143.7 (C-Ar), 155.7 
(C-Ar), 167.5 (C=O); HRMS calcd. for C23H31N6OSi (ES+) m/z 435.2323 [M+H]
+
, found 
435.2323. 
Note: Unable to visualise all carbon signals by NMR. 
4-(6-Ethynyl-9H-purin-2-ylamino)benzamide (208) 
 
TIPS-protected purine 240 (86 mg, 0.20 mmol), KF (57 mg, 0.99 mmol) and 18-crown-6 (5 
mg, 0.020 mmol) were reacted in THF (2 ml) according to general procedure Q. 
Purification via chromatography on silica (9:1 DCM/MeOH) afforded the desired compound 
as a yellow solid (41 mg, 0.15 mmol, 74%). Rf 0.25 (9:1 DCM/MeOH); M.p. 180-190 °C 
(decomposed); λmax (EtOH/nm) 220, 302; IR (cm
-1
) 3267, 2164, 2024, 1653, 1602; 
1
H NMR 
(500 MHz, DMSO-d6) 4.89 (1H, s, -C≡CH), 7.17 (1H, s, -CONHH’), 7.70 (1H, s, -
CONHH’), 7.83 (2H, d, J = 8.7 Hz, H-2’/H-6’), 7.87 (2H, d, J = 8.7 Hz, H-3’/H-5’), 8.35 
(1H, s, H-8), 10.00 (1H, s, C
2
-NH), 13.23 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 
87.3 (C≡CH), 116.9 (C-Ar), 126.3 (C-Ar), 128.2 (C-Ar), 143.6 (C-Ar), 155.7 (C-Ar), 167.6 
(C=O); HRMS calcd. for C14H11N6O (ES+) m/z 279.0994 [M+H]
+
, found 279.0989. 
Note: Unable to visualise all carbon signals by NMR. 
4-Amino-N-methylbenzamide (238)
255
 
 
Methyl ester 235 (0.413 g, 2.70 mmol) and methylamine (40% aqueous solution, 10 ml) were 
reacted according to general procedure S. Chromatography on silica (19:1 DCM/MeOH) 
gave the desired compound as a pale yellow solid (0.396 g, 2.64 mmol, 98%). Rf 0.36 (19:1 
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DCM/MeOH); M.p. 173-176 °C (Lit.
255
 178-180 °C); λmax (EtOH/nm) 236, 270; IR (cm
-1
) 
3399, 3336, 3228, 2934, 1627; 
1
H NMR (500 MHz, DMSO-d6) 2.72 (3H, d, J = 4.6 Hz, 
NHCH3), 5.57 (2H, s, Ar-NH2), 6.53 (2H, d, J = 8.6 Hz, H-3/H-5), 7.55 (2H, d, J = 8.6 Hz, 
H-2/H-6), 7.94 (1H, br, NHCH3); 
13
C NMR (125 MHz, DMSO-d6) 26.0 (NHCH3), 112.5 (C-
Ar), 121.3 (C-Ar), 128.5 (C-Ar), 151.4 (C-Ar), 166.7 (C=O); LRMS (ES+) m/z 151.2 
[M+H]
+
. 
4-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)-N-methyl benzamide (241) 
 
2-Fluoropurine intermediate 160 (0.270 g, 0.85 mmol), aniline 238 (0.255 g, 1.70 mmol) and 
TFA (330 μl, 4.25 mmol) were reacted in TFE (4 ml) according to general procedure B. 
Purification via chromatography on KP-NH silica (9:1 DCM/MeOH) afforded the desired 
compound as a yellow oil (0.117 g, 0.26 mmol, 31%). Rf 0.51 (9:1 DCM/MeOH, KP-NH); 
λmax (EtOH/nm) 230, 283, 362; IR (cm
-1
) 3278, 3082, 2942, 2864, 2154, 2027, 1602; 
1
H 
NMR (500 MHz, DMSO-d6) 1.14-1.19 (21H, m, Si(CH(CH3)2)3), 2.78 (3H, d, J = 4.6 Hz, 
NHCH3), 7.77 (2H, d, J = 8.8 Hz, H-3’/H-5’), 7.89 (2H, d, J = 8.8 Hz, H-2’/H-6’), 8.23 (1H, 
q, J = 4.6 Hz, NHCH3), 8.31 (1H, s, H-8), 10.00 (1H, s, C
2
-NH), 13.19 (1H, br, H-9); 
13
C 
NMR (125 MHz, DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 26.1 (NHCH3), 
116.9 (C-Ar), 126.5 (C-Ar), 127.7 (C-Ar), 143.5 (C-Ar), 155.7 (C-Ar), 166.3 (C=O); HRMS 
calcd. for C24H33N6OSi (ES+) m/z 449.2480 [M+H]
+
, found 449.2480. 
Note: Unable to visualise all carbon signals by NMR. 
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4-(6-Ethynyl-9H-purin-2-ylamino)-N-methylbenzamide (209) 
 
TIPS-protected purine 241 (0.105 g, 0.23 mmol), KF (67 mg, 1.15 mmol) and 18-crown-6 (6 
mg, 0.023 mmol) were reacted in THF (2.5 ml) according to general procedure Q. 
Purification via chromatography on silica (9:1 DCM/MeOH) afforded the desired compound 
as a yellow solid (46 mg, 0.16 mmol, 69%). Rf  0.24 (9:1 DCM/MeOH); M.p. 180-190 °C 
(decomposed); λmax (EtOH/nm) 221, 301; IR (cm
-1
) 3275, 3109, 2163, 2111, 2022, 1605; 
1
H 
NMR (500 MHz, DMSO-d6) 2.78 (3H, d, J = 4.5 Hz, NHCH3), 4.89 (1H, s, -C≡CH), 7.78 
(2H, d, J = 8.8 Hz, H-2’/H-6’), 7.87 (2H, d, J = 8.8 Hz, H-3’/H-5’), 8.24 (1H, q, J = 4.5 Hz, 
CONH), 8.34 (1H, s, H-8), 9.99 (1H, s, C
2
-NH), 13.25 (1H, br, H-9); 
13
C NMR (125 MHz, 
DMSO-d6) 26.1 (NHCH3), 87.3 (C≡CH), 117.0 (C-Ar), 126.6 (C-Ar), 127.7 (C-Ar), 143.4 
(C-Ar), 155.7 (C-Ar), 166.3 (C=O); HRMS calcd. for C15H13N6O (ES+) m/z 293.1148 
[M+H]
+
, found 293.1145. 
Note: Unable to visualise all carbon signals by NMR. 
4-Amino-N,N-dimethylbenzamide (243)
256
 
 
4-Aminobenzoic acid (0.500 g, 3.65 mmol) was dissolved thionyl chloride (5 ml) and 1 drop 
of DMF was added. The solution was refluxed for 1 hour, after which point the solution was 
concentrated to dryness. Remaining thionyl chloride was removed through addition of 
toluene (5 ml) and removal of the azeotrope in vacuo. The resultant orange residue was 
suspended in dry THF (4 ml) and triethylamine (530 μl, 3.65 mmol), and dimethylamine (2M 
in THF, 5.50 ml, 10.9 mmol) was added under nitrogen. The reaction mixture was stirred at 
RT for 18 h, after which the solvent was removed in vacuo and the resultant residue was 
purified by chromatography on silica (19:1 DCM/MeOH). The desired compound was 
obtained as an off-white solid (0.348 g, 2.12 mmol, 58%). Rf 0.40 (19:1 DCM/MeOH); M.p. 
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150-153 °C (Lit.
256
 153 °C); λmax (EtOH/nm) 220, 272; IR (cm
-1
) 3428, 3335, 3236, 2925, 
1642; 
1
H NMR (500 MHz, DMSO-d6) 2.94 (6H, s, N(CH3)2), 5.47 (2H, s, Ar-NH2), 6.54 
(2H, d, J = 8.6 Hz, H-3/H-5), 7.14 (2H, d, J = 8.6 Hz, H-2/H-6); 
13
C NMR (125 MHz, 
DMSO-d6) 40.0 (N(CH3)2), 112.5 (C-Ar), 122.5 (C-Ar), 129.1 (C-Ar), 150.2 (C-Ar), 170.7 
(C=O); LRMS (ES+) m/z 165.2 [M+H]
+
. 
4-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)-N,N-dimethyl benzamide (244) 
 
2-Fluoropurine intermediate 160 (0.205 g, 0.64 mmol), aniline 243 (0.210 g, 1.28 mmol) and 
TFA (248 μl, 3.22 mmol) were reacted in TFE (4 ml) according to general procedure B. 
Purification via chromatography on KP-NH silica (19:1 DCM/MeOH) afforded the desired 
compound as a yellow oil (79 mg, 0.17 mmol, 27%). Rf 0.48 (19:1 DCM/MeOH, KP-NH); 
λmax (EtOH/nm) 283, 364; IR (cm
-1
) 2942, 2862, 2160, 2028, 1601; 
1
H NMR (500 MHz, 
DMSO-d6) 1.14-1.18 (21H, m, Si(CH(CH3)2)3), 2.98 (6H, s, N(CH3)2), 7.36 (2H, d, J = 8.5 
Hz, H-3’/H-5’), 7.88 (2H, d, J = 8.5 Hz, H-2’/H-6’), 8.29 (1H, s, H-8), 9.96 (1H, s, C2-NH), 
13.19 (1H, br, H-9); 
13
C NMR (125 MHz, CDCl3) 11.3 (Si(CH(CH3)2)3), 18.7 
(Si(CH(CH3)2)3), 40.0 (N(CH3)2), 100.6 (C≡C), 103.9 (C≡C), 118.5 (C-Ar), 128.3 (C-Ar), 
128.7 (C-Ar), 141.5 (C-Ar), 155.8 (C-Ar), 172.4 (C=O); HRMS calcd. for C25H35N6OSi 
(ES+) m/z 463.2636 [M+H]
+
, found 463.2641. 
Note: Unable to visualise all carbon signals by NMR. 
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4-(6-Ethynyl-9H-purin-2-ylamino)-N,N-dimethylbenzamide (210) 
 
TIPS-protected purine 244 (63 mg, 0.14 mmol), KF (41 mg, 0.70 mmol) and 18-crown-6 (4 
mg, 0.014 mmol) were reacted in THF (1.5 ml) according to general procedure Q. 
Purification via chromatography on silica (9:1 DCM/MeOH) afforded the desired compound 
as a yellow solid (27 mg, 0.088 mmol, 63%). Rf 0.29 (9:1 DCM/MeOH); M.p. 190-210 °C 
(decomposed); λmax (EtOH/nm) 292; IR (cm
-1
) 3101, 2111, 1599; 
1
H NMR (500 MHz, 
DMSO-d6) 2.98 (6H, s, N(CH3)2), 4.89 (1H, s, -C≡CH), 7.38 (2H, d, J = 8.4 Hz, H-2’/H-6’), 
7.86 (2H, d, J = 8.4 Hz, H-3’/H-5’), 8.33 (1H, s, H-8), 9.95 (1H, s, C2-NH), 13.23 (1H, s, H-
9); 
13
C NMR (125 MHz, DMSO-d6) 87.2 (C≡CH), 117.1 (C-Ar), 128.0 (C-Ar), 128.3 (C-
Ar), 142.0 (C-Ar), 155.8 (C-Ar), 170.2 (C=O); HRMS calcd. for C16H15N6O (ES+) m/z 
307.1302 [M+H]
+
, found 307.1302. 
Note: Unable to visualise all carbon signals by NMR – N-CH3 masked by solvent. 
N
1
,N
3
-Dimethyl-2-(4-nitrophenyl)malonamide (248) 
 
4-Nitrophenylacetic acid (0.598 g, 3.31 mmol), CDI (1.07 g, 6.62 mmol), DIPEA (1.15 ml, 
6.62 mmol) and methylamine (2M in THF, 6.60 ml, 13.2 mmol) were reacted in dry DMF 
(30 ml) according to general procedure J. Purification via silica gel chromatography (7:3 
Petrol/EtOAc) gave the desired compound as an off-white solid (0.608 g, 2.42 mmol, 73%). 
Rf 0.33 (7:3 Petrol/EtOAc); M.p. 221-224 °C; λmax (EtOH/nm) 273; IR (cm
-1
) 3405, 3311, 
3111, 2932, 1655, 1512; 
1
H NMR (500 MHz, DMSO-d6) 2.62 (6H, d, J = 4.6 Hz, 2 x 
NHCH3), 4.57 (1H, s, COCHCO), 7.65 (2H, d, J = 8.8 Hz, H-2/H-6), 8.11 (2H, q, J = 4.6 Hz, 
2 x NH), 8.21 (2H, d, J = 8.8 Hz, H-3/H-5); 
13
C NMR (125 MHz, DMSO-d6) 25.9 (N(CH3)2), 
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57.9 (COCHCO), 123.2 (C-Ar), 129.9 (C-Ar), 143.5 (C-Ar), 146.7 (C-Ar), 167.6 (2 x C=O); 
HRMS calcd. for C11H14N3O4 (ES+) m/z 252.0979 [M+H]
+
, found 252.0983. 
2-(4-Aminophenyl)-N
1
,N
3
-dimethylmalonamide (254) 
 
The nitro compound 248 (0.593 g, 3.05 mmol) and iron powder (1.70 g, 30.5 mmol) were 
reacted in acetic acid (30 ml) according to general procedure T. Purification on silica (9:1 
DCM/MeOH) gave the desired compound as a beige waxy solid (0.380 g, 2.32 mmol, 76%). 
Rf 0.35 (9:1 DCM/MeOH); M.p. 148-150 °C; λmax (EtOH/nm) 248, 292; IR (cm
-1
) 3414, 
3273, 3100, 2937, 1663, 1650, 1515; 
1
H NMR (500 MHz, DMSO-d6) 2.59 (6H, d, J = 4.6 
Hz, 2 x NHCH3), 4.11 (1H, s, COCHCO), 5.00 (2H, s, Ar-NH2), 6.49 (2H, d, J = 8.5 Hz, H-
3/H-5), 7.00 (2H, d, J = 8.5 Hz, H-2/H-6), 7.94 (2H, q, J = 4.6 Hz, 2 x NHCH3); 
13
C NMR 
(125 MHz, DMSO-d6) 25.7 (2 x NHCH3), 57.6 (COCHCO), 113.6 (C-Ar), 123.4 (C-Ar), 
128.6 (C-Ar), 147.8 (C-Ar), 169.7 (C=O); HRMS calcd. for C11H16N3O2 (ES+) m/z 222.1237 
[M+H]
+
, found 222.1239. 
N
1
,N
3
-Dimethyl-2-(4-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino) 
phenyl)malonamide (256) 
 
2-Fluoropurine 160 (0.198 g, 0.63 mmol), aniline 254 (0.277 g, 1.26 mmol) and TFA (120 µl, 
1.57 mmol) were reacted in TFE (6 ml) according to general procedure V. Purification 
through chromatography on KP-NH silica (19:1 DCM/MeOH) gave the desired compound as 
a yellow oil/gum (0.167 g, 0.32 mmol, 51%). Rf 0.35 (19:1 DCM/MeOH, KP-NH); λmax 
(EtOH/nm) 280, 354; IR (cm
-1
) 3287, 3085, 2943, 2864, 1663, 1603, 1573, 1521; 
1
H NMR 
(500 MHz, DMSO-d6) ) 1.13-1.23 (21H, m, Si(CH(CH3)2)3), 2.62 (6H, d, J = 4.7 Hz, (2 x 
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NHCH3), 4.28 (1H, s, COCHCO), 7.26 (2H, d, J = 8.7 Hz, H-2’/H-6’), 7.71 (2H, d, J = 8.7 
Hz, H-3’/H-5’), 8.02 (2H, q, J = 4.7 Hz, 2 x NHCH3), 8.23 (1H, s, H-8), 9.68 (1H, s, C
2
-NH), 
13.05 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 
(Si(CH(CH3)2)3), 25.8 (CH3), 26.9 (CH3), 57.8 (COCHCO), 118.4, 128.3 (C-Ar), 129.0 (C-
Ar), 139.9 (C-Ar), 142.7 (C-Ar), 153.9 (C-Ar), 156.2 (C-Ar), 169.2 (C=O); HRMS calcd. for 
C27H38N7O2Si (ES+) m/z 520.2851 [M+H]
+
, found 520.2847. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
2-(4-((6-Ethynyl-9H-purin-2-yl)amino)phenyl)-N
1
,N
3
-dimethylmalonamide (257) 
 
The TIPS-protected purine 256 (0.120 mg, 0.23 mmol), TBAF (1M in THF, 0.28 ml, 0.28 
mmol) and the TBAF scavenger bead system 231 (1.20 g, 10 x w/w) were reacted in THF (5 
ml) according to general procedure U. Chromatography on KP-NH silica (9:1 DCM/MeOH) 
afforded the target compound as a yellow solid (29 mg, 0.08 mmol, 35%). Rf 0.26 (9:1 
DCM/MeOH, KP-NH); M.p. 160-180 °C (decomposed); λmax (EtOH/nm) 277.0, 368.5; IR 
(cm
-1
) 3274, 2550, 2160, 2111, 2030, 1660; 
1
H NMR (500 MHz, DMSO-d6) 2.61 (6H, d, J = 
4.6 Hz, 2 x NHCH3), 4.28 (1H, s, COCHCO), 4.84 (1H, s, C≡CH), 7.27 (2H, d, J = 8.7 Hz, 
H-2’/H-6’), 7.69 (2H, d, J = 8.7 Hz, H-3’/H-5’), 8.04 (2H, q, J = 4.6 Hz, 2 x NHCH3), 8.28 
(1H, s, H-8), 9.65 (1H, s, C
2
-NH), 13.10 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 40.0 
(NHCH3), 58.7 (COCHCO), 118.9 (C-Ar), 129.1 (C-Ar); HRMS calcd. for C18H18N7O2 
(ES+) m/z 364.1516 [M+H]
+
, found 364.1520. 
Note: Unable to visualise all carbon environments by 
13
C NMR – insufficient material. 
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N,N-Dimethyl-2-(4-nitrophenyl)acetamide (247)
257
 
 
4-Nitrophenylacetic acid (0.600 g, 3.31 mmol), CDI  (1.07 g, 6.62 mmol), DIPEA (1.15 ml, 
6.62 mmol) and dimethylamine (2M in THF, 6.60 ml, 13.2 mmol) were reacted in dry DMF 
(30 ml) according to general procedure J. Silica gel chromatography (7:3 Petrol/EtOAc) 
afforeded the target compound as an off-white solid (0.204 g, 0.98 mmol, 30%). Rf 0.38 (7:3 
Petrol/EtOAc); M.p. 80-83 °C (Lit.
257
 87 °C); λmax (EtOH/nm) 270; IR (cm
-1
) 2937, 2449, 
1637, 1512; 
1
H NMR (500 MHz, CDCl3) 3.01 (3H, s, N-CH3), 3.08 (3H, s, N-CH3), 3.83 
(2H, s, COCH2), 7.45 (2H, d, J = 8.5 Hz, H-2/H-6), 8.21 (2H, d, J = 8.5 Hz, H-3/H-5); 
13
C 
NMR (125 MHz, CDCl3) 35.8 (N-CH3), 37.6 (N-CH3), 40.3 (COCH2), 123.8 (C-Ar), 130.1 
(C-Ar), 142.7 (C-Ar), 154.1 (C-Ar), 169.4 (C=O); LRMS (ES+) m/z 209.1 [M+H]
+
. 
2-(4-Aminophenyl)-N,N-dimethylacetamide (253)
258
 
 
The nitro compound 247 (0.133 g, 0.64 mmol) and iron powder (0.355 g, 6.39 mmol) were 
reacted in acetic acid (6 ml) according to general procedure T. Chromatography on silica 
(9:1 DCM/MeOH) gave the desired compound as a pale red oil (0.105 g, 0.58 mmol, 92%). 
Rf 0.40 (9:1 DCM/MeOH); λmax (EtOH/nm) 242, 291; IR (cm
-1
) 3414, 3342, 3230, 2933, 
1611, 1515; 
1
H NMR (500 MHz, DMSO-d6) 2.81 (3H, s, N-CH3), 2.96 (3H, s, N-CH3), 3.46 
(2H, s, COCH2), 4.89 (2H, s, Ar-NH2), 6.50 (2H, d, J = 8.4 Hz, H-3/H-5), 6.86 (2H, d, J = 8.4 
Hz, H-2/H-6); 
13
C NMR (125 MHz, DMSO-d6) 34.9 (N-CH3), 37.1 (N-CH3), 39.1 (COCH2), 
113.9 (C-Ar), 122.5 (C-Ar), 129.2 (C-Ar), 146.9 (C-Ar), 170.9 (C=O); LRMS (ES+) m/z 
179.1 [M+H]
+
. 
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N,N-Dimethyl-2-(4-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino) 
phenyl)acetamide (255) 
 
2-Fluoropurine 160 (73 mg, 0.23 mmol), aniline 253 (96 mg, 0.46 mmol) and TFA (45 µl, 
0.58 mmol) were reacted in TFE (3 ml) according to general procedure V. Purification by 
KP-NH silica chromatography (19:1 DCM/MeOH) gave the desired compound as a yellow 
oil/gum (69 mg, 0.14 mmol, 61%). Rf 0.32 (19:1 DCM/MeOH, KP-NH); λmax (EtOH/nm) 
278, 379; IR (cm
-1
) 3275, 3104, 2941, 2864, 1603, 1570; 
1
H NMR (500 MHz, DMSO-d6) 
1.13-1.23 (21H, m, Si(CH(CH3)2)3), 2.83 (3H, s, N-CH3), 3.00 (3H, s, N-CH3), 3.62 (2H, s, 
COCH2), 7.12 (2H, d, J = 8.6 Hz, H-2’/H-6’), 7.71 (2H, d, J = 8.6 Hz, H-3’/H-5’), 8.22 (1H, 
s, H-8), 9.60 (1H, s, C
2
-NH), 13.04 (1H, br, H-9); 
13
C NMR (125 MHz, CDCl3) 11.3 
(Si(CH(CH3)2)3), 18.8 (Si(CH(CH3)2)3), 35.9 (N-CH3), 37.7 (N-CH3), 40.1 (COCH2), 114.9 
(C-Ar), 115.5 (C-Ar), 120.9 (C-Ar), 121.6 (C-Ar), 129.6 (C-Ar), 140.1 (C-Ar), 171.6 (C=O); 
HRMS calcd. for C26H37N6OSi (ES+) m/z 477.2793 [M+H]
+
, found 477.2779. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
2-(4-((6-Ethynyl-9H-purin-2-yl)amino)phenyl)-N,N-dimethylacetamide (204) 
 
The TIPS-protected purine 255 (56 mg, 0.12 mmol), TBAF (1M in THF, 0.14 ml, 0.14 
mmol) and the TBAF scavenger bead system 231 (0.60 g, 10 x w/w) were reacted in THF (5 
ml) according to general procedure U. Chromatography on KP-NH silica (9:1 DCM/MeOH) 
afforded the desired compound as a yellow solid (27 mg, 0.08 mmol, 69%). Rf 0.33 (9:1 
DCM/MeOH, KP-NH); M.p. 120-130 °C (decomposed); λmax (EtOH/nm) 276.0, 378.0; IR 
(cm
-1
) 2932, 2538, 2110, 1607, 1575, 1530; 
1
H NMR (500 MHz, DMSO-d6) 2.84 (3H, s, N-
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CH3), 3.01 (3H, s, N-CH3), 3.62 (2H, s, COCH2), 4.83 (1H, s, C≡CH), 7.13 (2H, d, J = 8.6 
Hz, H-2’/H-6’), 7.69 (2H, d, J = 8.6 Hz, H-3’/H-5’), 8.26 (1H, s, H-8), 9.60 (1H, s, C2-NH), 
13.10 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 35.0 (N-CH3), 37.2 (N-CH3), 39.6 
(COCH2), 91.0 (C≡CH), 118.5 (C-Ar), 129.0 (C-Ar), 149.9 (C-Ar), 156.3 (C-Ar), 158.0 (C-
Ar), 170.5 (C=O); HRMS calcd. for C17H17N6O (ES+) m/z 321.1458 [M+H]
+
, found 
321.1462. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
2-(4-Aminophenyl)-N-methylacetamide (258)
255
 
 
4-Aminophenylacetic acid (0.601 g, 3.97 mmol), thionyl chloride (0.58 ml, 7.94 mmol), 
methanol (20 ml) and methylamine (40% aqueous solution, 20 ml) were reacted together 
according to general procedure W. Silica gel chromatography (19:1 DCM/MeOH) afforded 
the desired product as a pale orange oil (0.573 g, 3.49 mmol, 88%). Rf 0.39 (19:1 
DCM/MeOH); λmax (EtOH/nm) 242, 291; IR (cm
-1
) 3444, 3347, 3308, 3098, 1618, 1556, 
1515; 
1
H NMR (500 MHz, DMSO-d6) 2.55 (3H, d, J = 4.6 Hz, NHCH3), 3.18 (2H, s, 
COCH2), 4.89 (2H, s, Ar-NH2), 6.49 (2H, d, J = 8.4 Hz, H-3/H-5), 6.89 (2H, d, J = 8.4 Hz, 
H-2/H-6), 7.74 (1H, br, NHCH3); 
13
C NMR (125 MHz, DMSO-d6) 25.6 (NHCH3), 41.7 
(COCH2), 113.8 (C-Ar), 123.3 (C-Ar), 129.4 (C-Ar), 147.0 (C-Ar), 171.3 (C=O); LRMS 
(ES+) m/z 165.1 [M+H]
+
. 
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N-Methyl-2-(4-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino)phenyl) acetamide 
(260) 
 
2-Fluoropurine 160 (0.200 g, 0.63 mmol), aniline 258 (0.206 g, 1.26 mmol) and TFA (120 µl, 
1.57 mmol) were reacted in TFE (6 ml) according to general procedure V. Purification by 
KP-NH silica chromatography (19:1 DCM/MeOH) afforded the target compound as a yellow 
oil/gum (0.137 g, 0.30 mmol, 47%). Rf 0.37 (19:1 DCM/MeOH, KP-NH); λmax (EtOH/nm) 
279, 379; IR (cm
-1
) 3275, 2942, 2864, 1604, 1573, 1523; 
1
H NMR (500 MHz, DMSO-d6) 
1.13-1.23 (21H, m, Si(CH(CH3)2)3), 2.58 (3H, d, J = 4.7 Hz, NHCH3), 3.33 (2H, s, COCH2), 
7.15 (2H, d, J = 8.6 Hz, H-2’/H-6’), 7.70 (2H, d, J = 8.6 Hz, H-3’/H-5’), 7.84 (1H, q, J = 4.7 
Hz, NHCH3), 8.23 (1H, s, H-8), 9.61 (1H, s, C
2
-NH), 13.04 (1H, br, H-9); 
13
C NMR (125 
MHz, DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 25.6 (CH3), 41.8 (COCH2), 
118.4, 119.9, 128.9 (C-Ar), 133.1 (C-Ar), 142.7 (C-Ar), 156.3 (C-Ar), 170.8 (C=O); HRMS 
calcd. for C25H35N6OSi (ES+) m/z 463.2636 [M+H]
+
, found 463.2631. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
2-(4-((6-Ethynyl-9H-purin-2-yl)amino)phenyl)-N-methylacetamide (203) 
 
The TIPS-protected purine 260 (0.130 g, 0.28 mmol), TBAF (1M in THF, 0.34 ml, 0.34 
mmol) and the TBAF scavenger bead system 231 (1.30 g, 10 x w/w) were reacted in THF (5 
ml) according to general procedure U. Chromatography on KP-NH silica (9:1 DCM/MeOH) 
gave the target compound as a yellow solid (50 mg, 0.16 mmol, 58%). Rf 0.26 (9:1 
DCM/MeOH, KP-NH); M.p. 140-160 °C (decomposed); λmax (EtOH/nm) 276.0, 371.0; IR 
(cm
-1
) 3414, 3092, 2531, 2112, 1611, 1577, 1530; 
1
H NMR (500 MHz, DMSO-d6) 2.58 (3H, 
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d, J = 4.6 Hz, NHCH3), 3.33 (2H, s, COCH2), 4.82 (1H, s, C≡CH), 7.16 (2H, d, J = 8.5 Hz, 
H-2’/H-6’), 7.68 (2H, d, J = 8.5 Hz, H-3’/H-5’), 7.86 (1H, q, J = 4.6 Hz, NHCH3), 8.25 (1H, 
s, H-8), 9.60 (1H, s, C
2
-NH), 13.09 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 25.6 
(NHCH3), 41.8 (COCH2), 86.9 (C≡CH), 118.5 (C-Ar), 129.0 (C-Ar), 139.1 (C-Ar), 142.7 (C-
Ar), 156.3 (C-Ar), 170.8 (C=O); HRMS calcd. for C16H15N6O (ES+) m/z 307.1302 [M+H]
+
, 
found 307.1306. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
N-Methyl-3-nitrobenzamide (261)
259
 
 
3-Nitrobenzoic acid (0.502 g, 2.99 mmol), phosphorus trichloride (288 µl, 3.29 mmol) and 
methylamine (2M in THF, 3.74 ml, 7.48 mmol) were reacted in dry MeCN (15 ml) according 
to general procedure W. Purification on silica (7:3 Petrol/EtOAc) gave the desired 
compound as a beige solid on cooling (0.535 g, 2.97 mmol, 99%). Rf 0.33 (7:3 
Petrol/EtOAc); M.p. 175-177 °C (Lit.
259
 175 °C); λmax (EtOH/nm) 241; IR (cm
-1
) 3352, 3285, 
3093, 1637, 1619, 1559, 1524; 
1
H NMR (500 MHz, DMSO-d6) 2.83 (3H, d, J = 4.6 Hz, 
NHCH3), 7.79 (1H, dd, J = 7.9 and 8.0 Hz, H-5), 8.28 (1H, ddd, J = 1.0, 1.6 and 7.9 Hz, H-
6), 8.38 (1H, ddd, J = 1.0, 2.4 and 8.0 Hz, H-4), 8.65-8.68 (1H, m, H-2), 8.84 (1H, br, 
NHCH3); 
13
C NMR (125 MHz, DMSO-d6) 26.4 (NHCH3), 121.8 (C-Ar), 125.7 (C-Ar), 130.1 
(C-Ar), 133.4 (C-Ar), 135.8 (C-Ar), 147.8 (C-Ar), 164.4 (C=O); LRMS (ES+) m/z 181.1 
[M+H]
+
. 
3-Amino-N-methylbenzamide (264)
260
 
 
The nitro compound 261 (0.420 g, 2.33 mmol) and iron powder (1.30 g, 23.3 mmol) were 
reacted in acetic acid (20 ml) according to general procedure T. Purification of the crude 
using chromatography on silica (19:1 DCM/MeOH) gave the desired compound as a beige 
solid on cooling (0.276 g, 1.84 mmol, 79%). Rf 0.38 (19:1 DCM/MeOH); M.p. 98-100 °C; 
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λmax (EtOH/nm) 217, 313; IR (cm
-1
) 3465, 3412, 3294, 3221, 1634, 1580, 1547; 
1
H NMR 
(500 MHz, DMSO-d6) 2.74 (3H, d, J = 4.6 Hz, NHCH3), 5.19 (2H, s, Ar-NH2), 6.67 (1H, 
ddd, J = 1.0, 2.4 and 7.9 Hz, H-4), 6.92 (1H, ddd, J = 1.0, 1.6 and 7.7 Hz, H-6), 7.02 (1H, dd, 
J = 1.6 and 2.4 Hz, H-2), 7.06 (1H, dd, J = 7.7 and 7.9 Hz, H-5), 8.15 (1H, q, J = 4.6 Hz, 
NHCH3); 
13
C NMR (125 MHz, DMSO-d6) 26.2 (CH3), 112.7 (C-Ar), 114.0 (C-Ar), 116.2 (C-
Ar), 128.6 (C-Ar), 135.5 (C-Ar), 148.6 (C-Ar), 167.4 (C=O); LRMS (ES+) m/z 151.1 
[M+H]
+
. 
N-Methyl-3-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino) benzamide (266) 
 
2-Fluoropurine 160 (0.202 g, 0.63 mmol), aniline 264 (0.190 g, 1.26 mmol) and TFA (120 µl, 
1.57 mmol) were reacted in TFE (6 ml) according to general procedure V over 3 h. 
Chromatography on KP-NH silica (19:1 DCM/MeOH) gave the target compound as a yellow 
oil/gum (0.101 g, 0.23 mmol, 37%). Rf 0.30 (19:1 DCM/MeOH, KP-NH); λmax (EtOH/nm) 
276; IR (cm
-1
) 3069, 2942, 2865, 2161, 1580; 
1
H NMR (500 MHz, DMSO-d6) 1.10-1.25 
(21H, m, Si(CH(CH3)2)3), 2.78 (3H, d, J = 4.5 Hz, NHCH3), 7.32-7.36 (2H, m, H-5’/H-6’), 
7.89-7.93 (1H, m, H-4’), 8.19-8.21 (1H, m, H-2’), 8.24 (1H, s, H-8), 8.30 (1H, q, J = 4.5 Hz, 
NHCH3), 9.81 (1H, s, C
2
-NH), 13.14 (1H, br, H-9); 
13
C NMR (125 MHz, CDCl3) 11.3 
(Si(CH(CH3)2)3), 18.7 (Si(CH(CH3)2)3), 27.0 (NHCH3), 117.7 (C-Ar), 120.3 (C-Ar), 121.9 
(C-Ar), 129.1 (C-Ar), 132.8 (C-Ar), 135.3 (C-Ar), 142.0 (C-Ar); HRMS calcd. for 
C24H33N6OSi (ES+) m/z 449.2480 [M+H]
+
, found 449.2480. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
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3-((6-Ethynyl-9H-purin-2-yl)amino)-N-methylbenzamide (206) 
 
The TIPS-protected purine 266 (72 mg, 0.16 mmol), TBAF (1M in THF, 0.19 ml, 0.19 
mmol) and the TBAF scavenger bead system 231 (0.70 g, 10 x w/w) were reacted in THF (5 
ml) according to general procedure U. Chromatography on KP-NH silica (9:1 DCM/MeOH) 
gave the target compound as a yellow solid (29 mg, 0.10 mmol, 63%). Rf 0.24 (9:1 
DCM/MeOH, KP-NH); M.p. 200-220 °C (decomposed); λmax (EtOH/nm) 274.0, 363.5; IR 
(cm
-1
) 3302, 3252, 3113, 1607; 
1
H NMR (500 MHz, DMSO-d6) 2.79 (3H, d, J = 4.5 Hz, 
NHCH3), 4.86 (1H, s, C≡CH), 7.33-7.39 (2H, m, H-5’/H-6’), 7.92-7.97 (1H, m, H-4’), 8.16-
8.18 (1H, m, H-2’), 8.29 (1H, s, H-8), 8.36 (1H, q, J = 4.5 Hz, NHCH3), 9.78 (1H, s, C
2
-NH), 
13.20 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 26.3 (NHCH3), 87.1 (C≡CH), 117.7 
(C-Ar), 120.8 (C-Ar), 128.2 (C-Ar), 132.2 (C-Ar), 135.4 (C-Ar), 140.9 (C-Ar), 156.1 (C-Ar), 
167.1 (C=O); HRMS calcd. for C15H13N6O (ES+) m/z 293.1145 [M+H]
+
, found 293.1149. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
N,N-Dimethyl-3-nitrobenzamide (262)
261
 
 
3-Nitrobenzoic acid (0.499 g, 2.99 mmol), phosphorus trichloride (288 µl, 3.29 mmol) and 
dimethylamine (2M in THF, 3.74 ml, 7.48 mmol) were reacted in dry MeCN (15 ml) 
according to general procedure X. Chromatography on silica (7:3 Petrol/EtOAc) gave the 
target compound as a beige solid (0.560 g, 2.88 mmol, 96%). Rf 0.36 (7:3 Petrol/EtOAc); 
M.p. 81-84 °C (Lit.
261
 83-84 °C); λmax (EtOH/nm) 243; IR (cm
-1
) 3083, 2941, 1626, 1527; 
1
H 
NMR (500 MHz, CDCl3) 3.03 (3H, s, N-CH3), 3.18 (3H, s, N-CH3), 7.64 (1H, dd, J = 7.7 and 
8.0 Hz, H-5), 7.80 (1H, ddd, J = 1.2, 1.4 and 7.7 Hz, H-6), 8.29-8.33 (2H, m, H-2/H-4); 
13
C 
NMR (125 MHz, CDCl3) 35.5 (N-CH3), 39.5 (N-CH3), 122.3 (C-Ar), 124.4 (C-Ar), 129.7 (C-
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Ar), 133.2 (C-Ar), 137.9 (C-Ar), 148.2 (C-Ar), 166.4 (C=O); LRMS (ES-) m/z 195.1 
[M+H]
+
. 
3-Amino-N,N-dimethylbenzamide (265)
261
 
 
The nitro compound 262 (0.200 g, 1.03 mmol) and iron powder (0.57 g, 10.3 mmol) were 
reacted in acetic acid (10 ml) according to general procedure T. Purification on silica gel 
(19:1 DCM/MeOH) gave the target compound as a golden oil (0.142 g, 0.86 mmol, 84%). Rf 
0.41 (19:1 DCM/MeOH); λmax (EtOH/nm) 243, 302; IR (cm
-1
) 3413, 3342, 3232, 2930, 1598, 
1579; 
1
H NMR (500 MHz, DMSO-d6) 2.90 (3H, s, N-CH3), 2.94 (3H, s, N-CH3), 5.21 (2H, s, 
Ar-NH2), 6.46 (1H, ddd, J = 1.1, 1.4 and 7.4 Hz, H-4), 6.54 (1H, dd, J = 1.4 and 2.3 Hz, H-
2), 6.59 (1H, ddd, J = 1.1, 2.3 and 8.0 Hz, H-6), 7.05 (1H, dd, J = 7.4 and 8.0 Hz, H-5); 
13
C 
NMR (125 MHz, DMSO-d6) 112.0 (C-Ar), 113.9 (C-Ar), 114.5 (C-Ar), 128.6 (C-Ar), 137.2 
(C-Ar), 148.6 (C-Ar), 170.8 (C=O); LRMS (ES+) m/z 165.1 [M+H]
+
. 
Note: Unable to visualise all carbon environments by 
13
C NMR – masked by solvent peak. 
N,N-Dimethyl-3-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino) benzamide (267) 
 
2-Fluoropurine 160 (0.121 g, 0.38 mmol), aniline 265 (0.125 g, 0.76 mmol) and TFA (73 µl, 
0.95 mmol) were reacted in TFE (4 ml) according to general procedure V over 3 h. 
Purification by KP-NH silica chromatography (19:1 DCM/MeOH) gave the target compound 
as a yellow oil/gum (81 mg, 0.18 mmol, 47%). Rf 0.34 (19:1 DCM/MeOH, KP-NH); λmax 
(EtOH/nm) 228, 317; IR (cm
-1
) 3079, 2942, 2864, 2057, 1576, 1538; 
1
H NMR (500 MHz, 
DMSO-d6) 1.13-1.23 (21H, m, Si(CH(CH3)2)3), 2.96 (3H, s, N-CH3), 3.00 (3H, s, N-CH3), 
6.93 (1H, ddd, J = 1.1, 1.2 and 7.7 Hz, H-6’), 7.33 (1H, dd, J = 7.7 and 7.9 Hz, H-5’), 7.76-
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7.80 (1H, m, H-4’), 7.95 (1H, m, H-2’), 8.27 (1H, s, H-8), 9.82 (1H, s, C2-NH), 13.13 (1H, 
br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 39.6 
(N-CH3), 116.3 (C-Ar), 119.0 (C-Ar), 128.4 (C-Ar), 136.9 (C-Ar), 141.0 (C-Ar), 147.7 (C-
Ar); HRMS calcd. for C25H35N6OSi (ES+) m/z 463.2636 [M+H]
+
, found 463.2632. 
Note: Unable to visualise all carbon environments by 
13
C NMR – masked by solvent. 
3-((6-Ethynyl-9H-purin-2-yl)amino)-N,N-dimethylbenzamide (207) 
 
The TIPS-protected purine 267 (52 mg, 0.11 mmol), TBAF (1M in THF, 0.13 ml, 0.13 
mmol) and the TBAF scavenger bead system 231 (0.50 g, 10 x w/w) were reacted in THF (5 
ml) according to general procedure U. Chromatography on KP-NH silica (9:1 DCM/MeOH) 
gave the target compound as a yellow solid (23 mg, 0.08 mmol, 69%). Rf 0.33 (9:1 
DCM/MeOH, KP-NH); M.p. 175-190 °C (decomposed); λmax (EtOH/nm) 274.5, 362.5; IR 
(cm
-1
) 3281, 2558, 2160, 2031, 1976, 1575; 
1
H NMR (500 MHz, DMSO-d6) 2.96 (3H, s, N-
CH3), 3.00 (3H, s, N-CH3), 4.86 (1H, s, C≡CH), 6.94 (1H, ddd, J = 1.3, 2.0 and 7.6 Hz, H-
6’), 7.34 (1H, dd, J = 7.6 and 7.7 Hz, H-5’), 7.80-7.83 (1H, m, H-4’), 7.88 (1H, dd, J = 1.3 
and 1.4 Hz, H-2’), 8.30 (1H, s, H-8), 9.82 (1H, s, C2-NH), 13.17 (1H, br, H-9); 13C NMR 
(125 MHz, DMSO-d6) 35.0 (N-CH3), 39.4 (N-CH3), 116.4 (C-Ar), 118.9 (C-Ar), 119.3 (C-
Ar), 128.4 (C-Ar), 136.7 (C-Ar), 156.0 (C-Ar), 170.2 (C=O); HRMS calcd. for C16H15N6O 
(ES+) m/z 307.1302 [M+H]
+
, found 307.1306. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
N-(3-Nitrophenyl)acetamide (269)
262
 
 
3-Nitroaniline (0.503 g, 3.62 mmol) was added to acetic anhydride at RT. The yellow 
solution was stirred at RT for 30 mins, over which time a white precipitate formed. Water (20 
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ml) was added, and the mixture was extracted with DCM (2 x 40 ml). The combined organic 
extracts were washed with 1M HCl (20 ml), sat. NaHCO3 solution (20 ml) and brine (20 ml). 
The organic phase was dried (MgSO4) and concentrated in vacuo, and the resultant crude was 
triturated with Et2O (20 ml). The desired product was obtained as a white solid, collected by 
filtration (0.334 g, 1.85 mmol, 51%). Rf 0.27 (7:3 Petrol/EtOAc); M.p. 153-156 °C (Lit.
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152-153 °C); λmax (EtOH/nm) 241, 329; IR (cm
-1
) 3261, 3193, 3129, 3097, 1672, 1599, 1547, 
1526; 
1
H NMR (500 MHz, DMSO-d6) 2.10 (3H, s, CH3), 7.60 (1H, dd, J = 8.2 and 8.3 Hz, 
H-5), 7.88-7.91 (2H, m, H-4/H-6), 8.62 (1H, dd, J = 2.1 and 2.2 Hz, H-2); 
13
C NMR (125 
MHz, DMSO-d6) 24.0 (CH3), 113.0 (C-Ar), 117.5 (C-Ar), 124.9 (C-Ar), 130.1 (C-Ar), 140.4 
(C-Ar), 147.9 (C-Ar), 169.0 (C=O); LRMS (ES+) m/z 181.1 [M+H]
+
. 
N-(3-Aminophenyl)acetamide (270)
263
 
 
The nitro compound 269 (0.272 g, 1.51 mmol) and iron powder (0.845 g, 15.1 mmol) were 
reacted in acetic acid (15 ml) according to general procedure T. Purification on silica (9:1 
DCM/MeOH) afforded the desired compound as a pale red oil (0.206 g, 1.37 mmol, 91%). Rf 
0.46 (9:1 DCM/MeOH); λmax (EtOH/nm) 223, 297; IR (cm
-1
) 3245, 3074, 2621, 1658, 1608, 
1545; 
1
H NMR (500 MHz, DMSO-d6) 1.99 (3H, s, CH3), 5.01 (2H, s, Ar-NH2), 6.21-6.25 
(1H, m, H-4), 6.63-6.67 (1H, m, H-6), 6.89 (1H, dd, J = 7.9 and 8.0 Hz, H-5), 6.92 (1H, dd, J 
= 1.8 and 1.9 Hz, H-2), 9.58 (1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) 24.0 (CH3), 104.7 
(C-Ar), 106.9 (C-Ar), 109.1 (C-Ar), 128.8 (C-Ar), 139.9 (C-Ar), 148.9 (C-Ar), 167.8 (C=O); 
LRMS (ES+) m/z 151.1 [M+H]
+
. 
  
347 
 
N-(3-((6-((Triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino)phenyl) acetamide (271) 
 
2-Fluoropurine 160 (0.230 g, 0.72 mmol), aniline 270 (0.216 g, 1.44 mmol) and TFA (140 µl, 
1.80 mmol) were reacted in TFE (7 ml) according to general procedure V. Purification by 
KP-NH silica chromatography (19:1 DCM/MeOH) afforded the target compound as a yellow 
oil/gum (0.200 g, 0.45 mmol, 62%). Rf 0.29 (19:1 DCM/MeOH, KP-NH); λmax (EtOH/nm) 
276, 375; IR (cm
-1
) 3109, 2942, 2862, 1667, 1603, 1577, 1534; 
1
H NMR (500 MHz, DMSO-
d6) 1.13-1.19 (21H, m, Si(CH(CH3)2)3), 2.04 (3H, s, CH3), 7.17 (1H, dd, J = 7.9 and 8.0 Hz, 
H-5’), 7.21-7.25 (1H, m, H-6’), 7.53-7.57 (1H, m, H-4’), 7.76-7.80 (1H, m, H-2’), 8.23 (1H, 
s, H-8), 9.65 (1H, s, CONH), 9.85 (1H, s, C
2
-NH), 13.05 (1H, br, H-9); 
13
C NMR (125 MHz, 
DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 23.9 (CH3), 110.1, 112.8, 113.9, 
128.4 (C-Ar), 139.3 (C-Ar), 141.0 (C-Ar), 168.0 (C=O); HRMS calcd. for C24H33N6OSi 
(ES+) m/z 449.2480 [M+H]
+
, found 449.2479. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
N-(3-((6-Ethynyl-9H-purin-2-yl)amino)phenyl)acetamide (211) 
 
The TIPS-protected purine 271 (0.151 mg, 0.33 mmol), TBAF (1M in THF, 0.40 ml, 0.40 
mmol) and the TBAF scavenger bead system 231 (1.50 g, 10 x w/w) were reacted in THF (5 
ml) according to general procedure U. Chromatography on KP-NH silica (9:1 DCM/MeOH) 
gave the desired compound as a yellow solid (48 mg, 0.16 mmol, 48%). Rf 0.29 (9:1 
DCM/MeOH, KP-NH); M.p. 160-180 °C (decomposed); λmax (EtOH/nm) 251.5, 275.5, 
362.0; IR (cm
-1
) 3266, 2546, 2112, 1668, 1605, 1581, 1536; 
1
H NMR (500 MHz, DMSO-d6) 
2.04 (3H, s, COCH3), 4.84 (1H, s, C≡CH), 7.19 (1H, dd, J = 7.8 and 7.9 Hz, H-5’), 7.24 (1H, 
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m, H-6’), 7.55 (1H, m, H-4’), 7.77 (1H, m, H-2’), 8.27 (1H, s, H-8), 9.63 (1H, s, C2-NH), 
9.88 (1H, s, CONH), 13.12 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 23.9 (COCH3), 
87.0 (C≡CH), 110.0 (C-Ar), 112.7 (C-Ar), 113.9 (C-Ar), 128.4 (C-Ar), 139.3 (C-Ar), 141.0 
(C-Ar), 156.3 (C-Ar), 168.1 (C=O); HRMS calcd. for C15H13N6O (ES+) m/z 293.1145 
[M+H]
+
, found 293.1149. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
2-(2-Nitrophenyl)acetamide (274)
264
 
 
2-Nitrophenylacetic acid (1.00 g, 5.52 mmol), thionyl chloride (0.81 mmol, 11.0 mmol), 
methanol (50 ml) and ammonium hydroxide solution (50 ml) were reacted together according 
to general procedure W. Chromatography on silica (19:1 DCM/MeOH) gave the target 
compound as an off-white solid (0.837 g, 4.65 mmol, 84%). Rf 0.27 (19:1 DCM/MeOH); 
M.p. 156-159 °C (Lit.
264
 160-161 °C); λmax (EtOH/nm) 257; IR (cm
-1
) 3393, 3188, 2919, 
2852, 1646, 1610, 1577, 1514; 
1
H NMR (500 MHz, DMSO-d6) 3.86 (2H, s, COCH2), 6.99 
(1H, s, CONHH’), 6.47-6.54 (3H, m, CONHH’ and H-4/H-6), 7.66 (1H, ddd, J = 1.3, 7.4 and 
7.6 Hz, H-5), 8.00 (1H, dd, J = 1.3 and 8.0 Hz, H-3); 
13
C NMR (125 MHz, DMSO-d6) 39.3 
(COCH2), 124.4 (C-Ar), 128.0 (C-Ar), 131.0 (C-Ar), 133.2 (C-Ar), 133.4 (C-Ar), 149.2 (C-
Ar), 170.4 (C=O); LRMS (ES+) m/z 181.2 [M+H]
+
. 
2-(2-Aminophenyl)acetamide (276)
265
 
 
The nitro compound 274 (0.352 g, 1.94 mmol), ammonium formate (1.23 g, 19.4 mmol) and 
palladium on carbon (35 g, 10% w/w) were reacted in methanol (20 ml) according to general 
procedure G. Chromatography on silica (9:1 DCM/MeOH) gave the target compound as a 
pale pink solid (0.226 g, 1.51 mmol, 78%). Rf 0.35 (9:1 DCM/MeOH); M.p. 93-96 °C (Lit.
265
 
114-115 °C); λmax (EtOH/nm) 236, 288; IR (cm
-1
) 3395, 3188, 1689, 1654, 1615; 
1
H NMR 
(500 MHz, DMSO-d6) 2.45 (2H, s, COCH2), 5.10 (2H, br, Ar-NH2), 6.52 (1H, ddd, J = 1.2, 
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7.4 and 7.7 Hz, H-5), 6.65 (1H, dd, J = 1.1 and 7.7 Hz, H-3), 6.92-6.96 (2H, m, H-4 and 
CONHH’), 7.00 (1H, dd, J = 1.2 and 7.4, H-6), 7.50 (1H, s, CONHH’); 13C NMR (125 MHz, 
DMSO-d6) 39.2 (COCH2), 115.0 (C-Ar), 116.4 (C-Ar), 120.5 (C-Ar), 127.2 (C-Ar), 130.3 
(C-Ar), 147.0 (C-Ar), 173.0 (C=O); LRMS (ES+) m/z 151.1 [M+H]
+
.  
6-Chloro-9-(4-methoxybenzyl)-9H-purin-2-amine (279) 
 
4-Methoxybenzylchloride (0.88 ml, 6.49 mmol) was added to a solution of 2-amino-6-
chloropurine (1.00 g, 5.90 mmol) and K2CO3 (0.90 g, 6.49 mmol) in dry DMF (30 ml). The 
reaction mixture was heated at 60 °C for 18 h before being cooled to RT and evaporated to 
dryness in vacuo. The resultant residue was purified by silica gel chromatography (19:1 
DCM/MeOH) to give the target compound as a pale yellow solid (1.47 g, 5.07 mmol, 86%). 
Rf 0.29 (19:1 DCM/MeOH); M.p. 170-173 °C; λmax (EtOH/nm) 224, 310; IR (cm
-1
) 3440, 
3310, 3201, 3076, 2957, 2831, 1610, 1561, 1512; 
1
H NMR (500 MHz, DMSO-d6) 3.70 (3H, 
s, OCH3), 5.19 (1.4 H, s, N
9
-CH2), 5.46 (0.6 H, s, N
7
-CH2), 6.64 (0.6 H, s, C
2
-NH2 [N
7
-
PMB]), 6.89 (2H, d, J = 8.8 Hz, H-3’/H-5’), 6.93 (1.4 H, s, C2-NH2 [N
9
-PMB]), 7.12 (0.6 H, 
d, J = 8.8 Hz, N
7
-[H-2’/H-6’]), 7.23 (1.4 H, d, J = 8.8 Hz, N9-[H-2’/H-6’]), 8.19 (0.7 H, s, H-
8 [N
9
-PMB]), 8.52 (0.3 H, s, H-8 [N
7
-PMB]); 
13
C NMR (125 MHz, DMSO-d6) 45.6 (N
9
-
CH2), 48.7 (N
7
-CH2), 55.0 (N
7
-OCH3), 55.1 (N
9
-OCH3), 114.1 (C-Ar), 123.2 (C-Ar), 127.9 
(C-Ar), 128.1 (C-Ar), 128.5 (C-Ar), 128.8 (C-Ar), 143.1 (C-Ar), 149.4 (C-Ar), 149.8 (C-Ar), 
153.9 (C-Ar), 158.8 (C-Ar), 158.9 (C-Ar), 159.9 (C-Ar), 160.0 (C-Ar), 164.4 (C-Ar); HRMS 
calcd. for C13H13ClN5O (ES+) m/z 290.0803 [M+H]
+
, found 290.0808. 
Note: Greater number of 
13
C NMR signals than environments due to regioisomers. 
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9-(4-Methoxybenzyl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (280) 
 
6-Chloropurine intermediate 279 (0.502 g, 1.73 mmol), (triisoproplsilyl)acetylene (0.46 ml, 
2.07 mmol), copper iodide (6 mg, 0.03 mmol), Pd(PPh3)2Cl2 (21 mg, 0.03 mmol) and 
triethylamine (0.60 ml, 4.31 mmol) were reacted in DMF (17 ml) according to general 
procedure N. Purification by chromatography on silica (1:1 Petrol/EtOAc) gave the target 
compound as a pale yellow solid (0.518 g, 1.19 mmol, 69%). Rf 0.59 (1:1 Petrol/EtOAc); 
M.p. 121-124 °C;λmax (EtOH/nm) 230, 344; IR (cm
-1
) 3487, 3296, 3183, 2944, 2866, 1594, 
1567, 1511; 
1
H NMR (500 MHz, DMSO-d6) 1.09-1.17 (21H, m, Si(CH(CH3)2)3), 3.72 (3H, s, 
OCH3), 5.21 (2H, s, N
9
-CH2), 6.68 (2H, s, C
2
-NH2), 6.90 (2H, d, J = 8.7 Hz, H-3’/H-5’), 7.23 
(2H, d, J = 8.7 Hz, H-2’/H-6’), 8.19 (1H, s, H-8); 13C NMR (125 MHz, DMSO-d6) 10.6 
(Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 45.2 (N
9
-CH2), 55.1 (OCH3), 97.1 (C≡C-Si), 101.9 
(C≡C-Si), 114.0 (C-Ar), 127.9 (C-Ar), 128.6 (C-Ar), 128.8 (C-Ar), 140.3 (C-Ar), 143.4 (C-
Ar), 153.7 (C-Ar), 158.8 (C-Ar), 160.4 (C-Ar); HRMS calcd. for C24H34N5OSi (ES+) m/z 
436.2527 [M+H]
+
, found 436.2527. 
2-Iodo-9-(4-methoxybenzyl)-6-((triisopropylsilyl)ethynyl)-9H-purine (278) 
 
Isoamyl nitrite (140 µl, 0.69 mmol) was added to a solution of the 2-aminopurine 280 (100 
mg, 0.23 mmol), diiodomethane (93 µl, 1.15 mmol) and copper iodide (48 mg, 0.25 mmol) in 
dry THF (2 ml). The reaction mixture was heated at reflux for 1 h, before being cooled and 
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evaporated to dryness. The residue was purified using silica gel chromatography (4:1 
Petrol/EtOAc) to afford the target compound as pale yellow oil (0.110 g, 0.20 mmol, 87%). 
Rf 0.32 (4:1 Petrol/EtOAc); λmax (EtOH/nm) 229, 312; IR (cm
-1
) 2948, 2866, 1610, 1558, 
1512; 
1
H NMR (500 MHz, CDCl3) 1.13-1.23 (21H, m, Si(CH(CH3)2)3), 3.80 (3H, s, OCH3), 
5.30 (2H, s, N
9
-CH2), 6.88 (2H, d, J = 8.6 Hz, H-3’/H-5’), 7.23 (2H, d, J = 8.6 Hz, H-2’/H-
6’), 7.90 (1H, s, H-8); 13C NMR (125 MHz, CDCl3) 11.2 (Si(CH(CH3)2)3), 18.7 
(Si(CH(CH3)2)3), 47.1 (N
9
-CH2), 55.4 (OCH3), 99.8 (C≡C-Si), 105.3 (C≡C-Si), 114.6 (C-Ar), 
118.8 (C-Ar), 126.4 (C-Ar), 129.7 (C-Ar), 135.1 (C-Ar), 142.4 (C-Ar), 145.0 (C-Ar), 152.6 
(C-Ar), 160.0 (C-Ar); HRMS calcd. for C24H32IN4OSi (ES+) m/z 547.1385 [M+H]
+
, found 
547.1377. 
2-(2-((9-(4-Methoxybenzyl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl) 
amino)phenyl)acetamide (281) 
 
2-Iodopurine intermediate 278 (0.268 g, 0.49 mmol), aniline 276 (88 mg, 0.59 mmol), 
Pd2(dba)3 (45 mg, 0.05 mmol), XPhos (23 mg, 0.05 mmol) and K2CO3 (0.150 g, 1.09 mmol) 
were reacted in MeCN (5 ml) according to general procedure M. Purification by silica gel 
chromatography (3:2 Petrol/EtOAc) gave the desired compound as a pale yellow oil (0.102 g, 
0.18 mmol, 37%). Rf 0.20 (3:2 Petrol/EtOAc); λmax (EtOH/nm) 276; IR (cm
-1
) 3422, 3283, 
3150, 2942, 2864, 1667, 1593, 1575, 1512; 
1
H NMR (500 MHz, DMSO-d6) 1.12-1.21 (21H, 
m, Si(CH(CH3)2)3), 3.50 (2H, s, N
9
-CH2), 3.73 (3H, s, OCH3), 5.22 (2H, s, COCH2), 6.92 
(2H, d, J = 8.7 Hz, H-3’’/H-5’’), 7.05 (1H, ddd, J = 1.0, 7.3 and 7.4 Hz, H-4’), 7.18 (1H, s, 
CONHH’), 7.24-7.29 (2H, m, H-5’/H-6’), 7.30 (2H, d, J = 8.7 Hz, H-2’’/H-6’’), 7.78 (1H, s, 
CONHH’), 7.84-7.87 (1H, m, H-3’), 8.38 (1H, s, H-8), 9.75 (1H, s, C2-NH); 13C NMR (125 
MHz, DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 45.9 (COCH2), 55.1 (OCH3), 
98.5 (C≡C-Si), 101.6 (C≡C-Si), 114.0 (C-Ar), 122.2 (C-Ar), 122.9 (C-Ar), 126.8 (C-Ar), 
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127.7 (C-Ar), 128.4 (C-Ar), 129.2 (C-Ar), 129.4 (C-Ar), 130.2 (C-Ar), 138.8 (C-Ar), 140.4 
(C-Ar), 144.4 (C-Ar), 152.8 (C-Ar), 156.3 (C-Ar), 158.9 (C-Ar), 173.8 (C=O); HRMS calcd. 
for C32H41N6O2Si (ES+) m/z 569.3055 [M+H]
+
, found 569.3051. 
1-(3-Nitrophenyl)propan-2-one (284)
266
 
 
Acetic anhydride (10.4 ml, 110 mmol) was added to a solution of 3-nitrophenylacetic acid 
(2.00 g, 11.0 mmol) in dry pyridine (4.50 ml, 55.2 mmol). The reaction mixture was heated at 
reflux under N2 for 4 h, before being concentrated in vacuo. The brown residue was 
suspended in a mixture of conc. HCl (1 ml) and EtOH (8 ml), and the suspension was heated 
at reflux for 1 h. The resultant solution was poured onto ice water (50 ml) and the mixture 
was extracted with EtOAc (3 x 30 ml). The combined organic extracts were dried (MgSO4), 
concentrated in vacuo, and the crude product purified by silica gel chromatography (4:1 
Petrol/EtOAc). The target compound was obtained as a pale yellow oil which crystallised on 
standing (1.33 g, 7.43 mmol, 68%). Rf 0.26 (4:1 Petrol/EtOAc); M.p. 62-65 °C (Lit.
266
 62 
°C); λmax (EtOH/nm) 263; IR (cm
-1
) 3076, 1719, 1518; 
1
H NMR (500 MHz, CDCl3) 2.28 
(3H, s, CH3), 3.88 (2H, s, CH2), 7.53-7.56 (2H, m, H-4/H-5), 8.07-8.10 (1H, m, H-2), 8.14-
8.18 (1H, m, H-6); 
13
C NMR (125 MHz, CDCl3) 29.9 (CH3), 49.7 (CH2), 122.2 (C-Ar), 124.5 
(C-Ar), 129.5 (C-Ar), 135.8 (C-Ar), 135.9 (C-Ar), 149.4 (C-Ar), 188.9 (C=O); LRMS (ES-) 
m/z 178.1 [M-H]
-
. 
2-Methyl-2-(3-nitrobenzyl)-1,3-dithiane (285) 
 
1,3-Propanedithiol (0.77 ml, 7.70 mmol) and boron trifluoride diethyl etherate (1.58 ml, 12.8 
mmol) were added to a solution of ketone 284 (1.15 g, 6.42 mmol) in dry DCM (30 ml) at 0 
°C. The solution was stirred under N2 at RT for 18 h, before being washed with sat. NaHCO3 
solution (20 ml). The organic phase was dried through a phase separator, concentrated in 
vacuo, and the crude residue purified via silica gel chromatography (4:1 Petrol/EtOAc). The 
desired compound was obtained as an off-white crystalline solid on cooling (1.50 g, 5.56 
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mmol, 87%). Rf 0.44 (4:1 Petrol/EtOAc); M.p. 75-78 °C; λmax (EtOH/nm) 261; IR (cm
-1
) 
2933, 2907, 1525; 
1
H NMR (500 MHz, CDCl3) 1.56 (3H, s, CH3), 1.97-2.11 (2H, m, 
C(SCH2)2CH2), 2.88-3.05 (4H, m, C(SCH2)2CH2), 3.37 (2H, s, Ar-CH2), 7.50 (1H, dd, J = 
7.6 and 7.7 Hz, H-5), 7.61-7.65 (1H, m, H-6), 8.15-8.18 (2H, m, H-2/H-4); 
13
C NMR (125 
MHz, CDCl3) 24.9 (C(SCH2)2CH2), 26.7 (C(SCH2)2CH2), 27.6 (CH3), 46.8 (Ar-CH2), 48.6 
(C(SCH2)2CH2), 122.1 (C-Ar), 125.7 (C-Ar), 128.6 (C-Ar), 137.1 (C-Ar), 138.1 (C-Ar), 
147.9 (C-Ar); LRMS (ES+) m/z 270.2 [M+H]
+
. 
3-((2-Methyl-1,3-dithian-2-yl)methyl)aniline (286) 
 
Nitro compound 285 (1.00 g, 3.71 mmol) and tin(II) chloride (2.81 g, 14.8 mmol) were 
reacted in ethanol (40 ml) according to general procedure D. Following silica gel 
chromatography (7:3 Petrol/EtOAc) the desired compound was obtained as an off-white solid 
on cooling (0.760 g, 3.17 mmol, 85%). Rf 0.41 (7:3 Petrol/EtOAc); M.p. 73-75 °C; λmax 
(EtOH/nm) 235, 291; IR (cm
-1
) 3444, 3349, 2941, 2913, 1612, 1585; 
1
H NMR (500 MHz, 
DMSO-d6) 1.48 (3H, s, CH3), 1.80-1.92 (2H, m, C(SCH2)2CH2), 2.82-2.99 (4H, m, 
C(SCH2)2CH2), 3.02 (2H, s, Ar-CH2), 4.94 (2H, s, Ar-NH2), 6.41 (1H, ddd, J = 1.2, 1.6 and 
7.6 Hz, H-6), 6.44 (1H, ddd, J = 1.2, 2.2 and 7.7 Hz, H-4), 6.46-6.48 (1H, m, H-2), 6.91 (1H, 
dd, J = 7.6 and 7.7 Hz, H-5); 
13
C NMR (125 MHz, DMSO-d6) 24.9 (C(SCH2)2CH2), 25.8 
(C(SCH2)2CH2), 27.4 (CH3), 47.2 (Ar-CH2), 49.1 (C(SCH2)2CH2), 112.3 (C-Ar), 116.6 (C-
Ar), 118.7 (C-Ar), 128.0 (C-Ar), 136.5 (C-Ar), 147.9 (C-Ar); HRMS calcd. for C12H18NS2 
(ES+) m/z 240.0875 [M+H]
+
, found 240.0878. 
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N-(3-((2-methyl-1,3-dithian-2-yl)methyl)phenyl)-6-((triisopropylsilyl)ethynyl)-9H-purin-
2-amine (287) 
 
2-Fluoropurine 160 (0.195 g, 0.61 mmol), aniline 286 (0.220 g, 0.92 mmol) and TFA (117 µl, 
1.53 mmol) were reacted in TFE (6 ml) according to general procedure V. Purification 
through chromatography on KP-NH silica (19:1 DCM/MeOH) gave the target compound as a 
yellow oil/gum (0.182 g, 0.34 mmol, 56%). Rf 0.41 (19:1 DCM/MeOH, KP-NH); λmax 
(EtOH/nm) 276, 379; IR (cm
-1
) 3072, 2942, 2863, 1595, 1575, 1533; 
1
H NMR (500 MHz, 
CDCl3) 1.17-1.26 (21H, m, Si(CH(CH3)2)3), 1.58 (3H, s, CH3), 1.97-2.03 (2H, m, 
C(SCH2)2CH2), 2.87-2.93 (4H, m, C(SCH2)2CH2), 3.19 (2H, s, Ar-CH2), 7.00-7.04 (1H, m, 
H-6’), 7.28 (1H, dd, J = 7.7 and 7.8 Hz, H-5’), 7.38 (1H, s, H-8), 7.39 (1H, s, C2-NH), 7.44-
7.47 (1H, m, H-2’), 7.49-7.54 (1H, m, H-4’), 11.80 (1H, s, H-9); 13C NMR (125 MHz, 
CDCl3) 11.3 (Si(CH(CH3)2)3), 18.7 (Si(CH(CH3)2)3), 25.1 (C(SCH2)2CH2), 
26.7(C(SCH2)2CH2), 27.6 (CH3), 47.5 (Ar-CH2), 49.2(C(SCH2)2CH2), 100.9 (C≡C), 101.6 
(C≡C), 119.1 (C-Ar), 123.2 (C-Ar), 126.4 (C-Ar), 128.6 (C-Ar), 129.3 (C-Ar), 137.3 (C-Ar), 
138.7 (C-Ar), 141.0 (C-Ar), 142.4 (C-Ar), 153.5 (C-Ar), 156.5 (C-Ar); HRMS calcd. for 
C28H40N5S2Si (ES+) m/z 538.2489 [M+H]
+
, found 538.2484. 
1-(3-((6-((Triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino)phenyl)propan-2-one (288) 
 
[Bis(trifluoroacetoxy)iodo]benzene (0.158 g, 0.37 mmol) was added to a solution of the 
dithiane protected purine 287 (0.132 g, 0.25 mmol) in MeOH/H2O (9:1, 25 ml). After stirring 
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at RT for 10 min, the solution was diluted with sat. NaHCO3 solution (30 ml) and the 
resultant suspension was extracted with DCM (2 x 20 ml). The combined organic extracts 
were dried through a phase separator, evaporated to dryness, and the resultant residue was 
purified by silica gel chromatography (19:1 DCM/MeOH). The desired compound was 
obtained as a yellow oil/gum (98 mg, 0.22 mmol, 88%). Rf 0.33 (19:1 DCM/MeOH); λmax 
(EtOH/nm) 277; IR (cm
-1
) 3402, 2943, 2865, 2363, 2160, 1705, 1597, 1577, 1542; 
1
H NMR 
(500 MHz, CDCl3) 1.14-1.25 (21H, m, Si(CH(CH3)2)3), 2.16 (3H, s, CH3), 3.67 (2H, s, CH2), 
6.85-6.89 (1H, m, H-6’), 7.27 (1H, dd, J = 7.7 and 7.9 Hz, H-5’), 7.40-7.45 (2H, m, H-4’ & 
C
2
-NH), 7.52-7.56 (1H, m, H-2’), 7.70 (1H, s, H-8), 11.44 (1H, br, H-9); 13C NMR (125 
MHz, CDCl3) 11.3 (Si(CH(CH3)2)3), 18.7 (Si(CH(CH3)2)3), 29.4 (CH3), 51.0 (CH2), 100.8 
(C≡C), 101.5 (C≡C), 118.5 (C-Ar), 120.5 (C-Ar), 123.9 (C-Ar), 129.4 (C-Ar), 135.1 (C-Ar), 
139.9 (C-Ar), 156.4 (C-Ar), 206.8 (C=O); HRMS calcd. for C25H34N5OSi (ES+) m/z 
448.2527 [M+H]
+
, found 448.2527. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
1-(3-((6-Ethynyl-9H-purin-2-yl)amino)phenyl)propan-2-one (199) 
 
The TIPS-protected purine 288 (90 mg, 0.20 mmol), TBAF (1M in THF, 0.24 ml, 0.24 
mmol) and the TBAF scavenger bead system 231 (0.90 g, 10 x w/w) were reacted in THF (5 
ml) according to general procedure U. Silica gel chromatography (9:1 DCM/MeOH) gave 
the desired compound as a yellow solid (43 mg, 0.14 mmol, 70%). Rf 0.43 (9:1 
DCM/MeOH); M.p. 90-110 °C (decomposed); λmax (EtOH/nm) 273; IR (cm
-1
) 3260, 3082, 
2964, 2827, 2113, 1705, 1604, 1578, 1537; 
1
H NMR (500 MHz, DMSO-d6) 2.15 (3H, s, 
COCH3), 3.71 (2H, s, COCH2), 4.84 (1H, s, C≡CH), 6.77-6.80 (1H, m, H-6’), 7.24 (1H, dd, J 
= 7.8 and 7.9 Hz, H-5’), 7.52 (1H, dd, J = 1.4 and 1.6 Hz, H-2’), 7.75-7.78 (1H, m, H-4’), 
8.28 (1H, s, H-8), 9.64 (1H, s, C
2
-NH), 13.14 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 
29.3 (COCH3), 50.2 (COCH2), 79.0 (C≡C), 87.0 (C≡C), 116.8 (C-Ar), 119.5 (C-Ar), 122.3 
(C-Ar), 128.5 (C-Ar), 135.0 (C-Ar), 140.9 (C-Ar), 156.2 (C-Ar), 206.1 (C=O); HRMS calcd. 
for C16H14N5O (ES+) m/z 292.1193 [M+H]
+
, found 292.1197. 
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N,N-Dimethyl-1-(3-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino)phenyl)  
methanesulfonamide (291) 
 
Trifluoroethylsulfonate ester 193 (0.164 g, 0.29 mmol), dimethylamine (2M in THF, 0.29 ml, 
0.58 mmol) and DBU (86 µl, 0.58 mmol) were reacted in dry THF (3 ml) according to 
general procedure O. Chromatography on KP-NH silica (19:1 DCM/MeOH) afforded the 
target compound as a yellow oil/gum (0.148 g, 0.29 mmol, 100%). Rf 0.50 (19:1 
DCM/MeOH, KP-NH); λmax (EtOH/nm) 276, 366; IR (cm
-1
) 3084, 2942, 2864, 2160, 1599, 
1577, 1539; 
1
H NMR (500 MHz, DMSO-d6) 1.13-1.23 (21H, m, Si(CH(CH3)2)3), 2.74 (6H, s, 
N-(CH3)2), 4.34 (2H, s, SO2CH2), 6.97-7.01 (1H, m, H-6’), 7.29 (1H, dd, J = 7.9 and 8.0 Hz, 
H-5’), 7.80 (1H, dd, J = 1.6 and 1.7 Hz, H-2’), 7.87 (1H, ddd, J = 1.0, 1.7 and 8.0 Hz, H-4’), 
8.27 (1H, s, H-8), 9.78 (1H, s, C
2
-NH), 12.25 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 
10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 37.4 (N-(CH3)2), 54.0 (SO2CH2), 98.0 (C≡C-
Si), 101.7 (C≡C-Si), 118.0 (C-Ar), 120.5 (C-Ar), 123.5 (C-Ar), 128.4 (C-Ar), 129.7 (C-Ar), 
141.0 (C-Ar), 156.1 (C-Ar); HRMS calcd. for C25H37N6O2SSi (ES+) m/z 513.2462 [M+H]
+
, 
found 513.2451. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
1-(3-((6-Ethynyl-9H-purin-2-yl)amino)phenyl)-N,N-dimethylmethane sulfonamide (289) 
 
The TIPS-protected purine 291 (0.139 g, 0.27 mmol), TBAF (1M in THF, 0.33 ml, 0.33 
mmol) and the TBAF scavenger bead system 231 (1.40 g, 10 x w/w) were reacted in THF (5 
ml) according to general procedure U. Silica gel chromatography (9:1 DCM/MeOH) 
afforded the target compound as a yellow solid (56 mg, 0.16 mmol, 58%). Rf 0.42 (9:1 
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DCM/MeOH); M.p. 90-110 °C (decomposed); λmax (EtOH/nm) 275, 367; IR (cm
-1
) 3253, 
3126, 2966, 2926, 2852, 2113, 1599, 1580, 1540; 
1
H NMR (500 MHz, DMSO-d6) 2.76 (6H, 
s, N(CH3)2), 4.36 (Ar-CH2), 4.85 (1H, s, C≡CH), 6.98-7.01 (1H, m, H-6’), 7.31 (1H, dd, J = 
7.8 and 8.0 Hz, H-5’), 7.73-7.76 (1H, m, H-2’), 7.84-7.89 (1H, m, H-4’), 8.29 (1H, s, H-8), 
9.75 (1H, s, C
2
-NH), 13.1 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 37.4 (N(CH3)2), 
54.0 (Ar-CH2), 90.7 (C≡C), 118.1 (C-Ar), 120.7 (C-Ar), 123.7 (C-Ar), 125.6 (C-Ar), 128.5 
(C-Ar), 129.7 (C-Ar), 140.9 (C-Ar), 150.5 (C-Ar), 156.2 (C-Ar); HRMS calcd. for 
C16H17N6O2S (ES+) m/z 357.1128 [M+H]
+
, found 357.1134. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
1-((Methylsulfonyl)methyl)-3-nitrobenzene (293)
267
 
 
Sodium methanesulfinate (0.306 g, 3.01 mmol) in ethanol (2 ml) was added to a solution of 
3-nitrobenzyl bromide (0.502 g, 2.31 mmol) in ethanol (6 ml). The mixture was heated  at 80 
°C for 2 h, before being cooled and concentrated in vacuo. The resultant residue was 
partitioned between DCM (15 ml) and water (10 ml), and the organic phase was dried 
through a phase separator. The solvent was removed and the crude residue purified on silica 
gel (1:1 Petrol/EtOAc) to give the target compound as a white solid (0.467 g, 2.17 mmol, 
94%). Rf 0.39 (1:1 Petrol/EtOAc); M.p. 119-121 °C (Lit.
267
 105-106 °C); λmax (EtOH/nm) 
260; IR (cm
-1
) 3018, 2989, 2935, 1521; 
1
H NMR (500 MHz, CDCl3) 2.91 (3H, s, CH3), 4.40 
(2H, s, CH2), 7.66 (1H, dd, J = 7.6 and 7.7 Hz, H-5), 7.83 (1H, ddd, J = 1.3, 1.5 and 7.7 Hz, 
H-6), 8.29-8.33 (2H, m, H-2/H-4); 
13
C NMR (125 MHz, CDCl3) 39.9 (CH3), 60.2 (CH2), 
124.2 (C-Ar), 125.5 (C-Ar), 130.0 (C-Ar), 130.2 (C-Ar), 136.8 (C-Ar), 153.7 (C-Ar); LRMS 
(ES-) m/z 214.1 [M-H]
-
. 
3-((Methylsulfonyl)methyl)aniline (294)
268
 
 
The nitro compound 293 (0.695 g, 3.23 mmol) and iron powder (1.80 g, 32.3 mmol) were 
reacted in acetic acid (30 ml) according to general procedure T. Silica gel chromatography 
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(9:1 DCM/MeOH) afforded the target compound as an off-white solid (0.532 g, 2.87 mmol, 
89%). Rf 0.42 (9:1 DCM/MeOH); M.p. 123-126 °C (Lit.
268
 126 °C); λmax (EtOH/nm) 243, 
298; IR (cm
-1
) 3463, 3373, 3221, 3011, 2970, 2930, 1625, 1603; 
1
H NMR (500 MHz, 
DMSO-d6) 2.87 (3H, s, CH3), 4.27 (2H, s, CH2), 5.16 (2H, s, Ar-NH2), 6.52-6.55 (1H, m, H-
6), 6.56 (1H, ddd, J = 1.0, 2.2 and 8.0 Hz, H-4), 6.58-6.60 (1H, m, H-2), 7.02 (1H, dd, J = 7.8 
and 8.0 Hz, H-5); 
13
C NMR (125 MHz, DMSO-d6) 59.8 (CH2), 113.9 (C-Ar), 116.1 (C-Ar), 
118.2 (C-Ar), 128.9 (C-Ar), 129.4 (C-Ar), 148.7 (C-Ar); LRMS (ES+) m/z 186.1 [M+H]
+
. 
Note: Unable to visualise all carbon environments by 
13
C NMR – masked by solvent peak. 
N-(3-((Methylsulfonyl)methyl)phenyl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine 
(295) 
 
2-Fluoropurine intermediate 160 (0.213 g, 0.67 mmol), aniline 294 (0.248 g, 1.34 mmol) and 
TFA (130 µl, 1.67 mmol) were reacted in TFE (7 ml) according to general procedure V. 
KP-NH silica chromatography (19:1 DCM/MeOH) gave the target compound as a yellow 
oil/gum (0.134 g, 0.28 mmol, 42%). Rf 0.36 (19:1 DCM/MeOH, KP-NH); λmax (EtOH/nm) 
277, 369; IR (cm
-1
) 3338, 2942, 2864, 1599, 1577, 1539; 
1
H NMR (500 MHz, DMSO-d6) 
1.11-1.20 (21H, m, Si(CH(CH3)2)3), 2.94 (3H, s, CH3), 4.40 (2H, s, Ar-CH2), 6.96-7.01 (1H, 
m, H-4’), 7.27-7.31 (1H, dd, J = 7.9 and 8.1 Hz, H-5’), 7.77-7.80 (1H, m, H-2’), 7.85-7.90 
(1H, m, H-6’), 8.26 (1H, s, H-8), 9.79 (1H, s, C2-NH), 13.11 (1H, br, H-9); 13C NMR (125 
MHz, DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 39.7 (CH3), 59.9 (CH2), 98.0 
(C≡C), 101.7 (C≡C) 118.4 (C-Ar), 120.8, 123.6 (C-Ar), 128.5 (C-Ar), 129.2 (C-Ar), 141.0 
(C-Ar), 143.1 (C-Ar), 145.9 (C-Ar), 156.1 (C-Ar); HRMS calcd. for C24H34N5O2SSi (ES+) 
m/z 484.2197 [M+H]
+
, found 484.2197. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
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6-Ethynyl-N-(3-((methylsulfonyl)methyl)phenyl)-9H-purin-2-amine (290) 
 
The TIPS-protected purine 295 (0.111 g, 0.23 mmol), TBAF (1M in THF, 0.28 ml, 0.28 
mmol) and the TBAF scavenger bead system 231 (1.10 g, 10 x w/w) were reacted in THF (5 
ml) according to general procedure U. Silica gel chromatography (9:1 DCM/MeOH) 
afforded the desired compound as a pale yellow solid (52 mg, 0.15 mmol, 66%). Rf 0.36 (9:1 
DCM/MeOH); M.p. 180-200 °C (decomposed); λmax (EtOH/nm) 275.0, 346.5; IR (cm
-1
) 
3330, 3257, 2982, 2919, 2116, 1607, 1548, 1492; 
1
H NMR (500 MHz, DMSO-d6) 2.97 (3H, 
s, -SO2CH3), 4.43 (2H, s, -SO2CH2), 4.83 (1H, s, C≡CH), 6.98-7.02 (1H, m, H-4’), 7.32 (1H, 
dd, J = 7.9 and 8.0 Hz, H-5’), 7.69-7.73 (1H, m, H-2’), 7.85-7.89 (1H, m, H-6’), 8.27 (1H, s, 
H-8), 9.77 (1H, s, C
2
-NH), 13.11 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 59.8 
(SO2CH2), 79.0 (C≡CH), 87.0 (C≡CH), 118.5 (C-Ar), 121.0 (C-Ar), 123.8 (C-Ar), 128.6 (C-
Ar), 128.9 (C-Ar), 129.3 (C-Ar), 139.5 (C-Ar), 140.9 (C-Ar), 143.0 (C-Ar), 153.9 (C-Ar), 
156.1 (C-Ar); HRMS calcd. for C15H14N5O2S (ES+) m/z 328.0863 [M+H]
+
, found 328.0868. 
9-(4-Methoxybenzyl)-2-amino-9H-purine-6-carbonitrile (299) 
 
PMB-protected purine 277 (1.47 g, 5.07 mmol) was suspended in MeCN (100 ml), to which 
tetraethylammonium cyanide (1.59 g, 10.2 mmol) and DABCO (1.14 g, 10.2 mmol) were 
added, and the mixture was stirred at RT for 18 h. Conc. NH3 solution (10 ml) was added and 
stirring was continued for a further 30 min. The solvent was removed in vacuo and the 
residue was suspended in sat. brine solution (100 ml) and extracted with THF (3 x 100 ml). 
The combined organic extracts were concentrated and purified via chromatography on silica 
(19:1 DCM/MeOH) to give the desired compound as a yellow solid (0.956 g, 3.40 mmol, 
67%). Rf 0.66 (19:1 DCM/MeOH); M.p. 171-175 °C; λmax (EtOH/nm) 357, 227; IR (cm
-1
) 
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3470, 3293, 3180, 3100, 2957, 2158, 2032, 1611; 
1
H NMR (500 MHz, DMSO-d6) 3.73 (3H, 
s, OCH3), 5.24 (2H, s, N
9
-CH2), 6.91 (2H, d, J = 8.8 Hz, H-3’/H-5’), 7.12 (2H, s, C
2
-NH2), 
7.27 (2H, d, J = 8.7 Hz, H-2’/H-6’), 8.44 (1H, s, H-8); 13C NMR (125 MHz, DMSO-d6) 45.5 
(N
9
-CH2), 55.1 (OCH3), 113.5 (quat-C), 114.1 (quat-C), 114.5 (quat-C), 128.2 (C-Ar), 129.0 
(C-Ar), 129.7 (C-Ar), 146.3 (C-Ar), 154.9 (C-Ar), 158.9 (C-Ar), 160.5 (C-Ar); HRMS calcd. 
for C14H13N6O (ES+) m/z 281.1145 [M+H]
+
, found 281.1152. 
Note: Unable to distinguish between aromatic and nitrile 
13
C NMR signals. 
2-Amino-9H-purine-6-carbonitrile trifluoroacetate (300) 
 
The PMB-protected purine 299 (0.803 g, 2.86 mmol) was reacted in TFA (15 ml) according 
to general procedure K for 5 h. Purification by chromatography on silica (9:1 DCM/MeOH) 
gave the target compound as a yellow solid (0.657 g, 2.40 mmol, 84%). Rf 0.31 (19:1 
DCM/MeOH); M.p. 260-280 °C (decomposed); λmax (EtOH/nm) 224, 352; IR (cm
-1
) 3441, 
3327, 3226, 2708, 2159, 1677, 1642; 
1
H NMR (500 MHz, DMSO-d6) 6.91 (2H, s, C
2
-NH2), 
8.32 (1H, s, H-8), 12.22 (2H, br, N
9(+)
-H2); 
13
C NMR (125 MHz, DMSO-d6) 114.8 (C≡N), 
116.0 (q, JCF = 272.8 Hz, CF3), 128.0 (C-Ar), 128.8 (C-Ar), 145.3 (C-Ar), 156.7 (C-Ar), 
157.7 (C-Ar), 160.5 (C=O); 
19
F NMR (470 MHz, DMSO-d6) -73.5 (CF3); HRMS calcd. for 
C6H5N6 (ES+) m/z 161.0570 [M+H]
+
, found 161.0568. 
2-Fluoro-9H-purine-6-carbonitrile (301) 
 
2-Aminopurine 300 (0.650 g, 2.37 mmol), sodium nitrite (0.329 g, 4.76 mmol) and HBF4 (48 
wt. % in H2O, 20 ml) were reacted according to general procedure A. Purification via 
chromatography on silica (9:1 DCM/MeOH) afforded the desired compound as a beige solid 
(0.111 g, 0.67 mmol, 28%). Rf 0.44 (9:1 DCM/MeOH); M.p. 176-179 °C; λmax (EtOH/nm) 
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195; IR (cm
-1
) 3100, 2700, 2158, 2021, 1626; 
1
H NMR (500 MHz, DMSO-d6) 8.87 (1H, s, 
H-8), 14.36 (1H, s, H-9); 
13
C NMR (125 MHz, DMSO-d6) 113.7 (C≡N), 150.9 (d, JCF = 5.7 
Hz, C-Ar), 157.1 (d, JCF = 211.3 Hz, C
2
-Ar);
 19
F NMR (470 MHz, DMSO-d6) -52.01 (C
2
-F); 
LRMS (ES+) m/z 164.1 [M+H]
+
. 
Note: Unable to visualise all quaternary carbon signals by 
13
C NMR – poorly soluble. 
2-(3-Aminophenyl)acetamide (297) 
 
The methyl ester 234 (0.230 g, 1.39 mmol) and ammonium hydroxide solution (15 ml) were 
reacted together according to general procedure S. Chromatography on silica (7:3 
Petrol/EtOAc) gave the target compound as an off-white solid (0.160 g, 1.07 mmol, 77%). Rf 
0.32 (7:3 Petrol/EtOAc); M.p. 156-158 °C; λmax (EtOH/nm) 238; IR (cm
-1
) 3410, 3300, 3175, 
1666, 1607; 
1
H NMR (500 MHz, DMSO-d6) 3.19 (2H, s, COCH2), 5.00 (2H, s, Ar-NH2), 
6.40-6.43 (2H, m, H-4/H-6), 6.46-6.48 (1H, br, H-2), 6.81 (1H, s, CONHH’), 6.92 (1H, dd, J 
= 7.7 and 7.8 Hz, H-5), 7.34 (1H, s, CONHH’); 13C NMR (125 MHz, DMSO-d6) 42.6 
(COCH2), 112.0 (C-Ar), 114.6 (C-Ar), 116.6 (C-Ar), 128.6 (C-Ar), 136.9 (C-Ar), 148.4 (C-
Ar), 172.4 (C=O); LRMS (ES+) m/z 151.2 [M+H]
+
. 
2-(3-(6-Cyano-9H-purin-2-ylamino)phenyl)acetamide (296) 
 
2-Fluoropurine intermediate 301 (10 mg, 0.06 mmol) and aniline 297 (18 mg, 0.12 mmol) 
were combined in DMSO (1 ml) and heated in a sealed vial at 100 °C for 72 h. The solvent 
was removed in vacuo and the residue was purified via chromatography on silica (9:1 
DCM/MeOH) to give the desired product as a yellow solid (9 mg, 0.03 mmol, 50%). Rf 0.32 
(9:1 DCM/MeOH); M.p. 170-180 °C (decomposed); λmax (EtOH/nm) 273; IR (cm
-1
) 3427, 
3268, 3118, 2828, 2160, 2030, 1686; 
1
H NMR (500 MHz, DMSO-d6) 3.36 (2H, s, COCH2), 
6.91 (2H, m, CONHH’/H-6’), 7.22-7.26 (1H, m, H-5’), 7.46 (1H, s, CONHH’), 7.50-7.54 
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(1H, m, H-2’), 7.69-7.73 (1H, m, H-4’), 8.50 (1H, s, H-8), 9.94 (1H, s, C2-NH), 13.52 (1H, 
br, H-9); HRMS calcd. for C14H12N7O (ES+) m/z 294.1101 [M+H]
+
, found 294.1098. 
Note: Insufficient material for 
13
C NMR. 
Methyl 2-(3-nitrophenyl)acetate (303)
269
 
 
3-Nitrophenylacetic acid (0.500 g, 2.76 mmol) and thionyl chloride (400 μl, 5.52 mmol) were 
reacted in dry methanol (25 ml) according to general procedure R. The crude product was 
purified using silica gel chromatography (17:3 Petrol/EtOAc) to give the desired compound 
as a colourless oil (0.501 g, 2.56 mmol, 93%). Rf 0.36 (17:3 Petrol/EtOAc); λmax (EtOH/nm) 
272, 320; IR (cm
-1
) 2985, 2359, 1728, 1530; 
1
H NMR (500 MHz, DMSO-d6) 3.65 (3H, s, 
OCH3), 3.93 (2H, s, CH2), 7.64 (1H, dd, J = 7.9 and 8.1 Hz, H-5), 7.75-7.78 (1H, m, H-6), 
8.15 (1H, ddd, J = 0.9, 2.3 and 7.9 Hz, H-4), 8.18-8.21 (1H, m, H-2); 
13
C NMR (125 MHz, 
DMSO-d6) 51.9 (OCH3), 121.9 (C-Ar), 124.3 (C-Ar), 129.7 (C-Ar), 136.5 (C-Ar), 136.7 (C-
Ar), 147.7 (C-Ar), 171.1 (C=O); LRMS (ES+) m/z 196.3 [M+H]
+
. 
Note: Unable to visualise all carbon signals by NMR – masked by solvent. 
Methyl 2-methyl-2-(3-nitrophenyl)propanoate (304) 
 
Sodium hydride (60% dispersion in mineral oil, 90 mg, 2.25 mmol) was added portion-wise 
to a solution of the ester 303 (0.200 g, 1.02 mmol) and methyl iodide (160 μl, 2.56 mmol) in 
dry THF (2 ml) at 0 °C. The reaction mixture was stirred at 0 °C for 20 min, before being 
warmed to RT and stirred for a further 18 h. The reaction was quenched with acetic acid (1 
ml) and the solvent was removed in vacuo. The crude residue was purified on silica (17:3 
Petrol/EtOAc) to give the desired compound as a pale orange oil (0.124 g, 0.56 mmol, 55%). 
Rf 0.45 (17:3 Petrol/EtOAc); λmax (EtOH/nm) 270, 308; IR (cm
-1
) 2983, 2954, 2361, 2341, 
1730, 1527; 
1
H NMR (500 MHz, DMSO-d6) 1.59 (6H, s, C(CH3)2), 3.63 (3H, s, OCH3), 7.67 
(1H, dd, J = 7.9 and 8.1 Hz, H-5), 7.82 (1H, ddd, J = 1.0, 1.9 and 7.9 Hz, H-6), 8.12 (1H, dd, 
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J = 1.9 and 2.3 Hz, H-2), 8.15 (1H, ddd, J = 1.0, 2.3 and 8.1 Hz, H-4); 
13
C NMR (125 MHz, 
DMSO-d6) 26.1 (C(CH3)2), 46.3 (C(CH3)2), 52.4 (OCH3), 120.2 (C-Ar), 121.9 (C-Ar), 130.0 
(C-Ar), 132.9 (C-Ar), 146.5 (C-Ar), 147.8 (C-Ar), 175.6 (C=O); LRMS (ES+) m/z 224.2 
[M+H]
+
. 
2-Methyl-2-(3-nitrophenyl)propanamide (305) 
 
Methyl ester 304 (0.110 g, 0.49 mmol) was dissolved in concentrated ammonium hydroxide 
(5 ml) and the resultant solution was heated in a sealed vessel at 60 °C for 18 h. The solvent 
was removed in vacuo and the residue was dissolved in dry DCM (5 ml) and treated with 
thionyl chloride (72 μl, 0.98 mmol) and 1 drop of DMF. The solution was stirred at RT under 
nitrogen for 15 min, after which point the solvent was removed in vacuo. The residue was 
dissolved in dry THF (5 ml) and the solution was added drop-wise to concentrated 
ammonium hydroxide (3 ml). The mixture was stirred at RT for 18 h, before the solvent was 
removed in vacuo. The crude residue was purified via chromatography on KP-NH silica (7:3 
Petrol/EtOAc) to give the desired compound as a white solid (72 mg, 0.35 mmol, 71%). Rf 
0.29 (7:3 Petrol/EtOAc, KP-NH); M.p. 116-118 °C; λmax (EtOH/nm) 220, 270; IR (cm
-1
) 
3391, 3208, 2965, 1650, 1535; 
1
H NMR (500 MHz, DMSO-d6) 1.51 (6H, s, C(CH3)2), 7.06 
(1H, s, CONHH’), 7.11 (1H, s, CONHH’), 7.65 (1H, dd, J = 8.0 and 8.0 Hz, H-5), 7.81 (1H, 
ddd, J = 1.0, 1.8 and 8.0 Hz, H-6), 8.12 (1H, ddd, J = 1.0, 2.3 and 8.0 Hz, H-4), 8.15 (1H, dd, 
J = 1.8 and 2.3 Hz, H-2); 
13
C NMR (125 MHz, DMSO-d6) 26.4 (C(CH3)2), 48.1(C(CH3)2), 
120.5 (C-Ar), 121.3 (C-Ar), 129.7 (C-Ar), 133.0 (C-Ar), 176.9 (C=O); HRMS calcd. for 
C10H13N2O3 (ES+) m/z 209.0921 [M+H]
+
, found 209.0924. 
2-(3-Aminophenyl)-2-methylpropanamide (307) 
 
Nitro aromatic 305 (0.392 g, 1.88 mmol), pallladium on carbon (40 mg, 10% w/w) and 
ammonium formate (1.19 g, 18.8 mmol) were reacted in methanol (20 ml) according to 
general procedure G over 18 h. Chromatography on silica (19:1 DCM/MeOH) gave the 
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desired compound as an off-white solid (0.311 g, 1.75 mmol, 93%). Rf 0.21 (19:1 
DCM/MeOH); M.p. 117-120 °C; λmax (EtOH/nm) 243; IR (cm
-1
) 3410, 3337, 3172, 2982, 
1665; 
1
H NMR (500 MHz, DMSO-d6) 1.36 (6H, s, C(CH3)2), 5.10 (2H, br, Ar-NH2), 6.40 
(1H, ddd, J = 0.8, 2.1 and 7.9 Hz, H-6), 6.47-6.50 (1H, m, H-4), 6.54-6.56 (1H, m, H-2), 6.72 
(1H, s, CONHH’), 6.78 (1H, s, CONHH’), 6.94 (1H, dd, J = 7.9 and 8.0 Hz, H-5); 13C NMR 
(125 MHz, DMSO-d6) 26.8 (C(CH3)2), 45.7 (C(CH3)2), 111.5 (C-Ar), 111.8 (C-Ar), 113.2 
(C-Ar), 128.5 (C-Ar), 146.9 (C-Ar), 148.3 (C-Ar), 178.1 (C=O); HRMS calcd. for 
C10H15N2O (ES+) m/z 179.1179 [M+H]
+
, found 179.1180. 
2-(3-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)phenyl)-2-
methylpropanamide (308) 
 
2-Fluoropurine intermediate 160 (0.197 g, 0.62 mmol), aniline 307 (0.220 g, 1.24 mmol) and 
TFA (240 μl, 3.10 mmol) were reacted in TFE (4 ml) according to general procedure B. 
Purification via chromatography on silica (19:1 DCM/MeOH) afforded the desired compound 
as a yellow oil (0.127 g, 0.27 mmol, 43%). Rf 0.28 (19:1 DCM/MeOH); λmax (EtOH/nm) 270, 
368; IR (cm
-1
) 3094, 2964, 2943, 2162, 1970, 1659; 
1
H NMR (500 MHz, DMSO-d6) 1.13-
1.19 (21H, m, Si(CH(CH3)2)3), 1.45 (6H, s, C(CH3)2), 6.80 (1H, s, CONHH’), 6.89 (1H, s, 
CONHH’), 7.04-7.07 (1H, m, H-6’), 7.21 (1H, dd, J = 7.9 and 8.1 Hz, H-5’), 7.65-7.69 (1H, 
m, H-4’), 7.86-7.88 (1H, m, H-2’), 8.25 (1H, s, H-8), 9.65 (1H, s, C2-NH), 13.07 (1H, br, H-
9); 
13
C NMR (125 MHz, DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 26.8 
(C(CH3)2), 46.0 (C(CH3)2), 97.7 (C≡C), 116.1 (C-Ar), 116.2 (C-Ar), 116.6 (C-Ar), 117.1 (C-
Ar), 128.0 (C-Ar), 128.5 (C-Ar), 138.1 (C-Ar), 140.7 (C-Ar), 146.6 (C-Ar), 147.1 (C-Ar), 
156.2 (C-Ar), 159.4 (C-Ar), 177.6 (C=O); HRMS calcd. for C26H37N6OSi (ES+) m/z 
477.2793 [M+H]
+
, found 477.2796. 
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2-(3-(6-Ethynyl-9H-purin-2-ylamino)phenyl)-2-methylpropanamide (302) 
 
TIPS-protected purine 308 (0.108 g, 0.23 mmol), KF (65 mg, 1.13 mmol) and 18-crown-6 (6 
mg, 0.023 mmol) were reacted in THF (2.5 ml) according to general procedure Q. 
Purification via chromatography on KP-NH silica (9:1 DCM/MeOH) afforded the desired 
compound as a yellow solid (37 mg, 0.12 mmol, 51%). Rf 0.29 (9:1 DCM/MeOH, KP-NH); 
M.p. 140-160 °C (decomposed); λmax (EtOH/nm) 274; IR (cm
-1
) 3270, 2975, 2853, 2155, 
1979, 1659, 1599; 
1
H NMR (500 MHz, DMSO-d6) 1.45 (6H, s, -C(CH3)2), 4.82 (1H, s, -
C≡CH), 6.80 (1H, s, -CONHH’), 6.84 (1H, s, -CONHH’), 6.90-6.92 (1H, m, H-6’), 7.22 (1H, 
dd, J = 8.1 and 8.2 Hz, H-5’), 7.74-7.76 (2H, m, H-2’/H-4’), 8.27 (1H, s, H-8), 9.60 (1H, s, 
C
2
-NH), 13.11 (1H, br, H-9);
 13
C NMR (125 MHz, MeOD) 23.8 (C(CH3)2), 49.4 (C(CH3)2), 
102.4 (C≡C), 122.8 (C-Ar), 124.6 (C-Ar), 125.9 (C-Ar), 128.9 (C-Ar), 130.1 (C-Ar); HRMS 
calcd. for C17H17N6O (ES+) m/z 321.1463 [M+H]
+
, found 321.1458. 
Note: Unable to visualise all carbon signals by NMR. 
5-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)indolin-2-one (319) 
 
2-Fluoropurine intermediate 160 (0.319 g, 1.00 mmol), 5-amino-1,3-dihydro-2H-indol-2-one 
(0.298 g, 2.01 mmol) and TFA (390 μl, 5.02 mmol) were reacted in TFE (5 ml) according to 
general procedure B. Purification via chromatography on KP-NH silica (17:3 DCM/MeOH) 
afforded the desired compound as a orange oil (0.143 g, 0.32 mmol, 32%). Rf 0.45 (17:3 
DCM/MeOH, KP-NH); λmax (EtOH/nm) 255, 300, 374; IR (cm
-1
) 2941, 2864, 2154, 1685; 
1
H 
NMR (500 MHz, DMSO-d6) 1.14-1.19 (21H, m, Si(CH(CH3)2)3), 3.47 (2H, s, COCH2), 6.74 
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(1H, d, J = 8.4 Hz, H-3’), 7.51-7.54 (1H, m, H-4’), 7.72-7.75 (1H, br, H-6’), 8.19 (1H, s, H-
8), 9.54 (1H, s, indole NH), 10.23 (1H, s, C
2
-NH), 13.03 (1H, br, H-9); 
13
C NMR (125 MHz, 
DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.5 (Si(CH(CH3)2)3), 36.1 (COCH2), 97.6 (C≡C), 101.9 
(C≡C), 108.8 (C-Ar), 115.9 (C-Ar), 117.8 (C-Ar), 125.9 (C-Ar), 128.3 (C-Ar), 135.1 (C-Ar), 
137.7 (C-Ar), 139.9 (C-Ar), 142.3 (C-Ar), 153.9 (C-Ar), 156.5 (C-Ar), 176.2 (C=O); HRMS 
calcd. for C24H31N6OSi (ES+) m/z 447.2323 [M+H]
+
, found 447.2322. 
5-((6-Ethynyl-9H-purin-2-yl)amino)indolin-2-one (309) 
 
The TIPS-protected purine 319 (66 mg, 0.15 mmol), TBAF (1M in THF, 0.18 ml, 0.18 
mmol) and the TBAF scavenger bead system 231 (0.60 g, 10 x w/w) were reacted in THF (5 
ml) according to general procedure U. Chromatography on silica (9:1 DCM/MeOH) gave 
the desired compound as an orange solid (29 mg, 0.10 mmol, 67%). Rf 0.38 (9:1 
DCM/MeOH); M.p. 130-160 °C (decomposed); λmax (EtOH/nm) 285.0, 375.5; IR (cm
-1
) 
2835, 2161, 2112, 2028, 1977, 1668; 
1
H NMR (500 MHz, DMSO-d6) 3.48 (2H, s, CH2), 4.83 
(1H, s, C≡CH), 6.74 (1H, d, J = 8.4 Hz, H-7’), 7.53 (1H, dd, J = 1.4 and 8.4 Hz, H-6’), 7.69-
7.71 (1H, m, H-4’), 8.24 (1H, s, H-8), 9.51 (1H, s, lactam-NH), 10.26 (1H, s, C2-NH), 13.08 
(1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 36.1 (CH2), 86.7 (C≡CH), 108.8 (C≡CH), 
115.9 (C-Ar), 117.9 (C-Ar), 125.9 (C-Ar), 135.0 (C-Ar), 156.5 (C-Ar), 176.2 (C=O); HRMS 
calcd. for C15H11N6O (ES+) m/z 291.0990 [M+H]
+
, found 291.0989. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
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Di-tert-butyl 2-(3-fluoro-2-nitrophenyl)malonate (321)
270
 
 
2,6-Difluoronitrobenzene (0.501 g, 3.14 mmol), di-tert-butyl malonate (775 μl, 3.46 mmol) 
and potassium carbonate (0.780 g, 5.65 mmol) were combined in dry DMF (9 ml) and heated 
at 60 °C for 18 h, after which the reaction mixture was neutralised with 1M HCl, and 
extracted with Et2O (3 x 20 ml). The combined organic extracts were dried (Na2SO4), 
concentrated in vacuo, and purified via chromatography on silica (9:1 Petrol/EtOAc) to give 
the desired compound as a yellow oil (0.681 g, 1.92 mmol, 61%). Rf 0.56 (9:1 Petrol/EtOAc); 
λmax (EtOH/nm) 230; IR (cm
-1
) 2981, 2937, 1727; 
1
H NMR (500 MHz, CDCl3) 1.50 (18H, s, 
(OC(CH3)3)2), 4.66 (1H, s, CH), 7.22-7.26 (1H, m, H-4), 7.42-7.45 (1H, m, H-6), 7.50-7.55 
(1H, m, H-5); 
13
C NMR (125 MHz, CDCl3) 27.8 (-OC(CH3)3), 54.8 (COCHCO), 83.3 
(OC(CH3)3), 116.9 (C-Ar), 125.9 (C-Ar), 129.1 (C-Ar), 132.1 (C-Ar), 153.0 (C-Ar), 155.1 
(C-Ar), 165.7 (C=O); LRMS (ES-) m/z 354.2 [M-H]
-
. 
Di-tert-butyl 2-(3-(4-methoxybenzylamino)-2-nitrophenyl)malonate (322) 
 
Malonate 321 (0.527 g, 1.48 mmol) was combined with 4-methoxybenzylamine (575 μl, 4.44 
mmol) in THF (15 ml). The reaction mixture was heated at 80 °C for 18 h, after which the 
solvent was removed in vacuo. The crude residue was purified via chromatography on silica 
(9:1 Petrol/EtOAc) to give the desired product as a dark orange oil (0.460 g, 1.04 mmol, 
70%). Rf 0.25 (9:1 Petrol/EtOAc); λmax (EtOH/nm) 241; IR (cm
-1
) 3409, 2980, 2360, 1727; 
1
H NMR (500 MHz, DMSO-d6) 1.49 (18H, s, (OC(CH3)3)2), 3.81 (3H, s, OCH3), 4.38 (2H, d, 
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J = 4.7 Hz, CH2NH), 4.83 (1H, s, CH), 6.73 (1H, dd, J = 1.0 and 7.5 Hz, H-4), 6.80 (1H, dd, 
J = 1.0 and 8.7 Hz, H-6), 6.89 (2H, d, J = 8.8 Hz, H-3’/H-5’), 7.25 (2H, d, J = 8.8 Hz, H-
2’/H-6’), 7.31 (1H, dd, J = 7.5 and 8.7 Hz, H-5); 13C NMR (125 MHz, CDCl3) 27.9 (-
OC(CH3)3), 47.2 (NHCH2), 55.3 (OCH3), 57.5 (COCHCO), 82.4 (-OC(CH3)3), 113.8 (C-Ar), 
114.3 (C-Ar), 118.1 (C-Ar), 128.5 (C-Ar), 129.3 (C-Ar), 133.7 (C-Ar), 167.2 (C=O); HRMS 
calcd. for C25H33N2O7 (ES+) m/z 473.2282 [M+H]
+
, found 473.2281. 
7-Aminoindolin-2-one (324)
271
 
 
Ammonium formate (1.07 g, 17.0 mmol) and palladium on carbon (0.080 g, 10% w/w) were 
added to a solution of malonate 322 (0.802 g, 1.70 mmol) in acetic acid (17 ml). The mixture 
was heated under microwave irradiation at 100 °C for 80 min, after which point the 
microwave vial was vented, and the catalyst was removed via filtration through Celite
®
. The 
solvent was removed in vacuo and the resulting residue was dissolved in EtOAc (30 ml) and 
washed with sat. NaHCO3 solution (3 x 30 ml). The organic extract was dried (Na2SO4) and 
concentrated, and the crude residue was purified via chromatography on silica (9:1 
DCM/MeOH) to give the N-acetylated product as an off-white solid (0.146 g, 0.77 mmol, 
crude yield 45%). The solid was suspended in methanol (8 ml) and treated with acetyl 
chloride (330 μl, 4.62 mmol) at RT. The suspension slowly entered solution and after 1 hour 
the solvent was removed in vacuo. The residue was partitioned between EtOAc (10 ml) and 
sat. NaHCO3 solution (10 ml) and the organic extract was dried (Na2SO4) and concentrated to 
dryness. Purification of the crude residue via chromatography on silica (1:4 Petrol/EtOAc) 
gave the desired compound as a beige solid (91 mg, 0.61 mmol, 36%). Rf 0.44 (1:4 
Petrol/EtOAc); M.p. 249-251 °C (Lit.
271
 247-249 °C); λmax (EtOH/nm) 255; IR (cm
-1
) 3425, 
3363, 3247, 1694; 
1
H NMR (500 MHz, DMSO-d6) 3.41 (2H, s, CH2), 4.81 (2H, s, Ar-NH2), 
6.47-6.49 (1H, m, H-4), 6.50 (1H, dd, J = 1.0 and 8.0 Hz, H-6), 6.69 (1H, ddd, J = 8.0 and 
8.1 Hz, H-5); 
13
C NMR (125 MHz, DMSO-d6) 36.3 (COCH2), 112.6 (C-Ar), 113.6 (C-Ar), 
122.0 (C-Ar), 125.7 (C-Ar), 128.9 (C-Ar), 131.5 (C-Ar), 176.0 (C=O); LRMS (ES+) m/z 
149.1 [M+H]
+
. 
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7-(6-(2-(Triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)indolin-2-one (325) 
 
2-Fluoropurine intermediate 160  (0.120 g, 0.37 mmol), aminoindolinone 324 (0.110 g, 0.75 
mmol) and TFA (142 μl, 1.85 mmol) were reacted in TFE (4 ml) according to general 
procedure B. Purification via chromatography on KP-NH silica (19:1 DCM/MeOH) 
afforded the desired compound as a orange oil (54 mg, 0.12 mmol, 32%). Rf 0.36 (19:1 
DCM/MeOH); λmax (EtOH/nm) 255, 359; IR (cm
-1
) 3351, 3251, 3070, 2943, 2866, 2159, 
1704; 
1
H NMR (500 MHz, DMSO-d6) 1.14-1.19 (21H, m, Si(CH(CH3)2)3), 3.52 (2H, s, CH2), 
6.90-7.00 (2H, m, H-4’/H-5’), 7.58-7.62 (1H, m, H-6’), 8.20 (1H, s, H-8), 9.00 (1H, s, indole 
NH), 10.08 (1H, s, C
2
-NH), 13.05 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 10.6 
(Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 36.0 (COCH2), 119.2 (C-Ar), 121.1 (C-Ar), 126.3 
(C-Ar), 156.6 (C-Ar), 175.9 (C=O); HRMS calcd. for C24H31N6OSi (ES+) m/z 447.2323 
[M+H]
+
, found 447.2323. 
Note: Unable to visualise all carbon signals by NMR. 
7-((6-Ethynyl-9H-purin-2-yl)amino)indolin-2-one (310) 
 
The TIPS-protected purine 325 (99 mg, 0.22 mmol), TBAF (1M in THF, 0.27 ml, 0.27 
mmol) and the TBAF scavenger bead system 231 (1.00 g, 10 x w/w) were reacted in THF (5 
ml) according to general procedure U. Purification on silica (9:1 DCM/MeOH) afforded the 
target compound as a pale orange solid (43 mg, 0.14 mmol, 67%). Rf 0.27 (9:1 
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DCM/MeOH); M.p. 195-225 °C (decomposed); λmax (EtOH/nm) 244.0, 361.0; IR (cm
-1
) 
3248, 2363, 2169, 2013, 1978, 1662; 
1
H NMR (500 MHz, DMSO-d6) 3.52 (2H, s, CH2), 4.81 
(1H, s, C≡CH), 6.93 (1H, dd, J = 7.4 and 7.7 Hz, H-5’), 6.95-6.98 (1H, m, H-4’), 7.61-7.67 
(1H, m, H-6’), 8.23 (1H, s, H-8), 8.96 (1H, s, lactam-NH), 10.11 (1H, s, C2-NH), 13.08 (1H, 
br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 36.4 (CH2), 119.6 (C-Ar), 121.4 (C-Ar); HRMS 
calcd. for C15H11N6O (ES+) m/z 291.0990 [M+H]
+
, found 291.0989. 
Note: Unable to visualise all carbon environments by 
13
C NMR – insufficient material. 
Methyl methyl(phenethyl) carbamate (326)
272
 
 
A solution of methyl chloroformate (1.59 ml, 20.6 mmol) in Et2O (5 ml) was added dropwise 
over 30 min to the biphasic mixture of N-methyl-phenethylamine (2.00 ml, 13.8 mmol) and 
K2CO3 (5.71 g, 41.3 mmol) in Et2O (20 ml) and water (20 ml). The mixture was stirred at RT 
for 1 hour, before the organic phase was removed and washed with 1M HCl (20 ml), dried 
(MgSO4) and evaporated to dryness. The resultant crude residue was purified using silica gel 
chromatography (4:1 Petrol/EtOAc) to give the target compound as a colourless liquid (2.44 
g, 11.9 mmol, 86%). Rf 0.44 (4:1 Petrol/EtOAc); λmax (EtOH/nm) 259; IR (cm
-1
) 3027, 2950, 
1697; 
1
H NMR (500 MHz, DMSO-d6, 348 K) 2.79 (2H, t, J = 7.6 Hz, NCH2CH2), 2.80 (3H, 
s, N-CH3), 3.45 (2H, t, J = 7.6 Hz, NCH2CH2), 3.56 (3H, s, OCH3), 7.19-7.23 (3H, m, H-
2/H-4/H-6), 7.28-7.32 (2H, m, H-3/H-5); 
13
C NMR (125 MHz, CDCl3, 298 K) 34.1 (N-CH3), 
34.6 (N-CH3), 50.6 (CH2), 51.1 (CH2), 52.5 (OCH3), 126.3 (C-Ar), 128.5 (C-Ar), 128.8 (C-
Ar), 139.0 (C-Ar), 153.7 (C=O); LRMS (ES+) m/z 194.2 [M+H]
+
.  
2-Methyl-3,4-dihydroisoquinolin-1(2H)-one (328)
273
 
 
The methyl carbamate 326 (1.77 g, 9.16 mmol) was heated in Eaton’s reagent (10 ml) under 
microwave irradiation conditions at 120 °C for 15 min. The resultant brown oil was dissolved 
in EtOAc (100 ml) and slowly added to a stirred sat. NaHCO3 solution (100 ml). The mixture 
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was shaken, and the organic phase washed with brine (50 ml), dried (MgSO4) and 
concentrated in vacuo. Chromatography on silica (4:1 Petrol/EtOAc) gave the desired 
compound as a colourless oil (1.30 g, 8.09 mmol, 88%). Rf 0.26 (4:1 Petrol/EtOAc); λmax 
(EtOH/nm) 229; IR (cm
-1
) 2941, 2871, 1641, 1604, 1578; 
1
H NMR (500 MHz, CDCl3) 3.02 
(2H, t, J = 6.7 Hz, NCH2CH2), 3.17 (3H, s, N-CH3), 3.58 (2H, t, J = 6.7 Hz, NCH2CH2), 
7.17-7.20 (1H, m, H-5), 7.34 (1H, ddd, J = 1.1, 7.5 and 7.6 Hz, H-7), 7.42 (1H, ddd, J = 1.4, 
7.4 and 7.5 Hz, H-6), 8.10 (1H, dd, J = 1.4 and 7.6 Hz, H-8); 
13
C NMR (125 MHz, CDCl3) 
27.9 (NCH2CH2), 35.2 (N-CH3), 48.1 (NCH2CH2), 126.9 (C-Ar), 127.0 (C-Ar), 128.1 (C-Ar), 
129.4 (C-Ar), 131.5 (C-Ar), 138.0 (C-Ar), 164.8 (C=O); LRMS (ES+) m/z 162.1 [M+H]
+
. 
2-Methyl-7-nitro-3,4-dihydroisoquinolin-1(2H)-one (330) 
 
Fuming HNO3 (42 µl, 1.01 mmol) was added to conc. H2SO4 (2 ml) at 0 °C. A solution of the 
isoquinolinone 328 (0.135 g, 0.84 mmol) in conc. H2SO4 (0.5 ml) was added dropwise, and 
the solution was stirred at 0 °C for 30 min. The mixture was poured onto ice water (15 ml) 
and the resulting precipitate collected by filtration and washed with cold water (5 ml). The 
filtrand was dried in a vacuum oven to give the target compound as a white solid (100 mg, 
0.48 mmol, 57%). Rf 0.29 (19:1 DCM/MeOH); M.p. 137-140 °C; λmax (EtOH/nm) 220, 255; 
IR (cm
-1
) 2925, 2868, 1647, 1610, 1518; 
1
H NMR (500 MHz, DMSO-d6) 3.07 (3H, s, N-
CH3), 3.14 (2H, t, J = 6.7 Hz, NCH2CH2), 3.62 (2H, t, J = 6.7 Hz, NCH2CH2), 7.61 (1H, d, J 
= 8.3 Hz, H-5), 8.31 (1H, dd, J = 2.5 and 8.3 Hz, H-6), 8.56 (1H, d, J = 2.5 Hz, H-8); 
13
C 
NMR (125 MHz, DMSO-d6) 27.1 (NCH2CH2), 34.6 (N-CH3), 46.7 (NCH2CH2), 121.7 (C-
Ar), 125.8 (C-Ar), 129.2 (C-Ar), 130.2 (C-Ar), 146.2 (C-Ar), 146.6 (C-Ar), 161.6 (C=O); 
HRMS calcd. for C10H11N2O3 (ES+) m/z 207.0764 [M+H]
+
, found 207.0765. 
7-amino-2-methyl-3,4-dihydroisoquinolin-1(2H)-one (331) 
 
The nitro compound 330 (0.947 g, 4.59 mmol) and iron powder (2.56 g, 45.9 mmol) were 
reacted in acetic acid (45 ml) according to general procedure T. Purification on silica (19:1 
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DCM/MeOH) afforded the desired compound as a pale yellow solid (0.678 g, 3.85 mmol, 
84%). Rf 0.24 (19:1 DCM/MeOH); M.p. 131-133 °C; λmax (EtOH/nm) 224, 330; IR (cm
-1
) 
3439, 3359, 3330, 3234, 2931, 1635, 1599, 1576, 1498; 
1
H NMR (500 MHz, DMSO-d6) 2.77 
(2H, t, J = 6.7 Hz, NCH2CH2), 2.99 (N-CH3), 3.45 (2H, t, J = 6.7 Hz, NCH2CH2), 5.12 (2H, 
s, Ar-NH2), 6.66 (1H, dd, J = 2.5 and 8.0 Hz, H-6), 6.91 (1H, d, J = 8.0 Hz, H-5), 7.15 (1H, 
d, J = 2.5 Hz, H-8); 
13
C NMR (125 MHz, DMSO-d6) 26.3 (NCH2CH2), 34.6 (N-CH3), 47.9 
(NCH2CH2), 112.3 (C-Ar), 117.1 (C-Ar), 125.4 (C-Ar), 127.6 (C-Ar), 129.4 (C-Ar), 147.4 
(C-Ar), 164.1 (C=O); HRMS calcd. for C10H13N2O (ES+) m/z 177.1022 [M+H]
+
, found 
177.1021. 
2-Methyl-7-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino)-3,4-
dihydroisoquinolin-1(2H)-one (317) 
 
2-Fluoropurine 160 (0.225 g, 0.71 mmol), aniline 331 (0.250 g, 1.41 mmol) and TFA (136 µl, 
1.77 mmol) were reacted in TFE (7 ml) according to general procedure V. Chromatography 
on KP-NH silica (19:1 DCM/MeOH) gave the desired product as a yellow oil/gum (0.142 g, 
0.30 mmol, 42%). Rf 0.37 (19:1 DCM/MeOH, KP-NH); λmax (EtOH/nm) 279; IR (cm
-1
) 
3390, 3136, 2941, 2864, 2167, 1609, 1577, 1538; 
1
H NMR (500 MHz, DMSO-d6) 1.12-1.23 
(21H, m, Si(CH(CH3)2)3), 2.91 (2H, t, J = 6.6 Hz, NCH2CH2), 3.04 (3H, s, N-CH3), 3.53 (2H, 
t, J = 6.6 Hz, NCH2CH2), 7.19 (1H, d, J = 8.3 Hz, H-5’), 7.90 (1H, dd, J = 2.3 and 8.3 Hz, H-
6’), 8.25 (1H, s, H-8), 8.27 (1H, d, J = 2.3 Hz, H-8’), 9.77 (1H, s, C2-NH), 13.14 (1H, br, H-
9); 
13
C NMR (125 MHz, DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 26.6 
(NCH2CH2), 34.6 (N-CH3), 47.6 (NCH2CH2), 97.9 (C≡C), 101.7 (C≡C), 117.3 (C-Ar), 121.6 
(C-Ar), 127.2 (C-Ar), 129.2 (C-Ar), 131.0 (C-Ar), 139.5 (C-Ar), 156.2 (C-Ar), 163.7 (C=O); 
HRMS calcd. for C26H35N6OSi (ES+) m/z 475.2636 [M+H]
+
, found 475.2635. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
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7-((6-Ethynyl-9H-purin-2-yl)amino)-2-methyl-3,4-dihydroisoquinolin-1(2H)-one (312) 
 
The TIPS-protected purine 317 (98 mg, 0.21 mmol), TBAF (1M in THF, 0.25 ml, 0.25 
mmol) and the TBAF scavenger bead system 231 (1.00 g, 10 x w/w) were reacted in THF (5 
ml) according to general procedure U. Chromatography on silica (9:1 DCM/MeOH) gave 
the target compound as a yellow solid (36 mg, 0.11 mmol, 54%). Rf 0.34 (9:1 DCM/MeOH); 
M.p. 280-300 °C (decomposed); λmax (EtOH/nm) 276; IR (cm
-1
) 3117, 2945, 2108, 1641, 
1608, 1575, 1540; 
1
H NMR (500 MHz, DMSO-d6) 2.92 (2H, t, J = 6.6 Hz, NCH2CH2), 3.04 
(3H, s, N-CH3), 3.54 (2H, t, J = 6.6 Hz, NCH2CH2), 4.85 (1H, s, C≡CH), 7.20 (1H, d, J = 8.3 
Hz, H-5’), 7.89 (1H, dd, J = 2.3 and 8.3 Hz, H-6’), 8.26 (1H, d, J = 2.3 Hz, H-8’), 8.28 (1H, 
s, H-8), 9.73 (1H, s, C
2
-NH), 13.2 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 26.6 
(NCH2CH2), 34.6 (N-CH3), 47.6 (NCH2CH2), 87.0 (C≡C), 117.4 (C-Ar), 121.7 (C-Ar), 127.2 
(C-Ar), 129.2 (C-Ar), 131.1 (C-Ar), 139.5 (C-Ar), 156.2 (C-Ar), 163.7 (C=O); HRMS calcd. 
for C17H15N6O (ES+) m/z 319.1302 [M+H]
+
, found 319.1307. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
N-Methyl-2-(4-nitrophenyl)acetamide (332)
274
 
 
4-Nitrophenylacetic acid (1.00 g, 5.52 mmol), thionyl chloride (0.81 mmol, 11.0 mmol), 
methanol (50 ml) and methylamine (40% aqueous solution, 50 ml) were reacted together 
according to general procedure W over 72 h. Chromatography on silica (19:1 DCM/MeOH) 
gave the target compound as an off-white solid (0.916 g, 5.08 mmol, 92%). Rf 0.31 (19:1 
DCM/MeOH); M.p. 157-160 °C (Lit.
274
 159 °C); λmax (EtOH/nm) 271; IR (cm
-1
) 3260, 3084, 
2943, 2844, 1638, 1565, 1505; 
1
H NMR (500 MHz, DMSO-d6) 2.60 (3H, d, J = 4.7 Hz, 
NHCH3), 3.58 (2H, s, COCH2), 7.53 (2H, d, J = 9.0 Hz, H-2/H-6), 8.09 (1H, br, NHCH3), 
8.18 (2H, d, J = 9.0 Hz, H-3/H-5); 
13
C NMR (125 MHz, DMSO-d6) 25.6 (NHCH3), 41.9 
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(ArCH2), 123.3 (C-Ar), 130.3 (C-Ar), 144.5 (C-Ar), 146.2 (C-Ar), 169.3 (C=O); LRMS 
(ES+) m/z 195.2 [M+H]
+
. 
2-Methyl-7-nitro-1,2-dihydroisoquinolin-3(4H)-one (333)
217
 
 
Paraformaldehyde (19 mg, 0.62 mmol) was added to a suspension of the N-methyl 
carboxamide 332 (102 mg, 0.51 mmol) in Eaton’s reagent (1 ml). The mixture was heated in 
a sealed vial at 80 °C for 6 h, after which point the brown solution was cooled to RT, diluted 
with ice water (5 ml) and neutralised with 50% NaOH solution. The resultant suspension was 
extracted with EtOAc (3 x 10 ml) and the combined organic extracts were dried (MgSO4) and 
concentrated in vacuo. The crude residue was purified by chromatography on silica gel (19:1 
DCM/MeOH) to give the target compound as a pale orange solid (78 mg, 0.38 mmol, 75%). 
Rf 0.30 (19:1 DCM/MeOH); M.p. 151-154 °C; λmax (EtOH/nm) 273; IR (cm
-1
) 3041, 2875, 
1637, 1597, 1500; 
1
H NMR (500 MHz, DMSO-d6) 2.98 (3H, s, N-CH3), 3.70 (2H, s, N-CH2), 
4.64 (2H, s, COCH2), 7.50 (1H, d, J = 8.4 Hz, H-5), 8.13 (1H, dd, J = 2.3 and 8.4 Hz, H-6), 
8.20 (1H, d, J = 2.3 Hz, H-8); 
13
C NMR (125 MHz, DMSO-d6) 33.6 (N-CH3), 37.0 (N-CH2), 
51.1 (COCH2), 120.4 (C-Ar), 122.1 (C-Ar), 128.3 (C-Ar), 134.0 (C-Ar), 141.0 (C-Ar), 146.0 
(C-Ar), 166.9 (C=O); LRMS (ES+) m/z 207.1 [M+H]
+
. 
7-Amino-2-methyl-1,2-dihydroisoquinolin-3(4H)-one (334) 
 
The nitro compound 333 (0.348 g, 1.69 mmol) and iron powder (0.943 g, 16.9 mmol) were 
reacted in acetic acid (17 ml) according to general procedure T. Purification via silica gel 
chromatography (19:1 DCM/MeOH) gave the desired compound as a pale orange solid 
(0.196 g, 1.11 mmol, 66%). Rf 0.25 (19:1 DCM/MeOH); M.p. 167-170 °C; λmax (EtOH/nm) 
241, 296; IR (cm
-1
) 3426, 3343, 3241, 3023, 2871, 1612, 1502; 
1
H NMR (500 MHz, DMSO-
d6) 2.94 (3H, s, N-CH3), 3.31 (2H, s, COCH2), 4.34 (2H, s, N-CH2), 4.99 (2H, s, Ar-NH2), 
6.42 (1H, d, J = 2.2 Hz, H-8), 6.46 (1H, dd, J = 2.2 and 8.0 Hz, H-6), 6.82 (1H, d, J = 8.0 Hz, 
H-5); 
13
C NMR (125 MHz, DMSO-d6) 33.5 (N-CH3), 35.8 (COCH2), 52.0 (N-CH2), 110.1 
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(C-Ar), 113.2 (C-Ar), 119.1 (C-Ar), 127.3 (C-Ar), 132.1 (C-Ar), 147.0 (C-Ar), 168.6 (C=O); 
HRMS calcd. for C10H13N2O (ES+) m/z 177.1022 [M+H]
+
, found 177.1019. 
2-Methyl-7-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino)-1,2-
dihydroisoquinolin-3(4H)-one (335) 
 
2-Fluoropurine 160 (0.145 g, 0.45 mmol), aniline 334 (0.160 g, 0.91 mmol) and TFA (87 µl, 
1.14 mmol) were reacted in TFE (5 ml) according to general procedure V. Purification 
through chromatography on KP-NH silica (19:1 DCM/MeOH) gave the desired compound as 
a yellow oil/gum (0.138 g, 0.29 mmol, 64%). Rf 0.39 (19:1 DCM/MeOH, KP-NH); λmax 
(EtOH/nm) 277; IR (cm
-1
) 2943, 2864, 1605, 1577, 1537; 
1
H NMR (500 MHz, DMSO-d6) 
1.13-1.22 (21H, m, Si(CH(CH3)2)3), 2.98 (3H, s, N-CH3), 3.46 (2H, s, COCH2), 4.48 (2H, s, 
N-CH2), 7.10 (1H, d, J = 8.4 Hz, H-5’), 7.66 (1H, dd, J = 2.1 and 8.4 Hz, H-6’), 7.73-7.77 
(1H, m, H-8’), 8.25 (1H, s, H-8), 9.71 (1H, s, C2-NH), 13.08 (1H, br, H-9); 13C NMR (125 
MHz, DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 33.6 (N-CH3), 36.1 (COCH2), 
52.2 (N-CH2), 97.8 (C≡C-Si), 101.8 (C≡C-Si), 114.7 (C-Ar), 117.5 (C-Ar), 124.8 (C-Ar), 
127.0 (C-Ar), 131.8 (C-Ar), 139.2 (C-Ar), 142.7 (C-Ar), 156.2 (C-Ar), 168.2 (C=O); HRMS 
calcd. for C26H35N6OSi (ES+) m/z 475.2636 [M+H]
+
, found 475.2631. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
7-((6-Ethynyl-9H-purin-2-yl)amino)-2-methyl-1,2-dihydroisoquinolin-3(4H)-one (314) 
 
The TIPS-protected purine 335 (0.112 g, 0.24 mmol), TBAF (1M in THF, 0.28 ml, 0.28 
mmol) and the TBAF scavenger bead system 231 (1.10 g, 10 x w/w) were reacted in THF (5 
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ml) according to general procedure U. Silica gel chromatography (9:1 DCM/MeOH) 
afforded the target compound as a yellow solid (41 mg, 0.13 mmol, 54%). Rf 0.41 (9:1 
DCM/MeOH); M.p. 200-220 °C (decomposed); λmax (EtOH/nm) 274.5, 346.5; IR (cm
-1
) 
3292, 3086, 2963, 2774, 2104, 1610, 1551, 1494; 
1
H NMR (500 MHz, DMSO-d6) 2.98 (3H, 
s, N-CH3), 3.46 (2H, s, Ar-CH2), 4.49 (2H, s, Ar-CH2), 4.84 (1H, s, C≡CH), 7.11 (1H, d, J = 
8.5 Hz, H-5’), 7.65-7.71 (2H, m, H-6’/H-8’), 8.28 (1H, s, H-8), 9.69 (1H, s, C2-NH), 13.13 
(1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 33.6 (N-CH3), 36.1 (Ar-CH2), 52.1 (Ar-CH2), 
78.9 (C≡CH), 87.0 (C≡CH), 114.8 (C-Ar), 117.6 (C-Ar), 124.9 (C-Ar), 127.0 (C-Ar), 131.8 
(C-Ar), 139.1 (C-Ar), 156.2 (C-Ar), 168.2 (C=O); HRMS calcd. for C17H15N6O (ES+) m/z 
319.1302 [M+H]
+
, found 319.1301. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
2-(3-Amino-(N-tert-Butyloxycarbonyl)phenyl)acetic acid (347)
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2-(3-Aminophenyl)acetic acid (1.00 g, 6.62 mmol) and di-tert-butyl dicarbonate (1.60 g, 7.28 
mmol) were reacted in dioxane (20 ml), 1M NaOH solution (10 ml) and water (10 ml) 
according to general procedure P. The desired compound was obtained as a pale orange oil 
which solidified on cooling (1.58 g, 6.29 mmol, 95%). Rf 0.41 (2:3 Petrol/EtOAc); M.p. 100-
102 °C; λmax (EtOH/nm) 237; IR (cm
-1
) 3301, 2981, 2159, 1694; 
1
H NMR (500 MHz, 
DMSO-d6) 1.48 (9H, s, -C(CH3)3), 3.49 (2H, s, COCH2), 6.83-6.87 (1H, m, H-6), 7.18 (1H, 
dd, J = 7.9 and 8.0 Hz, H-5), 7.26-7.30 (1H, m, H-4), 7.41-7.44 (1H, m, H-2), 9.32 (1H, s, 
Ar-NH), 12.29 (1H, s, -CO2H); 
13
C NMR (125 MHz, DMSO-d6) 28.1 (-C(CH3)3), 41.1 
(COCH2), 78.9 (-C(CH3)3), 116.5 (C-Ar), 118.9 (C-Ar), 123.1 (C-Ar), 128.4 (C-Ar), 135.4 
(C-Ar), 139.5 (C-Ar), 152.7 (COC(CH3)3), 172.6 (-CO2H); LRMS (ES+) m/z 252.1 [M+H]
+
. 
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tert-Butyl 3-((2-aminoethylcarbamoyl)methyl)phenyl carbamate (348) 
 
CDI (1.86 g, 11.5 mmol) and DIPEA (2.00 ml, 11.5 mmol) were added to a solution of 
carboxylic acid 347 (1.44 g, 5.73 mmol) in dry THF (25 ml) under nitrogen. The mixture was 
stirred at RT for 1.5 h, after which point it was added via canular to a solution of 
ethylenediamine (2.30 ml, 34.4 mmol) in dry THF (20 ml). The resulting suspension was 
stirred at RT for 18 h, after which point the solvent was removed in vacuo. The crude residue 
was purified using silica gel chromatography (7:3 DCM/MeOH) to give the desired 
compound as an thick colourless oil (1.48 g, 5.04 mmol, 88%). Rf 0.32 (7:3 DCM/MeOH); 
λmax (EtOH/nm) 239; IR (cm
-1
) 3304, 2981, 2930, 1694, 1639; 
1
H NMR (500 MHz, DMSO-
d6) 1.48 (9H, s, -C(CH3)3), 2.57 (2H, t, J = 6.4 Hz, CONHCH2CH2), 3.04 (2H, dt, J = 5.9 and 
6.4 Hz, CONHCH2CH2), 3.18 (2H, s, CH2CO), 3.40 (2H, br, NH2), 6.84-6.87 (1H, m, H-4), 
7.15 (1H, dd, J = 8.0 and 8.2 Hz, H-5), 7.23-7.26 (1H, m, H-6), 7.43 (1H, br, H-2), 8.01 (1H, 
t, J = 5.9 Hz, CONH), 9.32 (1H, s, Ar-NH); 
13
C NMR (125 MHz, DMSO-d6) 28.1 (C(CH3)3), 
42.4 (CH2), 42.6 (CH2), 78.9 (C(CH3)3), 118.7 (C-Ar), 122.8 (C-Ar), 128.3 (C-Ar), 139.4 (C-
Ar), 152.7 (carbamate C=O), 170.0 (amide C=O); HRMS calcd. for C15H24N3O3 (ES+) m/z 
294.1812 [M+H]
+
, found 294.1817. 
tert-Butyl 3-((2-(4-nitrobenzo[c][1,2,5]oxadiazol-7-ylamino)ethyl-carbamoyl)methyl) 
phenyl carbamate (349) 
 
4-Chloro-7-nitrobenzofurazan (0.145 g, 0.73 mmol) in DMF (1 ml) was added dropwise to a 
solution of carboxylic acid 347 (0.194 g, 0.66 mmol) and triethylamine (110 μl, 0.79 mmol) 
in DMF (4 ml). The resultant dark red solution was stirred at RT with exclusion of light for 
18 h. The solvent was removed in vacuo and the crude residue was purified on silica gel (19:1 
DCM/MeOH) to give the desired compound as an orange solid (0.270 g, 0.59 mmol, 90%). 
Rf 0.38 (19:1 DCM/MeOH); M.p. 184-186 °C; λmax (EtOH/nm) 241, 339; IR (cm
-1
) 3388, 
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3304, 3086, 2938, 1722, 1681; 
1
H NMR (500 MHz, DMSO-d6) 1.46 (9H, s, -C(CH3)3), 3.32 
(2H, s, CH2CO), 3.37-3.40 (2H, m, CONHCH2CH2NH), 3.52-3.55 (2H, m, 
CONHCH2CH2NH), 6.40 (1H, d, J = 9.0 Hz, H-5’), 6.80-6.82 (1H, m, H-4), 7.09 (1H, dd, J 
= 8.0 and 8.0 Hz, H-5), 7.19-7.22 (1H, m, H-6), 7.42 (1H, br, H-2), 8.24 (1H, t, J = 5.8 Hz, 
CONH), 8.47 (1H, d, J = 9.0 Hz, H-6’), 9.27 (1H, s, Ar-NHBoc), 9.40 (1H, br, CH2CH2NH); 
13
C NMR (125 MHz, DMSO-d6) 28.1 (C(CH3)3), 30.7 (CH2), 42.5 (CH2), 79.0 (C(CH3)3), 
116.4 (C-Ar), 118.8 (C-Ar), 122.7 (C-Ar), 128.2 (C-Ar), 139.4 (C-Ar), 144.8 (C-Ar), 145.3 
(C-Ar), 152.7 (carbamate C=O); HRMS calcd. for C21H25N6O6 (ES+) m/z 457.1830 [M+H]
+
, 
found 457.1830. 
Note: Unable to visualise all carbon signals by NMR. 
N-(2-(4-Nitrobenzo[c][1,2,5]oxadiazol-7-ylamino)ethyl)-2-(3-aminophenyl) acetamide 
(351) 
 
Boc-protected aniline 349 (0.154 g, 0.34 mmol) was reacted with TFA (260 μl, 3.40 mmol) in 
DCM (4 ml) according to general procedure L. Chromatography on silica (9:1 
DCM/MeOH) afforded the desired compound as a dark orange solid (0.110 g, 0.31 mmol, 
92%). Rf 0.43 (9:1 DCM/MeOH); M.p. 180-182 °C; λmax (EtOH/nm) 210, 342; IR (cm
-1
) 
3412, 3352, 3238, 3079, 3031, 1622, 1595; 
1
H NMR (500 MHz, DMSO-d6) 3.22 (2H, s, 
CH2CO), 3.38 (2H, dt, J = 5.9 and 6.2 Hz, CONHCH2CH2), 3.52-3.57 (2H, m, 
CONHCH2CH2), 4.97 (2H, s, Ar-NH2), 6.32-6.35 (1H, m, H-4), 6.37-6.41 (2H, m, H-6/H-5’), 
6.44 (1H, dd, J = 1.8 and 1.9 Hz, H-2), 6.85 (1H, dd, J = 7.7 and 7.9 Hz, H-5), 8.14 (1H, t, J 
= 5.9 Hz, CONH), 8.46 (1H, d, J = 8.2 Hz, H-6’), 9.42 (1H, br, CH2CH2NH); HRMS calcd. 
for C16H17N6O4 (ES+) m/z 357.1306 [M+H]
+
, found 357.1311. 
Note: Unable to visualise 
13
C signals by NMR. 
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N-(2-(4-Nitrobenzo[c][1,2,5]oxadiazol-7-ylamino)ethyl)-2-(3-(6-(2-
(triisopropylsilyl)ethynyl)-9H-purin-2-ylamino)phenyl)acetamide (353) 
 
2-Fluoropurine intermediate 160  (0.100 g, 0.31 mmol), aniline 351 (0.220 g, 0.62 mmol) and 
TFA (120 μl, 1.57 mmol) were reacted in TFE (3 ml) according to general procedure B, 
with the reaction proceeding over 96 h. Purification via chromatography on silica (19:1 
DCM/MeOH) afforded the desired compound as a dark orange oil (28 mg, 0.04 mmol, 14%). 
Rf 0.31 (19:1 DCM/MeOH); λmax (EtOH/nm) 275, 339; IR (cm
-1
) 3233, 2941, 2864, 2161, 
1979, 1644, 1577; 
1
H NMR (500 MHz, DMSO-d6) 1.13-1.20 (21H, m, Si(CH(CH3)2)3), 3.37 
(2H, s, CH2CO), 3.41 (2H, m, CONHCH2CH2), 3.57 (2H, m , CONHCH2CH2), 6.37-6.44 
(2H, m, H-6’/H-5’’), 6.77-6.80 (1H, m, H-4’), 7.13 (1H, dd, J = 7.9 and 8.0 Hz, H-5’), 7.54-
7.57 (1H, m, H-2’), 7.75 (1H, d, J = 8.6 Hz, H-6’’), 8.20-8.24 (2H, m, CONH & H-8), 8.47 
(1H, br, CH2CH2NH), 9.65 (1H, s, C
2
-NH), 13.07 (1H, br, H-9) ; HRMS calcd. for 
C32H39N10O4Si (ES+) m/z 655.2920 [M+H]
+
, found 655.2918. 
Note: Insufficient material for 
13
C NMR. 
N-(2-(4-Nitrobenzo[c][1,2,5]oxadiazol-7-ylamino)ethyl)-2-(3-(6-ethynyl-9H-purin-2-
ylamino)phenyl)acetamide (344) 
 
TIPS-protected purine 353 (22 mg, 0.034 mmol), KF (10 mg, 0.17 mmol) and 18-crown-6 (1 
mg, 0.003 mmol) were reacted in THF (1 ml) according to general procedure Q. 
Purification via chromatography on silica (19:1 DCM/MeOH) afforded the desired compound 
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as an orange/red solid (14 mg, 0.029 mmol, 85%). Rf 0.14 (19:1 DCM/MeOH); M.p. 150-160 
°C (decomposed); λmax (EtOH/nm) 274; IR (cm
-1
) 3373, 3320, 2118, 1656, 1565; 
1
H NMR 
(500 MHz, DMSO-d6) 3.35-3.45 (6H, m, CH2CH2/CH2CO), 4.82 (1H, s, -C≡CH), 6.42 (1H, 
d, J = 8.9 Hz, H-5’’), 6.77-6.80 (1H, m, H-6’), 7.15 (1H, dd, J = 7.8 and 7.9 Hz, H-5’), 7.50-
7.53 (1H, m, H-2’), 7.73-7.76 (1H, m, H-4’), 8.24 (2H, m, CONH/H-8), 8.46 (1H, d, J = 8.9 
Hz, H-6’’), 9.41 (1H, br, CH2NH), 9.63 (1H, s, C
2
-NH), 13.10 (1H, s, H-9); HRMS calcd. for 
C23H19N10O4 (ES+) m/z 499.1585 [M+H]
+
, found 499.1580. 
Note: Insufficient material for 
13
C NMR. 
tert-Butyl (3-(2-((2-acetamidoethyl)amino)-2-oxoethyl)phenyl) carbamate (350) 
 
Acetic anhydride (67 μl, 0.71 mmol) was added to a solution of aminoethylcarboxamide 348 
(0.188 g, 0.64 mmol) in pyridine (5 ml). The resulting solution was stirred at RT for 18 h, 
after which point the solvent was removed in vacuo. The crude residue was purified via 
chromatography on silica (19:1 DCM/MeOH) to give a colourless oil, which was triturated 
with petrol to give the desired compound as a white solid (0.165 g, 0.49 mmol, 77%). Rf 0.39 
(19:1 DCM/MeOH); M.p. 156-158 °C; λmax (EtOH/nm) 239; IR (cm
-1
) 3317, 2976, 1688, 
1643; 
1
H NMR (500 MHz, DMSO-d6) 1.47 (9H, s, C(CH3)3), 1.79 (3H, s, CH3CO), 3.06-3.10 
(4H, m, CH2CH2), 3.33 (2H, s, CH2CO), 6.85-6.87 (1H, m, H-4), 7.15 (1H, dd, J = 8.0 and 
8.2 Hz, H-5), 7.23-7.27 (1H, m, H-6), 7.41 (1H, br, H-2), 7.87 (1H, br, CH2NH), 8.07 (1H, 
br, CH2NH), 9.30 (1H, s, Ar-NH); 
13
C NMR (125 MHz, DMSO-d6) 22.6 (Ac-CH3), 28.1 
(C(CH3)3), 38.3 (CH2), 38.4 (CH2), 42.5 (COCH2), 78.9 (C(CH3)3), 116.3 (C-Ar), 118.7 (C-
Ar), 122.8 (C-Ar), 136.7 (C-Ar), 139.4 (C-Ar), 152.8 (carbamate C=O), 169.3 ( amide C=O), 
170.1 (amide C=O); HRMS calcd. for C17H26N3O4 (ES+) m/z 336.1918 [M+H]
+
, found 
336.1922. 
  
381 
 
N-(2-Acetamidoethyl)-2-(3-aminophenyl)acetamide (352) 
 
TFA (340 μl, 4.40 mmol) was added to a solution of the Boc-protected aniline 350 (0.147 g, 
0.44 mmol) in DCM (4 ml). The resulting solution was stirred at RT for 18 h, after which 
point the solvent was removed in vacuo and the residue was partitioned between EtOAc (15 
ml) and sat. NaHCO3 solution (15 ml). Both phases were concentrated in vacuo, after which 
the residue was taken up in methanol (10 ml) and stirred at RT for 30 min. The insoluble 
inorganic salts were removed by filtration and the filtrate concentrated to dryness. The crude 
residue was purified on KP-NH silica (19:1 DCM/MeOH) to give the desired compound as 
an off-white solid (84 mg, 0.36 mmol, 81%). Rf 0.31 (19:1 DCM/MeOH, KP-NH); M.p. 109-
112 °C; λmax (EtOH/nm) 216; IR (cm
-1
) 3421, 3295, 3094, 2988, 2938, 2029, 1633, 1548; 
1
H 
NMR (500 MHz, DMSO-d6) 1.79 (3H, s, CH3CO), 3.06-3.09 (4H, m, CH2CH2), 3.22 (2H, s, 
CH2CO), 4.98 (2H, s, Ar-NH2), 6.37-6.43 (2H, m, H-4/H-6), 6.45 (1H, dd, J = 1.8 and 1.9 
Hz, H-2), 6.91 (1H, dd, J = 7.6 and 7.8 Hz, H-5), 7.86 (1H, br, CH2NH), 7.97 (1H, br, 
CH2NH); 
13
C NMR (125 MHz, DMSO-d6) 22.6 (Ac-CH3), 38.3 (CH2), 38.4 (CH2), 42.7 
(COCH2), 112.0 (C-Ar), 114.5 (C-Ar), 116.5 (C-Ar), 128.6 (C-Ar), 136.7 (C-Ar), 148.5 (C-
Ar), 169.3 (C=O), 170.4 (C=O); HRMS calcd. for C12H18N3O2 (ES+) m/z 236.1394 [M+H]
+
, 
found 236.1397. 
N-(2-Acetamidoethyl)-2-(3-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-
yl)amino)phenyl)acetamide (354) 
 
2-Fluoropurine intermediate 160  (0.140 g, 0.44 mmol), aniline 352 (0.210 g, 0.88 mmol) and 
TFA (175 μl, 2.26 mmol) were reacted in TFE (3 ml) according to general procedure B, 
with the reaction proceeding over 72 h. Purification by chromatography on silica (19:1 
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DCM/MeOH) afforded the desired compound as a yellow oil (0.118 g, 0.21 mmol, 48%). Rf 
0.36 (19:1 DCM/MeOH); λmax (EtOH/nm) 274, 368; IR (cm
-1
) 3282, 2943, 2865, 2161, 1645, 
1605; 
1
H NMR (500 MHz, DMSO-d6) 1.14-1.20 (21H, m, Si(CH(CH3)2)3), 1.79 (3H, s, 
CH3CO), 3.09-3.12 (4H, m, CH2CH2), 3.37 (2H, s, COCH2), 6.83-6.86 (1H, m, H-6’), 7.20 
(1H, dd, J = 7.8 and 7.9 Hz, H-5’), 7.53-7.56 (1H, m, H-2’), 7.76-7.79 (1H, m, H-4’), 7.88 
(1H, br, CH2NH), 8.06 (1H, br, CH2NH), 8.24 (1H, s, H-8), 9.66 (1H, s, C
2
-NH), 13.09 (1H, 
br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 22.6 
(Ac-CH3), 38.3 (CH2), 38.5 (CH2), 42.7 (COCH2), 116.5 (C-Ar), 128.2 (C-Ar), 136.5 (C-Ar), 
156.3 (C-Ar), 169.3 (C=O), 170.2 (C=O); HRMS calcd. for C28H40N7O2Si (ES+) m/z 
534.3007 [M+H]
+
, found 534.3004. 
Note: Unable to visualise all carbon signals by NMR. 
N-(2-Acetamidoethyl)-2-(3-((6-ethynyl-9H-purin-2-yl)amino)phenyl)acetamide (345) 
 
TIPS-protected purine 354 (58 mg, 0.11 mmol), KF (32 mg, 0.55 mmol) and 18-crown-6 (3 
mg, 0.011 mmol) were reacted in THF (1 ml) according to general procedure Q. 
Purification via chromatography on silica (19:1 DCM/MeOH) afforded the desired compound 
as a yellow solid (28 mg, 0.074 mmol, 68%). Rf 0.22 (19:1 DCM/MeOH); M.p. 185-210 °C 
(decomposed); λmax (EtOH/nm) 274; IR (cm
-1
) 3265, 2113, 1646, 1604, 1577; 
1
H NMR (500 
MHz, DMSO-d6) 1.79 (3H, s, CH3CO), 3.08-3.12 (4H, m, CH2CH2), 3.37 (2H, s, CH2CO), 
4.84 (1H, s, -C≡CH), 6.83-6.86 (1H, m, H-6’), 7.21 (1H, dd, J = 7.9 and 8.0 Hz, H-5’), 7.51-
7.54 (1H, m, H-2’), 7.75-7.78 (1H, m, H-4’), 7.91 (1H, br, CH2NH), 8.09 (1H, br, CH2NH), 
8.28 (1H, s, H-8), 9.62 (1H, s, C
2
-NH), 13.07 (1H, s, H-9); 
13
C NMR (125 MHz, DMSO-d6) 
22.6 (Ac-CH3), 38.3 (CH2), 38.5 (CH2), 42.6 (COCH2), 86.9 (C≡CH), 116.6 (C-Ar), 119.2 
(C-Ar), 121.8 (C-Ar), 128.2 (C-Ar), 136.5 (C-Ar), 140.7 (C-Ar), 156.2 (C-Ar), 169.3 (C=O), 
170.2 (C=O); HRMS calcd. for C19H20N7O2 (ES+) m/z 378.1673 [M+H]
+
, found 378.1675. 
Note: Unable to visualise all carbon signals by NMR. 
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N-(2-Fluoroethyl)-2-(3-nitrophenyl)acetamide (357) 
 
3-Nitrophenylacetic acid (0.500 g, 2.76 mmol), phosphorus trichloride (265 µl, 3.04 mmol) 
and 2-fluoroethylamine hydrochloride (0.686 g, 6.90 mmol) were reacted in dry MeCN (15 
ml) according to general procedure X. Purification by chromatography on silica (4:1 
Petrol/EtOAc) gave the desired compound as a pale yellow solid (0.453 g, 2.00 mmol, 72%). 
Rf 0.41 (4:1 Petrol/EtOAc); M.p. 116-119 °C; λmax (EtOH/nm) 263; IR (cm
-1
) 3296, 3088, 
2941, 1648, 1556, 1514; 
1
H NMR (500 MHz, DMSO-d6) 3.38 (2H, ddt, J = 5.0, 5.2 and 27.9 
Hz, NHCH2), 3.64 (2H, s, COCH2), 4.44 (2H, dt, J = 5.2 and 47.5 Hz, CH2F), 7.62 (1H, dd, J 
= 7.8 and 8.0 Hz, H-5), 7.71-7.74 (1H, m, H-6), 8.09-8.13 (1H, m, H-4), 8.17 (1H, dd, J = 1.8 
and 1.9 Hz, H-2), 8.46 (1H, t, J = 5.0 Hz, NHCH2); 
13
C NMR (125 MHz, DMSO-d6) 41.3 
(COCH2), 82.4 (d, JCF = 165.1 Hz, CH2F), 121.5 (C-Ar), 123.7 (C-Ar), 129.6 (C-Ar), 136.0 
(C-Ar), 138.4 (C-Ar), 147.6 (C-Ar), 169.6 (C=O); HRMS calcd. for C10H12FN2O3 (ES+) m/z 
227.0826 [M+H]
+
, found 227.0829. 
Note: Unable to visualise all carbon environments by 
13
C NMR – masked by solvent peak. 
2-(3-Aminophenyl)-N-(2-fluoroethyl)acetamide (359) 
 
The nitro compound 357 (0.436 g, 1.93 mmol), palladium on carbon (50 mg, 10% w/w) and 
ammonium formate (1.21 g, 19.3 mmol) were reacted in methanol (20 ml) according to 
general procedure G. Purification by silica gel chromatography (1:1 Petrol/EtOAc) afforded 
the target compound as a pale red oil (0.333 g, 1.70 mmol, 88%). Rf 0.39 (1:1 Petrol/EtOAc); 
λmax (EtOH/nm) 241, 290; IR (cm
-1
) 3293, 3073, 2938, 1642, 1552, 1516; 
1
H NMR (500 
MHz, DMSO-d6) 3.26 (2H, s, CH2CO), 3.35 (2H, ddt, J = 5.2, 5.3 and 27.3 Hz, NHCH2), 
4.42 (2H, dt, J = 5.2 and 47.6 Hz, CH2F), 4.99 (2H, s, Ar-NH2), 6.38-6.43 (2H, m, H-4/H-6), 
6.45-6.48 (1H, m, H-2), 6.92 (1H, dd, J = 7.6 and 7.7 Hz, H-5), 8.19 (1H, t, J = 5.3 Hz, 
NHCH2); 
13
C NMR (125 MHz, DMSO-d6) 42.5 (COCH2), 82.4 (d, JCF = 164.5 Hz, NHCH2), 
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112.1 (C-Ar), 114.5 (C-Ar), 116.5 (C-Ar), 128.6 (C-Ar), 136.6 (C-Ar), 148.4 (C-Ar), 170.6 
(C=O); HRMS calcd. for C10H14FN2O (ES+) m/z 197.1085 [M+H]
+
, found 197.1085. 
Note: Unable to visualise all carbon environments by 
13
C NMR – masked by solvent peak. 
2-(3-Nitrophenyl)-N-(2,2,2-trifluoroethyl)acetamide (358) 
 
3-Nitrophenylacetic acid (0.100 g, 0.55 mmol), 2,2,2-trifluoroethylamine (110 µl, 1.38 
mmol) and phosphorus trichloride (53 µl, 0.61 mmol) were reacted in dry acetonitrile (3 ml) 
according to general procedure X. Purification by silica chromatography (7:3 Petrol/EtOAc) 
gave the target compound as pale brown oil that solidified on cooling (0.117 g, 0.45 mmol, 
81%). Rf 0.42 (7:3 Petrol/EtOAc); M.p. 134-136 °C; λmax (EtOH/nm) 262; IR (cm
-1
) 3289, 
3086, 1663, 1557, 1536; 
1
H NMR (500 MHz, DMSO-d6) 3.72 (2H, s, CH2CO), 3.94 (2H, dq, 
J = 6.4 and 9.8 Hz, CH2CF3), 7.63 (1H, dd, J = 7.9 and 8.0 Hz, H-5), 7.70-7.74 (1H, m, H-6), 
8.13 (1H, ddd, J = 1.8, 2.1 and 8.0 Hz, H-4), 8.17 (1H, dd, J = 1.8 and 2.1 Hz, H-2), 8.89 
(1H, t, J = 6.4 Hz, NH); 
13
C NMR (125 MHz, DMSO-d6) 40.9 (CH2CO), 121.6 (C-Ar), 123.7 
(C-Ar), 124.7 (q, JCF = 279.2 Hz, CF3), 129.7 (C-Ar), 136.0 (C-Ar), 137.9 (C-Ar), 147.6 (C-
Ar), 170.2 (C=O); 
19
F NMR (470 MHz, DMSO-d6) -70.8; HRMS calcd. for C10H10F3N2O3 
(ES+) m/z 263.0638 [M+H]
+
, found 263.0643. 
Note: Unable to visualise all carbon environments by 
13
C NMR – masked by solvent peak. 
2-(3-Aminophenyl)-N-(2,2,2-trifluoroethyl)acetamide (360) 
 
Nitro compound 358 (0.755 g, 2.88 mmol), palladium on carbon (75 mg, 10% w/w) and 
ammonium formate (1.81 g, 28.8 mmol) were reacted in methanol (30 ml) according to 
general procedure G. Chromatography on silica (7:3 Petrol/EtOAc) gave the target 
compound as a beige solid (0.602 g, 2.59 mmol, 90%).  Rf 0.16 (7:3 Petrol/EtOAc); M.p. 83-
85 °C; λmax (EtOH/nm) 239, 291; IR (cm
-1
) 3282, 3211, 3083, 1653, 1560; 
1
H NMR (500 
MHz, DMSO-d6) 3.32 (2H, s, CH2CO), 3.89 (2H, dq, J = 6.4 and 9.9 Hz, CH2CF3), 4.99 (2H, 
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s, Ar-NH2), 6.38-6.44 (2H, m, H-4/H-6), 6.44-6.47 (1H, m, H-2), 6.92 (1H, dd, J = 7.8 and 
7.8 Hz, H-5), 8.61 (1H, t, J = 6.4 Hz, CONH); 
13
C NMR (125 MHz, DMSO-d6) 42.1 
(CH2CO), 112.2 (C-Ar), 114.5 (C-Ar), 116.4 (C-Ar), 124.7 (q, JCF = 279.4 Hz, CF3), 128.6 
(C-Ar), 136.1 (C-Ar), 148.5 (C-Ar), 171.1 (C=O); 
19
F NMR (470 MHz, DMSO-d6) -70.8; 
HRMS calcd. for C10H12F3N2O (ES+) m/z 233.0896 [M+H]
+
, found 233.0900. 
Note: Unable to visualise all carbon environments by 
13
C NMR – masked by solvent peak. 
N-(2,2,2-Trifluoroethyl)-2-(3-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl) 
amino)phenyl)acetamide (361) 
 
2-Fluoropurine 160 (0.250 g, 0.78 mmol), aniline 360 (0.364 g, 1.57 mmol) and TFA (150 µl, 
1.96 mmol) were reacted in TFE (8 ml) according to general procedure B over 48 h. 
Chromatography on KP-NH silica (19:1 DCM/MeOH) gave the target compound as a yellow 
oil/gum (0.199 g, 0.37 mmol, 48%). Rf 0.29 (19:1 DCM/MeOH); λmax (EtOH/nm) 276, 351; 
IR (cm
-1
) 3277, 2945, 2865, 1668, 1605, 1578, 1538; 
1
H NMR (500 MHz, DMSO-d6) 1.13-
1.22 (21H, m, Si(CH(CH3)2)3), 3.48 (2H, s, CH2CO), 3.92 (2H, dq, J = 6.4 and 9.8 Hz, 
CH2CF3), 6.83-6.86 (1H, m, H-6’), 7.21 (1H, dd, J = 7.8 and 7.9 Hz, H-5’), 7.58-7.60 (1H, m, 
H-2’), 7.75-7.78 (1H, m, H-4’), 8.24 (1H, s, H-8), 8.71 (1H, t, J = 6.4 Hz, CONH), 9.66 (1H, 
s, C
2
-NH), 13.07 (1H, br, H-9); 
13
C NMR (125 MHz, CDCl3) 11.3 (Si(CH(CH3)2)3), 18.7 
(Si(CH(CH3)2)3), 41.0 (q, JCF = 32.8 Hz, CH2CF3), 43.5 (COCH2), 101.6 (C≡C-Si), 118.3 (C-
Ar), 119.7 (C-Ar), 123.2 (C-Ar), 129.8 (C-Ar), 134.8 (C-Ar), 140.5 (C-Ar), 171.6 (C=O); 
HRMS calcd. for C26H34F3N6OSi (ES+) m/z 531.2510 [M+H]
+
, found 531.2512. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
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2-(3-((6-Ethynyl-9H-purin-2-yl)amino)phenyl)-N-(2,2,2-trifluoroethyl) acetamide (356) 
 
The TIPS-protected purine 361 (0.128 g, 0.24 mmol), TBAF (1M in THF, 0.29 ml, 0.29 
mmol) and the TBAF scavenger bead system 231 (1.30 g, 10 x w/w) were reacted in THF (5 
ml) according to general procedure U. Chromatography on KP-NH silica (9:1 DCM/MeOH) 
gave the desired compound as a yellow solid (50 mg, 0.13 mmol, 54%). Rf 0.32 (9:1 
DCM/MeOH, KP-NH); M.p. 135-155 °C (decomposed); λmax (EtOH/nm) 273.5, 364.0; IR 
(cm
-1
) 3277, 2121, 2033, 1662; 
1
H NMR (500 MHz, DMSO-d6) 3.48 (2H, s, COCH2), 3.93 
(2H, dq, J = 6.3 and 9.9 Hz, CH2CF3), 4.84 (1H, s, C≡CH), 6.83-6.87 (1H, m, H-6’), 7.22 
(1H, dd, J = 7.8 and 7.9 Hz, H-5’), 7.53-7.56 (1H, m, H-2’), 7.76-7.80 (1H, m, H-4’), 8.28 
(1H, s, H-8), 8.74 (1H, t, J = 6.3 Hz, CONH), 9.64 (1H, s, C
2
-NH), 13.13 (1H, br, H-9); 
13
C 
NMR (125 MHz, MeOD) 41.5 (q, JCF = 35.3 Hz, CH2CF3), 43.7 (COCH2), 68.2 (C≡C), 78.7 
(C≡C), 118.8 (C-Ar), 120.8 (C-Ar), 123.5 (C-Ar), 125.9 (q, JCF = 277.7, CF3), 129.9 (C-Ar), 
136.7 (C-Ar), 142.1 (C-Ar), 144.5 (C-Ar), 158.4 (C-Ar), 174.6 (C=O); HRMS calcd. for 
C17H14F3N6O (ES+) m/z 375.1176 [M+H]
+
, found 375.1179. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
N-(2-Fluoroethyl)-2-(3-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl) 
amino)phenyl)acetamide (362) 
 
The acid 186 (0.105 g, 0.23 mmol), 2-fluoroethylamine hydrochloride (93 mg, 0.93 mmol), 
CDI (75 mg, 0.47 mmol) and DIPEA (120 µl, 0.70 mmol) were reacted in dry DMF (5 ml) 
according to general procedure J. Purification of silica gel (19:1 DCM/MeOH) gave the 
target compound as a yellow oil/gum (88 mg, 0.18 mmol, 77%). Rf 0.24 (19:1 DCM/MeOH); 
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λmax (EtOH/nm) 276, 375; IR (cm
-1
) 3273, 3075, 2943, 2864, 2165, 1649, 1576, 1536; 
1
H 
NMR (500 MHz, DMSO-d6) 1.13-1.23 (21H, m, Si(CH(CH3)2)3), 3.37 (2H, ddt, J = 5.1, 5.2 
and 27.4 Hz, NHCH2), 4.44 (2H, dt, J = 5.1 and 47.2 Hz, CH2F), 6.83-6.87 (1H, m, H-6’), 
7.20 (1H, dd, J = 7.8 and 7.9 Hz, H-5’), 7.55-7.58 (1H, m, H-2’), 7.75-7.79 (1H, m, H-4’), 
8.24 (1H, s, H-8), 8.28 (1H, t, J = 5.2 Hz, NHCH2), 9.65 (1H, s, C
2
-NH), 13.07 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 42.4 
(COCH2), 82.4 (d, JCF = 163.9 Hz, CH2F), 116.6, 119.3, 128.2 (C-Ar), 132.1 (C-Ar), 136.4 
(C-Ar), 155.7 (C-Ar); HRMS calcd. for C26H36FN6OSi (ES+) m/z 495.2698 [M+H]
+
, found 
495.2693. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
2-(3-((6-Ethynyl-9H-purin-2-yl)amino)phenyl)-N-(2-fluoroethyl)acetamide (355) 
 
The TIPS-protected purine 362 (98 mg, 0.20 mmol), TBAF (1M in THF, 0.24 ml, 0.24 
mmol) and the TBAF scavenger bead system 231 (1.00 g, 10 x w/w) were reacted in THF (5 
ml) according to general procedure U. Silica gel chromatography (9:1 DCM/MeOH) gave 
the target compound as a yellow solid (33 mg, 0.10 mmol, 49%). Rf 0.39 (9:1 DCM/MeOH); 
M.p. 105-120 °C (decomposed); λmax (EtOH/nm) 274.0, 367.5; IR (cm
-1
) 3078, 2448, 2158, 
2112, 2033, 1977, 1646; 
1
H NMR (500 MHz, DMSO-d6) 3.32-3.43 (4H, m, 
CH2CO/NHCH2), 4.44 (2H, dt, J = 5.1 and 47.3 Hz, CH2F), 4.82 (1H, s, C≡CH), 6.84-6.88 
(1H, m, H-6’), 7.21 (1H, dd, J = 7.8 and 7.9 Hz, H-5’), 7.51-7.53 (1H, m, H-2’), 7.78 (1H, 
dd, J = 1.4 and 7.9 Hz, H-4’), 8.25 (1H, s, H-8), 9.64 (1H, s, C2-NH), 13.11 (1H, s, H-9); 13C 
NMR (125 MHz, DMSO-d6) 39.9 (d, JCF = 20.8 Hz, NHCH2), 42.4 (COCH2), 82.4 (d, JCF = 
165.0 Hz, CH2F), 86.9 (C≡CH), 119.4 (C-Ar), 121.8 (C-Ar), 128.2 (C-Ar), 136.4 (C-Ar), 
140.6 (C-Ar), 153.9 (C-Ar), 156.2 (C-Ar), 170.4 (C=O); HRMS calcd. for C17H16FN6O 
(ES+) m/z 339.1364 [M+H]
+
, found 339.1369. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
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9-(4-Methoxybenzyl)-N-(pyridin-2-yl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine 
(372) 
 
The 2-iodopurine 278 (0.199 g, 0.36 mmol), 2-aminopyridine (41 mg, 0.44 mmol), Pd2(dba)3 
(37 mg, 0.04 mmol), XPhos (20 mg, 0.04 mmol) and K2CO3 (110 mg, 0.80 mmol) were 
reacted in MeCN (4 ml) according to general procedure M. Silica gel chromatography (7:3 
Petrol/EtOAc) gave the desired compound as a pale yellow oil/gum (0.164 g, 0.32 mmol, 
89%). Rf 0.39 (7:3 Petrol/EtOAc); λmax (EtOH/nm) 259, 341; IR (cm
-1
) 3174, 2943, 2864, 
1732, 1594, 1572, 1540, 1515; 
1
H NMR (500 MHz, CDCl3) 1.19-1.29 (21H, m, 
Si(CH(CH3)2)3), 3.81 (3H, s, OCH3), 5.31 (2H, s, N
9
-CH2), 6.90 (2H, d, J = 8.4 Hz, H-3’’/H-
5’’), 6.93-6.96 (1H, m, H-4’), 7.28 (2H, d, J = 8.4 Hz, H-2’’/H-6’’), 7.67-7.72 (1H, m, H-5’), 
7.88 (1H, s, H-8), 8.24 (1H, s, C
2
-NH), 8.37 (1H, ddd, J = 0.8, 0.9 and 4.8 Hz, H-3’), 8.44-
8.48 (1H, m, H-6’); 13C NMR (125 MHz, CDCl3) 11.3 (Si(CH(CH3)2)3), 18.7 
(Si(CH(CH3)2)3), 46.9 (N
9
-CH2), 55.4 (OCH3), 101.0 (C≡C-Si), 101.6 (C≡C-Si), 112.0 (C-
Ar), 114.5 (C-Ar), 117.4 (C-Ar), 127.3 (C-Ar), 129.4 (C-Ar), 130.1 (C-Ar), 137.7 (C-Ar), 
142.1 (C-Ar), 143.2 (C-Ar), 148.2 (C-Ar), 152.9 (C-Ar), 153.0 (C-Ar), 155.1 (C-Ar), 159.8 
(C-Ar); HRMS calcd. for C29H37N6OSi (ES+) m/z 513.2793 [M+H]
+
, found 513.2778. 
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9-(4-Methoxybenzyl)-N-(pyridin-3-yl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine 
(373) 
 
The 2-iodopurine 278 (0.208 g, 0.38 mmol), 3-aminopyridine (43 mg, 0.46 mmol), Pd2(dba)3 
(37 mg, 0.04 mmol), XPhos (19 mg, 0.04 mmol) and K2CO3 (116 mg, 0.84 mmol) were 
reacted in MeCN (4 ml) according to general procedure M. Chromatography on silica (7:3 
Petrol/EtOAc) gave the desired compound as a pale yellow oil/gum (0.112 g, 0.22 mmol, 
58%). Rf 0.37 (7:3 Petrol/EtOAc); λmax (EtOH/nm) 273, 344; IR (cm
-1
) 3248, 3176, 2942, 
2864, 1574, 1548, 1514; 
1
H NMR (500 MHz, CDCl3) 1.17-1.29 (21H, m, Si(CH(CH3)2)3), 
3.81 (3H, s, OCH3), 5.29 (2H, s, N
9
-CH2), 6.90 (2H, d, J = 8.5 Hz, H-3’’/H-5’’), 7.25-7.31 
(3H, m, H-2’’/H-6’’ & H-2’), 7.42 (1H, s, C2-NH), 7.87 (1H, s, H-8), 8.16-8.20 (1H, s, H-4’), 
8.28-8.32 (1H, m, H-6’), 8.89-8.92 (1H, m, H-2’); 13C NMR (125 MHz, CDCl3) 11.3 
(Si(CH(CH3)2)3), 18.7 (Si(CH(CH3)2)3), 46.9 (N
9
-CH2), 55.4 (OCH3), 100.8 (C≡C), 101.9 
(C≡C), 114.5 (C-Ar), 123.5 (C-Ar), 125.3 (C-Ar), 127.1 (C-Ar), 129.3 (C-Ar), 130.2 (C-Ar), 
136.8 (C-Ar), 140.3 (C-Ar), 142.3 (C-Ar), 142.9 (C-Ar), 143.2 (C-Ar), 152.9 (C-Ar), 155.8 
(C-Ar), 159.8 (C-Ar); HRMS calcd. for C29H37N6OSi (ES+) m/z 513.2793 [M+H]
+
, found 
513.2786. 
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9-(4-Methoxybenzyl)-N-(pyridin-4-yl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine 
(374) 
 
The 2-iodopurine 278 (0.209 g, 0.38 mmol), 4-aminopyridine (43 mg, 0.46 mmol), Pd2(dba)3 
(37 mg, 0.04 mmol), XPhos (19 mg, 0.04 mmol) and K2CO3 (116 mg, 0.84 mmol) were 
reacted in MeCN (4 ml) according to general procedure M. Chromatography on silica (7:3 
Petrol/EtOAc) afforded the target compound as a yellow oil/gum (0.101 g, 0.20 mmol, 53%). 
Rf 0.37 (7:3 Petrol/EtOAc); λmax (EtOH/nm) 281, 344; IR (cm
-1
) 3169, 2943, 2865, 1589, 
1571, 1514; 
1
H NMR (500 MHz, CDCl3) 1.19-1.30 (21H, m, Si(CH(CH3)2)3), 3.82 (3H, s, 
OCH3), 5.33 (2H, s, N
9
-CH2), 6.91 (2H, d, J = 8.7 Hz, H-3’’/H-5’’), 7.29 (2H, d, J = 8.7 Hz, 
H-2’’/H-6’’), 7.55 (1H, s, C2-NH), 7.62-7.65 (2H, m, H-3’/H-5’), 7.93 (1H, s, H-8), 8.46-8.50 
(2H, m, H-2’/H-6’); 13C NMR (125 MHz, CDCl3) 11.2 (Si(CH(CH3)2)3), 18.7 
(Si(CH(CH3)2)3), 47.1 (N
9
-CH2), 55.4 (OCH3), 100.6 (C≡C), 102.5 (C≡C), 112.2 (C-Ar), 
114.5 (C-Ar), 126.9 (C-Ar), 129.3 (C-Ar), 142.2 (C-Ar), 143.7 (C-Ar), 146.8 (C-Ar), 150.0 
(C-Ar), 152.8 (C-Ar), 155.1 (C-Ar), 159.8 (C-Ar); HRMS calcd. for C29H37N6OSi (ES+) m/z 
513.2793 [M+H]
+
, found 513.2780.  
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9-(4-Methoxybenzyl)-N-(pyrimidin-4-yl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-
amine (375) 
 
The 2-iodopurine 278 (0.206 g, 0.38 mmol), 4-aminopyrimidine (44 mg, 0.46 mmol), 
Pd2(dba)3 (37 mg, 0.04 mmol), XPhos (19 mg, 0.04 mmol) and K2CO3 (116 mg, 0.84 mmol) 
were reacted in MeCN (4 ml) according to general procedure M. Chromatography on silica 
(1:1 Petrol/EtOAc) gave the target compound as a yellow oil/gum (0.126 g, 0.25 mmol, 
66%). Rf 0.28 (1:1 Petrol/EtOAc); λmax (EtOH/nm) 276, 341; IR (cm
-1
) 3157, 2941, 2864, 
1565, 1514; 
1
H NMR (500 MHz, CDCl3) 1.17-1.30 (21H, m, Si(CH(CH3)2)3), 3.81 (3H, s, 
OCH3), 5.33 (2H, s, N
9
-CH2), 6.91 (2H, d, J = 8.5 Hz, H-3’’/H-5’’), 7.27 (2H, d, J = 8.5 Hz, 
H-2’’/H-6’’), 7.95 (1H, s, H-8), 8.40-8.45 (1H, m, H-6’), 8.55-8.60 (1H, m, H-5’), 8.67 (1H, 
s, C
2
-NH), 8.92-8.95 (1H, br, H-2’); 13C NMR (125 MHz, CDCl3) 11.3 (Si(CH(CH3)2)3), 18.6 
(Si(CH(CH3)2)3), 47.1 (N
9
-CH2), 55.4 (OCH3), 100.6 (C≡C), 102.8 (C≡C), 108.4 (C-Ar), 
114.6 (C-Ar), 126.8 (C-Ar), 129.3 (C-Ar), 131.0 (C-Ar), 142.0 (C-Ar), 144.1 (C-Ar), 152.8 
(C-Ar), 154.0 (C-Ar), 157.2 (C-Ar), 158.3 (C-Ar), 158.4 (C-Ar), 159.9 (C-Ar); HRMS calcd. 
for C28H35N7OSi (ES+) m/z 514.2745 [M+H]
+
, found 514.2740. 
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9-(4-Methoxybenzyl)-N-(pyrimidin-2-yl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-
amine (376) 
 
The 2-iodopurine 278 (0.208 g, 0.38 mmol), 2-aminopyrimidine (44 mg, 0.46 mmol), 
Pd2(dba)3 (37 mg, 0.04 mmol), XPhos (19 mg, 0.04 mmol) and K2CO3 (116 mg, 0.84 mmol) 
were reacted in MeCN (4 ml) according to general procedure M. Purification on silica (1:1 
Petrol/EtOAc) gave the desired compound as a yellow oil/gum (95 mg, 0.18 mmol, 47%). Rf 
0.30 (1:1 Petrol/EtOAc); λmax (EtOH/nm) 266, 341; IR (cm
-1
) 3241, 3170, 2943, 2865, 2360, 
2337, 1711, 1571, 1514; 
1
H NMR (500 MHz, CDCl3) 1.17-1.31 (21H, m, Si(CH(CH3)2)3), 
3.81 (OCH3), 5.35 (2H, s, N
9
-CH2), 6.88 (2H, d, J = 8.7 Hz, H-3’’/H-5’’), 6.92-6.95 (1H, br, 
H-5’), 7.40 (2H, d, J = 8.7 Hz, H-2’’/H-6’’), 7.89 (1H, s, H-8), 8.70-8.75 (2H, m, H-4’/H-6’), 
9.20 (1H, s, C
2
-NH); 
13
C NMR (125 MHz, CDCl3) 11.3 (Si(CH(CH3)2)3), 18.7 
(Si(CH(CH3)2)3), 47.1 (N
9
-CH2), 55.3 (OCH3), 100.9 (C≡C), 101.8 (C≡C), 114.4 (C-Ar), 
114.6 (C-Ar), 127.2 (C-Ar), 129.8 (C-Ar), 130.0 (C-Ar), 143.9 (C-Ar), 154.1 (C-Ar), 158.3 
(C-Ar), 158.8 (C-Ar), 159.8 (C-Ar); HRMS calcd. for C28H35N7OSi (ES+) m/z 514.2745 
[M+H]
+
, found 514.2739. 
5-Aminopyrimidine (384)
276
 
 
5-Amino-4,6-dichloropyrimidine (0.500 g, 3.05 mmol), ammonium formate (1.92 g, 30.5 
mmol) and palladium on carbon (50 mg, 10% w/w) were reacted in methanol (30 ml) 
according to general procedure G over 1 h. Chromatography on silica (9:1 DCM/MeOH) 
gave the target compound as a pale yellow solid (0.239 g, 2.51 mmol, 82%). Rf 0.32 (9:1 
DCM/MeOH); M.p. 160-165 °C (Lit.
276
 173-174 °C); λmax (EtOH/nm) 245, 315; IR (cm
-1
) 
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3341, 3178, 3025, 2745, 1662, 1554; 
1
H NMR (500 MHz, DMSO-d6) 5.54 (2H, s, Ar-NH2), 
8.09 (2H, s, H-4/H-6), 8.35 (1H, s, H-2); 
13
C NMR (125 MHz, DMSO-d6) 141.4 (C-Ar), 
142.9 (C-Ar), 146.7 (C-Ar); LRMS (ES+) m/z 96.1 [M+H]
+
. 
9-(4-Methoxybenzyl)-N-(pyrimidin-5-yl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-
amine (377) 
 
The 2-iodopurine 278 (0.220 g, 0.40 mmol), 5-aminopyrimidine 384 (46 mg, 0.48 mmol), 
Pd2(dba)3 (37 mg, 0.04 mmol), XPhos (19 mg, 0.04 mmol) and K2CO3 (122 mg, 0.89 mmol) 
were reacted in MeCN (4 ml) according to general procedure M. Silica gel chromatography 
(1:1 Petrol/EtOAc) gave the target compound as a yellow oil/gum (124 mg, 0.24 mmol, 
60%). Rf 0.28 (1:1 Petrol/EtOAc); λmax (EtOH/nm) 276, 351; IR (cm
-1
) 3370, 3066, 2942, 
2865, 1586, 1532, 1513; 
1
H NMR (500 MHz, CDCl3) 1.18-1.31 (21H, m, Si(CH(CH3)2)3), 
3.81 (OCH3), 5.30 (2H, s, N
9
-CH2), 6.91 (2H, d, J = 8.8 Hz, H-3’’/H-5’’), 7.26 (2H, d, J = 8.8 
Hz, H-2’’/H-6’’), 7.44 (1H, br, C2-NH), 7.92 (1H, s, H-8), 8.92 (1H, s, H-2’), 9.18 (2H, s, H-
4’/H-6’); 13C NMR (125 MHz, CDCl3) 11.3 (Si(CH(CH3)2)3), 18.7 (Si(CH(CH3)2)3), 47.1 
(N
9
-CH2), 55.4 (OCH3), 100.4 (C≡C), 103.0 (C≡C), 114.6 (C-Ar), 126.8 (C-Ar), 129.3 (C-
Ar), 130.5 (C-Ar), 135.2 (C-Ar), 142.2 (C-Ar), 143.7 (C-Ar), 146.3 (C-Ar), 152.2 (C-Ar), 
152.9 (C-Ar), 155.1 (C-Ar), 159.8 (C-Ar); HRMS calcd. for C28H36N7OSi (ES+) m/z 
514.2745 [M+H]
+
, found 514.2739. 
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N-(Pyridin-2-yl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (378) 
 
The PMB-protected purine 372 (0.143 g, 0.28 mmol) and TFA (3 ml) were reacted according 
to general procedure K. Chromatography on silica (19:1 DCM/MeOH) gave the target 
compound as a yellow oil (0.123 g, 0.24 mmol, 85%). Rf 0.31 (19:1 DCM/MeOH); λmax 
(EtOH/nm) 267, 354; IR (cm
-1
) 3258, 3120, 2942, 2864, 1592, 1572, 1541; 
1
H NMR (500 
MHz, DMSO-d6) ) 1.12-1.23 (21H, m, Si(CH(CH3)2)3), 6.97 (1H, ddd, J = 0.8, 5.1 and 7.2 
Hz, H-5’), 7.75 (1H, ddd, J = 1.2, 7.2 and 7.6 Hz, H-4’), 7.27-7.34 (3H, m, H-3’/H-6’ & H-
8), 9.85 (1H, s, C
2
-NH), 13.22 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 10.6 
(Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 98.6 (C≡CH), 101.8 (C≡CH), 112.1 (C-Ar), 117.1 
(C-Ar), 129.5 (C-Ar), 137.5 (C-Ar), 139.7 (C-Ar), 143.5 (C-Ar), 147.8 (C-Ar), 153.2 (C-Ar), 
153.7 (C-Ar), 155.0 (C-Ar); HRMS calcd. for C21H29N6Si (ES+) m/z 393.2217 [M+H]
+
, 
found 393.2218. 
N-(Pyridin-3-yl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (379) 
 
The PMB-protected purine 373 (98 mg, 0.19 mmol) and TFA (4 ml) were reacted according 
to general procedure K. Silica gel purification (19:1 DCM/MeOH) gave the target 
compound as a yellow oil/gum (67 mg, 0.17 mmol, 89%). Rf 0.30 (19:1 DCM/MeOH); λmax 
(EtOH/nm) 273, 341; IR (cm
-1
) 3123, 3067, 2942, 2865, 1590, 1574, 1541; 
1
H NMR (500 
MHz, MeOD) 1.22-1.29 (21H, m, Si(CH(CH3)2)3), 7.38 (1H, dd, J = 4.7 and 8.3 Hz, H-5’), 
8.14 (1H, dd, J = 1.2 and 4.7 Hz, H-6’), 8.23 (1H, s, H-8), 8.36-8.40 (1H, m, H-4’), 8.96-8.98 
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(1H, m, H-2’); 13C NMR (125 MHz, MeOD) 12.5 (Si(CH(CH3)2)3), 19.1 (Si(CH(CH3)2)3), 
100.8 (C≡C), 125.0 (C-Ar), 127.2 (C-Ar), 139.7 (C-Ar), 140.7 (C-Ar), 142.4 (C-Ar), 157.8 
(C-Ar); HRMS calcd. for C21H29N6Si (ES+) m/z 393.2217 [M+H]
+
, found 393.2218. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
N-(Pyridin-4-yl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (380) 
 
The PMB-protected purine 374 (95 mg, 0.19 mmol) and TFA (4 ml) were reacted according 
to general procedure K. Silica gel chromatography (19:1 DCM/MeOH) gave the desired 
compound as a yellow oil/gum (62 mg, 0.16 mmol, 84%). Rf 0.33 (19:1 DCM/MeOH); λmax 
(EtOH/nm) 280, 347; IR (cm
-1
) 3263, 3088, 2942, 2865, 2717, 1600, 1568; 
1
H NMR (500 
MHz, MeOD) 1.21-1.30 (21H, m, Si(CH(CH3)2)3), 7.90 (2H, dd, J = 1.5 and 5.0 Hz, H-3’/H-
5’), 8.30 (2H, dd, J = 1.5 and 5.0 Hz, H-2’/H-6’), 8.31 (1H, s, H-8); 13C NMR (125 MHz, 
MeOD) 12.5 (Si(CH(CH3)2)3), 19.1 (Si(CH(CH3)2)3), 101.2 (C≡C), 102.4 (C≡C), 113.7 (C-
Ar), 145.4 (C-Ar), 149.9 (C-Ar), 150.1 (C-Ar), 157.2 (C-Ar); HRMS calcd. for C21H29N6Si 
(ES+) m/z 393.2217 [M+H]
+
, found 393.2211. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
N-(Pyrimidin-4-yl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (381) 
 
The PMB-protected purine 375 (117 mg, 0.23 mmol) and TFA (4 ml) were reacted according 
to general procedure K. Purification using chromatography on silica (19:1 DCM/MeOH) 
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afforded the desired compound as a yellow oil/gum (87 mg, 0.22 mmol, 96%). Rf 0.36 (19:1 
DCM/MeOH); λmax (EtOH/nm) 278, 340; IR (cm
-1
) 3076, 2943, 2865, 2376, 2291, 1586, 
1493; 
1
H NMR (500 MHz, MeOD) 1.21-1.31 (21H, m, Si(CH(CH3)2)3), 8.37 (1H, s, H-8), 
8.50 (1H, d, J = 6.1 Hz, H-5’), 8.59 (1H, dd, J = 1.2 and 6.1 Hz, H-6’), 8.76 (1H, d, J = 1.2 
Hz, H-2’); 13C NMR (125 MHz, MeOD) 12.5 (Si(CH(CH3)2)3), 19.1 (Si(CH(CH3)2)3), 102.3 
(C≡C), 109.7 (C-Ar), 146.4 (C-Ar), 157.4 (C-Ar), 158.9 (C-Ar); HRMS calcd. for 
C20H28N7Si (ES+) m/z 394.2170 [M+H]
+
, found 394.2166. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
N-(Pyrimidin-2-yl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (382) 
 
The PMB-protected purine 376 (84 mg, 0.16 mmol) and TFA (4 ml) were reacted according 
to general procedure K. Purification on silica gel (19:1 DCM/MeOH), followed by KP-NH 
silica (9:1 DCM/MeOH) gave the target compound as a yellow oil/gum (35 mg, 0.09 mmol, 
56%). Rf 0.34 (9:1 DCM/MeOH); λmax (EtOH/nm) 265, 341; IR (cm
-1
) 3229, 3167, 2941, 
2863, 1606, 1572; 
1
H NMR (500 MHz, DMSO-d6) 1.23-1.30 (21H, m, Si(CH(CH3)2)3), 7.01 
(1H, dd, J = 4.7 and 4.7 Hz, H-5’), 8.40 (1H, s, H-8), 8.56 (2H, d, J = 4.7 Hz, H-4’/H-6’), 
10.25 (1H, s, C
2
-NH), 13.42 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 10.6 
(Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 98.8 (C≡C), 101.58 (C≡C), 114.6 (C-Ar), 144.7 (C-
Ar), 154.0 (C-Ar), 158.0 (C-Ar), 159.2 (C-Ar); HRMS calcd. for C20H28N7Si (ES+) m/z 
394.2170 [M+H]
+
, found 394.2169. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
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N-(Pyrimidin-5-yl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (383) 
 
The PMB-protected purine 377 (100 mg, 0.19 mmol) and TFA (4 ml) were reacted according 
to general procedure K. Purification on silica gel (19:1 DCM/MeOH) gave the desired 
compound as a yellow oil/gum (66 mg, 0.17 mmol, 89%). Rf 0.34 (19:1 DCM/MeOH); λmax 
(EtOH/nm) 276, 351; IR (cm
-1
) 3080, 2944, 2865, 1600, 1571, 1534; 
1
H NMR (500 MHz, 
MeOD) 1.21-1.29 (21H, m, Si(CH(CH3)2)3), 8.27 (1H, br, H-8), 8.75 (1H, s, H-2’), 9.31 (2H, 
s, H-4’/H-6’); 13C NMR (125 MHz, MeOD) 12.5 (Si(CH(CH3)2)3), 19.1 (Si(CH(CH3)2)3), 
101.3 (C≡C), 138.3 (C-Ar), 147.2 (C-Ar), 151.4 (C-Ar), 157.2 (C-Ar); HRMS calcd. for 
C20H28N7Si (ES+) m/z 394.2170 [M+H]
+
, found 394.2172. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
6-Ethynyl-N-(pyridin-2-yl)-9H-purin-2-amine (364) 
 
The TIPS-protected purine 378 (83 mg, 0.21 mmol), TBAF (1M in THF, 0.25 ml, 0.25 
mmol) and the TBAF scavenger bead system 231 (0.80 g, 10 x w/w) were reacted in THF (5 
ml) according to general procedure U. Chromatography on KP-NH silica (9:1 DCM/MeOH) 
gave the desired compound as an off-white solid (21 mg, 0.09 mmol, 43%). Rf 0.30 (9:1 
DCM/MeOH, KP-NH); M.p. 240-260 °C (decomposed); λmax (EtOH/nm) 252.0, 339.0; IR 
(cm
-1
) 3268, 3163, 2158, 2106, 2033, 1977; 
1
H NMR (500 MHz, DMSO-d6) 4.90 (1H, s, 
C≡CH), 6.98 (1H, ddd, J = 0.9, 5.0 and 7.0 Hz, H-5’), 7.77 (1H, ddd, J = 1.9, 7.0 and 7.1 Hz, 
H-4’), 8.27-8.32 (2H, m, H-3’/H-6’), 8.37 (1H, s, H-8), 9.77 (1H, s, C2-NH), 13.29 (1H, br, 
H-9); 
13
C NMR (125 MHz, DMSO-d6) 78.9 (C≡CH), 87.6 (C≡CH), 112.0 (C-Ar), 117.1 (C-
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Ar), 137.6 (C-Ar), 147.8 (C-Ar), 153.2 (C-Ar), 155.0 (C-Ar); HRMS calcd. for C12H9N6 
(ES+) m/z 237.0883 [M+H]
+
, found 237.0885. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
6-Ethynyl-N-(pyridin-3-yl)-9H-purin-2-amine (365) 
 
The TIPS-protected purine 379 (62 mg, 0.21 mmol), TBAF (1M in THF, 0.19 ml, 0.19 
mmol) and the TBAF scavenger bead system 231 (0.60 g, 10 x w/w) were reacted in THF (5 
ml) according to general procedure U. Chromatography on silica (9:1 DCM/MeOH) gave 
the desired compound as an beige solid (23 mg, 0.10 mmol, 46%). Rf 0.26 (9:1 
DCM/MeOH); M.p. 220-240 °C (decomposed); λmax (EtOH/nm) 270, 340; IR (cm
-1
) 3190, 
3073, 2925, 2826, 2109, 1577, 1543; 
1
H NMR (500 MHz, DMSO-d6) 4.88 (1H, s, C≡CH), 
7.31-7.35 (1H, m, H-5’), 8.15 (1H, dd, J = 1.2 and 4.6 Hz, H-6’), 8.24 (1H, ddd, J = 1.2, 1.6 
and 8.3 Hz, H-4’), 8.33 (1H, s, H-8), 8.94-8.96 (1H, m, H-2’), 9.88 (1H, s, C2-NH); 13C NMR 
(125 MHz, DMSO-d6) 78.8 (C≡C), 87.3 (C≡C), 123.3 (C-Ar), 124.6 (C-Ar), 137.5 (C-Ar), 
140.3 (C-Ar), 141.8 (C-Ar), 155.9 (C-Ar); HRMS calcd. for C12H9N6 (ES+) m/z 237.0883 
[M+H]
+
, found 237.0886. 
Note: Unable to visualise all carbon environments by 
13
C NMR – insufficient material. 
6-Ethynyl-N-(pyridin-4-yl)-9H-purin-2-amine (366) 
 
The TIPS-protected purine 380 (57 mg, 0.15 mmol), TBAF (1M in THF, 0.17 ml, 0.17 
mmol) and the TBAF scavenger bead system 231 (0.60 g, 10 x w/w) were reacted in THF (5 
ml) according to general procedure U. Chromatography on silica (9:1 DCM/MeOH) 
afforded the target compound as an beige solid (23 mg, 0.09 mmol, 61%). Rf 0.21 (9:1 
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DCM/MeOH); M.p. 240-260 °C (decomposed); λmax (EtOH/nm) 282, 339; IR (cm
-1
) 3191, 
2113, 1604, 1532; 
1
H NMR (500 MHz, DMSO-d6) 4.93 (1H, s, C≡CH), 7.80 (2H, dd, J = 1.3 
and 5.1 Hz, H-3’/H-5’), 8.36 (2H, m, H-2’/H-6’), 8.40 (1H, br, H-8), 10.21 (1H, s, C2-NH), 
13.34 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 78.7 (C≡C), 87.7 (C≡C), 112.0 (C-Ar), 
147.2 (C-Ar), 149.8 (C-Ar), 155.3 (C-Ar); HRMS calcd. for C12H9N6 (ES+) m/z 237.0883 
[M+H]
+
, found 237.0885. 
Note: Unable to visualise all carbon environments by 
13
C NMR – insufficient material. 
6-Ethynyl-N-(pyrimidin-2-yl)-9H-purin-2-amine (368) 
 
The TIPS-protected purine 382 (26 mg, 0.07 mmol), TBAF (1M in THF, 80 µl, 0.08 mmol) 
and the TBAF scavenger bead system 231 (0.30 g, 10 x w/w) were reacted in THF (3 ml) 
according to general procedure U. Chromatography on silica (9:1 DCM/MeOH) gave the 
target compound as an beige solid (9 mg, 0.04 mmol, 54%). Rf 0.24 (9:1 DCM/MeOH); M.p. 
260-280 °C (decomposed); λmax (EtOH/nm) 256; IR (cm
-1
) 3248, 2991, 2112, 1608, 1572, 
1546; 
1
H NMR (500 MHz, DMSO-d6) 4.89 (1H, s, C≡CH), 7.01 (1H, dd, J = 4.7 and 4.8 Hz, 
H-5’), 8.42 (1H, s, H-8), 8.57 (2H, d, J = 4.7 Hz, H-4’/H-6’), 10.23 (1H, s, C2-NH), 13.45 
(1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 87.6 (C≡C), 114.6 (C-Ar), 158.0 (C-Ar); 
HRMS calcd. for C11H8N7 (ES+) m/z 238.0836 [M+H]
+
, found 238.0838. 
Note: Unable to visualise all carbon environments by 
13
C NMR – insufficient material. 
6-Ethynyl-N-(pyrimidin-5-yl)-9H-purin-2-amine (369) 
 
The TIPS-protected purine 383 (57 mg, 0.14 mmol), TBAF (1M in THF, 0.17 ml, 0.17 
mmol) and the TBAF scavenger bead system 231 (0.60 g, 10 x w/w) were reacted in THF (5 
400 
 
ml) according to general procedure U. Chromatography on silica (9:1 DCM/MeOH) gave 
the desired compound as an beige solid (14 mg, 0.06 mmol, 42%). Rf 0.22 (9:1 
DCM/MeOH); M.p. 250-270 °C (decomposed); λmax (EtOH/nm) 255; IR (cm
-1
) 3251, 2812, 
2112, 1606, 1549; 
1
H NMR (500 MHz, DMSO-d6) 4.93 (1H, s, C≡CH), 8.38 (1H, s, H-8), 
8.77 (1H, s, H-2’), 9.22 (2H, s, H-4’/H-6’), 10.08 (1H, s, C2-NH), 13.30 (1H, br, H-9); 13C 
NMR (125 MHz, DMSO-d6) 136.2 (C-Ar), 145.9 (C-Ar), 150.9 (C-Ar), 155.3 (C-Ar); HRMS 
calcd. for C11H8N7 (ES+) m/z 238.0836 [M+H]
+
, found 238.0835. 
5-Amino-2-fluoro-N-methylbenzamide (392) 
 
5-Amino-2-fluorobenzoic acid (0.498 g, 3.22 mmol), thionyl chloride (0.47 mmol, 6.44 
mmol), methanol (30 ml) and methylamine (40% aqueous solution, 30 ml) were reacted 
according to general procedure W. Purification using silica gel chromatography (9:1 
DCM/MeOH) afforded the target compound as a pale red oil (0.390 g, 2.32 mmol, 72%). Rf 
0.40 (9:1 DCM/MeOH); λmax (EtOH/nm) 218, 317; IR (cm
-1
) 3338, 3240, 3060, 2942, 1637, 
1535, 1491; 
1
H NMR (500 MHz, DMSO-d6) 2.75 (3H, d, J = 4.6 Hz, NHCH3), 5.16 (2H, s, 
Ar-NH2), 6.63 (1H, ddd, J = 3.0, 4.7 and 8.8 Hz, H-4), 6.81 (1 H, dd, J = 3.0 and 6.1 Hz, H-
6), 6.92 (1H, dd, J = 8.8 and 10.6 Hz, H-3), 8.00 (1H, m, NHCH3); 
13
C NMR (125 MHz, 
DMSO-d6) 26.2 (NHCH3), 114.0 (d, JCF = 1.8 Hz, C-Ar), 116.1 (d, JCF = 23.9 Hz, C-Ar), 
116.6 (d, JCF = 7.6 Hz, C-Ar), 123.6 (d, JCF = 15.1 Hz, C-Ar), 145.1 (d, JCF = 1.3 Hz, C-Ar), 
151.0 (d, JCF = 235.1 Hz, C-Ar), 164.5 (C=O); HRMS calcd. for C8H10FN2O (ES+) m/z 
169.0772 [M+H]
+
, found 169.0771.  
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2-Fluoro-N-methyl-5-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino) benzamide 
(393) 
 
2-Fluoropurine 160 (0.240 g, 0.75 mmol), aniline 392 (0.253 g, 1.50 mmol) and TFA (145 µl, 
1.88 mmol) were reacted in TFE (7 ml) according to general procedure V. Purification 
using chromatography on KP-NH silica (19:1 DCM/MeOH) gave the target compound as a 
yellow oil/gum (0.169 g, 0.36 mmol, 48%). Rf 0.39 (19:1 DCM/MeOH, KP-NH); λmax 
(EtOH/nm) 274, 373; IR (cm
-1
) 3472, 3312, 3073, 2943, 2865, 1639, 1609, 1543; 
1
H NMR 
(500 MHz, DMSO-d6) 1.13-1.20 (21H, m, Si(CH(CH3)2)3), 2.79 (3H, d, J = 4.6 Hz, NHCH3), 
7.21 (1H, dd, J = 9.3 and 9.7 Hz, H-3’), 7.82-7.86 (1H, m, H-4’), 8.06 (1H, dd, J = 2.5 and 
6.0 Hz, H-6’), 8.21-8.26 (2H, m, NHCH3 & H-8), 9.86 (1H, s, C
2
-NH), 13.17 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 26.2 
(NHCH3), 98.0 (C≡C-Si), 101.7 (C≡C-Si), 115.8 (d, JCF = 23.6 Hz, C-Ar), 119.0 (d, JCF = 2.4 
Hz, C-Ar), 121.5 (C-Ar), 124.0 (d, JCF = 15.9 Hz, C-Ar), 128.9 (C-Ar), 132.8 (C-Ar), 137.2 
(d, JCF = 2.7 Hz, C-Ar), 139.9 (C-Ar), 142.9 (C-Ar), 154.9 (d, JCF = 276.9 Hz, C-Ar), 164.3 
(C=O); HRMS calcd. for C24H32FN6OSi (ES+) m/z 467.2385 [M+H]
+
, found 467.2382. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
2-Fluoro-5-((6-ethynyl-9H-purin-2-yl)amino)-N-methylbenzamide (385) 
 
The TIPS-protected purine 393 (0.152 g, 0.33 mmol), TBAF (1M in THF, 0.39 ml, 0.39 
mmol) and the TBAF scavenger bead system 231 (1.50 g, 10 x w/w) were reacted in THF (6 
ml) according to general procedure U. Purification on silica gel (9:1 DCM/MeOH) gave the 
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target compound as a yellow solid (65 mg, 0.21 mmol, 63%). Rf 0.21 (9:1 DCM/MeOH); 
M.p. 240-260 °C (decomposed); λmax (EtOH/nm) 272.0, 340.0; IR (cm
-1
) 3306, 2544, 2112, 
1637, 1614, 1582, 1552; 
1
H NMR (500 MHz, DMSO-d6) 2.79 (3H, d, J = 4.6 Hz, NHCH3), 
4.86 (1H, s, C≡CH), 7.23 (1H, dd, J = 9.2 and 9.8 Hz, H-3’), 7.86-7.92 (1H, m, H-4’), 7.99-
8.03 (1H, m, H-6’), 8.22 (1H, q, J = 4.6 Hz, NHCH3), 8.29 (1H, s, H-8), 9.82 (1H, s, C
2
-NH), 
13.21 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 26.2 (NHCH3), 78.9 (C≡CH), 87.2 
(C≡CH), 115.9 (d, JCF = 23.6 Hz, C-Ar), 119.2 (C-Ar), 121.5 (d, JCF = 6.5 Hz, C-Ar), 123.9 
(d, JCF = 16.3 Hz, C-Ar), 137.2 (C-Ar), 139.7 (C-Ar), 153.5 (d, JCF = 243.6, Ar-CF), 156.0 
(C-Ar), 164.2 (C=O); HRMS calcd. for C15H12FN6O (ES+) m/z 311.1051 [M+H]
+
, found 
311.1053. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
Methyl 5-amino-2-chlorobenzoate (395)
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Methyl 2-chloro-5-nitrobenzoate (0.500 g, 2.32 mmol) and iron powder (1.29 g, 23.2 mmol) 
were reacted in acetic acid (23 ml) according to general procedure T. Silica gel 
chromatography (7:3 Petrol/EtOAc) afforded the target compound as a pale brown oil (0.332 
g, 1.79 mmol, 77%). Rf 0.32 (7:3 Petrol/EtOAc); λmax (EtOH/nm) 219, 256, 330; IR (cm
-1
) 
3462, 3374, 3231, 2952, 1716, 1624, 1600; 
1
H NMR (500 MHz, DMSO-d6) 3.81 (3H, s, 
OCH3), 5.53 (2H, s, Ar-NH2), 6.71 (1H, dd, J = 2.8 and 8.8 Hz, H-4), 6.98 (1H, d, J = 2.8 Hz, 
H-6), 7.15 (1H, d, J = 8.8 Hz, H-3); 
13
C NMR (125 MHz, DMSO-d6) 52.2 (OCH3), 115.3 (C-
Ar), 117.0 (C-Ar), 117.9 (C-Ar), 130.0 (C-Ar), 130.9 (C-Ar), 147.8 (C-Ar), 166.0 (C=O); 
LRMS (ES+) m/z 186.1 [M+H]
+
. 
5-Amino-2-chloro-N-methylbenzamide (396) 
 
Methylamine (40% aqueous solution, 19 ml) and methyl ester 395 (0.347 g, 1.87 mmol) were 
reacted according to general procedure S. Following silica gel purification (19:1 
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DCM/MeOH) the desired compound was obtained as a pale red waxy solid on cooling (0.238 
g, 1.29 mmol, 69%). Rf 0.43 (19:1 DCM/MeOH); M.p. 94-96 °C; λmax (EtOH/nm) 251, 311; 
IR (cm
-1
) 3432, 3339, 3281, 3087, 2941, 1635, 1615, 1595, 1551; 
1
H NMR (500 MHz, 
DMSO-d6) 2.71 (3H, d, J = 4.6 Hz, NHCH3), 5.37 (2H, s, Ar-NH2), 6.55-6.59 (2H, m, H-
4/H-6), 7.05 (1H, d, J = 8.9 Hz, H-3), 8.16 (1H, q, J = 4.6 Hz, NHCH3); 
13
C NMR (125 MHz, 
DMSO-d6) 25.8 (NHCH3), 113.6 (C-Ar), 115.2 (C-Ar), 115.5 (C-Ar), 129.7 (C-Ar), 137.3 
(C-Ar), 147.6 (C-Ar), 167.3 (C=O); HRMS calcd. for C8H10ClN2O (ES+) m/z 185.0476 
[M+H]
+
, found 185.0475. 
2-Chloro-N-methyl-5-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino) benzamide 
(397) 
 
2-Fluoropurine 160 (0.202 g, 0.63 mmol), aniline 396 (0.234 g, 1.27 mmol) and TFA (122 µl, 
1.58 mmol) were reacted in TFE (6 ml) according to general procedure V. Purification 
through chromatography on KP-NH silica (19:1 DCM/MeOH) gave the desired compound as 
a yellow oil/gum (0.106 g, 0.22 mmol, 35%). Rf 0.55 (19:1 DCM/MeOH, KP-NH); λmax 
(EtOH/nm) 281, 370; IR (cm
-1
) 3268, 3091, 2943, 2864, 1572, 1530; 
1
H NMR (500 MHz, 
DMSO-d6) 1.13-1.21 (21H, m, Si(CH(CH3)2)3), 2.76 (3H, d, J = 4.6 Hz, NHCH3), 7.37 (1H, 
d, J = 8.8 Hz, H-3’), 7.79 (1H, dd, J = 2.4 and 8.8 Hz, H-4’), 7.97 (1H, d, J = 2.4 Hz, H-6’), 
8.28 (1H, s, H-8), 8.34 (1H, q, J = 4.6 Hz, NHCH3), 9.99 (1H, s, C
2
-NH), 13.22 (1H, br, H-
9); 
13
C NMR (125 MHz, DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 24.7 
(NHCH3), 111.1 (C-Ar), 121.3 (C-Ar), 126.7 (C-Ar), 133.6 (C-Ar), 152.2 (C-Ar), 155.4 (C-
Ar), 167.0 (C=O); HRMS calcd. for C24H32ClN6OSi (ES+) m/z 483.2090 [M+H]
+
, found 
483.2079. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
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2-Chloro-5-((6-ethynyl-9H-purin-2-yl)amino)-N-methylbenzamide (386) 
 
The TIPS-protected purine 397 (87 mg, 0.18 mmol), TBAF (1M in THF, 0.22 ml, 0.22 
mmol) and the TBAF scavenger bead system 231 (0.90 g, 10 x w/w) were reacted in THF (4 
ml) according to general procedure U. Chromatography on silica (9:1 DCM/MeOH) gave 
the target compound as a yellow solid (39 mg, 0.12 mmol, 66%). Rf 0.23 (9:1 DCM/MeOH); 
M.p. 180-200 °C (decomposed); λmax (EtOH/nm) 278.5, 363.5; IR (cm
-1
) 2250, 2112, 1575, 
1532; 
1
H NMR (500 MHz, DMSO-d6) 2.77 (3H, d, J = 4.6 Hz, NHCH3), 4.87 (1H, s, C≡CH), 
7.39 (1H, d, J = 8.6 Hz, H-3’), 7.83-7.90 (2H, m, H-4’/H-6’), 8.30 (1H,br, H-8), 8.34 (1H, q, 
J = 4.6 Hz, NHCH3), 9.96 (1H, s, C
2
-NH), 13.25 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-
d6) 25.9 (NHCH3), 87.3 (C≡CH), 117.6 (C-Ar), 119.7 (C-Ar), 120.8 (C-Ar), 129.5 (C-Ar), 
137.2 (C-Ar), 139.8 (C-Ar), 143.2 (C-Ar), 153.5 (C-Ar), 155.7 (C-Ar), 167.0 (C=O); HRMS 
calcd. for C15H11ClN6ONa (ES+) m/z 349.0575 [M+Na]
+
, found 349.0578. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
Methyl 5-chloro-2-(trifluoromethyl)benzoate (398) 
 
O-Methyl-N,N’-diisopropylisourea (1.16 ml, 6.41 mmol) was added to a solution of 5-chloro-
2-(trifluoromethyl)benzoic acid (1.20 g, 5.34 mmol) in MeCN (20 ml). The reaction mixture 
was heated under microwave irradiation conditions at 120 °C for 5 min, before being filtered 
and the filtrate evaporated to dryness. The crude residue was purified by chromatography on 
silica (9:1 Petrol/EtOAc) to give the desired compound as a colourless liquid (0.911 g, 3.82 
mmol, 72%). Rf 0.61 (9:1 Petrol/EtOAc); λmax (EtOH/nm) 220, 274; IR (cm
-1
) 2958, 1738, 
1601, 1573; 
1
H NMR (500 MHz, CDCl3) 3.97 (3H, s, OCH3), 7.60 (1H, dd, J = 2.0 and 8.5 
Hz, H-4), 7.71 (1H, d, J = 8.5 Hz, H-3), 7.80 (1H, d, J = 2.0 Hz, H-6); 
13
C NMR (125 MHz, 
CDCl3) 53.1 (OCH3), 122.9 (C-Ar), 123.0 (q, JCF = 274.5 Hz, CF3), 128.3 (q, JCF = 5.4 Hz, 
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C-Ar), 130.5 (C-Ar), 131.3 (C-Ar), 132.6 (q, JCF = 1.9 Hz, C-Ar), 138.2 (C-Ar), 165.9 
(C=O); LRMS (ES+) m/z 239.1 [M
35
Cl+H]
+
, 241.1 [M
37
Cl+H]
+
. 
Methyl 5-((4-methoxybenzyl)amino)-2-(trifluoromethyl)benzoate (400) 
 
The chloro-aromatic intermediate 398 (0.480 g, 2.01 mmol), 4-methoxybenzylamine (315 µl, 
2.41 mmol), palladium(II) acetate (45 mg, 0.20 mmol), 2-(dicyclohexylphosphino)3,6-
dimethoxy-2′,4′,6′-triisopropyl-1,1′-biphenyl (BrettPhos) (100 mg, 0.20 mmol) and Cs2CO3 
(0.785 g, 2.41 mmol) were suspended in THF (20 ml) in a sealed vial and the mixture was 
degassed for 15 min. The reaction mixture was heated at 90 °C for 1 h, before being filtered 
through Celite
®
 and the filtrate concentrated in vacuo. Purification of the crude residue on 
silica (9:1 Petrol/EtOAc) afforded the target compound as a white crystalline solid on cooling 
(0.484 g, 1.43 mmol, 71%). Rf 0.22 (9:1 Petrol/EtOAc); M.p. 87-90 °C; λmax (EtOH/nm) 270; 
IR (cm
-1
) 3391, 3007, 2843, 1707, 1610, 1513; 
1
H NMR (500 MHz, DMSO-d6) 3.73 (3H, s, 
ArOCH3), 3.81 (3H, s, CO2CH3), 4.28 (2H, d, J = 5.9 Hz, NHCH2), 6.76 (1H, dd, J = 2.0 and 
8.7 Hz, H-4), 6.91 (2H, d, J = 8.6 Hz, H-3’/H-5’), 6.93 (1H, d, J = 2.0 Hz, H-6), 7.21 (1H, t, J 
= 5.9 Hz, NHCH2), 7.27 (2H, d, J = 8.6 Hz, H-2’/H-6’), 7.46 (1H, d, J = 8.7 Hz, H-3); 
13
C 
NMR (125 MHz, DMSO-d6) 45.2 (NHCH2), 52.5 (-CO2CH3), 55.0 (ArOCH3), 112.7 (q, JCF 
= 20.3 Hz, C-Ar), 112.8 (C-Ar), 113.8 (C-Ar), 124.4 (q, JCF = 271.1 Hz, CF3), 127.9 (q, JCF = 
5.2 Hz, C-Ar), 128.4 (C-Ar), 130.6 (C-Ar), 131.7 (C-Ar), 151.2 (C-Ar), 158.3 (C-Ar), 167.3 
(C=O); HRMS calcd. for C17H17F3NO3 (ES+) m/z 340.1155 [M+H]
+
, found 340.1159. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
Methyl 5-amino-2-(trifluoromethyl)benzoate (401) 
 
The PMB-protected aniline 400 (0.302 g, 0.89 mmol) and TFA (9 ml) were reacted according 
to general procedure K. Purification on silica gel (7:3 Petrol/EtOAc) gave the desired 
406 
 
compound as a pale yellow oil (0.186 g, 0.85 mmol, 96%). Rf 0.36 (7:3 Petrol/EtOAc); λmax 
(EtOH/nm) 260, 309; IR (cm
-1
) 3392, 3323, 3228, 2954, 1718, 1603, 1580; 
1
H NMR (500 
MHz, DMSO-d6) 3.81 (3H, s, OCH3), 6.11 (2H, s, Ar-NH2), 6.75 (1H, dd, J = 2.4 and 8.7 Hz, 
H-4), 6.89 (1H, d, J = 2.4 Hz, H-6), 7.43 (1H, d, J = 8.7 Hz, H-3); 
13
C NMR (125 MHz, 
DMSO-d6) 52.5 (OCH3), 113.8 (C-Ar), 114.4 (C-Ar), 128.0 (q, JCF = 5.3 Hz, C-Ar), 131.7 
(C-Ar), 142.5 (C-Ar), 152.0 (C-Ar), 167.2 (C=O); LRMS (ES+) m/z 220.1 [M+H]
+
. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
5-Amino-N-methyl-2-(trifluoromethyl)benzamide (402) 
 
Methylamine (40% aqueous solution, 8 ml) and methyl ester 401 (0.160 g, 0.73 mmol) were 
reacted according to general procedure S over 48 hours. Purification by silica gel 
chromatography (9:1 DCM/MeOH) gave the target compound as an off-white solid (0.140 g, 
0.64 mmol, 88%). Rf 0.39 (9:1 DCM/MeOH); M.p. 185-188 °C; λmax (EtOH/nm) 256; IR 
(cm
-1
) 3442, 3349, 3231, 1616, 1574, 1553; 
1
H NMR (500 MHz, DMSO-d6) 2.70 (3H, d, J = 
4.7 Hz, NHCH3), 5.94 (2H, s, Ar-NH2), 6.55 (1H, d, J = 2.3 Hz, H-6), 6.63 (1H, dd, J = 2.3 
and 8.6 Hz, H-4), 7.33 (1H, d, J = 8.6 Hz, H-3), 8.20 (1H, q, J = 4.7 Hz, NHCH3); 
13
C NMR 
(125 MHz, DMSO-d6) 25.9 (NHCH3), 112.0 (C-Ar), 111.8 (q, JCF = 31.8 Hz, C-Ar), 112.3 
(C-Ar), 112.6 (C-Ar), 124.7 (q, JCF = 271.6 Hz, CF3), 127.4 (q, JCF = 5.0 Hz, C-Ar), 138.0 (q, 
JCF = 1.8 Hz, C-Ar), 151.8 (C-Ar), 168.2 (C=O); HRMS calcd. for C9H9F3N2ONa (ES+) m/z 
241.0559 [M+H]
+
, found 241.0562. 
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5-((9-(4-Methoxybenzyl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino)-N-methyl-
2-(trifluoromethyl)benzamide (403) 
 
2-Iodopurine intermediate 278 (0.234 g, 0.43 mmol), aniline 402 (0.112 g, 0.51 mmol), 
Pd2(dba)3 (37 mg, 0.04 mmol), XPhos (19 mg, 0.04 mmol) and K2CO3 (0.130 g, 0.94 mmol) 
were reacted in MeCN (4 ml) according to general procedure M. Purification by silica gel 
chromatography (1:1 Petrol/EtOAc) gave the desired compound as a yellow oil (0.247 g, 0.39 
mmol, 91%). Rf 0.44 (1:1 Petrol/EtOAc); λmax (EtOH/nm) 281, 358; IR (cm
-1
) 3287, 3092, 
2943, 2865, 1656, 1576, 1536, 1514; 
1
H NMR (500 MHz, DMSO-d6) 1.11-1.20 (21H, m, 
Si(CH(CH3)2)3), 2.75 (3H, d, J = 4.6 Hz, NHCH3), 3.71 (3H, s, OCH3), 5.35 (2H, s, N
9
-CH2), 
6.92 (2H, d, J = 8.8 Hz, H-3’’/H-5’’), 7.37 (2H, d, J = 8.8 Hz, H-2’’/H-6’’), 7.66 (1H, d, J = 
9.0 Hz, H-3’), 7.91 (1H, dd, J = 2.0 and 9.0 Hz, H-4’), 8.13 (1H, d, J = 2.0 Hz, H-6’), 8.44 
(1H, q, J = 4.6 Hz, NHCH3), 8.54 (1H, s, H-8), 10.40 (1H, s, C
2
-NH); 
13
C NMR (125 MHz, 
DMSO-d6) 10.5 (Si(CH(CH3)2)3), 18.3 (Si(CH(CH3)2)3), 26.0 (NHCH3), 46.2 (N9-CH2), 55.0 
(OCH3), 99.2 (C≡C-Si), 101.2 (C≡C-Si), 114.1 (C-Ar), 116.5 (C-Ar), 117.4 (q, JCF = 31.5 
Hz, C-Ar), 117.5 (C-Ar), 124.2 (q, JCF = 271.8 Hz, CF3), 126.9 (q, JCF = 5.0 Hz, C-Ar), 128.3 
(C-Ar), 129.2 (C-Ar), 129.6 (C-Ar), 137.6 (q, JCF = 2.4 Hz, C-Ar), 140.3 (C-Ar), 144.0 (C-
Ar), 145.2 (C-Ar), 152.4 (C-Ar), 155.3 (C-Ar), 158.9 (C-Ar), 167.9 (C=O); HRMS calcd. for 
C33H40F3N6O2Si (ES+) m/z 637.2929 [M+H]
+
, found 637.2926. 
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N-Methyl-2-(trifluoromethyl)-5-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-
yl)amino)benzamide (404) 
 
PMB-protected purine 403 (0.198 g, 0.31 mmol) and TFA (3 ml) were reacted according to 
general procedure K over 18 h. Purification using chromatography on silica (19:1 
DCM/MeOH) gave the desired compound as a pale yellow oil/gum (0.148 g, 0.29 mmol, 
94%). Rf 0.42 (19:1 DCM/MeOH); λmax (EtOH/nm) 282, 356; IR (cm
-1
) 3103, 2944, 2865, 
1652, 1576, 1534; 
1
H NMR (500 MHz, DMSO-d6) 1.13-1.22 (21H, m, Si(CH(CH3)2)3), 2.76 
(3H, d, J = 4.6 Hz, NHCH3), 7.64 (1H, d, J = 8.9 Hz, H-3’), 7.93-7.97 (1H, m, H-4’), 8.02-
8.05 (1H, m, H-6’), 8.33-8.39 (2H, m, NHCH3 & H-8), 10.27 (1H, s, C
2
-NH), 13.32 (1H, br, 
H-9); 
13
C NMR (125 MHz, DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 26.0 
(NHCH3), 98.7 (C≡C), 116.2 (C-Ar), 117.3 (C-Ar), 124.2 (q, JCF = 272.7 Hz, CF3), 126.8 (q, 
JCF = 5.0 Hz, C-Ar), 137.6 (C-Ar), 144.2 (C-Ar), 155.3 (C-Ar), 167.9 (C=O); HRMS calcd. 
for C25H32F3N6OSi (ES+) m/z 517.2353 [M+H]
+
, found 517.2349. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
5-((6-Ethynyl-9H-purin-2-yl)amino)-N-methyl-2-(trifluoromethyl) benzamide (388) 
 
The TIPS-protected purine 404 (0.123 g, 0.24 mmol), TBAF (1M in THF, 0.29 ml, 0.29 
mmol) and the TBAF scavenger bead system 231 (1.20 g, 10 x w/w) were reacted in THF (5 
ml) according to general procedure U. Silica gel chromatography (9:1 DCM/MeOH) gave 
the target compound as a beige solid (54 mg, 0.15 mmol, 63%). Rf 0.18 (9:1 DCM/MeOH); 
M.p. 340-350 °C (decomposed); λmax (EtOH/nm) 282.5, 350.0; IR (cm
-1
) 3274, 3117, 2831, 
409 
 
2115, 1593, 1383; 
1
H NMR (500 MHz, DMSO-d6) 2.76 (3H, d, J = 4.6 z, NHCH3), 4.93 (1H, 
s, C≡CH), 7.67 (1H, d, J = 8.8 Hz, H-3’), 7.92 (1H, d, J = 2.0 Hz, H-6’), 8.03 (1H, dd, J = 2.0 
and 8.8 Hz, H-4’), 8.34-8.42 (2H, m, NHCH3 & H-8), 10.23 (1H, s, C
2
-NH), 13.37 (1H, br, 
H-9); 
13
C NMR (125 MHz, DMSO-d6) 26.0 (NHCH3), 78.7 (C≡CH), 87.7 (C≡CH), 116.4 (C-
Ar), 117.1 (C-Ar), 117.2 (C-Ar), 117.3 (C-Ar), 124.2 (q, JCF = 271.8 Hz, C-Ar), 127.0 (q, JCF 
= 4.7 Hz, C-Ar), 137.5 (q, JCF = 2.4 Hz, C-Ar), 144.1 (C-Ar), 155.4 (C-Ar), 167.8 (C=O); 
HRMS calcd. for C16H12F3N6O (ES+) m/z 361.1019 [M+H]
+
, found 361.1023. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
Methyl 2-methoxy-5-nitrobenzoate (405)
278
 
 
Sodium hydride dispersion in mineral oil (0.140 g, 60%, 3.48 mmol) was added to dry 
methanol (20 ml) sowly. Once the reaction had subsided, methyl 2-chloro-5-nitrobenzoate 
(0.503 g, 2.32 mmol) was added and the reaction mixture was heated at 50 °C for 4 h. The 
solvent was removed in vacuo and the resultant residue was dissolved in EtOAc (20 ml) and 
washed with brine (20 ml). The organic phase was dried (MgSO4) and evaporated to dryness, 
and the crude product was purified using chromatography on silica gel (7:3 Petrol/EtOAc). 
The target compound was acquired as an off-white solid on cooling (0.344 g, 1.63 mmol, 
70%). Rf 0.39 (7:3 Petrol/EtOAc); M.p. 99-101 °C (Lit.
278
 99-100 °C); λmax (EtOH/nm) 219, 
299; IR (cm
-1
) 3391, 3088, 2959, 2849, 1703, 1609, 1585, 1512; 
1
H NMR (500 MHz, 
DMSO-d6) 3.85 (3H, s, Ar-OCH3), 3.99 (3H, s, -CO2CH3), 7.41 (1H, d, J = 9.2 Hz, H-3), 
8.44 (1H, dd, J = 3.0 and 9.2 Hz, H-4), 8.49 (1H, d, J = 3.0 Hz, H-6); 
13
C NMR (125 MHz, 
DMSO-d6) 52.5 (OCH3), 57.0 (OCH3), 113.5 (C-Ar), 120.2 (C-Ar), 126.4 (C-Ar), 129.0 (C-
Ar), 139.9 (C-Ar), 163.0 (quat-C), 164.2 (quat-C); LRMS (ES+) m/z 212.1 [M+H]
+
. 
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Methyl 5-amino-2-methoxybenzoate (406)
279
 
 
The nitro compound 405 (0.854 g, 4.04 mmol) and iron powder (2.26 g, 40.4 mmol) were 
reacted in acetic acid (40 ml) according to general procedure T. Silica gel chromatography 
(1:1 Petrol/EtOAc) gave the desired compound as a pale yellow oil (0.735 g, 3.88 mmol, 
96%). Rf 0.37 (1:1 Petrol/EtOAc); λmax (EtOH/nm) 218, 341; IR (cm
-1
) 3428, 3360, 3237, 
2950, 2836, 1712, 1628, 1500; 
1
H NMR (500 MHz, CDCl3) 3.85 (3H, s, OCH3), 3.89 (3H, s, 
OCH3), 6.84 (2H, s, Ar-NH2), 7.16-7.20 (2H, m, H-3/H-4), 7.28-7.31 (1H, m, H-6); 
13
C NMR 
(125 MHz, CDCl3) 52.1 (OCH3), 56.8 (OCH3), 114.1 (C-Ar), 118.2 (C-Ar), 120.4 (C-Ar), 
139.5 (C-Ar), 152.4 (C-Ar), 166.8 (C-Ar), 176.0 (C=O); LRMS (ES+) m/z 182.1 [M+H]
+
. 
5-Amino-2-methoxy-N-methylbenzamide (407) 
 
Methyl ester 406 (0.660 g, 3.64 mmol) and methylamine (40% aqueous solution, 30 ml) were 
reacted according to general procedure S. Purification by chromatography on silica (9:1 
DCM/MeOH) gave the target compound as a pale yellow oil (0.480 g, 2.66 mmol, 73%). Rf 
0.44 (9:1 DCM/MeOH); λmax (EtOH/nm) 218, 335; IR (cm
-1
) 3335, 3242, 2942, 2833, 1640, 
1606, 1541; 
1
H NMR (500 MHz, DMSO-d6) 2.78 (3H, d, J = 4.7 Hz, NHCH3), 3.76 (3H, s, 
OCH3), 4.81 (2H, s, Ar-NH2), 6.66 (1H, dd, J = 3.0 and 8.6 Hz, H-4), 6.84 (1H, d, J = 8.6 Hz, 
H-3), 7.10 (1H, d, J = 3.0 Hz, H-6), 8.09 (1H, q, J = 4.7 Hz, NHCH3); 
13
C NMR (125 MHz, 
DMSO-d6) 26.2 (NHCH3), 56.2 (OCH3), 113.3 (C-Ar), 115.8 (C-Ar), 117.3 (C-Ar), 122.9 (C-
Ar), 142.4 (C-Ar), 148.4 (C-Ar), 165.6 (C=O); HRMS calcd. for C9H13N2O2 (ES+) m/z 
181.0972 [M+H]
+
, found 181.0971. 
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2-Methoxy-N-methyl-5-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl) amino)benzamide 
(408) 
 
2-Fluoropurine 160 (0.196 g, 0.62 mmol), aniline 407 (0.222 g, 1.23 mmol) and TFA (120 µl, 
1.54 mmol) were reacted in TFE (6 ml) according to general procedure V. Purification by 
KP-NH silica chromatography (19:1 DCM/MeOH) afforded the target compound as a yellow 
oil/gum (0.136 g, 0.28 mmol, 45%). Rf 0.45 (19:1 DCM/MeOH, KP-NH); λmax (EtOH/nm) 
240, 277, 379; IR (cm
-1
) 3394, 3275, 3102, 2943, 2864, 1645, 1607, 1573, 1536; 
1
H NMR 
(500 MHz, DMSO-d6) 1.13-1.20 (21H, m, Si(CH(CH3)2)3), 2.80 (3H, d, J = 4.5 Hz, NHCH3), 
3.85 (3H, s, OCH3), 7.06 (1H, d, J = 9.1 Hz, H-3’), 7.83 (1H, dd, J = 2.4 and 9.1 Hz, H-4’), 
8.09 (1H, d, J = 2.4 Hz, H-6’), 8.13 (1H, q, J = 4.5 Hz, NHCH3), 8.21 (1H, s, H-8), 9.61 (1H, 
s, C
2
-NH), 13.08 (1H, br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 
(Si(CH(CH3)2)3), 26.3 (NHCH3), 56.0 (OCH3), 97.7 (C≡C-Si), 101.8 (C≡C-Si), 112.1 (C-
Ar), 121.0 (C-Ar), 122.3 (C-Ar), 123.3 (C-Ar), 134.0 (C-Ar), 139.9 (C-Ar), 142.5 (C-Ar), 
151.5 (C-Ar), 156.4 (C-Ar), 165.5 (C=O); HRMS calcd. for C25H35N6O2Si (ES+) m/z 
479.2585 [M+H]
+
, found 479.2581. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
2-Methoxy-5-((6-ethynyl-9H-purin-2-yl)amino)-N-methylbenzamide (387) 
 
The TIPS-protected purine 408 (0.122 g, 0.25 mmol), TBAF (1M in THF, 0.31 ml, 0.31 
mmol) and the TBAF scavenger bead system 231 (1.20 g, 10 x w/w) were reacted in THF (5 
ml) according to general procedure U. Silica gel chromatography (9:1 DCM/MeOH) 
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afforded the desired compound as a yellow solid (49 mg, 0.15 mmol, 61%). Rf 0.27 (9:1 
DCM/MeOH); M.p. 290-310 °C (decomposed); λmax (EtOH/nm) 237.0, 275.0, 346.5; IR (cm
-
1
) 3364, 3167, 3010, 2104, 1636, 1608, 1540, 1492; 
1
H NMR (500 MHz, DMSO-d6) 2.81 
(3H, d, J = 4.6 Hz, NHCH3), 3.86 (3H, s, OCH3), 4.83 (1H, s, C≡CH), 7.09 (1H, d, J = 9.0 
Hz, H-3’), 7.87 (1H, dd, J = 2.8 and 9.0 Hz, H-4’), 8.06 (1H, d, J = 2.8 Hz, H-6’), 8.15 (1H, 
q, J = 4.6 Hz, NHCH3), 8.25 (1H, s, H-8), 9.55 (1H, s, C
2
-NH), 13.12 (1H, br, H-9); 
13
C 
NMR (125 MHz, DMSO-d6) 26.3 (NHCH3), 55.0 (OCH3), 79.0 (C≡CH), 86.9 (C≡CH), 112.1 
(C-Ar), 121.1 (C-Ar), 122.4 (C-Ar), 123.1 (C-Ar), 133.9 (C-Ar), 151.6 (C-Ar), 156.5 (C-Ar), 
165.5 (C=O); HRMS calcd. for C16H15N6O2 (ES+) m/z 323.1251 [M+H]
+
, found 323.1258. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
Methyl 2-cyano-5-nitrobenzoate (409) 
 
Methyl 2-chloro-5-nitrobenzoate (100 mg, 0.46 mmol), zinc cyanide (30 mg, 0.26 mmol), 
zinc powder (6 mg, 0.09 mmol) and bis(tri-tert-butylphosphino)palladium(0) (28 mg, 0.05 
mmol) were suspended in DMA (3 ml) in a sealed vial and the mixture was degassed for 15 
min. The reaction mixture was heated at 95 °C for 1 h, before sat. NaHCO3 solution (2 ml) 
was added. The mixture was extracted with EtOAc (2 x 10 ml) and the combined organic 
extracts were washed with brine (10 ml), dried (MgSO4) and evaporated to dryness. 
Purification of the crude residue by chromatography on silica (4:1 Petrol/EtOAc) gave the 
target compound as an off-white solid (90 mg, 0.44 mmol, 96%). Rf 0.34 (4:1 Petrol/EtOAc); 
M.p. 143-146 °C; λmax (EtOH/nm) 214, 257; IR (cm
-1
) 3114, 3051, 2964, 2868, 2235, 1725, 
1606, 1533; 
1
H NMR (500 MHz, DMSO-d6) 3.99 (3H, s, OCH3), 8.34 (1H, d, J = 8.4 Hz, H-
3), 8.60 (1H, dd, J = 2.4 and 8.5 Hz, H-4), 8.71 (1H, d, J = 2.4 z, H-6); 
13
C NMR (125 MHz, 
DMSO-d6) 53.4 (OCH3), 116.0 (quat-C), 116.9 (quat-C), 125.1 (C-Ar), 127.7 (C-Ar), 133.6 
(C-Ar), 136.9 (C-Ar), 149.5 (C-Ar), 162.5 (C=O); LRMS (ES+) m/z 207.1 [M+H]
+
. 
Note: Unable to differentiate cyano 
13
C NMR signal from aromatic carbon. 
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Methyl 5-amino-2-cyanobenzoate (410) 
 
The nitro compound 409 (0.648 g, 3.14 mmol) and iron powder (1.75 g, 31.4 mmol) were 
reacted in acetic acid (30 ml) according to general procedure T. Silica gel chromatography 
(1:1 Petrol/EtOAc) gave the desired compound as an off-white solid (0.470 g, 2.67 mmol, 
85%). Rf 0.45 (1:1 Petrol/EtOAc); M.p. 173-176 °C; λmax (EtOH/nm) 233, 286, 341; IR (cm
-
1
) 3458, 3363, 3237, 2957, 2208, 1711, 1639, 1597; 
1
H NMR (500 MHz, DMSO-d6) 3.86 
(3H, s, OCH3), 6.45 (2H, s, Ar-NH2), 6.80 (1H, dd, J = 2.4 and 8.4 Hz, H-4), 7.24 (1H, d, J = 
2.4 Hz, H-6), 7.54 (1H, d, J = 8.4 Hz, H-3); 
13
C NMR (125 MHz, DMSO-d6) 95.6 (C-Ar), 
115.1 (C-Ar), 116.3 (C-Ar), 119.0 (C-Ar), 132.9 (C≡N), 136.2 (C-Ar), 152.7 (C-Ar), 164.7 
(C=O); HRMS calcd. for C9H9N2O2 (ES+) m/z 177.0659 [M+H]
+
, found 177.0658. 
(E)-6-Amino-2-methyl-3-(methylimino)isoindolin-1-one (413) 
 
Methylamine (40% aqueous solution, 10 ml) was added to methyl ester 410 (0.163 g, 0.93 
mmol) and the resultant red solution was stirred at RT for 18 h. Removal of the solvent in 
vacuo, followed by silica gel chromatography (9:1 DCM/MeOH) gave the undesired 
compound as a pale yellow solid (0.131 g, 0.69 mmol, 74%). Rf 0.33 (9:1 DCM/MeOH); 
M.p. 187-190 °C; λmax (EtOH/nm) 243, 271, 356; IR (cm
-1
) 3418, 3332, 3218, 2917, 2868, 
1704, 1649, 1615; 
1
H NMR (500 MHz, DMSO-d6) 3.01 (3H, s, amide N-CH3), 3.53 (3H,s, 
imine N-CH3), 6.13 (2H, s, Ar-NH2), 6.80 (1H, dd, J = 2.2 and 8.4 Hz, H-5), 6.92 (1H, d, J = 
2.2 Hz, H-7), 7.77 (1H, d, J = 8.4 Hz, H-4); 
13
C NMR (125 MHz, DMSO-d6) 24.5 (Amide N-
CH3), 37.2 (Imine N-CH3), 106.8 (C-Ar), 116.0 (C-Ar), 116.4 (C-Ar), 127.3 (C-Ar), 134.4 
(C-Ar), 152.2, 152.8, 167.2 (C=O); HRMS calcd. for C10H12N3O (ES+) m/z 190.0975 
[M+H]
+
, found 190.0975. 
Note: Unable to distinguish 
13
C NMR signals at 152.2 and 152.8. 
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(E)-6-((9-(4-Methoxybenzyl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl) amino)-2-
methyl-3-(methylimino)isoindolin-1-one (416) 
 
The 2-iodopurine 278 (0.310 g, 0.57 mmol), aniline 413 (0.128 g, 0.48 mmol), Pd2(dba)3 (55 
mg, 0.06 mmol), XPhos (29 mg, 0.06 mmol) and K2CO3 (0.173 g, 1.25 mmol) were reacted 
in MeCN (6 ml) according to general procedure M. Silica gel chromatography (1:1 
Petrol/EtOAc) gave the target compound as a pale yellow oil/gum (0.190 g, 0.31 mmol, 
54%). Rf 0.39 (1:1 Petrol/EtOAc); λmax (EtOH/nm) 281, 352; IR (cm
-1
) 3298, 2942, 2864, 
1725, 1661, 1577, 1543; 
1
H NMR (500 MHz, DMSO-d6) 1.12-1.22 (21H, m, Si(CH(CH3)2)3), 
3.09 (3H, s, amide N-CH3), 3.64 (3H, s, imine N-CH3), 3.70 (3H, s, OCH3), 5.36 (2H, s, N
9
-
CH2), 6.92 (2H, d, J = 8.6 Hz, H-3’’/H-5’’), 7.47 (2H, d, J = 8.6 Hz, H-2’’/H-6’’), 8.01-8.08 
(2H, m, H-4’/H-5’), 8.48-8.52 (1H, m, H-7’), 8.54 (1H, s, H-8), 10.48 (1H, s, C2-NH); 13C 
NMR (125 MHz, DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 24.7 (amide N-
CH3), 37.4 (imine N-CH3), 42.2 (N
9
-CH2), 55.1 (OCH3), 99.2 (C≡C), 101.2 (C≡C), 111.4 (C-
Ar), 114.1 (C-Ar), 121.2 (C-Ar), 126.7 (C-Ar), 128.2 (C-Ar), 129.5 (C-Ar), 129.6 (C-Ar), 
133.6 (C-Ar), 140.3 (C-Ar), 143.9 (C-Ar), 145.1 (C-Ar), 152.2, 152.4, 155.3 (C-Ar), 158.9 
(C-Ar), 166.9 (C=O); HRMS calcd. for C34H42N7O2Si (ES+) m/z 608.3164 [M+H]
+
, found 
608.3159. 
Note: Unable to distinguish 
13
C NMR signals at 152.2 and 152.4. 
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(E)-2-Methyl-3-(methylimino)-6-((6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl) 
amino)isoindolin-1-one (417) 
 
The PMB-protected purine 416 (0.144 g, 0.24 mmol) and TFA (5 ml) were reacted according 
to general procedure K. Purification on silica gel (19:1 DCM/MeOH) gave the desired 
compound as a yellow oil/gum (90 mg, 0.18 mmol, 75%). Rf 0.55 (19:1 DCM/MeOH); λmax 
(EtOH/nm) 282, 370; IR (cm
-1
) 3344, 3071, 2943, 2865, 1712, 1659, 1598, 1577, 1547; 
1
H 
NMR (500 MHz, DMSO-d6) 1.13-1.23 (21H, m, Si(CH(CH3)2)3), 3.08 (3H, s, amide N-CH3), 
3.63 (3H, s, imine N-CH3), 7.98 (1H, dd, J = 2.0 and 8.5 Hz, H-5’), 8.05 (1H, d, J = 8.5 Hz, 
H-4’), 8.35 (1H, br, H-8), 8.50 (1H, d, J = 2.0 Hz, H-7’), 10.39 (1H, s, C2-NH), 13.39 (1H, 
br, H-9); 
13
C NMR (125 MHz, DMSO-d6) 10.6 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 24.7 
(amide N-CH3), 37.4 (imine N-CH3), 98.6 (C≡C), 111.1 (C-Ar), 115.1 (C-Ar), 121.2 (C-Ar), 
126.7 (C-Ar), 133.6 (C-Ar), 144.2 (C-Ar), 152.2 (C=N), 155.4 (C-Ar), 167.0 (C=O); HRMS 
calcd. for C26H34N7OSi (ES+) m/z 488.2589 [M+H]
+
, found 488.2583. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
(E)-6-((6-Ethynyl-9H-purin-2-yl)amino)-2-methyl-3-(methylimino) isoindolin-1-one 
(418) 
 
The TIPS-protected purine 417 (76 mg, 0.16 mmol), TBAF (1M in THF, 0.19 ml, 1M, 0.19 
mmol) and the TBAF scavenger bead system 231 (0.80 g, 10 x w/w) were reacted in THF (4 
ml) according to general procedure U. Silica gel chromatography (9:1 DCM/MeOH) 
afforded the target compound as a yellow solid (27 mg, 0.08 mmol, 53%). Rf 0.34 (9:1 
DCM/MeOH); M.p. 280-300 °C (decomposed); λmax (EtOH/nm) 286, 347; IR (cm
-1
) 3253, 
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3062, 2957, 2922, 2700, 2116, 1720, 1653, 1606; 
1
H NMR (500 MHz, DMSO-d6) 3.08 (3H, 
s, amide N-CH3), 3.63 (3H, s, imine N-CH3), 4.92 (1H, s, C≡CH), 8.02 (1H, dd, J = 1.8 and 
8.5 Hz, H-5’), 8.07 (1H, d, J = 8.5 Hz, H-4’), 8.39 (1H, s, H-8), 8.44 (1H, d, J = 1.8 Hz, H-
7’), 10.34 (1H, s, C2-NH), 13.45 (1H, br, H-9); 13C NMR (125 MHz, DMSO-d6) 24.7 (amide 
N-CH3), 37.4 (imine N-CH3), 78.7 (C≡C), 87.6 (C≡C), 111.2 (C-Ar), 121.0 (C-Ar), 121.2 
(C-Ar), 126.8 (C-Ar), 133.6 (C-Ar), 144.1 (C-Ar), 152.2 (C=N), 155.3 (C-Ar), 167.0 (C=O); 
HRMS calcd. for C17H14N7O (ES+) m/z 332.1254 [M+H]
+
, found 332.1255. 
Note: Unable to visualise all carbon environments by 
13
C NMR. 
2-Cyano-5-nitrobenzoic acid (420) 
 
NaOH solution (2.6 ml, 1M, 2.6 mmol) was added to a suspension of the methyl ester 409 
(0.502 g, 2.43 mmol) in methanol (7.5 ml). After stirring at RT for 30 min, the resultant 
suspension was filtered, and the filtrate diluted with water (15 ml). The filtrate was washed 
with EtOAc (15 ml), before being adjusted to pH 3-4 with 2M HCl. The solution was 
extracted with EtOAc (2 x 20 ml), and the combined organic extracts were dried (MgSO4) 
and concentrated in vacuo. The resultant solid was combined with the filtrand from the 
reaction mixture and dried in a vacuum oven. The target compound was obtained as an off-
white solid (0.359 g, 1.87 mmol, 77%). Rf 0.22 (7:3 DCM/MeOH, 0.1% AcOH); M.p. >350 
°C; λmax (EtOH/nm) 261; IR (cm
-1
) 3514, 3329, 3240, 3101, 2243, 1608, 1520; 
1
H NMR (500 
MHz, DMSO-d6) 8.04 (1H, d, J = 8.4 Hz, H-3), 8.30 (1H, dd, J = 2.4 and 8.4 Hz, H-4), 8.67 
(1H, d, J = 2.4 Hz, H-6); 
13
C NMR (125 MHz, DMSO-d6) 116.9 (quat-C), 118.0 (quat-C), 
123.8 (C-Ar), 124.4 (C-Ar), 135.4 (C-Ar), 145.1 (C-Ar), 149.1 (C-Ar), 163.9 (C=O); HRMS 
calcd. for C8H3N2O4 (ES+) m/z 191.0098 [M+H]
+
, found 191.0097. 
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2-Cyano-N,N-dimethyl-5-nitrobenzamide (421) 
 
The carboxylic acid 420 (0.500 g, 2.57 mmol), dimethylamine hydrochloride (0.251 g, 3.09 
mmol), EDC (0.740 g, 3.86 mmol), HOBt (0.453 g, 3.35 mmol) and DIPEA (0.54 ml, 3.09 
mmol) were combined in dry DMF (30 ml) and stirred at RT under N2 for 18 h. The solvent 
was removed under reduced pressure and the residue was dissolved in water (50 ml) and 
extracted with DCM (3 x 50 ml). The combined organic extracts were dried through a phase 
separator, evaporated to dryness, and the crude residue purified by chromatography on silica 
(1:1 Petrol/EtOAc) to give the target compound as a pale yellow solid (0.522 g, 2.38 mmol, 
92%). Rf 0.42 (1:1 Petrol/EtOAc); M.p. 199-202 °C; λmax (EtOH/nm) 253; IR (cm
-1
) 3096, 
3032, 2940, 2234, 1633, 1531; 
1
H NMR (500 MHz, DMSO-d6) 2.88 (3H, s, N-CH3), 3.07 
(3H, s, N-CH3), 8.27 (1H, d, J = 9.0 Hz, H-3), 8.41-8.44 (2H, m, H-4/H-6); 
13
C NMR (125 
MHz, DMSO-d6) 34.6 (N-CH3), 38.3 (N-CH3), 114.5 (C-Ar), 115.7 (C≡N), 122.3 (C-Ar), 
124.4 (C-Ar), 135.3 (C-Ar), 141.9 (C-Ar), 149.8 (C-Ar), 164.8 (C=O); HRMS calcd. for 
C10H10N3O3 (ES+) m/z 220.0717 [M+H]
+
, found 220.0714. 
5-Amino-2-cyano-N,N-dimethylbenzamide (422) 
 
The nitro compound 421 (0.492 g, 2.24 mmol) and iron powder (1.25 g, 22.4 mmol) were 
reacted in acetic acid (20 ml) according to general procedure T. Chromatography on silica 
gel (19:1 DCM/MeOH) gave the desired compound as an off-white solid (0.333 g, 1.76 
mmol, 79%). Rf 0.40 (19:1 DCM/MeOH); M.p. 174-176 °C; λmax (EtOH/nm) 282; IR (cm
-1
) 
3389, 3345, 3222, 2208, 1659, 1592, 1561; 
1
H NMR (500 MHz, DMSO-d6) 2.84 (3H, s, N-
CH3), 2.99 (3H, s, N-CH3), 6.34 (2H, br, Ar-NH2), 6.50 (1H, d, J = 2.2 Hz, H-6), 6.63 (1H, 
dd, J = 2.2 and 8.6 Hz, H-4), 7.45 (1H, d, J = 8.6 Hz, H-3); 
13
C NMR (125 MHz, DMSO-d6) 
34.2 (N-CH3), 37.9 (N-CH3), 92.7 (C-Ar), 110.8 (C-Ar), 113.4 (C-Ar), 118.7 (C≡N), 134.2 
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(C-Ar), 142.0 (C-Ar), 152.9 (C-Ar), 167.5 (C=O); HRMS calcd. for C10H12N3O (ES+) m/z 
190.0975 [M+H]
+
, found 190.0976. 
2-Cyano-5-((9-(4-methoxybenzyl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino)-
N,N-dimethylbenzamide (423) 
 
2-Iodopurine intermediate 278 (0.289 g, 0.53 mmol), aniline 422 (0.120 g, 0.63 mmol), 
Pd2(dba)3 (46 mg, 0.05 mmol), XPhos (24 mg, 0.05 mmol) and K2CO3 (0.160 g, 1.16 mmol) 
were reacted in MeCN (5 ml) according to general procedure M. Silica gel chromatography 
(1:1 Petrol/EtOAc) gave the desired compound as a yellow oil/gum (0.224 g, 0.37 mmol, 
74%). Rf 0.40 (1:1 Petrol/EtOAc); λmax (EtOH/nm) 226, 309; IR (cm
-1
) 2942, 2864, 2221, 
1635, 1586, 1514; 
1
H NMR (500 MHz, DMSO-d6) 1.14-1.22 (21H, m, Si(CH(CH3)2)3), 2.89 
(3H, s, N-CH3), 3.06 (3H, s, N-CH3), 3.72 (3H, s, OCH3), 5.36 (2H, s, N
9
-CH2), 6.91 (2H, d, 
J = 8.7 Hz, H-3’’/H-5’’), 7.32 (2H, d, J = 8.7 Hz, H-2’’/H-6’’), 7.82 (1H, d, J = 8.6 Hz, H-
3’), 7.90 (1H, dd, J = 2.1 and 8.6 Hz, H-4’), 8.05 (1H, d, J = 2.1 Hz, H-6’), 8.56 (1H, s, H-8), 
10.55 (1H, s, C
2
-NH); 
13
C NMR (125 MHz, DMSO-d6) 10.5 (Si(CH(CH3)2)3), 18.4 
(Si(CH(CH3)2)3), 34.4 (N-CH3), 38.2 (N-CH3), 46.2 (N
9
-CH2), 55.1 (OCH3), 99.3 (C≡C), 
99.4 (C-Ar)), 101.1 (C≡C), 114.1 (C-Ar), 115.2 (C-Ar), 117.8 (C≡N), 118.0 (C-Ar), 128.2 
(C-Ar), 129.0 (C-Ar), 129.8 (C-Ar), 133.9 (C-Ar), 140.2 (C-Ar), 141.3 (C-Ar), 144.9 (C-Ar), 
145.6 (C-Ar), 152.4 (C-Ar), 154.9 (C-Ar), 158.9 (C-Ar), 167.1 (C=O); HRMS calcd. for 
C34H42N7O2Si (ES+) m/z 608.3164 [M+H]
+
, found 608.3160. 
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Appendix 
Enzyme 
MAPK
APK2 
AurA PKCz Rsk1 PRAK Erk1 PKD2 CK1d Chk1 
% inhib. 6 0.078* 9 8 -3 8 3 8 11 
Enzyme ABL FYN LYN Chk2 MET LCK SRC GSK3β Erk2 
% inhib. 39 10 9 13 6 17 22 9 2 
Enzyme PKA AKT2 INSR P38α AKT1 Msk1 Msk2 P38γ PKD1 
% inhib. 1 3 -3 -1 13 6 -6 -1 31 
Enzyme 
MARK
2 
BMX 
CSNK
1A1 
PKD3 BRSK1 Nek2 PIM1 SGK2 SGK3 
% inhib. 27 0.83* 5 26 12 0.088* 18 7 11 
Enzyme ARG 
DCAM
KL2 
Rsk2 Rsk3 BRSK1 PKC-α PKC-β1 PKC-γ PKC-δ 
% inhib. 32 -2 12 14 5 15 2 29 29 
Enzyme PKC-ε PKC-η PKC-θ       
% inhib. 8 17 35       
Table A1: Kinase inhibition following treatment with 1 µM 176 (NCL-00017509) for ProfilerPro
®
 plates. 
 Percentage activity remaining at 1 µM Inhibitor 
Kinase 147 km 176 km 34 km 
MKK1 95 18 46 2 16 1 
MKK2 103 4 75 8 15 0 
MKK6 105 2 109 4 54 5 
ERK1 102 1 105 13 79 9 
ERK2 91 13 92 4 70 3 
JNK1 82 6 67 10 85 10 
JNK2 96 8 92 3 101 7 
JNK3 89 2 111 18 91 6 
p38a 
MAPK 
110 7 103 12 106 3 
p38b 
MAPK 
85 5 94 2 86 3 
p38g 
MAPK 
99 10 100 18 97 6 
p38d 
MAPK 
96 3 129 14 105 0 
ERK8 86 7 108 2 14 2 
420 
 
RSK1 95 15 84 5 7 0 
RSK2 72 2 88 19 16 0 
PDK1 87 12 63 1 35 10 
PKBa 91 2 116 6 124 18 
PKBb 75 27 98 4 110 23 
SGK1 103 14 93 16 64 1 
S6K1 98 5 102 16 25 2 
PKA 90 10 108 0 100 10 
ROCK 2 91 6 89 2 23 1 
PRK2 103 14 99 6 16 3 
PKCa 95 5 108 3 86 2 
PKCγ 105 10 98 4 114 5 
PKCz 104 7 104 1 94 6 
GCK 78 3 71 8 14 1 
MINK1 87 6 92 0 13 0 
MLK1 54 24 40 11 9 2 
MLK3 33 5 29 0 17 2 
TAO1 115 13 101 7 95 5 
ASK1 96 1 128 10 68 0 
TAK1 50 0 37 4 31 16 
IRAK1 83 9 92 4 33 6 
IRAK4 86 6 85 3 24 1 
RIPK2 89 3 93 1 44 1 
OSR1 93 4 103 2 84 6 
TTK 80 5 92 5 35 4 
MPSK1 101 7 92 21 100 6 
Src 91 7 100 5 56 10 
Lck 110 16 113 1 59 5 
CSK 102 12 79 7 82 2 
YES1 108 7 92 6 29 3 
ABL 87 8 70 16 87 21 
BTK 63 11 95 8 87 10 
JAK2 75 1 30 0 40 4 
SYK 88 14 117 7 83 2 
ZAP70 114 9 119 2 88 4 
FGF-R1 97 3 74 9 84 17 
HER4 61 14 87 10 126 11 
IGF-1R 97 6 115 5 59 16 
IR 85 17 86 1 9 0 
IRR 87 3 92 5 67 1 
TrkA 109 7 74 7 31 2 
VEG-FR 97 22 64 5 9 1 
EPH-A2 105 17 122 2 110 7 
EPH-A4 106 15 107 8 105 7 
EPH-B1 93 1 95 1 91 14 
EPH-B2 106 13 104 15 108 9 
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EPH-B3 99 2 88 8 122 10 
EPH-B4 104 22 108 12 118 11 
BRSK1 93 17 110 8 12 3 
BRSK2 95 2 103 11 12 0 
MELK 93 6 115 1 10 5 
NUAK1 72 26 17 3 10 3 
CK1d 82 9 91 5 82 27 
CK2 93 5 94 13 28 1 
DYRK1A 93 2 107 11 3 0 
DYRK2 90 4 112 12 6 2 
DYRK3 89 6 113 4 6 1 
NEK2a 4 1 11 0 9 2 
NEK6 101 15 103 10 79 3 
IKKb 72 13 118 10 84 1 
IKKe 84 0 60 1 14 2 
TBK1 91 23 51 7 10 0 
PIM1 101 5 108 0 38 4 
PIM2 103 15 106 7 95 13 
PIM3 92 4 114 12 27 3 
SRPK1 75 26 94 5 67 4 
EF2K 106 12 107 6 96 4 
EIF2AK3 96 6 100 7 96 8 
HIPK1 105 29 57 7 32 5 
HIPK2 94 8 115 6 22 4 
HIPK3 99 15 107 6 29 7 
CLK2 77 11 63 3 6 2 
PAK2 96 9 102 6 92 19 
PAK4 70 7 71 15 44 4 
PAK5 93 13 84 6 103 27 
PAK6 97 1 102 0 81 2 
MST2 79 11 90 5 30 4 
MST3 92 4 
  
103 16 
MST4 96 4 94 4 41 2 
PKD1 104 18 120 13 43 4 
STK33 74 9 72 10 34 7 
MSK1 87 5 129 20 60 0 
MNK1 91 18 110 1 116 45 
MNK2 101 4 82 1 71 4 
MAPKAP-
K2 
102 13 78 9 68 3 
MAPKAP-
K3 
89 15 94 3 105 14 
PRAK 101 15 103 8 30 5 
CAMKKb 101 19 103 4 23 2 
CAMK1 95 14 138 18 55 5 
SmMLCK 97 15 107 1 9 0 
PHK 89 9 126 6 6 2 
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DAPK1 93 5 85 4 13 1 
CHK1 77 18 38 4 15 2 
CHK2 73 10 59 4 31 0 
GSK3b 87 0 100 10 30 6 
CDK2-
Cyclin A 
83 7 96 10 46 1 
PLK1 89 11 115 6 116 3 
Aurora A 95 9 69 4 55 1 
Aurora B 77 13 67 7 103 2 
TLK1 95 5 96 0 90 9 
LKB1 100 3 95 11 91 9 
AMPK 83 2 60 1 6 0 
MARK1 92 10 87 4 14 7 
MARK2 93 12 95 3 100 4 
MARK3 101 24 96 10 8 1 
MARK4 90 3 89 9 27 1 
TIE2 100 3 111 1 111 33 
BRK 74 1 103 13 117 7 
MEKK1 85 7 104 6 105 4 
TTBK1 81 21 - - 86 4 
TESK1 89 15 - - 97 0 
WNK1 109 12 - - 117 4 
DDR2 
    
107 11 
CDK9-
cyclin T1 
79 4 - - 106 4 
SIK2 78 12 - - 63 53 
SIK3 88 0 - - 33 5 
TSSK1 79 8 - - 16 2 
CK1y2 83 0 - - 56 11 
Table A2: Kinase inhibition data for 147 (NCL-00016727) and 176 (NCL-00017509) and the literature 
irreversible Nek2 inhibitor 34 from the National Centre for Protein Kinase Profiling, Dundee University. 
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